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Inflammation in frontotemporal lobar  
degeneration: cerebrospinal fluid  
signature of progranulin mutation carriers
D. Galimberti, R. Bonsi, C. Fenoglio, M. Serpente, S. Cioffi, 
G.G. Fumagalli, L. Ghezzi, A. Arighi, E. Scarpini
University of Milan, Ospedale Policlinico, Milan, Italy
Background and aims: Mutations in progranulin gene 
(GRN) are one of the major causes of autosomal dominant 
Frontotemporal Lobar Degeneration (FTLD). Progranulin 
displays anti-inflammatory properties and is a ligand of 
tumor necrosis factor receptor 2, expressed on microglia. A 
few cytokines and chemokines are altered in cerebrospinal 
fluid (CSF) from patients with sporadic FTLD, whereas no 
information is available in familial cases.
Methods or Materials or Case Report: To evaluate, 
through Bioplex, levels of 84 inflammatory molecules, 
including cytokines, chemokines, and related receptors, 
in CSF and matched serum, from patients carrying GRN 
mutations as compared with non-carriers and controls.
Results: Mean±SD Monocyte Chemoattractant Protein-1 
(MCP-1) levels were significantly increased in CSF 
from sporadic FTLD patients as compared with controls 
(334.27±151.5 vs 159.7±49 pg/ml; P=0.01). In GRN 
mutation carriers versus controls, CSF levels of MCP-1 
were unchanged, whereas Interferon-γ-inducible protein-10 
(IP-10-CXCL10) levels were increased (809.17±240.0 
versus 436.61±202.5 pg/ml; P=0.012). In the same group, 
Tumor Necrosis Factor (TNF)a and Interleukin (IL)-15 
levels were decreased (3.18±1.41 versus 35.68±30.5 pg/
ml; P=0.013 and 9.34±5.54 versus 19.15±10.03 pg/ml; 
P=0.023, respectively). Conversely, CCL-5 or regulated 
upon activation, normal T-cell Expressed, and secreted 
(RANTES) levels were decreased in patients, with or 
without mutations, as compared with controls (4.63±3.3 
and 2.58±2 vs 87.57±70 pg/ml; P<0.05). Moreover, IP-
10, IL-15 and RANTES CSF levels were not influenced 
by age, whereas MCP-1 levels increased with age (r=0.48; 
P=0.007).
Conclusion: These results demonstrate that different 
inflammatory molecules are de-regulated in CSF from 
patients with sporadic FTLD as compared with GRN 
FTLD, suggesting the existence of different inflammatory 
mechanisms possibly implicated in neuronal death.
Disclosure: Nothing to disclose
P1102
Physical activity as a predictor of clinical 
course in mild AD: the Danish Alzheimer’s 
Intervention Study
K.S. Frederiksen1, F. Waldorff2, G. Waldemar1
1Danish Dementia Research Centre, Dept. of Neurology, 
Rigshospitalet, Copenhagen, Denmark, 2The Research 
Unit for General Practice and Section of General Practice, 
Department of Public Health, University of Copenhagen, 
Copenhagen, Denmark
Background and aims: Alzheimer’s disease (AD) is 
associated with cognitive and functional decline. Moreover, 
neuropsychiatric sympotms such as apathy and anxiety are 
common. The objectives were to examine whether baseline 
physical activity was associated with global cognition, 
neuropsychiatric symptoms, quality of life (QoL), and 
activities of daily living (ADL) function at 12-month 
follow-up.
Methods: Data from the Danish Alzheimer’s Intervention 
StudY (DAISY) were used. Patients had recently diagnosed 
mild (MMSE>20) AD. Baseline physical activity level was 
assessed by questionnaire. Proxies rated patients physical 
activity level as ”no physical activity”,”less” or ”>4 hours” 
per week. At 12-month follow-up, global cognitive function 
was assessed using MMSE, QoL using QoL-AD and Euro-
QoL-5D VAS (EQ-5D VAS), neuropsychiatric symptoms 
with NeuroPsychiatric Inventory Questionnaire (NPIQ) 
and ADL with Alzheimer’s Disease Cooperative Study-
ADL scale (ADCS-ADL). 12-month follow-up scores were 
analysed in linear regression analysis (covariates: baseline 
MMSE, gender, age, group-allocation).
Results: In total 327 patients (Age (mean, SD): 76.2, 
±7.2; gender f/m: 177/151; MMSE (mean, SD): 24.0, 
±2.6) were included.Significant associations were found 
for EQ-5D VAS (β: 16.07; SE: ±3.49; p<0.0001) and for 
QoL-AD (β: 4.33; SE: ±1.09; p<0.0001). For NPI-Q a 
lower score (β:-1.88; SE: ±0.80; p=0.021) indicating fewer 
neuropsychiatric symptoms in physicially active patients, 
was found. Finally, being physically active was associated 
with better ADL function (β: 9.55; SE: ±2.78; p=0.001).
Conclusion: Physical activity predicts better functional 
level in 4 of 5 outcomes at 12-month follow-up in the early 
phase of AD.
Disclosure: Nothing to disclose
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Impact of physical activity on nursing 
home placement and mortality in 
mild Alzheimer’s disease: the Danish 
Alzheimer’s disease Intervention StudY 
(DAISY)
K.S. Frederiksen1, F. Waldorff2, G. Waldemar1
1Danish Dementia Research Centre, Dept. of Neurology, 
Rigshospitalet, Copenhagen, Denmark, 2The Research Unit 
for General Practice and Section of General Practice, , 
Department of Public Health, University of Copenhagen, 
Copenhagen, Denmark, Copenhagen, Denmark
Background and aims: Alzheimer’s disease (AD) is 
associated with increased mortality rates and increased 
risk of nursing-home placement, compared to age-
matched healthy elderly subjects. Several factors, such as 
comorbidities may be contributing factors. In the present 
study we investigated whether physical activity may be 
associated with lower mortality rates and risk of nursing-
home placement in patients with mild AD.
Methods: Data from the Danish Alzheimer’s Intervention 
StudY (DAISY) were used. All patients had recently 
diagnosed mild (MMSE>20) AD. Physical activity level 
at baseline was assessed by questionnaire. Patients were 
followed for 3 years. Data on all-cause mortality and 
nursing-home placement were collected. Cox proportional-
hazard regression analysis with mortality and nursing-
home placement as outcomes and physical activity level as 
dependent variable was carried out. Covariates were social 
participation, Carlston Comorbidity Index, ADL function 
(Alzheimer’s disease cooperative study – Activities of daily 
living scale) disease-specific Quality of Life (Quality of 
Life – Alzheimer’s disease scale) and MMSE at baseline, 
age and gender. 
Results: In total 327 patients (Age (mean, SD): 76.2, ± 7.2; 
gender f/m: 177/151; MMSE (mean, SD): 24.0, ±2.6) had 
data on proxy-rated physical activity levels available, and 
were included.
There were no significant associations between physical 
activity and mortality or nursing-home placement, although 
survival curves indicated a separation of the two groups 
(see figure 1 and 2). Survival curves for nursing-home 
placement indicated the largest separation.
Conclusion: Several factors may contribute to mortality 
and risk of nursing-home placement in patients with mild 
AD. Being physically active may not reduce mortality or 
nursing-home placement.
Disclosure: Nothing to disclose
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P1104
Quantitative EEG applying the statistical 
recognition pattern method: a useful tool 
in the dementia diagnostic work-up.
P. Høgh1, K. Engedal2, J. Snaedal3, V. Jelic4, B.B. Andersen5, 
M. Naik6, L.O. Wahlund4, A.R. Øksengaard4
1Copenhagen University Hospital, Roskilde, Memory 
Disorders Research Unit, Dept of Neurology, Roskilde, 
Denmark, 2Norwegian Advisory Unit for Ageing and Health,, 
Vestfold Health Trust, Oslo, Norway, 3Landspitali - National 
University Hospital, Reykjavik, Iceland. , Ophthalmology, 
Reykjavik, Iceland, 4Center for Alzheimer Research, 
Karolinska Institute, Section for Clinical Geriatrics, NVS 
Department, Stockholm, Sweden, 5Danish Dementia Research 
Cente, Neurology, Copenhagen, Denmark, 6Deakoness 
Hospital, Department of Geriatric Medicine, Bergen, Norway
Background and aims: The aim of the study was to 
examine the discriminatory power of the quantitative EEG 
(qEEG) applying the statistical pattern recognition (SPR) 
method to separate Alzheimer’s Disease (AD) patients 
from elderly persons without dementia and from other 
dementia patients. 
Methods: Participants were recruited from six Nordic 
memory clinics, 372 unselected patient, mean age 71.7 
(s.d. 8.6), 54% women and 146 healthy old people, mean 
age 66.5 (s.d. 7.7), 60% women. After a standardized and 
comprehensive assessment clinical diagnoses were made 
according to international accepted criteria by at least two 
clinicians. EEG was recorded in a standardized way and 
analyzed independently of the clinical diagnoses using the 
SPR method.
Results: In receiver operating characteristic (ROC) 
analyses the qEEG separated AD from healthy old persons 
with an area under the curve (AUC) of 0.90, representing 
sensitivity (SS) of 84% and specificity (SP) of 81%. The 
qEEG further separated patients with Lewy body dementia 
or Parkinson’s disease dementia from AD with AUC of 0.9, 
SS 85% and SP 87%.
Conclusion: The qEEG using the SPR method could be a 
useful tool in the dementia diagnostic work-up.
Disclosure: Nothing to disclose
P1105
Long-term follow-up of idiopathic normal 
pressure hydrocephalus treated with 
ventriculo-peritoneal programmable valve
I. Illán-Gala, J. Pérez-Lucas , A. Martín-Montes,  
J. Máñez-Miró, G. Ruiz-Ares, E. Díez-Tejedor
Hospital Universitario La Paz, Neurology department and 
Stroke center, Madrid, Spain
Background and aims: Idiopathic normal pressure 
hydrocephalus (iNPH) is considered a treatable cause of 
dementia. We aimed to study the frequency of the diagnosis 
and surgery-related complications as well as clinical and 
functional outcomes in a cohort of patients with iNPH 
treated with ventriculo-peritoneal programmable valve 
(VPPV).
Methods: Observational cohort study of patients diagnosed 
of probable iNPH and shunted between 2008 and 2013 in 
a neurosurgical reference center. We studied demographic 
data, vascular risk factors, symptoms at diagnosis and 
neuroimaging. Clinical improvement was classified in four 
categories (normalization, partial improvement, equivocal 
improvement and no improvement) and the functional level 
was assessed by the modified Rankin scale (mRS). 
Sample selection
Results: 29 patients were included (5.4 cases per million 
per year) with a mean follow-up time of 37.8 months. The 
mean age was 73.9 years, 62.1% were male and 65.5% had 
hypertension. Clinical improvement (complete or partial) 
was observed in 58% after one year and in 48% at the end 
of the follow-up. The age, the presence of hypertension and 
the occurence of surgery-related complications were higher 
in the group with poor symptomatic response at first year. 
One patient died, 20.7% suffered from severe complications 
and 69% were dependent (mRS ≥ 3) at the end of follow-up. 
Age at diagnosis was independently associated with worse 
clinical response at one year and increased dependence at 
follow-up.
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Symptomatic outcome after 6 months, one year and three years of 
VPPV placement
Comparison between functional level at diagnosis and at the end of 
the follow-up.
Conclusion: Symptomatic benefit of VPPV was partial and 
transient, with a high frequency of complications and bad 
functional outcome in long-term follow-up especially in the 
oldest patients.    
Disclosure: Nothing to disclose
P1106
Have opioids replaced antipsychotics in 
the treatment of behavioural symptoms in 
dementia?
C. Jensen-Dahm1, A. Nørgaard1, C. Gasse2, G. Waldemar1
1Danish Dementia Research Center, Copenhagen, Denmark, 
2National Centre for Register based Research, Aarhus, 
Denmark
Background and aims: Antipsychotics are often prescribed 
to treat neuropsychiatric symptoms (NPS) in dementia, 
but have been associated with serious adverse events and 
increased mortality, which has led to safety regulations 
worldwide. Recently it has been suggested that opioids may 
be used to treat NPS (Husebo BMJ 2011). The aim of this 
study was to investigate time trends of antipsychotic and 
opioid drug use in patients with dementia in Denmark from 
2000-2013.
Methods : Population-based observational study with time 
series of cross-sectional studies and conducted by use of 
Danish nationwide registers including the entire elderly 
population (age≥65) of Denmark. The registers were used 
to identify patients with dementia and identify users of 
opioids and antipsychotics from 2000 to 2013.
Results: From 2000 to 2013 prevalence of antipsychotic 
drug use among patients with dementia decreased by 35.8% 
(from 31.3% to 20.1%), but during the same period opioids 
increased by 37.9% (from 24.2% to 33.8%) (figure 1). 
Among elderly without dementia antipsychotic drug use 
decreased by 37.8% (from 4.5% to 2.8%) and opioid use 
increased by 15.4% (from 14.9% to 17.2%) (figure 2).
Figure 1
Figure 2
Conclusion: From 2000 to 2013 the use of antipsychotics 
among patients with dementia decreased, but during the 
same period use of opioids increased. The marked increase 
could be explained by a higher awareness among physicians 
of the importance of sufficient pain treatment. However, the 
high use of opioids is concerning and the association with 
a decrease in antipsychotics suggest that opioids may be 
used for managing NPS and to some extent have replaced 
antipsychotics.
Disclosure: Nothing to disclose
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Altered default mode network connectivity 
during visual processing in patients with 
mild cognitive impairment (an fMRI study)
L. Krajcovicova1, M. Barton2, N. Elfmarkova1, M. Mikl2,  
R. Mareček2, I. Rektorova1
1CEITEC - Central European Institute of Technology, 
Masaryk University, Brno, Czech Republic, Applied 
Neuroscience Research Group, Brno, Czech Republic, 
2CEITEC - Central European Institute of Technology, 
Masaryk University, Brno, Czech Republic, Multimodal and 
Functional Imaging Research Group, Brno, Czech Republic
Background and aims: The default mode network (DMN) 
is characterized by continuous activity during the resting 
state that decreases during goal-directed tasks.  The object 
of our study was to detect specific alterations in DMN 
connectivity when switching from baseline to task condition 
(here the visual task) in 17 patients with mild cognitive 
impairment (MCI) as compared to 18 healthy controls 
(HC) and 15 patients with Alzheimer’s disease (AD) using 
psychophysiological interactions (PPI) analysis. 
Methods: The fMRI protocol (a complex visual scene-
encoding task) was performed using a 1.5 T Siemens 
Symphony scanner.  PPI analysis was used to assess the 
effect of the visual task on connectivity with the posterior 
cingulate/precunes (PCC/P, i.e. the posterior DMN node). 
Age, gender, education and a measure of atrophy were used 
as covariates.
Results: When switching to task, HC showed decreased 
DMN connectivity with the left middle temporal /middle 
occipital gyrus (MTG/MOG) and PCC/P bilaterally while 
MCI showed decreased DMN connectivity with bilateral 
precuneus only. Comparing HC and MCI resulted in a 
significant difference in the PPI effect in the right superior 
temporal gyrus (STG) and this difference became stronger 
in AD. In addition, MCI subjects as compared to AD group 
showed significant differences in bilateral precuneus. 
Conclusion: We have found specific disturbances in 
connectivity between the DMN and the ventral visual 
pathway in MCI patients during the visual processing. 
These changes were more pronounced in AD patients. 
Disclosure: The study was supported by the project 
“CEITEC - Central European Institute of Technology” 
(CZ.1.05/1.1.00/02.0068) from the European Regional 
Development Fund and by the project of specific research 
LF MU Brno no. 0975/2013
P1108
Following the spreading of brain  
structural changes in Alzheimer’s disease: 
a longitudinal, multimodal MRI study
D. Mattavelli1, F. Agosta1, M. Weiler1, E. Canu1, M. Copetti2, 
G. Magnani3, A. Marcone4, E. Pagani1, M. Balthazar5,  
G. Comi3, A. Falini6, M. Filippi1
1San Raffaele Scientific Institute, Vita-Salute San Raffaele 
University, Neuroimaging Research Unit, Milan, Italy, 
2IRCCS-Ospedale Casa Sollievo della Sofferenza, 
Biostatistics Unit, San Giovanni Rotondo, Italy, 3San 
Raffaele Scientific Institute, Vita-Salute San Raffaele 
University, Department of Neurology, Milan, Italy, 4San 
Raffaele Scientific Institute, Vita-Salute San Raffaele 
University, Department of Clinical Neuroscience, Milan, 
Italy, 5University of Campinas, Laboratory of Neuroimaging, 
Campinas, Brazil, 6Università Vita-Salute San Raffaele, 
Neuroradiology, Milan, Italy
Background and aims: Longitudinal studies combining 
volumetric and diffusion tensor (DT) MRI measures may 
contribute to clarify the network-based degeneration model 
of Alzheimer’s disease (AD). This study investigated grey 
matter (GM) atrophy and white matter (WM) tract damage 
progression in AD.
Methods : T1-weighted and DT MRI from 14 patients with 
probable AD were obtained at baseline and after a 16±3 
month period. At baseline, CSF samples from patients and 
MRI from 37 controls were also acquired. Regional GM 
volume loss and DT MRI metrics from the interhemispheric 
and major long-association WM tracts were obtained. MRI 
metrics were compared between patients and controls, and 
changes over time were evaluated in patients.
Results: At baseline, patients showed cortical atrophy in the 
medial temporal and parietal regions and WM damage to 
corpus callosum, cingulum and inferior (ILF) and superior 
longitudinal (SLF) fasciculi bilaterally, and left uncinate 
relative to controls. During follow up, AD patients showed 
a progression of WM damage to the corpus callosum, 
SLF bilaterally, left ILF and right cingulum, while no GM 
atrophy was detected compared to baseline. Patients with 
higher baseline cerebrospinal fluid total tau showed greater 
WM integrity loss at follow up.
Conclusion: In AD, WM tract damage progresses over 
time and is likely to be driven by non-Aβ processes. The 
different temporal dynamics of GM and WM changes in 
AD suggest that DT MRI may provide additional markers 
to monitor disease progression.
Disclosure: Italian Ministry of Health (#GR-2010-
2303035).
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Does the side of stroke determine the side 
of pneumonia?
P. Alves1, C. Silva1, J. Baptista2, B. Lima3, M. Jacinto4, 
A.C. Fonseca1
1Centro Hospitalar Lisboa Norte - Hospital de Santa Maria, 
Neurology, Lisbon, Portugal, 2Hospital Fernando da Fonseca, 
Infectious diseases, Lisbon, Portugal, 3Hospital Curry Cabral, 
Infectious diseases, Lisbon, Portugal, 4Hospital do Espírito 
Santo, Internal Medicine, Évora, Portugal
Background and aims: Pneumonia is a frequent 
complication after stroke. Previous studies using 
ultrasonographic, radiographic and plethysmographic 
methods have demonstrated an alteration of diaphragmatic 
excursion on the side of paresis.
We aimed to determine if there is an association between 
the paretic side and the laterality of pneumonia after stroke.
Methods: A retrospective analysis of a consecutive cohort 
of patients admitted to a stroke unit from 2008 to 2014 was 
performed. Patients with the diagnosis of acute stroke and 
pneumonia were included. The laterality of pneumonia was 
determined through blinded-observation of chest x-rays by 
two researchers and, in case of disagreement, by a third one. 
The exclusion criteria were: absence of/or bilateral paresis; 
lack of radiological evidence of/or bilateral pneumonia; 
absence of concordance on pneumonia laterality by at least 
two observers; and bilateral encephalic lesions. Fisher’s 
exact test was applied to study the association between the 
side of paresis and pneumonia. 
Results: 88 patients were included. The median age was 69 
years. 56% (n=49) had an ischemic stroke and 44% (n=39) 
a brain haemorrhage. 53% (n=47) presented right side 
paresis. The pneumonia was considered to be in the right 
side in 86% (n=76) with a Kappa value of interobserver 
concordance for laterality of 0.39. No significant statistic 
association was found between the side of paresis and 
pneumonia in included patients (p=1.0) and in the subgroups 
of patients with ischaemic stroke (p=0.67) or haemorrhagic 
stroke (p=1.0).
Conclusion: No association was found between the side of 
pneumonia and paresis. The predominance of right-sided 
pneumonia probably results from aspiration events.  
Disclosure: Nothing to disclose
P1110
Axial myoclonus after ischaemic stroke
P. Alves, M. de Carvalho, R. Peralta, R. Geraldes,  
A.C. Fonseca, T. Pinho e Melo
Centro Hospitalar Lisboa Norte - Hospital de Santa Maria, 
Neurology, Lisbon, Portugal
Background and aims: Myoclonus is a rare manifestation 
of stroke. The most common are asterixis, a subtype of 
negative myoclonus, after thalamic lesions. There are no 
reports of axial muscles myoclonus after stroke.    
Case Report: A 67-year-old female was admitted due 
to decreased muscular strength and numbness on her left 
side of sudden onset. She had a past medical history of 
rheumatic atrial fibrillation not effectively anticoagulated 
with warfarin and an ischaemic stroke one year before 
with mild left appendicular ataxia and left upper limb 
hypoesthesia as sequelae.
At admission, neurological examination disclosed 
hemiparesis, severe superficial hypoesthesia and 
appendicular ataxia on the left side. The diagnosis of acute 
ischemic stroke was made and alteplase was administered. 
After being upraised, eight hours following endovenous 
thrombolysis, marked postural instability due to apparent 
sudden reduction in the cervical and dorsal axial muscle 
tonus was noticed.  Magnetic resonance imaging revealed 
acute ischaemic lesions in the right thalamo-capsular 
and hippocampal areas. Electromyography recording 
disclosed negative myoclonus in the left upper limb and 
right paraspinal muscles and both negative and positive 
myoclonus in left paraspinal muscles (figure). No epileptic 
activity was observed on electroencephalography.
During follow up, there was a progressive improvement 
of the neurological deficits, including postural instability. 
After three months myoclonus were no longer present 
without any specific treatment.
Electromyographic recordings of right deltoid (top), right D5 
paraspinal (middle) and left D5 paraspinal dorsal muscles (bottom) 
showing periods of muscular atonia with 100-150ms of duration.
Results: The temporal association between the appearance 
and the evolution of myoclonus and the other neurological 
deficits supports a causal relationship.
Conclusion: To our best knowledge this is the first report 
of axial myoclonus after stroke.
Disclosure: Nothing to disclose
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Microbleeds: not more hemorrhagic 
transformation after thrombolysis
M. Annan1, J.-P. Cottier2, M. Gaudron1, M. Dejobert2,  
B. De Toffol1, S. Debiais3
1CHRU Bretonneau, Neurology, 2CHRU Bretonneau, 
radiology, 3CHRU Bretonneau, neurology, Tours, France
Background and aims: Microbleeds (MB) are suspected 
to increase the hemorrhagic risk after thrombolysis for 
ischemic stroke (IS), but their exact significance is unclear. 
New imaging methods such as susceptibility weighted 
imaging (SWI) are more efficient to detect these MB. The 
main aim of this study was to look for a link between MB 
and hemorrhagic transformation after thrombolysis for IS.
Methods: This study was conducted prospectively between 
June 2012 and June 2013 in our stroke unit of Tours, France. 
All patients treated with intravenous thrombolysis for IS 
within 4.5 hours after onset of symptoms, and with a 3Tesla 
Magnetic Resonance Imaging (3T MRI) as first imaging 
were included. MB were counted on SWI according to 
BOMBs classification proposed by Cordonnier et al. in 
2009. Hemorrhagic transformation were evaluated on SWI 
on a second MRI performed 7±3 days later according to 
the European Cooperative Acute Stroke Study (ECASS) 
classification.
Results: A total of 91 patients were included. Among them, 
28 (30.7%) had MB on the first MRI. 17 (61%) patients 
with MB had HT, of which 2 (7%) were symptomatic. 
Those rates were respectively of 53% and 10% in patients 
without MB. The difference was not significative, the odd 
ratio (OR) was 1.43(0.56-3.65) for all-type of HT, and 
0.65(0.12-3.47) for symptomatic HT.
Conclusion: In our study, MB detected with SWI are not 
significantly correlated to the risk of HT after thrombolysis. 
SWI increase detection of bleeding, such as MB or HT. 
Using SWI for the detection of both MB and HT is new in 
the literature.
Disclosure: Nothing to disclose
P1112
Blood rheology and endothelial 
dysfunction in acute ischemic stroke
M. Azhermacheva1, V.M. Alifirova1, P.D. Plotnikov Denis1, 
O. Aliev2
1Siberian State Medical University, Department of neurology 
and neurosurgery, Tomsk, Russian Federation, 2Federal 
State Budgetary Scientific Institution “Research Institute of 
Pharmacology and Regenerative Medicine named after E.D. 
Goldberg”, Tomsk, Russian Federation
Background and aims: To assess endothelial dysfunction 
and blood rheology in acute ischemic stroke (IS).
Methods: The study included 49 patients with acute IS 
(age 64.5±12 years, mean±SD) and 20 control patients 
(56.3±4.7 years). High-resolution ultrasonography 
(TOSHIBA XCARIO SSA-660A) was used to measure 
intima-media thickness (IMT) and brachial artery (BA) 
diameters at rest and following 5 min of forearm occlusion. 
BA reactivity (brachial artery flow-mediated vasodilation 
(FMD) and glyceryl trinitrate (GTN)-mediated-dilatation) 
was assessed by method of D. Celermajer in 15-17 day of 
stroke. Hemorheological indexes were assessed in the first 
12 hours and 8-20 day of stroke. All patients with acute 
stroke were treated legis artis.
Results: Significantly detected a difference IMT in patients 
with stroke (0.72±0.19) and in control group (0.6±0.13, 
p<0.05). BA diameters in rest in patients with stroke 
(3.80±0.13) were higher than in control group (3.61±0.20, 
p<0.05). Assessing of endothelial dysfunction was found 
the decreasing of FMD and the increasing of GTN-
mediated-dilatation. Coefficient of endothelial dysfunction 
(GTN-mediated dilatation/FMD) was significantly higher 
in patients with acute IS (2.60±0.21) than in control 
group (1.45±0.19). Patients in the acute phase of IS had 
significant changes in hemorheological parameters which 
can be described as hyperviscosity syndrome: increased 
whole blood and plasma viscosity, plasma fibrinogen 
concentration, aggregation of erythrocytes and decreased 
red blood cell deformability. The strong correlations 
(r>0.86) between blood rheology indexes, brachial arterial 
reactivity and IMT were revealed.
Conclusion: In spite of the treatment, patients in acute IS 
had severe endothelial dysfunction and significant changes 
in hemorheological parameters.
Disclosure: Nothing to disclose
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Changes in etiology and vascular burden 
of first ever Polish stroke patients from 
1995 to 2013.
J. Bembenek, M. Karliński, A. Baranowska, A. Czlonkowska
Institute of Psychiatry and Neurology, 2nd Department of 
Neurology, Warsaw, Poland
Background and aims: Our aim was to investigate long-
term changes in profile, vascular risk factors and pre-stroke 
management in Polish patients with acute stroke.
Methods: This is a retrospective registry-based analysis of 
consecutive acute stroke patients from a highly urbanized 
area (Warsaw, Poland) admitted to a single stroke center 
between 1995 and 2013. A total of 4770 patients were 
divided to time periods: 1995-1999 (n=529), 2000-2004 
(n=1253), 2005-2009 (n=1320) and 2010-2013 (n=871). 
Results: The proportion of ischaemic strokes (88.2% 
to 90.9%) and male patients (45.2% to 46.2%) remained 
stable throughout the study period. Patients became older 
(from 72 to 76 years), more burdened with pre-existing 
hypertension (from 61.1% to 72.8%) and less often without 
pre-existing disability (84.3% to 67.4%). There was an 
increase in pre-stroke use of antihypertensives in patients 
with hypertension (from 77.8% to 90.5%), antiplatelets 
in patients with coronary artery disease (from 33.9% 
to 56.5%), vitamin K antagonists in patients with atrial 
fibrillation (from 6.3% to 39.8%) and statins (from 7.6% to 
26.3%). Baseline stroke severity has decreased (from 9 to 6 
points on the National Institutes of Stroke Scale) as well as 
the proportion of strokes due to small-vessel disease (from 
22.0% to 8.3%). 
Conclusion: Over the last two decades the profile of Polish 
stroke patients has changed significantly. Their increasing 
age and better management of pre-exisitng vascular risk 
factors were accompanied by decreasing baseline deficit 
and lower proportion of strokes attributed to small-vessel 
disease.
Disclosure: Nothing to disclose
P1114
TIA hits at younger age in low income 
areas within one city - the Budapest 
Districts 8-12 Project
D. Bereczki1, A. Ajtay2, I. Vastagh2, I. Szőcs2, A. Folyovich3
1Budapest, Hungary, 2Semmelweis University, Department 
of Neurology, Budapest, Hungary, 3Szent János Kórház, 
Department of Neurology and Stroke, Budapest, Hungary
Background and aims: Transient ischemic attack – TIA – 
is a major risk factor for stroke needing urgent evaluation. 
It is known that stroke appears at younger age in 
socioeconomically deprived regions. We test whether this 
age difference also exists for TIAs by comparing the least 
and the most wealthy of the 23 districts of the Hungarian 
capital city of Budapest.
Methods: We analyzed the database of the National Health 
Insurance Fund for patients living in the least (districts 8) 
and the most wealthy (district 12) regions, a population 
of 130,000 inhabitants, with the ICD-10 diagnosis of G45 
established by any specialists in the inpatient or outpatient 
settings in the period of 2002-2007.
Results: Overall 4667 patients were diagnosed with TIA in 
the study period. Of the patients 35.4% were hospitalized 
for any reason. The diagnosis of TIA was assigned without 
neurological examination in 23.5% of the cases. Mean age 
of patients with the diagnosis of TIA was 4 years younger 
in the less wealthy district (61.9 vs. 65.9 years, p<0.01).
Conclusion: In the Hungarian healthcare system two-
thirds of the patients with the diagnosis of TIA are treated 
in the outpatient setting, one out of 4 is not evaluated by 
neurologists, and patients are significantly younger in less 
wealthy areas. Socioeconomic deprivation is associated 
with younger age at disease onset not only for strokes 
but also for TIA. To achieve more efficient secondary 
prevention, healthcare policy should give higher preference 
for TIA patients in middle income countries, focusing on 
low-income regions.
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Locked-in syndrome after traumatic 
basilar artery dissection - a case report
T. Bourinaris, D. Kiourtidis, J. Rudolf, T. Tsironis, I. Tsiptsios
Thessaloniki, Greece
Background and aims: Basilar artery dissection is an 
unusual presentation of ischemic stroke. The event is either 
spontaneous or traumatic resulting in acute or delayed 
dissection. We report a case of a 46-year-old male presenting 
with locked-in syndrome, caused by multiple ischemic 
infarcts due to a traumatic basilar artery dissection.
Methods: A 46-year-old man was presented at the 
emergency department following a head trauma caused 
by a fall from a bike. At presentation the patient was 
stuporous without focal neurological signs, but was 
eventually intubated because of deterioration of his level 
of consciousness. An emergency brain CT scan revealed a 
linear stress fracture of the posterior wall of the sphenoid 
sinus. A brain MRI showed extended ischemic infarcts 
in occipital lobes, thalami, pons, medulla oblongata and 
left cerebellar hemisphere, while the MRA that followed 
revealed a distal basilar artery dissection.
Results: After extubation the patient had locked-in-
syndrome with spastic quadriplegia, ophtalmoplegia 
and loss of brainstem reflexes, while retaining and 
communicating by eye blinking. A detailed workup 
excluded any other possible causes of the infarcts. Follow-
up neuroimaging with intracranial MRA one month later 
confirmed the diagnosis showing eventual restoration of 
blood flow at the basilar artery.
Conclusion: Isolated traumatic basilar artery dissection 
is a rare event, since the concomitant involvement of the 
vertebral arteries is usually reported. This case is unique 
for the absence of major skull injuries or dislocations of 
anatomic structures, as well as for the lack of involvement 
of the extra- and intracranial sections of the vertebral 
arteries.
Disclosure: Nothing to disclose
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Background and aims: To analyze the etiology of recurrent 
ischemic stroke and to investigate in which cases a different 
cause was detected in the second event.
Methods:: Observational study of patients with ischemic 
stroke (2010-2014). Variables: Baseline/clinical data, prior 
cerebral infarction (CI) or transient ischemic attack (TIA). 
Etiologies of current and previous stroke/TIA and their 
concordance were recorded.
Results: A total of 1197 patients were included, 57.1% 
were male, mean age 70.5 years. 18.5% (222) had a prior 
ischemic stroke (CI 58.1%, TIA 34.2% and TIA+CI 7.7%). 
The cause of the previous stroke was: undetermined / 
unreported (53.2%), cardioembolic (17.1%), lacunar 
(13.3%), atherothrombotic (9.2%) and unusual (3.2%). 
The concordance between past and present etiology was 
analyzed, being the most consistent cardioembolic (94.7%), 
followed by atherothrombotic (74.1%) and unusual (62.5%), 
with low agreement in the lacunar (30%) and undetermined 
(39.8%) (P <0.0001). The most frequent cause of recurrence 
in lacunar and undetermined / unreported stroke was the 
cardioembolic cause (37.5% and 40%, respectively). In 
39.8% of prior strokes of undetermined etiology, a current 
cause was not identified. The mean time to recurrence was 
higher in those who changed etiology respect to those who 
maintained the previous (73.1 vs. 46.3 months, P=0.003).
Conclusion: The etiologic subtype that most frequently 
recurs with the same etiology is cardioembolic stroke. 
Current cardioembolic cause is more frequent in patients 
with prior lacunar or undetermined/unreported strokes. In 
up to one third of patients with stroke of undetermined / 
unreported cause, no etiology is found after recurrence.
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Multiple simultaneous spontaneous 
intra-cerebral hemorrhages: long-term 
outcome.
Y. Chen, D. Leys, H. Henon, S. Bombois, F. Pasquier,  
C. Cordonnier
Univ. Lille Nord de France, UDSL, CHU Lille, U 1171, Lille, 
France
Background and aims: In hospital databases, multiple 
simultaneous spontaneous intracerebral hemorrhages 
(ICH-m) account for 0.7% to 5.6% of all ICH. Their 
long-term outcome has never been systematically and 
prospectively investigated. We aimed at identifying the 
long-term outcome of patients with ICH-m.
Methods: We prospectively recruited consecutive adults 
with ICH-m, and followed them up for at least 4.5 years. 
We classified patients into 3 groups: (i) definite or probable 
cerebral amyloid angiopathy (CAA); (ii) deep perforating 
vasculopathy; and (iii) unknown causes.
Results: Of 562 consecutive patients with intracerebral 
hemorrhages, 32 had multiple simultaneous spontaneous 
intracerebral hemorrhages (5.7%): 8 (25%) with probable 
cerebral amyloid angiopathy, 5 (16%) with deep perforating 
vasculopathy, and 19 (59%) with intracerebral hemorrhages 
of unknown cause. At the last visit (cumulative follow-up 
of 39.5 person-year), 27 patients (84%) had died, and 3 
of the 5 survivors were independent. Late onset seizures, 
recurrent intracerebral hemorrhages (symptomatic or not), 
and new brain microbleeds were mainly found in patients 
with probable cerebral amyloid angiopathy.
Conclusion: ICH-m is a rare but extremely severe 
expression of ICH. Survivors with CAA are more likely 
to develop late seizures and new hemorrhagic lesions. 
Because of low survival rates, large multicentre cohort 
studies are needed for a better understanding of this rare 
condition.
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CPM test-retest reliability of two heat pain 
protocols
Y. Granovsky1, A. Miller2, T. Alon1, O. Goldstein2,  
E. Sprecher1, D. Yarnitsky1
1Rambam Health Care Campus, Haifa, Israel, 2Rambam 
healthcare campus, Haifa, Israel
Background and aims: The assessment of pain inhibitory 
mechanisms using conditioned pain modulation (CPM) is 
relevant clinically in prediction of pain and of analgesic 
efficacy. The practical transformation of the CPM paradigm 
into a clinical tool, however, depends on its reliability 
along time. In this paper we present reliability data for two 
thermal heat CPM protocols specifically developed with the 
intention of improving reliability of the CPM assessment.
Methods: A cohort of young healthy subjects (total N=30, 
15 females) participated in a dual-session study consisted 
of two CPM protocols : (1) Two-Thermodes, one for 
conditioning stimuli, and a second for test-stimuli, in a 
classical parallel CPM design- introducing test stimulus 
first, and then the conditioning and repeated test stimuli in 
parallel, and (2) Single test-stimulus (STS) protocol with 
a single administration of a contact heat test-stimulus, 
partially overlapped in time by a remote shorter contact 
heat as conditioning stimulus. Reliability was assessed 
using intraclass correlation (ICC) analysis. 
Results: Test-retest reliability was assessed within 3-7 
days. The STS-CPM had superior reliability (ICC2,1=0.59) 
over the Two-Thermodes (ICC2,1=0.21) protocol. 
Conditioned test-stimulus pain scores were of fair 
(ICC2,1=0.43) reliability for the STS, but not for the Two-
Thermodes protocol (ICC2,1=0.20). 
ICC values for main CPM-related variables
Conclusion: The newly developed STS-CPM paradigm 
has superior reliability over a parallel CPM protocol, and 
should be further investigated for its clinical relevance. 
Disclosure: No author has potential conflict of interests. Dr. 
Yelena Granovsky is a paid scientific consultant of Medoc 
Ltd.  This study was funded by a grant from the Office of 
the Technion’s Vice President for Research.
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Effect of body mass index on CS Fopening 
pressure
S. Al-Othman1, H. Mistry1, R. Atkinson1, R. Mohanraj2
1Salford Royal Hospital NHS foundation trust, Neurology, 
Salford, United Kingdom, 2Salford, United Kingdom
Background and aims: Opening pressure of cerebrospinal 
fluid (CSF), measured by lumbar puncture (LP) may be 
influenced by patients’ body habitus. Abnormalities of CSF 
pressure such as Idiopathic Intracranial Hypertension are 
thought to be more common in patients with high body 
mass index (BMI). It is important to ascertain normal 
values of CSF opening pressure for patients in each BMI 
category. We analysed the relationship between BMI and 
CSF opening pressure in 279 patients undergoing LP to 
ascertain normal values for patients of varying BMI. 
Methods: Data on height, weight and CSF opening 
pressures of patients who underwent elective LP were 
analysed. Patients with known or suspected intracranial 
hyper- or hypotension were excluded, as were those whose 
eventual diagnosis was one known to affect CSF opening 
pressure. Data on 279 patients were included.
Results: Obese patients (BMIs >30, n=90) had a median 
CSF opening pressure of 23cm of CSF (range 10-36), 
which was significantly higher than that for overweight 
patients (BMI 25-30, n=84); 16.75cm of CSF (8-31) and 
for those with normal or low BMI (<25, n=105); 14cm of 
CSF (range 7.5-31).  There was a statistically significant 
correlation between CSF opening pressure and BMI 
(Pearson’s product-moment correlation: 0.628). We used 
linear regression to show a significant relationship between 
BMI and CSF opening pressure: coefficient 0.611 (p<0.001, 
95% CI- 0.521 - 0.700).
Conclusion: Normal values of CSF opening pressure are 
significantly higher in obese and overweight patients. There 
is a linear relationship between BMI and CSF opening 
pressure. 
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Reliability and repeatability of testing  
Visual Evoked Potentials in migraine
A. Ambrosini1, G. Coppola2, E. Iezzi1, F. Pierelli3,  
J. Schoenen4
1IRCCS Neuromed, Pozzilli (Isernia), Italy, 2IRCCS G.B. 
Bietti Foundation, Rome, Italy, 3“Sapienza“ University Polo 
Pontino, Latina, Italy, 4CHR CItadelle - University of Liège, 
Liege, Belgium
Background: In most studies migraineurs have an interictal 
habituation deficit of visual evoked potentials (VEP). This, 
however, was not confirmed in some studies, which was 
attributed to low reliability and repeatability.
Aim: To test  in healthy volunteers (HV) and episodic 
migraineurs (EM): 1) reliability of VEP habituation 
measures by comparing blinded and non-blinded analyses; 
2) VEP repeatability by evaluating two recordings separated 
in time.
Methods: To test VEP reliability, pattern-reversal VEP 
were recorded in 22 HV and 44 EM. Two researchers, one 
of which was totally blinded to subjects and diagnosis, 
independently analysed single trials and calculated 
habituation percentages. To test VEP repeatability, two 
VEP recordings, separated by a time interval ranging from 
7 to 120 days, were performed in 12 HV and 9 EM.
Results: In both the blinded and the non-blinded analysis 
VEP habituation was normal in HV, but deficient in EM. 
The difference between HV and EM was significant for 
both procedures (p=0.038 and p<0.001) and data were 
significantly correlated (overall r=0.780, p<0.0000001). 
When recordings were repeated twice, habituation values 
and differences between study groups were similar in the 
two recordings, and intraindividual data for both recordings 
were significantly correlated  (overall r=0.700, p=0.0004).
Conclusion: We confirm that VEP habituation is interictally 
deficient in episodic migraineurs also when analyses 
are blinded and  recordings repeated. Low reliability or 
repeatibility can thus not explain the discrepant results 
found by others.
Disclosure: Nothing to disclose
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Successful treatment with jugular 
stenting of exercise-induced intracranial 
hypertension mimicking status  
migrainosus
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I. Meyer1, P. Correia1
1CHUV, Lausanne, Neurology , Lausanne, Switzerland, 
2Bern University Hospital, University of Bern, Department 
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Background:cerebri mention venous outflow as a 
potential cause. We describe a patient developing episodic 
exercise-induced intracranial hypertension manifesting as 
status migrainosus years after internal jugular vein (JV) 
obstruction. 
Methods: The clinical and radiological findings are 
described and the probable pathogenesis and treatment 
discussed.
Results: An 18-year-old non-obese male had a motorcycle 
accident resulting in left brachial plexus avulsion and 
asymptomatic left vertebral artery dissection. Seven years 
later, he had prolonged headache episodes, precipitated by 
strenuous sporting activities, fulfilling criteria for status 
migrainosus. Head CT and fundoscopy were normal. 
Lumbar punctures showed severe intracranial hypertension 
(IH >50 cmH2O) during but not after attacks with complete 
headache relief within 20 minutes. Oral acetazolamide 
was unsuccessful. CT venography during an episode 
showed compression of transverse sinuses and cervical 
MR venogram confirmed chronic (likely posttraumatic) 
subocclusion of left JV and stenosis of right JV, most likely 
from central venous catheterization. Because of worsening 
episodes including aphasia, hemiparesis and Cushing 
reflex, right JV stenting was performed. Several in-stent 
thromboses occurred despite antithrombotic treatment, 
causing additional episodes of IH.These resolved under 
quadruple antithrombotic therapy which was tapered over 
3 years, and the patient became asymptomatic under aspirin 
only.
Conclusion: Episodic severe IH in our patient probably 
occurred because of exercise-induced pressure elevation 
in the vena cava, causing decompensation of a borderline 
venous return from bilateral posttraumatic JV obstruction. 
Pathophysiology-based treatment with JV stenting was 
initially complicated by recurrent in-stent thromboses,but 
resolved under quadruple antithrombotic treatment which 
was tapered.
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Clinical picture of Epicrania Fugax:  
a prospective series of 55 cases
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Valladolid, Neurology, Valladolid, Spain, 3hospital Clínico 
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Background and aims: Epicrania fugax (EF) has 
been included in the research appendix of International 
Classification of Headache Disorders, III edition. It is 
defined by brief, recurrent pain attacks, moving forwards 
or backwards across the surface of one hemicranium. We 
aim to analyze clinical characteristics of a series of patients 
attended in an outpatient headache office in a tertiary 
hospital.
Methods: We considered consecutive patients with EF from 
March 2008 to January 2015. We prospectively assessed 
spatial and temporal features of paroxysms, quality and 
intensity of pain, and presence of accompaniments, triggers 
or interictal pain.
Results: 55 patients (40 females, 15 males) out of 3357 
attended during inclusion period (1.6%) were diagnosed 
with EF. Mean age at onset 42.8 ± 17.2 years (range: 18-
84). In 39 cases (70.9%) forward radiation, in 15 (27.3%) 
backward, whilst in 1 (1.8%) paroxysms described both 
trajectories. In forward EF, pain stemmed in occipital (29, 
72.5%) or parietal scalp (9, 22.5%) and ended at eye (22, 
55%) or forehead (12, 30%). When backward EF, pain 
radiated from frontal region (7, 43.7%) or eye (5, 31.2%) to 
occipital (9, 56.2%) or parietal scalp (4, 25%). Pain quality 
was mainly described as electric (50, 90.9%), and intensity 
rated as 6.8±1.8 (3-10). Complete sequence was very 
brief (usually <10 seconds). 8 (14.5%) patients identified 
triggers, commonly neck movements and 19 (34.5%) 
associated autonomic features, mainly lacrimation.
Conclusion: This new series reinforces the proposal of EF 
as a new headache syndrome. Characteristics of forward 
and backward EF were comparable in our series.
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Different type of headache syndromes in 
patients with idiopathic intracranial  
hypertension (IIH)
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Background and aims: Idiopathic Intracranial 
Hypertension (IIH) is a neurologic syndrome characterized 
by elevated intracranial pressure in the absence of 
intracerebral abnormalities or hydrocephalus. The most 
frequent symptom is headache. We aimed to investigate 
different types of headache sydromes that may accompany 
the disease in 57 patients.
Methods: Total of 57 patients who were diagnosed with 
IIH according to modified Dandy Criteria was included in 
the study. Detailed headache history was questioned. The 
patients were also asked to fill in detailed headache forms 
specially prepared to question different headache types.
Results: In the 51.8% of the patients included in the study, 
we observed different headache sydromes accompanying 
or associating with IIH. 33.9% of the patients had 
stabbing headache whereas 12.5% had migraine like-
headache,  7.1% had tension type headache and 5.4% had 
hemicrania continua.
Conclusion: Migraine, tension type and medication 
overuse headaches are known to accompany IIH since long 
time. In our patient group, distinctively from the literature, 
stabbing headache was more common. 
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Reduced baroreflex sensitivity in cluster 
headache patients
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P.J. Jennum4, R. Jensen5
1Copenhagen, 2Frederiksberg Hospital, Clinical Physiology 
and Nuclear Medicine, Frederiksberg, 3Glostrup Hospital, 
Diagnostic Department, clinical physiology and nuclear 
medicine section, Frederiksberg, 4Glostrup - Copenhagen, 
5University of Copenhagen, Neurology, Copenhagen, 
Denmark
Background and aims: Important elements of cluster 
headache (CH) pathophysiology may be seated in the 
posterior hypothalamus. Cranial autonomic features are 
inherent, but involvement of systemic autonomic control 
is still debated.  The aim of this investigation was to 
characterize autonomic function by investigating baroreflex 
sensitivity (BRS) in CH patients.
Methods: 26 CH patients (in bout) and an equal number 
of age-, sex- and BMI-matched controls underwent head-
up tilt table test.  BRS was determined by the sequence 
method. 
Results: Compared to controls, patients exhibited a blunted 
shortening of RR intervals to falls in systolic blood pressure 
(SBP) (14.3 vs. 22.3 ms/mmHg, P<0.05) in the supine 
position. Also, compared to controls, BRS was lower in 
patients having suffered an attack within the past 12 h (12.5 
vs. 22.3 ms/mmHg, P<0.01), opposed to those patients who 
had not (16.0 ms/mmHg, P>0.05). In the tilted position the 
drop in SBP at the carotid sinuses was higher in patients 
who had recently suffered an attack. Despite this they 
exhibited a less marked shortening of RR intervals when 
compared to patients who had been attack free for longer.
Conclusion: CH patients exhibit a blunting of BRS 
which may be affected by the attacks themselves. The 
fast RR interval fluctuations used in this method reflects 
cardiovagal responses, thus the blunted responses are 
suggestive of dysfunction in the parasympathetic division 
of the autonomic nervous system or in the central relay of 
impulses from the baroreceptors.
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Expression of CCR5 on T-cells in  
progressive multifocal 
leukoencephalopathy-associated immune 
reconstitution inflammatory syndrome: 
Rationale for the use of Maraviroc
G. Martin-Blondel1, J. Bauer2, B. Pignolet3, E. Uro-Coste4,  
D. Biotti5, D. Averseng-Peaureaux5, N. Fabre5, H. Dumas6,  
F. Bonneville7, H. Lassmann8, B. Marchou1, R. Liblau9,  
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Background and aims: Therapeutic strategies that 
modulate the deleterious immune response underlying 
progressive multifocal leukoencephalopathy-associated 
immune reconstitution inflammatory syndrome (PML-
IRIS) are warranted. Maraviroc, an antagonist of the CCR5 
chemokine receptor, has been suggested to be beneficial in 
preventing or treating PML-IRIS. We investigated whether 
the molecular target of maraviroc is expressed on T-cells 
circulating and infiltrating PML-IRIS lesions.
Methods: We analyzed brain lesions of 7 patients with in-
flammatory forms of PML, 2 with iatrogenic immunosup-
pression (1 Natalizumab-treated MS patient and 1 patient 
treated for chronic lymphocytic leukemia) and 5 HIV-in-
fected patients. We are furthermore analyzing CCR5 ex-
pression by blood circulating T-cells in nine natalizumab-
treated patients at the onset of PML and of PML-IRIS.
Results: In all cases, histological analysis revealed 
demyelinating lesions and the presence of JC virus-
infected cells, confirming PML. CD8+ T-cells dominate 
in the inflammatory infiltrates. Confocal fluorescence 
staining showed that 93.7±2.2% of the perivascular and 
parenchymal CD8+ T-cells express CCR5. CD4+ T-cells 
and macrophagic/microglial cells also expressed CCR5, 
albeit at weaker levels than CD8+ T-cells. The two non HIV-
infected patients were treated with maraviroc to prevent or 
treat PML-IRIS, with a favorable outcome. Analysis of 
CCR5 expression by circulating CD8+ T-cells is ongoing.
Conclusion: Since the CCR5/CCL5 axis is implicated in 
T-cell activation and in leukocyte trafficking to the brain, 
our results suggest that CCR5 antagonists can mitigate 
the deleterious immune response underlying PML-IRIS, 
deserving further studies.
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infection with mycobacterium bovis in an 
immunocompetent young female
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Case Report: We report the case of a 23-year-old women 
from Morocco with disseminated intracerebral tuberculo-
sis. In November 2013 our pregnant patient suffered from 
an epileptic seizure with aphasia, myoclonia of head and 
right arm and secondary generalization for the first time. 
Further seizures occurred during delivery and in following 
months, EEG was performed and anticonvulsive medica-
tion with valproic acid started, she suffered from ongoing 
seizures. Except repeated gynaecological infections in 
2013 there were no signs of immune deficiency. Neurolo-
gical status and physical examination were without patho-
logical findings disregarding language barrier. Laboratory, 
faecal diagnostic, cerebrospinal fluid and further examina-
tions remained without trend-setting findings. Magnetic re-
sonance imaging of brain revealed multifocal lesions with 
blood-brain barrier disorder and distinct perifocal edema. 
Acid-proof rods could not be proved. We discussed cere-
bral metastasis, sarcoidosis and tuberculosis. Cerebral bi-
opsy verified inflammatory granulomatous process with 
epithelioid cellular histiocytes and Langhans giant cells. 
We started medical treatment with a combination of etham-
butol, rifampicin, isoniazid and pyrazinamid, cortison and 
vitamin B6. Biopsy culture result revealed Mycobacterium 
tuberculosis complex, subspecies M. bovis, as far as we 
know a rare finding. In follow up examination after 6 and 
12 weeks of therapy patient presented with stable disease 
with mild remission of MRI findings, we replaced pyrazi-
namid by fluorochinolone due to agent resistence. What did 
we learn? It is tremendous important to force diagnostic 
steps in order to find the diagnosis. The key to the diagnosis 
in our case and gold standard finally was the culture from 
the cerebral biopsy.
MRI T1 contrast medium
MRI T2 FLAIR dark fluid
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symptoms in Lyme borreliosis patients
S. Cihelková
Charles University Prague, Department of Infectious 
Diseases of 1st Medical Faculty, Prague, Czech Republic
Background and aims: Although a neuropsychiatric 
symptom in Lyme borreliosis (LB) is frequent and may 
be a tool for monitoring and diagnosis of neuroborreliosis, 
the data of prevalence are poor, especially about such 
symptoms as somatization, interpersonal irritability and 
fatique.. The aim of this study was to assess the frequency 
of each symptom common in LB or inflammatory diseases, 
not only psychiatric illnesses and their relationship.
Methods: The 40 consecutive patients with all stages of 
LB, diagnosed at Department of infectious Diseases of 1nd 
Medical Faculty of Charles University in Prague and 30 
healthy controls were included to the study. All patients 
were examined by self-evaluated scales for mood, fatigue 
and personality - BDI II, BAI II, SCL-90, Fatigue MS scale, 
EOD II.A or B, Hamilton depression and anxiety scales. 
Results: The most common symptoms were fatigue and 
abnormal or pathological interpersonal irritability and 
somatization (according SCL score); these symptoms seem 
to be associated with depression (45%) and anxiety (80%) 
as symptoms, not as psychiatric disorders. Interestingly, the 
scare from LB is associated with these symptoms in 87%. It 
is important to take enough time to inform patients.
Conclusion: The study confirmed a results of previous 
study – the symptoms  depresssion and anxiety prevalence. 
Furthermore, the somatization, interpersonal irritability 
and fatique are also important for medical care and next 
investigation.
Disclosure: Nothing to disclose
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Herpes Human Virus-7 (HHV-7) myelitis  
in an HIV-infected patient successfully  
treated with foscarnet
A. Escobar-Villalba1, I. Corral Corral1, P. Pérez Torre1,  
J. Buisan1, M. Rodriguez2, J.C. Galan2, P. Agüero Rabes1, 
E. Viedma-Guiard2, M.M. Kawiorski1, C. Estevez-Fraga2
1Hospital Ramón y Cajal, Neurology, Madrid, Spain,  
2Hospital Ramon y Cajal, Madrid, Spain
Background and aims: HHV7 reactivation has been 
occasionally reported  as a cause of encephalitis or myelitis 
in transplant recipients, but to our knowledge it has never 
been associated with neurological disease in HIV-infected 
patients. We report a case of acute myelitis in an HIV-
infected patient, with sustained HHV-7 DNA amplification 
in cerebrospinal fluid (CSF) and a favourable response to 
foscarnet.  
Case Report: A 40-year-old man with HIV infection 
known for 8 years, was admitted with asymmetric hypoe-
sthesia in legs and paraparesis which progressed along 30 
days. He was receiving treatment with efavirenz, tenofovir, 
emtricitabine (atripla) and his CD4 count was 580/mm3 and 
HIV viral load was undetectable. Magnetic resonance ima-
ging showed a focal central hyperintensity on T2 and STIR 
sequences, on the thoracic spinal cord, with slight enhance-
ment after intravenous gadolinium. CSF contained 4 lym-
phocytes and 19.98mg/dl proteins. All microbiological stu-
dies were negative except for HHV-7 DNA amplification 
in CSF. With a diagnosis of idiopathic transverse myelitis, 
treatment with high-dose intravenous methylprednisolone 
was initiated. However, paraparesis continued worsening, 
and a second CSF obtained twelve days after the first one 
resulted again in HHV-7 amplification.  
Results: The patient was treated with a 2 week course of 
foscarnet, and a rapid neurological improvement was noted. 
After treatment PCR for HHV-7 in CSF was negative. 
Neurological exam was normal one month after treatment 
initiation.
Conclusion: HHV-7 reactivation may cause neurological 
disease in patients with HIV infection. Foscarnet is an 
effective treatment in HHV-7 associated myelitis.
Disclosure: Nothing to disclose
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Unusual neurological immune 
reconstitution syndrome in HIV
P. Holmes1, R. Kulasegaram2
1Guy’s and St Thomas‘ Hospitals, Neurology, London, United 
Kingdom, 2Guys and St Thomas‘ Hospitals, HIV and GU 
Medicine, London, United Kingdom
Background and aims: When started on anti-retroviral 
therapy (ARV), and associated with a decline in plasma 
HIV-RNA and a rise in CD4 count, a subset of patients 
with HIV infection deteriorate clinically due to an 
inflammatory process termed immune reconstitution 
inflammatory syndrome (IRIS). This condition results from 
the restoration of the immune system that upon activation 
can be detrimental to the host. Among the various clinical 
manifestations, central nervous system involvement is 
associated with greater morbidity and mortality. There 
are two versions, a paradoxical one occurring when an 
opportunistic infection, responding to treatment before 
ARV therapy, deteriorates after initiating ARVs and an 
unmasking variant where a disease that was cryptic prior 
to starting ARVs, presents after starting ARVs with florid, 
inflammatory symptoms.
Methods: We present 5 cases of an unusual neurological 
IRIS manifestation that is rare and highlights the importance 
of the clinical history, neuroimaging and adherence 
to ARV. The condition occurs as a result of variable 
compliance with ARV and appears as an HIV encephalitic 
IRIS manifestation due to intermittent documented high 
CSF viraemia. Pathogen-related factors and features of 
the host immune response determine the predisposition to 
neuro-IRIS. MR imaging is unique as shown.
Results: Patients presented with progressive severe 
multifocal neurological symtpoms and signs and as a result 
of severe inflammation and swellling developed decreasing 
levels of consciousness prompting ITU admission and use 
of high dose steroids.
T2-weighted MRI showing diffuse cortical swelling and subcortical 
grey and white matter high signal
T2-weighted MRI showing near complete resolution of the changes 
after steroids and ARV
Conclusion: The condition appears to be that of a rebound 
HIV viral encephalitis. Imaging features are dramatic but 
show near complete resolution after steroids and ARV 
compliance.
Disclosure: Nothing to disclose
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The spectrum of viral CNS infections in 
Southern Germany - demographic, clinical 
and laboratory findings
M. Kaminski, V. Grummel, A. Berthele, B. Hemmer
Klinikum rechts der Isar, Technische Universität München, 
Neurology, Munich, Germany
Background and aims: Viral infections of the central 
nervous system (CNS) are frequently observed in 
Germany. However, no study has systematically addressed 
spectrum of viruses, frequency and seasonal distribution 
causing meningitis and meningoencephalitis/encephalitis. 
Moreover, the impact of specific viral-CNS-infections on 
clinical and laboratory findings is poorly defined.
Methods: Data of 176 adult patients diagnosed 
from 01/2007-06/2014 with viral meningitis and 
meningoencephalitis/encephalitis at our hospital was 
collected by chart review. Analyzed demographic data 
included age, sex and month-of-infection. We studied 
frequency of each detectable virus-group and reviewed 
accordingly laboratory-parameters in cerebrospinal fluid 
(CSF) and serum. In addition, we performed column 
statistics of demographic and clinical data and compared 
laboratory-data of virus-groups.
Results: In our cohort, viral meningitis was caused in 36% 
by enterovirus (EV), 18% by herpes-simplex-virus (HSV), 
13% by varicella-zoster-virus (VZV) and 11% by early-
tick-borne-encephalitis (TBE). Viral meningoencephalitis/
encephalitis was caused in 16% by HSV, 11% by VZV and 
2% by TBE. Mean age was 45y at diagnosis. Incidence of 
VZV and EV caused infections was highest during summer, 
HSV infections showed no seasonal preference. VZV 
meningitis had a bimodal distribution with a peak below 
30y and above 70y. CSF-cell-count, CSF-lactate, albumin-
quotient and serum-CRP were highest in HSV and lowest 
in EV mediated CNS infections.
Conclusion: PCR for HSV, VZV and EV in CSF and TBE 
serology determine the causative virus in over 60% of tested 
patients. EV-infections were most common and show lower 
inflammatory changes in CSF and serum. By contrast HSV-
infections, not showing a seasonal preference, have a higher 
inflammatory response in CSF and serum.
Disclosure: Nothing to disclose
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Detection of human herpesvirus 7 DNA 
in CSF in adult patients with neurological 
disorders
S. Sainz de la Maza1, M.J. López-Martínez1,  
M.M. Kawiorski1, A. De Felipe Mimbrera1,  
A. Alonso-Canovas1, M.J. Rodríguez2, J.C. Galán2,  
I. Corral1
1Hospital Universitario Ramon y Cajal, Neurology, Madrid, 
Spain, 2Hospital Universitario Ramón y Cajal, Microbiology, 
Madrid, Spain
Background and aims: Human herpesvirus type 7 (HHV-
7) possess neurotropism. Neurological manifestations 
associated with HHV-7 have been described in primary 
infection in children, and very occasionaly in viral 
reactivation in immunocompromised patients. However, 
prevalence of HHV-7 DNA amplification in CSF from 
general population is not known, and the role of  HHV-
7 reactivation as a cause in central nervous system (CNS) 
diseases in immunocompetent adults has not yet been 
defined.
Methods: Retrospective analysis of clinical and microbio-
logical features of adults with neurological symptoms who 
underwent lumbar puncture, and had a multiplex polymera-
se chain reaction (PCR) for herpesviruses and enteroviruses 
performed in CSF. 
Results: A total of 251 subjects (121 female) were included. 
Mean age 55 years [15-89]. HHV-7 DNA was detected in 
4/169 CSF samples from patients with diagnosis of non-
infectious neurological disorders (Specificity 0.976), and 
in 1/36 from patients with microbiologically confirmed 
CNS infections (Specificity 0.972). HHV-7 DNA was also 
detected in CSF samples from 6 patients with probable 
CNS infections (compatible clinical syndrome and CSF 
changes) in the absence of causative agent: 4 meningitis, 
1 encephalitis, 1 myelitis. The latter two, with severe 
CNS infections, were treated with Foscarnet, achieving 
improvement of symptoms and disappearance of HHV-7 
DNA in follow-up CSF.
Conclusion: Detection of HHV-7 DNA in CSF as a false 
positive result or asymptomatic reactivation in patients with 
neurological conditions is uncommon. HHV-7 reactivation 
may cause CNS disease in immunocompetent adults. 
Foscarnet seems to be an adequate treatment for HHV-7 
CNS disease
Disclosure: Nothing to disclose
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Neurological manifestations among  
patients with HIV – active tuberculosis 
coinfection, Sudan 2014
M. Taha1, A. M. Hussein2, M. Dafaallah3, M. Alfaki1,  
M.A. Abdelrahim4
1daoud research group, khartoum, Sudan, 2Faculty of 
medicine, University of Khartoum, Department of Neurology, 
khartoum, Sudan, 3daoud research group, 4Khartoum, Sudan
Introduction: At least one-third of the 35.3 million 
people living with HIV worldwide are infected with latent 
tuberculosis. Tuberculosis is the most common presenting 
illness among people living with HIV, including those 
who are taking antiretroviral treatment. There were an 
estimated 1.1 million HIV positive new TB cases globally 
in 2012. Around 75% of these people live in sub-Saharan 
Africa (WHO HIV-Associated TB Facts 2013). Despite its 
great burden, neurological manifestations have not been 
described yet in patients with HIV-active tuberculosis, 
although tuberculosis and HIV have synergistic influence 
on immunity system which may contribute to change in 
prevalence or severity of CNS involvement in patients with 
HIV-active TB coinfection.
Objectives: To study neurological manifestations in 
patients with HIV-active tuberculosis
Methods: A case series study of 58 consecutive patients with 
laboratory confirmed HIV- active tuberculosis coinfection 
attending tertiary hospital for tuberculosis treatment was 
conducted. Data about neurological symptoms and signs 
– conducted by a neurologist- were collected from each 
patient. Patients approval was obtained.
Results: 24% of 58 patients were found to have 
neurological manifestations in clinical assessment. This 
table demonstrates the neurological manifestations and 
their frequency.
Conclusion: the frequency of neurological manifestations 
among patients with HIV-active TB coinfection was found 
to be higher compared to that of patients with HIV only; 
20% (Wadia et al, 2001).
Disclosure: Nothing to disclose
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Longitudinal assessment of frontal  
cognitive impairment in patients with  
motor neuron disease
P.M. Ferraro1, F. Agosta1, E. Canu1, E.G. Spinelli1, N. Riva2, 
M. Copetti3, G. Comi4, M. Filippi1
1San Raffaele Scientific Institute, Vita-Salute San Raffaele 
University, Neuroimaging Research Unit, Milan, Italy, 2San 
Raffaele Hospital, Milan, Italy, 3IRCCS-Ospedale Casa 
Sollievo della Sofferenza, Biostatistics Unit, San Giovanni 
Rotondo, Italy, 4San Raffaele Scientific Institute, Vita-Salute 
San Raffaele University, Department of Neurology, Milan, 
Italy
Background and aims: To test the progression of frontal 
cognitive impairment in patients with motor neuron disease 
(MND).
Methods: 28 non-demented patients with recently 
diagnosed sporadic MND were followed prospectively 
with clinical and neuropsychological evaluation every 3 
and 6 months respectively, for a maximum follow-up of 
24 months. Cognitive assessment was performed using the 
MMSE, verbal fluency tests, and the Test of Attentional 
Performance (TAP). The TAP, which is administered through 
an automated computerized system, permits to investigate 
the whole spectrum of frontal involvement in ALS, 
reducing verbal and/or physical disability. Longitudinal 
linear models were used to assess clinical and cognitive 
variable changes over time and the relationship between 
baseline clinical features and cognitive deterioration.
Results: During follow-up, MND patients experienced 
a progressive worsening of motor disability, with a 
statistically significant decrease over time of the ALSFRSR 
scale score (p<0.001), total MRC (p<0.001) and ALS 
severity scale (p<0.001), and increase of the upper motor 
neuron score (p<0.001). MND patients also showed a 
significant deterioration of the global cognition (p=0.04), 
semantic fluency (p=0.03), and several frontal measures 
(p ranging from <0.001 to 0.04). The TAP showed that 
sustained attention, behavioural control and interference 
tendency significantly decreased over time. The progressive 
cognitive decline was independent of baseline motor 
clinical characteristics.
Conclusion: Longitudinal analyses using computerize-
based, sensitive executive measures revealed a progressive 
cognitive decline which appeared relatively early in the 
course of MND.
Disclosure: Italian Ministry of Health (#RF-2010-
2313220).
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MRI biomarkers in sporadic amyotrophic 
lateral sclerosis: a follow-up study.
G. Grolez1, C. MOREAU1, V. Danel Brunaud1, P. Jissendi2, 
R. Lopes2, A. Monnet2, J. Hodel2, P. Besson2, T. Hamel2,  
C. Delmaire2, L. Defebvre1, D. Devos3
1Department of Movement Disorders, Lille Nord de France 
University, CHU Lille, Lille, France, 2Department of 
Neuroradiology, Lille Nord de France University, CHU Lille, 
Lille, France, 3Lille Nord de France University, CHU Lille, 
Lille, France, Department of Movement Disorders; INSERM 
U1171; Department of Movement Disorders, Lille, France
Background and aims: Amyotrophic lateral sclerosis 
(ALS) is a neurodegenerative disease, which mainly 
affects motor neurons in cerebral cortex and spinal cord. 
Recently, regional iron overload has been demonstrated 
in the medulla of SOD mice model. Iron (measured by 
the R2* sequence of the magnetic resonance imaging, 
MRI) can further enhances free radicals formation by the 
mitochondrial dysfunction. The aim of our study was to 
assess the most sensitive MRI biomarkers of ALS with 
longitudinal analysis.
Methods: 29 ALS patients and 21 healthy volunteers were 
included. 29 patients had a baseline analysis and 19 patients 
had a second MRI examination after 4 months. The R2*, 
volumetry, spectroscopy and diffusion tensor imaging 
(DTI) sequences were analyzed with 3 Teslas brain and 
medulla MRI.
Results: At baseline, diffuse brain atrophy and higher R2*/
volume ratios were observed in patients as compared with 
controls with predominance in motor cortex and bulbar 
area. DTI and spectroscopy results correlated with volume 
assessment, with increased mean diffusivity and decreased 
N-acetyl aspartate/creatine ratios. The follow up showed a 
significant higher R2* value and atrophy in cervical spinal 
cord.
Conclusion: To date, the most sensitive parameter to 
diagnose ALS remains brain atrophy. The most sensitive 
parameters of disease progression were the R2* value and 
the volume of cervical spinal cord. The latter  could be very 
promising as surrogate biomarkers with the resolution of 
technical difficulties.
Disclosure: The authors have no financial disclosures to 
make or potential conflicts of interest to report in relation 
to this investigator-driven study. The study was funded by 
the French Ministery of Health: PHRC (Projet Hospitalier 
Recherche Clinique) grants : Protocol ID: 2008-006842-25.
© 2015 European Journal of Neurology, 22 (Suppl. 1), 120–483
Poster presentation with discussion      141
P1135
Auditory mismatch negativity (MMN) as a 
marker for motor neuron disease
P.M. Iyer1, B. Michels2, B. Nasseroleslami3, E.C. Lalor4,  
O. Hardiman3
1Dublin, Ireland, 2 Trinity College, School of Engineering, 
Dublin 2, Ireland, 3 Trinity College, Trinity Biomedical 
Science Institute,, Dublin 2, Ireland, 4, Trinity College, School 
of Engineering, Dublin 2, Ireland
Background and aims: There is an urgent need to develop 
biomarkers in Amyotrophic Lateral Sclerosis (ALS) as 
it is heterogeneous in phenotype, genotype and disease 
progression and prognosis. We studied whether auditory 
mismatch negativity (MMN) could be used as a marker 
in ALS, using spectral EEG. MMN is the difference 
between EEG responses when a deviant tone is presented 
unexpectedly while listening to standard tones.
Methods: We acquired data from 14 patients with ALS 
(13 spinal onset, 1 bulbar), age ranging between 35 to 81 
years (mean 63) (10 male, 4 female) and 14 age and sex 
matched controls. The patients were within first 18 months 
of diagnosis.
They underwent 128 channel EEG using Biosemi system. 
MMN was acquired while patients viewed a silent movie to 
capture their attention. They were presented with a mixture 
of standard and deviant tones via headphones for 3 blocks 
each lasting for 7 minutes using presentation software for 
the oddball experiment.
The results were analyzed using a custom written software 
in MATLAB and EEGLAB.
Results: MMN in the fronto- central region in scalp was 
twice in value among patients compared to controls. 
(p<0.05)
Conclusion: MMN is a measure of involuntary attention 
shift mediated by anterior insular cortex which is part 
of Salience network. We postulate that increased MMN 
among ALS patients is secondary to altered network pattern 
in ALS which can be used as a marker in ALS.  Analysis 
is ongoing  among  70 ALS patients to assess whether we 
could elicit signature changes among ALS subgroups.
Disclosure: Nothing to disclose
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Clinicopathological findings of 
amyotrophic lateral sclerosis complicated 
with parkinsonism.
Y. Izumi1, H. Sumikura2, K. Fujita1, H. Nodera1, T. Kawarai1, 
Y. Nishida3, F. Udaka4, S. Murayama2, R. Kaji1
1Tokushima University Hospital, Neurology, Tokushima, 
Japan, 2Tokyo Metropolitan Geriatric Hospital and Institute 
of Gerontology, Neuropathology, Tokyo, Japan, 3Itsuki 
Hospital, Neurology, Tokushima, Japan, 4Sumitomo Hospital, 
Neurology, Osaka, Japan
Background and aims: Amyotrophic lateral sclerosis 
(ALS) combined with other clinical features (dementia or 
parkinsonism) is defined as a ALS-Plus syndrome and its 
rarity has limited detailed neuropathological evaluation.
Methods: We collected 5 cases of ALS who experienced 
precedent parkinsonism. All the patients underwent 
a thorough neurological examination as well as brain 
imaging. Four of the patients died of respiratory failure 
and underwent autopsy, and one respiratory bounded case 
underwent skin biopsy.
Results: All patients were without family history 
of neurodegenerative disorders and resistant to anti-
parkinsonism therapies. The average period to death 
or respiratory support was 12 months after the onset of 
ALS. Four autopsy cases revealed the following findings 
consistent with ALS: (1) the corticospinal tracts exhibiting 
bilateral degeneration; (2) loss of spinal anterior horn cells 
and gliosis; (3) sparing of posterior columns, Clarke’s 
columns, intermediate lateral columns, and the Onuf’s 
nucleus, and (4) the presence of Bunina bodies in the lower 
motor neurons and TDP-43-positive neuronal and glial 
cytoplasmic inclusions throughout the central nervous 
system. In addition, two cases revealed Lewy bodies and 
another two revealed tau pathology, which were consistent 
with Parkinson’s disease (PD) and progressive supranuclear 
palsy (PSP), respectively. The finding of skin biopsy 
showed Lewy type α-synucleinopathy, suggesting PD.
Conclusion: We describe rare neuropathological 
combination of ALS and parkinsonism. All patients had 
rapid progression after onset of ALS. Concurrent presence 
of TDP43 plus either α-synuclein or tau in an individual 
might suggest novel pathogenesis of neurodegeneration.  
Disclosure: Nothing to disclose
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Biomarker discovery, safety and  
feasibility of G-CSF compassionate use in 
ALS patients
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A. Schneider5, M. Deppe6, U. Bogdahn1
1University of Regensburg, Neurology, Regensburg, Germany, 
2University of Ulm, Neurology, Ulm, Germany, 3University 
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Background and aims: Granulocyte-colony-stimulating 
factor (G-CSF) is a long-term established and safe 
hematopoietic growth factor that may potentially 
compensate rapid neuronal loss in ALS patients by 
neuroprotection, increased neurogenesis, neural 
differentiation. We initiated long-term compassionate use 
of G-CSF as well as longitudinal follow up of ALS patients 
and potential biomarkers for patient safety.
Methods: 23 ALS patients (15m, 8f, mean ALS-FRS-r at 
start 36.75) were treated with G-CSF plus standard therapy. 
Application modes were individually adapted. Monthly 
visits with ALSFRS-r, clinical chemistry, and bone marrow 
mobilization parameters were performed. Pyramidal tract 
integrity by fractional anisotropy (FA), quantification 
of motor units by improved Motor Unit Number Index 
(i-MUNIX), and functional/differentiation markers for 
stem cells were obtained as biomarkers every 3 months 
during long-term treatment (> 4 yrs.).
Results: Safety and compliance were excellent, G-CSF was 
well tolerated. G-CSF resulted in effective hematopoietic 
stem cell mobilization. Disease progression correlated 
significantly (p<0,0001) with i-MUNIX, and as trend 
with FA. During disease progression patients with lower 
ALS-FRS-r mobilized less monocytes and CD34+38- stem 
cells, but more eosinophils. Colony Forming Units for 
bone marrow stem cell potential were further analyzed. 
In retrospective analysis a significant decrease in ALS 
progression rate and clinical relevant prolongation of 
overall survival of G-CSF patients in comparison to 
the current Pro-ACT database indicates high safety of 
prolonged G-CSF treatment.
Conclusion: Long-term administration of G-CSF in ALS 
patients is safe and feasible. i-MUNIX, FA, and bone 
marrow differentiation parameters are very promising 
biomarkers for ALS treatment development. A prospective 
trial is urgently needed.
Disclosure: Nothing to disclose
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Background and aims: Hirayama disease (HD), also 
referred to as juvenile muscular atrophy of distal upper 
extremity, brachial benign focal amyotrophy, is one of the 
motor neuron disease but it has benign course. Although 
HD is frequently reported in Asia, little is known about 
characteristics of HD in Korea. We analyzed clinical 
feature, electrophysiological and radiologic findings.
Methods: We retrospectively reviewed the medical records 
of patients who were diagnosed Hirayama disease accepted 
according to the proposed criteria (Hirayama et al. 2006).
Results: Total 65 patients were analyzed. The male to 
female ratio was 31.5. Mean age of symptom onset was 
16.97 years. Period of progression was 28.16 months. 
Unilateral involvement was 55 patients (84.6%) and 
bilateral involvement was 10 patients (15.4%). Tremor in 
affective limb was most commonly observed in 30 patients 
(46.2%), fasciculation was observed in 11 (16.9%) and 
cold paresis was noted in 7 (10.8%). Muscle atrophy was 
predominantly hand muscles (96.9%) and forearm muscles 
(35.4%). The Electrophysiological findings revealed that 
low compound muscle action potential (CMAP) was found 
in the median nerve and ulnar nerves in affective limbs. 
Denervation potentials of electromyography (EMG) were 
commonly noted in distal muscles. Interestingly, among 
55 patients who performed EMG in unaffected arm, 22 
patients (40%) had abnormality of EMG. The cervical 
MRI in neutral position was shown that focal cord atrophy 
(81.5%), flattening of cervical cord (13.8%) and abnormal 
curvature (7.7%).
Conclusion: This is the first and the largest study of 
Hirayama disease in Korea. 
Disclosure: Nothing to disclose
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MRI-based cerebellar volume  
measurements as a biomarker of  
disease progression of spinocerebellar  
degeneration
F. Maki, D. Hara, S. Tanaka, R. Sasaki, Y. Hasegawa
St.Marianna University School of Medicine, Department of 
Internal Medicine Division of Neurology, Kawasaki, Japan
Background and aims: We aimed to explore a suitable 
method to normalize cerebellar volumes measured by MRI 
for the evaluation of disease progression of spinocerebellar 
degeneration (SCD).
Methods: We measured cerebellar volumes using MRI 
in 12 SCD patients (MSA; 3, CCA; 2, SCA1; 1, SCA3; 
3, SCA6; 2, SCA unknown; 1) and 30 controls. All 
measurements were performed with commercially available 
software TRI/3D-VOL (RATOC System Engineering, CO.) 
by means of automatic extraction of cerebellar area with 
linear interpolation of the slices encompassing the whole 
cerebellum. Cerebellar volumes were normalized either 
by anteroposterior diameter of cranium or infratentorial 
cranial volume. We examined inter-rater variability and 
test-retest reliability using a dataset obtained from controls 
and compared correlation coefficients between ICARS and 
cerebellar volumes normalized by two different methods.
Results: In control subjects, body height, body weight, 
cranial anteroposterior diameter and infratentorial cranial 
volume were significantly correlated with cerebellar 
volumes. Age was not associated with cerebellar volume. 
Mean cerebellar volumes in male and female were 123.5ml 
and 108.7ml, respectively (p=0.01). Inter-rater variability 
was 0.986 and test-retest reliability was 0.988. Effects of 
volume correction methods using cranial anteroposterior 
diameter and infratentorial cranial volume were similar. In 
SCD patients, correlation coefficients between cerebellar 
volumes corrected by these two methods and total scores of 
ICARS, were also similar, 0.294 (p=0.000), the other was 
0.298 (p=0.000).
Conclusion: MRI-based cerebellar volume corrected 
by the cranial anteroposterior diameter appeared to be a 
simple, consistent, reproducible and reliable biomarker of 
disease progression of SCD.
Disclosure: Nothing to disclose
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Evaluation of efficacy of opicapone in 
Parkinson’s disease patients with motor 
fluctuations: phase III, randomized,  
double-blind, placebo and active- 
controlled study (BIPARK I)
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T. Nunes3, J.F. Rocha3, P. Soares-da-silva3
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Background and aims: Opicapone (OPC) is a novel once-
daily and long-acting peripheral COMT-inhibitor under 
investigation for Parkinson’s disease (PD). The aim of this 
study was to investigate the efficacy and safety of OPC 
(5, 25 and 50 mg) compared with entacapone (ENT) and 
placebo, in levodopa-treated patients with PD and motor 
fluctuations.
Methods: This was a multinational, 14 to 15-week, double-
blind, placebo- and active-controlled study. The primary 
efficacy variable was the change from baseline in absolute 
OFF-time based on patient diaries. The key secondary 
efficacy endpoint was the proportion of OFF- and ON-
responders (≥ 1 hour improvement). Safety was assessed 
by adverse events (AEs), laboratory, vital-signs, ECG, 
physical and neurological examinations.
Results: 600 patients were randomized to placebo 
(N=121), 5mg-OPC (N=122), 25mg-OPC (N=119), 50mg-
OPC (N=116) or ENT (N=122). Both 50mg-OPC and ENT 
significantly decreased the OFF-time (1.95 h [p=0.0015] 
50mg-OPC and -1.61 h [p=0.0141] ENT vs. -0.93 h 
placebo) and increased the ON-time without troublesome 
dyskinesia (1.82 h [p=0.0016] 50mg-OPC and 1.57 h 
[p=0.0150] ENT vs. 0.78 h placebo). Significantly more 
patients receiving 25mg- or 50mg-OPC achieved the OFF-
time responder endpoint (60.3% [p=0.0464] 25mg-OPC 
and 69.6% [p=0.0011] 50mg-OPC vs. 47.5% placebo), 
while 5mg-OPC and ENT missed statistical significance. A 
significantly higher proportion of ON-responders was also 
found for the 50mg-OPC group (65.2% [p=0.0028]). OPC 
and ENT were generally safe and well tolerated.
Conclusion: OPC, particularly 50mg-OPC, was effective 
in reducing OFF-time in PD patients with a favourable 
profile compared to ENT.
Disclosure: Nothing to disclose
P1142
Pooled efficacy analysis of opicapone as 
adjunctive therapy to levodopa in patients 
with Parkinson’s disease and motor  
fluctuations.
J. Ferreira1, A. Lees2, A. Santos3, N. Lopes3, R. Costa3, 
C. Oliveira3, R. Pinto3, T. Nunes3, J.F. Rocha3,  
P. Soares-da-silva3
1Instituto de Medicina Molecular, Neurological Clinical 
Research Unit, Lisbon, Portugal, 2National Hospital for 
Neurology and Neurosurgery, London, United Kingdom, 
3BIAL – Portela & Cª – S.A., Dept. R&D, S. Mamede do 
Coronado, Portugal
Background and aims: The objective of this analysis was 
to evaluate the efficacy of opicapone (OPC) in patients with 
Parkinson’s disease and motor fluctuations across phase III 
studies.
Methods: Patient-level data of matching treatment arms of 
two multicentre, 14 to 15-week, double-blind, randomised, 
placebo- and active-controlled studies (BIPARK I and II) 
was integrated (placebo, 25mg-OPC and 50mg-OPC). The 
studies had similar designs and measurement instruments. 
The primary efficacy variable was the change from baseline 
in absolute OFF-time based on patient’s diaries. Key 
secondary measure was the OFF- and ON-time responder 
rates (≥ 1 hour).
Results: 758 subjects were included in the pooled efficacy 
set (n=255 placebo, n=241 25mg-OPC, n=262 50mg-OPC). 
Either 25mg- or 50mg-OPC significantly reduced OFF-
time (1.56 h [p=0.0106] 25mg-OPC and -1.94 h [p<0.0001] 
50mg-OPC vs. -0.97 h placebo) and increased the ON-time 
without troublesome dyskinesia (1.43 h [p=0.0083] 25mg-
OPC and 1.80 h [p<0.0001] 50mg-OPC vs. 0.72 h placebo). 
Significantly more patients receiving 25mg- and 50mg-
OPC achieved the OFF- and ON-time responders endpoint 
(60.2% to 64.6% [p<0.005]).
Conclusion: Treatment with OPC is effective in reducing 
OFF-time and increasing ON-time without troublesome 
dyskinesia.
Disclosure: Nothing to disclose
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Molecular imaging and psychometric 
predictors of cognitive outcome in 
Parkinson’s disease: evidences from a 
5-year follow-up study
D. Frosini1, E. Unti1, C. Pagni1, M. Giuntini1, E. Del Prete1, 
D. Volterrani2, U. Bonuccelli1, R. Ceravolo1
1University of Pisa, Department of Clinical and Experimental 
Medicine, Pisa, Italy, 2University of Pisa, Department of 
Translational Research and New Technologies in Medicine 
and Surgery, Pisa, Italy
Background and aims: Dopamine transporter (DAT) 
imaging is a diagnostic tool for Parkinson’s Disease (PD) 
but it is also suggested as prognostic marker for motor and 
non motor outcomes. The ability of coping intersecting 
pentagons is considered a predictor of cognitive decline. 
We aimed to evaluate the prognostic role of DAT imaging 
and pentagon copy for cognitive outcome in a cohort of PD 
patients with a follow-up of five years.    
Methods: 95 de novo PD patients underwent 123I-FP-CIT 
SPECT at baseline. Striatal indices were calculated with 
Basal Ganglia Matching Tool. All patients were assessed 
with UPDRS III for motor impairment and MMSE for 
cognition at baseline and each year for the five years of 
follow-up. Occurrence of dementia during the follow-up 
was recorded. 
Results: During the follow-up 18% of patients developed 
dementia. Patients who developed dementia had lower 
striatal binding at baseline (p<0.01). The frequency of 
impairment in pentagon copy was significantly higher in PD 
who developed dementia (χ2=9.9,p<0.001). Binary logistic 
regression analysis was performed. The model contained 
two independent variables (striatal uptake and pentagon 
copy) was statistically significant (χ2=20.7,p<0.001) and 
as whole it was able to predict the 35% of the variance 
in cognitive outcome. Both variables independently 
contributed to the model with an Odd Ratio respectively of 
15.9 and 4.9 for low striatal baseline uptake and pentagon 
copy impairment. 
Conclusion: Our findings indicate that DAT imaging 
performed at baseline and visuospatial and constructional 
ability as evaluated by pentagon copy intersection test are 
associated with cognitive outcome in PD patients.
Disclosure: Nothing to disclose
P1144
Advanced neuroimaging techniques to 
assess brain structural abnormalities in 
writer’s cramp primary dystonia
S. Galantucci1, F. Agosta1, L. Sarro1, A. Tomic2, P. Valsasina3, 
M. Svetel2, A. Sodero1, N.D. Kresojevic2, V.S. Kostic2,  
M. Filippi1
1San Raffaele Scientific Institute, Vita-Salute San Raffaele 
University, Neuroimaging Research Unit, Milan, Italy, 
2University of Belgrade, Clinic of Neurology, Faculty of 
Medicine, Belgrade, Serbia, 3San Raffaele Scientific Institute, 
Vita-Salute San Raffaele University, 1Neuroimaging Research 
Unit, Milan, Italy
Background and aims: To investigate cortical and 
subcortical gray matter (GM) and white matter (WM) 
patterns of alterations characterizing Writer’s Cramp (WC) 
primary dystonia.
Methods: T1-weighted and diffusion tensor (DT) MRI 
scans were obtained from 19 WC patients and 30 controls. 
Surface-based morphometry analysis was used to assess 
cortical measures. FMRIB-FIRST tool in FSL was used to 
segment basal ganglia on 3D T1-weighted images; then, 
volumes and DT MRI metrics were measured for each GM 
nucleus. TBSS was used to perform a voxel-wise analysis 
of DT MRI metrics. The effects of disease severity were 
examined by correlating GM and WM metrics with disease 
duration and WC severity scales.
Results: Increases in cortical area and volume were found 
bilaterally in paracentral and postcentral gyri as well as 
supramarginal and temporo-occipital gyri in WC patients 
compared with controls. No cortical thickness abnormalities 
were found. Relative to controls, WC patients did not show 
significant differences in the basal ganglia volumes, while 
they showed altered DT MRI metrics of the right caudate, 
pallidum and putamen. WM microstructural analysis in 
WC showed increased diffusivities of the corpus callosum 
and thalamic radiations bilaterally, and right corticospinal 
tracts and major associative tracts. WCRS score correlated 
with WM damage of the corpus callosum.
Conclusion: These findings corroborate the hypothesis 
that WC dystonia is a complex disturbance which results 
from the involvement of both sensorimotor and associative 
neural circuits. Advanced MRI techniques may give insight 
in the pathophysiology of this multifaceted disease.
Disclosure: Nothing to disclose
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Spasmodic dysphonia primary dystonia is 
associated with cortical and subcortical 
alterations: a multimodal imaging study
S. Galantucci1, F. Agosta1, L. Sarro1, A. Tomic2, P. Valsasina3, 
M. Svetel2, A. Sodero1, N.D. Kresojevic2, V.S. Kostic2,  
M. Filippi1
1San Raffaele Scientific Institute, Vita-Salute San Raffaele 
University, Neuroimaging Research Unit, Milan, Italy, 
2University of Belgrade, Clinic of Neurology, Faculty of 
Medicine, Belgrade, Serbia, 3San Raffaele Scientific Institute, 
Vita-Salute San Raffaele University, 1Neuroimaging Research 
Unit, Milan, Italy
Background and aims: To assess the patterns of cortical 
and subcortical gray matter (GM) and white matter (WM) 
damage in patients with Spasmodic Dysphonia (SD) 
primary focal dystonia.
Methods: T1-weighted and diffusion tensor (DT) MRI 
scans were obtained from 13 SD patients and 30 controls. 
TBSS was applied to compare DT MRI indices (i.e., mean 
[MD], radial [radD] and axial diffusivities, and fractional 
anisotropy [FA]) between groups on a voxel-by-voxel 
basis. Cortical measures were analyzed using surface-
based morphometry. FMRIB-FIRST tool in FSL was used 
to segment basal ganglia on T1-weighted images, and 
volumes and DT MRI metrics of GM nuclei were measured.
Results: Compared with controls, SD patients showed 
increased MD, radD and decreased FA of the corpus 
callosum and major WM tracts, mainly in the right 
hemisphere. Cortical surface analysis showed that SD 
patients compared to controls had cortical volume increase 
of the left postcentral, supramarginal and fusiform gyri, 
while a widespread cortical volume and area decrease 
was found in the right hemisphere, involving pre- and 
postcentral gyri and frontal and parietal lobes. SD patients 
compared to controls did not show significant differences 
in the basal ganglia volumes, while altered DT MRI metrics 
were found in right caudate, pallidum and putamen.
Conclusion: Structural alterations in SD patients seem to 
involve both GM and WM, with different patterns in right 
and left hemisphere. Such changes may suggest a complex 
network disorder underlying the pathophysiology of the 
disease. Advanced neuroimaging studies may give further 
insight into the understanding of this complex disorder.
Disclosure: Nothing to disclose
P1146
Clinical phenotype and genotype of 
spinocerebellar ataxia type 3 in a Yemenite 
Jewish subpopulation
R. Zaltzman1, R. Sharony2, C. Klein1, C. Gordon1
1Meir Medical Center, Neurology, Kfar Saba, Israel, 2Meir 
Medical Center, Genetics, Kfar Saba, Israel
Background and aims: Spinocerebellar ataxia type 3 
(SCA-3) has been reported in many ethnic backgrounds 
with at least four clinical phenotypes. Our objective was to 
delineate the clinical phenotype and genotype of Yemenite 
Jewish SCA-3 patients living in Israel.
Methods: Clinical and family pedigrees data of 125 
Yemenite Jewish SCA3 patients were collected in our 
Machado-Joseph Disease Out-patient Clinic. All examined 
patients underwent a detailed neurological and bedside 
vestibular examination. For genetic testing, CAG repeats 
size of the ATXN3 gene was measured, and patients with 
expanded CAG repeats >44 were diagnosed genetically as 
having SCA-3.
Results: We were able to associate most of our 125 patients 
into 17 families. Mean age of disease onset (AO) was 44 
years.  The most common clinical features were gait, truncal 
and limb ataxia, dysarthria. Vestibulo-Ocular Reflex (VOR) 
loss was found in 90% of the patients. The mean number 
of CAG repeats in the ATXN3 gene of the diseased allele 
was 67 (range 55 to 76). AO was inversely correlated to 
the number of CAG repeats (r=-0.7) and was significantly 
earlier among male patients. Though no genetic anticipation 
was found, offspring AO was significantly earlier than AO 
of their parents. In addition, paternal offspring expressed 
the disease significantly earlier than maternal offspring.
Conclusion: VOR deficit detected on bedside examination 
should be added as part of the phenotype of Yemenite 
Jewish SCA-3 patients. Our clinical genetic findings are in 
partial agreement with other SCA-3 population studies and 
are relevant in patients‘ management and design of further 
studies.
Disclosure: Nothing to disclose
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Genetic and phenotypic characteristics  
of Hungarian patients with 
Neurodegeneration with Brain Iron  
Accumulation (NBIA)
Z. Grosz1, R. Bencsik2, A. Lengyel2, A. Gal2, V. Reményi3,  
G. Tamas1, P. Klivényi4, M.J. Molnár2, B. Kalman5, P. Ács5
1Budapest, Hungary, 2Genomic Medicine and Rare Disorders, 
Budapest, Hungary, 3Institute of Genomic Medicine and 
Rare Disorders, Budapest, Hungary, 4University of Szeged, 
Department of Neurology, Szeged, Hungary, 5University of 
Pécs, Pécs, Hungary
Background and aims: NBIA is a neurodegenerative 
disease causing progressive movement disorder. In the past 
decade it underwent a great deal of change and became a 
dynamically developing field of the neurodegenerative 
disorders. Due to several genetic alteration have been found 
classification had to be laid on new bases, and still many 
expected to be on the way. Symptoms may vary on a wild 
spectra even in the same subgroup of NBIA. The factors 
that influence disease severity and rate of progression are 
unknown. 
Methods: Patients with movement disorders and MR signs 
of distinct iron deposition were tested to the whole coding 
regions of PANK2, PLA2G6, MPAN and CP genes by 
direct Sanger sequencing. Copy number variations were 
tested by MLPA. Detected mutations were analyzed by 
Polyphen2, SIFT, Mutation Assessor, LRT softwares.
Results: Pathogenic mutations were detected 17 out of 
36 NBIA patients. 37.5% of them were MPAN mutations, 
which is higher proportion than reported in the literature. 
Others were PANK2 (5 patients), ceruloplazmin (3 patients) 
and PLA2G6 (3 patients) gene mutations. Some subgroups 
have hallmark features but clinical spectra varies on a broad 
spectrum between patients even in the same subgroup.
Conclusion: In Hungary MPAN mutations are the most 
common. Even in mild cases with extrapyramidal symptoms 
suspicious to NBIA genetic testing should be considered.
Disclosure: The study was supported by the National Brain 
Research Program.
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Peripheral neuropathy in Parkinson’s  
disease: an in vivo confocal microscopy 
study
L. Vieira1, R. Anjos1, A. De Sousa2, N. Silva1, A.L. Basílio1, 
V. Santos Maduro1, N. Alves1, P. Candelária1
1Centro Hospitalar de Lisboa Central, Ophthalmology, 
Lisbon, Portugal, 2Centro Hospitalar de Lisboa Central, 
Neurology, Lisbon, Portugal
Background and aims: Peripheral neuropathy (PN) has 
been described in patients with Parkinson’s disease (PD) 
treated with dopaminergic therapy. Corneal confocal 
microscopy (CCM) provides in-vivo imaging of corneal 
nerve fibers and has been used to analyze nerves alterations 
in a variety of ocular diseases, after corneal surgery and in 
systemic diseases, like diabetes. The purpose of our study is 
to analyze corneal sensation and whether CCM can detect 
alterations in corneal nerve morphology in patients with 
PD.
Methods: A prospective case-control study was conducted 
in ten patients with PD (under long-term dopaminergic 
medication) and ten age and sex-matched healthy 
subjects. Patients underwent neurological and complete 
ophthalmological evaluation. Corneal sensitivity testing 
was performed with a Cochet-Bonnet esthesiometer and 
corneal sub-basal nerve morphology assessment with 
CCM (Heidelberg Retina Tomograph II/Rostock Cornea 
Module).
Results: Patients with PD had decreased corneal sensation 
in comparison with control group. Corneal nerve fiber 
morphology differed between the groups: PD patients had 
lower nerve fiber density, nerve fiber length and nerve 
branch density and higher nerve tortuosity comparatively 
to healthy subjects (p<0.05).
Conclusion: As far as we know, this is the first study to 
detect corneal sub-basal nerve changes in patients with PD. 
CCM may be used to detect signs of PN and follow patients 
doing dopaminergic therapy.
Disclosure: Nothing to disclose
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Are magnetic resonance imaging features 
of the nigrostriatal system biomarkers for 
Parkinson’s disease?
L. Hopes1, G. Grolez1, C. Moreau1, R. Lopes2,  
G. Rychewaert1, N. Carriere1, F. Auger3, C. Laloux4,  
M. Petrault4, J.-C. Devedjian4, M.M.P.R. Bordet5,  
L. Defebvre6, P. Jissendi2, C. Delmaire2, D. Devos6
1Department of Movement Disorders and Neurology, Lille 
University Hospital, Lille University, Lille, France, Lille, 
France, 2Department of Neuroradiology, Lille Nord de France 
University, CHU Lille, Lille, France, Lille, France, 3IMPRT, 
Plateforme d’imagerie du vivant, Université de Lille 2, Lille, 
France, 4Lille University, Lille, France, 5INSERM U1171, 
Faculty of Medicine, Lille University, Lille, France, Lille, 
France, 6Lille, France
Background and aims: Magnetic resonance imaging 
(MRI) can be used to identify biomarkers in Parkinson’s 
disease (PD); higher R2* values reflect iron overload and 
thus high levels of oxidative stress, whereas volume and/or 
shape changes reflect neuronal death. We sought to assess 
iron overload in the nigrostriatal system and characterize its 
relationship with focal and overall atrophy of the striatum 
in the pivotal stages of PD.
Methods: 20 control participants and 70 PD patients at 
different disease stages (untreated de novo patients, treated 
early-stage patients and advanced-stage patients with 
L-dopa-related motor complications) were included in the 
study. We determined the R2* values in the substantia nigra 
(SN), putamen and caudate nucleus, together with striatal 
volume and shape analysis. We also measured R2* in a 
MPTP mouse model and two years later in the early-stage 
PD patients.
Results: The R2* values in the SN, putamen and caudate 
nucleus were significantly higher in de novo PD patients 
than in controls. Early-stage patients displayed significantly 
higher R2* values in the SN (with changes in striatal 
shape), relative to de novo patients. Measurements after a 
two-year follow-up in patients and characterization of the 
acute MPTP mouse model confirmed that R2* changed 
rapidly with disease progression. Advanced-stage patients 
displayed significant atrophy of the putamen and caudate 
nucleus, relative to earlier disease stages.
Conclusion: Each pivotal stage in PD appears to 
be characterized by putative MRI biomarkers in the 
nigrostriatal region: iron overload at the de novo stage, 
striatal shape changes at early-stage disease and generalized 
striatal atrophy at advanced disease.
Disclosure: Nothing to disclose
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Correlation between MRI-based cerebellar 
volume and severity of ataxia as evaluated 
by ICARS in subtypes of spinocerebellar 
degeneration.
D. Hara, S. Tanaka, F. Maki, R. Sasaki, Y. Hasegawa
St.Marianna University School of Medicine, Department of 
Internal Medicine Division of Neurology, Kawasaki, Japan
Background and aims: Progression of clinical symptoms 
and cerebellar atrophy may vary among subtypes of 
spinocerebellar degeneration (SCD) and multiple system 
atrophy (MSA).To explore a sensitive biomarker for 
predicting disease progression in individual patients with 
SCD and MSA, we investigated correlations between MRI-
based cerebellar volume and the International Cooperative 
Ataxia Rating Scale (ICARS) among different clinical 
subtypes on a cross-sectional basis.
Methods: MRI-based cerebellar volume and ICARS score 
were evaluated in 52 SCD patients (CCA:18, SCA1 :3, 
SCA2 :3, SCA3: 7, SCA6 :13, SCA31:2 unknown type: 6) 
and 34 MSA patients. Cerebellar volumes were measured by 
TRI/3D-VOL (RATOC System Engineering Co) software 
using DICOM data. For the statistical analysis, volume 
index (Vdx) was used, which was a cerebellar volume 
normalized by anteroposterior diameter of cranium.
Results: Significant correlation between ICRAS total 
score and Vdx was observed in all disease subtypes (Y=-
0.002X + 0.016, Spearman’s Ro=-0.322, p=0.000). ICARS 
domain I and II were also significantly correlated with 
Vdx (Ro=-0.36 [p=0.000] and Ro=-0.214 [p=0.003]), but 
domain III and IV were not. Correlation coefficient varied 
among patients with different subtype, Ro=0.632 (p=0.000) 
in MSA, Ro=0.545 (p=0.005) in SCA6. Significantly 
correlation was not observed in SCA (1,2,3,31, other) and 
CCA.
Conclusion: In SCD patients  ICARS total score, ICARS 
domain I and II were significantly correlated with cerebellar 
volume normalized by anteroposterior diameter of cranium, 
especially in patients with MSA and SCA6. 
Disclosure: Nothing to disclose
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The state of the sensory afferentation in 
patients with writer’s cramp
V. Hleb, S. A. Likhachev, G. Zabrodzets, T. Charnukha
Minsk, Belarus
Background and aims: To evaluate the state of the sensory 
afferentation in patients with writer’s cramp (WC).
Methods or Materials or Case Report: Somatosensory 
evoked potentials were recorded using the diagnostic 
complex VikingSelect, Nicolet (USA). We  studied 42 
patients with WC (age  38.5±4.6 years, duration of disease 
- 5.3±0.64 years, the ratio of men and women – 1.36:1, the 
dominant hand was the right hand) and control group of 30 
healthy volunteers (age  38.5±4.6 years, the ratio of men 
and women – 1,36:1, the dominant hand was the right hand) 
(p>0.05). We investigated the variation of the peak-to-peak 
amplitude N20/P24, peak-to-peak latency N13/P20 and 
differences of these parameters between the right and left 
hands in patients with WC.
Results: The value of the peak-to-peak amplitude N20/P24 
at C3’/C4’ was 1,73 [0.20; 2.29] (median [25%; 75%]) in 
the study group and 2.12 [1.19; 3.94] in the control group, 
decrease in the peak-to-peak amplitude was statistically 
significant  (р=0.035). There was no significant difference 
in peak-to-peak latency N13/P20 in patients with WC 
compared with the control group (P>0.05) and  in the 
amplitude N20/P24, latency N13/P20 in the right and left 
hands in patients with WC and control (P>0.05).
Conclusion: These results support the view that 
somatosensory evoked potentials can be used to investigate 
the dysfunction of the sensory afferentation in patients 
with WC. The present study shows that the WC is 
accompanied not only by the motor dysfunction, but also 
by the dysfunction of the sensory afferentation according to 
somatosensory evoked potentials.
Disclosure: Nothing to disclose
P1152
Abstract cancelled
150      Poster presentation with discussion
© 2015 European Journal of Neurology, 22 (Suppl. 1), 120–483
P1153
Neurodegeneration with Brain Iron  
Accumulation type I: clinical, genetic, 
radiographic delineation and impact on 
quality of life
J. Jesus Ribeiro, M. Sousa, M. Tábuas-Pereira, M. Baptista,  
F.V. Moreira, C. Januário
Centro Hospitalar e Universitário de  Coimbra, Coimbra, 
Portugal
Background and aims: Neurodegeneration with brain iron 
accumulation (NBIA) type I is one of the major subtypes 
of a group of disorders characterized by basal ganglia iron 
deposition.The development of new techniques of genetic 
sequencing and neuroimaging allows to delineate the 
different phenotypes of NBIA type I and it is essential to 
establish the impact on the quality of life in such patients.
Methods: 9 patients with clinical features consistent with 
NBIA type I, evaluated with Fahn-Marsden Dystonia 
Rating scale (FMDRS), underwent genetic testing and 
performed magnetic resonance imaging (MRI). Quality of 
life was assessed with Parkinson’s Disease Questionnaire 
(PDQ-39).
Results: 80% of our patients had late-onset disease (mean 
age 20 years ± 2.4). The most common presenting sign was 
dystonia, mainly blepharospasm. We obtained a Pearson 
correlation of 0.893 (p = 0.003) between total scores of 
FMDRS and PDQ-39. All patients had mutations in the 
gene encoding pantothenate kinase 2 (PANK2), 63% in 
homozygosity. 8 patients showed the sign „eye of the tiger“ 
on MRI but one of them, homozygous for a PANK2 gene 
mutation, did not present this typical sign even later during 
the course of the disease.
Conclusion: Dystonia was the most common 
extrapyramidal feature. There was a strong correlation 
between the degree of dystonia and impact on quality of 
life. The missense mutation more frequently detected was 
c.1070G>C (p.Arg357Pro), common in the Portuguese 
population. Unlike several published reports, the “eye of 
the tiger” sign did not present an absolute correlation with 
PANK2 mutations.
Disclosure: Nothing to disclose
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Decreased cerebrospinal fluid levels 
of chromogranin A in early stages of 
Parkinson’s disease may predict earlier 
development of orthostatic hypotension
M. Kaiserova1, H. Prikrylova Vranova1, J. Galuszka2,  
D. Stejskal3, K. Mensikova1, J. Zapletalova4, J. Mares1,  
P. Kanovsky1
1Faculty of Medicine and Dentistry, Palacky University and 
University Hospital, Department of Neurology, Olomouc, 
Czech Republic, 2Faculty of Medicine and Dentistry, Palacky 
University and University Hospital, Department of Internal 
Medicine I - Cardiology, Olomouc, Czech Republic, 3Central 
Moravian Hospital County Inc., Department of Laboratory 
Medicine and Department of Medicine, Prostejov, Czech 
Republic, 4Faculty of Medicine and Dentistry, Palacky 
University and University Hospital, Department of Medical 
Biophysics, Olomouc, Czech Republic
Background and aims: Orthostatic hypotension (OH) in 
Parkinson’s disease (PD) is probably caused by pronounced 
vasomotor and cardiac sympathetic dysfunction. CgA is 
co-released from vesicles together with catecholamine 
hormones and is frequently localized within neurons of the 
rostral ventrolateral medulla oblongata (RVLM). About 
two-thirds of RVLM neurons express a catecholaminergic 
phenotype (C1 cells). These cells are critical for the full 
expression of sympathoexcitatory responses generated 
by the RVLM. There is a selective loss of C1 adrenergic 
neurons in PD patients. The aim of the study was to 
test the hypothesis of an association between the CSF 
chromogranin A (CgA) level and blood pressure changes 
during the upright position on a tilt table.
Methods: 20 L-DOPA-naïve patients in the early stage 
of PD and twenty controls were involved. All patients 
underwent CSF examination, head-up tilt table test and 
electromyography of the lower limbs.
Results: CSF CgA levels were significantly lower in 
the patients with PD than in the controls (median 86.0 
vs. 141.0, P = 0.001). There was a significantly positive 
correlation between the CSF CgA level and diastolic blood 
pressure change (Pearson correlation 0.717; Sig (2-tailed) 
0.0004). The CSF CgA levels were lower in patients with 
OH compared to patients without OH (median 52 vs. 121.6; 
P = 0.002).
Conclusion: This study may help to clarify the mechanism 
of orthostatic dysregulation in PD patients. Decreased 
CSF CgA level may indicate an increased risk for the 
development of orthostatic hypotension in the earlier stages 
of PD.
Disclosure: This study was supported by the grant projects 
IGA MZ CR NT-12221, IGA_LF_2014_018
© 2015 European Journal of Neurology, 22 (Suppl. 1), 120–483
Poster presentation with discussion      151
P1155
Functional (psychogenic) movement  
disorders of the eyes, face, and tongue.
D. Kaski1, A. Bronstein1, M. Edwards2, J. Stone3
1Imperial College London, London, United Kingdom, 
2Institute of Neurology, London, United Kingdom, 3University 
of Edinburgh, Edinburgh, United Kingdom
Background and aims: Functional (psychogenic) 
neuro logical symptoms are commonly encountered in 
neurological practice. Eye, face and tongue movement 
disorders are a frequent but perhaps under-recognized 
feature of patients with functional symptoms. 
Methods: A literature and personal database  review of 
the common symptoms and signs of cranial functional 
movements with a focus on the eyes (convergence spasm, 
voluntary nystagmus, convergence paralysis, and functional 
limitation of gaze), face and tongue (eyelid closure, mouth 
deviation, platysma contraction, and tongue deviation).    
Results: We describe the common symptoms and signs 
of functional movement disorders affecting the eyes, face, 
and tongue. In functional eye movement disorders ocular 
movements may be normal during the casual examination, 
becoming abnormal when the eyes are formally assessed. 
Several distinctive features point towards a functional facial 
movement disorder; for example, platysma is commonly 
contracted which leads to the corner of the mouth being 
pulled down on one side. This is why this particular 
symptom is commonly misattributed to stroke.      
Conclusion: Identification of a functional eye and facial 
movement disorder is aided by looking for positive 
features in the examination, and in particular the casual 
examination. Failure to correctly classify and diagnose 
functional disorders may lead to significant iatrogenic 
damage, perpetuate illness beliefs and deny the patient the 
appropriate treatment.  
Disclosure: Nothing to disclose
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Assessment of the quality of life of 




Background and aims: Objective: to assess the quality of 
life of caretakers who looked after patients with PD and to 
identify factors influencing negatively on their lives.
Methods: We consecutively examined 50 pairs of PD 
patients and their caretakers. Caregiver Burden Inventory 
(CBI) was used to assess the burden of PD on the caretakers. 
To assess the influence of PD on the caretakers we used: 
the United Parkinson’s Disease Rating Scale (UPDRS), the 
Hoehn and Yahr Scale (H-Y Scale), the Activity of Daily 
Living Scale (ADL), the Parkinson’s Disease Question-
naire (PDQ-39), the Wakefield Depression Rating Scale 
(WDRS), the Montreal Cognitive Assessment (MoCA) and 
the Mini-Mental State Examination (MMSE).
Results: According to the data of investigations, ADL and 
PDQ-39 (P=0.001), as well as the age of the caretakers 
(40.5±4.2 years, P=0.002) were the main predictors of CBI. 
According to WDRS, 54% of caretakers has depression. 
33% and 26% of patients had cognitive dysfunctions in 
MMSE and MoCA, respectively. 
Conclusion: Many factors might comprehensively affect 
the burden of PD on caretakers of the patients. Attention 
needs to be given to the early identification of factors that 
generating stress on caretakers in order to improve their 
quality of life.
Disclosure: Nothing to disclose
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The eff﻿icacy and safety of daclizumab 
high-yield process (DAC HYP) in patients 
previously treated with disease-modifying 
therapies: subgroup analyses from the  
DECIDE study
E. Havrdova1, L. Kappos2, K. Selmaj3, D.L. Arnold4,  
A. Boyko5, M. Kaufman6, H. Wiendl7, J. Rose8,  
S. Greenberg9, M. Sweetser10, P. Wang10, L. Barbato10
1First Faculty of Medicine, Charles University in Prague, 
Prague, Czech Republic, 2University Hospital Basel, Basel, 
Switzerland, 3Medical University of Lodz, Lodz, Poland, 
4NeuroRx Research and Montreal Neurological Institute , 
Montreal, Canada, 5Russian Research and Science Medical 
University named by Pirogov, MMSC, Moscow, Russian 
Federation, 6Cole Neurological Institute, University of 
Tennessee - Knoxville, Knoxville, TN, USA, 7University 
of Münster, Münster, Germany, 8University of Utah 
Department of Neurology and the Neurovirology Research 
Laboratory, VASLCHCS, Salt Lake City, UT, USA, 9AbbVie 
Biotherapeutics Inc., Redwood City, CA, USA, 10Biogen Idec, 
Cambridge, MA, USA
Background and aims: The DECIDE study demonstrated 
the efficacy and safety of DAC HYP compared with 
intramuscular interferon beta-1a (IFN beta-1a) in patients 
with relapsing-remitting multiple sclerosis (RRMS). The 
objective of these analyses was to evaluate the efficacy 
and safety of DAC HYP versus IFN beta-1a in patients 
participating in DECIDE who had previously been treated 
with disease-modifying therapies (DMT) for MS.
Methods: Patients (age 18–55 years; Expanded Disability 
Status Scale 0–5) were randomised to subcutaneous DAC 
HYP 150mg every 4 weeks or intramuscular IFN beta-
1a 30mcg once weekly for 96–144 weeks. Primary and 
secondary efficacy endpoints and safety were analysed 
in patients who had received treatment with interferon 
beta, glatiramer acetate or other DMT for MS, excluding 
steroids, before enrollment in DECIDE.
Results: 380/919 (41%) patients in the DAC HYP group 
and 376/922 (41%) patients in the IFN beta-1a group had 
previously been treated with DMT for MS. The point 
estimates for each of the primary and secondary study 
endpoints favoured DAC HYP compared with IFN beta-
1a (Table). Among patients previously treated with DMT 
for MS, infections were observed in 73% and 62%, skin 
and subcutaneous tissue disorders in 43% and 22%, and 
elevations of alanine/aspartate aminotransaminases in 
8%/6% and 7%/5% of patients in the DAC HYP group and 
IFN beta-1a group, respectively.
Conclusion: The results of these subgroup analyses reflect 
the overall findings from DECIDE and demonstrate the 
efficacy and safety profile of DAC HYP compared with 
IFN beta-1a in patients previously treated with DMT for 
MS.
Disclosure: This study was funded by Biogen Idec and 
AbbVie Biotherapeutics Inc. Writing and editorial support 
for the preparation of this abstract was provided by Excel 
Scientific Solutions; funding was provided by Biogen Idec 
and AbbVie Biotherapeutics Inc.
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Teriflunomide (Aubagio[R]) pregnancy  
registry: design and enrolment  
procedures for pregnant women with  
multiple sclerosis exposed to teriflunomide
K. Hellwig1, C. Lebrun-Frenay2, D. Rog3, M. Benamor4, 
S. Tcherny-Lessenot4, P. Truffinet4, A. Ghezzi5
1St. Josef Hospital at Ruhr University Bochum, Bochum, 
Germany, 2Hôpital Pasteur, Nice, France, 3Greater 
Manchester Neurosciences Centre, Salford Royal NHS 
Foundation Trust, Salford, United Kingdom, 4Genzyme, 
a Sanofi company, Chilly-Mazarin, France, 5Ospedale di 
Gallarate, Gallarte, Italy
Background and aims: Teriflunomide, approved for 
treatment of relapsing-remitting multiple sclerosis (MS), 
is contraindicated for use in pregnancy, based on signs 
of developmental toxicity in rats and rabbits. During 
teriflunomide clinical trials, pregnancies occurred without 
signs of structural or functional deficits in newborns, but 
were too few to exclude reproductive toxicity. Therefore, it is 
important to continue to collect data regarding teriflunomide 
exposure in pregnancy. The International Teriflunomide 
Pregnancy Exposure Registry will compare birth defects 
(congenital malformations, foetal deaths, termination due 
to foetal anomaly) in teriflunomide-exposed pregnant 
women with those reported by the European Surveillance 
of Congenital Anomalies (EUROCAT).
Methods: The registry is a voluntary, multinational, 
prospective, observational, exposure-registration study. 
Pregnant women with MS with teriflunomide exposure 
(any dose any time after day 1 of last menstrual period until 
pregnancy end) can enrol. National Coordinators will liaise 
with healthcare professionals to collect information on 
teriflunomide-exposed pregnancies and coordinate patient 
enrolment in the registry. The registry will recruit 196 
women to achieve 104 live births, providing 80% power 
to detect a 3.95-fold increase in risk ratio of birth defects 
associated with teriflunomide exposure vs EUROCAT. 
Pregnancy outcome data including birth defects and infant 
characteristics during the first year of life will be collected.
Results: Enrolment commenced early 2015 and will 
continue until December 2019. Interim results will be 
reported when available.
Conclusion: This registry aims to provide data on 
pregnancy outcomes and infant development during the 
first year of life from teriflunomide-exposed pregnancies, 
and will help physicians provide better counselling for 
women exposed to teriflunomide during pregnancy.
Disclosure: Study supported by Genzyme, a Sanofi 
company.
P1160
Five-year follow-up of delayed-release 
dimethyl fumarate in RRMS: integrated 
clinical eff﻿icacy data from the DEFINE, 
CONFIRM, and ENDORSE Studies
M. Hutchinson1, R. Gold2, R.J. Fox3, J.T. Phillips4,  
A. Bar-Or5, L. Kappos6, S. Sheikh7, R. Zhang7, M. Yang7,  
N.C. Kurukulasuriya7
1St. Vincent’s University Hospital, Dublin, Ireland, 2St. Josef 
Hospital, Ruhr University, Bochum, Germany, 3Mellen Center 
for Multiple Sclerosis Treatment and Research, Cleveland 
Clinic, Cleveland, USA, 4Multiple Sclerosis Program, Baylor 
Institute for Immunology Research, Dallas, USA, 5Montreal 
Neurological Institute and Hospital, McGill University, 
Montreal, Canada, 6University Hospital, Basel Neurology, 
Basel, Switzerland, 7Biogen Idec, Inc., Cambridge, USA
Background and aims: Delayed-release dimethyl fumarate 
(DMF; also known as gastro-resistant DMF) demonstrated 
efficacy and acceptable safety in patients with relapsing-
remitting multiple sclerosis (RRMS) in the Phase 3 DEFINE 
and CONFIRM studies; ENDORSE is an 8-year extension 
of DEFINE/CONFIRM. We report long-term (5-year 
minimum follow-up) clinical efficacy outcomes with DMF.
Methods: Patients randomised to DMF 240 mg twice (BID) 
or three times daily (TID) in DEFINE/CONFIRM continued 
the same dosage in ENDORSE. Patients randomised to 
placebo (PBO; DEFINE/CONFIRM) or glatiramer acetate 
(GA; CONFIRM) were re-randomised 1:1 to DMF 240 
mg BID or TID. Data were analysed (14 May 2014 cutoff) 
by treatment arm in parent/extension study. Results for the 
approved dosage of DMF (240 mg BID) are reported.
Results: Of 2,079 patients completing DEFINE/CONFIRM, 
1,736 were dosed in ENDORSE, including 501 BID/BID, 
249 PBO/BID, and 118 GA/BID patients. With continuous 
DMF (BID/BID), adjusted annualised relapse rates (ARRs) 
remained low over five years (two years parent study; 
three years ENDORSE). Low ARRs were also observed 
in ENDORSE among patients switched from PBO or GA 
(Table). Low proportions of patients were estimated to 
have disability progression (24-week confirmed Expanded 
Disability Status Scale progression) at 5 years in the BID/
BID, PBO/BID, and GA/BID groups (0.186 [95% confidence 
interval, CI, 0.153‒0.224], 0.211 [95% CI, 0.162‒0.271], 
and 0.257 [95% CI, 0.184‒0.352], respectively).
Conclusion: Treatment with DMF was associated with low 
relapse rates and low disability progression over 5 years. 
Results support the use of DMF as a long-term treatment 
for patients with RRMS.
Disclosure: Study supported by: Biogen Idec 
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Natalizumab discontinuation is associated 
to a rebound of cognitive impairment in 
multiple sclerosis patients
P. Iaffaldano, R.G. Viterbo, D. Paolicelli, V. Direnzo,  
M. D‘Onghia, M. Trojano
University of Bari, Department of Basic Medical Sciences, 
Neurosciences and Sense Organs, Bari, Italy
Background and aims: Clinical and radiological disease 
reactivation has been described after Natalizumab(NTZ) 
discontinuation. Whether this disease reactivation involves 
also cognitive functions is not known to date. The aim of 
this work was to evaluate the effect of NTZ suspension on 
cognitive functions.
Methods: Patients underwent a neuropsychological 
evaluation using the Brief Repeatable Battery (BRB), and 
the Stroop Test (ST) at baseline, during NTZ treatment 
and after 1 year of NTZ discontinuation. The Cognitive 
Impairment Index (CII) as a measure of global cognitive 
function was calculated for each patient. The annualized-
relapse-rate (ARR) and the number of gadolinium 
enhancing lesions (GD) were recorded for each patient, 
before, during and after the NTZ treatment.
Results: In 82 RRMS patients , baseline ARR(1.90±0.85 vs 
0.30±0.56), number of GD lesions (1.3±1.72 vs 0.17±0.49), 
and CII (14.11±6.79 vs 10.61±7.06) significantly 
(p<0.0001) decreased during NTZ treatment. Twenty-
eight of these patients interrupted NTZ treatment and were 
evaluated for a 1-year period (12.87±7.62 months) after 
treatment suspension. At the end of this period the ARR 
(0.50±0.64 vs 0.93±0.86, p=0.042), the number of GD 
lesions (0.18±0.48 vs 0.54±0.51, p=0.004) and the CII 
(9.79±8.16 vs 12.86±7.72, p<0.0001) showed a significant 
increase.
Conclusion: The beneficial effect of NTZ on cognitive 
functions is lost after the discontinuation of the drug. 
The rebound of the cognitive impairment after NTZ 
discontinuation goes in parallel with the clinical and 
radiological disease reactivation. Our data reinforce the 
hypothesis that, in the short-term, NTZ exerts its positive 
impact on cognitive functions by means of its anti-
inflammatory properties.
Disclosure: Nothing to disclose
P1162
Teriflunomide hair photography project: 
analysis by a dermatologist
a. Jackson1, L. Hendin Travis2, A. Okai3, L. Farnett4,  
S. Cavalier4, D. Stam4, K. Liu4, K.R. Edwards5
1Baton Rouge Clinic, Baton Rouge, USA, 2Phoenix 
Neurological Associates Ltd, Phoenix, USA, 3Multiple 
Sclerosis Treatment Center of Dallas, Dallas, USA, 4Genzyme, 
a Sanofi company, Cambridge, USA, 5Multiple Sclerosis 
Center of Northeastern New York, Latham, USA
Background and aims: Teriflunomide is a once-daily oral 
immunomodulator approved for relapsing-remitting MS. 
In phase 3 trials, 13% of patients receiving teriflunomide 
14 mg experienced hair thinning compared with 4% 
receiving placebo. Teriflunomide-associated hair thinning 
is likely due to telogen effluvium, a type of hair loss 
caused by premature transition of follicles to the resting 
phase. Here, photographs of self-reported hair thinning are 
analysed from a dermatological perspective.
Methods: Patients who reported hair thinning to health 
care professionals (HCPs) during teriflunomide treatment 
were eligible for inclusion. At onset and resolution, HCPs 
completed hair thinning questionnaires, ranking patient-
perceived severity from 0 to 10. With a standardized 
protocol and camera, patients were photographed from 5 
standard views (anterior, posterior, left lateral, right lateral, 
anterior superior) and an optional manipulated view with 
hair pulled back. The severity of hair loss will be classified 
from a dermatological perspective.
Results: At presentation, all of the 31 cases were classified 
by HCPs as mild or moderate. Follow-up visits took 
place on average 268 days (9 months) after onset of hair 
thinning. Complete/near-complete resolution or marked 
improvement was reported in 26/31 patients at follow up. 
Results from the dermatological analysis will be presented.
Conclusion: Hair thinning in these patients was consistent 
with observations from the clinical trial programme: 
cases were usually mild and most patients recovered 
fully. Dermatological classification of teriflunomide-
associated hair thinning will help HCPs to inform patients’ 
expectations in advance of treatment.
Disclosure: Study supported by Genzyme, a Sanofi company.
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Periventricular lesion burden in multiple 
sclerosis correlates with cortical thinning
M. Jehna1, L. Pirpamer2, M. Khalil2, F. Stulnig2, S. Fuchs2,  
S. Ropele2, C. Langkammer2, A. Pichler2, H. Deutschmann1, 
F. Fazekas2, C. Enzinger2
1Medical University of Graz, Department of Radiology, 
Graz, Austria, 2Medical University of Graz, Department of 
Neurology, Graz, Austria
Background and aims: It has been suggested recently that 
cortical pathology in multiple sclerosis (MS) may at least 
partly be caused by factors in the cerebrospinal fluid (CSF). 
We thus hypothesised that MS related tissue changes in 
compartments close to the CSF such as periventricular 
lesions might correlate with cortical pathology.
Methods: We investigated 91 patients with a clinically 
isolated syndrome (CIS) and 69 patients with relapsing-
remitting MS (RRMS) (mean age: CIS: 31.4±9.0; RRMS: 
33.0±8.7 years, mean disease duration: CIS: 7.2±15 
months; RRMS: 8.0±6.5 years, median EDSS: CIS: 1, 
0-3.5; RRMS: 1.25, 0-4) with 3.0T MRI. MS lesions were 
semi-automated segmented on the FLAIR images. To 
quantify periventricular lesion load (PV-LL), we generated 
ventricle masks and dilated them by a voxel factor of 3. 
Lesions within the dilated ventricle margin were classified 
as periventricular. Cortical pathology was assessed via 
cortical mean thickness (CMT) and compared to data from 
59 healthy controls (HC) (mean age: 29.1±7.4 years).
Results: Compared to HC, CIS and RRMS patients 
demonstrated significantly reduced CMT (Figure 1). 
Even after controlling for ventricular atrophy, increased 
periventricular lesion occupancy (percentage of PV-LL) 
significantly correlated with decreased CMT in RRMS (r: 
-0.314, p=0.009) but not in CIS (r: 0.016, p=0.882) patients 
(Figure 2).
Figure 1: Differences in cortical thinning between HC and CIS (on the 
left) and HC and RRMS (on the right).
Figure 2: Correlation between increased PV-LL and reduced CMT in 
CIS (on the left) and RRMS (on the right).
Conclusion: The correlation between increased periventri-
cular lesion burden and decreased CMT suggestive of 
subpial cortical pathology supports the concept that 
common CSF-mediated factors might play a role in the 
accumulation of brain damage in MS, particularly in 
patients with relapsing-remitting inflammation.
Disclosure: This study was funded by the Austrian MS-
research society (Vienna, Austria).
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Autoantibodies of MS patients recognizing 
brain lipids react mainly with cholesterol
A. Jurewicz1, M. Domowicz1, G. Galazka1,  
A. Ewiak-Paszynska1, C. Raine2, K. Selmaj1
1Medical University of Lodz, Department of Neurology, Lodz, 
Poland, 2Albert Einstein College of Medicine, Department of 
Pathology, New York, USA
Background and aims: Increasing data indicate that lipids 
might induce autoimmune responses and determine the 
course of multiple sclerosis (MS).
Methods: Lipid fractions isolated by Folch procedure 
from MS and control brains, characterized by thin 
layer chromatography (TLC) were used as antigens 
in ELISA assays with serum of RR-MS patients 
(n=10) and control patients (n=10). In control set of 
experiments serum immunoreactivity with synthetic 
lipids: L-α-lysophophatidylocholiline, cholesterol, 
galactocerebrosides, β2-glycoprotein 1 (β2-GP1) and 
cardiolipin was assessed. To confirm antibody binding 
specificity, IgG and IgM were purified by affinity (IgG) or 
exclusion chromatography (IgM), digested with pepsin and 
papain and used for ELISA.
Results: As assessed by TLC, in MS brains dominated 
neutral lipids and all lipid fractions contained cholesterol 
esters. In control brains dominated phospholipids and 
cholesterol esters were scarcely present. IgG and IgM of 
MS serum bound to almost all lipid fractions with higher 
efficacy than IgG and IgM of control serum. To assess 
the specificity of lipid binding by MS serum, purified IgG 
and IgM, were digested and generated F(ab)2 fragments 
showed high binding to lipid fractions in contrary to Fc 
fragments. To further characterize lipids recognized by 
MS serum synthetic lipids were used as antigen in ELISA 
assays. Only cholesterol was found to bind IgG and IgM 
with high efficacy. Preabsorbtion of MS serum with 
cholesterol significantly decreased subsequent IgG and 
IgM recognition of lipid fractions by up 70% confirming 
specific cholesterol recognition by serum of MS patients.
Conclusion: These results indicate that IgG and IgM of 
MS serum specifically recognize cholesterol.
Disclosure: Nothing to disclose
P1165
Five-year follow-up of delayed-release 
dimethyl fumarate in relapsing-remitting 
multiple sclerosis: MRI outcomes from 
DEFINE, CONFIRM, and ENDORSE
T. Yousry1, D.L. Arnold2, R.J. Fox3, R. Gold4, E. Havrdova5, 
L. Kappos6, D. MacManus1, S. Sheikh7, R. Zhang7, M. Yang7, 
N.C. Kurukulasuriya7
1University College London Institute of Neurology, Queen 
Square Multiple Sclerosis Centre, NMR Research Unit, 
London, United Kingdom, 2NeuroRx Research, Montreal 
Neurological Institute, McGill University, Montreal, Canada, 
3Mellen Center for Multiple Sclerosis Treatment and Research, 
Cleveland Clinic, Cleveland, USA, 4St. Josef Hospital, Ruhr 
University, Bochum, Germany, 5Department of Neurology, First 
Faculty of Medicine, Charles University in Prague, Prague, 
Czech Republic, 6University Hospital, Basel Neurology, Basel, 
Switzerland, 7Biogen Idec, Inc., Cambridge, USA
Background and aims: ENDORSE is an 8-year extension 
of the 2-year DEFINE/CONFIRM studies that demonstrated 
efficacy and safety of delayed-release dimethyl fumarate 
(DMF; also known as gastro-resistant DMF) in patients with 
relapsing-remitting multiple sclerosis. We report long-term 
(5-year minimum follow-up) integrated magnetic resonance 
imaging (MRI) outcomes with DMF.
Methods: Patients initially randomised in DEFINE/
CONFIRM to DMF 240 mg twice (BID) or three times daily 
(TID) continued the same dosage in ENDORSE; patients 
randomised to placebo (PBO) or glatiramer acetate (GA) 
were re-randomised 1:1 to DMF BID or TID. Brain MRI 
scans were obtained yearly in ENDORSE from an MRI 
cohort. Data for DMF BID (as of 14 May 2014) are reported.
Results: Of 982 MRI cohort patients completing DEFINE/
CONFIRM, 746 received treatment in ENDORSE; 363 
received DMF BID (211 BID/BID, 104 PBO/BID, 48 GA/
BID). Among the 152 BID/BID patients remaining after 
5 years’ follow-up, 63% were free of new/enlarging T2 
lesions and 73% were free of new T1 hypointense lesions 
during Year 3 of ENDORSE; 88% were free of gadolinium-
enhancing lesions at ENDORSE Year 3 scan. MRI outcomes 
(T2 lesions) by yearly interval are reported for BID/BID 
patients and patients who switched to DMF (Table).
Conclusion: Reduced frequency of new MRI lesions 
was maintained throughout 5 years with continued DMF 
therapy. After switching to DMF, patients demonstrated 
MRI outcomes similar to those observed with DMF in 
DEFINE/CONFIRM. These findings, together with clinical 
efficacy and acceptable safety profile, support DMF as 
a valuable long-term treatment option for patients with 
RRMS.
Disclosure: Study supported by: Biogen Idec
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Adiponectin and not leptin is associated 
with genetic susceptibility to multiple  
sclerosis
E. Kantorova1, D. Cierny2, P. Petrova3, P. Slezak4,  
J. Michalik5, T. Adam3, S. Sivak1, V. Nosal6, E. Kurca7
1Martin, Slovakia, 2Jessenius Faculty of Medicine, Comenius 
University Bratislava, Institute of Medical Biochemistry, 
Martin, Slovakia, 3Faculty Hospital in Olomouc, Czech 
Republic, Department of Clinical Biochemistry, Olomouc, 
Slovakia, 4Comenius University, Bratislava, Department 
of simulation and virtual medical education, Bratislava, 
Slovakia, 5Neurology Clinic and Jessenius medical faculty, 
Comenius university, Martin, Slovak republic, Neurology, 
Martin, Slovakia, 6Jessenius Faculty of Medicine, Comenius 
University Bratislava, Neurology, Martin, Slovakia, 7Jessenius 
Faculty of Medicine, Comenius University Bratislava, 
Neurology, martin, Slovakia
Background and aims: Multiple sclerosis (MS) is an 
inflammatory-autoimmune demyelinating disease of the 
CNS affecting genetically susceptible individuals. Genetic 
susceptibility interacts with environmental factors. A role 
of adipose tissue and adipokines as environmental factors 
of MS should be clarified.
Methods or Materials or Case Report: We investigated a 
potential relationship between adipokinese, adipose-tissue 
and HLA antigen DRB1 (single nucleotid polymorphism rs 
3135388), specific markers of genetic susceptibility to MS.
Total of 74 pacients MS completed the study. Patients 
with RR and SP forms were included. The mean age was 
40.8±10.5, disease duration 11.1±4.8. Rate of disability 
was 3.7±1.4 (range 0-10), measured by EDSS. Adipose-tis-
sue mass was assessed by BMI, mean value was 25.3±5.6. 
Leptin and adiponectin were tested by ELISA method. Sta-
tistical analysis: nonparametric Kendall-tau b test, multiva-
riant regression analysis.
Results:  We found significant association of leptin with 
EDSS (r=0.22, p=0.006), and adiponectin with EDSS 
(r=-0.17, p=0.036). In multivariant regression analysis both 
leptin (parcial correlation 0,28, p=0.017) and adiponectin 
(parcial correlation -0.19, p=0.012) were found to be good 
BMI-dependent predictors of progression of disability. 
However, adiponectin, and not leptin, correlated with the 
carriage of HLADRB1 and rs 3135388 A (r=0.16, p=0.053) 
in MS patients.
Conclusion: Adipokines, released from an excessive 
adipose tissue, are potent modulators of inflammatory 
activity in MS. Adiponectin is associated with genetic 
susceptibility of MS. 
Disclosure: Work has been supported by Project ESF 
ITMS kód: 26110230067.
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Evaluation of the safety, efficacy and  
retention of mitoxantrone in Cypriot  
patients with primary progressive multiple 
sclerosis.
E. Kkolou, E. Gaglia, J. Toufexis, M. Pantzaris
The Cyprus Institute of Neurology and Genetics, Clinical 
Department, Nicosia, Cyprus
Background and aims: Primary Progressive Multiple 
Sclerosis (PPMS) is a chronic debilitating neurological 
disease for which no treatment is currently available. The 
purpose of our study was to evaluate the real life safety, 
efficacy and retention of Mitoxantrone (MTX) in Cypriot 
patients with PPMS.
Methods: 38 adult patients were studied retrospectively 
for 2 years. Patients were treated with 18-20mg of MTX 
every 3 months up to a cumulative dose of 140mg-160 mg. 
Our review assessed patents’ EDSS progression, treatment 
emergent adverse events (AEs) and MTX withdrawal rates.
Results: A significant reduction in disease progression was 
observed after the first year of MTX treatment compared 
with the year before (p=0.014). Reduction in disease 
progression was however not sustained for the second 
year of treatment (p=0.374). Nevertheless, seven patients 
(18%) responded to MTX therapy experiencing no disease 
progression during the two years of treatment. 17 patients 
(45 %) discontinued treatment protocol: 9 (24%) within 
the first and 8 (21%) within the second year of treatment. 
Main discontinuation reasons were patients’ decision / 
lack of efficacy (21%) and cardiovascular AEs (13%). 21 
patients (55%) experienced AEs. Most frequently reported 
were cardiovascular AEs (16%), psychological/psychiatric 
AEs (13%), nausea and vomiting (13%) and hematological 
abnormalities (10%).
Conclusion: Overall, Mitoxantrone failed to demonstrate 
reduction in disease progression in patients with PPMS. 
Since, however, 18% of our patients remained clinically 
stable throughout the 2-year treatment protocol, larger 
studies are required to identify possible factors affecting 
the response of PPMS patients to MTX treatment.
Disclosure: Nothing to disclose
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Evaluation of the relationship between 
restless legs syndrome, sleep disturbance 
and quality of life measures in patients 
with multiple sclerosis
A. Koskderelioglu, M. Gedizlioglu, O. Onder
Izmir Bozyaka Education and Research Hospital, Department 
of Neurology, Izmir, Turkey
Background and aims: We aimed to find out prevalence 
and severity of the restless legs syndrome (RLS) in patients 
with multiple sclerosis (MS). We examined the relationship 
with fatigue, quality of life (QoL) and sleep disturbance in 
MS patients experiencing RLS.
Methods: We recruited 183 consecutive MS patients. 
Restless legs syndrome is diagnosed according to the 
essential criteria defined by International Restless Legs 
Syndrome Study Group (IRLSSG). The disease severity 
is determined using the IRLSSG severity scale. Gender, 
age, disease duration, MS pattern, EDSS scores were 
documented. Beck Depression Inventory, Fatigue Severity 
Scale (FSS), Epworth Sleepiness Scale (ESS), Pittsburgh 
Sleep Quality Index (PSQI) and MS Quality of Life-54 
(MSQoL-54) questionnaires were applied to the patients. 
Results: Of the 183 patients 154 (84.5%) had relapsing-
remitting, 21 (11.5%) secondary progressive and 8 (4.4%) 
primary progressive MS. Mean age was 40.95±1.09, di-
sease duration 9.43±6.22 years and EDSS scores 2.1±1.74. 
43 patients (23.5%) were diagnosed with RLS. Statistical 
analysis showed a strong association with poor sleep, de-
creased quality of life, increased fatigue and depressive 
mood (p=0.004, p=0.002, p=0.003, p=0.002 respectively). 
The scores of FSS, physical composite scores of the MS-
QoL-54 and PSQI had significant correlation with RLS se-
verity (p=0.045, p=-0.038, p=0.001 respectively). 
Conclusion: Comorbid RLS exerts a remarkable negative 
impact on fatigue, sleep quality, mood and QoL in MS 
patients. Awareness of RLS among MS patients and early 
treatment may contribute to an improvement in their quality 
of life.
Disclosure: Nothing to disclose
P1169
Lebanese Multiple Sclerosis Registry  
(OLSEP): first report
S. Koussa1, A. Awada1, H. Abboud1, J. Hatem1, H. Korri1,  
K. Abou-Khaled1, J. Helou1, M. Thibault2, A. Tourbah3
1Hotel Dieu de France Hospital, Neurology, Beirut, Lebanon, 
2CHU de Dijon, Neurology, Dijon, France, 3Rheims, France
Background and aims:  Following the guidelines of 
management of MS in Lebanon, an “observatoire“ of MS 
in Lebanon was initiated in November 2012. Aims are 
to report the preliminary results of the Lebanese registry 
“OLSEP“. The long-term objectives are to follow-up 
patients, report the effect of DMD on long term disability 
and follow-up on the efficacy and safety of new treatments
Methods: Data of patients with MS in Lebanon were 
collected between November 2012 and April 2013. 
Descriptive statistics are reported.    
Results: Patients: 282 patients with MS were included in 
the observation. Sex ratio F/M is 2.42. A history of familial 
MS was reported in 11.7% of cases. Geographical origin: 
29.45% of patients are originated from Mount Lebanon, 
21.56% from South Lebanon,18.4% from Beirut, 16.56% 
from Bekaa and 15.33% from North Lebanon. Nearly 45% 
of patients are unemployed and one out of three is not 
married. Concerning environmental factors, one third are 
smokers and the level of Vitamin D is <20ng/ml in 50% 
of patients. Mean age of first symptoms was 31.04 years, 
most frequently monofocal, with sensitive symptoms, and 
involving the spinal cord. Patients were most often in a RR 
phase of the disease, and 2/3 patients had an EDSS <3.5. 
Fatigue was reported in 48% of patients
Conclusion: The preliminary descriptive data of the 
OLSEP in Lebanon shows results that are comparable 
to other registries. Myelitis is predominant as presenting 
syndrome, and vitamin D levels are low in nearly half of 
the evaluated patients
Disclosure: Nothing to disclose
© 2015 European Journal of Neurology, 22 (Suppl. 1), 120–483
Poster presentation with discussion      159
P1170
Safety, tolerability, and immunogenicity  
of peginterferon Beta-1a: combined  
analyses of the Phase III ADVANCE study 
and interim analysis from the extension 
study ATTAIN
M. Kremenchutzky1, J. White2, S. Liu2, Y. Cui2, S. Hung2,  
A. Seddighzadeh2, V. Evilevitch2, G. Sabatella2
1Western University , London, Canada, 2Biogen Idec Inc., 
Cambridge, USA
Background and aims: ATTAIN is a 2-year extension 
study of ADVANCE; the following analysis examines 
subcutaneous peginterferon beta-1a (PEG-IFN) safety, 
tolerability, and immunogenicity in relapsing-remitting 
multiple sclerosis (RRMS) patients up to the ATTAIN Year 
1 interim cutoff (August 1 2014). 
Design/methods: Patients aged 18–65 were assigned 
to either PEG-IFN dosed every 2 or 4 weeks, or delayed 
treatment (placebo for Year 1 followed by PEG-IFN every 
2 or 4 weeks for subsequent years). Delayed treatment 
patients were included in appropriate analysis groups 
based on Year 2 dosing. All patients are in the process of 
transitioning to every 2 week dosing in accordance with 
approved labels (post-interim cut-off).
Results: At cutoff, mean time of drug exposure was 
127.0 weeks (range: 2-224). Over all years of treatment 
in ADVANCE and ATTAIN, incidence of adverse events 
(AEs) were 96% (n=710/740) and 96% (n=697/728), and 
incidence of serious AEs (including relapses) were 21% 
(n=157/740) and 28% (n=202/728), every 2 and 4 weeks, 
respectively. Incidence of discontinuations due to AEs 
were 8% (n=62/740) and 7% (n=54/728) every 2 and 4 
weeks, respectively. Incidence of persistent antibodies 
over all years of treatment in ADVANCE and ATTAIN 
were: interferon-binding antibodies: 6% (42/706) and 
4% (25/706), interferon-neutralizing antibodies: <1% 
(n=6/715) and <1% (n=2/716), and anti-PEG antibodies: 
3% (n=20/681) and 5% (n=37/682), every 2 weeks and 
every 4 weeks, respectively.
Conclusion: In RRMS patients, long-term safety and 
tolerability of PEG-IFN remains favorable (without 
previously unseen events recorded), and development of 
persistent neutralizing antibodies over all years is very low.
Disclosure: This study has been sponsored by Biogen Idec 
Inc. (Cambridge, MA, USA). 
P1171
Ability of clinical and visual perceptive 
computing motor assessments to reflect 
daily activity in patients with multiple  
sclerosis
T. Krüger1, K. Otte2, B. Kayser2, S. Mansow-Model2,  
A. Grobelny1, E. Gusho1, T. Schmitz-Hübsch3, F. Paul4,  
A. Brandt5, J. Behrens1
1Charité – University Medicine Berlin, NeuroCure Clinical 
Research Center, Berlin, Germany, 2Motognosis UG 
(haftungsbeschränkt), Berlin, Germany, 3Charité, Department 
of Neurology, Berlin, Germany, 4Charité, NeuroCure Clinical 
Research Center and Department of Neurology, Berlin, 
Germany, 5Motognosis UG (haftungsbeschränkt) and Charité, 
NeuroCure Clinical Research Center, Berlin, Germany
Background and aims: In clinical care and research, 
clinical assessments should reflect changes in patients’ 
quality-of-life. Patients with multiple sclerosis (MS) 
experience motor impairment, reducing physical activity 
and negatively impacting patients’ everyday life. Motor 
impairment is routinely assessed by expanded disability 
status scale (EDSS) and the Timed 25-Foot Walk Test 
(T25FW). Gait and stance tests using perceptive computing 
based on Microsoft’s Kinect promise reliable and rater-
independent assessments. Objective of the on-going study is 
to investigate to which extent different clinical assessments 
reflect MS patients’ daily activity.
Methods: Daily activity of 20 MS patients and 20 
matched controls is measured using SenseWear activity 
monitors (SAM) for a 7-day-period and expressed as the 
mean moderate-to-vigorous-physical-activity in min/day 
(MVPA) from the SMA’s recordings from all days. Motor 
impairment is assessed using EDSS, T25FW as well as 
Kinect-based short maximum speed walk (SMSW) and 
postural control (POCO). Patient questionnaires include the 
12-Item MS Walking Scale (Walk-12).
Results: Wearing of SAM was well tolerated and recorded 
data of good quality. Preliminary data analysis from 6 
patients showed that MVPA showed a mild correlation with 
rater-dependent EDSS scores (unsigned (u) Spearman’s 
Rho=0.35), but good to excellent correlation with objective 
assessments T25FW, SMSW and POCO (all uRho >0.75). 
Correlation with self-reported walking disability (Walk-12) 
was moderate (uRho=0.6).
Conclusion: Commonly used clinical motor assessments 
reflect daily activity in MS patients. Objective tests show a 
higher association with daily activity than subjective tests 
and questionnaires. Final analysis will include associations 
with regard to detailed factors of daily activity.
Disclosure: This study is partly funded by Novartis Pharma 
GmbH Arzneimittel, Carmerstraße 18, 10623 Berlin.
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Interleukine 17 is not detected in 
active MS patients’ sera but in CSF in 
radiologically and clinically isolated 
syndromes
C. Lebrun Frenay1, M. Cohen1, F. Bucciarelli2,  
B. Seitz-Polzi3, A. Cornille3, B. Pignolet4, S. Benzaken3,  
D. Brassat5
1Pasteur, Nice, France, 2Purpan, Toulouse, France, 3Archet, 
Nice, France, 4inserm, Toulouse, France, 5Hopital PPR - CHU 
Purpan, Neurology, Toulouse, France
Background and aims: Increased serum IL-17 levels 
are associated with numerous autoimmune diseases. In 
MS, exploratory studies reported increased levels in CSF 
but results in detecting IL-17 in serum are controversied, 
sometimes detected during relapses or in case of IFNbeta 
non response.
We investigate levels of IL-17 in serum and CSF in patients 
diagnosed as Radiologically Isolated syndrome, Clinically 
Isolated Syndrome or active multiple sclerosis  patients 
(RIS, CIS, A MS) as a marker of inflammatory condition.
Methods: 1177 patients with active MS, defined by 2 recent 
relapses and gadolinium enhancing lesions, 35 patients 
diagnosed with RIS, 35 with CIS.The cytokine IL-17 A 
was measured in Serum and CSF using a FIDIS Human 
cytokine IL17 kit.
Results: IL-17A was not detected in blood samples neither 
in AMS nor in RIS or CIS patients excepted for 25 AMS 
patients with a mean of 0.52 pg/ml (0.09-1.33). The detection 
rate of IL-17 A was strictly identical in the CSF of RIS or 
CIS patients, respectively 0.70 pg/ml (0.31-1.46) and 0.72 
pg/ml (0.31-1.46). No correlation was found between CSF 
IL level and number of Barkhof Criteria on the initial brain 
MRI, detection of brain or spinal gadolinium enhancing 
lesions, presence of spinal cord lesions,CSF increased IgG 
Index or detection of oligoclonal band.
Conclusion: These findings strongly suggest that in RIS 
and in CIS patients, intrathecal activation of the IL-17 
is similar, confirming that RIS is the initial step of the 
demyelinating disease.
Disclosure: On behalf CFSEP, BIONAT and BEST 
MS groups B Pignolet and F Bucciarelli received grants 
NCT00942214 and NCT01981161 
P1173
Colesevelam HCl for accelerated 
elimination of teriflunomide, and 
monitoring of teriflunomide concentration 
using dried blood spot assay
C. Lunven1, Z. Guo2, A. Filali-Ansary1, S. Turpault2,  
A. Delfolie1, N. Boyanova3, N. Fauchoux4
1Sanofi R&D, Chilly-Mazarin, France, 2Sanofi US, 
Bridgewater, USA, 3Genzyme, a Sanofi company, Cambridge, 
USA, 4Biotrial, Rennes, France
Background and aims: Teriflunomide is a once-daily oral 
immunomodulator approved for treatment of relapsing-
remitting MS. In cases of emerging toxicity, overdose, or 
pregnancy, elimination of teriflunomide can be accelerated 
by oral administration of cholestyramine. Compared with 
cholestyramine, colesevelam HCl may offer improved 
tolerability for patients. We report an open-label study to 
assess the effectiveness of colesevelam HCl for accelerated 
elimination of teriflunomide. Teriflunomide concentrations 
were assessed in parallel in plasma and dried blood spot 
(DBS) samples.
Methods: Healthy subjects aged 18–45 years received 
teriflunomide 70mg once daily for 5 days, followed by 
an 11-day accelerated elimination procedure (AEP) of 
colesevelam HCl (4.375g total daily dose, 4 x 625mg + 
3 x 625mg). If plasma teriflunomide concentration was 
>0.02µg/mL at AEP end, subjects received precautionary 
cholestyramine 4g tid until it was ≤0.02µg/mL. 
Teriflunomide concentrations were determined in plasma 
and finger-prick DBS. Safety and tolerability were also 
evaluated.
Results: In the 18 subjects enrolled, mean (standard 
deviation) plasma teriflunomide concentration was 
36.3(6.42)µg/mL at AEP start, and 1.33(0.833)µg/mL after 
the 11-day AEP; a 96.1% decrease. All subjects received 
cholestyramine to eliminate residual teriflunomide. Finger-
prick DBS concentrations were correlated with plasma 
concentrations (R-squared=0.97); DBS methodology was 
selective, repeatable, and reproducible. The drugs were 
well tolerated; no unexpected safety signals emerged.
Conclusion: Colesevelam HCl administration accelerated 
teriflunomide elimination, with a 96% decrease in plasma 
teriflunomide concentration after 11 days. Correlation 
between plasma and finger-prick DBS concentrations 
was demonstrated. Together, these findings may 
provide additional options for monitoring teriflunomide 
concentration and for accelerated elimination of 
teriflunomide in the real-world setting.
Disclosure: Study supported by Genzyme, a Sanofi 
company.
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Evaluation of relapses as a surrogate 
marker for confirmed disability  
progression in relapsing-remitting  
multiple sclerosis patients treated with 
peginterferon beta-1a using the Prentice 
criteria
X. You1, T. Scott2, S. Shang1, B. Sperling1
1Biogen Idec Inc., Cambridge, USA, 2Allegheny General 
Hospital, Department of Neurology , Pittsburgh, USA
Background and aims: It is not known whether the 
treatment effect of subcutaneous peginterferon beta-1a 
(PEG-IFN) on confirmed disability progression (CDP) in 
relapsing-remitting multiple sclerosis patients in the Phase 
III ADVANCE study was fully driven by its effect on 
relapses. Using the Prentice criteria, we evaluated whether 
relapses could serve as a surrogate marker for CDP for the 
treatment effect of PEG-IFN every 2 weeks versus placebo 
over 1 year in the ADVANCE study, and for the treatment 
effect of intramuscular interferon beta-1a once weekly 
versus placebo over 2 years in the MSCRG study.
Methods : The four Prentice criteria are: 1. treatment effect 
is significant for S; 2. treatment effect is significant for T; 
3. T is significantly correlated with S; 4. treatment effect 
on T can be fully explained by S, where T is the “true” 
outcome (24-week CDP) and S is the surrogate marker 
(relapses). For S to qualify as a surrogate marker for T, 
all four Prentice criteria must be met according to the 
corresponding p-values.
Results: In the ADVANCE study, the first three Prentice 
criteria were met. However, criterion 4 failed because 
treatment effect on CDP is still significant (coefficient for 
treatment effect=-0.6126, p=0.0323) after adjusting for 
relapses. In the MSCRG study, all four criteria were met.
Conclusion: Relapses qualify as a surrogate marker for 
24-week CDP in the MSCRG study for intramuscular 
interferon beta-1a but not in the ADVANCE study for PEG-
IFN, implying that PEG-IFN might have an additional 
effect on CDP beyond its effect on relapses.
Disclosure: This study has been sponsored by Biogen Idec 
Inc. (Cambridge, MA, USA). 
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Progressive aphasia, cortical blindness 
and cortical deafness in MELAS  
syndrome
P. Pérez Torre, A. Escobar Villalba, F. Acebrón, R. Álvarez 
Velasco, P. Agüero Rabes, N. García Barragán, J. Buisán 
Catevilla, I. Corral Corral
Hospital Ramón y Cajal, Madrid, Spain
Background and aims: MELAS syndrome (myopathy, 
encephalopathy, lactic acidosis and stroke-like episodes) 
frequently presents cortical disorders. Acute progressive 
bilateral involvement of temporo-parieto-occipital cortex 
is rare. We report a patient with MELAS syndrome who 
suffered a progressive episode with hemianopsia, aphasia, 
cortical blindness and cortical deafness.
Case Report: A 30-year-old male patient, with no relevant 
family history, was admitted with left homonymous 
hemianopsia. Eighteen months before he had repeated 
seizures for which he was receiving levetiracetam.  Two 
weeks after admission rapidly progressive neurological 
worsening developed in four days, with memory deficits, 
predominantly sensory aphasia, cortical blindness, cortical 
deafness and seizures. The patient was aggressive and could 
contact only by touch. Serial magnetic resonance imaging 
showed progressive extensive bilateral lesions involving 
temporo-parieto-occipital cortex, with mild edema. Lesions 
were hyperintense in T2-weighted sequences and showed 
restriction in diffusion sequences. 
Image 1 (axial). Hyperintense lesions in Flair-Spair sequences 
involving temporo-occipital cortex.
Image 2 (coronal). Hyperintense lesions in Flair-Spair sequences 
involving temporo-parietal cortex.
Image 3 (sagital). Hyperintense lesions in Flair-Spair sequences 
involving temporo-parieto-occipital cortex.
Results: Analysis showed high lactate levels in blood and 
cerebrospinal fluid. A muscle biopsy showed no myopathy 
or ragged red fibers. The genetic study confirmed a MELAS 
mutation at the base pair 3243A-G. Empirical treatment 
with coenzyme Q and vitamin complexes resulted in 
significant improvement after 3 months.
Conclusion: MELAS syndrome should be considered 
in young adults with progressive cortical lesions despite 
normal muscle biopsy.
Disclosure: Nothing to disclose
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ANO10 mutation causing an autosomal 
recessive cerebellar ataxia in two siblings
D. Rudd1, S. Omer2, M. McEntagart3
1Tooting, 2St George’s Hospital, Neurology, 3St George’s 
Hospital, Clinical Genetics, London, United Kingdom
Background and aims: Autosomal recessive cerebellar 
ataxias are a clinically diverse group of conditions. 
Despite recent advances in gene sequencing techniques, 
approximately half of patients do not receive a molecular 
diagnosis.
Methods: We report the cases of two siblings with a 
cerebellar syndrome characterised by progressive ataxia, 
nystagmus and dysarthria with onset of symptoms in 
the third decade of life. In both cases marked cerebellar 
atrophy was noted on Magnetic Resonance Imaging (MRI). 
Molecular genetic testing revealed that both individuals 
were compound heterozygous for two pathogenic variants 
in Anoctamin 10 (ANO10), predicted to lead to premature 
termination of gene translation.
Results: A genetic panel comprising 57 genes for hereditary 
ataxia was performed. Sanger sequencing revealed two 
pathogenic ANO10 variants; c132dupAp.(Asp45fs) and 
c96delAp.(Glu33fs).
Conclusion: ANO10, also known as TMEM16K, is 
postulated to encode a calcium activated chloride channel, 
with highest expression within the adult brain and retina. 
Mutations in ANO10 have been reported in only five 
families worldwide. The phenotype encompasses cerebellar 
ataxia, dysarthria, eye movement abnormalities and severe 
cerebellar atrophy, with variable additional features of 
cognitive impairment, motor neurone involvement, seizures 
and retinal degeneration. More recently, ANO10 mutations 
have been associated in two patients with deficiencies in 
Coenzyme Q10, with supplementation leading to a mild 
improvement in the clinical symptoms. Our case report 
helps further define the clinical spectrum of this rare 
condition.




Investigation of four vitamin D receptor 
(VDR) gene polymorphisms in sporadic 
amyotrophic lateral sclerosis
N. Török1, R. Török2, P. Klivényi2, J. Engelhardt2, L. Vécsei1
1Szeged, Hungary, 2University of Szeged, Department of Neu-
rology, Szeged, Hungary
Background: There are aberrations in vitamin D–endo-
crine system in sporadic amyotrophic lateral sclerosis 
(SALS). Vitamin D deficiency and the rise of the levels 
of calcium and parathormon were measured in the sera of 
ALS patients. Diverse proteins were identified which link 
vitamin D to the theories of the selective degeneration of 
motor neurons too, albeit alterations of the VDR gene have 
not been reported.
Objective: Our aim was to investigate the single nucleotide 
polymorphisms of VDR gene in SALS patients in Hungary.
Methods: 77 SALS patients and 98 healthy controls were 
enrolled to reveal the supposed different proportion of the 
alleles of the VDR receptor. Restriction fragment length 
polymorphism was used. For data analysis, SPSS software 
20.0 was utilized.
Results: One of the investigated SNPs (ApaI CC genoty-
pe) was significantly lower (p=0.002) in the group of ALS 
patients than in controls. The age at onset of the disease 
of the patients carrying this or the other alleles were not 
significantly different.
Conclusion: One of the four examined polymorphisms of 
the VDR gene (ApaI CC genotype) seems to be protective 
from SALS in Hungarian population. However, due to the 
low number of cases, another study from the Central Euro-
pean region is needed. Our previous results suggest that the 
effect of Vitamin D may inhibit the local CNS inflammati-
on and induce the synthesis of calcium-binding proteins in 
motor neurons. To our knowledge, this is the first described 
SNP in the literature which may have protective effect in 
this devastating disease.
Disclosure: Nothing to disclose
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Oculodentodigital dysplasia with massive 
brain calcifications and a new pathogenic 
mutation
G. Tumminelli1, I. Di Donato1, A. Rufa1, A. De Luca2,  
S. Salvatore1, M. Di Giovanni1, A. Federico1
1University of Siena, Neurology and Neurometabolic Diseases 
Unit, Department of Medicine, Surgery and Neuroscience, 
Sienna, Italy, 2IRCCSCSS, San Giovanni Rotondo e Istituto 
CSS-Mendel, Rome, Italy
Background and aims: Oculodentodigital dysplasia 
(ODDD) [MIM 164200] is a rare autosomal dominant 
disorder caused by mutations in the gap junction alpha 1 
(GJA1) gene, on chromosome 6, encoding for connexin 43. 
Typical signs include type III syndactyly of the fourth and 
fifth finger, microphtalmia, microcornea, short palpebral 
fissures, microdontia, enamel hypoplasia and neurological 
disturbances (spastic paraparesis, ataxia, neurogenic 
bladder dysfunction and occasionally mental retardation). 
Case Report: We report a 59-year-old man, observed for 
progressive gait disturbances and unsteadiness. presenting 
since birth bilateral type III syndactyly of the third, fourth and 
fifth finger (surgically corrected) and bilateral syndactyly 
of second and third toe. Decreased visual acuity with 
glaucoma and cataracts, microdontia, caries and teeth loss 
were evident since childhood. Clinical examination showed 
the classical ODDD features. Neurologically, blindness, 
unsteady and spastic gait, spasticity of inferior limbs were 
present. A CT scan revealed gross calcifications of basal 
ganglia and cerebellar nuclei bilaterally. MRI showed thin 
corpus callosum and mildly enlarged ventricles. P and Ca 
metabolism examination, including PTH, was normal.
Classical ODDD features in our patient
Results: The clinical findings suggested ODDD, with 
some atypical features rarely reported (massive brain 
calcifications). Molecular genetic analysis of the GJA1 
gene revealed a heterozygous missense mutation 
(NM_000165.3:c.124G>C;p.Glu42Gln) never previously 
reported which, according to bioinformatical studies, resul-
ted pathogenic
Conclusion: In conclusion, this case expands the know-
ledge of the ODDD syndrome, with the evidence of a new 
mutation of connexin 43 gene and the possibility that this 
gene may also alter the brain microvessels leading to massi-
ve brain calcifications, as seen in Fahr’s syndrome.  
Gross calcifications in basal ganglia and cerebellar nuclei
Disclosure: Nothing to disclose
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The implementation of the next generation 
sequencing (NGS) to identify the genetic 
background of the autism spectrum  
disorder (ASD) in Hungarian patients
N.A. Varga1, K. Pentelényi1, P. Balicza1, V. Hársfalvi1,  
V. Reményi1, J. Koller1, C. Prekop2, S. Magyarósi1,  
M.J. Molnár1
1Institute of Genomic Medicine and Rare Disorders, 
Semmelweis University, Neurology, Budapest, Hungary, 
2Vadaskert Kórház és Szakambulancia, Budapest, Hungary
Background and aims: The genetic background of ASD 
is highly heterogeneous. The first step is to distinct the 
monogenic forms from complex, multifactorial forms.
Our aim is to explore the effectivity of NGS in the screening 
of syndromic-monogenic forms in our Hungarian ASD 
cohort, and to estimate the frequency of mutations in the 
genes related to ASD.
Methods: Our cohort consisted of 47 patients. We 
performed NGS on MiSeq platform targeted on 103 known 
and candidate genes related to ASD (Illumina Trusight 
Autism). Before the NGS the FMR1 gene were screened 
out by Asuragen AmplideX PCR Kit.
Results: The genetic analysis detected in 45 patients 
rare variants in 39 genes. Phenotypically 29 patients 
were considered as idiopathic ASD patient, 18 had an 
additional feature beside autism. In 2 patients we detected 
FMR1 full mutation. In 1 case the ASD associated to 
muscular dystrophy, the NGS detected point mutations 
in the dystrophin genes. In a boy presenting symptoms 
of CHARGE syndrome, a CHD7 frameshift mutation 
confirmed the diagnosis. In case of a boy profoundly 
affected, with multifocal epilepsy, the CDKL5 missense 
mutation is supposed to be pathogenic on the bases of a 
similar case. In the most cases pathogenic SNPs were found 
in CDH8, LAMC3, MET, NLGN3, SHANK2, SHANK3, 
VPS13A genes supporting their strong predisposing effect 
on the ASD. In these cases the segregation analysis of the 
families are going on.
Conclusion: The identification of the monogenic forms 
is extremely important because only in this case we can 
determine the reoccurrence risk and can offer prenatal 
testing.
Disclosure: The project is supported by the Hungarian 
Government, financed by the Research and Technology 
Innovation Fund. KTIA_AIK_12-1-2013-0017
P1182
Friedreich’s ataxia in Norway
I.M. Wedding1, S.P. Henriksen2, M. Kroken3, T. Berge2, 
T. Fiskerstrand4, K.K. Selmer3, C. Tallaksen1
1Oslo, Norway, 2Oslo University Hospital, Research Unit 
for Neuroscience, Oslo, Norway, 3Oslo University Hospital, 
Department of Medical Genetics, Oslo, Norway, 4Haukeland 
University Hospital, Department of Medical Genetics, Ber-
gen, Norway
Background and aims: Friedreich’s ataxia (FRDA) is an 
autosomal recessive hereditary ataxia, due to degeneration 
of the dorsal root ganglia and dorsal medulla. It is described 
as the most common hereditary ataxia in Caucasians, with 
an estimated prevalence of 1/50000 and a carrier frequency 
up to 1/60 in Europe. In 95-98% of the cases homozygous 
GAA repeat expansions in the FXN-gene lead to reduced 
levels of the mitochondrial protein Frataxin. FRDA expec-
ted to be rare in Norway compared to Europe. Previous pre-
valence studies show variations from of 1/100 000 (1974) 
in Western Norway to 1/1350000 in the South-Eastern part 
of Norway (2008). The aims of this project was to assess 
the prevalence and carrier frequency of FRDA in the who-
le of Norway. In addition, we wanted to give a thorough 
clinical and molecular characterisation of the Norwegian 
FRDA patients and healthy carriers, including GAA repeat 
expansion sizes and frataxin levels.
Methods: Patients were collected through nation-wide 
hospital archive searches and examined clinically. Carrier 
frequency, GAA repeat expansion size and frataxin protein 
levels were analyzed with previously described methods.
Results: 29 genetically confirmed FRDA patients were 
found, corresponding to a total prevalence of 1/176 000 
in Norway. Among ethnic Norwegians the prevalence was 
1/191 000. The carrier frequency among ethnic Norwegians 
is 1/210.
Conclusion: In this first comprehensive study of FRDA in 
Scandinavia, the prevalence and carrier frequency of FRDA 
in Norway is lower than in Central Europe, but higher than 
previously described in Norway.
Disclosure: Nothing to disclose
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Application of whole exome sequencing 
to study a cohort of Greek patients with 
heterogeneous neurological disorders
H. Latsoudis1, E. Vogiatzi1, A. Evangeliou2,  
V. Mastorodemos1, D. Kotzamani1, K. Monti2, D. Zafeiriou2, 
G. Amoiridis1, A. Plaitakis1, I. Zaganas1
1University of Crete, Neurology, Heraklion, Crete, Greece, 
2Aristotle University of Thessaloniki, Pediatrics, Thessaloniki, 
Greece
Background and aims: Next generation sequencing 
methodologies, including whole exome sequencing (WES), 
are gaining grounds in the investigation of neurological 
diseases. In this study, we aimed to evaluate the diagnostic 
efficacy of WES in a cohort of Greek patients with various 
neurological syndromes.
Methods: Patients presenting to study clinicians with 
neurological syndromes suspected to be genetic in origin 
were offered WES, on the basis of predefined criteria. After 
obtaining informed consent, WES was performed on 27 
patients (14 females and 13 males; mean age=23.4±23.8yrs, 
range 2-71yrs) in a CLIA certified laboratory, aiming 
at a 50X coverage. Data analyses were performed in the 
Neurology Laboratory, University of Crete, Greece, by 
integrating clinical information with published phenotypic 
data. Findings were verified by Sanger sequencing.
Results: The overall diagnostic rate of WES was 44.4% 
(12/27 patients). Specifically, causal variants were 
identified in the following genes: NF1 (Neurofibromatosis 
type I), EPM2A (Lafora disease), CLCN1 (congenital 
myotonia), CAPN3 (muscular dystrophy), ISPD (muscular 
dystrophy), TARDBP (ALS/FTLD), PAX6 (nystagmus/
aniridia syndrome), NIPBL (Cornelia de Lange syndrome), 
GAA (Pompe disease), CPT2 (rhabdomyolysis), ALDOB 
(hereditary fructose intolerance) and PDHX (lactic 
acidosis). In 2 cases (NF1, CLCN1), WES was chosen over 
targeted sequencing due to lower cost. In the remaining 10 
cases, WES provided final diagnosis after several costly 
and laborious diagnostic tests were inconclusive.
Conclusion: In our cohort of selected neurologic patients, 
WES showed high diagnostic yield and was cost effective. 
These data offer support to the value of WES to resolve 
the diagnostic odyssey of patients with heterogeneous 
neurogenetic disorders.
Disclosure: Nothing to disclose
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P1184
Red-flag symptom clusters in  
transthyretin familial amyloid  
polyneuropathy (TTR-FAP)
I. Conceicao1, A. González Duarte2, L. Obici3, H. Schmidt4, 
D. Simoneau5, M.-L. Ong6, L. Amass7
1CHLN, Hospital de Santa Maria and Clinical and 
Translational Physiology Unit, Physiology Institute, Faculty 
of Medicine, IMM, Lisbon, Portugal, 2Instituto Nacional de 
Ciencias Médicas y Nutrición Salvador Zubirán, México 
City, Mexico, 3Amyloidosis Research and Treatment Center, 
Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, 
4Universitätsklinikum Münster, Münster, Germany, 5Pfizer 
Inc., Paris, France, 6Pfizer Inc., New York/NY, USA, 7Pfizer 
Inc., Collegeville/PA, USA
Background: TTR-FAP is a progressive, fatal, autosomal-
dominant disorder characterised by extracellular deposition 
of transthyretin-derived amyloid fibrils in various organs, 
particularly peripheral and autonomic nerves, heart, 
gastrointestinal tract, kidneys, eyes, and connective tissue 
of the transverse carpal ligament. Due to its phenotypic 
variability and non-specificity of symptoms, the condition 
can be difficult to recognise and manage. Misdiagnosis is 
common and definitive diagnosis can be delayed for years, 
postponing adequate management and genetic counselling 
and leading to possible irreversible damage.
Objective: To improve disease awareness and provide a 
practical guide when to suspect TTR-FAP with the goal to 
shorten time to diagnosis.
Methods: Considering all known characteristics and 
manifestations of TTR-FAP, combinations of red-flag signs 
and symptoms that should arouse suspicion of TTR-FAP 
were identified. Selection was guided by relevant published 
literature, common misdiagnoses, and the authors’ expert 
clinical experience in diagnosing and treating patients with 
TTR-FAP.
Results: See Figures 1 and 2.
Conclusion: TTR-FAP should be suspected if progressive 
peripheral polyneuropathy and one (or a combination) of 
the following symptoms are observed: early autonomic 
dysfunction, cardiac involvement, severe chronic 
diarrhoea, constipation, or alternating bouts of constipation 
and diarrhoea, inexplicable weight loss, carpal tunnel 
syndrome, renal impairment, or vitreous opacity. Common 
misdiagnoses include chronic inflammatory demyelinating 
polyneuropathy (CIDP), progressive diabetic neuropathy, 
and paraneoplastic syndrome. Family history should be 
investigated and a small-fibre assessment, nerve conduction 
studies, electro- and echocardiogram, laboratory 
evaluations, transthyretin genotyping and tissue biopsy 
should be performed. Early diagnosis is key to effective 
patient management and prevention of disease progression.
Disclosure: Funded by Pfizer Inc.
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Cutaneous silent period in the assessment 
of small nerve fibres of peripheral nerves 
in lower limbs in patients with diabetes
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Background and aims: The prevalence of neuropathy 
in patients with diabetes is about 30% and approximately 
50% of patients may develop polyneuropathy during the 
course of metabolic disease. Routine electrophysiological 
examination reflects the function of large, but not the 
function of small nerve fibres. The purpose of our study 
was to evaluate the function of small nerve fibres measuring 
cutaneous silent period (CSP) of the peripheral nerves on 
lower limbs.
Methods: The evaluation of large diameter nerve fibres was 
performed by standard neurophysiological examination, 
CSP by stimulation of the sural nerve and detection over 
tibialis anterior muscle. The onset latency was recorded 
at the beginning of voluntary muscle activity suppression 
and the late latency at the start of new muscle activity. The 
difference between the latencies reflects the duration of 
CSP.
Results: In our study we included 20 diabetic patients 
(mean age 56.2±12.3 years) with mean duration of diabetes 
11.90±10.2 years. The nerve conduction parameters 
and CSP values were compared with the corresponding 
parameters of the control group (47 subjects). The onset 
latency L1 was prolonged in half of the diabetic patients. 
The duration of CSP in patients (Figure 1) was significantly 
shorter - mean 41.08±14.80 ms vs. 57.64±13.84 ms in the 
control group (p<0.005). The peroneal and tibial motor 
velocities in the patients group were decreased (p<0.001) 
and H-reflex latencies prolonged (p<0.005).
Figure. Cutaneous silent period.
Conclusion: CSP is a useful method in detecting the 
small nerve fibres involvement in diabetic patients and 
completing the routine electrophysiological evaluation.
Disclosure: Nothing to disclose
P1186
Prognostic factors affecting long term 
disability in polyneuropathy associated 
with antibodies to myelin associate  
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Background and aims: Anti-MAG polyneuropathy is a 
progressive immune-mediated neuropathy whose disease 
course can be highly variable. The purpose of our study was 
to identify prognostic factors affecting long-term disability 
in a prospective cohort of 43 patients evaluated during a 15 
years-long follow-up.
Methods: Clinical, demographical, and neurophysiological 
data were collected every 6 months, Several prognostic 
factors were considered including age, gender, type of 
treatment, serum anti-MAG IgM titer, serum IgM protein 
level at baseline, and electrophysiological pattern. Outcome 
measures were worsening of muscle strength, disability, 
sensory function, and development of hematologic 
malignancy.
Results: Median age at first visit was 70 years, median 
anti-MAG IgM titer at baseline was 20.61 BTU. 
Electrophysiological assessment was consistent with a pure 
demyelinating polineuropathy in 17.07%; the remaining 
82.93% showed axonal or mixed pattern. Disability, muscle 
strength, and sensory function progressed and worsened 
significantly between the first and the last visit. No 
statistical significant change was observed in quality of life. 
Survival analyses showed that factors influencing disability 
were therapy (longer stability in treated patients, p=0,026), 
electrophysiological pattern (longer stability in axonal 
or mixed forms, p=0,030), and age (longer stability in 
younger patients, p=0.045). Older age (≥70 years) was also 
associated with higher risk of sensory function worsening 
(p=0.05). No statistical significant prognostic factors 
were detected for muscle strength outcome, haematology 
malignancy, and quality of life.
Conclusion: Our results suggest that younger age, axonal 
or mixed electrophysiological pattern, and therapy could 
be considered useful prognostic factor of decrease risk of 
disability in anti-MAG neuropathy.
Disclosure: Nothing to disclose
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and electrophysiological features in three 
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Background and aims: The rare sensory variant of 
Guillain-Barré Syndrome (GBS) was well defined in a series 
of eight patients with an acute pure sensory neuropathy 
(Oh et al, 2001). Only single case reports and small series 
meeting these criteria have been barely reported. We 
describe clinical and electrophysiological features of three 
new patients with sensory GBS. 
Methods: We carried out a retrospective study of patients 
diagnosed with GBS in the last five years. Inclusion criteria 
for sensory GBS: Acute sensory neuropathy, monophasic 
course, arreflexia, no weakness or only minimal motor in-
volvement and albuminocytological dissociation. Patients 
with an alternative diagnosis were excluded.
Results: Out of 59 patients with GBS, 3 (5%) had an acute 
sensory neuropathy. All 3 patients were males, with a medi-
an age of 35±17.7 years. In all of them, an infectious event 
was found in the previous two weeks. Distal paresthesia 
was the presenting symptom. Neurological examination 
was suggestive of an acute sensory ataxic neuropathy in 
patient 1, acute sensory large and small fiber neuropathy 
in patient 2 and acute sensory small-fiber neuropathy in 
patient 3. Arreflexia and albuminocytological dissociation 
were present in all three patients. Sensory conduction stu-
dies showed a pattern of an abnormal median-normal sural 
sensory response in patients 1 and 2 and were normal in 
patient 3. Serum antiganglioside antibodies were negative. 
2 patients were treated with immunoglobulins and all of 
them experienced a complete recovery. 
Conclusion: Sensory GBS includes subtypes with different 
clinical features and electrophysiological findings. Further 
studies are needed to develop a practical nosological 
classification. 
Disclosure: Nothing to disclose
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Background and aims: Chronic inflammatory 
demyelinating polyradiculoneuropathy (CIDP), 
multifocal motor neuropathy (MMN) and paraproteinemic 
demyelinating neuropathy are the main chronic 
demyelinating dysimmune neuropathies. We aim to study 
the spectrum of these neuropathies in a Tertiary University 
Hospital.
Methods: We carried out a retrospective study of patients 
diagnosed with CIDP, paraproteinemic neuropathy and 
MMN evaluated in our hospital in the last five years (2009-
2014). Patients were included if they fulfilled the diagnostic 
criteria of the EFNS/PNS task force.
Results: 30 patients (50% males) with a median age at 
onset of symptoms of 57±17 years were studied. CIDP was 
the most frequent diagnosis (83%). 8 of them (32%) had 
an atypical CIDP, including 2 patients with Lewis-Sumner 
syndrome, 2 cases of pure sensory and 2 pure motor 
neuropathy, another patient with a focal CIDP and another 
case with combined central and peripheral demyelination 
(CCPD). MMN and distal adquired demyelinating 
symmetric neuropathy (DADS) were less frequent (7% 
and 10%). Relapsing and remitting disease was evident 
in 6 patients (20%). 5 patients (17%) had associated a 
monoclonal gammpopathy (80% IgM). Neurofascin IgG4 
antibodies were evident in one patient with disabling 
tremor and poor response to immunoglobulins treatment. 
All patients with DADS neuropathy had positive antibodies 
against myelin-associated glycoprotein (anti-MAG).
Conclusion: Chronic demyelinating dysimmune 
neuropathies are heterogeneous. Typical CIDP was the 
most frequent type, followed by DADS neuropathy and 
MMN. CIDP associated with neurofascin IgG4 antibodies 
was only found in 1 case and no patient had anti-contactin-1 
antibodies.
Disclosure: Nothing to disclose
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Background and aims: Type 2 diabetes mellitus is a 
frequent disease and diabetic neuropathy is one of the most 
common microvascular complications that affect these 
patients. There are a lot of evidence suggesting the role of 
oxidative stress and genetic susceptibility in developement 
and progression of diabetic complication. We investigated 
the relation between polymorphism in genes related to 
oxidative stress such as MnSOD Val16Ala and CAT 
C-262T and the presence of diabetic neuropathy.
Methods: Samples were collected from 85 patients with type 
2 diabetes mellitus (54 patients with diabetic neuropathy 
confirmed through clinical exam and electrophysiological 
studies and 31 patients without diabetic neuropathy) and 98 
healthy controls and genotyped by using polymerase chain 
reaction and restriction fragment length polymorphism 
(PCR-RFLP) methods. 
Results: Chi square test revealed no significant difference 
in genotype frequency for type 2 diabetes mellitus 
patients and healthy controls with a p=0.62 for MnSOD 
Val16Ala polymorphism and p=0.26 for catalase C-262T 
polymorphism. We found that MnSOD   Val16Ala genotype 
frequencies were significantly different between patients 
with type 2 diabetes mellitus with and without diabetic 
neuropathy p<0.05. Individuals carrying Val/Val genotype 
had a greater risk for diabetic neuropathy comparing with 
Ala/Ala genotype (OR:1.422, CI: 1.07 to 2.66, p=0.04). 
We found no statistical difference in patients with diabetes 
mellitus for catalase C-262T polymorphism (p=0.95). 
Conclusion: This study indicates that MnSOD Val16Ala 
polymorphism may be associated with diabetic neuropathy 
and the Val/Val genotype may be a risk factor for the 
disease. Further studies are needed for conclusive results 
due to the small number of studied cases. 
Disclosure: This paper was published under the frame of 
European Social Found, Human Resources Development 
Operational Programme 2007-2013, project no. 
POSDRU/159/1.5/S/136893
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Background and aims: Peripheral neuropathy can be 
a manifestation of systemic or nonsystemic vasculitis. 
Nonsystemic vasculitis neuropathy is restricted to peripheral 
nerves with no evidence of further systemic involvement. It 
is rare and the prognosis is good with immunosuppressive 
treatment.
Case Report: A 43-year-old male presented with 
symmetric painful paraesthesias in his fingers, lower legs 
and the foot soles. The pain in the feet was severe and 
allodynic. Prior to admission an unremarkable MR of the 
cervical spine and brain and a CSF analysis were made. 
There was no evidence of a paraneoplastic neuropathy 
or systemic vasculitis. The clinical examination revealed 
dysaesthesia and allodynia in his feet. The reflexes were 
preserved. Electrophysiology showed axonal neuropathy 
and a varying degree of pathology in individual nerves. 
Thermal detection thresholds were pathologic. A sural 
nerve biopsy showed an inflammatory neuropathy affecting 
walls of small and medium scaled vessels with paravasal 
lymphocytic infiltration without vessel wall necrosis. The 
muscle revealed neurogenic atrophy without inflammation. 
Results: After diagnosis of a microvasculitic neuropathy 
the patient received methyprednisolon 80 mg/day for one 
week and a maintainance dose of 40 mg/day. Symptoms 
improved.
Conclusion: This patient presented a painful symmetric 
neuropathy, but showed asymmetric changes in 
electrophysiology. The preservation of reflexes could 
suggest small fiber neuropathy. Histopathology confirmed 
the diagnosis of vasculitis and the symptoms improved 
with steroid therapy.
The classification of this type of neuropathy is difficult, 
in absence of serologic markers and vessel wall necrosis, 
and point to a microvasculitis resembling microscopic 
polyangiits associated neuropathy.
Disclosure: Nothing to disclose
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Variable clinical aspects of neuralgic 
amyotrophy
M. Suzuki, M. Takeuchi, Y. Shimizu, K. Kitagawa
Tokyo Women’s Medical University, Tokyo, Japan
Background and aims: Neuralgic amyotrophy (NA, 
also known as Parsonage-Turner syndrome) exists in an 
inherited and an idiopathic form, characterized by sudden 
attacks of severe neuropathic pain in the shoulder or arm. 
The idiopathic version is an acute monophasic brachial 
plexus disorder of unknown cause, but the condition is 
generally thought to be an immune system.
Methods: We retrospectively reviewed all medical records 
of our institution from April 2005 to December 2014. We 
studied clinical manifestations of NA cases, and reviewed 
the literature.
Results: We identified 4 males and 3 females, aged from 35 
to 71 year-old. Two revealed anti-ganglioside antibodies. 
Two had herpes zoster virus infection and one had hepatitis 
E infection precedentially. A residural pain case had also 
tendonitis in the long head of biceps brachii muscle, 
which is a cause of frozen shoulder. MRI was useful to see 
swelling of the nerve trunks and evidence of denervation 
involving muscles. 6 had intravenous immunoglobulin 
(IVIG) therapy and 2 of them also had methylprednisolone 
pulse therapy (MPPT), revealed favourable response, 
especially for their pain. 2 showed recurrence course. In the 
literature, some NA cases showed good response for IVIG.
Conclusion: Medical interrogation in detail is most 
important to diagnose for NA. IVIG or MPPT may be 
one of potential therapeutics for NA, however the efficacy 
remains to be established.
Disclosure: Nothing to disclose
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Background and aims: Polyneuropathy due to Diabetes 
Mellitus is acquired, while Fabry Polyneuropathy is caused 
by a rare metabolic disorder. Both polyneuropathies have 
impacts on motor, sensory and autonomic funtions and may 
effect one or two of them more predominantly. In this study 
we aimed to  investigate and compare the affects of these 
polyneuropathies on quality of life.
Methods: 18 Fabry patients from the same family aged 
between 8 and 51 years and 18 Type 2 diabetic patients 
aged between 50 and 60 were enrolled in the study. Detailed 
neurological examination, electroneuromyography, Lanss 
and DN4 tests, life quality scores and Beck Depression 
tests were performed for each patient.
Results: In Fabry group, 1 of the patients had axonal 
polyneuropathy, while 15 of the diabetic patients had 
mixed and 3 of them had axonal polyneuropathy. Patients 
in both groups had scores over 12 in Lanss and over 4 in 
DN4 meaning they all had neuropathic pain. Lanss scores 
were statistically significantly higher in the diabetic group 
(p<0.05). Beck Depression test scores did not show any 
statistically meaningful differences between the two groups 
(p>0.05). Life quality index scores for diabetic patients 
were statistically significantly worse than the Fabry group 
(p<0.05).
Conclusion: Fabry disease affects unmyelinated fibers at 
younger ages when compared to the diabetic patients whose 
myelinated fibers are influenced predominantly. Both 
diseases deteriorate quality of life, which seems to begin at 
younger ages in the Fabry group. Having information about 
these facts of both diseases can help therapy strategies and 
taking early precautions.
Disclosure: Nothing to disclose
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Inferior parietal cortex hypoperfusion is 
the most specific to Alzheimer’s disease 
with positive CSF biomarkers
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Background and aims: Regional brain hypoperfusion 
occupy an essential place in recently formulated diagnostic 
criteria for Alzheimer’s disease (AD). Our objective was 
to determine the SPECT hypoperfusion pattern in patients 
with CSF AD signature (1st: abnormal Aß1-42 and 
abnormal t-tau or p-tau; 2nd: p-tau/Aß1-42 > 0.11) and to 
evaluate its diagnostic accuracy in a clinical population of 
the Amiens academic Memory Clinic. 
Methods: This retrospective study selected 120 patients, 
examined in Amiens Memory Clinic, with a lumbar 
puncture (with a CSF biomarkers (Aß1-42, t-tau and p-tau) 
measurement), imaged with a cerebral HMPAo SPECT 
and a cerebral MRI. Clinical diagnoses were: suggestive 
of AD (n=34), possible or probable AD (n=29), others 
causes of cognitive impairment (n=57). SPECTs were 
semiquantitative rated by a nuclear practitioner blinded 
to clinical and biological data. Beforehand 9 regions of 
interest were determined.
Results: CSF AD signature (abnormal Aß1-42 and 
abnormal t-tau or p-tau: n=24; p-tau/Aß1-42: n=45) was 
associated with inferior parietal ratio minus lateral dorsal 
frontal ratio (OR: 0.906; 95%CI: 0.835-0.983, p=0.017). 
This pattern discriminates patients with CSF AD signature 
(1st) from patients with others causes of cognitive 
impairment with a sensitivity of 71%, a specificity of 65%, 
a negative predictive value (NPV) of 90% and a positive 
predictive value of 33%.    
Conclusion: Hypoperfusion in the inferior parietal area 
was the most sensitive and specific feature of AD diagnosed 
using clinical and CSF biomarkers criteria. This pattern had 
a NPV of 90%, and so was highly useful to discriminate AD 
from others causes of cognitive impairment.
Disclosure: Nothing to disclose
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Neuronal correlates of anosognosia 
for memory impairment in Alzheimer’s 
disease: the role of posterior cingulate 
cortex.
N. Antoine, E. Amico, M.A. Bahri, C. Bastin, E. Salmon
University of Liège, Cyclotron Research Centre, Liege, 
Belgium
Background and aims: Anosognosia for memory deficits 
has major impact on caring for Alzheimer’s disease (AD). 
However, the neural mechanisms of anosognosia in AD 
remain unclear. The aim of this study was to acquire 
multimodal brain imaging in a sample of patients, to 
evaluate the contribution of brain regions to anosognosia in 
AD. Here are the functional analysis results with a new and 
original methodology for the investigation of resting-state 
functional Magnetic Resonance Imaging (fMRI) spatial 
pattern.
Methods: Functional connectivity of cerebral areas is not 
a static phenomenon, but exhibits spontaneous fluctuations 
over time. Point process analysis applied on functional data 
has revealed that much of the information regarding brain 
connectivity is contained in a fraction of critical time points 
of a resting state dataset. Resting-state fMRI volumes on 31 
patients with probable AD were acquired and reduced to a 
spatiotemporal point process by selecting time points in the 
PCC at which the signal is higher than a given threshold. 
Participants’ awareness of current memory functioning 
was assessed with the memory awareness rating scale. The 
population was split in two (matched) groups following the 
degree of awareness for memory deficit.
Results: Anosognosic patients demonstrated decreased 
connectivity between the PCC and the left temporoparietal 
junction, the ventromedial prefrontal cortex and the 
superior temporal cortex.
Conclusion: The PCC is a hub region of the default mode 
network (DMN), notably involved in self-referential 
processing. These new results suggest that the disturbance 
of the PCC with others regions of the DMN are implicated 
in loss of self-knowledge in AD.
Disclosure: Nothing to disclose
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Background and aims: To study the effectiveness of 
physical exercise training as a treatment opportunity in 
elderly diagnosed with mild to moderate dementia in 
addition to pharmaceutical therapy.
Methods: Longitudinal randomized study; 40 participants 
with mild to moderate dementia (AD, mixed or vascular), 
no major motor function impairment; randomized in 2 
groups: with physical exercise training intervention(I): 
5/7, 12 weeks (20 participants) and control group(C) 
(20 participants). We assessed cognitive and global 
evaluation scores (MMSE, Clock Drawing Test, R-ACE-R: 
Addenbrooke’s Cognitive Examination/Romanian-version, 
Reisberg), functional tests (ADL, IADL), neuropsychiatric 
inventory (NPI-Q), GDS (Geriatric Depression Scale short 
version), QOL-AD (quality of life in AD) and SPPB(Short 
Physical Performance Battery). Follow-up after inclusion 
at 3, 6, 9 and 12 weeks (T1-T2-T3-T4-T5).
Results: Groups were homogenous at inclusion (T1), 
mean age:79.35, 80% women, 90% from urban area. 5 
patients withdrew from the study. Statistically significant 
differences between groups at T5 were for: Clock Drawing 
Test[t(32)=3.28, p<0.005], total R-ACE-R [t(32)=2.28, 
p<0.005], R-ACE-R subscores: F(verbal-fluency)[t(32) 
=4.26, p<0.001] and VS(visuo-spatial)[t(32)=3.37, 
p<0.005], IADL[t(32)=2.06, p<0.005], GDS[t(32)=-2.28, 
p<0.005], QOL-AD[t(32)=2.06, p<0.005] and SPPB[t(32) 
=2.30, p<0.05] for 5 chair stands test: t(32) = 2.82, p<0.005.
Mean scores of tests at T5 (after 12 weeks from inclusion) with 
statistically significant differences between I (intervention with 
Physical Exercise Training) and C (control) groups.
Evolution of R-ACE-R scores from T1 (inclusion) to T5 (12 weeks) 
for I (intervention with Physical Exercise Training) and C (control) 
groups.
Evolution of GDS scores from T1 (inclusion) to T5 (12 weeks) for I 
(intervention with Physical Exercise Training) and C (control) groups.
Conclusion: Physical exercise training proves to be an 
effective intervention for elderly with mild to moderate 
dementia, with positive results in cognitive (especially 
executive function) and functionality scores, with 
supplementary benefits on mood disorders (reduces 
depression), improving the quality of life of patients with 
dementia.
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Background and aims: To assess white matter (WM) 
tract damage in patients with atypical Alzheimer’s disease 
(AD), including early age-of-onset AD (EOAD), logopenic 
variant of primary progressive aphasia (lvPPA) and 
posterior cortical atrophy (PCA) using diffusion tensor 
MRI, and to identify similarities and differences across the 
AD spectrum.
Methods: WM tract damage and cortical atrophy were 
assessed in 28 EOAD, 12 lvPPA and 13 PCA patients relative 
to age- and sex-matched healthy subjects. Conjunction and 
interaction analyses were used to define overlapping and 
syndrome-specific patterns of brain damage.
Results: EOAD, lvPPA and PCA patients shared a 
common pattern of WM damage involving the body of 
the corpus callosum, fornix, and main anterior-posterior 
pathways, and cortical atrophy of the left temporo-parietal 
regions and precuneus. EOAD patients had also a specific 
damage to the genu and splenium of the corpus callosum, 
and parahippocampal tract bilaterally. In all AD patients, 
particularly in the two focal forms (lvPPA and PCA), 
WM damage was more severe and widely distributed than 
expected on the basis of cortical atrophy.
Conclusion: In atypical AD clinical phenotypes, the 
distribution of WM damage exceeds cortical atrophy 
and may reflect the dissemination of pathology through 
structural connections from atrophic to unaffected cortical 
regions. WM degeneration may be an early marker of AD 
pathology in EOAD and focal AD forms.
Disclosure: Italian Ministry of Health (Grant #GR-2010-
2303035).
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Selective FDG-PET changes on right 
amygdala and temporal pole predict  
impairments of socio-emotional  
processing in the behavioural variant of 
frontotemporal dementia
C. Cerami1, A. Dodich2, C. Crespi2, N. Canessa3,  
S. Iannaccone4, A. Marcone4, S. Cappa3, D. Perani2
1San Raffaele Scientific Institute, Vita-Salute San Raffaele 
University, Department of Clinical Neurosciences, Milan, 
Italy, 2Vita-Salute San Raffaele University, Milan, Italy, 
3San Raffaele Scientific Institute, Milan, Italy, 4San Raffaele 
Hospital, Milan, Italy
Background and aims: The behavioural variant of 
frontotemporal dementia (bvFTD) is characterized by socio-
emotional processing abnormalities ranging from mild 
emotional blunting to loss of sympathy and empathy or 
inappropriate social behaviours. In this study, we evaluate [18F]
FDG-PET correlates of social cognition impairments in bvFTD.
Methods: 15 probable bvFTD patients were enrolled. An 
experimental neuropsychological battery assessed different 
facets of social cognition (i.e., knowledge of social norms, 
emotions recognition, affective and cognitive empathy 
and attribution of intentions and emotions). 19 cognitively 
normal subjects were included in the behavioural analysis 
as control group. Each patient underwent a [18F]FDG-PET 
scan with an optimized method of voxel-based normalization 
and comparison analyses. Correlations analyses between 
behavioural performances and the metabolic values were 
performed on fronto-temporal and limbic Region of Interests 
(ROIs) according to know brain networks involved in social 
cognition functioning.
Results: Compared to controls, bvFTD displayed significant 
lower performances on all social tasks. Right amygdala 
emerged as key structure for all the investigated abilities of 
social cognition. Additionally, right temporal pole correlated 
with affective empathy and ToM, and recognition of emotions 
from facial expression. Noteworthy, a significant correlation 
between the disgust recognition and left insula metabolism 
was also identified.
Conclusion: The presence of right limbic and temporal 
metabolic changes in bvFTD predicts low performances on 
socio-emotional tasks, particularly in those involving affective-
emotional cues. Insula metabolic changes are responsible of 
disgust recognition impairment. Selective disease-specific 
vulnerability on social cognition networks hubs may be 
detected by voxel-based [18F]FDG-PET analysis, even at the 
individual level.
Disclosure: This work has been partially supported by the 
MIUR grant “I meccanismi neurocognitivi alla base delle 
interazioni sociali” (PRIN2010XPMFW4_008), and by the 
Università degli Studi di Milano-Bicocca CARIPLO grant 
„Dottorato ad alta Formazione in Psicologia Sperimentale, 
Linguistica e Neuroscienze Cognitive“. Dr. Cerami was 
funded by Fondazione Eli-Lilly (Eli-Lilly grant 2011 
„Imaging of neuroinflammation and neurodegeneration 
in prodromal and presymptomatic Alzheimer’s disease 
phases“)
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Self-assessment of change in driving in 
relation to current driving performance on 
a driving simulator in patients with various 
neurological conditions
A. Economou1, M.H. Kosmidis2, I. Beratis3, A. Liosidou3,  
E. Papadimitriou4, G. Yannis4, S. Papageorgiou3
1University of Athens, Department of Psychology, Athens, 
Greece, 2Aristotle University of Thessaloniki, Department 
of Psychology, Thessaloniki, Greece, 3“Attikon” University 
General Hospital, Department of Neurology, Athens, Greece, 
4National Technical University of Athens , Department of 
Transportation Planning and Engineering, Athens, Greece
Background and aims: To examine self-assessment of 
driving change in relation to objective driving measures 
derived from a driving simulation experiment in neurology 
patients and controls. Perception of change in driving 
ability with age and cognitive decline is important for the 
self-monitoring of driving and the realistic adaptation to 
challenging driving situations. Such situations are difficult 
to investigate during on-road driving.
Methods: Participants: In these analyses, 157 drivers 
participated: 65 controls (> 43 years), 50 mild cognitive 
impairment (MCI) patients, 23 mild Alzheimer’s disease 
(AD) patients, and 19 Parkinson’s disease (PD) patients. 
Different numbers of participants entered different analyses.
Measures: Questionnaire measures: Selected questions 
from a driving behaviour questionnaire asking the driver 
to rate his driving in a variety of driving environments and 
conditions in relation to 5 years prior on a 5-point Likert 
scale. Driving measures: Average speed (in km), average 
lateral position (distance of the vehicle from the right road 
border in meters), headway average (average distance from 
the vehicle ahead in meters), number of times of speed limit 
violations, number of crashes at unexpected incidents.
Results: Average speed, lateral position, and headway 
average were z-transformed based on the entire control 
sample of 102 participants and participants’ z-scores were 
correlated with responses to the self-rating questions. The 
driving measures were poorly associated with self-rating 
performance.
Conclusion: Self-rating of driving change is not related to 
objective performance, though the slower speed and greater 
headway distance of the AD and PD patients may reflect an 
adaptation to decline in abilities.
Disclosure: National Strategic Reference Framework 




Grey matter and white matter MRI  
markers of cognitive progression in early 
and late onset variants of Alzheimer’s  
disease
F. Agosta1, F. Caso1, D. Mattavelli1, M. Copetti2,  
G. Magnani3, E. Canu1, A. Marcone4, M. Falautano3,  
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1San Raffaele Scientific Institute, Vita-Salute San Raffaele 
University, Neuroimaging Research Unit, Milan, Italy, 
2IRCCS-Ospedale Casa Sollievo della Sofferenza, 
Biostatistics Unit, San Giovanni Rotondo, Italy, 3San Raffaele 
Scientific Institute, Vita-Salute San Raffaele University, 
Department of Neurology, Milan, Italy, 4San Raffaele 
Scientific Institute, Vita-Salute San Raffaele University, 
Department of Clinical Neuroscience, Milan, Italy, 
5Università Vita-Salute San Raffaele, Neuroradiology, Milan, 
Italy
Background and aims: To assess grey (GM) and white 
matter (WM) MRI measures as predictors of cognitive 
progression in early-onset (EOAD) and late-onset 
Alzheimer’s disease (LOAD).
Methods: T1-weighted and diffusion tensor (DT) MRI was 
obtained from 48 LOAD and 28 EOAD, who were followed 
prospectively with 6-month clinical and neuropsychological 
evaluations (mean follow-up: 12.9 months [maximum: 43.4 
months]). At baseline, regional GM and WM damage was 
evaluated. Longitudinal linear models assessed cognitive 
changes over time and relationships between MRI and 
cognitive evolution.
Results: At a similar stage, EOAD presented with more 
severe multidomain cognitive deficits, greater brain 
atrophy, but similar WM tract damage relative to LOAD. 
Compared with LOAD, EOAD patients showed a faster 
progression during follow-up, mainly in executive, memory 
and language domains. In EOAD, baseline atrophy of the 
cingulate, frontotemporal and parietal GM was related to 
the executive function worsening, while damage to corpus 
callosum, cingulum, frontotemporal and frontoparietal 
connections bilaterally predicted the visuospatial abilities 
deterioration. In LOAD, volumes of the left anterior 
cingulum, insula, inferior frontal and parietal cortices 
contributed to executive deficit progression, while the 
memory decline was predicted by damage to corpus 
callosum, cingulum and frontotemporal and frontoparietal 
tracts bilaterally.
Conclusion: In addition to GM atrophy, WM damage 
contributes to cognitive progression in both LOAD 
and EOAD, with differences between the two variants 
probably related to a distinct distribution of pathological 
abnormalities. DT MRI could be considered an additional 
biomarker of neurodegeneration predictive of cognitive 
impairment years later in AD.
Disclosure: Italian Ministry of Health (#GR-2010-
2303035).
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The neuroprotective effect of cilnidipine in 
an animal model of ischemic stroke
H. Choi1, D. L. Koo2, K.-Y. Lee1, Y.J. Lee1, S.-H. Koh1
1Department of Neurology, Hanyang University College 
of Medicine , Seoul, Korea, Republic of, 2Department of 
Neurology, Seoul National University Boramae Hospital, 
Seoul, Korea, Republic of
Background and aims: Cerebral infarction causes 
permanent neuronal loss, which is associated with severe 
morbidity and mortality. Because hypertension is the 
main risk factor for cerebral infarction and most patients 
with hypertension take daily antihypertensive drugs, the 
neuroprotective effects and mechanisms of those drugs 
need to be investigated. cilnidipine, a long-acting, second-
generation 1,4-dihydropyridine inhibitor of L- and N-type 
calcium channels has been reported to reduce oxidative 
stress in our previous study. In this study, we confirmed 
whether cilnidipine has therapeutic effects in an animal 
model of cerebral infarction. 
Methods: After determination of cilnidipine, a total of 
128 rats were subjected to middle cerebral artery occlusion 
(MCAO). Neurobehavioral function test and brain MRI 
were performed similar infarct sized rats are randomized 
to either cilnidipine treatment group or control group. 
Drug treatment was performed with reperfusion after 2 hrs 
occlusion. Western blots and immunohistochemistry were 
also performed after 24 hr occlusion. 
Results: Initial infarct volume on DWI was not significantly 
different in cilnidipine treatment group and control group. 
But FLAIR MRI at 24 hrs showed significantly reduced 
infarct volume in cilnidipine treatment group compared 
with control group. cilnidipine treatment significantly 
decreased the number of TUNEL-positive cells compared 
to control group. Western blot and immunohistochemistry 
showed increased expression of phosphorylated Akt 
(Ser473) and Bcl-2 and decreased expression of Bax and 
cleaved caspase-3. 
Conclusion: These results suggested that pretreatment 
with cilnidipine had a neuroprotective effect in ischemic 
brain and this property is one of the important profiles that 
are implicated in brain protection.
Disclosure: Nothing to disclose
P1210
Posterior reversible encephalopathy 
syndrome – clinical and radiological 
characterization of a six-year Portuguese 
case series
A. Costa1, J. Filipe2, C. Reis2, E. Azevedo1, P. Abreu1
1Centro Hospitalar S. João, Neurology, Porto, Portugal, 
2Centro Hospitalar S. João, Neuroradiology, Porto, Portugal
Background and aims: Posterior reversible encephalopathy 
syndrome (PRES) is diagnosed by suggestive clinical 
manifestations and radiological criteria. Our aim was to 
relate clinical manifestations, aetiology and prognosis with 
MRI features.
Methods: A retrospective analysis of clinical and 
radiological data of PRES patients was performed in a 
central university hospital from 2008-2014. Kruskal-Wallis 
one-way analysis of variance (statistical significance 
p<0.05) was used to compare categorical data.
Results: 13 patients (9 women) with a median age of 35 
years (range: 11-74) were included. Most frequent onset 
clinical manifestations were seizures (n=9) and visual 
abnormalities (n=4). Most prevalent PRES aetiologies were 
acute high blood pressure (n=9) and immunosuppression 
(n=4). MRI was performed in all patients (time until 
MRI - median: 4 days, range: 1-12). The following 
brain MRI patterns were observed, according to lesions 
distribution:  holohemispheric (n=3), isolated superior 
frontal sulcal (n=3) and parietoccipital (n=5). Partial 
expression of the above patterns was observed in 2 
patients. Concomitant focal areas of diffusion restriction 
were evident in 7 patients. Focal haemorrhages were found 
in 3 patients and sulcal subarachnoid haemorrhage in 2 
patients. Cortical and/or leptomeningeal areas of contrast 
enhancement (n=3) were related to seizures (p=0.026), 
consciousness impairment at onset (p=0.048) and death 
(p=0.026). We found no association between other clinical 
features and MRI.
Conclusion: Nowadays MRI is mainly used to accurately 
diagnose PRES in a patient with suggestive clinical 
manifestations.  Defining MRI patterns, presence of 
ischemic, haemorrhagic lesions and contrast enhancement 
may be additional important information to monitor the 
disease and to determine its prognosis. 
Disclosure: Nothing to disclose
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Impact of serum thyroid-stimulating  
hormone on functional outcome in  
patients with acute ischemic  
cerebrovascular event
B. Delpont, C. Aboa-Eboulé, J. Durier, B. Daubail,  
M. Giroud, Y. Béjot
Dijon Stroke Registry, EA4184, University Hospital and 
Medical School of Dijon, Neurology, Dijon, France
Background and aims: Hypothyroidism may influence 
outcome of patients with ischemic stroke. We evaluated the 
association between serum thyroid-stimulating hormone 
(TSH) levels at admission and functional outcome at 
discharge in patients with acute ischemic cerebrovascular 
event.
Methods: Patients with acute ischemic stroke or TIA 
who were admitted to the department of Neurology of 
the University Hospital of Dijon, France, were identified 
between January 2010 and December 2011. Demographic 
and clinical data including initial clinical severity were 
recorded. Serum TSH was measured within the first 18h of 
onset. TSH levels were analysed according to the tertiles of 
their distribution (<0.902 vs 0.902-1.67 vs >1.67 mmol/L). 
Associations between TSH levels and functional outcome 
at discharge assessed by the modified Rankin scale score 
were analyzed using ordinal logistic regression models.
Results: 934 patients (mean age 71.8 ± 22.2, 61% men) 
were recorded including 731 ischemic strokes and 203 
TIAs. In multivariable analyses, high TSH levels at 
admission were associated with a better functional outcome 
at discharge (OR=0.39; 95% CI: 0.28-0.55, p<0.001 for 
tertile 2 vs tertile 1; OR=0.39; 95% CI: 0.29-0.56, p<0.001 
for tertile 3 vs tertile 1). Consistent results were observed 
when considering stroke patients only (OR=0.43; 95% CI: 
0.31-0.60, p<0.001 for tertile 2 vs tertile 1; OR=0.44; 95% 
CI: 0.31-0.62, p<0.001 for tertile 3 vs tertile 1).
Conclusion: High TSH levels are associated with better 
functional outcome in patients with acute ischemic 
cerebrovascular event, independently of confounding 
variables including initial severity. Neuroprotective 
properties or neuroplatic changes could be involved to 
explain this finding.
Disclosure: Nothing to disclose
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Recurrent episodes of acute reversible 
encephalopathy: the first Greek case of 
‘CADASIL-coma’
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1University of Athens, Attikon University Hospital, Second 
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Italy, 4University of Athens, Research Unit of Radiology 
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Background and aims: The cardinal clinical features 
of Cerebral Autosomal Dominant Arteriopathy 
with Subcortical Infracts and Leucoencephalopathy 
(CADASIL), are recurrent strokes, migraine, cognitive 
impairment and psychiatric disturbances. The disease is 
caused by mutations in the notch3 gene on chromosome 19. 
The clinical course is variable and atypical phenotypes such 
as acute reversible encephalopathy have been reported.
Case Report: We describe a CADASIL case with a rare 
phenotype.
Results: A 64-year-old female patient of Caucasian 
origin, was referred to our Department with an acute 
encephalopathy preceded by an episode of severe migraine. 
Her past medical history included migraine since she was in 
her 20s, arterial hypertension, hyperuricemia. Significantly, 
over the past nine years she had had three similar episodes 
of reversible encephalopathy without a definite diagnosis. 
During the first episode she had developed generalized tonic-
clonic seizures and was since then under treatment with 
valproic acid. She was also under treatment with fluoxetine 
due to a mood disorder with mild depressive symptoms. On 
admission, she was disorientated and confused with limited 
speech content and she gradually entered an apathetic state. 
Clinical examination revealed mild right hemiparesis and 
mild pyrexia (<37.4°C). CSF examination was normal 
and EEG showed slow wave activity across the left 
hemisphere. MRI findings were classic for CADASIL. Ten 
days later she made full recovery. Genetic testing is under 
way to molecularly confirm the diagnosis of reversible 
encephalopathy in the context of CADASIL.
Conclusion: CADASIL should be considered as 
possible diagnosis in patients presenting with reversible 
encephalopathy, especially when combined with migraine 
and stroke-like episodes.
Disclosure: Nothing to disclose
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Carotid artery intima-media thickness as a 
marker of small or large vessel disease in 
ischemic stroke
F.J. Díaz de Terán1, P. Martínez Sánchez1,  
B. Fuentes Gimeno1, J. Rodríguez Pardo De Donlenbún1,  
C. Calle De Miguel1, J. Pérez Lucas1, E.M. Alba Suarez1,  
I. Illán Gala1, J. Máñez Miró1, B.E. Sanz Cuesta2,  
G. Ruiz Ares3, E. Díez Tejedor1
1Hospital Universitario La Paz, Neurology, Madrid, Spain, 
2Madrid, Spain, 3Hospital La Paz, Neurology, Madrid, Spain
Background and aims: Some studies relate the carotid 
intima media thickness (IMT) to small vessel disease (SVD) 
whilst others relate it to atheromatous large vessel disease 
(LVD). Our objective was to study the impact that has IMT 
in each of these entities, analysing their relationship in 
patients with cerebral infarction (CI).
Methods: Observational cohort study including CI patients. 
Study period: 2010-2014. Duplex carotid ultrasonography 
was performed in all patients during the first 48 hours after 
admission and mean IMT as well as the presence of atheroma 
plaques were recorded. SVD was defined as the presence 
of lacunar infarcts or moderate-important leukoaraiosis in 
neuroimaging, and LVD as extra/ intracranial brain arteries 
atheromatosis. Patients were classified into 4 groups: 1) 
SVD, 2) LVD, 3) SVD+LVD and 4) not SVD nor LVD. 
Multiple linear regression analyses were conducted to 
evaluate the association between SVD/LVD and IMT
Results: Overall, 823 patients were included, 57.2% male, 
mean age 70.9 years. Multivariate analysis showed that 
SVD (beta coefficient [ET]=0.050 [0.0197]) as well as 
LVD (Beta coefficient [SE]=0.048 [0.0167]) were related 
to mean IMT, being this association higher in case of 
SVD+LVD group (beta coefficient [SE]= 0.065 [0.0171]). 
Bonferroni test showed that the greatest difference was 
between the SVD+LVD and the group without SVD or 
LVD.
Conclusion: Both SVD and LVD are associated with mean 
IMT and this association is greater when they coexist. This 
non-invasive and easily reproducible measure is a useful 
tool to estimate vascular damage what could contribute to a 
more effective prevention.
Disclosure: Nothing to disclose
P1214
Transplantation of adult subventricular 
zone derived neural progenitor cells – an 
analysis of optimal cell delivery routes and 
their underlying mechanisms of action
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Background and aims: With neuroprotective approaches 
having failed until recently, focus on experimental stroke 
research has switched towards manipulation of post-
ischemic neuroregeneration. Transplantation of neural 
progenitor cells (NPCs) is a promising strategy for 
promotion of neurological recovery. Yet, fundamental 
questions including the optimal cell delivery route still 
have to be addressed.
Methods: C57BL6 mice were exposed to transient focal 
cerebral ischemia and allowed to survive for as long 
as 84 days post-stroke. At six hours post-stroke, NPCs 
were grafted using six different cell delivery routes, 
i.e. intravenous, intraarterial, ipsilateral intrastriatal, 
contralateral intrastriatal, ipsilateral intraventricular and 
intracortical injection. Control mice received PBS only.    
Results: Intralesional numbers of GFP+ NPCs were high 
after ipsilateral intrastriatal transplantation, whereas other 
injection paradigms yielded small numbers of grafted cells. 
However, acute neuroprotection and improved functional 
outcome was observed after both systemic (intraarterial and 
intravenous) and ipsilateral intrastriatal transplantation. 
Whereas systemic cell delivery induced acute and long-
term neuroprotection, reduction of brain injury after 
ipsilateral intrastriatal cell grafting was only temporary, in 
line with the loss of transplanted NPCs in the brain. Both 
systemic and ipsilateral intrastriatal NPC delivery reduced 
microglial activation and leukocyte invasion, reducing free 
radical formation within the ischemic brain. Noteworthy, 
only systemic NPC administration stabilized the blood-
brain-barrier and reduced leukocytosis in the blood. 
Although intraarterial NPC transplantation was as effective 
as intravenous cell grafting, mortality of stroke mice was 
high using this delivery route. 
Conclusion: Intravenous delivery of NPCs in our 
experimental model is an attractive and effective strategy 
for stroke therapy that deserves further proof-of-concept 
studies.    
Disclosure: Nothing to disclose
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The bed cycling test: a bedside test for 
unilateral cerebral dysfunction
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1University Hospital, Department of Neurology and German 
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3University Hospital, Department of Neurology, Munich, 
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Background and aims: Analogously to the forearm rolling 
test to detect unilateral upper limb dysfunction a so-called 
bed cycling test (BCT) was developed and evaluated to 
detect mild to moderate unilateral lower limb dysfunction 
and compared to the leg holding test.
Methods: In a prospective examiner-blinded study 60 
patients with MRI or CT proven acute focal cerebral 
hemisphere lesions and a mild to moderate unilateral 
paresis of the lower limb (graduated 3-4/5 on MRC scale) 
and 60 control persons with normal imaging and without 
obvious focal signs were examined using a battery of 
clinical tests including the filmed BCT and leg holding 
test. Nine examiners, who were blinded to the diagnosis, 
evaluated these tests presented to them on videos. 
The Example patient performing bed cycling test (BCT). Patient is 
lying on his back. Both legs are flexed in the hip. The patient is asked 
to air cycle rapidly with closed eyed forwards for 10 seconds and 
backwards for 10 seconds (bed cycling test). 
Results: The BCT was rated right positive in 35.5% 
compared to leg holding test in 26.0%. Examiners had false 
negative results in 29.1 % of cases using BCT and 44.7% 
using leg holding test. In 36.7% only BCT was pathological 
while leg holding test was unremarkable, In conclusion 
BCT is more sensitive (64.3%) than leg holding test 
(46.2%) while the specificity of leg holding test (85.6%) 
is higher than of BCT (70.1%) to detect a cerebral lesion 
affecting the lower limb.
Conclusion: The BCT is a useful additional clinical bedside 
test to detect subtle unilateral cerebral lesions, especially 
when regular neurological examination is unremarkable. 
The BCT is easy to perform and can be added to the 
neurological routine examination.
Disclosure: This study was supported by the BMBF to the 
IFB (grant code 01 EO 0901).
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Misdiagnosis of the central variant of  
posterior reversible encephalopathy
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H. Nzwalo1
1Centro Hospitalar do Algarve, Neurology, Faro, Portugal, 
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Background and aims: Posterior reversible encephalopa-
thy syndrome (PRES) is a neurological complication 
characterized by different manifestations associated 
vasogenic edema in the parietal-occipital lobes. Its central 
variant (CV) refers to the exclusive or predominant 
brainstem involvement.
Case Report: A 49-year-old hypertensive woman was 
admitted to our stroke unit after onset of left homonymous 
hemianopia. She was stable (170/97 mmHg). Brain MRI 
showed a right-sided posterior cerebral artery (PCA) 
ischemic stroke. Recent history was remarkable for diffuse 
brainstem glioma (DBSG) diagnosed in the previous year, 
treated with radiotherapy and temozolamide, with complete 
clinical and radiological remission.   DBSG was diagnosed 
after the finding of “de novo” extensive brainstem lesion on 
MRI preformed because of hypertensive encephalopathy 
(HE) manifested with severe headache, confusion and 
refractory high blood pressure (≥230/130mmHg). The 
MRI lesion was not present 5 months earlier. Apart from 
papilledema, the examination was normal. With blood 
pressure normalization, manifestations disappeared (3 
days).
Results: Stroke investigation was negative. The presence 
of associated radiation induced leukoencephalopathy 
supported a presumptive diagnosis of radiation-induced 
PCA disease.
Conclusion: The absence of brainstem signs in a patient 
with a presumable rapidly growing brainstem lesion and 
complete resolution during follow up, are unexpected 
findings of DBSG. On contrary, the triad of HE, remarkable 
clinical-radiological dissociation and striking total 
reversibility of any extensive brainstem lesion is highly 
suggestive of CV of PRES. Because brainstem biopsy is 
not universally performed in presumed cases of DBSG, 
considering the diagnosis of this rare variant of PRES 
is fundamental to avoid unnecessary investigations and 
treatments.
Disclosure: Nothing to disclose
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No evidence for retinal damage evolving 
from reduced retinal blood flow in  
internal carotid artery stenosis
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E.M. Kadas1, A. Brandt1, A. Kauert2, S.J. Schreiber3,  
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Background and aims: High-grade internal carotid artery 
stenosis (CS) may lead to impaired retinal blood flow. The 
objective of this study was to examine the influence of 
chronic reduced retinal blood flow in CS on morphological 
or functional measures of the retina.
Methods: Patients with unilateral CS (lumen reduction 
≥50%, ECST-criteria) were grouped according to the 
grade of the stenosis and the direction of blood flow in the 
ophthalmic artery (OA). Transorbital duplex ultrasound 
was performed to assess optic nerve sheath diameter and 
optic nerve diameter. In addition, retinal perfusion was 
evaluated by analysis of central retinal artery (CRA) blood 
flow velocities. Retinal spectral domain optical coherence 
tomography (OCT) examinations were performed to 
acquire retinal nerve fibre layer thickness, total macular 
volume, ganglion cell/inner plexiform layer volume, and 
optic nerve head volume. Visual function was measured by 
high- and low contrast visual acuity. Intra-patient inter-eye 
statistics were performed for all parameters.
Results: 27 CS patients were enrolled (table 1). Eyes 
with CS ≥80% and retrograde OA blood flow showed a 
significant reduction of CRA peak systolic velocities (No-
CS side: 0.130±0.035 m/s, CS side: 0.098±0.028; p=0.005; 
n=12; figure 1). OCT, ultrasound and visual functional 
parameters did not show a significant difference.
Table 1: Demografic details for different CS groups. N total = 27. CS = 
carotid artery stenosis, ICA = internal carotid artery, OA = ophthalmic 
artery, SD = standard deviation. 
Figure 1: Inter-eye comparison of peak systolic blood flow velocities 
in the central retinal artery (CRA) for different CS groups. **p<0.01. 
CS = carotid artery stenosis, OA = ophthalmic artery.
Conclusion: Our data shows that a CS induced 
hemodynamic impairment of CRA blood flow does not 
lead to gaugeable morphological or functional changes of 
the retina. The collateral pathway of the retrograde OA, 
however, seems to be an important factor for the retinal 
blood supply.
Disclosure: Nothing to disclose
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Self-awareness of performance in  
cognitive testing: differences between  
healthy elderly and patients with 
Parkinson’s disease (PD)
S. Fragkiadaki1, N. Andronas1, I. Beratis1,  
D. Kontaxopoulou1, D. Pavlou2, A. Liozidou1, A. Economou3, 
G. Yannis2, S. Papageorgiou1
1Athens University Medical School, 2nd Neurology Clinic, 
Attikon Hospital, Athens, Greece, 2National Technical 
University of Athens, School of Civil Engineering, 
Department of Transportation Planning and Engineering, 
Athens, Greece, 3National University of Athens, Department 
of Psychology, Athens, Greece
Background and aims: The concept of “self-estimation” 
reflects the ability of an individual to evaluate his own 
performance with relatively objective terms. A limited 
number of studies have systematically studied this topic 
in Parkinson’s Disease (PD) patients. The scope of the 
present study was to compare objective measures of 
neuropsychological performance with the subjective 
evaluation of the corresponding performance as well as to 
investigate differences in the self-assessment profile of PD 
patients and cognitively intact individuals.
Methods: 28 participants diagnosed with PD (25 males, 
age=63.13±11.32 years, disease duration=5.26±4.11 
years, Hoehn&Yahr=1.9±0.4) and 33 matched for age and 
education control subjects (30 males, age=59.82±10.27 
years) were examined with an extended battery of 
neuropsychological tests. After every test they were asked 
to self-evaluate their performance by comparing it to what 
they considered as average for people of their age and 
educational level. This self-evaluation was reported on a 
scale ranging from -100 to +100.
Results: Significant differences were found in the self-
assessment patterns of the two groups in episodic memory 
measures for verbal and visuospatial material as well as 
on tasks engaging executive, attentional and reaction time 
resources. PD patients overestimated their performance on 
attentional and visuospatial tasks while control participants 
underestimated their performance on measures of verbal 
and visuospatial episodic memory.
Conclusion: The current results indicate the presence of a 
generalized difficulty of patients with PD in assessing their 
performance on neuropsychological measures that could 
reflect an impairment in monitoring mechanisms due to 
their neurological condition.
Disclosure: Nothing to disclose
P1219
Amnestic mild cognitive impairment due 
to Alzheimer’s disease is specifically  
characterized by APOE4 status but not 
mesial temporal atrophy using a visual  
rating scale
D.A. García-Estévez1, M. Marey-Garrido2,  
J.A. Bravo-Ricoy3
1Hospital Comarcal de Monforte de Lemos, Unit of 
Neurology, Monforte de Lemos, Spain, 2Hospital Comarcal 
de Monforte de Lemos, Radiology Sevice, Monforte de 
Lemos, Spain, 3Hospital Comarcal de Monforte de Lemos, 
Epidemiology Service, Monforte de Lemos, Spain
Background: The use of biomarkers (total-Tau, phospho-
Tau, amyloid-β peptide) in the cerebrospinal fluid (CSF) 
are useful to identify patients with amnestic mild cognitive 
impairment (MCI) due to Alzheimer’s disease (MCI-AD), 
and so we could start the treatment with both drugs and 
cognitive therapy in this early predementia phase. Other 
variables as age, severity of temporal atrophy, APOE status, 
first degree relatives of dementia (FDR) and the score in 
different cognitive tests could be altered in these patients.
Aim: To identify in a sample of amnestic MCI (aMCI), using 
the biomarkers of AD in CSF, who have a prodromal AD 
and which clinical and paraclinical variables characterize 
them.
Patients and Methods: We have studied 38 patients with 
aMCI using the Memory Alteration Test (M@T). All of the 
patients underwent a lumbar puncture and the biomarkers of 
AD in their CSF were analyzed and the dementia Hulstaert 
index was calculated. A magnetic resonance imaging was 
done to measure the atrophy of the hyppocampal and 
mesial temporal areas using a visual rating scale (MTA 
rating). The APOE status was determined in all patients.
Results: 28 out of 38 patients were classified as MCI-
AD using the Hulstaert index and phospho-Tau value. 
Comparing with MCI- no AD patients we did not find 
significative differences in age, M@T score, MTA rating 
and FA. However, MCI-AD patients were characterized by 
to be carrier of APOE4.
Conclusion: Patients with aMCI can be diagnosed as 
prodromal Alzheimer’s disease using biomarkers in CSF 
(Hulstaert index) and APOE status but not by MTA rating.
Disclosure: Nothing to disclose
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Multi-channel EEG analysis of a stimulus 
dependent deliberation process leading  
to a decision for releasing an adequate 
motor command
S. Henz1, J. Werner1, D. Kutz1, W. Hürster2, F. Kolb1,  
J. Nida-Rümelin3
1University of Munich, Institute of Physiology, Munich, 
Germany, 2Research and Consulting, Munich, Germany, 
3University of Munich, Department of Philosophy IV, Munich, 
Germany
Background and aims: The aim of this study was to deter-
mine whether a deliberative process is detectable in EEG 
recordings. Deliberation was related to an evaluation of 
short-lasting visual stimuli leading to a decision for relea-
sing adequate motor commands.
Methods: 25 young and healthy, right handed participants 
had to press one of two buttons in a simple motor task 
and a color-word Stroop task. In the simple motor task 
participants knew which button to press, whilst in the color-
word Stroop task they had to press with the right index 
finger when meaning and color coincided, or with the left 
index finger when meaning and color were disparate.
Results: In simple motor task EEGs a sequence of positive 
(P) and negative (N) cortical potentials (P1-N1-P2), 
assumed to be related to the processing of the performed 
movement, was observed. The sequence was similar in 
EEGs of participants having to deliberate over how to 
respond but was preceded by a slowly increasing negativity 
terminating in a maximum negativity (N0).
Conclusion: The N0 was assumed to represent the end 
of the deliberation process during the Stroop task. The 
duration of the increasing slope terminating in N0 may 
reflect the duration of the deliberation process. Our data 
suggest the existence of neurophysiological correlates of 
deliberative processes. 
Disclosure: Nothing to disclose
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Seasonal changes in the incidence of  
transient global amnesia
O. Keret, N. Lev, I. Steiner
Rabin Medical Center, Beilinson Hospital, Department of 
Neurology, Petach Tikva, Israel
Background and aims: Transient global amnesia (TGA) 
is a stereotypic condition, characterized by anterograde and 
retrograde amnesia that typically resolves within 24 hours. 
The pathophysiology of TGA is still unclear. We noted that 
patients hospitalized with TGA tend to appear in seasonal 
clusters. We therefore retrospectively reviewed the monthly 
occurrence of TGA in our patient population.
Methods: In our department every patient with acute pre-
sentation of amnesia is hospitalized for observation and 
evaluation. We reviewed the prevalence of TGA in our pa-
tient population between the years 2005 and 2013. 
Results: During this period, 86 patients who met the criteria 
for TGA were hospitalized. Annual incidence ranged from 4 
to 16. There were 32 men and 54 women, their age ranging 
n 32 to 79, (mean age of 61+10.3). Two prevalence peaks 
within each year were observed: November-December and 
March with monthly rate “climbs” and “descends” from 
each of these peaks. 
Conclusion: We are unaware that the seasonal occurrence 
of TGA was examined before. The hypothesis that TGA is 
due, at least in some patients, to infection, probably viral, 
is based on this observation of seasonal distribution of. It 
should be examined and verified in other cohorts.
Disclosure: Nothing to disclose
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Screening for postoperative delirium  
in patients with acute hip fracture:  
assessment of predictive factors
A. Koskderelioglu1, O. Onder1, M. Gucuyener1, T. Altay2,  
C. Kayali2, M. Gedizlioglu1
1Izmir Bozyaka Education and Research Hospital, 
Department of Neurology, Izmir, Turkey, 2Izmir Bozyaka 
Education and Research Hospital, Departement of 
Orthopaedics and Traumatology, Izmir, Turkey
Background and aims: The aim of this study is to estimate 
the incidence and risk factors of delirium during the early 
postoperative period following hip fracture surgery. 
Furthermore, we investigated the accuracy of Confusion 
Assessment Method for the Intensive Care Unit (CAM-
ICU) for detection and assessment of delirium.
Methods: We consecutively recruited the patients older than 
65 years undergoing hip fracture surgery in the orthopaedics 
clinic during the study period. The presence of delirium 
was determined daily by two of the authors according to 
CAM-ICU criteria. A further evaluation was made with the 
reference standard DSM-IV criteria for delirium by another 
author unaware of the former. Their cognitive function 
was evaluated with the Mini-Mental State Examination 
(MMSE) and a possible depressive mood with the Beck 
Depression Inventory (BDI). Baseline characteristics, 
as well as ASA classification and clinical outcomes were 
analyzed for the correlation with accompanying delirium.
Results: Among 109 patients, 20 (18.3%) were diagnosed 
with delirium. The concurrent validity of CAM-ICU was 
good (kappa=0.84). Specificity was 98.9%, and sensitivity 
was 80%. Multivariate regression analysis showed that 
MMSE (p=0.001) and BDI scores (p=0.002) correlated 
with the occurrence of delirium. 
Conclusion: Our results point that CAM-ICU is highly 
sensitive and specific to identify delirium in hip fracture 
patients in the postoperative period. Among all of the risk 
factors, cognitive impairment and depressive mood were 
strongly associated with postoperative delirium. We suggest 
that a preoperative assessment of cognition and depression 
may be useful for identifying patients with higher risk of 
postoperative delirium.
Disclosure: Nothing to disclose
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Quality of life and neuropsychiatric  
symptoms in patients with clinically  
isolated syndrome
J. Laczó1, E. Hynčicová2, M. Vyhnálek2, J. Vecánová2,  
J. Libertínová2, I. Kovárová3, T. Nikolai2, J. Hort1,  
E. Meluzinová2
1International Clinical Research Center, St. Anne’s University 
Hospital Brno, Brno, Czech Republic, 22nd Faculty of 
Medicine, Charles University in Prague and Motol University 
Hospital, Department of Neurology, Prague, Czech Republic, 
31st Faculty of Medicine, Charles University in Prague and 
General University Hospital in Prague, Department of 
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Background and aims: Health-related quality of life 
is poorer and neuropsychiatric symptoms including 
depression, anxiety and apathy together with fatigue are 
more common in patients with multiple sclerosis (MS). 
These conditions have not been investigated in patients 
with clinically isolated syndrome (CIS), who are at higher 
risk of developing MS.
The aim was to describe factors that may influence health-
related quality of life and describe which neuropsychiatric 
symptoms are present in patients with CIS.
Methods: Patients with CIS on interferon-beta (n=44; 
8.1±9.5 months on medication; EDSS 1.6±0.7) underwent 
clinical examination, brain MRI, cerebrospinal fluid 
assessment and neuropsychological examination including 
questionnaire measuring health-related quality of life––
RAND-36 item Health Survey (SF-36), and following 
neuropsychiatric scales: Beck Depression Inventory (BDI), 
Beck Anxiety Inventory (BAI), Apathy Evaluation Scale 
(AES) and Fatigue Severity Scale (FSS). Results were 
compared to age, gender and education matched healthy 
controls (n=32).
Results: Patients with CIS had according to SF-36 poorer 
general health conditions (p<.001), physical functioning 
(p=.003) and more bodily pain, which interfered with their 
normal work (p=.001), but were not limited in their life 
due to physical health. Patients did not manifest increased 
fatigue on FSS scale. Patients manifested more anxiety 
(BAI) and depressive (BDI) symptoms but no apathy 
(AES).
Conclusion: Poorer physical functioning as well as 
depression and anxiety are reported already in patients with 
CIS. With exception of bodily pain, they do not interfere 
with patients’ work and activities of daily living. Contrary 
to previous studies with MS patients, patients with CIS do 
not report increased fatigue or apathy.
Disclosure: This study was supported by European 
Regional Development  Fund - Project FNUSA-ICRC 
(No. CZ.1.05/1.1.00/02.0123) and by project ICRC-
ERA-HumanBridge (no. 316345), Ministry of Health, 
Czech Republic - conceptual development of research 
organization, University Hospital Motol, Prague, Czech 
Republic 00064203 and Institutional Support of Laboratory 
Research Grant No. 2/2012 (699002).
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Modulation of fMRI amygdaloid activation 
combined with the recording of  
electrodermal resistance in response to 
variations in emotional intensity
B. Louise1, A. Comte2, L. Tatu1, J.L. Millot3, T. Moulin1,  
E. Medeiros de Bustos1
1CHRU J. Minjoz , Neurology, Besancon, France, 2INSERM, 
Fonctional neuroimaging , Besancon, France, 3Besançon 
Laboratory of Intergrative and Clinical Neuroscience, 
Besancon, France
Background and aims: Although the development 
of functional imaging techniques has established the 
implication of the amygdala in the emotional process, 
its specific role remains controversial. The aim of this 
study was to highlight the sensitivity of the amygdala to 
emotional intensity (arousal).
Methods: We conducted an analysis of the modulation of 
amygdala activation according to variation in emotional 
intensity via an fMRI event-related protocol. Monitoring 
of electrodermal activity, a marker of psychophysiological 
emotional perception and which reflects the activation of the 
autonomic nervous system, was carried out concurrently. 
18 subjects (10 men; aged from 22 to 29 years) looked at 
emotionally positive photographs.
Results: We demonstrated that the left and right amygdalae 
were sensitive to changes in emotional intensity, 
activating more in response to stimuli with higher arousal. 
Furthermore, electrodermal responses were more frequent 
for the most intense stimuli, demonstrating the concomitant 
activation of the autonomic nervous system.
Conclusion: These results highlight the sensitivity of 
the amygdala to the intensity of positive emotions, and 
in conjunction with results in the literature on negative 
emotions, prove the role of the amygdala in the perception 
of intensity.
Disclosure: Nothing to disclose
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Novel computerized neglect test reveals 
an ipsilesional spatial attention bias in 
acute right hemisphere stroke patients  
without hemispatial neglect
B. Machner1, I. Koenemund1, P. Bays2, J. von der Gablentz1, 
C. Helmchen1, A. Sprenger1
1University of Luebeck, Dept. of Neurology, Lübeck, 
Germany, 2University College London, Institute of Neurology, 
London, United Kingdom
Background and aims: Diagnosis of hemispatial neglect is 
mainly based on clinical observation and neuropsychological 
paper-pencil test batteries. We questioned whether right 
hemisphere stroke patients without clinical signs of neglect 
and normal performance in established paper-pencil tests 
may still have an ipsilesional spatial attention bias.
Methods: We investigated 33 acute right hemisphere stroke 
patients, 20 were assigned to the “Neglect group” based on 
their pathological performance in a paper-pencil test battery 
for neglect, 13 with normal test performance constituted 
the “RBD group” (right brain damage without neglect). 
Patients, as well as 11 healthy control subjects, underwent 
a novel computerized visual search task resembling a real 
life situation, where a paperclip had to be found on a desk 
among other distractors (“Desk scene”, 100 trials). We 
recorded eye movements and reaction times and analysed 
the number of trials with correct target detection.
Results: Despite completely normal paper-pencil test 
performance, RBD patients showed a clear ipsilesional 
spatial attention bias in the Desk scene. They performed on 
a better absolute level as compared to the Neglect group, but 
revealed a similarly steep attentional gradient from right to 
left. The further left the target, the lower the detection rate 
and the higher the reaction time. RBD patients’ fixations 
also revealed a mild rightward shift.
Conclusion: There is an ipsilesional spatial attention bias 
in right hemisphere stroke patients that is not detected by 
standard paper-pencil tests for neglect. This pathological 
bias may impair patients in the demanding situations of 
daily living, which should be considered in the rehabilitation 
process.
Disclosure: Nothing to disclose
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S-adenosyl methionine (SAMe) reverses 
the development of tolerance to analgesic 
activity of morphine in rats
J. Katyal, H. Kumar, D. Joshi, Y.K. Gupta
AIIMS, New Delhi, Pharmacology, New Delhi, India
Background: Chronic administration of morphine results 
in development of tolerance to its analgesic effects, 
limiting its clinical usefulness in pain management. Role 
of S-adenosyl methionine (SAMe) in morphine tolerance 
was evaluated.
Methods: Morphine tolerance was developed by daily ad-
ministration of morphine at 3 or 7mg/kg, intraperitoneally 
(ip) for 5 days. Male Wistar rats (150-250g), were divided 
into 6 groups (n=6) and received SAMe 800 mg/kg orally 
(po), morphine 3mg/kg or 7mg/kg (ip), or combination of 
SAMe followed by morphine either dose 45 min later for 5 
days. The analgesic activity was determined using tail flick 
analgesiometer (Techno, India). In a separate set of expe-
riments, SAMe was administered for five days. On the 4th 
and 5th day naloxone (1mg/kg), subcutaneous (sc) was gi-
ven 15 min before SAMe to study opioidergic involvement.
Results: Morphine per se at 3 and 7mg/kg showed tolerance 
to analgesic activity after day 3 and day 1 respectively. 
SAMe per se showed analgesic effect after three days of 
repeated administration. Co-administration of morphine 
and SAMe reversed morphine tolerance. On the other 
hand, naloxone per se and when given with SAMe had no 
significant effect on tail flick latencies.
Conclusion: S-adenosyl methionine not only per se has 
an analgesic activity but also can reverse the tolerance to 
analgesic effect of morphine. This analgesic action of SAMe 
appears to be independent of opioidergic involvement.




Nizhniy Novgorod, Russian Federation
Background and aims: Celiac disease (CD) is an 
autoimmune enteropathy triggered by the ingestion of 
gluten. CD, migraine and fibromyalgia (FM) are the 
common disorders of the population. The aim of the study 
was to access the prevalence of migraine and FM among 
CD patients.
Methods: We examined 200 CD patients and 100 patients 
with reflux esophagitis and without CD from the control 
group for migraine. All patients fulfilled the headache diary 
during three months before diagnosis of migraine was made 
and six months of the gluten diet. They had neurological 
and instrumental examination and questioned on FM, 
restless legs syndrome, large and small fibers neuropathies, 
depression, anxiety.
Results: CD group had the migraine syndrome four times 
more often than. In CD group the migraine attacks were 2.5 
times more frequent, but the duration of the attacks was less 
long. The migraine attacks in CD group were less intensive 
and had a late debut. The attacks were more frequent in 
CD patients who were older than 50 years old. The attacks 
disappeared in 25% of the CD patients with migraine 
syndrome who were on the agluten diet and 38% had 
reduction of the intensity and/or the attacks frequency. FM 
was three times more frequent in CD patient group (22%). 
Conclusion: We revealed the association between the 
migraine syndrome and CD and the high efficiency of the 
agluten diet. Also we found the direct correlation between 
FM and small fibre neuropathy, restless legs syndrome, 
depression, anxiety in CD patient group.
Disclosure: Nothing to disclose
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Anodal transcranial direct stimulation 
(tDCS) targeting the anterior cingulate 
gyrus for the treatment of chronic cluster 
headache: a proof-of-concept trial
D. Magis, A. Cosseddu, S.L. Sava, K. D‘Ostilio, J. Schoenen
headache research unite, neurology, Liege, Belgium
Background: There is a need for better treatments 
in chronic cluster headache (CCH). In responders to 
percutaneous occipital nerve stimulation the subgenual 
anterior cingulate gyrus was found hypermetabolic (Magis 
et al.2011). We reasoned that activation of this area by 
transcranial neurostimulation could be effective in CCH.
Aim: To explore the preventive effect of anodal (i.e. 
activating) transcranial direct current stimulation (tDCS) 
targeting the anterior cingulate gyrus in CCH patients.
Methods: CCH patients applied tDCS (2mA) daily for 20 
minutes during 4 weeks with anode positioned over the 
forehead (FpZ), and cathode over C7. Therapeutic effects 
were monitored with paper diaries.
Results: 9 CCH patients were enrolled up to now: 7 
completed the trial, 2 were not satisfied and dropped 
out. In evaluable patients mean weekly attack frequency 
decreased by 44% after 3 weeks (W-test: p = 0.03) and by 
34% after 4 weeks (n=6; W-test: p = 0.04). Four weeks after 
the last stimulation, attacks had decreased by 73% (n=5). 
The first 3 enrolled patients had superficial skin burns under 
the adhesive cathode electrode. Sponge electrodes were 
used for all subsequent patients without any adverse effect. 
This study is ongoing and will include 20 patients.
Conclusion: Anodal tDCS targeting the anterior cingulate 
gyrus may be promising for the preventive treatment of 
chronic cluster headache according to the interim results of 
this ongoing proof-of-concept study. The use of adhesive 
electrodes is not recommended.
Disclosure: This trial was funded by the Fondation Roi 
Baudouin.  Devices were provided by Cefaly Technology®. 
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Thermal pain threshold in migraine:  
comparison between episodic or chronic 
migraine patients and healthy volunteers 
using QST
S.L. Sava, R. Baschi, A. Cosseddu, K. D‘Ostilio,  
V. De Pasqua, J. Schoenen, D. Magis
Headache Research Unit, Departement of Neurology, Liege, 
Belgium
Background and aims: Cutaneous allodynia is frequent 
interictally in migraine, more so in chronic (CM) than in 
episodic migraine (EM) (Schwedt et al 2011). In this study 
we assessed thermal pain thresholds with quantitative 
sensory testing (QST) in healthy volunteers (HV) and 
episodic (EM) or chronic migraineurs (CM) between 
attacks.
Methods: Cold and heat sensory (CST & HST) and pain 
thresholds (CPT & HPT) were measured in 28 HV, 21 EM 
and 18 CM patients between attacks with a Medoc° Ther-
mal Sensory Analyser. During incrementing or decremen-
ting caloric stimulation with a 5.7 cm² probe placed on the 
forearm or the forehead subjects were asked to press a but-
ton when the stimulus was perceived and when it became 
painful. The means of 3 stimulations were compared bet-
ween groups with One-Way ANOVA.
Results: There were no significant differences in forehead 
QST between the 3 groups. By contrast, in the forearm 
CST was increased in CM (28.35°C) compared to HV 
(29.72°C) (p=0.02; F=3.73), while HST was decreased 
(CM=35.27°C; HV=34.13°C) (p=0.004; F=5.93) and CPT 
decreased (CM=19.12°C; HV=12.69°C) (p=0.02; F=3.93). 
QST was not different between EM and HV.
Conclusion: Decreased forearm cold pain thresholds 
suggest that chronic migraine patients have selective 
extracephalic cold allodynia between attacks. Since 
forehead thermonociceptive thresholds are normal, this is 
probably not a consequence of the headache. Whether it 
might be explained by malfunctioning endogenous pain 
control or eventually involvement of the cold/menthol 
sensing TRPM8 receptor, of which the gene is associated 
with migraine in GWAS, deserves further research.
Disclosure: Nothing to disclose
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Modulation of the nociceptive blink reflex 
by repetitive transcranial magnetic  
stimulation in healthy volunteers:  
comparison of visual or motor cortex  
stimulation.
S.L. Sava, A. Cosseddu, K. D‘Ostilio, V. De Pasqua,  
J. Schoenen, D. Magis
Headache Research Unit, Departement of Neurology, Liege, 
Belgium
Background and aims: Connexions between cortex 
and the trigeminal system may play a role in migraine. 
Repetitive transcranial magnetic stimulation (rTMS) of 
visual (Sava et al., 2014) or motor cortex (M1) (De Vito 
et al. 2009) modulates the trigeminal nociceptive system. 
In this study we searched which of visual or motor cortex 
rTMS has the greatest effect.
Methods: Nociception specific blink reflexes (nBR) were 
recorded in 37 healthy volunteers (HV). rTMS of visual 
cortex was performed in 22 HV, M1 rTMS in 15 HV. With 
a figure-of-eight coil 800 pulses were delivered at 1 Hz or 
10 Hz in random order on separate days. Before and after 
rTMS we measured sensory and pain thresholds, R2 area 
under the curve (AUC) and habituation on 15 averagings 
partitioned in 3 blocks of 5 responses.
Results: 1 Hz rTMS over visual cortex decreased pain 
threshold (p=0.001), increased R2 AUC of the 1st nBR 
block bilaterally (p=0.02) and increased habituation 
contralaterally (p=0.0002). 10 Hz rTMS over the visual 
cortex had no effect on nBR.
Over M1, 1 and 10 Hz rTMS increased habituation 
contralaterally (p=0.004 and p=0.01 respectively), but had 
no effect on pain thresholds or nBR amplitude.
Conclusion: Visual rTMS is more effective on trigeminal 
nociception than M1 rTMS. In HV the visual cortex seems 
to have stronger functional connexions with the trigeminal 
nociceptive system than the motor cortex, which may have 
implications for the use of rTMS to treat trigeminal pain.
Disclosure: Nothing to disclose
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Central sensitisation phenomena in  
chronic migraine and chronic orofacial 
Pain
M.D.L.A. Mangas Guijarro1, A. Gil Martinez2,  
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1La Paz University Hospital. IdiPAZ Health Research Institute 
, Neurology. Headache Clinic, Madrid, Spain, 2La Paz 
University Hospital. CSEU La Salle. Autónoma of Madrid 
University, Physiotherapy, Madrid, Spain, 3La Paz University 
Hospital, Physiotherapy, Madrid, Spain, 4La Paz University 
Hospital. IdiPAZ Health Research Institute, Neurology.  
Headache Clinic, Spain, Spain, 5Hospital Universitario la 
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Stroke center, Madrid, Spain
Background and aims: Previous studies have suggested 
the presence of central nociceptive impairment in chronic 
migraine(CM) and chronic orofacial pain(COP) attributed 
to temporomandibular disorders(TMD), but available 
results are conflicting. In addition, some chronic pain 
comorbidity, such as anxiety or depression are known to 
affect pain sensitivity. Our aim was to investigate central 
sensitisation, disability and psychiatric comorbidity in 
patients with CM and COP attributed to TMD compared to 
healthy subjects.
Methods: Cross-sectional observational study with 33 
subjects suffering from CM, 23 heterogeneous COP 
and  26 matched healthy controls. Bilateral multi-segmental 
pressure pain thresholds (PPTs), temporal sumamation of 
pain (TSP), and information about duration-of-pain history, 
Neck Disability Index (NDI), Craniofacial Pain Disability 
Inventory (CF-PDI), Beck Depression Inventory (BDI) and 
State Trait Anxiety Inventory (STAI) scores were analyzed.
Results: 82 participants (79 women), mean age, 47.2 years 
(21-70). On average, there were significant differences in 
PPTs (all sites: P<0.001), TSP (all sites: P<0.009), NDI 
(P<0.001), CF-PDI (P<0.001) and BDI score (P<0.02) in 
patients with CM and COP as compared to healthy controls. 
Nevertheless, there were no significant differences in the 
magnitude of PPT decreases, as well as in TSP and BDI 
between both groups (P>0.05). PPT levels over distant 
pain-free areas were positively correlated to PPTs over 
trigemino-cervical areas (P<0.01). Additionally, positive 
correlation between duration-of-pain history and TSP was 
found (P<0.05). 
Conclusion: The results revealed bilateral widespread 
pressure pain hypersensitivity in patients with CM and 
COP attributed to TMD. These findings support the view 
that central sensitization mechanisms are involved in both 
conditions.
Disclosure: Nothing to disclose
188      Poster presentation with discussion
© 2015 European Journal of Neurology, 22 (Suppl. 1), 120–483
P1232
Vestibular migraine: clinical characteristics 
in a series of 24 cases
E. Martínez Velasco1, M. Ruiz Piñero1, M. de Lera2,  
M. Pedraza2, A. Juanatey3, L. Blanco3, J.A. Cámara-Arnaz4, 
J.I. Benito-Orejas4, A.L. Guerrero2
1Valladolid, Spain, 2Valladolid Hospital, Neurology, 
Valladolid, Spain, 3Clinic Hospital, Neurology, Valladolid, 
Spain, 4Clinic Hospital, Otorhinolaryngology, Valladolid, 
Spain
Background and aims: Vestibular Migraine (VM) 
has been included in the appendix of the International 
Classification of Headache Disorders (ICHD-III). It is 
defined by vestibular symptoms of moderate to severe 
intensity, associated with headache with migrainous 
features, visual aura or photo-phonophobia. We aimed to 
analyze demographic and clinical characteristics of a series 
of 24 cases.  
Methods: We considered consecutive patients who 
attended from January 2014 to January 2015 in an 
outpatient headache office. We gathered age at inclusion, 
age at onset of migraine and VM, and intensity, duration 
and characteristics of vestibular symptoms. We excluded 
patients with other vestibular disorders.
Results: 24 patients (16 females, 8 males) were included. 
Age at inclusion was 28.8±12.5 years (14-52), at migraine 
onset 19.2±9.6 (7-46) and at VM onset 24.4±11.1 (7-46). 
5 patients (20.8%) fulfilled criteria of chronic migraine. 
Regarding vestibular symptoms, 2 patients (8.3%) rated 
them as severe and occurred in 85.4±21.4% (40-100) of 
migraine attacks. Duration of episodes was quite variable. 
Vertigo was described as internal in 6 patients (25%), 
external in 17 (70.8%) and both internal an external in one 
(4.2%). In 9 cases (37.5%) vertigo was spontaneous, in 20 
(83.3%) positional and in 11 (45.8%) motion-induced. No 
patient described visually induced vertigo or head motion 
dizziness with nausea. Aural fullness (16.7%) and tinnitus 
(33.3%) were common accompanying symptoms.
Conclusion: Vestibular migraine diagnosed according to 
ICHD-III criteria is not uncommon in a headache office. 
Most frequent vestibular symptoms are spontaneous, posi-
tional and motion-induced vertigo.
Disclosure: Nothing to disclose
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Fahr’s disease: heterogeneous clinical 
manifestations of an under-recognized  
disease
L. Magistrelli1, M. Carecchio1, B. Garavaglia2, A. Stecco3,  
C. Barzaghi4, C. Comi5, R. Cantello6
1Novara, Italy, 2Milan, Italy, 3Department of Translational 
Medicine, Section of Radiology, . Department of Translational 
Medicine, Section of Radiology    , Novara, Italy, 4“C.Besta” 
Milan, Italy  , Molecular Neurogenetics Unit, Milan, Italy, 
5University of Eastern Piedmont, “Amedeo Avogadro”, 
Novara, Italy    , Department of Translational Medicine, 
Section of Neurology, Novara, Italy, 6Novara, Italy
Background and aims: Fahr’s disease (FD) is characterized 
by intracranial calcifications mainly involving basal ganglia 
and dentate nuclei. Three causative genes (SLC20A2, 
PDGFB, PDGFRB) have been discovered so far. Clinical 
presentation is heterogeneous and sometimes diagnosis 
may be incidental.  Our aim is to define the aetiological, 
clinical, genetic spectrum of patients with a radiological CT 
scan consistent with FD. 
Methods: We investigated all the reports of CT brain 
scan performed at the Radiology Department of Maggiore 
Hospital, Novara, Italy, from 2008 to 2014 using “Fahr” 
and “basal ganglia calcifications” as keywords. The 
selected scans were reviewed by an expert neuroradiologist 
who excluded those not consistent with FD, according to 
Manyam.  Thereafter, we analyzed available clinical and 
laboratory records. In a few patients, regularly followed-up 
at the Neurology Department, we also performed genetic 
analyses. 
Results: Out of 194/58000 patients with evidence of 
cerebral calcifications, only 67 had a CT scan consistent 
with FD. Secondary causes were ruled out; genetic analysis 
was performed in 9 patients [Table 1], with mutations in 
SCL20A2 gene identified in three cases (c.338C>G in a 
66-year-old man with focal chorea of the hand, c.1463A>G 
in a 61-year-old woman with subjective memory 
complaints, and c.1765G>A in an 82-year-old woman 
with drowsiness, visual hallucinations and short stature). A 
PDGFRB mutation (c.676C>T) was detected in a 33-year-
old man with paroxysmal kinesigenic dystonia.   
Characteristics of patients genetically tested
Conclusion: FD can present with different clinical pictures 
and sometimes diagnosis can be incidental. Some cases 
may go undiagnosed, making FD more frequent than 
previously thought. 
Disclosure: Nothing to disclose
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Optical coherence tomography in 
Huntington’s disease: a potential 
biomarker for cognitive decline?
A. Monteiro1, A. Costa1, C. Andrade1, J. Beato2, S. Penas2,  
J. Guimaraes1, F. Reis2, C. Garrett1
1Centro Hospitalar de São João, Neurology, Porto, Portugal, 
2Centro Hospitalar de São João, Ophthalmology, Porto, 
Portugal
Background and aims: The diagnosis of Huntington’s 
disease (HD) is mostly based on motor manifestations. 
Cognitive changes, however, are early and debilitating HD 
manifestations. We have previously studied the correlation 
of spectral-domain optical coherence tomography (SD-
OCT) retinal and choroidal changes with disease stage and 
severity. The aim of the present study was to investigate 
their correlation with cognitive status in HD.
Methods: A prospective cross-sectional observational 
study was performed including 15 eyes of 8 HD patients. 
Cognition was evaluated using the Verbal Fluency test, the 
Stroop Color Word Test and Symbol Digit Modality Test. 
Patients underwent examination using Enhanced Depth 
Imaging (EDI) SD-OCT. Peripapillary retinal nerve fibre 
thickness (PRNFL), peripapillary choroidal thickness 
(PCT), macular and choroidal thickness (MT, CT) and 
volumes (MV, CV) were evaluated.
Results: Positive correlations were found between verbal 
fluency and several PRNFL, PCT, MT, MV, CT and 
CV measures, such as the average (r=0.629, p=0.012) 
and temporal (r=0.609, p=0.016) PRNFL, average 
PCT (r=0·591, p=0·020), superior nasal PCT (r=0.626, 
p=0.013), total MV (r=0.554, p=0.032) and CV (r=0.549, 
p=0.034). The Symbol Digit Modality test also positively 
correlated with several retinal and choroidal measures, 
such as the superior central (r=0.849, p<0.001), temporal 
central (r=0.794, p<0.001) and inferior central MT 
(r=0.850, p<0.001). The same holds true for the STROOP-
interference test (example, temporal central MT, r=0.900, 
p<0.001) (partial results).    
Conclusion: Retinal and choroidal thickness and volume 
reductions seem to be related with cognitive impairment 
in HD. These measurements may be useful biomarkers of 
cognitive decline onset and progression in HD.
Disclosure: Nothing to disclose
P1235
New clinical biomarkers in early 
Parkinson’s Disease (PD): preliminary  
results of the PRO-DY-GI cohort
C. Moreau1, A. Delval2, D. Devos3, T. Perez4,  
N. Danel-Buhl2, K. Dujardin5, L. Defebvre2
1Lille, France, 2CHRU Lille, Lille, France, 3Lille Nord de 
France University, CHRU Lille, Lille, France, Department 
of Movement Disorders; INSERM U1171; Department of 
Movement Disorders, Lille, France, 4CHRU Lille, Lille, 
France, 5Inserm, U1171, Troubles cognitifs dégénératifs et 
vasculaires, Lille, Lille, France
Background and aims: The aim of this prospective study 
is to identify biomarkers predicting axial symptoms’ 
progression in early PD patients.
Methods and Materials: 67 early and de novo PD 
patients were successively examined in off drug condition 
at baseline and after 2 years. All of them displayed less 
than 3 years of disease evolution since the first symptom; 
29 were de novo PD patients and 28 were early PD 
patients, 10 patients were excluded for diagnosis reasons.
Assessments included clinical evaluation (MDS UPDRS 1 
to 4), dysarthria evaluation by a speech therapist, gait and 
rhythm abnormailities evaluations, neuropsychological 
functions, swallow and respiratory functions assessed by 
a questionnaire and videofluorography plus functionnal 
respiratory testings.
Results: Results from the 57 patients revealed that 50% 
displayed a mild dysarthria, with significant worsening of 
phonetical realisation after 2 years in men only. Paroxysmal 
rhythm abnormalities were frequent with freezing of upper 
or lower limb observed in 63% of the patients for at least 
one evaluation, and festination in 77% of the patients. Oral 
festination was only present in 10% of the cases in good 
correlation with axial/ gait disorders. 60% of the patients 
displayed asymptomatic oral phase swallowing qualitative 
abnormalities and 30% displayed abnormal pharyngeal 
phase with pharyngeal  resisuals, none of the patients 
presented aspiration. Respiratory analysis demonstrated 
an inspiratory  insufficiency in 30% of the patients, with 
diaphragmatic muscular alteration, unresponsive to phrenic 
nerve magnetic stimulation.
Conclusion: Here we demonstrated the occurence of 
asymptomatic clinical axial biomarkers in newly diagnosed 
PD patients. 
Disclosure: DR Moreau acts as scientific advisor for 
aguettant, Abbvie and Medtronics
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Evaluation of non-motor symptoms in  
opicapone treated Parkinson’s disease  
patients: results from a double-blind,  
randomized, placebo-controlled study and 
open-label extension.
C. Oliveira1, A. Lees2, J. Ferreira3, N. Lopes1, R. Costa1,  
R. Pinto1, T. Nunes1, J.F. Rocha1, P. Soares-da-silva1
1BIAL – Portela & Cª – S.A., Dept. R&D, S. Mamede do 
Coronado, Portugal, 2National Hospital for Neurology 
and Neurosurgery, London, United Kingdom, 3Instituto de 
Medicina Molecular, Neurological Clinical Research Unit, 
Lisbon, Portugal
Background and aims: Opicapone (OPC) is a novel once-
daily peripheral COMT inhibitor shown to be effective in 
reducing OFF-time in Parkinson’s disease (PD) patients 
with motor fluctuations. Here we report the effect of OPC 
in non-motor symptoms of PD in patients who enrolled the 
BIPARK-II study.
Methods: Multinational, 14 to 15-week, double-blind 
(DB), placebo-controlled study evaluating 2 OPC doses 
(25 and 50mg), followed by a 1-year open-label (OL) 
extension where all patients received OPC. OL extension 
started with 25mg-OPC irrespective of prior DB treatment. 
One week after, either OPC, levodopa or anti-PD drugs 
could be adjusted based on individual response. Non-motor 
symptoms were assessed by the Non-Motor Symptoms 
Scale (NMSS) at different time points, including baseline, 
end of DB and end of OL. Statistical analysis at DB 
endpoint were based on an ANCOVA model.
Results: At baseline the mean NMSS scores were 36.7 for 
50mg-OPC and 38.2 for 25mg-OPC and placebo. At the end 
of the DB period, the NMSS total score slightly improved 
across OPC and placebo groups, with no significant 
differences between them (-2.02 for 25mg-OPC, -4.9 for 
50mg-OPC and -5.2 for placebo). Numerical differences 
in favor of OPC were seen for the sleep/fatigue domain. 
At the OL 1-year endpoint a mean improvement of -4.2 in 
NMSS total score was still observed. No deterioration of 
any particular domain was observed.
Conclusion: Treatment with OPC was associated with 
minimal but generally positive effects on non-motor 
symptoms of PD. Importantly there was no worsening of 
dysautonomia, hallucinations or cognitive dysfunction.
Disclosure: Nothing to disclose
P1237
Real time imaging of stomach motility  
in patients with REM-sleep behavior  
disorder and denovo Parkinson’s disease
E. Paule, T. Hasemann, D. Vadasz, K. Eggert, G. Mayer,  
S. Knake, W.H. Oertel
Philipps-University, Department of Neurology, Marburg, 
Germany
Background and aims: Gastrointestinal dysfunction is 
a frequently observed early non-motor symptom of de 
novo PD. Neuropathological evidence exists for affection 
of the enteric system by alpha-synuclein aggregopathy in 
PD.  However it is unclear when this affection starts. We 
selected gastric motility as indicator for gastrointestinal 
(dys-)function and focused our investigation on subjects 
with 1) early motor manifestations of PD (denovo PD) 
or 2) suffering from RBD, with a risk of >80 % for later 
developing PD. Data was compared with healthy controls 
(HC).
Methods: After having a standardized breakfast subjects 
underwent a gastric MRI to visualize the peristalsis of the 
gastric wall. MRI videos were analyzed by measuring am-
plitudes, distances and durations of three peristaltic waves 
(mean of 3 waves = Δ).We calculated the gastric motility 
index (GMI) using the formula: Δamplitude x Δdistance/
Δtime.
Results: 21 denovo PD subjects, 19 RBD subjects and 
21 HCs were studied. Patients with de novo PD had 
significantly reduced amplitudes (p<0.001) and GMI 
(p=0.002) compared to HCs. In patients with RBD there 
was a trend towards a reduced amplitude (p=0.071) as well 
as towards a lower GMI (p=0.131).    
Conclusion: Our study shows a disturbed gastric motility 
visualized by real-time MRI in patients with de novo PD 
and - to a lesser extent - in patients with likely prodromal 
PD, i.e. RBD. MRI seems to be a promising method to 
investigate gastrointestinal dysfunction as an early non-
motor symptom in patients with PD and may be also in 
patients at risk to develop PD.    
Disclosure: The study was supported by a grant of the 
International Parkinson Fonds Germany (http://www.
parkinsonfonds.de/).  W. H. Oertel is Hertie Senior 
Reserarch Professor.  This abstract was presented at the 
International MDS Congress in San Diego, USA, June 
15th 2015.
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P1238
Gait disturbances in patients after  
methanol intoxication
K. Peterová1, H. Brozova1, J. Klempir1, I. Lišková1,  
S. Zakharov2, D. Pelclová2, E. Ruzicka1
1Charles University in Prague, The Department of Neurology, 
Prague, Czech Republic, 2Charles University in Prague, 
Department of Occupational Medicine, Prague, Czech 
Republic
Background: Methanol intoxication is a severe condition, 
resulting in visual and neurological impairment. In 2012-
2013,121 cases of methanol intoxication were reported in 
Czech Republic.
Aim: To evaluate gait disturbances after methanol 
intoxication.
Methods: We investigated 44 patients (9 females, aged 
48±SD25years) 3-10 months after methanol intoxication. 
Examination consisted of Fall Efficiency Scale (FES-I) 
questionnaire, clinical tests of gait and balance (Timed 
Up and Go test - TUG, 10 Meter Walking Test – 10MWT, 
Pull test, Romberg test) and gait analysis on the Gaitrite 
walkway. Findings were compared with 44 age and sex 
matched healthy persons.
Results: 29/44(66%) patients reported instability 
according to FES-I, 2/44(4.5%) had abnormal pull test and 
6/44(13.6%) a positive Romberg test. Patients were slower in 
TUG (8.91±2.05vs.5.65±0.95s, p<0.001) and fast 10MWT 
(3.42±0.69vs.2.55±0.50s, p<0.05) compared to controls. 
On Gaitrite, patients had shorter strides during fast walking 
(0.85±0.14vs.0.94±0.11m, p<0.001) and lower cadence 
(134.67±12.46vs.148.61±16.13step/min; p<0.001). While 
walking with closed eyes, patients presented wider base 
(13.15±3.48vs.10.40±3.42cm; p<0.001) and longer double 
support phase (25.43±5.75%vs.22.75±3.57%, p<0.01) 
compared to controls.
Conclusion: 66% of patients after methanol intoxication 
suffer from instability. They differ in several gait parameters 
compared to controls, especially while fast walking and 
with closed eyes. Our findings confirm the toxic effects of 
methanol metabolites on the nervous system, inducing  gait 
disorders and instability.
Disclosure: Study support: General University Hospital 
in Prague, RVO-VFN64165 Charles University in Prague, 





Optimizing effects of botulinum toxin 
treatment by pre and post injection  
activity
M. Relja1, M. Maravic2
1Zagreb, Croatia, 2Medical School , Department of Neurolo-
gy, Zagreb, Croatia
Background and aims: To investigate whether pre and 
post injection activation program (physiotherapy) during 
treatment of cervical dystonia (CD) patients with botuli-
num toxin-type A (ona and rima botulinum toxin; BTX-A) 
could increase and prolong the duration of clinical benefit.
Methods and patients: A total of 33 patients (20 female, 
13 male; age range 23-65 y; disease duration >1year) who 
had improved significantly to BTX-A treatment during first 
year of treatment (the last dose of BTX-A was injected at 
least 5 months before the study) were enrolled into the sin-
gle-blind, cross-over study. Each patients was injected with 
previously used effective dose of ona and/or rimabotulinum 
toxin (BTX-A 100-200 U) CD was assessed using validated 
scale for CD (TWSTRS, ADL, pain score) every 2 weeks. 
In addition, patients were asked to contact clinic immedia-
tely when they deemed the effect of BTX-A. Only during 
second injection of BTX-A (second study period) activati-
on of injected muscles (with help of physiotherapist) was 
performed 15 minutes before and immediately after BTX-A 
injection (30 minutes daily during 2 weeks post injection). 
Physical activity protocoil included active stretching to in-
crease muscle activity.
Results: BTX-A was effective in improving CD symptoms 
during both treatment periods. But the duration of clinical 
improvement was significantly longer (10-15 days) during 
second study period when the same BTX-A dose was in-
jected in combination with activation procedure physiothe-
rapy.
Conclusion: Our results indicate that pre and post-injec-
tion activation manegement could increase the duration of 
BTX-A, and that the physiotherapy could prolong the inter-
vals between injections.
Disclosure: Nothing to disclose
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Identification of extreme phenotype of  
essential tremor: a step toward gene  
identification
M. Renaud, C. Marcel, G. Rudolf, O. Lagha-Boukbiza,  
J.-B. Chanson, M. Anheim, C. Tranchant
CHU Strasbourg, Neurologie, Strasbourg, France
Background and aims: Essential tremor (ET) is the most 
common movement disorder frequently characterized by a 
family history of ET. We aimed at exploring patients with 
ET to identify distinct phenotypic subgroups in order to fa-
cilitate the identification of genes responsible for ET. 
Methods: Between June 2011 and November 2013, 68 
consecutive patients suspected with ET were included in 
the prospective, monocentric study. Following items were 
collected: family history, age of onset, clinical features, be-
nefit of alcohol and drugs, results of electrophysiological 
recording.
Results: 68 patients were investigated. 14 patients who 
were diagnosed with psychogenic (5 patients) or dystonic 
tremor (9 patients) were excluded. Regarding the 54 pati-
ents diagnosed with ET, the mean age of onset was 48 years 
(6-77), and mean disease duration 15 years (1-55). Mean 
frequency of upper limbs tremor was 6.3 Hz (3.8-11). Age 
of onset had a bimodal distribution, consistent with pheno-
typic subgroups. 29 patients (54%) had a family history of 
ET. In the group of patients whose age of onset was before 
30 years, benefit of alcohol (p<0.01) and family history of 
ET (p<0.01) were significantly more frequent and the di-
sease progression was less severe (p<0.0001). 
Conclusion: Our data support that distinct phenotypic 
subgroups of ET may be encountered. We recommend to 
first study separately extreme phenotype of ET, particularly 
clear autosomal dominant families with early age at onset 
(< 30 years) and response to alcohol in order to facilitate 
the identification of genes responsible for ET. Electromyo-
graphic recording remains a strong support to distinguish 
ET from differential diagnosis.
Disclosure: Nothing to disclose
P1242
Interleaving programming in DBS, a better 
symptom control tool in Parkinson’s and 
dystonia patients
D. Reyes, V. Salanga, T. Khan, N. Galvez-Jimenez
Cleveland Clinic Florida, Pauline Braathen Neurological 
Center, Weston, USA
Background and aims: Deep brain stimulation (DBS) is 
a surgical therapeutic option for patients with Parkinson’s 
disease (PD) or dystonia. Interleaving stimulation enables 
two separate combinations of contacts in the same lead 
with simultaneous stimulation of two different anatomical 
areas. To determine clinical improvement by using interlea-
ving programming in patients with PD or dystonia.
Methods: Prospective study involving a series of cases. 
Patients with PD or dystonia with DBS implanted coming 
to the clinic were included. The Unified Parkinson Disease 
Rating Scale (UPDRS) or Dystonia Rating Scale (DRS) 
were applied to PD or Dystonia patients respectively, while 
randomly in off stage (off medications and off DBS pro-
gramming), on single-programming and finally on interle-
aving mode.  
Results: All four patients were male. The PD patients were 
older than 60 years with UPDRS score of 55 or more during 
the Off stage. PD patients on DBS interleaving stimulation 
mode demonstrated an average of 51% clinical improve-
ment on the UPDRS compared to 37% on single- program-
ming. Two of three PD patients demonstrated improvement 
in their rigidity scores and all had hypokinetic symptoms 
improvement but no significant improvement in the tremor 
section. One patient with genetic torsion dystonia on in-
terleaving showed a 54% reduction in the Dystonia Rating 
Scale. No side effects on the interleaving mode.
Conclusion: Interleaving is a useful tool to control electri-
cal stimulation of a wider region, with a cumulative benefit. 
STN or Thalamic interleaving programming may provide 
additional improvement. And favors submaximal amplitu-
de, with a more localized stimulation and a broader anato-
mical area with less side effects.
Disclosure: Nothing to disclose
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Caffeine exposure and the risk of 
Parkinson’s disease: an update of a  
systematic review and meta-analysis of 
observational studies
F. Rodrigues, D. Caldeira, J. Ferreira, J. Costa
Instituto de Medicina Molecular, Clinical Pharmacology 
Unit, Lisbon, Portugal
Background and aims: It is well established – although 
poorly understood - that a complex and multifactorial rela-
tion between genetic and environmental factors takes place 
in Parkinson’s disease (PD). Indeed, PD belongs to the 
ever-growing group of diseases that occur less frequently 
in coffee-drinkers.
Objectives: To quantify the association between caffeine 
intake and PD.
Methods: This is an update of a published systematic re-
view and meta-analysis by our group in 2010. Data sour-
ces: MEDLINE, Web of Science, EMBASE, LILACS and 
reference lists, up to April/2014, no restrictions made. Eli-
gibility criteria: observational studies evaluating the relati-
on between exposure to coffee/caffeine and the risk of PD. 
Study appraisal and synthesis: Authors performed record 
selection, study screening and data collection independent-
ly. Quantitative data synthesis used random-effects meta-
analysis. Heterogeneity and publication bias were quanti-
fied.
Results: 37 studies were included (figure 1). Caffeine ex-
posure was associated with a 31% reduction in the risk of 
developing PD (RR:0.69; 95%CI: 0.63 to 0.76, I2=49.7%) 
(figure 2). Similar results were attained when considering 
only cohort studies, without the expense of heterogeneity. 
Risk reduction was found for both men (RR: 0.73, 95%CI: 
0.65–0.80, I2=0.0%) and women (RR:0.76, 95%CI: 0.63–
0.90, I2=14.9%), as well as for women under hormonal 
replacement therapy (HRT) (RR:0.67, 95%CI: 0.46–0.88, 
I2=6.5%). Publication bias was not detected (figure 3).
Flow-chart
Meta-analysis for the association between caffeine and Parkinson’s 
disease 
Funnel plot
Conclusion: These results reinforce the inverse association 
between caffeine intake and PD risk and extend, for the first 
time, this relationship to women including those underta-
king HRT    
Disclosure: Nothing to disclose
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Levodopa induced dyskinesias: increased 
serotonin to dopamine transporter ratios 
in the putamen of Parkinson’s disease  
patients
A.-A. Roussakis1, M. Politis2, D. Towey3, P. Piccini1
1Imperial College, Neurology, London, United Kingdom, 
2Kings College Hospital, Neurosciences, London, United 
Kingdom, 3Imperial College, Nuclear Medicine, London, 
United Kingdom
Background and aims: Serotonergic mechanisms play a 
key role in the development of the Levodopa-induced dys-
kinesias (LIDs) in patients with Parkinson’s disease (PD). 
We hypothesised that an unfavourable serotonin-to-dopa-
mine terminal ratio in the putamen would be most detri-
mental in PD patients with dyskinesias. We investigated the 
role of serotonin (SERT) to dopamine transporter (DAT) 
binding ratios in the development of LIDs in PD patients.
Methods: 28 patients with advanced PD [17 with LIDs;11 
stable] and 12 age and gender-matched healthy controls 
(HCs) were studied with [11C]DASB PET and [123I]FP-
CIT SPECT, which are respective specific markers of DAT 
and SERT availability in vivo. We have employed a simp-
lified reference tissue model using cerebellar reference for 
the quantification of [11C]DASB, whereas a semi-quantifi-
cation approach was used for [123I]FP-CIT. We estimated 
uptake values in the putamen.
Results: PD patients showed decreases in [123I]FP-CIT 
binding(p<0.001) compared to HCs, 51% in the stable and 
62% in the LIDs group. PD patients showed decreases in 
[11C]DASB binding (p<0.01), but there were no differen-
ces between the stable (37% loss) and LIDs (31% loss) 
groups. PD patients with LIDs had 103% increased [11C]
DASB to [123I]FP-CIT binding ratio, whereas in the PD 
stable group the ratio was increased by 76%, relative to 
HCs. Higher [11C]DASB to [123I]FP-CIT binding ratio 
correlated with longer disease duration for the 28 PD pati-
ents (r=0.52;p<0.01).
Conclusion: SERT to DAT ratio increases as PD progres-
ses and patients experience LIDs. Our findings support the 
role of serotonin terminals within the dopaminergic dener-
vated striatum for the development of LIDs.
Disclosure: Nothing to disclose
P1245
Evaluation of global impressions of 
change in opicapone-treated patients  
with Parkinson’s disease and motor  
fluctuations compared to placebo and 
entacapone.
A. Santos1, J. Ferreira2, A. Lees3, R. Pinto1, N. Lopes1,  
J.F. Rocha1, T. Nunes1, P. Soares-da-Silva1,4
1BIAL – Portela & Cª – S.A., Dept. R&D, S. Mamede do 
Coronado, Portugal, 2Instituto de Medicina Molecular, Neu-
rological Clinical Research Unit, Lisbon, Portugal, 3National 
Hospital for Neurology and Neurosurgery, London, United 
Kingdom, 4Department of Pharmacology & Therapeutics fac. 
of Medicine, University Porto, Portugal
Background and aims: The subject’s and investigator’s 
global assessment of change (SGAC and IGAC) are com-
monly used instruments in clinical trials that provide means 
for evaluating perceptions about the change in overall con-
dition with treatment.
Methods: Multinational, double-blind, 14- to 15-week, 
placebo- and active-controlled study (BIPARK I). SGAC 
and IGAC were secondary efficacy endpoints. SGAC and 
IGAC were performed in comparison to prior enrolment in 
the study (“very much improved” to “very much worse”). 
Both were analysed with a non-parametric van Elteren’s 
test stratified by region.
Results: 590 patients were included in the analysis: pla-
cebo (N=120), 5mg-OPC (N=119), 25mg-OPC (N=116), 
50mg-OPC (N=115) and entacapone (N=120). The pro-
portion of patients (SGAC) reporting to have “minimally”, 
“much” or “very much improved” ranged between 63.7% 
to 72.1% for OPC groups vs. 50.9% for placebo and 52.5% 
for entacapone. The improvement tendency was signifi-
cant for 25mg-OPC (p=0.0055; p=0.0370) and 50mg-OPC 
(p=0.0008; p=0.0091) compared to placebo and entaca-
pone, respectively. The proportion of patients assessed by 
investigators (IGAC) as having improved ranged between 
60.3% and 73.0% for OPC groups vs. 49.9% for placebo 
and 50.9% for entacapone. The improvement tendency was 
significant for 50mg-OPC (p=0.0005 and p=0.0070 vs. pla-
cebo and entacapone, respectively). No tendency was appa-
rent for entacapone when compared to placebo.
Conclusion: OPC was associated with favourable ratings 
in patient’s and clinician’s global impressions of change, in 
contrast to no difference for entacapone compared to place-
bo in either of these assessments.
Disclosure: Nothing to disclose
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Improvement of verticality perception after 
cerebrospinal fluid drainage in idiopathic 
normal pressure hydrocephalus
C. Selge, R. Schniepp, A. Zwergal, S. Bardins,  
A. Schepermann, J. Bergmann, K. Jahn
Department of Neurology and German Center for Vertigo and 
Balance Disorders, Munich, Germany
Background and aims: Idiopathic normal pressure hyd-
rocephalus (iNPH) is a disorder consisting of gait distur-
bance, cognitive impairment, and urinary symptoms. Most 
patients show postural imbalance with a tendency to fall 
backwards. The diagnostic test used to predict whether pa-
tients might benefit from shunt surgery is the spinal tap test 
with drainage of 30 to 50 ml of cerebrospinal fluid (CSF). 
The aim of our study was to investigate verticality percep-
tion in the pitch plane as a possible new method for the 
evaluation of iNPH.
Methods: A Spacecurl® device was used to measure the 
subjective postural vertical (SPV) of 20 patients with iNPH 
(criteria of the International iNPH Guidelines) before and 
after CSF - drainage. The device was tilted in the sagittal 
(pitch) and frontal (roll) plane. Blindfolded patients had to 
indicate the SPV.
Results: Before CSF-drainage patients showed an impaired 
verticality perception in pitch, with a significant backward 
deviation of the SPV (mean±SD -3.7±3.6 deg; values of 
healthy subjects: -1.7 deg to 2.3 deg; pt-test = 0.03). After 
CSF-drainage patients showed a significant improvement 
of their verticality perception with normalization of the 
SPV in the pitch plane (-0.9±1.9 deg; pt-test = 0.001). In 
the roll plane patients showed no abnormalities before and 
after CSF-drainage.
Conclusion: The SPV test in pitch shows a reversible al-
tered verticality perception in patients with iNPH. A link 
between the gait disorder, abnormal verticality perception, 
and falls in NPH is likely. The SPV might be a promising 
diagnostic test and prognostic indicator of a positive res-
ponse to shunt surgery in suspected iNPH.
Disclosure: Nothing to disclose
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Gradient-like organization of the subtha-
lamic nucleus with respect to emotional 
arousal: a neuroanatomical study with 
deep brain stimulation in Parkinson’s di-
sease
T. Serranova1, T. Sieger2, F. Ruzicka1, P. Dusek1, P. Vostatek3, 
D. Stastna4, D. Novak5, E. Ruzicka1, D. Urgosik4, R. Jech1
1Dept. of Neurology and Center of Clinical Neuroscience, 
Charles University in Prague, 1st Faculty of Medicine and 
General University Hospital, Prague, Czech Republic, 2Fa-
culty of Electrical Engineering, Czech Technical University, 
Dept. of Cybernetics, Prague, Czech Republic, 3Dept. of 
Cybernetics, Faculty of Electrical Engineering, Czech Tech-
nical University, Prague, Dept. of Cybernetics, Faculty of 
Electrical Engineering, Czech Technical University, Czech 
Republic, 4Dept. of Stereotactic and Radiation Neurosurgery, 
Na Homolce Hospital, Prague, Czech Republic, 5Dept. of Cy-
bernetics, Faculty of Electrical Engineering, Czech Technical 
University, Prague, Czech Republic
Background and aims: Changes in emotional processes 
have been reported after subthalamic deep brain stimulation 
(STN-DBS) in Parkinson’s disease (PD). Considering the 
functional organization of the subthalamic nucleus (STN), 
we hypothesized that STN-DBS might have a differential 
impact on subjective experience of emotional valence (un-
pleasantness/pleasantness) and arousal to affective stimuli 
in relation to the electrode position within the STN.  
Methods: 20 PD patients (all men; off-medication) viewed 
pictures depicting primary rewarding (erotica and food), 
aversive fearful or neutral stimuli and performed ratings 
according to emotional valence and arousal in STN-DBS 
switched ON- and OFF-conditions. The active electro-
de contact positions in the STN were determined on T1-
weighted MRI. The ON vs. OFF ratings differences and 
their relation to the active contact positions were assessed 
using linear models.
Results: In the DBS ON-condition, patients attributed lo-
wer valence scores to the aversive pictures compared with 
the OFF-condition (P < .01). The active electrode contact 
position and ON vs. OFF differences in ratings correlated 
significantly only for arousal but not for valence. Pati-
ents with more anteriorly located contacts rated affective 
pictures as more arousing while patients with more pos-
terior contacts as less arousing in the DBS ON-condition 
(P<0.05).
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Correlation between active contact position and ON vs. OFF differen-
ces in arousal ratings
Conclusion: While the arousal was systematically influ-
enced by position of the stimulating contact in the STN, the 
valence of fearful stimuli was shifted towards more nega-
tive with the STN-DBS switched on regardless to the elec-
trode position. These results may reflect anterio-posterior 
gradient of emotional processing in the STN and support 
functional segregation of valence and arousal at the basal 
ganglia level.
Disclosure: Nothing to disclose
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Dysphagia in Parkinson’s disease:  
High-risk defining clinical parameters
J.A. Simons1, N. Eisemann2, U.M. Fietzek3, A. Katalinic4
1University of Luebeck, Institute for Social Medicine and 
Epidemiology, Lübeck, Germany, 2University of Luebeck, 
Institute for Cancer Epidemiology, Lübeck, Germany, 3Schoen 
Clinic, Center for Parkinson’s Disease and Movement Disor-
ders, Munich, Germany, 4University of Luebeck, Institute for 
Social Medicine and Epidemiology, Institute for Cancer Epi-
demiology, Lübeck, Germany
Background and aims: Dysphagia is a highly relevant 
symptom in Parkinson’s disease (PD). Clinical identifica-
tion is complex, and  often occurs too late with presentation 
of life-threatening complications, e.g. aspiration pneumo-
nia or malnutrition/dehydration.
Our aim was to define high-risk groups for oropharyngeal 
dysphagia and laryngeal aspiration using clinical parame-
ters reported to have positive correlation with dysphagia 
severity in PD.
Methods: Consecutively enrolled PD patients of a Ger-
man movement disorders center underwent neurological 
examinations as well as clinical and fiberoptic endoscopic 
swallowing evaluations. Along the severity grades of un-
derlying rating-scales they were allocated to 3 groups: no 
dysphagia(A), oropharyngeal dysphagia(B), and dysphagia 
with penetration/aspiration(C). Cut-off values for high-risk 
groups (A vs C, or A vs B+C) were determined from ROC 
curves for modified Hoehn&Yahr scale (HY), UPDRSIII, 
disease duration, age, drooling score scale, dysarthria 
score, and body mass index. Relative risks and 95%-confi-
dence intervals were calculated.
Results: The 77 patients (mean age 70.5±8.4, median HY 
3) were classified to group A(21), B(34), and C(22). De-
termined cutoffs were identical for both outcome groups 
(Figure 1). Dysphagia risk was significantly increased for 
almost all parameters. Highest clinical relevance was ascer-
tained for UPDRSIII and HY (Table 1).
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Figure 1 shows the ROC curves for examined outcome groups of these 
two clinical parameters discovered as strongest risk factors for dys-
phagia. 
Table 1 shows the relative risks for laryngeal aspiration and/or oropha-
ryngeal dysphagia symptoms for Parkinson’s disease patients with the 
strongest clinical risk factors identified.
Conclusion: Motor performance with UPDRSIII ≥26 and 
disease stage with HY ≥4 were shown to be high risk fac-
tors for dysphagia. In clinical practice patients presenting 
these cutoffs should be screened for dysphagia with a vali-
dated disease-specific questionnaire1 or undergo additional 
diagnostics.
1. Simons JA, et al.Development and validation of a 
new screening questionnaire for dysphagia in early 
stages of Parkinson’s disease.ParkinsonismRelatDis-
ord2014;20(9):992–998
Disclosure: Nothing to disclose
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Representation of dynamic visual stimuli 
along the visual cortical hierarchy: an fMRI 
study in optic neuritis patients
T. Benoliel, N. Raz, N. Levin
Hadassah Hebrew University Medical Center , Neurology, 
Jerusalem, Israel
Background and aims: We had recently suggested that 
while delayed visual evoked potential (VEP) latencies in 
the affected eyes (AEs) stem from optic nerve demyelina-
tion, latencies in the fellow eyes (FEs) reflect an adaptive 
process at the cortical level, to compensate for the delayed 
arrival of visual information via the affected side. The cur-
rent study is aimed to define the cortical mechanisms that 
underlie this newly defined adaptive process.
Methods: We studied 13 patients, all of whom had reco-
vered from a single episode of optic neuritis, and 13 mat-
ched controls. Visual testing, VEP, and optical coherence 
tomography were assessed. fMRI examination included 
dynamic visual functions and retinotopic mapping to define 
the borders of visual cortical areas.  
Results: Reduced activity in early but not in higher visu-
al areas were seen in both the affected and fellow eyes, 
as compared to controls.  When comparing fMRI-signal 
strength between adjacent visual areas, we found that in 
the FEs, cortical activation significantly decreased between 
primary visual cortex (V1) and V2, a decrease which was 
not found in the AEs or controls. Finally, we showed that 
inter-eye differences in VEP latencies correlate with corti-
cal activation of the FEs but not the AEs. 
Conclusion: The similar cortical activation patterns in the 
affected and fellow eyes; the decreased in the level of acti-
vation between areas V1 and V2 which was seen uniquely 
in the FEs and the correlation between the cortical activity 
elicited by the FE and the delta VEP support an early corti-
cal modulatory process in the FE following recovery from 
optic neuritis.
Disclosure: This study was supported in part by the Sidney 
and Judy Swartz fund for research in multiple sclerosis.
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Temporal aspects of visual perception in 
demyelinative diseases
N. Raz, G. Shear-Yeshuv , A. Bick, N. Levin
Hadassah Hebrew University Medical Center , Neurology, 
Jerusalem, Israel
Background and aims: In chronic optic neuritis patients, 
timing of signal conduction is specifically affected, thus it 
stands to reason that temporal vision will be similarly af-
fected.
Herein we assess temporal aspects of visual perception, 
including temporal resolution and motion perception, and 
their dependency on conduction velocities, following optic 
neuritis.
Methods: Critical Flicker fusion frequency (CFFF), two 
motion perception tasks [object-from-motion (OFM) and 
number-from-motion (NFM) extraction tasks]; high and 
low contrast acuities and Visual Evoked Potentials (VEPs) 
were assessed in 23 optic neuritis patients.  
Results: Strong correlations were found between the vari-
ous dynamic visual function scores. Furthermore, regressi-
on models revealed that each of the dynamic visual func-
tions significantly predicted VEP latencies. These findings 
were specific to patients’ affected eyes and were not evident 
for static visual functions. Fellow eyes‘ VEP latencies were 
best predicted by the VEP latencies of the affected eyes. 
Conclusion: Delayed signal conduction is functionally 
manifested as impaired temporal resolution and motion 
perception. The specificity of these findings to the patients’ 
affected eyes and to dynamic (as opposed to static) visual 
functions highlights the precision of dynamic visual func-
tions for identifying demyelinative attack. Prolonged VEP 
latencies in the fellow eyes seem to stem from different 
patho-physiological processes.
Disclosure: This study was supported in part by the Sidney 
and Judy Swartz fund for research in multiple sclerosis.
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Rituximab treatment after natalizumab 
discontinuation in relapsing-remitting  
multiple sclerosis (RR-MS) patients with 
high risk of PML
S. Malucchi1, M. Capobianco1, M. Malentacchi1,  
A. Di Sapio1, M. Matta1, A. Oggero2, M. Lo Re3,  
A. Bertolotto1
1San Luigi Hospital, Multiple Sclerosis Centre, Orbassano, 
Italy, 2San Luigi Hospital, Multiple Sclerosis Centre, orbassa-
no, Italy, 3Dipartimento di Biomedicina Sperimentale e Neu-
roscienze Clinche, University of Palermo, Palermo, Italy
Background and aims: To evaluate clinical and radiologi-
cal efficacy of rituximab in RR-MS patients who stop nata-
lizumab treatment.
Patients and methods: 14 MS patients treated with natali-
zumab for a median number of 42 infusions stopped it for 
high risk of PML; 10 out of 14 were switched to rituximab, 
for the impossibility to use alternative drugs; the other 4 
received fingolimod and then switched to rituximab due 
to hepatotoxicity or lack of efficacy. Rituximab (375mg/
mq i.v.) was administered every week for 4 weeks; patients 
underwent monthly CD19 dosage; second infusion was ad-
ministered in case of disease reactivation or CD19 increase. 
A wash out period of 2 months from natalizumab suspen-
sion was planned; in real practice median wash out period 
was 3.3 months (1 patient decided to start rituximab after 
8 months). Brain MRI was performed in each patient with 
the same protocol before starting rituximab and then at six 
and twelve months after it. Median follow up after drug 
initiation is 11.7 months.
Results: 9 out of 10 patients switching directly from natali-
zumab to rituximab showed radiological and clinical stabi-
lity during the wash out period; the patient who started ritu-
ximab 8 months after natalizumab withdrawal experienced 
disease reactivation during the wash out period. Radiologi-
cal stability was observed at 6 months after rituximab in all 
the patients and at 12 months in those patients with a follow 
up one year (5 patients).
Conclusion: The work is in progress but preliminary data 
suggest that rituximab is a valid therapy after natalizumab 
discontinuation.
Disclosure: Nothing to disclose
P1253
Does the number of CSF oligoclonal bands 
have a prognostic role in patients with  
clinically isolated syndromes?
V. Martinelli1, G. Passerini2, G. Dalla Costa1, M.J. Messina1, 
L. Moiola1, M. Rodegher1, B. Colombo1, M. Locatelli2,  
G. Comi1, R. Furlan3
1San Raffaele Hospital, Neurological Department, Milan, Ita-
ly, 2San Raffaele Hospital, Laboraf, Milan, Italy, 3San Raffae-
le Hospital, Neuroimmunological Research Unit, Milan, Italy
Background and aims: The aim of the current study is to 
evaluate whether the number of oligoclonal bands (OCBs) 
in the cerebrospinal fluid (CSF) in patients with clinically 
isolated syndromes (CIS) adds further information to the 
already known prognostic factors for conversion to multi-
ple sclerosis (MS).
Methods: A total of 219 patients hospitalized from 2005 to 
2012 at San Raffaele Hospital, Italy were included. We eva-
luated baseline CSF as well as clinical and brain MRI data.
Results: During follow-up (median: 5.04 years) 92 pati-
ents (42%) developed clinically definite MS (CDMS). CSF 
OCBs were present in 153 patients (69.9%), of whom 68 
developed subsequently the disease (p 0.05). The number 
of CSF OCBs further stratified the risk of CDMS:  patients 
with a high number (5-9 and 10-14 CSF OCBs) of CSF 
OCBs were particularly at risk of CDMS, with more than 
a 1.5-fold and 2.5-fold increase in risk respectively [HRs 
(95% CIs): 1.91 (1.06-3.45) and 2.92 (1.33-4.39)], while no 
further increase in the HRs of disease was observed for pa-
tients with a very high number (≥ 15 OCBs) of CSF OCBs. 
The results did not change after adjusting for the other cli-
nical and MRI covariates.
Conclusion: The number of CSF OCBs has potential pro-
gnostic value and could be helpful for clinical decision-
making.
Disclosure: Nothing to disclose
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Teriflunomide: pooled hepatic safety  
outcomes from placebo-controlled  
studies and long-term extensions
M. Marziniak1, M.S. Freedman2, M. Benamor3, P. Truffinet3, 
K. Thangavelu4, T.P. Leist5
1kbo-Isar-Amper-Klinikum München-Ost, Haar, Germany, 
2University of Ottawa and the Ottawa Hospital Research Ins-
titute, Ottawa, Canada, 3Genzyme, a Sanofi company, Chilly-
Mazarin, France, 4Genzyme, a Sanofi company, Cambridge, 
USA, 5Comprehensive Multiple Sclerosis Center, Thomas 
Jefferson University Hospital, Philadelphia, USA
Background and aims: Elevations of liver enzymes have 
been observed in patients with relapsing multiple sclerosis 
who received teriflunomide in clinical trials. Here we report 
hepatic safety outcomes from teriflunomide clinical trials.
Methods: Two data pools were used: Pool A, placebo-
controlled studies (phase 2 [NCT01487096], TEMSO 
[NCT00134563], TOWER [NCT00751881], TOPIC 
[NCT00622700]); Pool B, teriflunomide-treated patients 
(14mg or 7mg) from Pool A and long-term extensions of 
phase 2 and TEMSO (NCT00228163, NCT00803049).
Hepatic assessments included treatment-emergent adverse 
events (TEAEs) and laboratory parameters. Patients with 
confirmed alanine aminotransferase (ALT) >3x upper limit 
of normal were required to discontinue treatment.
Results: In pool A (n=3044), incidence of hepatic TEAEs 
was higher in teriflunomide groups (14mg, 21.5%; 7mg, 
19.8%; placebo, 15.2%), mainly due to asymptomatic ALT 
increase. Incidence of serious hepatic TEAEs was low 
and similar across groups (14mg, 2.2%; 7mg, 2.1%; pla-
cebo, 2.7%), as was discontinuation due to hepatic TEA-
Es (14mg, 4.2%; 7mg, 4.5%; placebo, 3.9%). 8 patients 
(14mg, 2; 7mg, 1; placebo, 5) experienced ALT and bili-
rubin elevations consistent with Hy’s law; all had potenti-
al alternative explanations. Most ALT increases occurred 
within 6 months of treatment initiation, were mild or mo-
derate, and usually resolved without corrective treatment. 
Similar trends were observed in Pool B (n=2338): 3.5% pa-
tients experienced serious hepatic TEAEs and 6% patients 
discontinued treatment due to hepatic TEAEs over up to 6 
years’ follow-up.
Conclusion: This pooled analysis was consistent with the 
individual teriflunomide studies and no new or unexpected 
hepatic safety signal was identified. Nonetheless, precauti-
onary hepatic monitoring is required as per local labelling.
Disclosure: Study supported by Genzyme, a Sanofi com-
pany. 
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The potential role of gut immunity in  
multiple sclerosis
M.J. Messina1, M. Falcone2, A. Mariani3, C. Sorini2,  
P.A. Testoni3, G. Comi1, V. Martinelli1
1San Raffaele Scientific Institute, Vita-Salute San Raffaele 
University, Department of Neurology, Milan, Italy, 2Diabetes 
Research Institute, IRCCS San Raffaele Scientific Institute, 
Division of Immunology, Transplantation and Infectious Di-
seases, Milan, Italy, 3IRCCS San Raffaele Scientific Institute 
- Vita Salute San Raffaele University, Gastroenterology and 
Gastrointestinal Endoscopy Unit, Division of Experimental 
Oncology, Milan, Italy
Background and aims: Several lines of evidence in ani-
mal models of Multiple Sclerosis (EAE) indicate that gut 
immunity is instrumental to maintain immune tolerance to-
wards self-tissues also at sites distal to the intestine. Some 
environmental factors (diet etc.) seem to increase the risk 
to develop Multiple Sclerosis (MS) in genetically-at risk 
individuals by altering gut immunity. The aim of our study 
is to assess the potential role of gut immunity in MS patho-
genesis.
Methods: So far we analyzed gut immune cell subsets in 
peripheral blood (PBMC) and intestinal mucosal samples 
isolated from 20 Relapsing-Remitting (RR) patients and 
age and sex-matched healthy controls who underwent eso-
phago-gastro-duodenal endoscopy (EGDS) for diagnostic 
purposes. All MS patients had not received corticosteroid 
treatment in the six months before the EGDS. 
Results: We found that effector Th17 cells that play a cru-
cial role in the pathogenesis of experimental models of 
MS, are present in the intestinal mucosa but not in PBMC. 
Importantly, MS patients showed an increased Th17/
FoxP3+Treg cell ratio compared to healthy controls, indi-
cating a preferential differentiation of effector Th17 cells in 
their gut mucosa. 
Conclusion: Although our data are preliminary, they sug-
gest a specific immune cell defect of the Treg/Th17 balance 
in the intestinal mucosa of MS patients. They validate pre-
vious reports in EAE and provide the first evidence that gut 
immunity modulate MS pathogenesis in humans. Our next 
goal is to determine whether microbiota composition is re-
sponsible for the alterations of gut immunity and altered 
Treg/Th17 cell balance in MS patients.
Disclosure: Nothing to disclose
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The Framingham cardiovascular risk score 
in multiple sclerosis
M. Moccia1, R. Lanzillo1, R. Palladino2, G.T. Maniscalco1,  
A. De Rosa1, C.V. Russo1, M. Massarelli1, A. Carotenuto1,  
E. Postiglione1, O. Caporale2, M. Triassi2, V. Brescia Morra1
1Federico II University, Naples, Italy, Department of Neu-
rosciences, Reproductive Science and Odontostomatology, , 
Naples, Italy, 2Federico II University, Department of Public 
Health, Naples, Italy
Background and aims: Some cardiovascular risk factors 
have been suggested to raise the risk of multiple sclerosis 
(MS), and to modify its course. However, such factors pos-
sibly interact, thus determining a global cardiovascular risk. 
We aim to compare the global cardiovascular risk of sub-
jects with and without MS by the simplified 10-year Fra-
mingham General Cardiovascular Disease Risk Score (FR), 
and to evaluate its importance on MS-related outcomes.
Methods: Age, gender, smoking status, body mass index 
(BMI), systolic blood pressure, type II diabetes, and use 
of antihypertensive medications have been recorded in 
subjects with and without MS to estimate the FR, an in-
dividualised percentage risk score estimating the 10-year 
likelihood of cardiovascular events.    
Results: We identified 265 MS subjects, and matched 530 
controls at the “Federico II” University Hospital, Nap-
les, Italy. T-test showed similar FR in cases and controls 
(p=0.212), however secondary progressive MS presented 
significantly higher FR when compared to relapsing re-
mitting MS (p<0.001). Linear regression analysis showed 
a direct relationship between FR and Expanded Disabili-
ty Status Scale (EDSS) (p<0.001) and MS Severity Scale 
(MSSS) (p<0.001).
Conclusion: The FR, evaluating the global cardiovascular 
health by the interaction among different risk factors, rela-
tes to MS disability, severity and course. 
Disclosure: Nothing to disclose
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Detection of intrathecal inflammation: CSF 
reference values for immunoglobulin free 
light chains (FLC)
F. Mojib-Yezdani, M. Senel, H. Tumani
University of Ulm, Neurology , Ulm, Germany
Background and aims: Oligoclonal bands (OCB) or IgG-
index are the most widely used CSF test to detect intrat-
hecal IgG synthesis. However, determination of OCB is 
non-quantitative and demands methodological expertise. 
The quantitative IgG-index is associated with a sensitivi-
ty lower than that of OCB. Several studies indicated that 
elevated kappa free light chains (KFLC) and lambda free 
light chains (LFLC) in CSF might offer a quantitative tool 
for detection of intrathecal humoral inflammation by avo-
iding aforementioned limitations of OCB and IgG-index. 
We aimed to determine CSF reference values for KFLC and 
LFLC to evaluate their diagnostic relevance in multiple scl-
erosis (MS) and pathogen-related CNS diseases.
Methods: Paired CSF and serum samples (n=1459) from 
the Department of Neurology, University of Ulm (Germa-
ny) were analyzed prospectively over a period of 1.5 ye-
ars including n=1039 samples from patients with non-in-
flammatory neurological diseases (NIND). KFLC, LFLC, 
Albumin, IgG and lactate were measured by automated 
nephelometry. OCB were detected by isoelectric focusing 
(IEF) followed by immunoblotting.
Results: CSF-serum ratios of KFLC (Q KFLC) were plot-
ted against the respective ratios of albumin. The upper 
97.5% confidence interval are shown as the approximately 
upper reference values indicated in figure 1a for Q KFLC 
and figure 1b for Q LFLC. Data from patients with MS are 
evaluated based on these albumin ratio related reference 
range and compared to previously published results.
figure 1a
figure 1b
Conclusion: CSF FLC is a rapid and easy to standardize 
tool to detect intrathecal humoral inflammation and to im-
prove performance of OCB and IgG-index in the context of 
MS diagnostics.
Disclosure: Nothing to disclose
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Very late-onset myasthenia gravis in  
Slovak Republic
I. Martinka1, J. Bednarik2, M. Soskova1, K. Sitarova1,  
P. Spalek1
1University Hospital Bratislava, Department of Neurology, 
Bratislava, Slovakia, 2University Hospital Brno, Department 
of Neurology, Brno, Czech Republic
Background and aims: Recently there has been an incre-
ase in the incidence of myasthenia gravis (MG) in patients 
over 70 years. The objective of this study is to analyze the 
clinical features and basic epidemiologic parameters in 
patients with very late-onset MG (VLOMG) >70 years in 
Slovakia.
Methods: We reviewed 1950 MG patients from 1978 to 
2014. The method of research was to review medical re-
cords. We analyzed age at onset, sex, clinical symptoms, 
presence of thymoma, anti-AChR and anti-MuSK antibo-
dies  and basic epidemiologic parameters.
Results: We observed VLOMG in 355 patients (18.2%). 
Prevalence of VLOMG was 29.5/1 million inhabitants on 
31st Dec. 2014. The average annual incidence of VLOMG 
for the last  10 years is 3.8 /1 million population. Out of 
the 355 patients, 183 are women (51.6%) and 172 men 
(48.4%). The mean age at onset was 75.2 years, women 
75.7, men 74.5. MG presented initially with ocular symp-
toms in 73 patients (20.7%), bulbar muscle weakness was 
present at onset in 161 patients (45.3%). 12 patients (3.4%) 
had MG associated with thymoma. Autoantibodies were 
investigated in 298 patients. 279 patients (93.6%) have 
AChR-positive MG, 2 patients (0.7%) MuSK-positive MG, 
17 patients (5.7%) have double-seronegative MG. 
Conclusion:  VLOMG occurs in 18% of all patients with 
MG in Slovakia, with slight predominance of women. In 
VLOMG patients dominates AChR-positivity (93.6%) and 
predominantly bulbar muscle weakness at onset. 
Disclosure: Nothing to disclose
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From the experience of the Italian  
National Registry a novel tool to dissect 
the phenotypic complexity of  
facioscapulohumeral muscular dystrophy: 
the comprehensive clinical evaluation 
form
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Institute Carlo Besta, Milan, 8Department of Neurosciences, 
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sina, 15University of Verona, Department of Neurological and 
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Background and aims: For the last 20 years, the diagnosis 
of facioscapulohumeral muscular dystrophy (FSHD) has 
been confirmed by the detection of one D4Z4 allele with a 
reduced number (≤ 8) of repeats at 4q35. In the meantime, 
several atypical phenotypes have been observed among 
D4Z4 reduced allele (DRA) carriers sometimes with un-
expected mode of inheritance. In some cases the high 
frequency of FSHD molecular signature, also detected in 
healthy individuals and in asymptomatic relatives of pro-
bands, might have influenced diagnosis because of a biased 
correlation between a generic ‘myopathic’ phenotype and 
the detection of a DRA. There is therefore the need to ge-
nerate tools that support diagnosis and genetic counseling 
in FSHD.
Methods: The Italian Clinical Network developed the first 
FSHD clinical form in 2009; since then we systematically 
analyzed distribution of muscle impairment in over 500 in-
dex cases and 300 families and populate the Italian Natio-
nal Registry for FSHD (INRF) with standardized clinical 
information on certified FSHD patients and families. Based 
on our six-year experience, we designed and validated a 
Comprehensive Clinical Evaluation Form (CCEF), defi-
ning phenotypic categories by the combination of different 
clinical features.
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Results: Through the CCEF we classify: category A, sub-
jects with typical FSHD phenotype;  category B, subjects 
with incomplete FSHD phenotype;  category C, asympto-
matic subjects, and category D, myopathic subjects without 
typic FSHD features.
Conclusion: We propose the widespread use of CCEF to 
ameliorate the classification of patients and families, to 
generate information to unravel the genetic complexity of 
FSHD, and to serve as a major tool for trial readiness.
Disclosure: Supported by Telethon Italy, Grant GUP13012, 
P1261
Natural history of sarcoglycanopathies: 
analysis of 74 Moroccan families.
G.A. Mpandzou, N. Birouk, L. Errguig , H. Belaidi,  
R. Ouazzani
Centre hospitalier Ibn Sina – Université Mohamed V – Souis-
si, Service de neurophysiologie clinique, Rabat, Morocco
Background and aims: Sarcoglycanopathies (SG) are au-
tosomal recessive progressive limb-girdle muscular dystro-
phies (LGMD), due to α-, β-, γ- and δ-sarcoglycan gene 
mutations, respectively leading to LGMD2D, E, C and F. 
In North Africa, γ-SG is the most common. The disease 
progression is highlighted by analysing 82 patients from 74 
Moroccan families.
Methods: Throughout a 21-year time lapse, 82 patients 
were regularly followed-up during an average of 3.7±2.9 
years (SD) [Min:Max; 1-13]. The SG diagnosis was esta-
blished from protein immunostaining on muscle biopsy 
(97.6%) and/or mutational analysis. Disease progression 
was assessed annually using two functional scores, musc-
le strength, climbing stairs and walking perimeter. Clinical 
and paraclinical characteristics were reported to age at on-
set.
Results: γ-SG was diagnosed in 80 patients and α-SG in 
two cases. Consanguinity rate was 68.3% and age at on-
set, 7.1±2.9 years [1-19]. Difficulty to walk appeared after 
1.6±3 years [0-17], and loss of ambulation after 7.3±4.6 
years [2-22]. Reduction in respiratory functional vital ca-
pacity below 50% was found in ten patients at 21.5±9.4 
years of age [11-43]. Five patients suffered from cardiac 
function impairment with decrease of left ventricular ejec-
tion fraction at 25±12.5 years of age [14-45], eight patients 
from cardiomyopathy at 19±12 years of age [8-45].
Conclusion: The analysis of SG natural history highlights 
disease prognosis and can thus help in anticipating medical 
management to improve patient’s quality of life. 
Disclosure: Nothing to disclose
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A complex phenotype characterized by 
epilepsy, movement disorders, mental  
retardation and exercise-induced  
myoglobinuria caused by two different 
rare disorders
O. Musumeci1, E. Ferlazzo2, G. Annesi3, S. Romeo1,  
C. Rodolico1, U. Aguglia4, A. Toscano1
1University of Messina, Messina, Italy, 2University Magna 
Grecia, Catanzaro, Italy, 3CNR, Cosenza, Italy, 4Reggio Cala-
bria, Reggio Calabria, Italy
Background and aims: GLUT-1 Deficiency Syndrome 
(DS) is a rare encephalopathy, caused by impaired glucose 
transport into the brain, usually presenting with early-onset 
epilepsy, movement disorders, developmental delay and 
microcephaly; rhabdomyolysis has never been observed in 
such patients.
Case Report: We report a 44-year-old man, who presen-
ted, since the age of 20, recurrent episodes of rhabdomyo-
lysis after exercise or prolonged fasting; he also showed a 
mild mental retardation and sporadic choreo-athetoid mo-
vements. His 14-year-old son had a psychomotor develop-
mental delay with episodes of drowsiness, head drop and 
choreo-athetoid movements occurring mainly at fasting or 
after physical exercise. Neurological examination revealed 
microcephaly, mild spastic ataxia and mental retardation.
EEG was normal in the proband but in the son showed, 
during fasting, diffuse spike-wave discharges disappearing 
after food intake. Brain MRI was normal in both. CSF ana-
lysis revealed hypoglycorrhachia (40 mg/dl) in the son. 
Results: Clinical and laboratory findings suggested to 
search for mutations in SCL2A1 (GLUT-1) that revealed 
an heterozygous mutation (R333W) in both confirming the 
diagnosis of DS. To better define the recurrent exercise-
induced rhabdomyolysis in the father,  a forearm ischemic 
test (normal), EMG (myopathic pattern) and muscle biopsy 
(unspecific changes) were performed. After having exclu-
ded common metabolic causes of recurrent rhabdomyoly-
sis, VLCAD gene analysis in the father showed two known 
heterozygous mutations (p.G185S and p.R385W) whereas 
the son carried only the p.G185S.
Conclusion: In conclusion our data evidenced a case of 
“double trouble” suggesting that, when a known phenotype 
is accompanied by some atypical features, an alternative 
explanation of unusual presentations is required
Disclosure: Nothing to disclose
P1263
Echocardiography in patients with  
myotonic dystrophy type 1
S.Z. Peric, T. Paunic, V. Dobricic, I. Novakovic, I. Basta,  
D. Lavrnic, V. Rakocevic-Stojanovic
Neurology Clinic, Clinical Center of Serbia, School of Medi-
cine, University of Belgrade, Belgrade, Serbia
Background and aims: To analyze results of echocardio-
graphic examination in a large cohort of patients with myo-
tonic dystrophy type 1 (DM1).
Methods: During an 8-year period study comprised 111 
genetically confirmed DM1 patients (45% males, aged 
42.2±10.9 years, mean Muscular Impairment Rating Scale 
3.3±1.1) that were examined using echocardiography du-
ring their first hospitalization at the Neurology Clinic. They 
were matched for gender and age with 71 healthy controls 
(HCs).
Results: Dilatative cardiomyopathy was observed in 4.5% 
of DM1 patients and in no one of HCs (p>0.05), with si-
milar ejection fraction of the left ventricle in both groups 
of subjects (61.3±7.5% vs. 62.2±3.4%, p>0.05). Decreased 
contractility and impaired kinetics of the left ventricle were 
more frequent in DM1 patients compared to HCs (6.3% 
vs. 0.0%, p<0.05 and 9.7% vs. 0.0%, p<0.01). DM1 pati-
ents also had lower maximal mitral velocity (0.83±0.09 vs. 
0.88±0.08, p<0.01) and higher percentage of the mitral val-
ve prolapse (23.0% vs. 8.5%, p<0.05). On the other hand, 
tricuspid valve fibrosis (12.7% vs. 0.0%, p<0.01) and aortic 
regurgitation were even more common in HCs (9.9% vs. 
1.8%, p<0.05). Other echocardiographic parameters did not 
differ between groups.
Conclusion: Our study showed mild impairments of the 
heart structure and dynamics in DM1 patients. Dilatative 
cardiomyopathy was registered in less than 5% of patients. 
We found impaired left ventricle kinetics and mitral valve 
prolapse to be more common in DM1 than in HCs.
Disclosure: Nothing to disclose
206      Poster presentation with discussion
© 2015 European Journal of Neurology, 22 (Suppl. 1), 120–483
P1264
Multiple deletions in mitochondrial DNA in 
myofibrillar myopathy and centronuclear 
myopathy
J. Schäfer, U. Reuner, H. Reichmann, M. Meinhardt,  
S. Jackson
Dept. of Neurology, Dresden, Germany
Background and aims: Multiple deletions in mitochondri-
al DNA (mtDNA) are associated with mutations in nuclear 
genes which encode proteins either directly or indirectly 
involved in the replication or maintenance of mtDNA. To 
date, mutations in twelve nuclear genes, POLG, POLG2, 
C10orf2, SLC25A4, RRM2B, TK2, MPV17, DGUOK, 
OPA1, MFN2, MGME1, and DNA2 have been identified 
in patients with multiple deletions in mtDNA.
Mitochondrial changes have also been identified in skele-
tal muscle from patients with myofibrillar myopathy, with 
histochemical changes such as rubbed out fibres observed 
with COX and NADH staining, and focal clustering and 
depletion of mitochondria. Mitochondrial pathology, inclu-
ding COX negative and ragged red fibres, and paracrystal-
line inclusions have also been described in patients with 
centronuclear myopathy due to mutations in DNM2, which 
encodes Dynamin 2, a GTPase which is involved in mem-
brane trafficking.
Methods: We describe our clinical, histological and mole-
cular genetic findings in two patients with multiple mtDNA 
deletions. 
Results: In one patient, a 70-year-old male who presented 
with a history of exercise induced muscle pain and distal 
myopathy we identified a novel pArg2364His mutation in 
the gene FLNC which encodes the actin binding protein 
filamin-C. In the second patient, a 40-year-old male who 
presented at age 3 with ataxia and later developed facial 
myopathy, proximal muscle weakness, and CPEO, histo-
chemical investigation indicated centronuclear myopathy, 
and a p.Glu560Lys mutation in DNM2 was identified.
Conclusion: Our findings suggest that FLNC and DNM2 
should be added to the list of genes associated with multiple 
deletions in mtDNA
Disclosure: Nothing to disclose
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Muscle MRI in sarcoglycanopathies
G. Tasca1, M. Monforte1, G. Brisca2, A.D‘Amico3,  
J. Díaz-Manera4, L. Maggi5, N. Al Shaik6, A. Pichiecchio7,  
A. Berardinelli7, N. Løkken8, F. Munell9, A. Sanchez9,  
L. Morandi5, N. Voermans10, J. Dastgir11, M.C. Walter12,  
C. Bönnemann13, V. Straub14, S. Quijano-Roy15, R. Carlier15, 
J. Vissing16, E. Mercuri17, F. Muntoni18, E. Ricci1, E. Bertini1, 
B. Udd19, C. Bruno2
1Rome, Italy, 2IRCCS Giannina Gaslini, Genoa, Italy, 
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4Barcelona, Spain, 5Foundation Neurological Institute Carlo 
Besta, Milan, Italy, 6Dubowitz Neuromuscular Centre, Insti-
tute of Child Health, London, United Kingdom, 7C.Mondino 
National Neurological Institute, Pavia, Italy, 8Rigshospitalet, 
University of Copenhaegn, Copenhagen, Denmark, 9Vall 
d‘Hebrón University Hospital, Barcelona, Spain, 10NIJME-
GEN (GLD), The Netherlands, 11National Institute of Neuro-
logical Disorders and Stroke/NIH, Bethesda, USA, 12Munich, 
Germany, 13Bethesda, , 14Newcastle upon Tyne, , 15Hôpital 
Raymond Poincaré, Garches, France, 16Copenhagen, 17Catho-
lic University School of Medicine, Rome, Italy, 18London, UK, 
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Introduction: Sarcoglycanopathies (LGMD2C-2F) are 
Limb-Girdle Muscular Dystrophies caused by mutations in 
one of the four genes encoding for muscle sarcoglycans. 
The objective of this study is to characterize the pattern and 
spectrum of MRI involvement in a large cohort of patients 
with sarcoglycanopathy.
Methods: Lower limb MRI scans of LGMD2C-2F patients 
were collected in multiple neuromuscular referral centers in 
Europe and USA, ranging from severe childhood variants 
to milder adult onset forms. Muscle involvement was eva-
luated semiquantitatively on T1-weighted images accor-
ding to a visual score, and the global pattern was assessed 
as well.
Results: A common pattern of involvement was found 
in all the sarcoglycanopathies irrespective of the mutated 
gene. The most and earliest affected muscles were the ad-
ductors, glutei and posterior thigh groups, while lower leg 
muscles were relatively spared even in advanced disease. 
Conclusion: Muscle involvement on MRI is consistent 
in LGMD2C-F patients and some clues can be helpful in 
distinguishing sarcoglycanopathies from other LGMDs or 
dystrophinopathies, which represent the most common dif-
ferential diagnoses.  Muscle MRI can also provide insights 
about progressive involvement of the different muscles 
over time as well as about selective susceptibility or resis-
tance of specific muscles when one of the sarcoglycans is 
deficient. 
Disclosure: Nothing to disclose
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Traumatic events and amyotrophic lateral 
sclerosis: a European case-control study
E. Beghi, E. Pupillo, P. Messina, #&. EURALS Consortium
IRCCS - Istituto Mario Negri, Neuroscience, Milan, Italy
Background and aims: An Italian study on the associati-
on between amyotrophic lateral sclerosis (ALS) and trau-
ma found that antecedent, repeated and severe trauma may 
be risk factors for ALS. These data required replication in 
other countries.
Methods: A case–control study was undertaken in Italy, 
France, England, Ireland, and Serbia. Cases were patients 
with newly diagnosed ALS from seven population-based 
registries. For each case, two controls were selected from 
the general practitioners’ lists, matched for age, sex, and 
residency. Traumatic events occurred 5+ years before ALS 
onset were recorded with details on type, site, timing, se-
verity, and complications. The risks were assessed as odds 
ratios (ORs) with 95% confidence intervals (CI), crude and 
adjusted for age, sex, education, interviewee (patient or 
surrogate), physical activity, BMI, smoking, alcohol, and 
coffee.
Results: 575 patients and 1150 controls were enrolled. One 
or more traumatic events were reported by 28.7% of cases 
and 27.83% (OR 1.10; 95%CI 0.87–1.39). The ORs was 
1.34 (95%CI 1.04–1.72) for moderate traumatic events, 
1.54 (95%CI 1.24–1.92) for traumatic events leading to 
disability and 2.94 (95%CI 1.25–6.92) for 2+ traumatic 
brain injury (TBI).
Conclusion: Moderate to severe traumatic events and re-
peated TBI are risk factors for ALS.
Disclosure: Study supported by the American ALS Associ-
ation (grant 1524).
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ALS and cancer: is there a link?
D. Bertuzzo1, A. Calvo2, C. Moglia2, S. Cammarosano3,  
U. Manera2, I. Antonio1, F. Pisano4, G. Mora5, E. Bottacchi6, 
L. Mazzini7, E. Bersano7, M.C. Vigliani8, A. Chiò1
1Amyotrophic Lateral Sclerosis Center, Rita Levi Montalci-
ni Department of Neuroscience, University of Turin, Turin, 
2Amyotrophic Lateral Sclerosis Center, University of Turin,  
Rita Levi Montalcini Department of Neuroscience, University 
of Turin, Turin, 3Amyotrophic Lateral Sclerosis Center, Rita 
Levi Montalcini Department of Neuroscience, Amyotrophic 
Lateral Sclerosis Center, Amyotrophic Lateral Sclerosis 
Center, Rita Levi Montalcini Department of Neuroscience, 
University of Turin, Turin, 4Salvatore Maugeri Foundation, 
Istituto Di Ricovero e Cura a Carattere Scientifico, Scienti-
fic Institute of Veruno, Veruno, Italy, 5Fondazione Maugeri, 
Neurorehabilitation, Milan, Italy, 6Department of Neurology, 
Azienda Ospedaliera Regionale di Aosta, Azienda Unità 
Sanitaria Locale Valle d’Aosta, Aosta, Italy, 7Amyotrophic 
Lateral Sclerosis Center, Department of Neurology, Azienda 
Ospedaliero Universitaria Maggiore di Novara, Novara, Italy, 
8Neuroscience Institute of Torino, Turin, Italy
Background and aims: We investigated whether patients 
with ALS have a higher than expected incidence of cancer 
and how the co-occurrence of cancer modifies ALS prog-
nosis
Methods: The study population were the 1260 ALS ca-
ses incident in Piemonte and Valle d’Aosta in the period 
1995-2004. Only patients with cancers occurring in the 6 
months before or after the onset of ALS were included (46 
patients). The odds ratio of having a cancer was calculated 
using as reference the incidence rate of cancers in the same 
area for the period 2004-2006 (Cancer Registry of Piemon-
te Region). Odds ratio was calculated by gender and 5-year 
age-classes.
Results: Cancer in ALS was significantly more frequent 
than expected in both genders (men, OR 2,01; 99% c.i.1.15-
3.28; women 3.43; 1.78-5.95). The excess of cancers was 
mostly due to lung cancers (men 4.35, 1.51-9.68; women 
4.83, 0.58-14.97) and to breast cancers (6.16, 2.29-13.18). 
Patients with cancer had a significantly shorter survival 
than those without cancer (p=0.01); this difference was 
mainly due to patients with lung cancer.
Conclusion: Cancers, predominantly lung and breast can-
cers, have an incidence significantly higher than expected 
in ALS population. Patients with cancer have a worse clini-
cal progression than patients without cancer.
Disclosure: Nothing to disclose
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Do arterial hypertension and diabetes mo-
dify ALS phenotype and outcome?  
A population-based study
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1Amyotrophic Lateral Sclerosis Center, University of Turin,  
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Department of Neurology, Azienda Ospedaliero Universitaria 
Maggiore di Novara,  Novara, Italy, 5Department of Biologi-
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Turin, 6Salvatore Maugeri Foundation, IRCSS, Scientific 
Institute of Milano, Milan, Italy, 7Department of Neurology, 
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Background and aims: Several studies have assessed 
vascular risk factors in ALS. It has been reported that 
pre-morbid AH shortens the survival in ALS patients while 
diabetes mellitus type II (DM) delays the onset of motor 
symptoms
Methods: We include all the 712 ALS patients incident in 
the period 2007-2011 in Piemonte region (323 women and 
389 men, mean age at onset 66.7 years [SD 10.7]) and ret-
rospectively investigate the presence of AH and DM.
Results: Of the 712 patients, 314 (44.1%) had AH for at 
least 2 years before the onset of ALS, and 68 (9.6%) had 
DM. Patients with AH were significantly older (men, 68.4 
[9.0] vs. 64.8 [11.4]; women 70.4 [8.5] vs. 64.0 [11.6]; 
p=0.0001 for both). Pre-morbid AH or DM did not influ-
ence the site of onset of ALS (bulbar vs. spinal). The mean 
age at onset did not differ between patients with and wi-
thout DM (men, 67.9 [8.8] vs. 66.1 [10.8]; women, 68.7 
[8.7] vs. 66.9 [10.9]; p=n.s. for both). Survival from onset 
was reduced in women (p=0.05) but not in men with AH, 
and was not affected by the presence of DM
Conclusion: The presence of pre-morbid AH or DM did 
not influence neither phenotype nor survival of ALS pati-
ents
Disclosure: Nothing to disclose
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Prevalence of stroke symptoms among 
stroke-free residents: national data from 
Lebanon
R. Farah1, R. K. Zeidan2, M. Chahine3,  
R. Chahine3, P. Salameh4, H. Hosseini1
1Henri Mondor Hospital, Neurology , Paris, France, 2Ecole 
Doctorale Biologie Santé Biotechnologies, Université Tou-
louse III, Toulouse, France, 3Lebanese University- Faculty of 
Medecine, BEIRUT, Lebanon, 4Lebanese University-Faculty 
of Pharmacy, Beirut, Lebanon
Background and aims: Stroke symptoms are common 
among people without history of stroke or transient ische-
mic attack (TIA). Stroke symptoms may represent stro-
ke episodes that failed to reach the threshold for clinical 
diagnosis. The Middle East region is lacking data on the 
epidemiology of stroke. This study aimed to assess in the 
Lebanese population the prevalence of self-reported stro-
ke symptoms in a stroke and TIA free population, and the 
association of these symptoms with major risk factors for 
stroke.
Methods: We carried out a cross-sectional study using a 
multistage cluster sample from all over Lebanon. We in-
terviewed residents aged 40 years and more. Stroke sym-
ptoms were assessed using the Questionnaire for Verifying 
Stroke-Free Status.
Results: We included 1460 individuals (mean age 56.7 ± 
12.4 years; 763, 52.3% women). 175 individuals (12.1%, 
95% confidence interval [CI] 9.9%-14.3%) had experi-
enced at least one stroke symptom. Arterial hypertension 
(odds ratio [OR] 4.36; 95% CI 2.68-7.11), regular physical 
activity (OR 0.43; 95%CI 0.25-0.74), current waterpipe 
smoking (OR 4.06; 95% CI 2.42-6.82), cumulative cigaret-
tes’ smoking >7 pack-years (OR 2.44; 95%CI 1.53-3.91), 
history of heart disease (OR 3.44; 95%CI 2.07-5.75), Me-
diterranean diet score (OR 0.87 95%CI 0.76-0.99) and the 
Beirut distress scale (BDS-22) (OR1.04; 95%CI 1.02-1.06) 
were found to be associated with stroke symptoms.
Conclusion: This is the first study conducted in Lebanon, 
assessing stroke symptoms among stroke-free residents. 
Our study showed that almost 1 of 8 residents without 
history of stroke or TIA has had stroke symptoms. Major 
vascular risk factors are associated with these symptoms 
leaving place for prevention strategies.
Disclosure: Nothing to disclose
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Epidemiological data on the association of 
lacunar stroke and primary intracerebral 
hemorrhage: significant decline in  
incidence from 1998 to 2011
M.J.M.P. Correia1, R. Magalhães2, R.J.D.R. Felgueiras1,  
M.C. Silva2
1Porto, Portugal, 2Instituto Ciências Biomédicas Abel Salazar, 
Population Study Department, Porto, Portugal
Background and aims: Lacunar stroke and intracerebral 
haemorrhage share the hypertension as major risk factor. It 
would be expected that the chronic control of blood pres-
sure would decrease incidence of both pathologies. In this 
study we aim to compare trends in incidence of lacunar 
stroke and primary intracerebral haemorrhage eleven years 
apart.
Methods: Two prospective population-based studies 
(1998-2000 and 2009-2011) were used to estimate chan-
ges in stroke incidence. Identical definitions and sources 
of information were used to ascertain all first-ever-in-a-
lifetime strokes occurring in the metropolitan area of Porto. 
The Oxfordshire classification was used to define lacunar 
stroke. Patients were observed at onset and at three months.
Results: Between 1998 and 2011, ischemic stroke inci-
dence decreased from 2.02 (95% CI, 1.81-2.24) to 1.61 
(95% CI, 1.48-1.73) and primary intracerebral haemor-
rhage incidence decreased from 0.45 (95% CI, 0.36-0.57) 
to 0.23 (95% CI, 0.19-0.29). Among ischemic stroke sub-
types, LACI decrement from 0.79 (95% CI, 0.66-0.92) to 
0.43 (95% CI, 0.36-0.49) was the major contributor for the 
declining of ischemic stroke incidence. The decrement in 
LACI incidence was mostly evident in patients older than 
65 and cerebral haemorrhages decreased along all age-
groups.
Conclusion: The decrement of lacunar stroke incidence 
and of intracerebral haemorrhage incidence was similar 
and significant. Probably this trend results from preventive 
strategies for controlling blood pressure in the community. 
This epidemiological data corroborate hypertension as a 
major common underlying pathology for both entities.
Disclosure: Supported by FCT/FEDER project PIC/
IC/82858/2007
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The Brunei epidemiological study in  
stroke and multiple scelrosis (BEST) - 
a door-to-door survey
U. Meyding-Lamadé1, A. Lupat2, E.M. Craemer3,  
M. Luissin2, R. Wagner3, H. Becher4
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Background and aims: Stroke, the 2nd common cause of 
death and the leading cause for permanent disability,it has 
enormous emotional and socioeconomic impact on patients.
In 2011,WHO reported that 6.15 million people suffer from 
stroke worldwide. Aim is to investigate the distribution and 
determinants of stroke in the population. The information 
on prevalence of stroke is of utmost importance especially 
in the perspective in health policy making.
Methods: A cross-sectional study is performed among in-
habitants of Brunei aged 18 years or older. Data are collec-
ted through door-to-door visits with the use of a standar-
dized questionnaire. Blood pressure was measured twice 
during the interview. Participants targeted at intervals by 
means of the Poisson distribution to ensure representative-
ness of the population. 
Results: We will only report preliminary findings. From 
October 2013 until March 2014, 2991 participants were 
interviewed. Mean age was 40.0±15.0 years. Hypertensi-
on, one of the major risk factors for stroke, has a high pre-
valence. The mean body mass index was 26.7±6.0kg/m2, 
and the prevalence of obesity was found to be high with 
24% overall.
Conclusion: Observations regarding hypertension and 
BMI, especially in the younger age groups were alarming.
Comparing our study to studies from other countries, we 
find a significantly higher blood pressure in younger age 
groups. Public health policy makers should look into the 
planning and establishing of adequate resources for the dia-
gnosis and the treatment of stroke and establish prevention 
programs to reduce risk factor prevalence.
Disclosure: Nothing to disclose
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Familial, autosomal-dominant  
neurodegenerative parkinsonism with  
cognitive deterioration spanning five  
generations in a genetically isolated  
population of south-eastern Moravia, 
Czech Republic
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Background and aims: An epidemiological study con-
ducted over four years revealed an increased prevalence of 
neurodegenerative parkinsonism in a small, isolated region 
(10 villages, with a combined population of 8664, with ap-
prox. 2927 over 50 years of age) of south-eastern Moravia, 
Czech Republic. To obtain more detailed medical history 
information about the relatives of individuals with confir-
med parkinsonism in an isolated region with a rural popula-
tion in south-eastern Moravia, Czech Republic.
Methods: Detailed genealogical research was performed 
on the families of all the subjects with confirmed parkinso-
nism and the pedigrees were compiled; these were further 
amended on the basis of information obtained through a 
consecutive door-to-door survey and by means of local mu-
nicipal and church registers.
Results: In the first stage, three large pedigrees with a fa-
milial occurrence of parkinsonism were found; two of them 
originated in one of the region’s villages. In the second 
stage, these two pedigrees were completed into one large 
family tree.
Conclusion: The high prevalence of parkinsonism in the 
researched area is caused by the familial aggregation of 
parkinsonism that was found in two large family trees. This 
familial aggregation of parkinsonism is probably the result 
of the genetic isolation of the regional population due to the 
very low migration rate of its inhabitants to neighboring 
regions in the last two centuries.
Disclosure: Supported by the grants:  IGA MZ CR NT – 
14407 and IGA LF UP – 2014-018. 
P1273
Does abnormal temperature and rapid 
changes of atmospheric pressure affect 




Background and aims: There is inconsistence of evidence 
in literature about sort term effects of climate factors on 
acute cerebrovascular diseases. Our aim was to investigate 
relationships between short-term climate factors, such as 
temperature and atmospheric pressure and stroke.
Methods: We obtained all records 1 Jan 2013 – 30 Sept 
2014 from emergency healthcare registry of City of Minsk, 
Belarus, to estimate daily proportion of stroke. Only re-
cords with non-missing doctor-validated ICD10 codes were 
used to determine cases (ischemic, hemorrhagic or unspe-
cified stroke). We applied linear time-series regression 
models for stationary data to assess relationships between 
stroke and rapid 48h changes of atmospheric pressure, daily 
average and maximum temperature, and abnormally high 
temperature. 
Results: During the period, there were 993,812 records 
with daily average of 1,635 and 52 of total calls and stro-
ke cases (3%), respectively. Mean age of sample was 47.3 
years (SD27.7) with proportion of women 55%; of stroke 
subset – 67.4 years (SD 13.1) with 57% of women. High-
est peaks of stroke was in April 4.3% and 5.1% in July; 
lowest – in December – 2.1%. Final model was adjusted 
for season, month, day of the week, non-weekend holidays, 
as well as main predictors. Proportion of stroke was 0.5% 
(95%CI -0.2-1.1) higher over long weekends, 1.2% (95%CI 
-1.0-3.2) higher over 48h abnormal changes of atmospheric 
pressure and 2.4% (95%CI -0.5-5.6) higher during extre-
mely high temperature, however insignificantly. 
Conclusion: Our results suggest tendency to positive asso-
ciation of stroke with some climate factors, especially with 
abnormally high temperature. These findings need further 
confirmation. 
Disclosure: Nothing to disclose
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Birth month effect in multiple sclerosis:  
Is it a risk factor? A populatıon based  
study
M. Oztekin1, N. Öztekin2, M. Yılmaz3, S. Bilen3, F. Ak3
1MOH Ankara Diskapi Teaching and Research Hospital, Neu-
rology, Ankara, Turkey, 2Ankara, Turkey, 3ANH Traning and 
Research Hospital, Neurology, Ankara, Turkey
Background: Multiple sclerosis (MS) is a complex disor-
der, and the main causal factors seem to be environmental 
and enviromental -genetic interactions. In recent years, a 
month of birth effect on multiple sclerosis (MS) risk has 
been reported from different countries. The aim of the study 
is to determine whether risk of multiple sclerosis (MS) is 
associated with month of birth in a population based study, 
and if factors related to month of birth interact with genetic 
risk.
Methods: The study is designed as population based and 
family based controls and familial cases are also analysed. 
A post hoc pooled analysis of 1291 patients with definite 
MS, all born in this region were included in the study from 
the MS databases of two major centres for MS in Ankara. 
The birth dates of patients were recorded and grouped ac-
cording to the month of birth. The patients were also recor-
ded about their demographic features.
Results: The results of our study revealed that significantly 
fewer patients with MS were born in November compared 
with controls from the population  and unaffected siblings. 
A pooled analysis showed that significantly more people 
with MS were born in April and May. 
Conclusion: The results of our study, are in accordance 
with previous studies, have shown that there is a relation-
ship between month of birh an MS accumulation. The la-
titude of Ankara may be an explanation for the time span 
(April-May) in our results.The results of our our data show-
ed that there is an association between the month of birth 
and MS.
Disclosure: Nothing to disclose
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Consistent decreased functional connecti-
vity among the main cortical and subcorti-
cal functional networks in MS: relationship 
with disability and cognitive impairment
M.A. Rocca1, P. Valsasina2, L. Vacchi1, V.M. Leavitt3,  
G. Comi4, A. Falini5, M. Filippi1
1San Raffaele Scientific Institute, Vita-Salute San Raffaele 
University, Neuroimaging Research Unit, Milan, Italy, 2San 
Raffaele Scientific Institute, Vita-Salute San Raffaele Univer-
sity, 1Neuroimaging Research Unit, Milan, Italy, 3Columbia 
University Medical Center, Department of Neurology, New 
York, USA, 4San Raffaele Scientific Institute, Vita-Salute San 
Raffaele University, Department of Neurology, Milan, Italy, 
5Università Vita-Salute San Raffaele, Neuroradiology, Milan, 
Italy
Background and aims: To explore resting state (RS) func-
tional connectivity (FC) abnormalities within the main cor-
tical/subcortical brain networks in a large cohort of patients 
with multiple sclerosis (MS) with different clinical pheno-
types.
Methods: RS fMRI and a complete neuropsychologi-
cal evaluation were obtained from 202 MS patients (118 
relapsing-remitting [RR], 43 secondary progressive [SP], 
28 benign and 13 primary progressive MS) and 98 healthy 
controls. RS FC analysis was done using a seed-voxel cor-
relation with seven major cortical/subcortical hubs (poste-
rior cingulum, inferior parietal cortex, cuneus, postcentral 
gyrus, cerebellum, thalamus, and amygdala). Between-
group differences of RS FC and correlations with clinical/
neuropsychological scores were evaluated (SPM8).
Results: Compared to controls, MS patients showed a wi-
despread reduction of RS FC in all cortical/subcortical net-
works. In the visual and somatosensory networks, RS FC 
decrease was mainly found in bilateral parietal and superior 
occipital regions. RS FC decrease within the default and 
dorsal attention network involved the bilateral precuneus 
and superior/middle frontal regions. Decreased cerebellar 
RS FC was observed in the dorsal attention, thalamic and 
cerebellar networks. A decreased RS FC between the tha-
lamus and frontal regions was also detected. Compared to 
RRMS, SPMS patients showed reduced RS FC in the so-
matosensory and thalamic networks. Decreased cerebellar 
RS FC was correlated with higher EDSS. Decreased RS FC 
in frontal regions of the dorsal attention and default net-
works correlated with worse cognitive performances.
Conclusion: Cortical/subcortical RS FC is consistently 
reduced in MS patients and is clinically relevant, since it 
correlates with disability and cognitive impairment.
Disclosure: Partially supported by a grant from Italian Mi-
nistry of Health (GR-2009-1529671).
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Ultrasound fusion imaging for intracranial 
haemorrhage – a transcranial duplex  
ultrasound study
S. Schreiber1, J.M. Valdueza2, G. Bohner3, F. Connolly1
1Charité Universitätsmedizin Berlin, Dept. of Neurology, 
Berlin, Germany, 2Segeberger Kliniken, Dept. of Neurology, 
Bad Segeberg, Germany, 3Charité Universitätsmedizin Berlin, 
Dept. of Neuroradiology, Berlin, Germany
Background and aims: Transcranial duplex sonography 
(TCS) can identify acute intracranial hemorrhage as hy-
perechogenic B-mode lesions. However, the sensitivity is 
low as a high percentage of lesions cannot be found, even if 
the location is known from CT or MRI. Ultrasound fusion 
imaging (UFI) is a new technique which allows TCS analy-
sis in freely selectable insonation planes with simultaneous 
visualisation of corresponding pre-registered CT or MR 
images. We report about its application in a pilot series of 
patients with acute intracranial hemorrhage.
Methods: Patients were recruited from our stroke- or in-
tensive care unit if routine CT diagnosed acute intracrani-
al hemorrhage. UFI was performed as an acute combined 
image sequence of TCS and the routine CT aiming to de-
pict the hemorrhage by insonating exactly within the image 
plane of the hemorrhage using an Esaote Mylab Twice 
ultrasound system (Italien, Padua) with the commercially 
available software “Virtual Navigator”. Serial follow-up 
investigations were performed in all patients with positive 
ultrasound findings.
Results: 25 patients were studied including 21 mass he-
morrhages (1 cerebellar, 9 cortical, 11 basal ganglia), 3 ca-
vernoma hemorrhages (1 cortical, 2 basal ganglia) and 1 
subdural hematoma. Application of the UFI technology was 
possible in all studied patients. Hemorrhage was identified 
on TCS sequences as marked or moderate hyperechogeni-
city in a high percentage of mass hemorrhages, reproducib-
le on subsequent serial UFI investigations. Only one out of 
three studied cavernoma hemorrhages could be visualised.
Conclusion: UFI is a promising technique, which should 
be further evaluated concerning its applicability and reli-
ability in the diagnostic follow-up of intracranial hemor-
rhage.
Disclosure: S. Schreiber has been supported by Esaote by 
lending of a research Mylab Twice/Virtual navigator ultra-
sound system.
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Ultrasound MRI fusion imaging in muscle 
disease
K. Irlbacher1, F. Connolly1, H. Engelhardt1, W. Stenzel2, 
K. Hahn1, S. Schreiber1
1Charité Universitätsmedizin Berlin, Dept. of Neurology, 
Berlin, Germany, 2Charité Universitätsmedizin Berlin, Dept. 
of Neuropathology, Berlin, Germany
Background and aims: MRI and ultrasound are helpful 
tools in the diagnostic workup of muscle diseases. MRI is 
the best technique to identify muscle involvement patterns 
to find the optimal location of a muscle biopsy. However, 
MRI can not be taken into the operating room. US-MRI-
fusion imaging (UFI) is a new bedside technique permitting 
a combination of live ultrasound with simultaneous visua-
lisation of exactly matched MR images, derived from pre-
registered datasets. We report UFI application in a series of 
patients with muscle diseases, scheduled for biopsy.
Methods: Patients were recruited from our hospital if rou-
tine pre-biopsy MR-imaging (spin echo T1-, T2, STIR) 
was available. UFI was performed as an additional image 
sequence during pre-biopsy ultrasound using an Esaote 
Mylab Twice system (Italy, Padua) equipped with the “Vir-
tual Navigator“ software.
Results: UFI was performed in 57 patients. (muscle of 
the: upper leg 37, lower leg 14, hip 2, upper arm 4, lower 
arm 1). MRI-defined muscle segments of interest could be 
identified in all patients with the need of minor matching 
corrections during the insonation process. Ultrasound-MR 
comparison of affected muscles were not aleways congru-
ent. E.g. in regions with MR-suspected edema, US demons-
trated tissue hyperechogenicity, suggestive of fibrosis.
Conclusion: UFI is a promising technique, which should 
be further evaluated concerning its applicability and reli-
ability in the diagnostic of muscle diseases. Comparison 
of MRI and US might help to further differentiate muscle 
tissue alterations. However, this hypothesis has yet to be 
confirmed e.g. by histological evaluations.
Disclosure: S. Schreiber has been supported by Esaote by 
lending of a research Mylab Twice/Virtual navigator ultra-
sound system. 
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Exploration of functional and structural 
cerebral modifications underlying  
executive functioning impairment after  
an acute coronary syndrome:  
a multimodal MRI study.
C. Bernard1, G. Catheline2, T. Couffinhal3,  
S. Lassalle-Lagadec2, D. Callaert1, M. Allard2, I. Sibon4
1Univ. Bordeaux, INCIA, UMR 5287, Bordeaux, France, 
2Univ. Bordeaux, INCIA, UMR 5287, EPHE, Bor-
deaux, France, 3Centre Hospitalier de Bordeaux, Cen-
tre d‘Exploration, de Prévention et de Traitement de 
l‘Athérosclérose - Echographie vasculaire (CEPTA), Bor-
deaux, France, 4CHU Pellegrin, Bordeaux, France
Background and aims: Three to 6 months after an acute 
coronary syndrome (ACS), cognitive impairments are ob-
served in more than 30% of the patients, mainly in executi-
ve functioning. The aim of this study was to investigate the 
cerebral anatomo-functional substratum of this executive 
dysfunction using multimodal MRI.
Methods: 33 patients were recruited 4±1 months after an 
ACS. Executive functions were evaluated with the Trail 
Making Test B (TMTB) at baseline and 6 months later. We 
used normative data to determine the cognitive status of 
the patients at baseline and follow-up. The integrity of the 
whole cerebral macrostructure and microstructure was ex-
plored using Voxel-Based Morphometry and Tract-Based 
Spatial Statistics, respectively. Whole-brain resting state 
functional connectivity was investigated using Network-
Based Statistics.
Results: We identified 15 ‘cognitively normal’ patients, 
10 ‘transient impaired’ patients with an impairment only 
at baseline and 8 ‘impairing’ patients with an impairment 
only at follow-up. After a first ACS, no structural difference 
was observed between impaired and cognitively normal pa-
tients. At the functional level, compared to the ‘cognitively 
normal’ group, the ‘transient impaired’ patients presented 
an increased functional connectivity in a network centered 
on middle orbito-frontal regions, whereas the ‘impairing’ 
patients presented only a trend to a decreased of functional 
connectivity.
Conclusion: Two types of patients could be identified: tho-
se with a transient impairment associated with a hyper-con-
nected brain network and those with a delayed impairment 
with a trend to a decreased connectivity. Both would need 
further attention because they could have an increased risk, 
with different time trends, to develop permanent cognitive 
disorder.
Disclosure: Nothing to disclose
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Diagnostic and prognostic validity of 
quantitative EEG and SPECT markers in 
the early diagnosis of cognitive diseases
W. Staffen1, Y. Höller1, H. Zauner2, E. Trinka1, N. Strobl3
1Paracelsus Medizinische Privatuniversität , Neurology, Salz-
burg, Austria, 2Rehabilitationszentrum Großgmain, Gross-
gmain, Austria, 3Paracelsus Medizinische Privatuniversität, 
Neurology, Salzburg, Austria
Introduction: Dementia is a devastating disease with in-
creasing numbers worldwide and an early diagnosis would 
provide fast and effective care. Single photon emission 
computed tomography (SPECT) and Quantitative Elect-
roencephalography (qEEG) have become powerful tools 
in routine diagnostics. We investigated, whether both in-
dividual and combined use of such tools can discriminate 
between patients with Alzheimer’s disease (AD), amnestic 
Mild Cognitive Impairment (aMCI) and Subjective Cogni-
tive Complaints (SCC) and between patients with progres-
sive (PaMCI) vs. stable aMCI (SaMCI).
Methods: 160 patients (36 AD, 56 aMCI, 68 SCC) from 
the Memory Clinic Salzburg were retrospectively rediag-
nosed and grouped according to follow-up in PaMCi and 
SaMCi. Relative cerebral blood flow of 16 anatomical re-
gions was assessed in SPECT and quantitative parameters 
were extracted for qEEG (Hjorth complexity, mobility, 
activity; brainrate; Hurst Exponent). Correlations between 
cerebral hypoperfusion in SPECT and dysfunction in qEEG 
were sought.
Results: Differentiation of AD vs. SCC and AD vs. aMCI 
was significant in every SPECT region. No significant dif-
ference between aMCI and SCC was found. qEEG showed 
significant discrimination between AD vs. SCC and aMCI 
vs. SCC. Combining SPECT and qEEG showed increased 
accuracy for AD vs. aMCI. PaMCI vs. SaMCI differed sig-
nificantly in left temporal areas (SPECT) and right parietal-
occipital regions (qEEG).
Conclusion: qEEG dysfunctions occur at SCC stage whe-
reas neurodegenerative hypoperfusion is seen in later sta-
ges. Thus  a combination of qEEG and SPECT could enable 
to predict the progression of cognitive decline when aMCI 
stage has been reached. Further research is needed.
Disclosure: Nothing to disclose
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Brain atrophy rates and sustained  
disability over 10 years in multiple  
sclerosis
M.L. Stromillo1, A. Giorgio1, M. Battaglini1, F. Rossi1,  
A. De Leucio1, M.L. Bartolozzi2, M. Baldini2, L. Guidi2,  
M.P. Sormani3, E. Portaccio4, M.P. Amato4, N. De Stefano1
1University of Siena, Sienna, Italy, 2Hospital of Empoli, 
Empoli, Italy, 3University of Genoa, Biostatistics Unit, De-
partment of Health Sciences, Genoa, Italy, 4University of 
Florence, Florence, Italy
Background and aims: Brain atrophy is considered a sig-
nificant marker of disease progression in multiple sclerosis 
(MS). We assessed 10-year brain atrophy rates in MS pati-
ents and normal controls (NC).
Methods: At baseline, we studied 110 MS patients (relap-
sing-remitting [n=94], secondary progressive [n=8], prima-
ry progressive [n=8]) and NC (n=16). The two study groups 
were assessed again after 10.3±0.6 years. We acquired con-
ventional brain MRI at both time-points with the same pro-
tocol. Percent volume change in the whole brain (PBVC), 
grey matter (PGMVC) and white matter (PWMVC) were 
computed using modified SIENA/SIENAx software.
Results: MS patients had greater PBVC/y (-0.5±0.22% 
vs.-0.3±0.12%, p=0.003), PGMVC/y (-1.01±0.46% vs 
-0.73±0.19%, p=0.03) and PWMVC/y (-0.18±0.27% vs 
-0.01±-0.13%, p=0.03) than NC. In worsening patients 
(EDSS change≥1), PBVC/y was greater than in clinically 
stable patients (EDSS change<1) (p=0.007). In patients 
with minimal/no disability at baseline (EDSS≤3), PBVC/y 
and PGMVC/y were faster in patients who became disabled 
over the 10-year follow up (EDSS>3) than in those who did 
not (p<0.02). In a multivariate analysis, EDSS change >2 
after 10 years was best correlated with the combination of 
PGMVC/y, baseline T1-lesion count and annualized relap-
se rate≥0.5 (accuracy=82%, p<0.001).
Conclusion: Brain atrophy over 10 years is almost twice 
as faster in MS patients than in NC and occurs in both GM 
and WM. In the long term, sustained clinical worsening is 
best associated with progression of GM atrophy, alongside 
destructive lesions at baseline and high relapse rate. This is 
particularly true in patients with low disability at baseline.
Disclosure: The study was supported by FISM (grant 
2010/R/15) 
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Dopamine transporter SPECT provides 
instrumental diagnosis of akinetic crisis of 
parkinsonism and of neuroleptic  
malignant syndrome
A. Thomas1, G. Martino2, M. Capasso3, M. Nasuti4,  
L. Bonanni1, M. Onofrj1
1University Chieti Pescara, Dept of Neurosciences, Imaging 
and Medical sciences, 2Ospedale Clinicizzato Chieti, Dept of 
Radiology, 3ospedale clinicizzato Chieti, Dept of Neurosci-
ence, imaging and Medical sciences, Chieti, Italy, 4ospedale 
clinicizzato Chieti, Dept. of Radiology, Chieti, Italy
Proposal: Akinetic Crisis (AC) is akin to Neuroleptic 
Malignant Syndrome (NMS) and is the most severe and 
possibly lethal complication of parkinsonism. Diagnosis is 
today based only on clinical assessments yet is often mar-
red by concomitant precipitating factors. Our purpose is to 
evidence that AC and NMS can be reliably evidenced by 
FP/CIT Single Photon Emission Computerized Tomogra-
phy (SPECT) performed during the crisis.
Methods and Materials: Of 6 patients with AC with se-
vere akinesia, 5 were affected by Parkinson’s Disease or 
Lewy body dementia and the crisis was categorized as AC. 
1 was diagnosed as NMS because of exposure to risperido-
ne. In all FP/CIT SPECT was performed in the acute phase. 
SPECT was repeated 3-6 months after the acute event in 5 
patients. Semi quantitative evaluations were used to assess 
binding potentials (BP). As all patients were treated with 
life supporting measures and 4 patients were treated with 
apomorphine, at the same doses as used in the emergency 
treatment.
Results: During AC or NMS, BP values in caudate and pu-
tamen were reduced by 95-80% to noise level of the 97% 
inferior confidence limit, with a nearly complete loss of 
striatum dopamine transporter binding similar to the „ burst 
striatum“. However the follow-up re-evaluation in survi-
ving patients showed a recovery of values by 250-650% to 
the range expected of parkinsonism at the same disease du-
ration. No binding effects of apomorphine were observed.
Conclusion: By showing the outstanding binding reduc-
tion, presynaptic dopamine transporter ligand can provide 
instrumental evidence of AC in Parkinsonism and NMS.
Disclosure: Nothing to disclose
P1282
Clinical, neuropsychological and MRI  
findings in a cohort of Friedreich’s Ataxia 
patients
M. Vavla1, F. Arrigoni2, E. Petacchi3, A. Nordio4,  
A. de Luca2, E. Russo3, S. Pizzighello3, G. d‘Angelo5,  
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A. Martinuzzi3
1Conegliano, Italy, 2IRCCS E.Medea Research Institute, Neu-
roimaging Unit, Bosisio Parini, 3Scientific Institute IRCCS 
E. Medea, Conegliano and Pieve di Soligo Research Centre, 
Conegliano, Italy, 4IRCCS E.Medea Research Institute, Neu-
roimaging Unit, Bosisio, Italy, 5IRCCS E.Medea Research 
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Background and aims: Friedreich’s ataxia (FRDA) is an 
autosomal-recessive neurodegenrative conditions caused 
by a GAA repeat triplet. There are no quantitative objective 
biomarkers to show  reliable correlations with progression 
rate and disease severity.
Methods: 21 early-onset molecularly-defined FRDA pati-
ents underwent clinical-neuropsychological assessment. A 
subgroup of patients (n=17) and age-matched healthy con-
trols (HC) underwent a neuroimaging study protocol on a 
3T-MRI (DTI, fMRI). Non-parametric voxel-based permu-
tations were performed on the WM-maps regions-of-inte-
rest (ROI), via a general linear model (GLM) (p<0.05). An 
fMRI sequence was acquired during a simple block-design 
finger-tapping task.
Results: All patients were homozygous for GAA ex-
pansion (mean GAA1 653.7±221), but one with a point-
mutaion/170GAA. Age-at-onset: 10.6±4.6yrs, age-at-
assessment 26.9±10.3yrs, disease-duration 16.3±8.8yrs. 
Disease-severity: SARA 21.4±7.8; ICARS 53±18.6; FARS-
neur.exam 62.7±18.4. The motor performance influenced 
the IQtot. Deficit on executive and attentive functions were 
observed. We found altered FA and MD parameters, through 
voxel- and ROI-based analysis, in the cerebellar peduncles; 
corticospinal, lemnisceal systems, major commissural fib-
res, thalamic and optic radiations. A finger-tapping task de-
monstrated significantly higher cerebellar-cortex activation 
(lobule V, IV) in HC compared to FRDA.
Conclusion: We report our clinical and neuroimaging ex-
perience of a FRDA cohort in order to explore WM con-
nectivity and motor dysfunction. DTI changes in selec-
ted areas and BOLD-signal in the cerebellar, ipsilateral 
cerebellar-cortex in response to a simple motor task show 
strong intergroup-discriminating power and may prove to 
be useful paraclinical disease markers. A longitudinal study 
is needed to investigate and validate the sensitivity of these 
indicators.
Disclosure: Nothing to disclose
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Susceptibility weighted MRI can help dif-
ferentiating pathogenesis of white matter 
lesions in MS and CNS inflammatory vas-
culopathies
L. Vuolo1, G. Emmi2, G. Carlucci3, A.M. Repice3, C. Mechi3, 
M. Grammatico1, D. Prisco2, E. Silvestri4, A. Barilaro1,  
L. Emmi5, L. Massacesi3
1Careggi Hospital, Department of Neuroscience, Florence, 
Italy, 2Careggi Hospital, Departement of experimetal and 
clinic medicine, Florence, Italy, 3Careggi University Hospital-
University of Florence, Neurology 2, Florence, Italy, 4Careggi 
HospitalUniveristy of Florence, Departement of experime-
tal and clinic medicine, Florence, Italy, 5Careggi Hospital, 
Interdisciplinary internal Medicine-Autoimmune Diseases, 
Florence, Italy
Background and aims: MRI is a sensitive tool for detec-
ting brain white matter (WM) lesions, but its specificity 
may be low, particularly for lesions associated to chronic 
inflammatory vasculopathies, often difficult to differenti-
ate from multiple sclerosis (MS) lesions. However in the 
WM, MS lesions develop along a vein, a feature that could 
help characterize differences. In this study the frequency of 
perivenular lesions (PVL) was used as a marker for diffe-
rentiating WM MS lesions from those observed in systemic 
autoimmune diseases with inflammatory vasculopathies 
(SAD) and brain involvement.
Methods: Patients with MS (n= 30) and SAD involving 
brain (n= 20), have been selected for MRI (1.5T) evalu-
ation. Susceptibility weighted images (SWI) two minutes 
after gadolinium injection and volumetric FLAIR sequen-
ces were acquired. The total number of lesions was ana-
lyzed in the FLAIR scans, whereas the venules and their 
relations with the lesions, in the SWI scans co-registered on 
the FLAIR scans. Lesions were considered perivenular, if 
the lesional hyperintensities completely surrounded a vein 
in at least 1 plane. A vein was defined as a morphologically 
compatible hypointense signal visible in at least 2 perpen-
dicular plans.
Results: Preliminary data were obtained in 424 lesions 
(n=10 MS, 3 SAD). Number of lesions was lower in MS, 
whereas their volume was larger. Mean percentage of PVL 
was significantly higher (p<0.05; Wilcoxon’s test) in MS 
patients (81%±11) than in SAD (9.4%±10).
Conclusion: Although PVL can be detected also in SAD, 
their proportion out of total lesions seems remarkably hig-
her in MS, suggesting they represent a useful marker of 
disease
Disclosure: Nothing to disclose
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Quality of sleep in patients receiving  
androgen deprivation therapy for prostate 
cancer: evaluation of sleep disturbance, 
depression and fatigue
A. Koskderelioglu1, M. Gedizlioglu1, Y. Ceylan2,  
B. Gunlusoy2, N. Kahyaoglu1
1Izmir Bozyaka Education and Research Hospital, Depart-
ment of Neurology, Izmir, Turkey, 2Izmir Bozyaka Education 
and Research Hospital, Department of Urology, Izmir, Turkey
Background and aims: Androgen deprivation is a thera-
peutic option for patients with prostate cancer. However, 
it has negative effects on sleep quality and psychological 
condition. Here, we evaluated the appearance of sleep 
disturbances in patients on androgen deprivation therapy 
(ADT). 
Methods: Pittsburgh Sleep Quality Index (PSQI), Beck 
Depression Inventory (BDI), Epworth Sleepiness Scale 
(ESS), Fatigue Severity Scale (FSS) were administered to 
consecutive prostate cancer patients who underwent radi-
cal prostatectomy and are presently either under adjuvant 
ADT or followed in an unmedicated program (non-ADT). 
The results in ADT and non-ADT groups in addition to the 
demographic data and the features of the malignancy were 
statistically compared.
Results: Of the 67 patients enrolled, 31 (46.3%) were re-
ceiving adjuvant ADT and 36 were not. Age, disease du-
ration and education level showed no difference between 
the two groups. Compared with non-ADT group, the pa-
tients receiving ADT showed higher levels of depression 
(p=0.003), worse quality of sleep (p=0.001) and severe 
fatigue(p=0.005). ADT was significantly associated with 
depression, fatigue, and poor sleep. There was no signifi-
cant difference between the ADT and non-ADT patients 
in terms of excessive daytime sleepiness measured with 
ESS(p=0.249). PSQI scores showed a mild correlation 
with age and disease duration (p=0.048, p=0.05, respec-
tively). However, a high correlation with oncologic stage 
of the tumor, BDI, and FSS scores was observed (p=0.027, 
p=0.0001, p=0.0001, respectively). 
Conclusion: Adjuvant ADT is associated with worse sleep 
quality, depression and fatigue in patients with prostate 
cancer. To recognize such symptoms may remarkably im-
prove their quality of life.
Disclosure: Nothing to disclose
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The polymorphisms of ABCB1 gene  
influence the therapeutic efficacy of  
modafinil and venlafaxine in narcoleptic 
type 1
M. Moresco1, L.N. Riccardi2, F. Pizza3, L. Caporali4,  
S. Pelotti2, G. Plazzi3, V. Donadio1
1university of Bologna, Biomedical and Neuromotor Sciences 
(DIBINEM), Bologna, Italy, 2university of Bologna, Medical 
and Surgical Sciences (DIMES), Bologna, Italy, 3university of 
Bologna, Biomedical and Neuromotor Sciences (DIBINEM); 
IRCCS Istituto delle Scienze Neurologiche, Bologna, Bologna, 
Italy, 4university of Bologna, IRCCS Istituto delle Scienze 
Neurologiche, Bologna, Italy
Background and aims: Narcolepsy type 1 (NT1) is a 
chronic hypersomnia characterized by daytime sleepiness 
and cataplexy. NT1 treatments mostly target individual 
symptoms: wake-promoting agents (e.g. modafinil) are 
effective on sleepiness, antidepressants (e.g. venlafaxi-
ne) on cataplexy, while sodium oxybate (SO) is the only 
drug effective on both. NT1 patients variably respond to 
modafinil and venlafaxine thus affecting compliance. 
Given the potential influence of drug transmembrane trans-
port (glycoprotein-P) and/or metabolism (by cytochrome 
P450) on clinical response, we addressed the relation bet-
ween genetic polymorphisms in ABCB1 or CYP450 genes 
and clinical response to modafinil and venlafaxine in NT1 
patients.
Methods: Individual drug response and genotypes were as-
sessed in 107 NT1 patients (males/females 64/43, mean age 
38 years, SD±21.011) treated with modafinil and/or venla-
faxine at stable doses for at least three months. Minisequen-
cing was performed to detect single nucleotide polymor-
phisms (SNPs) in ABCB1 and in CYP450 genes (CYP2C9, 
CYP2C19, CYP2D6, CYP3A4, and CYP3A5). Patients 
with different responses to treatment were contrasted.
Results: ABCB1 polymorphisms were significantly as-
sociated with clinical response. The wild-type genotype 
1236C>T (P=0.011) and 2677C>T/A (P=0.023) were more 
represented in the modafinil non-responder versus responder 
group. Consequently, the haplotype 1236T/2677T/3435T 
was more represented (P=0.006) in the modafinil responder 
versus non-responder group. Similarly, the wild-type geno-
type of 1236C>T was more frequent (P=0.022) in the ven-
lafaxine non-responder versus responder patients. Finally, 
CYP450 genes did not show any significant association 
with treatment response.
Conclusion: ABCB1 genetic variants modulate therapeutic 
response to modafinil and venlafaxine and may partly exp-
lain pharmacoresistance in NT1 patients.
Disclosure: Nothing to disclose
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Insomnia and mental disorders: data from 
primary care
J. Peceliuniene1, A. Bunevicius2, V. Kasiulevicius1,  
N. Mickuviene3
1Vilnius University, Clinic of Internal Medicine, Family 
practice and Oncology, Vilnius, Lithuania, 2Institute of Neu-
rosciences of the LUHS, Laboratory of Clinical Research, 
Kaunas, Lithuania, 3Behavioral Medicine Institute, LUHS, 
Palanga, Lithuania
Background and aims: Mental disorders (MD) are high-
ly prevalent but poorly recognized in primary care (PC). 
Insomnia is most often thought of as both a medical sign 
and a symptom that can accompany several psychiatric dis-
orders. The aim of the study was to evaluate the rate and 
recognition of mental disorders in PC.
Methods or Materials or Case Report: 998 consecutive 
PC adult patients (average age 50,16±18,75), 320 male and 
678 female, were evaluated for MD twice: first time by 
general practitioner (GP), using his or her routine method, 
and, secondly, by using MINI International Neuropsychia-
tric Interview (MINI).
Results: Only 44.8 % of PC patients, who had no psych-
iatric diagnosis after GP evaluation, had no mental disor-
ders detected by MINI (Table1). MD were diagnosed for 
minority of patients (150 patients: 38 (11.9 %) male, 112 
(16.5%) female) by general practitioner, and the most com-
mon (30 %) diagnosis was insomnia, diagnosed in 50 pati-
ents of the sample.
The split between mental diagnoses by general practitioner and MINI 
International Neuropsychiatric Interview
Conclusion: Mental disorders are highly prevalent, how-
ever, poorly recognized in primary care. Our findings sug-
gest that the use of standard screening tool for mental dis-
orders such as MINI could play a critical role in diagnosing 
psychiatric disorders in primary care.
Disclosure: Nothing to disclose
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Nocturnal sleep stage transitions identify 
narcolepsy type-1 among central disor-
ders of hypersomnolence
F. Pizza1, S. Vandi1, M. Iloti1, C. Franceschini2, R. Liguori1, 
E. Mignot3, G. Plazzi1, V. Donadio1
1University of Bologna, Bologna, Italy, 2University of Parma, 
Parma, Italy, 3Stanford University, Stanford, USA
Background and aims: Previous studies disclosed high 
sleep-wake transitions in narcolepsy. We thus aimed at eva-
luating the reliability of nocturnal sleep dynamics in the 
differential diagnosis of central disorders of hypersomno-
lence.
Methods: 175 patients with hypocretin-deficient nar-
colepsy type 1 (NT1, n=79), narcolepsy type 2 (NT2, 
n=22), idiopathic hypersomnia (IH, n=22), and “subjecti-
ve” hypersomnolence (sHS, n=52) undergoing polysomno-
graphic (PSG) work-up including 48 hours of continuous 
PSG recording.
From nocturnal PSG conventional sleep macrostructure, 
occurrence of sleep onset REM period (SOREMP), sleep 
stages distribution and sleep stage transitions were calcula-
ted. Patient groups were compared, and receiver operating 
characteristic (ROC) curve analysis was used to test the di-
agnostic utility of nocturnal PSG data to identify NT1.
Results: Sleep macrostructure was mostly stable in the 
two nights of each diagnostic group. Narcoleptic patients 
had lower latency to REM sleep, and NT1 patients showed 
most awakenings, sleep stage transitions, and time spent 
in N1, as well as most SOREMPs at daytime PSG and at 
MSLT than all other groups. ROC curve analysis showed 
that nocturnal SOREMP (area under the curve of 0.724), 
percent of total sleep time spent in N1 (0.896±0.023), and 
the Wakefulness-Sleep transition index (0.796±0.034) had 
a good sensitivity and specificity profile to identify NT1, 
especially when used in combination (0.903±0.023), com-
parably to SOREMP number at continuous daytime PSG 
(0.899±0.026) and at MSLT (0.956±0.015).
Conclusion: Sleep macrostructure including stage transi-
tions can identify NT1 among central disorders of hyper-
somnolence.
Disclosure: Nothing to disclose
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Clinical trial design and strategies for  
developing pharmacological treatments 
for sleep bruxism
T. Roesel
Uniformed Services University of the Health Sciences, De-
partment of Medicine, Bethesda, Maryland, USA
Background and aims: Sleep bruxism is a neurological 
movement disorder leading to fatigue, teeth attrition, tem-
poromandibular joint pain disorders, and headaches. A re-
cent Cochrane review identifies the need for randomized 
clinical controlled trials (RCTs) to better develop pharma-
cological treatments for bruxism. Therefore, a trial design 
for drug testing is proposed using a newly available device 
for bruxism assessment. To determine nocturnal bruxism 
events, this noninvasive portable device measures masseter 
activity and monitors heart rate. Sample sizes for RCTs are 
calculated based on the number of episodes of bruxism per 
night (E/N).
Methods: Data from Deregibus, et al. (Clinical Oral In-
vestigations, 2014), was applied to the t-test for two in-
dependent variables from PS software with the following 
parameters:  type I error probability of 0.05, power of 0.9, 
allocation of 1:1, and 50% decrease in the mean of 30.5 
E/N, with a standard of deviation of 11.66 E/N.
Results: If the difference in the experimental and control 
means is 15 E/N (50% decrease), calculations reveal that 
14 experimental and 14 control subjects are needed to reject 
the null hypothesis.
Conclusion: Assuming that a 50% reduction in E/N re-
presents bruxism improvement, RCTs with this device are 
feasible, since only 28 study subjects are needed per trial. 
Though clonidine or clonazepam may reduce bruxism, the 
Cochrane review concluded that all studies so far have been 
inadequate. Thus, head-to-head drug trials and those using 
glutamate antagonists or γ-aminobutyric acid (GABA) ac-
tive agents are proposed.  Future studies are needed to iden-
tify pharmacological treatments that better control sleep 
bruxism.
Disclosure: Nothing to disclose
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Restless legs syndrome and transdermal 
fentanyle: a case of augmentation
H. Santos-Canelles
Coaña, Spain
Background and aims: Augmentation consists of the ex-
acerbation of restless legs syndrome (RLS) after the be-
ginning of a therapy. It is a well known complication in 
patients treated with first line therapies like dopaminergic 
agonists, but not in other cases.
Methods: Retrospective study of a case of RLS associa-
ted to transdermal fentanyl treatment. Assessment inclu-
des past medical history, interview about RLS symptoms, 
blood tests, cranial CT and spinal MRI.
Results: A 70-year-old man starts treatment with 50mg 
TID because of a lumbar vertebral compression fracture. 
It is later changed into transdermal fentanyl (8.4mg/3 days) 
because of lack of efficacy. One year later, he starts ha-
ving sporadically pain in his arms at nights that is relie-
ved by movement. During the next two years symptoms 
become dayly and extend to his four limbs, worsening at 
nights though pain is present nearly all day. Ferritin levels 
and cranial CT are normal and spinal MRI shows a lumbar 
compression fracture. Pain disappears completely when ro-
tigotine is started.
Conclusion: This is an atypical case of RLS both because 
of symptoms and also because of the drug associated to 
augmentation. Upper extremity symptoms only rarely de-
velop into RLS. Besides, opioids such as tramadol and oxy-
codone are being used as a second-line treatment for RLS 
and augmentation has only been described in few patients 
treated with tramadol. In this case, transdermal fentanyl is 
associated to the beginning and worsening of RLS. Aug-
mentation maybe shoud be considered as a possible com-
plication in long term treatment of RLS with opioids.
Disclosure: Nothing to disclose
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Obstructive sleep apnea syndrome in  
muscular versus neuronal disorders in  
children with Duchenne muscular  
dystrophy and spinal muscular atrophy
B. Zeydan1, G. Incesu2, G. Benbir1, A. Aydin3, S. Saltik3,  
C. Yalcinkaya1, D. Karadeniz1
1Istanbul University Cerrahpasa School of Medicine, De-
partment of Neurology, Istanbul, Turkey, 2Istanbul University 
Cerrahpasa School of Medicine, Istanbul, Turkey, 3Istanbul 
University Cerrahpasa School of Medicine, Department of 
Pediatrics, Istanbul, Turkey
Background and aims: Obstructive sleep apnea syndrome 
(OSAS) is rare in children, but there is an increased risk 
in case of association with neuromuscular diseases. Aim of 
this study is to compare sleep architecture and presence of 
sleep-related breathing disorders in muscular versus neuro-
nal disorders in children with Duchenne muscular dystro-
phy (DMD) and spinal muscular atrophy (SMA). 
Methods: We prospectively investigated children with 
DMD or SMA who were admitted to Child Neurology Cli-
nics in Pediatrics/Neurology Departments for the last one 
year. Nine male children, whose parents agreed to partici-
pate, had polysomnography.
Results: Five children had DMD and 4 children had SMA. 
Mean ages were 9.6±2.6 and 5.2±4.6 (p=0.190), body mass 
index values were 18.2±8.9 and 16.2±2.6 (p=1.000) in 
children with DMD and SMA, respectively. Polysomno-
graphic parameters (total sleep time, sleep latency, effici-
ency, percentages of sleep stages) were all similar. Apnea-
hypopnea index (AHI) was normal (below 1/hour) in all 
DMD cases, whereas all children with SMA had OSAS 
with mean AHI of 6.7±3.5 per hour (p=0.016). Periodic leg 
movements in sleep(PLMS) were present in 40% of child-
ren with DMD, 75% of children with SMA. PLMS index 
was also higher in children with SMA (10.5±8.8 versus 
3.0±4.2 per hour, p=0.159).
Conclusion: We interestingly observed that none of the 
children with DMD had OSAS, while all children with 
SMA had. Although these results should be confirmed in 
larger series, a very high comorbidity of OSAS in children 
with SMA is noteworthy and requires further attention to 
improve quality of life and respiratory status.
Disclosure: Nothing to disclose
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The relationship between serum  
melatonin levels and seep evaluation sca-
les in idiopathic Parkinson’s disease
A. Uysal, B.I. Tiftikcioglu, Y. Zorlu
İzmir Tepecik Education and Research hospital, Neurology, 
Izmir, Turkey
Background and aims: Sleep disorders, seen during the 
entire course of the disease, is one of the non-motor com-
plications of Idiopathic Parkinson Disease (IPD). Various 
sleep disturbances might be related to either disease symp-
toms, adverse effects of medications, or alterations in me-
latonin and other various sleep hormone levels. We aimed 
to compare patients diagnosed with IPD whom do not have 
sleep complaint with healthy controls by sleep evaluation 
scales, and serum melatonin levels.
Methods: 40 IPD patients (F/M:19/21) who are above 50 
years of age and 40 healthy, age and sex-matched control 
subjects (F/M:20/20) without any neurological, endocrino-
logical or sleep disorders were included in the study. Pitts-
burg Sleep Quality Index (PSQI) and Epworth Sleepiness 
Scale (ESS) were performed and serum melatonin levels 
were measured in blood samples taken at 00:00 and 05:00h 
in all subjects.
Results: There was a statistically significant difference bet-
ween the two groups in terms of PSQI and ESS. Although 
the serum melatonin levels at two different time points du-
ring night time were lower in patients with IPD compared 
to healthy controls, these differences did not reach statisti-
cal significance. There was a significant but weak correla-
tion between ESS scores and decrease in serum melatonin 
levels taken at 05:00 AM , but not between serum melato-
nin levels at 00:00 PM.
Conclusion: Although the sleep evaluation questionnaires 
such as Pittsburg Sleep Quality Index and Epworth Slee-
piness Scale provide highly sensitive information on sleep 
disorders, the serum melatonin levels do not.
Disclosure: Nothing to disclose
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Head-up tilt table test in differentiating 
neuropathic from hyperadrenergic type of 
postural orthostatic tachycardia syndrome 
(POTS)
L. Crnošija1, M. Krbot Skoric2, I. Adamec2, A. Mišmaš2,  
V. Miletić2, R. Šprljan-Alfirev2, A. Junaković2, A. Pavelić1, 
M. Lovrić3, M. Habek2
1School of medicine, University of Zagreb, Zagreb, Croatia, 
2University Hospital Centre Zagreb, Neurology, Zagreb, 
Croatia, 3University Hospital Centre Zagreb, Department of 
Laboratory Diagnostics, Zagreb, Croatia
Background and aims: The aim of this study was to inves-
tigate differences between hyperadrenergic and neuropa-
thic type of POTS in cardiovascular response to orthostatic 
provocation, and to create a diagnostic model that could 
effectively differentiate between the two, using only head-
up tilt table test (HUTT). 
Methods: 43 POTS patients (25 women, 18 men) un-
derwent HUTT protocol: 10-minute supine phase and 
30-minute 70° tilted phase. Tilted phase ended earlier if 
vasovagal syncope occurred or patient reported intolerab-
le symptom/s. Serum catecholamine levels were determi-
ned in 10th minute of supine and tilted phase, and patients 
were categorized into one of two types of POTS based on 
the norepinephrine level in the tilted phase (≥3.5 nmol/
L=hyperadrenergic). 
Results: 10 patients had hyperadrenergic (group 1) and 
33 had neuropathic (group 2) type of POTS. In group 1, 
80% of patients were men, and in group 2, 69.7% were 
women (p=0.005). Group 1 had higher values of heart rate 
during supine phase (82.6 ±16.3 bpm vs. 73.8 ±10.4 bpm, 
p=0.048). Group 2 had earlier tilted phase mean ending time 
(8.8 ±6.8 min vs. 21.2±4.5 min, p=0.001) (Figure 1) and lo-
wer values of diastolic blood pressure difference between 
1st minute of tilted phase and supine values (-1.7 ±7mmHg 
vs. 5.6 ±7.5mmHg, p=0.007) (Figure 2). Using observed 
differences in response to orthostatic provocation we deve-
loped a HUTT model for differentiating neuropathic POTS 
(Figure 3) with sensitivity of 76% and specificity of 80%.
Distribution of time to cessation of tilted phase of head-up tilt table test 
depending on type of POTS.
Dyastolic blood pressure (dBP) changes during head-up tilt table test 
in patients with hyperadrenergic and neuropathic type of postural or-
thostatic tachycardia syndrome.
Venn’s diagram of the proposed model.
Conclusion: Based on these findings it can be concluded 
that HUTT alone can differentiate between two types of 
POTS, saving time and resources. 
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Traumatic spinal cord injury and 24-hour 
blood pressure profile during primary  
rehabilitation
E.M. Hagen1, J. Vibjerg2, R.M. Hansen2
1National Hospital for Neurology and Neurosurgery, Queen 
Square, Autonomic Unit, London, United Kingdom, 2Spinal 
Cord Injury Center of Western Denmark, Regional Hospital of 
Viborg, Department of Neurology, Vyborg, Denmark
Background and aims: Spinal Cord injury (SCI) may in-
terrupt autonomic pathways leading to disturbed cardiova-
scular homeostasis. Studies have found that patients with 
SCI have an increased risk of atherosclerosis as a result of 
the injury itself. The aim of this study was to investigate 
how non-invasive 24-hour ambulatory blood pressure mea-
surement can be used in clinical praxis to identify distur-
bances in blood pressure (BP) regulation in patients with 
injuries above Th6 during primary rehabilitation, within 
one year after injury.
Methods: A 24-hour ambulatory BP monitor performed on 
consecutive patients with traumatic SCI admitted to prima-
ry rehabilitation at the Spinal Cord Injury Unit of Western 
Denmark.
Results: 14 SCI patients were included, 10 men and 4 wo-
men, aged 55.5±13.5 years (mean ± SD). Time since injury 
was 0.4±0.3 years. 6 patients had a complete cervical inju-
ry; five had an incomplete cervical injury and three patients 
a complete thoracic injury. The mean BP was 118/68 mmHg 
for complete cervical injuries, 134/85 mmHg for incomple-
te cervical injuries and 133/85 mmHg for complete thoracic 
injuries during daytime, and 116/64 mmHg, 105/64 mmHg 
and 124/77 mmHg respectively, during night-time. Systolic 
BP at night was higher than during the day in 29% of the 
patients (n=4), and 21% (n=3) were non-dippers. Nocturnal 
hypertension was present in 21% (n=3).
Conclusion: Ambulatory BP detected a high incidence of 
reversed dipping and nocturnal hypertension. Ambulatory 
BP monitoring provides useful information regarding BP 
during primary rehabilitation.
Disclosure: Nothing to disclose
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Central autonomic dysfunction upon  
orthostasis as a remainder of traumatic 
brain injury
M.J. Hilz1, J. Markus1, R. Wang1, S. Moeller1, T. Intravooth1, 
K. Hösl2, J. Koehn1
1University of Erlangen-Nuremberg, Department of Neurolo-
gy, Erlangen, Germany, 2Klinikum am Europakanal , Depart-
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Psychosomatic Medicine, Erlangen, Germany
Background and aims: Patients with a history of trauma-
tic brain injury (post-TBI-patients) have an unexplained in-
creased risk of mortality, possibly due to central autonomic 
dysfunction (CAD). To evaluate CAD in post-TBI-patients, 
we assessed cardiovascular-autonomic modulation at rest 
and upon standing in post-TBI-patients.
Methods: In 20 mild post-TBI-patients (4-78 months post-
TBI, 33±13 years, GCS-scores upon injury 13-15), 20 
moderate or severe TBI-patients (6-94 months post-TBI, 
33±9 years, GCS-scores <13), and 20 age-matched cont-
rols (29±10 years), we monitored respiration, RR-intervals 
(RRI) and systolic blood pressure (BPsys) at supine rest 
and upon standing. We calculated spectral powers of main-
ly sympathetic low (LF: 0.04-0.15Hz) and parasympa-
thetic high (HF: 0.15-0.5Hz) frequency RRI-fluctuations, 
sympathetic LF-powers of BPsys, RRI-LF/HF-ratios, and 
normalized (nu) LF- and HF-powers of RRI. We correlated 
autonomic parameters and GCS-scores (Spearman-test), 
and compared patient and control data while supine and 
standing (RANOVA; significance: p<0.05).
Results: While supine, BPsys and nuRRI-LF-powers were 
higher, RRI-HF-powers were lower in moderate and severe 
post-TBI-patients than in mild post-TBI-patients and cont-
rols. RRI-LF/HF-ratios were higher in moderate and severe 
post-TBI-patients than controls. nuRRI-LF-powers were 
higher, nuRRI-HF-powers were lower in mild post-TBI-
patients than controls.
Upon standing, only controls and mild post-TBI-patients 
increased BPsys and decreased RRI-HF-powers. Only con-
trols increased BPsys-LF-powers. Upon standing, nuRRI-
LF-powers, RRI-LF/HF-ratios correlated directly and nuR-
RI-HF-powers indirectly with GCS-scores.
Conclusion: While supine, TBI-patients had increased 
sympathetic activity. Upon standing, TBI-patients did not 
adequately increase sympathetic and reduce parasympathe-
tic modulation. The correlation between GCS-scores and 
autonomic parameters during orthostasis suggests increa-
sed CAD with increased TBI-severity.
Disclosure: The study was partially funded by the Inter-
national-Brain-Research-Foundation, IBRF, Flanders, NJ, 
USA.
© 2015 European Journal of Neurology, 22 (Suppl. 1), 120–483
Poster presentation with discussion      223
P2104
Autonomic dysfunction in Alzheimer’s  
disease
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M.M. Møller4, B.B. Andersen1, P. Høgh5, M. Ballegaard4
1Rigshospitalet, Danish Dementia Research Centre, Neuro-
logy, Copenhagen, Denmark, 2Aarhus University Hospital, 
Neurology, Aarhus, Denmark, 3Rigshopitalet, Clinical Neuro-
physiology, Copenhagen, Denmark, 4Rigshospitalet, Clinical 
Neurophysiology, Copenhagen, Denmark, 5Roskilde Hospital, 
Denmark, Roskilde, Denmark
Background and aims: Autonomic function has received 
little attention in Alzheimer’s disease (AD). AD pathology 
has an impact on brain regions which are important for cen-
tral autonomic control, but it is unclear if AD is associated 
with disturbance of autonomic function. We aimed to inves-
tigate autonomic function using standardized techniques in 
patients with AD and healthy age-matched controls.
Methods: 33 patients with mild to moderate AD and 30 
age- and gender-matched healthy controls, without sym-
ptoms of autonomic dysfunction, underwent standardized 
autonomic testing with deep breathing, Valsalva maneuver, 
head-up tilt and isometric handgrip test. Brachial pressu-
re curve and electrocardiogram were recorded for off-line 
analysis of blood pressure and beat-to-beat heart rate (HR).
Results: AD patients had impaired blood pressure respon-
ses to Valsalva maneuver (p<0.0001) and HR response to 
isometric contraction (p=0.0001). A modified composite 
autonomic scoring scale showed greater degree of autono-
mic impairment in patients compared to controls (patient: 
2.1 ± 1.6; controls: 0.9 ± 1.1, p=0.001). HR response to 
deep breathing and Valsalva ratio were similar in the two 
groups.
Conclusion: We identified autonomic impairment ranging 
from mild to severe in patients with mild to moderate AD, 
who did not report autonomic symptoms. Autonomic im-
pairment was mainly related to impairment of sympathetic 
function. The clinical implications of this finding are that 
in AD may be associated with autonomic disturbances, but 
patients with AD may rarely report symptoms of autonomic 
dysfunction. Future research should systematically evalua-
te symptoms of autonomic function and characterise risk 
factors associated with autonomic dysfunction.
Disclosure: Nothing to disclose
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Orthostatic hypotension and  
antihypertensive drugs
A. Mišmaš1, A. Bazina1, M. Krbot Skoric1, A. Ljilja2,  
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Croatia, 2Clinical Hospital Dubrava, Department of Internal 
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Background and aims: The aim of this study was to de-
termine how often patients older than 60 years who are di-
agnosed with orthostatic hypotension (OH) on the tilt-table 
test are taking antihypertensive medications and what kind. 
Methods: Medical records from the Autonomic Nervous 
system Laboratory, University Hospital Center Zagreb, 
Zagreb, Croatia were retrospectively reviewed in a period 
from April 2012 to April 2014 to identify patients older 
than 60 and diagnosed with OH by the tilt-table test. Data 
on sex, age, presenting symptoms, antihypertensive drugs 
and outcome were assessed.
Results: We identified 55 patients that met inclusion 
criteria, 33 males (60%), 22 females (40%); mean age 
70.43±7.79. The most common presenting complaints were 
transient loss of consciousness (syncope) (56.4%), insta-
bility (45.5%) and dizziness (32.7%). Among them 69.1% 
(N=38) were taking antihypertensive drugs; 30.9% (N=17) 
were taking 1; 20.0% (N=11) 2; 16.4%  (N=9) 3 and 1.8% 
(N=1) 4 antihypertensive medications. Patients were 
prescribed with angiotensin-converting-enzyme inhibitors 
in 34.5%; beta-blockers in 30.9%; diuretics in 27.3%; cal-
cium channel blockers 21.8%; alpha-blockers in 1.8% and 
other in 10.9% cases. All patients with OH were routinely 
given advice on antihypertensive drug reduction and dieta-
ry measures. Follow-up data were available for 26 (47.2%) 
patients and 18 (69.2%) reported clinical improvement.
Conclusion: Patients over 60 years with OH often take an-
tihypertensive drugs. Identification of the drugs and their 
reduction could help prevent iatrogenic OH and its com-
plications.
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The adventure of the Lion’s Mane: acute 
autonomic neuropathy induced by jellyfish 
toxicity.
R. Lonergan1, I. McGurgan2, P. Wiseman1, J. Duignan1,  
E. McGrath1, S. Connolly3, C. McGuigan4
1St. Vincent’s University Hospital, Neurology, Dublin, Ireland, 
2Dublin, Ireland, 3St Vincent’s University Hospital, Elm Park, 
Dublin 4, Ireland, Department of neurophysiology, Dublin, 
Ireland, 4St Vincent’s University Hospital, Department of 
Neurology, Dublin, Ireland
Background and aims: Cyanea capillata jellyfish sting 
may induce autonomic neuropathy.
Methods: A 51-year-old man presented with recurrent pos-
tural lightheadedness 3 days subsequent to anaphylactic 
shock requiring resuscitation. He had developed broncho-
spasm with collapse hours after a Lion’s Mane jellyfish sting 
whilst swimming. He recalled a minor sting 2 weeks earlier. 
He also described constipation, erectile dysfunction, urina-
ry hesitancy, and excessive sweating. Examination: afebrile 
but sweating profusely. Significant postural blood pressure 
drop (40 mmHg systolic BP) and tachycardia (>100 bpm). 
Abdomen distended with reduced bowel sounds. 
Results: Plain film of abdomen: dilated bowel loops.
ECG: sinus tachycardia. 
Nerve conduction studies demonstrated increased thermal 
thresholds on quantitative sensory threshold testing of feet.
R-R interval studies showed loss of variation between nor-
mal and deep breathing. Sympathetic skin response was re-
duced in the feet. Negative screening for other infectious/
inflammatory/metabolic/paraneoplastic causes. He was 
managed conservatively (fludrocortisone), with gradual 
reduction of symptoms. However, persistent postural light-
headedness after 3 months prompted intravenous immuno-
globulin therapy.
Conclusion: Clinical presentation with anaphylaxis and 
subsequent dysautonomia, with small fibre studies demons-
trating involvement of small unmyelinated C fibres,  sugge-
sted an autonomic neuropathy, likely secondary to cyanea 
capillata (Lion’s Mane) toxin, as previpusly rarely descri-
bed. In the phylum Cnidaria , a cnidocyte fires a venom-
containing  cnidocyst. Polypeptide venoms cause ion trans-
port abnormalities at cellular level, release inflammatory 
mediators, and act as direct toxins on nervous tissue/ auto-
nomic fibres. Associated fatality inspired a Sherlock Hol-
mes story (The Adventure of the Lion’s Mane). Awareness 
of this potential, serious complication may guide initial 
investigation and inform optimal management post-sting. 
Disclosure: Nothing to disclose
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Functional neurological symptoms in  
patients with postural tachycardia  
syndrome (PoTS)
L. Ricciardi1, A.P. Owens2, G. Ferrazzano3, V. Iodice2,  
C. Mathias2, M. Edwards1
1Institute of Neurology, London, United Kingdom, 2University 
College London, Autonomic Unit, National Hospital for Neu-
rology and Neurosurgery, Queen Square/Division of Clinical 
Neurology, Institute of Neurology,, London, United Kingdom, 
3University of Rome, Rome, Italy, Department of Neurology 
and Psychiatry, ’sapienza’ , Rome, Italy
Background and aims: Postural tachycardia syndrome 
(PoTS) is characterized by an increase in heart rate >30 
beats per minute (BPM) within 10 minutes of standing, or a 
maximum HR >120 BPM without orthostatic hypotension 
while standing. PoTS is often included in the differential 
diagnosis of chronic unexplained symptoms. Many patients 
with PoTS present comorbid functional somatic disorders, 
such as functional gastrointestinal or bladder disorders. To 
date no data are available regarding the co-occurrence of 
functional neurological symptoms (FNS) in these patients.
Aim: We retrospectively investigated the presence of FNS 
in consecutive patients referred to our London-based natio-
nal referral centre for autonomic disorders over a three-year 
period.
Methods: We reviewed the medical records of all consecu-
tive patients referred for suspected dysautonomia between 
2012 and 2014 who received a diagnosis of PoTS. We eva-
luated all cases for a diagnosis of FNS. We describe demo-
graphic and clinical characteristics of this population.
Results: We identified 559 patients with PoTS (F/M: 
500/59, mean age 36.0±11.4). Within this population, 
33(6%) patients also received a diagnosis of FNS (F/M: 
2/33, mean age 35.8±10.1). Non-epileptic attacks and mu-
scle jerks/spasm/twitches were the most frequent clinical 
presentation of FNS, each occurring in 27% (9/33) of the 
PoTS/FNS cases. Functional tremor was present in 18% 
(6/33), functional dystonia in 9% (3/33), functional wea-
kness in 15% (5/33) and sensory symptoms in 1 patient.
Conclusion: Our results confirm that PoTS mainly occurs 
in young, female patients. FNS can co-occur with PoTS, 
with non-epileptic attacks and functional movement disor-
ders the most frequent clinical manifestations.
Disclosure: Nothing to disclose
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Autonomic vasomotor dysfunctions In 
hand-arm vibration syndrome
Z. Stoyneva
Clinic of Occupational Diseases, Department of Neurology, 
Sofia, Bulgaria
Background and aims: Peripheral nervous, vascular and 
musculoskeletal disorders of the upper limbs are characte-
ristic for hand-arm vibration syndrome (HAVS).
AIM: to assess laser Doppler-recorded microcirculatory re-
activity in hand-arm vibration syndrome patients.
Methods and Materials: Skin fingerpulp perfusion (PU) 
was monitored of 20 patients with HAVS and 15 healthy 
controls as initial values and during heating test (up to 
440 C) and venoarteriolar posture test (with hands on the 
sternum and in dependency) by laser Doppler system Pe-
riFlux 4001 Master and PeriTemp4005 Heater (PERIMED, 
Stockholm, Sweden). Data were analyzed by Wilcoxon 
matched pairs signed rank test and Mann-Whitney U test 
for unpaired data by SPSS software package with level of 
significance p<0.05.
Results: The values of the initial mean perfusions in the 
HAVS patients were significantly lower compared to the 
healthy controls. Lower skin perfusions to local heating 
were measured due to significantly reduced microvascu-
lar responses and vasodilator thermal induced capacity in 
the patients compared to the healthy controls (p<0.0001). 
Abnormal venoarteriolar reflex responses with lacking or 
decreased perfusion reduction in hand dependency was 
established in HAVS patients due to local vasomotor dys-
function induced either by postganglionar sympathetic in-
sufficiency with vascular tone failure or/and altered smooth 
muscle cells’ responses.
Conclusion: Microcirculatory and autonomic vasomotor 
dysfunctions were found in HAVS patients. Laser Doppler 
flowmetry applied with functional tests is a reliable quanti-
tative noninvasive method for investigation of skin micro-
circulation and microvascular dysregulations.
Disclosure: Nothing to disclose
P2109
Wavelet analysis to differentiate dementia 
patients with and without autonomic dys-
function
W. Struhal1, C. Mahringer2, H. Lahrmann3, P. Buhl2,  
G. Ransmayr1
1Kepler University Clinic, Department for Neurology and 
Psychiatry, Linz, Austria, 2Kepler University Clinic, Depart-
ment for Medical Engineering, Linz, Austria, 3Vienna, Austria
Background and aims: Recent data suggest a high in-
cidence of autonomic dysfunction in patients suffering 
Alzheimer’s disease (AD) and Frontotemporal Dementia 
behavioural variant (bvFTD). The standard tests to investi-
gate cardiovascular function are time consuming and requi-
re compliance. Biomarker, which are easier to obtain with 
less compliance needed, would be of interest. This study 
evaluates the value of wavelet analysis of heart rate vari-
ability (HRV) data to differentiate dementia patients from 
dementia patients without autonomic involvement. 
Methods: Patients were prospectively enrolled at the De-
partment of Neurology and Psychiatry, AKH Linz. Patients 
were first evaluated employing standard autonomic tests 
(Ewing battery) and divided into 2 groups: A unremarkab-
le cardiovascular autonomic results, B pathologic cardio-
vascular autonomic results. HRV data derived from ECG 
recordings in supine and upright position (passive head up 
tilt test) were analysed using Morlet wavelets and results 
compared between both groups. 
Results: 28 patients were included (17 group A: 64.53 
±10.04 years, 4 male, 13 female and 11 group B with au-
tonomic dysfunction: 75.91±6.82 years, 3 male, 8 female). 
Group A showed significantly increased sympathetic power 
during orthostasis (+7.7% resulting in a sympathetic pro-
portion of 86% of total autonomic power) whereas group 
B showed no significant autonomic modulation during or-
thostatic stress. 
Conclusion: Patients with AD and bvFTD show a high 
incidence of impaired cardiovascular regulation during tilt 
test. Wavelet analysis of HRV in supine and upright positi-
on seems valuable for the evaluation of autonomic involve-
ment in this patient group and does not require compliance 
from the patient.
Disclosure: This study was funded by the National Bank of 
Austria (OeNB grant 13240).
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Eyeball pressure stimulation shows pa-
radox sympathetic activation in patients 
after moderate and severe traumatic brain 
injury
R. Wang1, T. Intravooth1, S. Moeller1, J. Koehn1,  
F. Aurnhammer2, H. Marthol1, M.J. Hilz1
1University of Erlangen-Nuremberg, Department of Neurolo-
gy, Erlangen, Germany, 2Waldkrankenhaus St. MarienGmbH, 
Department of Internal Medicine I and IV, Erlangen, Germany
Background and aims: Long-term mortality is increased 
in patients with a history of traumatic brain injury (TBI). 
The unknown pathophysiology might be related to cen-
tral-autonomic-network dysfunction compromising car-
diovascular regulation. In patients with a history of TBI, 
eyeball-pressure-stimulation (EPS), a parasympathetic car-
diovascular challenge, might uncover autonomic-dysfunc-
tion. In patients with a history of moderate or severe TBI, 
we determined whether EPS shows autonomic-cardiovas-
cular-dysregulation.
Methods: In 25 moderate-TBI-patients (33.00±10.23 ye-
ars, 3 to 120 months post-injury), 26 severe-TBI-patients 
(32.42±10.93 years, 5 to 144 months post-injury), and 
30 controls (29.13±9.77 years), we recorded respiration, 
RR-intervals (RRI), systolic and diastolic blood-pressu-
re (BPsys, BPdia), before and during EPS (120seconds; 
30mmHg), using an ophthalmologic ocular-pressure-de-
vice (Okulopressor®). We calculated spectral-powers of 
mainly sympathetic low (LF: 0.04-0.15Hz) and parasympa-
thetic high (HF: 0.15-0.5Hz) frequency RRI-fluctuations, 
sympathetically mediated LF-powers of BPsys, and RRI-
LF/HF-ratios, and calculated normalized (nu) LF- and HF-
powers of RRI. We compared parameters between groups 
before and during EPS by RANOVA with post-hoc analysis 
(significance: p<0.05).
Results: At rest, severe-TBI-patients had lower LF-BPsys-
powers than the controls. During EPS, only controls sig-
nificantly increased RRIs and HFnu-RRI-powers, and 
decreased LF-RRI-powers, LFnu-RRI-powers, RRI-LF/
HF-ratios, and LF-BPsys-powers. Moderate and severe 
post-TBI-patients significantly increased BPsys without 
changing any other parameter.
Conclusion: Even at rest, autonomic BP-modulation is 
compromised in severe-post-TBI-patients. During EPS, 
moderate- and severe-post-TBI-patients fail to activate 
parasympathetic cardiovascular modulation but show para-
dox sympathetic activation. This central-autonomic- dysre-
gulation might contribute to cardiovascular fatalities.
Disclosure: Acknowledgement: The study was partially 
funded by the International-Brain-Research-Foundation, 
IBRF, Flanders, NJ, USA.
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Drip and ship paradigm in acute ischemic 
stroke: meta-analysis of safety and  
efficacy
A.C.G. Fonseca1, M.A. Santos2
1MOSCAVIDE, Portugal, 2Hospital de Santa Maria, Neurolo-
gy, Lisbon, Portugal
Background: The sooner the treatment with intravenous 
alteplase is started in acute ischemic the higher the proba-
bility of a better outcome. One of the possible strategies 
to decrease time until start of treatment and increase the 
number of patients receiving alteplase is the “Drip and Ship 
paradigm”. In this approach the administration of intrave-
nous alteplase begins in the nearest hospital followed by 
immediate transfer to a stroke unit.
Aim: Meta-analysis of “drip and ship” efficacy and safety 
in acute ischemic stroke
Methods: Systematic review of PUBMED, EMBASE and 
Cochrane CENTRAL. Clinical trials or observational case-
control studies that compared in patients with acute ische-
mic the start of intravenous alteplase in the nearest hospi-
tal followed by transfer to a stroke unit versus the start of 
treatment with intravenous alteplase in a stroke unit were 
included. In order to evaluate efficacy, the functional status 
at hospital discharge and 3 months after stroke was used 
(independence=Rankin<3). To analyze safety, in-hospital 
mortality and symptomatic intracerebral hemorrhage were 
evaluated.
Results: From 94 studies, nine observational case-control 
studies were included with a total of 2200 patients. The-
re was not a statistical significant difference regarding the 
functional status at the time of hospital discharge OR 0.82 
95%CI (0.53-1.28) or at 3 months OR 1.22 95%CI (0.75-
1.97), symptomatic intracerebral hemorrhage OR 0.82 
95%CI (0.53-1.28) or in-hospital death OR 1.02 95%CI 
(0.74-1.41).
Conclusion: Published studies did not show a statistical 
significant difference regarding safety or efficacy of drip 
and ship versus beginning of treatment with intravenous 
alteplase at a stroke unit.
Disclosure: Nothing to disclose
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Hemostasis and hemorheology in acute 
ischemic stroke after i.v. thrombolysis
M. Gafarova1, M. Domashenko1, M. Maximova1,  
A. Shabalina2, M. Kostyreva2, D. Korobkova1, R. Konovalov3
1Research Center of Neurology, ASU, Moscow, Russian Fede-
ration, 2Research Center of Neurology, Hemostasis and He-
morheology, Moscow, Russian Federation, 3Research Center 
of Neurology, Radiology, Moscow, Russian Federation
Background and aims: Devastating effect of ischemic 
stroke (IS) is associated with impaired brain perfusion. 
Intravenous thrombolysis (IVT) may restore blood flow in 
large vessels and is believed to be able to improve microcir-
culation. Hemostatic and hemorheological changes might 
be essential for microcirculation in IS. The aim of the study 
was to evaluate the hemostasis and hemorheology in pati-
ents with IS treated with IVT and their associations with 
brain perfusion.
Methods: 70 patients (48M, 22W, mean age 61[54;69]) ad-
mitted with acute IS at first 4,5 hours after stroke onset were 
treated with IVT. Patients underwent neurological exami-
nation and blood tests before and after IVT and at 1st, 7th, 
21st day after IVT. Determination of hemostatic and hema-
tological parameters, kinetics of erythrocyte aggregation/
disaggregation and erythrocyte deformability, evaluation of 
platelet aggregation (PA) were conducted. CT-angiography, 
CT-perfusion, MRI of the brain were performed before and 
after IVT to identify occlusion/recanalization and to mea-
sure the size of penumbra and infarct core (IC).
Results: Adrenaline-induced PA was significantly higher in 
patients without recanalization after thrombolysis and se-
vere neurological deficit (NIHSS>14) after IVT. Decreased 
prothrombin time was associated with larger IC at first 24 
hours and more severe neurological deficit at 7 and 21 day. 
High leucocyte level and low lymphocyte level were mea-
sured at 1st day in patients with larger IC, higher NIHSS 
score and worse functional outcome. There was no correla-
tion of measured hemorheological and hemostatic parame-
ters with penumbra size.
Conclusion: Hemostatic and hematological disturbances 
are associated with infarct core size and clinical features in 
patients with IS after IVT.
Disclosure: Nothing to disclose
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Poor short-term outcome in patients with 
ischemic stroke and active cancer
T. Gattringer1, M. Kneihsl1, C. Enzinger1, G. Wünsch2,  
M. Khalil1, T. Urbanic-Purkart1, F. Payer1, K. Niederkorn1,  
F. Fazekas1
1Medical University of Graz, Neurology, Graz, Austria, 2Me-
dical University of Graz, Medical Informatics, Statistics and 
Documentation, Graz, Austria
Background and aims: In our aging society, ischemic 
stroke and cancer often co-occur. It is often difficult to de-
cide if this relationship is etiologically linked (such as from 
presumed procoagulatory carcinoma effects) or a chance 
finding and how it affects stroke outcome. In this work we 
examined clinical, neuroimaging and prognostic aspects 
of acute ischemic stroke (AIS) patients with known active 
cancer compared to AIS patients with stable malignoma.    
Methods: All AIS patients that were admitted to the neu-
rological department of our primary and tertiary care uni-
versity hospital between 2008 and 2014 were identified 
(n=4918). Of those, 319 patients had an additional diag-
nosis of cancer. Cancer patients were divided in “active 
cancer” (metastasis, ongoing chemo- or radiation therapy, 
n=73) and “non-active cancer” (remission, n=227) groups. 
The level of significance was set at p<0.05.
Results: Patients with active cancer were significantly 
younger (70.3±10.6 vs. 74.9±9.9 years), had more severe 
stroke syndromes (NIHSS: median 5 versus 3), more fre-
quently cryptogenic strokes (50.7 vs. 32.5%) and more of-
ten infarcts in multiple cerebrovascular territories (26 vs. 
5%) compared to patients with malignancies in remission. 
In-hospital mortality (median stay of 9 days) was signi-
ficantly increased in patients with active cancer (21.9 vs. 
6.1%).
Conclusion: Our findings of a high proportion of crypto-
genic stroke and infarcts in multiple vascular territories in 
AIS patients with concomitant active cancer support the 
role of active malignancies in stroke etiology. Furthermo-
re, this combination appears to entail a bad short-term pro-
gnosis even in the wake of at first relatively mild stroke 
syndromes.    
Disclosure: Nothing to disclose
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Platelet receptor expression in patients 
with atherothrombotic and lacunar stroke
V. Goldobin1, E. Klocheva1, O. Sirotkina2, T. Vavilova3
1NWSMU n.a. I.I.Mechnikov, Neurology, StPetersburg, Rus-
sian Federation, 2StPINP n.a. B.P.Konstantinov, Gatchina, 
Russian Federation, 3NWSMU n.a. I.I.Mechnikov, StPeters-
burg, Russian Federation
Background and aims: Platelet receptors are crucial for 
interaction between platelets and endothelial cells. Main 
platelet receptors are IIb/IIIa (fibrinogen) and 1b (vonWil-
lebrand factor). Their expression is essentially important in 
patients with atherothrombotic stroke (ATS) and lacunar 
infarction (LI).    
Methods: 48 patients with ATS (27 men, 21 women, age–
66.1±10.4 years), 47 patients with LI (23 men, 24 women, 
age–66.7±10.1 years) were examined during acute stage. 
We included patients with benign and uncomplicated course 
of stroke. Neurological examination, neurovisualisation, 
duplex scanning of brachiocephalic arteries, routine labora-
tory tests were performed. Flow cytometry was performed 
on day 9-11 of stroke onset. We used flow-cytometer CY-
TOMICS FC500 (Beckman Coulter, US) for detection of 
IIb/IIIa and α-chain of 1b receptor with fluorescent labeled 
antibodies CD61-FITC and VM16d-FITC.
Results: There was no difference in fibrinogen receptor ex-
pression upon platelets in men vs women with ATI and LI 
(both basal and adenosindiphosphate stimulated).
Density of GP1b upon platelet surface in men with LI was 
significantly higher compared with men with ATI (5.4±3.1 
vs. 4.0±1.3, p<0.05).
In women with ATS there was direct correlation between 1b 
expression and NIHSS score on day 30 (r=0.769, р<0.05). 
There was no such correlation in women with LI or in men 
with both ATI and LI.
Conclusion: Difference in expression of vonWillebrand 
factor receptors on platelets, connected with gender and pa-
thogenetic type of stroke was revealed. Mechanisms under-
lying such findings might be explored for specified antipla-
telet therapy because effectiveness of current antiplatelet 
therapy is not sufficient.    
Disclosure: Nothing to disclose
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Intracranial hemorrhage after non-urgent 
carotid recanalization: a hyperperfusion 
syndrome with devastating consequences
M. Gonzalez Delgado1, R. García2, E. Murias3, P. Vega3,  
E. Morales3, M. Alonso3, L. Camblor3, S. Calleja3
1Oviedo, Spain, 2Centro Médico de Asturias, Oviedo, Spain, 
3Hospital Universitario Central de Asturias, Oviedo, Spain
Background and aims: Hyperperfusion syndrome has 
been described as the triad of headache, neurological de-
ficit and seizures developing after carotid revascularization 
associated with hypertension and in the absence of cerebral 
ischemia. Intracranial hemorrhage is the most serious ma-
nifestation of cerebral hyperperfusion.
Methods: Consecutive patients who needed non-urgent in-
ternal carotid artery (ICA) recanalization, carotid stenting 
(CAS) or carotid endarterectomy (CEA) were studied from 
February 2005 to November 2014.
Results: 957 patients were studied. 6 of them (5 males and 
one female) presented ICH after ICA recanalization (CAS). 
Mean age was 71.6 (54-84) years. 4 patients presented as 
clinically symptomatic carotid pathology and 2 as asymp-
tomatic. Cranial CT at admission showed leukaraiosis in 2 
patients, was normal in 2. A borderline ischemic stroke was 
seen in a further 2 patients. At the time of the procedure, 
4 patients were under ASA. Another 2 were under Clopi-
dogrel and LMWH (nadroparin 0.8/24h). One was under 
nadroparin 0.6/24h and another under nadroparin 0.4/24h. 
Further 2 patients were under ASA and clopidogrel. After 
the procedure, 4 patients presented with neurological wor-
sening, one patient with a slight headache and another with 
transient neurological deficit prior to a decrease in the level 
of consciousness. Cranial CT showed an ipsilateral ICH in 
all cases. Half of the patients died.
Conclusion: ICH after non-urgent carotid recanalization 
had a poor prognosis. Neurological symptomatology rela-
ted with such may be trivial, namely, a slight headache. A 
careful antithrombotic treatment should be recommended, 
and high LMWH doses should be avoided.
Disclosure: Nothing to disclose
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Thoracic aortic calcification is associated 
with incident stroke in the general  
population in addition to established risk 
factors
D.M. Hermann1, N. Lehmann2, J. Gronewold1, M. Bauer3,  
A.A. Mahabadi3, C. Weimar1, K. Berger4, S. Moebus2,  
K.-H. Jöckel2, R. Erbel3, H. Kälsch3
1University Hospital Essen, Neurology, Essen, Germany, 2In-
stitute of Medical Informatics, Biometry and Epidemiology, 
University of Duisburg-Essen, Essen, Germany, 3University 
Hospital Essen, Cardiology, Essen, Germany, 4Institute of 
Epidemiology and Social Medicine, University of Münster, 
Münster, Germany
Background and aims: The aorta is a major source of ce-
rebral thromboembolism, but its role in stroke pathogene-
sis is not well understood. We examined whether thoracic 
aortic calcification (TAC), a marker of aortic plaque load, 
is associated with stroke in addition to established risk fac-
tors.
Methods: A total of 3930 subjects from the population-
based Heinz Nixdorf Recall study (45-75 years; 47.1% 
men) without previous stroke or coronary heart disease 
were evaluated for incident stroke events over 109.0 ± 23.3 
months. Cox proportional hazards regressions were used 
to examine associations with stroke of TAC in addition to 
established risk factors (age, sex, systolic blood pressure, 
LDL, HDL, diabetes, and smoking).
Results: 101 incident strokes occurred during the follow-
up period. Subjects suffering a stroke had significantly 
higher TAC values at baseline than the remaining subjects 
(median =83.1 [Q1;Q3 =4.7;472.9] vs. 15.7 [0.0;117.1]; 
P<0.001). In a multivariable Cox proportional hazards re-
gression, log (TAC + 1) (hazards ratio [HR] =1.09 [95% 
confidence interval =1.00-1.19]; P=0.044) was associated 
with stroke. Further analyses revealed that log (DTAC+1), 
i.e. calcification of the descending aorta (1.11 [1.02-1.20]; 
P=0.016), but not log (ATAC + 1), i.e. calcification of the 
ascending aorta (1.02 [0.93-1.11]; P=0.713), was associa-
ted with stroke.
Conclusion: Calcification of the thoracic aorta, more spe-
cifically its descending segment, is associated with incident 
stroke in addition to established risk factors.
Disclosure: Nothing to disclose
230      Poster presentation with discussion
© 2015 European Journal of Neurology, 22 (Suppl. 1), 120–483
P2117
Paracrine protective effects of HMGB1 in 
ischemic oligodendrocyte death
J.Y. Choi1, H.W. Lee2, B.G. Kim3
1Ajou University School of Medicine, Neurology, Suwon, 
Korea, Republic of, 2Ewha Womans University School of Me-
dicine, Neurology, Seoul, Korea, Republic of, 3Suwon, Korea, 
Republic of
Background and aims: Ischemic white matter injury is 
commonly encountered in clinical practices. Demyelinati-
on with oligodendrocyte (OL) loss is a prominent histopa-
thological feature. Therefore, protection of OLs from ische-
mic insults would be an important therapeutic strategy to 
overcome cognitive impairments caused by ischemic white 
matter injury. Previously, we found that Toll-like receptor 2 
(TLR2) expressed in OL lineage cells provides cell-autono-
mous protective effects. Here, we identified High-mobility 
Group protein B1 (HMGB1) as an endogenous TLR2 li-
gand to promote protective effect in ischemia-induced OL 
death.
Methods: Cultured primary OLs were exposed to oxygen-
glucosed deprivation (OGD). The death of OLs was mea-
sured by LDH assay. The amount of HMGB1 ih the condi-
tioned media (CM) was measured by Western blot and the 
protective activity of CM with or without immunodepletion 
was tested. For in vivo ischemic demyelination model, en-
dothelin was injected into unilateral internal capsule. Neu-
robehavioral recovery was measured by the corner test and 
the pole test.
Results: OLs under OGD released HMGB1 into bathing 
media. CM collected from OLs exposed to OGD exhibi-
ted protective activity against OGD-induced OL death in 
a TLR2-dependent manner. Immunodepletion of HMGB1 
from the conditioned media abolished the protective activi-
ty.Application of glycyrrhizin, a specific HMGB1 inhibitor, 
resulted in the aggravation of OGD-induced OL death. Ani-
mals with glycyrrhizin co-injection showed worsening neu-
robehavioral parameters in endothelin-induced white mat-
ter stroke model. The behavioral deficits were accompanied 
by expansion of demyelinating lesion by glycyrrhizin.
Conclusion: These results suggest that HMGB1 may act 
as an endogenous TLR2 ligand mediating protective effects 
on OLs after ischemic insult.
Disclosure: Nothing to disclose
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Delirium in the stroke unit – preliminary 
study on Polish population
E. Klimiec1, P. Moskal2, K. Kowalska1, P. Potoczek1,  
A. Srednicka3, K. Ochyra3, M. Kornas4, A. Słowik5,  
A. Klimkowicz-Mrowiec5
1Department of Neurology, University Hospital in Krakow, 
Cracow, Poland, 2University Hospital in Krakow, Cracow, 
Poland, 3Jagiellonian University Medical College, Cracow, 
Poland, 4The Institute of Applied Psychology, Jagiellonian 
University, Cracow, Poland, 5Department of  Neurology, Ja-
giellonian University Medical College, ul. Botaniczna 3, 31-503 
Krakow, Poland, Cracow, Poland
Background and aims: Delirium occurs in 10-48% of pa-
tient in the acute phase of stroke. The occurrence highly de-
pends on population and model of care. Knowledge about 
predisposing factors may be helpful in identifying patients 
at the highest risk of delirium. There were no studies on 
delirium in stroke units in countries of Central or Eastern 
Europe. We aimed to assess occurrence and predisposing 
factors for delirium after stroke or TIA in Polish population.
Methods: Consecutive patients admitted to the Stroke Unit, 
Department of Neurology, University Hospital, Krakow, 
with ischemic or haemorrhagic stroke or TIA were included 
in the study. Included patients were assessed on daily basis 
during the first week, DSM-V criteria were used for deliri-
um diagnosis. Information on demographical, medical, and 
stroke-related predisposing factors were collected. 
Results:  267 consecutive patients were included: 219 with 
ischemic stroke, 26 with haemorrhagic stroke and 22 with 
TIA. Delirium was observed in 21% of patients (n=57); 
12% (n=7) had hyperactive, 44% (n=25) hypoactive and 
44% (n=25) mixed subtype of delirium. Age (p=0.0001), 
use of anticholinergic drugs (p=0.036), cognitive impair-
ment (p=0.025), infections (p=0.0001), neglect (p=0.008), 
visual impairment (p=0.0001), higher severity of stroke 
(p=0.003) and stroke in anterior or posterior circulation 
(p=0.025) were identified as a risk factor for post-stroke 
delirium.    
Conclusion: One in five patients developed delirium du-
ring the first week of hospitalization. Almost half of them 
presented with hypoactive type, which is difficult to diag-
nose. Therefore, active screening should be implemented in 
routine practice, especially in predisposed patients.
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A meta-analysis of stentrievers versus 
other treatment modalities in mechanical 
thrombectomy for stroke
A. Kobayashi1, M. Pedracka2, A. Czlonkowska1
1Institute of Psychiatry and Neurology, 2nd Department of 
Neurology, Warsaw, Poland, 2Wyszynski Specialist District 
Hospital, Department of Neurology, Lublin, Poland
Background and aims: Mechanical thrombectomy has 
proved to be effective in management of ischaemic stroke 
with large artery occlusion in a large pragmatic trial – MR 
CLEAN, in which stentrievers were predominantly used. 
Previous neutral trials have allowed the use of different 
approaches including the MERCI and Penumbra devices, 
intraarterial thrombolysis, etc. and only 3.4% of patients 
were treated with a stentriever.
The aim of this study is to systematically review and meta-
analyze the results of controlled studies of stentrievers ver-
sus other endovascular treatment (EVT) modalities.
Methods: A literature search of studies of mechanical 
thrombectomy with stentrievers versus other EVT approa-
ches has been performed and results defined as recanaliza-
tion rates, mortality and death or disability defined as a mo-
fified Rankin score (mRS) 3-6 at 3 months metaanalyzed.
Results: 4 studies which included 561 patients in total (277 
treated with stentrievers and 284 with other EVT) have 
been identified. The recanalization rates using stentrievers 
versus other EVT were 76.2% and 52.1%, respectively 
(p<0.001). Death or disability at 90 days was 35.9% versus 
56.3%, respectively (p<0.001). 3 of the trials have analy-
zed death as an endpoint. The mortality rates were 22.6% 
versus 30.9%, respectively, showing a non-significant trend 
(p=0.07) towards reduced death rates in patients treated 
with a stentriever. 
Conclusion: Stentrievers showed a higher recanalization 
rate correlating with a lower chance of death or disability 
and a trend towards lower mortality. Combined with the 
results of MR CLEAN it is apparent that stentrievers are 
superior to other EVT and should be reference standard.
Disclosure: Adam Kobayashi has received travel grants 
from Balt Extrusion and Covidien/EV3
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POLR3A mutation: a rare cause of  
hypomyelinating leukodystrophy
S. Mrabet1, I. Kraoua1, I. Dorboz2, H. Ben Rhouma1,  
H. Klaa1, N. Ben Achour1, A. Rouissi1, S. Abdelhak3,  
O. Tanguy2, I. Ben Youssef Turki1
1National Institute Mongi Ben Hmida of Neurology, De-
partment of Child and Adolescent Neurology, Tunis, Tunisia, 
2Robert Debré Hospital, Department of pediatric Neurology, 
Paris, France, 3Pasteur Institute of Tunis, Laboratory of Bio-
medical Genomics and Oncogenetics, Tunis, Tunisia
Background and aims: Mutations in gene encoding the 
subunit A of RNA polymerase III (POLR3A) have been 
recently identified as genetic causes of hypomyelinating 
disorders. POLR3A mutations cause three rare and over-
lapping leukodystrophy phenotypes: tremor-ataxia with 
central hypomyelination (TACH), leukodystrophy with 
oligodontia (LO) hypomyelination, hypodontia and hypo-
gonadotropic hypogonadism (4H) syndrome.
Case Report:  We report on a Tunisian girl with TACH 
phenotype due to POL3A mutation.
Results: A 6-year-old girl was born to consanguineous pa-
rents. She had a similar illness as her brother who deceased 
at the age of 5 years. She had a normal psychomotor deve-
lopment. At age of 15 months, she presented unsteady gait. 
At 3 years, she developed tremor and at the age of 6 years, 
she presented school difficulties mainly on speech produc-
tion and writing. Neurological examination (6 years) show-
ed no mental retardation, nystagmus and cerebellar ataxia 
with action and intention tremor. She had no dental abnor-
malities and no signs of hypogonadism. Brain MRI show-
ed diffuse hypomyelination with involvement of U fibers. 
Fundus examination was normal. Sequence analysis iden-
tified a mutation of POLR3A (c.2011T>C, p.Trp671Arg).    
Conclusion: POL3A mutations should be evoked in pa-
tients with hypomyelination and early onset progressive 
cerebellar ataxia even in the absence of oligodentia and 
hypogonadism. Deep white matter hypomyelination is the 
MRI hallmark of this entity. Hypoplastic corpus callosum, 
involvement of pallidi and cerebellar atrophy are suggesti-
ve but lack in our patient. The identified mutation had been 
reported once in siblings of Mediterranean origin, born 
to consanguineous parents suggesting the possibility of a 
founder mutation.
Disclosure: Nothing to disclose
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Sjögren–Larsson syndrome in a Tunisian 
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H. Klaa1, N. Ben Achour1, A. Rouissi1, S. Abdelhak3,  
O. Tanguy2, I. Ben Youssef Turki1
1National Institute Mongi Ben Hmida of Neurology, De-
partment of Child and Adolescent Neurology, Tunis, Tunisia, 
2Robert Debré Hospital, Department of pediatric Neurology, 
Paris, France, 3Pasteur Institute of Tunis, Laboratory of Bio-
medical Genomics and Oncogenetics, Tunis, Tunisia
Background and aims: Sjögren–Larsson syndrome (SLS) 
is a rare autosomal recessive neurocutaneous disorder 
caused by mutations in ALDH3A2, which encodes fatty 
aldehyde dehydrogenase (FADH). This genodermatosis is 
characterized by congenital ichthyosis, mental retardation 
and spastic paraplegia or tetraplegia. We report on clinical 
and neuroimaging characteristics of SLS in 5 Tunisian pa-
tients.
Methods: Retrospective study over 10 years (2004-2014) 
including 5 patients with SLS. Clinical and imaging data 
were analyzed. 
Results:  5 patients (4M/1F) from three families were in-
cluded. Mean age of patients was 6.2 years. All patients 
presented with congenital ichthyosis and developed spastic 
paraplegia and mental retardation. Generalized dystonia 
and postural tremor was described respectively in one pa-
tient. Brain MRI was performed in 4 patients and showed 
T2 hypersintensity in the peri-trigona, brainstem and semi 
oval centers white matter. Proton magnetic resonance spec-
troscopy was made in 2 patients and showed abnormal peak 
compatible with lipid content. Ophthalmologic examinati-
on showed maculopathy with microcrystals, keratocon-
junctivitis and erythematous blepharitis in 2 patients.  Di-
agnosis of SLS was confirmed by enzymatic assay in one 
patient and by genetic analysis in 4.
Conclusion: We report on 5 patients with typical clinical 
presentation. The association of movement disorders in 2 
patients is uncommon. Indeed, dystonia was reported once 
and tremor has not been reported before. Spectroscopy 
reveals specific peak of lipids that make this noninvasive 
technique useful for the diagnosis of SLS. Classical clinical 
and imaging presentation of SLS is sufficient to directly 
analyze the ALDH3A2 gene to confirm diagnosis and to 
allow genetic counseling.
Disclosure: Nothing to disclose
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Atypical presentation of Bourneville Di-
sease
A. Roceanu1, O. A. Bajenaru2
1Bucharest, Romania, 2University Emergency Hospital 
Bucharest, Neurology, Bucharest, Romania
Background and aims: Tuberous sclerosis (Bournevil-
le Disease) is a congenital disease due to hyperplasia of 
ectodermal and mesodermal cells from the skin, nervous 
system, heart, kidney and other organs. The disease is in-
herited in autosomal dominant mode. Two tumor supressor 
genes were identified: TSC1 (9q34) who produce hamartin 
and TSC2 (16013.3) that produces tuberin. Clinically it is 
characterized by the triad adenoma sebaceum, epilepsy and 
mental retardation
Case Report: We present the case of a 27-year-old patient 
who developed renal failure in the l;ast 6 monts, with dia-
lysis treatment. He was referred to our clinic because he 
experienced  an epileptic seizure (a simple partial seizure).
The neurological interictal examination was normal. No 
mental retardation was disclosed. EEG showed bilaterally 
epileptiform discharges. A native cerebral CT demonstrated 
periventricular calcific lesions and cerebral IRM revealed 2 
subependymal giant cell astrocytoma (SGCA) localized in 
the cerebral ventricules, near Monro foramen, supporting 
the diagnosis of tuberous sclerosis. The general examination 
disclosed facial adenoma sebaceum. ECG and echocardio-
graphy were normal. Toraco-abdominal CT scan - ruled out 
tumor of  the kidney or other organs. Patient started evero-
limus (votubia) and anticonvulsant treatment.
Results: Clinical presentation and neuroimaging features 
were diagnosed Bourneville Disease. The particularity of 
the case is the lack of mental retardation and the limited 
seizure activity. No renal angiomyolipomas were found, the 
renal failures was due to glomerulonephritis.
Conclusion: TSC is a rare disease with a variable clinical 
presentation.
Disclosure: Nothing to disclose
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Early epileptic encephalopathy and  
aetiological investigation – How far to go?
J. Tomás1, C. Robalo1, P. Garcia2, I. Fineza1, M. Barbosa3,  
P. Maciel3
1CHUC, Pediatric Unit, Neurology, Coimbra, Portugal, 
2CHUC, Pediatric Unit, Metabolic diseases, Coimbra, Portu-
gal, 3School of Health Sciences, University of Minho, Life and 
Health Sciences Research Institute, Braga, Portugal
Background and aims: Early epileptic encephalopathies 
(EE) are severe neurologic conditions characterized by 
drug-resistant epileptic seizures and development delay/
regression. Multiple aetiologies are involved, including 
a recently described mutation on SLC35A2 gene, which 
codes a UDP-galactose transporter, inducing to a congeni-
tal disorder of glycosylation (CDG) type II. This mutation 
causes systemic symptoms, including commonly EE by 
CNS involvement.
Case Report: Male patient, 8-year-old actually. Followed 
in outpatient consultation since 10-months-old for poly-
morphic seizures, severe delayed psychomotor develop-
ment and acquired microcephaly. He had dysmorphic face, 
poor visual contact, hypotonia and stereotypies of the ext-
remities .
Results: Metabolic investigation and genetic studies for 
karyotype, Angelman and Rett syndromes (MECP2) mole-
cular studies were normal.  DNA leukocyte exome sequen-
cing revealed hemizygous pathogenic variant for SLC35A2 
gene, also present on skin fibroblasts. His mother was hete-
rozygote for this variation. Test for CDG (carbohydrate-de-
ficient transferrin levels) was normal. The patient was trea-
ted with sodium valproate, levetiracetam, benzodiazepines 
and rufinamide, without benefit. He is actually proposed for 
treatment with ketogenic diet.
Conclusion: We reported a case of EE that began in the 
first year of life, with a hemizygous pathogenic variant of 
SLC35A2 gene, inherited from the mother. EE associated 
with SLC35A2 variations were recently described and are 
still rare.
Disclosure: Nothing to disclose
P2125
Developmental chick neuronal activity 
measurement using silk fexible electrode
K. Torimitsu, T. Sonobe, Y. Takizawa, H. Takahashi,  
S. Watanabe
Tohoku Univ, Sendai, Japan
Background and aims: Continuous measurement of neu-
ral activity is important for understanding developmental 
changes of neurons. Flexible electrode is one of the ide-
al solution for long-term measurement of neural activity. 
We previously reported the electrical activity measurement 
using conductive polymers, such as PEDOT-PSS (poly(3,4-
ethylenedioxythiophene)-poly(styrenesulfonate)) with 
multielectrode array. It improves sensitivity and stability of 
the electrode. Here we use this conductive polymers to silk 
fibers to form flexible silk electrodes.
Methods: Pristine silk fibers were modified with conduc-
tive polymers for chick neural activity measurement. They 
were inserted in the brain and the tissue of mouse and chick 
after anesthetized. Developmental changes of their neural 
activities and their muscle activities were investigated. 
Results: Spontaneous beta waves were recorded depending 
on the development. Number of events and frequencies 
were changed on delevelopment. Evoked responses were 
also measured. As the conductive silk electrode is flexible 
and bio-compatible, long-term measurement could be pos-
sible. 
Conclusion: The conductive silk electrode allows us sus-
tainable activity monitoring. Long-term implantation of the 
electrode to the tissue indicates stable measurement capa-
bility. It would be a useful tool for in vivo analysis, such as 
develoment and free-moving behavior.
Disclosure: This work was performed in part under the 
knowledge based Medical Device Cluster, Miyagi, Japan, 
Regional innovation Strategy Support Program, MEXT 
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Work engagement during Neurology resi-
dency: results from the Attica Study
P. Zis1, A. Artemiadis2, M. Lykouri1, S. Xirou3,  
A. Roussopoulou1, E. Papageorgiou4, E. Bakola5,  
P. Iliopoulos6, I. Stavropoulos7, S. Katsavos8,  
F. Anagnostopoulos9
1Evangelismos General Hospital, Neurology, Athens, Greece, 
2417 General Military Hospital Nimts, Neurology, Athens, 
Greece, 3Eginition University Hospital, Neurology, Athens, 
Greece, 4Nikaia, Greece, 5Thriasio Hospital, Neurology, Elef-
sina, Greece, 6Pammakaristos Hospital, Neurology, Athens, 
Greece, 7Athens General Hospital “G. Gennimatas”, Neuro-
logy, Athens, Greece, 8Athens, Greece, 9Panteion University, 
Psychology, Athens, Greece
Background and aims: Work engagement is defined as a 
positive, fulfilling, work-related state of mind that is cha-
racterized by vigor, dedication and absorption.
The purpose of our cross-sectional study was to investigate 
work engagement among neurology residents in the regi-
on of Attica,Greece, and identify factors associated with 
it,based on the job demands-resources model(JD-R).
Methods: In total, 131 placements for neurology training 
over 18 hospitals are available. All residents were approa-
ched and were asked to participate in the study by ano-
nymously completing a questionnaire. Job demands were 
examined via a 17-item questionnaire assessing 4 charac-
teristics (emotional demands, intellectual demands, wor-
kload, home-work demands’ interface) and job resources 
were measured via a 14-item questionnaire assessing 4 cha-
racteristics (autonomy, opportunities for professional deve-
lopment, support from colleagues, supervisor’s support). 
Work engagement was measured by the Utrecht Work En-
gagement Scale.
Results: 116 residents participated in the study (response 
rate 88.5%). Univariate analysis showed that work engage-
ment was higher in females (47.4 versus 41.1, p=0.028). 
Moreover, work engagement correlated significantly with 
number of days off (Spearman’s rho=0.207, p=0.027) 
home-work demands’ interface (spearman’s rho=-0.198, 
p=0.034), autonomy (rho=0.423, p<0.001), supervisor’s 
support (rho=0.319, p=0.001) and opportunities for profes-
sional development (rho=0.610, p<0.001).
Conclusion: Work engagement during neurology residen-
cy is higher when opportunities for professional develop-
ment are more,supervisor’s support is present,autonomy is 
higher,days off are given and home-work demand’s inter-
face is less.Educators and program directors need to design 
interventions to promote residents’ resilience and mental 
health.
Disclosure: Nothing to disclose
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Neuroticism and job-related factors 
among neurology residents: results from 
the Attica Study
P. Zis1, A. Artemiadis2, M. Lykouri1, S. Xirou3,  
A. Roussopoulou1, E. Papageorgiou4, E. Bakola5,  
P. Iliopoulos6, I. Stavropoulos7, S. Katsavos8,  
F. Anagnostopoulos9
1Evangelismos General Hospital, Neurology, Athens, Greece, 
2417 General Military Hospital Nimts, Neurology, Athens, 
Greece, 3Eginition University Hospital, Neurology, Athens, 
Greece, 4Nikaia, Greece, 5Thriasio Hospital, Neurology, Elef-
sina, Greece, 6Pammakaristos Hospital, Neurology, Athens, 
Greece, 7Athens General Hospital “G. Gennimatas”, Neuro-
logy, Athens, Greece, 8Athens, Greece, 9Panteion University, 
Psychology, Athens, Greece
Background and aims: Neuroticism is a fundamental 
personality trait characterized by emotional instability and 
negative affect. Individuals who score high on neuroticism 
are more likely than the average to exhibit anxiety, hostility, 
depression, self-consciousness, impulsiveness, and vulne-
rability to stress. The purpose of our cross-sectional study 
was to investigate neuroticism among neurology residents 
in the region of Attica, Greece, and identify factors asso-
ciated with it, based on the job demands-resources model 
(JD-R).
Methods: In total, 131 placements for neurology training 
over 18 hospitals are available. All residents were approa-
ched and were asked to participate in the study by ano-
nymously completing a questionnaire. Job demands were 
examined via a 17-item questionnaire assessing 4 charac-
teristics (emotional demands, intellectual demands, wor-
kload, home-work demands’ interface) and job resources 
were measured via a 14-item questionnaire assessing 4 cha-
racteristics (autonomy, opportunities for professional deve-
lopment, support from colleagues, supervisor’s support). 
Neuroticism was examined via a 12-item scale, based on 
the NEO-Five Factor Inventory.
Results: 116 residents participated in the study (response 
rate 88.5%). Univariate analysis showed that neuroticism 
correlated significantly with home-work demands’ inter-
face (Spearman’s rho=0.384, p<0.001), emotional demands 
(rho=0.288, p=0.002), supervisor’s support (rho=-0.272, 
p=0.004) and opportunities for professional development 
(rho=-0.256, p=0.006).
Conclusion: Neuroticism among neurology residents is 
associated with high emotional demands, high home-work 
demands’ interface, poor supervisor’s support and decrea-
sed opportunities for professional development. Educators 
and program directors need to design interventions to pro-
mote residents’ resilience and mental health.
Disclosure: Nothing to disclose
236      Poster presentation with discussion
© 2015 European Journal of Neurology, 22 (Suppl. 1), 120–483
P2128
Establish a specialist in neurology  
program in Brunei Darussalam with the 
help of telemedicine
U. Meyding-Lamadé1, E.M. Craemer1, B. Bassa1, C. Chan2, 
A. Masri2, N. Yassin2, Z. Hanafi3, A. Aziz3, W. Hacke4
1Krankenhaus Nordwest, Klinik für Neurologie, Frankfurt am 
Main, Germany, 2Brunei Neuroscience Stroke and Rehabilita-
tion Centre, Jerudong, Brunei Darussalam, 3Universiti Brunei 
Darussalam, Jerudong, Brunei Darussalam, 4Universitätskli-
nikum Heidelberg, Heidelberg, Germany
Background and aims: Neurology will be one of the ma-
jor columns of medicine. A worldwide lack of neurologi-
cal knowledge there is an obvious need for specialists in 
neurology. Since 7/2010 a transcontinental cooperation bet-
ween the Brunei Neuroscience Stroke and Rehabilitation 
Centre(BNSRC), Brunei Darussalam(BD), the Department 
of Neurology, Krankenhaus Nordwest (KHNW), Frankfurt, 
Germany has been successfully implemented. BNSRC is 
the 1st neurological facility in BD, therefore local doctors 
has to be trained in neurology to ensure that they can handle 
the patients as well as to get a curriculum of neurology in 
order to become specialist in neurology. This program is es-
tablished and conducted by Universiti Brunei Darussalam, 
University of Heidelberg, Germany, Johns Hopkins, USA, 
KHNW and BNSRC.
Methods: Total duration shall normally be at least 60 
months full-time. We established a teleteaching program 
including on site teaching. Consisting of different modules; 
electrophysiology, EEG, clinical examination including 
scales for different diseases and the grand round. The grand 
round is basically a teaching ward round to discuss selected 
patients. Local doctors report the history, demonstrate phy-
sical symptoms,diagnostic work up and therapeutic strate-
gies are discussed as well as all medical findings.    
Results: 2 local doctors are enrolled, overall 7 doctors have 
taken part and passed all assessments.
Conclusion: Neurological diseases are a major column at 
present time and the prevention of neurological diseases are 
more important than ever. As there is a need of specialists in 
neurology worldwide, this specialist in neurology program 
can set a milestone in teaching of neurologic skills with the 
help of telemedicine to overcome distances.
Disclosure: Nothing to disclose
P2129
Setting up the Brunei Neuroscience  
Stroke and Rehabilitation Centre 
12,000km away with the help of  
Telemedicine – To teach to treat – to treat  
to teach
U. Meyding-Lamadé1, E.M. Craemer2, C. Chan3, N. Yassin3, 
C. Jacobi2, B. Bassa2, A. Masri3, I. Jafaar4, Z. Hanafi3,  
A. Aziz5, B. Kress6
1Krankenhaus Nordwest, Klinik für Neurologie, Frankfurt 
am Main, Germany, 2Krankenhaus Nordwest, Department of 
Neurology, Frankfurt am Main, Germany, 3Brunei Neuros-
cience Stroke and Rehabilitation Centre, Jerudong, Brunei 
Darussalam, 4Jerudong Park Medical Centre, Jerudong, Bru-
nei Darussalam, 5Universiti Brunei Darussalam, Jerudong, 
Brunei Darussalam, 6Krankenhaus Nordwest, Department of 
Neuroradiology, Frankfurt am Main, Germany
Background and aims: Due to the worldwide aging popu-
lation there is a need for specialist neurological knowledge. 
Our project in Brunei Darussalam (BD) offers to overcome 
distances and also a long-time benefit for patients. It com-
prises the set up of a local stroke unit, neurological inten-
sive care unit, normal wards and neurorehabilitation. This 
has been achieved by continuous medical education and 
telemedical consultation 
Methods: Set up of the Brunei Neuroscience Stroke and 
Rehabilitation Centre (BNSRC) started 7/2010. In order 
to overcome the distance,a telemedical network between 
the Department of Neurology of Krankenhaus Nordwest, 
Frankfurt, Germany (KHNW) and the BNSRC was esta-
blished. This cooperation includes the development of a 
“specialist in neurology” training program, accredited in 
BD and an international advisory board. Daily teleteaching 
as well as 24/7 tele-neurology services are offered. All neu-
rological laboratories have been set up on site, tele-cytolo-
gy, tele-electrophysiology, EEG and ultrasound.
Results: Patients with stroke, intracerebral hemorrhages, 
aneurysms, encephalitis and other neurological diseases as 
in-and out and rehab patients have been seen. We evaluated 
85% ischemic strokes and 15% hemorrhagic. Since 2010 
27 thrombolysis, 24 hemicraniectomies, hypothermia, in-
vasive intracranial pressure measurement have been also 
performed. We have achieved world class neurological in-
tensive care standards in a short period. Training programs 
and the back up with telemedicine are ideal for teaching 
and treating in neurology.    
Conclusion: Stroke is a major disease at the present time 
and prevention is more important than ever. Setting up 
BNSRC is not only a useful tool, for more it proved to be 
feasible and successful to cooperate irrespective of dis-
tance, religion and culture.    
Disclosure: Nothing to disclose
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Professionalism in the use of social  
networking sites: a survey among  
European residents and junior  
neurologists (RJN)
V. Papp1, A. Macerollo2, O. Györfi3, P. Balicza4, M. Moarcas5, 
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1Holstebro Hospital, Holstebro, Denmark, 2Aldo Moro Uni-
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logy, Budapest, Hungary, 4Institute of Genomic Medicine and 
Rare Disorders, Semmelweis University, Neurology, Buda-
pest, Hungary, 5Emergency Clinical County Hospital Brasov, 
Neurology, Brasov, Romania, 6King’s college London and 
King’s college hospital, Neurology, London, United Kingdom, 
7Evangelismos Hospital, Neurology, Athens, Greece, 8Tech-
nical University Dresden, Neurology, Dresden, Germany, 
9Medical Faculty, Johannes Kepler University Linz, Neurolo-
gy and Psychiatry, Linz, Austria, 10Christian-Doppler-Klinik, 
Paracelsus Medical University, Neurology, Salzburg, Austria
Background and aims: Social networking sites (SNS) 
have increased exponentially in popularity and use. While 
SNS can yield opportunities for communication, education 
and patient care, it may be a platform for unprofessional 
behaviour. This study was to assess definition and personal 
experience with professionalism for the use of SNS among 
European residents and junior neurologists (RJN).
Methods: A paper questionnaire was distributed to RJN 
during the ENS-EFNS congress (Istanbul, June 2014) at 
the booth of the EAYNT.
Results: 92 RJN (66.3 % female) from 20 different coun-
tries returned the survey. The majority (85.9%) uses Face-
book (FB), 52.2% have Twitter accounts. FB mostly has a 
status as platform to keep in touch with friends (72.2%). 
35.4% strongly disagree with accepting friend requests 
from patients, and to post patient information (69.6%) and 
work-related issues (40.5%). Some RJN assume that their 
posts can influence patients (36.7 %) and future employ-
ment (26.5 %). A minority (11.6%) states that it is com-
pletely appropriate to access SNS at work. Figure 1 sum-
marises domains of inappropriate postings during the last 
12 months. This concerned the workplace (46.7%), self 
(38.2%), hospital staff (33.4%) and patients (27.8%). 
Inappropriate social network posting during the last 12 months
Conclusion: The usage of SNS is common among RJS and 
inappropriate behaviour is frequently encountered. We de-
monstrate a considerable diversity of perception for profes-
sionalism and inadequate translation into daily practice. 
RJN need to be aware of institutional policies defining ap-
propriate online behaviour and post-graduate curricula may 
take education for principles of online professionalism into 
account.
Disclosure: Nothing to disclose
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Estimation of the direct cost of epilepsy 
among Sudanese patients attending  
charity clinic in Omdurman 2014
M.A. Abdelrahim1, M.M. Alfaki1, R.A. Alsherif1,  
M.D. Dafaalla1, M.I. Alfaki1, M.A. Taha1, A.S. Ahmed1,  
M.S. Abd Elmotalib1, M.A. Alnor1, D.N. Osman1,  
A.M. Hussein2
1Daoud Research Group, Khartoum, Sudan, 2Faculty of me-
dicine, University of Khartoum, Department of Neurology, 
Khartoum, Sudan
Background and aims: The economic burden of epilepsy 
in the developing countries didn’t receive enough attention. 
We have estimated the direct and some of the indirect costs 
of epilepsy among patients attending charity clinic in Su-
dan.
Methods: The study was performed on a case series of me-
dically treated Sudanese patients with epilepsy in a charity 
clinic. Data on clinical characteristics, utilization of medi-
cal services, and costs were collected from 38 patients in a 
standardized pre-tested format.
Results: Direct medical care costs was Sudanese Pounds 
(SDG) 2,395 (USD 417) per year per patient, of which an-
tiepileptic drugs SDG 1,587 (USD 276) accounted for the 
major cost component. Direct cost also included medical 
consultations and hospitalization charges SDG 148 (USD 
26), investigation costs SDG 146 (USD 25), and cost of 
travel to clinics SDG 514 (USD 90). Nonmedical direct 
costs - in form of traditional healers’ visits - were reported 
by 13.5% of the patients and estimated to be SDG 1,422 
(USD 251). The indirect cost was estimated for co-pati-
ents transportation (reported by 7.9% of the patients who 
are resident outside the state) estimated to be SDG 1,773 
(USD 308) per co-patient per year. Taken together, the ove-
rall mean annual cost for epilepsy per patient in our clinic 
was approximately SDG 2,724 (USD 474).
Conclusion: The results indicate that the economic burden 
of epilepsy patients is heavy, and the composition propor-
tions of the costs in Sudan have many similar features and 
some noteworthy differences with that of other countries.
Disclosure: Nothing to disclose
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with the quality of life and the costs of epi-
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patients attending charity clinic in  
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1Daoud Research Group, Khartoum, Sudan, 2Faculty of me-
dicine, University of Khartoum, Department of Neurology, 
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Background and aims: To assess the association of me-
dications adherence with the quality of life and the costs 
of epilepsy in a sample of Sudanese patients with epilepsy.
Methods: The study was performed on Daoud charity neu-
rological clinic epilepsy patients from June to September 
2014. Data on clinical characteristics, utilization of medical 
services, and costs were collected. Medication adherence 
was assessed using Morisky Medication Adherence Scale 
(MMAS-8). Quality of life was assessed using WHO Qua-
lity of Life Brief-26.
Results: There were 38 patients (71% males; mean age 
32.9 years). According to MMAS-8, (23.7%) of patients 
had a high adherence, (39.5%) had a medium adherence 
and (36.8%) had a low adherence rate. The mean total 
score of WHOQOL Brief was (91.8 out of 130). The over-
all mean annual costs were 2,778 Sudanese Pounds (USD, 
484). Adherence score was positively and significantly cor-
related with WHOQOL Brief total score (P=0.008), Phy-
sical Health domain score (P=0.007), Social relationships 
domain score (P=0.006), and environment domain score 
(P=0.007). Similar significant correlation was found bet-
ween the overall mean annual costs and the environment 
domain score (P=0.041). However, adherence was not as-
sociated with psychological domain score (P=0.054), the 
annual total costs of epilepsy (P=0.568) or the annual me-
dications costs of epilepsy (P=0.87).
Conclusion: We conclude that participants with low qua-
lity of life are more likely to have lower adherence to anti-
epileptic medications. In spite of the high annual costs of 
epilepsy, it does not affect patients’ adherence to medica-
tions. The psychological aspect of the quality of life of epi-
lepsy patients does not affect their medications adherence.
Disclosure: Nothing to disclose
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Status epilepticus in the elderly
K. Agan Yildrim1, I. Midi2, C. Aykut-Bingol3
1Istanbul, Turkey, 2Marmara University, Neurology,  
Istanbul, Turkey, 3Yeditepe University Hospital, Neurology, 
Istanbul, Turkey
Background and aims: The aim of this study was to eva-
luate the risk and prognostic factors and outcome of status 
epilepticus (SE) among elderly patients. We investigated 
clinical and demographic characteristics of patients over 60 
years of age who presented with SE.
Methods: Between 1998 and 2009, 165 (44 male, 121 fe-
male) consecutive patients over 60 years of age were inclu-
ded. We assessed etiology and type of treatment as a prog-
nostic factor to determine outcome.
Results: Median age was 73.8 (range 61-93). Nonconvulsi-
ve Status Epilepticus (NCSE) including Convulsive Status 
Epilepticus (CSE) turned to NCSE was the most frequent 
type (72.7%). An acute cerebrovascular disease (22.2%) 
was the most common etiology followed by acute metabo-
lic disturbances (17.6%) and remote symptomatic (cerebro-
vascular disease 15.8%, brain tumors 9.1%). Only 20.9% of 
the patients had a history of epilepsy before SE. 41.1% of 
the patients evolve in to refractory SE (RSE).
Conclusion: Status Epilepticus without a history of epi-
lepsy is common among elderly. Cerebrovascular disease 
either acute or remote symptomatic are amongst the most 
common causes. NCSE is the most common type of SE in 
elderly.
Disclosure: Nothing to disclose
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Effects of lamotrigine on bone mineral 
density
D. Aksoy1, D. Ataklı2
1Nicosia state hospital, neurology, Nicosia, Cyprus, 2Bakirköy 
psNeurological and Psychiatric Disease Teaching and Re-
search Hospital , neurology, Istanbul, Turkey
Background and aims: The objective of this study was to 
examine the effects of lamotrigine (LTG) monotherapy on 
bone mineral density in epilepsy patients taking LTG. 
Methods: In this cross-sectional study we analized data 
from 20 healthy women and 18 female idiopathic genera-
lised epilepsy patients who have been monitored in Bakir-
koy Neurological and Psychiatric Disease Teaching and 
Research Hospital Epilepsy Policlinic. Clinical and demo-
graphical properties of the patients were reviewed. Serum 
calcium, ionized calcium and vitamin D levels of the two 
groups were evaluated.
Results: The mean age of the epilepsy patients and the con-
trol group were 27.00±10.27 and 28.95±4.21 respectively. 
The mean disease period was 7.8±9.5 years (1-42). LTG 
treatment period was evaluated as 6.61±2.9 years (2-11). 
The mean dosage of LTG was 123.6±55.8mg/day (50-225). 
No significant differences were observed in calcium and io-
nized calcium levels between patient and the control group 
(p>0.05). On the other hand, vitamin D levels were lower 
in the patient group which was statistically significant 
(p=0.03). The duration of LTG use or daily LTG dosage 
had no correlation with the calcium, ionized calcium and 
vitamin D levels (p>0.05). 
Conclusion: Serum calcium and ionized calicium levels 
were found normal in patients receiving LTG monotherapy. 
However, Vitamin D concentrations were lower in patients 
than in control subjects. We suggest that calcium and vita-
min D levels in patients receiving LTG should be monitored 
closely. In addition, regular diet, physical exercise and ex-
posing their bare skin to sunlight should be recommended.
Disclosure: Nothing to disclose
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Mutation in the KCNQ2 gene – a rare 
cause for Rolandic epilepsy
I. Aleksandrova1, V. Bojinova-Tchamova1, N. Ivanova2,  
E. Slavkova1, P. Dimova3, V. Pejcheva2, K. Kamenarova2,  
R. Kuneva2, A. Jordanova2
1Clinic of Child Neurology, University Hospital for Active 
Treatment of Neurology and Psychiatry “St. Naum’’, Sofia, 
Bulgaria, 2Molecular Medicine Center, Medical University of 
Sofia, Sofia, Bulgaria, 3Epilepsy Surgery Center, Department 
of Neurosurgery, Multiprofile Hospital for Active Treatment 
”St. Ivan Rilski”, Sofia, Bulgaria
Background and aims: Benign epilepsy with centrotem-
poral spikes (BECTS) is the most common epilepsy syn-
drome in childhood. Diagnosis is based on typical clinical 
features and EEG. The prognosis is favorable with a com-
plete remission until puberty. The genetic factor in BECTS 
etiology is very interesting and a number of responsible 
genes have been defined. KCNQ2 mutations were initially 
described in benign familial neonatal seizures (BFNS), 
which, like in rolandic epilepsy, are age-related and with a 
favorable outcome. However, severe KCNQ2-related epi-
leptic encephalopathy has recently been reported. Familial 
cases of KCNQ2-related BFNS have also been described 
with a subsequent manifestation of rolandic epilepsy. In 
these cases, the role of the mutation for the earlier onset of 
BECTS is discussed.
Methods: We present the case of a boy who experienced 
generalized tonic-clonic seizures (GTCS) when 4 months 
old and seizures after falling asleep at the age of 3 years, 
which, based on the clinical and EEG features, were dis-
cussed as Rolandic seizures. The family history of the pati-
ent revealed that his brother had seizures that started when 
he was 5 days old and his father experienced seizures du-
ring infancy. These attacks, including the earlier GTCS of 
the patient, were discussed as BFNS and benign familial 
infantile seizures (BFIS) with post-BFIS development of 
BECTS in the proband.
Results: The genetic analysis showed mutation c.1174G>A 
(p.R333Q) of the KCNQ2 gene.
Conclusion: In such cases, the genetic analysis will allow 
genetic counseling for subsequent pregnancies and will fa-
cilitate the diagnosis and therapy of seizures occurring in 
other family members.
Disclosure: Nothing to disclose
P2137
Ictal asystole requiring pacemaker implan-
tation: combined EEG / ECG study of 5 
cases
R. Bartlam1, R. Mohanraj2
1University of Manchester, Manchester Medical School, Man-
chester, United Kingdom, 2Salford, United Kingdom
Background and aims: Seizures can lead to cardiac ar-
rhythmias by a number of mechanisms including activati-
on/inhibition of cortical autonomic centres, increase in va-
gal tone through activation of brainstem reflex centres and 
as a consequence of respiratory failure. Ictal asystole (IA) 
is a potential mechanism underlying Sudden Unexpected 
Death in Epilepsy (SUDEP). We analysed the clinical fea-
tures of 5 patients who developed IA requiring pacemaker 
implantation    
Methods: Patients with ictal arrhythmias identified from 
the video-telemetry and ambulatory EEG database at Gre-
ater Manchester Neurosciences Centre, as well as an inde-
pendent epilepsy residential care facility. Only those who 
had IA requiring pacemaker implantation were included in 
the analysis. A total of 5 patients were identified    
Results: Of the 5 patients with IA, 4 were female. All 5 
patients had focal epilepsy, and four had temporal lobe 
epilepsy. IA occurred with complex partial seizures, 2-45 
seconds (mean 25 seconds) after EEG seizure onset in all 
cases. Seizure onset was left sided in 2 patients, right sided 
in one, left sided onset with switch of lateralisation in one, 
and non-lateralised in 1 patient. 2 patients had traumatic 
encephalomalacia of the temporal lobe, and 1 patient had 
hippocampal sclerosis and 2 patients had no lesions de-
tected on MRI. Inter-ictal epileptiform activity was more 
pronounced during sleep in four patients. Asystole occurred 
following sleep related seizures in 3 of 5 patients.
Conclusion: IA was most frequently observed in patients 
with temporal lobe epilepsy, and in sleep related seizures. 
These findings maybe of relevance to SUDEP.
Disclosure: Nothing to disclose
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Hippocampal subfield volumes in physio-
logical déjà vu versus mesial temporal 
lobe epilepsy and schizophrenia
M. Brázdil
Brno, Czech Republic
Background and aims: A significantly less gray matter 
was recently revealed within a set of cortical (predomi-
nantly both-sided hippocampi) and subcortical regions in 
healthy subjects experiencing déjà vu (DV) when compared 
to déjà vu non-declarers. Despite observed GM volume dif-
ferences mirrored the distribution of GM volume reduction 
in subjects suffering from mesial temporal lobe epilepsy 
(MTLE), the pattern of GM differences within hippocam-
pi were distinctive between MTLE and DV. Schizophrenia 
(SCH) represents another condition in which hippocampal 
GM volume was found to be significantly decreased .
Methods: In this study we compared differences in GM 
volume within distinctive hippocampal subfields among 
healthy DV non-declarers (N=26) and healthy DV declarers 
(N=85), MTLE (N=47) and schizophrenia (N=46) patients 
alternatively. The images were automatically segmented 
and registered using SPM8 and its toolbox DARTEL. Local 
GM volume was corrected with respect to age, gender and 
total intracranial volume. The decrease of local GM volume 
across voxels (relatively to the nonDV group) was corre-
lated between DV and MTLE and between DV and SCH.
Results: The results revealed significant correlations bet-
ween GM volume reduction in DV and SCH as well as 
DV versus MTLE in the majority of analyzed hippocampal 
subfields. Importantly GM volume correlations were signi-
ficantly higher for SCH (than MTLE) within left CA4+DG, 
left and right CA2+3, and left presubiculum. The only 
significantly higher correlation for MTLE was observed 
within right subiculum.
Conclusion: Our findings reveal common structural fea-
tures of hippocampal involvement in physiological déjà 
and both investigated SCH and MTLE.
Disclosure: Nothing to disclose
P2139
An update on data from German Registry  
of Antiepileptic Drugs and Pregnancy 
(GRAP): risks of growth delay
H. Cakiroglu, M. Bengner, S. Nazari Dehkordi, B. Schmitz
Berlin, Germany
Background and aims: GRAP is an observational study 
to investigate pregnancies with antiepileptic drug (AED) 
exposition. Women who take AEDs at the time of concepti-
on are included and observed until 1 year post partum. We 
aimed to establish the influence of the prenatal exposure to 
AED and folate prophylaxis on fetal growth.
Methods: Until January 2015, 1078 pregnancies had been 
registered in GRAP. 940 of the women have given birth 
so far. The frequency of delayed growth referred to birth 
weight, body length and head circumference were ana-
lysed. Measurements under the 10th percentile were clas-
sified as growth delay.
Results: 80.9% of the women were treated in AED mo-
notherapy and 16.2% in polytherapy. 9.5% of the infants 
had based on their gestational age a low birth weight <10th 
percentile. Growth delay was more frequently observed in 
association with AED poly- compared to monotherapy. The 
three AEDs most frequently prescribed were lamotrigine 
(=362), valproate (n=141), and carbamazepine (n=133). In 
the three groups of AED monotherapy the rate for reduced 
birth weight (24.6%) and body length (16.5%) was highest 
for carbamazepine. 90.1% of the GRAP-women took folic 
acid. Among mothers without folate prophylaxis (n=40) 
there was a larger proportion of infants with reduced birth 
weight and body length.
Conclusion: Prenatal polytherapy with AEDs and nonexis-
ting folic acid supplementation seem to be potential risk 
factors for delayed fetal growth. Considering the low samp-
le sizes and missing confounding factors the statistical sig-
nificance will probably be clarified in future investigations.
Disclosure: Nothing to disclose
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Genome-wide changes in TDP43-depen-
dent splicing caused by endogenous mu-
tations are insufficient to cause neuronal 
degeneration in the laboratory mouse
H. Oliveira1, T. Ricketts2, P. Fratta3, E. Fisher3, V. Plagnol3,  
A. Acevedo-Arozena4
1MRC Harwell/University of Oxford, Oxford, United King-
dom, 2MRC Harwell, Neurodegeneration Group, Oxfordshire, 
United Kingdom, 3University College London, London, Uni-
ted Kingdom, 4MRC Harwell, Oxfordshire, United Kingdom
Background and aims: TDP43 is a highly conserved, ubi-
quitously expressed protein with multiple roles in RNA me-
tabolism, including alternative exon splicing, which plays a 
pivotal role in neurodegeneration. Abnormally aggregated 
cytoplasmic TDP43, which is cleaved, hyperphosphoryla-
ted and polyubiquitinated is a histopathological hallmark of 
Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal 
Dementia (FTD) and mutations in TARDBP (the gene en-
coding TDP43) are causative of ALS and FTD. Transgenic 
animal models engineered to over-express, knockdown or 
conditionally delete TDP43 have all been shown to develop 
neurodegeneration. Furthermore, dysregulation in TDP43-
dependent alternative exon splicing has been reported in 
many of these models, and thus hypothesised to lead to 
neurotoxicity.
Methods or Materials or Case Report: Using a reverse 
genetics approach we have characterised two ENU Tardbp 
mouse mutants with mutations in the second RNA Recog-
nition Domain (Phelynalanine to Isoleucine at amino acid 
residue 210) and in the Glycine-rich C-terminal (Methioni-
ne to Lysine at amino acid residue 323) of TDP43.
Extensive molecular and behavioural characterisation was 
performed longitudinally on heterozygous animals for both 
mutations.
Results: The results revealed that the F210I and M323K 
mutations have opposite effects in TDP43-dependent spli-
cing, with the former leading to a dose-dependent “loss of 
normal function” and the latter the opposite effect, at the 
genome wide level. Metabolic effects were seen in Tardbp-
F210I/+ females which displayed lower body weight 
throughout most its lives.
Nevertheless, neither TardbpF210I/+ or Tardbp323K/+ de-
veloped neurodegeneration.
Conclusion: Our results show, for the first time, that dysre-
gulation in TDP43-dependent splicing at the genome wide 
level is insufficient to cause neuronal toxicity in the mouse 
during its normal lifespan.
Disclosure: The research presented in this abstract has re-
ceived generous funding from the Medical Research Coun-
cil, Motor Neurone Disease Association, Genetics Society 
and Disease and Model Mechanisms.
P2141
Immunohistochemical studies of FUS in 




Background and aims: Several studies of skin in patients 
with sporadic amyotrophic lateral sclerosis (SALS) have 
shown unique morphological and biochemical alterations. 
The lack of bedsore formation even in the terminal stages 
in ALS patients is considered characteristic. Recently, mu-
tations in a gene coding the fused in sarcoma (FUS) have 
been identified in familial amyotrophic lateral sclerosis 
(ALS). Also, FUS has been found in neuronal cytoplasmic 
inclusions in sporadic ALS, suggesting that FUS has an 
important role in the neurodegeneration occurring in ALS, 
However, there has been no study of FUS in ALS skin.
Methods: We have performed a quantitative immuno-
reactive study of FUS in biopsied skins from 22 patients 
with sporadic ALS and from 22 controls. Routine formalin-
fixed paraffin-embedded 6 µm sections were immunostai-
ned according to standard techniques. A densitometric ana-
lysis was performed using an image analysis system.
Results: The proportion of FUS-immunoreactive (ir) cells 
in the epidermis in ALS patients was significantly higher 
(p<0.001) than in controls. There was a significant positive 
relationship (r=0.78, p<0.001) between the proportion and 
duration of illness in ALS patients. The optical density of 
FUS-ir cells in the epidermis in ALS patients is markedly 
stronger (p<0.001) than in controls. There was a significant 
positive relation (r=0.49, p<0.05) between the immunore-
activity and duration of illness in ALS patients.
Conclusion: These data suggest that changes of FUS in 
ALS skin are related to the disease process and that meta-
bolic alterations of FUS may take place in the skin of pati-
ents with ALS.
Disclosure: Nothing to disclose
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Radiotherapy (RT) of salivary glands as 
treatment of sialorrhea in patients with 
amyotrophic lateral sclerosis (ALS)  
requiring non-invasive ventilation (NIV)
A. Assouline1, J. Gonzalez-Bermejo2, P.-F. Pradat3,  
M.D.M. Amador4
1Centre Clinique de la Porte de Saint-Cloud, Radiotherapy, 
Boulogne-Billancourt, France, 2Pitié-Salpêtrière Universi-
ty Hospital, Pneumology, Paris, France, 3Pitié-Salpêtrière 
University Hospital, Neurology, Paris, France, 4Hôpital Pitié 
Salpétrière, Département des maladies du Système Nerveux 
Central, UF Neurométabolique, Paris, France
Background and aims: Sialorrhea in ALS patients is a fre-
quent and disabling problem that also limits efficiency and 
tolerance of non invasive ventilation (NIV). We recently 
demonstrated in a large series of ALS patients that radiothe-
rapy (RT) of the salivary glands is both efficient and safe. 
Performing this method in patients requiring NIV during 
decubitus is technically challenging since it needs to adapt 
the method of RT. 
Methods: A thermoplastic mask for RT was specifically 
designed to fit the NIV interface (figure 1). 5 ALS patients 
treated with NIV suffering from severe sialorrhea were tre-
ated with RT using this new mask. Treatment was delivered 
through a linear accelerator with 6 MV photons including 
both submandibular and parotid glands. Total RT dose 
was 10 Grays/2 fractions. RT efficacy was assessed with a 
9-grades Sialorrhea Scoring Scale (SSS).
Figure 1
Results: At the end of RT, all patients had improved: 4 had 
a complete response (80% CR: SSS 1-3) and 1 had a partial 
response (20% PR: SSS 4-5). A significant lasting salivary 
reduction was observed 3 months after RT completion: the-
re was 60% CR and 40% PR. Acute toxicity was observed 
in 2 patients (mild pain and saliva thickening). There was 
no grade 3-4 toxicity. All side effects resolved in the weeks 
following the end of treatment.
Conclusion: Radiotherapy method can be adapted for tre-
ating sialorrhea in ALS patients requiring NIV. This treat-
ment is both efficient and safe. Larger prospective studies 
remain needed to confirm these results and specify its po-
tential impact on NIV efficacy and tolerance and survival.
Disclosure: Nothing to disclose
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The wide clinical phenotype of Kennedy’s 
disease.
G. Querin1, E. da Re2, C. Bertolin2, M. Volpe1, N. Caretta1,  
C. Foresta1, M. Iafrate1, D. Corrado1, M. Silvano1,  
E. Pegoraro1, D. Pareyson3, M. Pennuto4, G. Sorarù2
1Università degli Studi di Padova, Padua, Italy, 2Università di 
Padova, Neuroscienze, Padua, Italy, 3Istituto Neurologico C. 
Besta, Milan, Italy, 4Università di Trento, Trent, Italy
Background and aims: KD is a neuromuscular disease 
caused by a CAG repeat expansion in the androgen receptor 
(AR) gene. AR is broadly expressed in the body, thus AR 
toxicity may involve organs other than the neuromuscular 
system. The aim of this study was to describe the clinical 
phenotype in a large population of Kennedy’s disease (KD) 
patients.   
Methods: A clinical protocol focused on androgen-linked 
functions was administered to 72 Caucasian KD patients. 
It included: neurological exam, blood tests (glucose and li-
pid metabolism, hormonal status, bone metabolism), bone 
density test, and EKG. Urinary and sexual functions were 
also assessed by the means of functional scores and prostate 
echography.    
Results: Mean age at onset was 46 years and lower limb 
weakness was reported as presenting symptom in most ca-
ses. Patients presented a tendency to overweight with sugar 
levels consistent with diabetes mellitus or with impaired 
glucose tolerance in almost 50% of cases. 38% of patients 
had borderline blood total cholesterol levels, while 15% 
had an overt hyperlipidemia. Hormonal assessment was 
unremarkable. Bone density test showed femoral osteope-
nia in 45% of patients regardless of their age. No significant 
heart rhythm disorders were recorded. One third (37%) of 
patients complained urinary symptoms, which scored mo-
derate to severe according to the functional scales and were 
unrelated to prostate hypertrophy. Erectile dysfunction was 
reported in 46% of cases. 
Conclusion: This study further widens the clinical spect-
rum of KD.    
Disclosure: Nothing to disclose
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Effects of cough augmentation on  
pulmonary morbidity, survival, and quality 
of life in patients with amyotrophic  
lateral sclerosis in respiratory failure:  
a randomised trial
M. Rafiq1, M. Bradburn2, C. McDermott1, P. Shaw1
1University of Sheffield, Neuroscience, Sheffield, United King-
dom, 2University of Sheffield, Clinical Trials Unit, Sheffield, 
United Kingdom
Background and aims: A major problem faced by patients 
with amyotrophic lateral sclerosis (ALS) in respiratory fai-
lure is inability to cough effectively and remove secretions 
from the airways.
Methods: A total of 40 eligible ALS patients were rando-
mised to breath-stacking technique (n=21) or mechanical 
insufflator/exsufflator MI-E (n=19) and followed-up at 3 
monthly intervals for at least 12 months or until death.
Results: There were 13 episodes of chest infection in 
the breath-stacking group and 19 episodes in MI-E group 
(p=0.87), requiring 90 and 95 days of antibiotics respec-
tively (p=0.85). There were 6 episodes of hospitalisation in 
each group (p=0.87). The mean duration of symptoms per 
chest infection was 6.9 days in the breath-stacking group 
and 3.9 days in MI-E group (p=0.16). Chance of hospita-
lisation, in the event of a chest infection was 0.46 in the 
breath-stacking group and 0.31 in MI-E group (p=0.47). 
Median survival in the breath-stacking group was 535 days 
and 266 days in the MI-E group (p=0.34). Quality of life 
was maintained above 75% of baseline for a median of 329 
days in the breath-stacking group and 205 days in MI-E 
group (p=0.41).
Conclusion: In ALS patients with respiratory failure, cough 
augmentation is likely to improve survival while maintai-
ning quality of life. The breath-stacking technique may be 
prescribed for domiciliary use with the onset of respiratory 
failure. MI-E may be useful in the event of a chest infection 
when it is likely to reduce the duration of antibiotic use and 
chance of hospitalisation.
Disclosure: Nothing to disclose
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Cerebral motor cortex at 7T MRI and  
clinical correlates in amyotrophic lateral 
sclerosis
G. Siciliano1, G. Donatelli2, I. Pesaresi2, M. Costagli3,  
E. Caldarazzo Ienco1, M. Fabbrini1, M. Rossi1, L. Biagi4,  
M. Tosetti4, M. Cosottini5
1Department of Clinical and Experimental Medicine, Neuro-
logical Clinic, University of Pisa, Pisa, Italy, 2Neuroradiology 
Unit, Department of Diagnostic and Interventional Radiolo-
gy, Azienda Ospedaliero-Universitaria Pisana (AOUP), Pisa, 
Italy, 3IMAGO7 Foundation, Pisa, Italy, 4Stella Maris Scien-
tific Institute, Pisa, Italy, 5Neuroradiology Unit, Department 
of Translational Research and of New Surgical and Medical 
Technologies, University of Pisa, Pisa, Italy
Background and aims: Amyotrophic lateral sclerosis 
(ALS) is a fatal neurodegenerative disease characterized by 
a progressive upper and lower motor neurons degenerati-
on. Previous studies reported thinning and hypointensity of 
motor cortex in ALS. We aim to investigate by 7T images 
the morphology of deeper layers of motor cortex in ALS 
patients and correlate these data with clinical parameters.
Methods and Materials: 13 ALS patients and 13 age-mat-
ched healthy subjects (HS) underwent a 7T-MR examinati-
on; a high-resolution GRE sequence targeted on motor cor-
tex was performed. Subjects were subjectively diagnosed 
on the basis of morphologic criteria, moreover thickness 
and signal intensity of deeper motor cortex were measured. 
Morphologic parameters were correlated with upper motor 
neuron burden (UMN-score), ALS-FRSr score and disease 
progression rate (DPR); patients were divided in “faster” 
and “slower” DPR.
Results: Sensitivity, specificity, PPV, NPV and diagnostic 
accuracy in distinguishing between patients and HS were 
low (69%, 77%, 75%, 71%, 73%) but UMN-score was si-
gnificantly higher in true-positives than in false-negative 
(p=0.002). Cortical thickness was lower in patients than in 
HS (p=0.002) and correlated with UMN-score (R=0.63). 
Signal intensity was lower in “faster” than in “slower” DPR 
(p-value= 0.004) and correlated with UMN-score (R=0.65), 
ALS-FRSr (R=0.62) and DPR (R=0.71).
Conclusion: High resolution imaging at 7T allows the stu-
dy of the fine structure of the cerebral motor cortex and 
may play a role as an early biomarker of UMN involvement 
in ALS patients. Further studies are necessary to confirm 
a role of UHF-MR imaging in monitoring the progression 
rate.
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Amyotrophic lateral sclerosis and  
schizophrenia in a family with C9orf72  
hexanucleotid expansion
J.F. Vázquez Costa1, J. Pérez Tur2, A. Sabater Ferragut3,  
P. Sopena Novales4, M. Frasquet Carrera5,  
M.T. Sevilla Mantecon1
1Hospital la Fe, Neurology, Valencia, Spain, 2IBV-CSIC, Mo-
lecular genetics, Valencia, Spain, 3Hospital la Fe, Psychiatry, 
Valencia, Spain, 4Hospital la Fe, Radiology, Valencia, Spain, 
5Valencia, Spain
Background and aims: An hexanucleotid expansion in 
C9orf72 is the most common genetic cause of amyotrophic 
lateral sclerosis (ALS) and Frontotemporal Dementia with 
TDP43 (FTD-TDP43). Recently, an aggregation of certain 
psychiatric diseases (schizophrenia and suicide) in relatives 
of C9orf72 positive ALS patients has been found. However, 
no family with ALS and schizophrenia patients carrying the 
C9orf72 expansion has been described.
Case Report: We describe two siblings, carrying a C9orf72 
expansion, diagnosed with ALS and schizophrenia.
Results: A 53-year-old woman with family history of ALS 
and Alzheimer’s disease, was evaluated after 1 year history 
of progressive weakness and atrophy in left hand. On exa-
mination, mild weakness and atrophy with hyperreflexia as 
well as an impairment of memory, language and executive 
functions were found. EMG confirmed the involvement of 
two regions; MRI and PET showed widespread (mainly 
parietal) brain atrophy and hypometabolism. She was di-
agnosed with probable ALS according to the El Escorial 
criteria and tested positive for C9orf72 expansion. After fa-
milial screening, her younger sister, a 49-year-old woman 
diagnosed with paranoid schizophrenia 30 years before, 
was also carrying the expansion. Her neurological exami-
nation was unremarkable but her memory and visuospatial 
functions were impaired. MRI did not show atrophy and 





Conclusion: We comprehensively describe for the first 
time clinical and neuroimaging characteristics of two 
C9orf72 positive siblings diagnosed with ALS and schi-
zophrenia. Our findings further reinforce the link between 
ALS and schizophrenia and suggest that different mecha-
nisms (neurodevelopmental vs neurodegenerative) could 
lead to diverse clinical pictures in C9orf72 carriers.
Disclosure: This research work was supported with a grant 
of the Research Institute of La Fe Hospital (IIS La Fe)
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Psychogenic tics with incongruent gait as 
a give away
R. Araújo, J. Ribeiro, S. Batista
CHUC, Neurology, Coimbra, Portugal
Background and aims: Psychogenic tics are amongst the 
rarest of functional movement disorders. Incongruity is 
key in the correct diagnosis of these particularly challen-
ging patients. Incongruity of gait disorder has recently been 
pointed out as a useful clue in diagnosing functional move-
ment disorders (Balint et al, 2014).
Case Report: A 32-year-old woman, with a previous his-
tory of anxiety but no history of tics or Tourette’s Syndro-
me, presented with acute-onset motor tics. The tics were 
complex, involved both arms and hands, and consisted of 
quick movements of the arms with dystonic posturing of 
the fingers, predominantly the second and fifth. Her relaxed 
demeanor suggested belle indifference. The movements 
were largely beyond the patient’s control, but were suppres-
sible to a certain degree. The disorder began abruptly after 
an altercation with the patient’s father. On gait evaluation, 
the patient displayed incongruity with the presenting mo-
vement disorder or with any type of organic gait disorder, 
with myoclonus, chorea and astasia-abasia with a narrow 
base. 
Tics while sitting, bilateral, with dystonic posturing. Belle indifference 
is also present.
Gait with prominent astasia-abasia, narrow base and chorea like move-
ments (while wearing heels).
Gait also displayed myoclonic-like jerks of the inferior limbs and sig-
nificant sway, always with a narrow base.
Results: The symptoms disappeared after diazepam 5 per os.
Conclusion: Gait is a solid give-away for diagnosing a 
functional movement disorder. Adult-onset tics are rare and 
could have prompted investigation for a secondary cause. 
The incongruity of the gait disorder and the patient’s res-
ponse to a benzodiazepine prevented unnecessary and po-
tentially harmful further testing. 
Disclosure: Nothing to disclose
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The impact of white matter damage on  
cognition in PSP syndrome: a DT MRI  
study
F. Caso1, F. Agosta1, M.A. Volonté2, A. Marcone3,  
M. Copetti4, F. Spagnolo2, M. Falautano2, A. Falini5,  
G. Comi2, M. Filippi1
1San Raffaele Scientific Institute, Vita-Salute San Raffaele 
University, Neuroimaging Research Unit, Milan, Italy, 2San 
Raffaele Scientific Institute, Vita-Salute San Raffaele Univer-
sity, Department of Neurology, Milan, Italy, 3San Raffaele 
Scientific Institute, Vita-Salute San Raffaele University, De-
partment of Clinical Neuroscience, Milan, Italy, 4IRCCS-Os-
pedale Casa Sollievo della Sofferenza, Biostatistics Unit, San 
Giovanni Rotondo, Italy, 5Università Vita-Salute San Raffaele, 
Neuroradiology, Milan, Italy
Background and aims: To explore the impact of white 
matter (WM) tract damage on cognitive performances in 
a relatively large sample of patients with probable progres-
sive supranuclear palsy syndrome (PSPs) using diffusion 
tensor (DT) MRI.
Methods: We enrolled 32 patients with probable PSPs in a 
moderate stage of the disease (mean H&Y score: 3.3) and 
22 matched healthy controls. Patients underwent an exten-
sive neuropsychological evaluation. DT MRI and tract-
based spatial statistics were used to assess the regional 
patterns of WM microstructural damage in patients relative 
to controls. Then, a regression analysis was conducted to 
correlate DT MRI metrics of the main WM tracts with co-
gnitive variables.
Results: PSPs patients showed prominent attentive-execu-
tive deficits that were related to the damage of specific WM 
tracts as revealed by DT MRI. The following significant 
correlations were observed: attentive matrices scores with 
WM damage of the fornix, left cingulum, superior longi-
tudinal fasciculus (SLF), right superior fronto-occipital 
fasciculus and bilateral cortico-spinal tract (CST); Raven 
matrices scores with fornix; token test scores with DT MRI 
measures of the fornix, bilateral inferior and middle cere-
bellar peduncle, cingulum, CST, inferior fronto-occipital 
fasciculus, inferior longitudinal fasciculus, left SLF and 
splenium of corpus callosum; fluencies scores with dama-
ge to bilateral superior cerebellar peduncles, left SLF and 
CST.
Conclusion: In PSPs, WM damage has a central role in the 
development of executive and language dysfunction.
Disclosure: CurePSP Foundation (#MD505-12_001). 
P2149
Favourable effect of safinamide on  
dyskinesia evolution over 2-year treatment 
of fluctuating Parkinson’s disease patients
C. Cattaneo1, E. Bonizzoni2, R. La Ferla3, M. Sardina3
1Bresso (Milan), Italy, 2University of Milan, Department of 
Clinical Science and Community, Section of Medical Statis-
tics and Biometry “G.A. Maccacaro”, Milan, Italy, 3Zambon 
SpA, Medical Department, Bresso (Milan), Italy
Background and aims: Safinamide (Xadago™, Zambon 
SpA, Italy), a new drug with a dual mechanism of action, 
has shown in study 018 to reduce, after 24 months of treat-
ment, the Dyskinesia Rating Scale (DRS) scores up to 31% 
from baseline, compared to 3% with placebo. The objecti-
ve of this post-hoc analysis it to investigate the long-term 
effect of safinamide vs. placebo on dyskinesia as add-on 
therapy in fluctuating Parkinson’s disease patients, treated 
with levodopa alone or in combination with dopamine ago-
nists and/or anticholinergics. 
Methods: The categorical changes in DRS scores were 
evaluated by stratifying the patients based on the presence 
or absence of dyskinesia at baseline and of changes in L-
dopa doses. 
Results: Safinamide 100 mg/day significantly improved the 
DRS score over 2 years of treatment, compared with place-
bo, both in patients with dyskinesia at baseline (p=0.0153) 
and in the overall population (p=0.0488). A borderline sta-
tistically significant improvement was also seen in patients 
with no changes in L-dopa dose (p=0.0546).These findings 
confirmed the results of a previous post-hoc analysis in pa-
tients with moderate to severe dyskinesia at baseline (DRS 
>4) showing a statistically significant decrease in DRS 
scores vs placebo at the dose of 100 mg (p=0.0317).
Conclusion: Patients treated with safinamide showed a si-
gnificant improvement of dyskinesia in the long-term, as 
measured by DRS scores, apparently not related to L-Dopa 
dose changes. This may be explained by the safinamide 
non-dopaminergic mechanism of action, causing an inhibi-
tory effect on glutamate release.
Disclosure: Carlo Cattaneo, Roberto La Ferla and Marco 
Sardina are employees of Zambon Pharma SpA. Erminio 
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Effect of Catecho-O-metyltransferase 
(COMT) genotype on the response to  
bilateral subthalamic deep brain  
stimulation (DBS-STN) in Parkinson’s  
disease (PD)
F. Cormier-Dequaire1, S. Buro2, K. Tahiri3, G. Mangone2,  
J. Kraemmer2, A. Welaratne4, C. Karachi5, A. Brice2,  
M.-L. Welter6, J.-C. Corvol1
1Pitié-Salpétriêre Hospital, Université Pierre et Marie Curie-
Paris 6, Centre de recherche de l‘Institut du Cerveau et de la 
Moelle épinière, INSERM UMRS_1127, CIC_1422, Départe-
ment de Neurologie, APHP, Paris, France, 2Pitié-Salpétriêre 
Hospital, Université Pierre et Marie Curie-Paris 6, Centre 
de recherche de l‘Institut du Cerveau et de la Moelle épini-
ère, INSERM UMRS_1127, CIC_1422, APHP, Paris, France, 
3Pitié-Salpêtrière Hospital,Université Pierre et Marie Curie 
Paris 6 , Pitié-Salpêtrière Hospital, Centre de Recherche de 
l‘Institut du Cerveau et de la Moelle épinière, Paris, France, 
4Pitié-Salpétriêre Hospital, Département de neurologie, 
APHP, Paris, France, 5Département de Neurochirurgie, 6Pitié-
Salpétriêre Hospital, Université Pierre et Marie Curie-Paris 
6, Centre de recherche de l‘Institut du Cerveau et de la Moel-
le épinière, INSERM UMRS_975, CIC_1422, Département de 
Neurologie, APHP, Paris, France
Background and aims: DBS-STN is proposed to PD pati-
ents at motor fluctuation stage and has been shown to alle-
viate motor symptoms. However, some patients have poor 
outcome. COMT genotype modifies dopa biodisponibility, 
dyskinesia, working memory. Our objective was to evalua-
te its influence on DBS-STN response.
Methods: We compared assessments preoperative and 12 
months after DBS-STN in PD patients. The COMT Valine 
(Val) 158 Methionine (Met) polymorphism was analyzed 
by allelic discrimination Taqman®assay. Statistical analy-
ses were performed with Statistica®software.
Results: Between 1996 and 2009, 309 PD patients under-
went DBS-STN surgery. Among them, 257 were genotyped 
for the polymorphism. 63 were Met/Met, 124 Val/Met, 70 
Val/Val. At baseline, we observed higher scores of UPDRS 
IV in Met allele carriers and an allele dose effect (Met/
Met 10.0 (±3.8), Met/Val 9.1 (±3.3), Val/Val 8.8 (±3.3), 
p=0.005), mainly due to dyskinesia subscores (p=0.006). 
Patients with the Val/Val genotype had higher global co-
gnitive efficiency scores (139.0 (±4.8) vs 137.6 (±10.1), 
p=0.03). After surgery, we observed a difference for UP-
DRS IV (p=0.003) and dyskinesia subscores (p=0.0002) 
with a greater decrease in Met allele carriers, an allele dose 
effect (Met/Met -7.6 (±4.6), Met/Val -7.0 (±4.0), Val/Val 
-6.1 (±4.2), p=0.005), and an interaction between the ef-
fects of DBS and COMT genotype on dyskinesia (p=0.03).
Patient characteristics
Effect of COMT Val/Met polymorphism on the becoming of patients 
who underwent DBS surgery 
Conclusion: Our study confirms the influence of COMT 
genotype on dyskinesia and cognition in PD patients. A gre-
ater diminution of dyskinesia under DBS-STN in Met/Met 
patients was observed, suggesting an interaction of COMT 
genotype with DBS STN response on dyskinesia. 
Disclosure: Nothing to disclose
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Is there a confounding effect of age on 
deep brain stimulation in patients with 
Parkinson’s disease (comparison with the 
EARLYSTIM study)?
V. Cozac1, M. Chaturvedi1, H. Bousleiman2, F. Hatz1,  
A. Meyer1, N. Schwarz1, R. Zimmermann1,  
U. Gschwandtner1, P. Fuhr1
1Universitätsspital Basel, Neurology and Neurophysiology, 
Basel, Switzerland, 2University of Basel, Swiss Tropical and 
Public Health Institute, Basel, Switzerland
Background and aims: To investigate the risks of deep 
brain stimulation in PD patients of relatively old age (older 
than 60 years).
Methodst: A retrospective sample of 33 patients with idio-
pathic PD who underwent DBS in Basel and Bern, Switzer-
land (age at operation: median 60.6y±9.7; 13 females) was 
investigated (Basel group). Mean period of follow-up after 
surgery was 25.9 months. Serious adverse events (SAE) 
were defined as any event leading to death, disability, pro-
longed or new hospitalization, according to the Medical 
Dictionary for Regulatory Activities, Version 14.1. We 
compared the outcome in the Basel group with the EARLY-
STIM trial (Schuepbach et al., 2013) with a neurostimula-
tion group (age: median 52.9±6.6 years) and a best medical 
treatment group (age: median 52.2±6.1 years). Chi-square 
test was used for statistical analysis.
Results: A total of 17 patients (51.5%) in the Basel group had 
at least one SAE. There was no difference in overall frequen-
cy of SAE between the groups, but SAE related to psychosis/
hallucination (p<0.001) were significantly different between 
the Basel group and the EARLYSTIM groups. One patient 
from Basel group deceased during the follow up period. In 
addition there were more reoperation cases in the Basel group 
(p=0.02) than in EARLYSTIM group.
Conclusion: While the gross profile of SAE is similar in 
older and younger patients treated with DBS, the incidence 
of psychosis and reoperations is higher in older patients. 
Older patients require increased attention to risk factors for 
neuropsychiatric consequences of DBS.
Disclosure: Nothing to disclose
P2153
Efficacy of sublingual apomorphine (APL-
130277) for the treatment of “Off” episodes 
in patients with Parkinson’s disease
R.A. Hauser1, J. Dubow2, B. Dzyngel2, T. Bilbault2,  
A. Giovinazzo2, A. Agro2
1USF Health Byrd Parkinson’s Disease and Movement Disor-
ders Center of Excellence, Tampa, USA, 2Cynapsus Therapeu-
tics, Toronto, Canada
Background and aims: Parkinson’s disease (PD) patients 
suffer from a variety of “Off” episodes as the disease pro-
gresses.  APL-130277 (APL) is a soluble film strip that sub-
lingually delivers apomorphine rapidly through absorption 
from the oral cavity. This study evaluated the efficacy of 
single treatments of APL-130277 in patients with PD. 
Methods: This was a phase 2, open-label, single-arm study. 
PD patients with at least one “Off” episode per day and 
>2 hours of total daily “Off” time were included. Patients 
were initially administered APL 10mg in the morning “Off” 
state. If a satisfactory response was not seen, APL was in-
creased in 5 mg increments until a clinically meaningful 
“On” was achieved, to a maximum dose of 30 mg. Change 
in MDS UPDRS Part III was evaluated from pre-dose mor-
ning “Off” state to 15, 30, 45, 60 and 90 minutes post-dose. 
Results: Baseline demographic data are presented in Table 
1. Fifteen of 19 patients achieved a full “On”. Mean change 
from pre-dose to post-dose MDS-UPDRS Part III is presen-
ted in Figure 1 and Mean percent change in MDS-UPDRS 
Part III is presented in Figure 2.
Table 1: Baseline Demographic Data
Figure 1: Change in MDS-UPDRS Part III Over Time Following APL-
130277 Administration
Figure 2: Percent Change in MDS-UPDRS Part III Over Time Fol-
lowing APL-130277 Administration
Conclusion: APL provided rapid, clinically meaningful 
improvement in MDS-UPDRS Part III scores for PD pa-
tients in the “Off” state. Much of the benefit was sustained 
through 90 minutes. A range of doses were utilized but over 
half responded to the two lowest doses of APL (10 and 15 
mg). APL-130277 may be an effective, easy to administer 
medication for the on-demand management of “Off” episo-
des in PD patients.
Disclosure: RAH was an investigator and has received 
compensation from Cynapsus Therapeutics for research ac-
tivities. JD, BD, TB, AG and AA are employees of Cynap-
sus Therapeutics and hold stock or stock options.
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Safety of sublingual apomorphine  
(APL-130277) for the treatment of OFF  
episodes in patients with Parkinson’s  
disease.
S. Isaacson1, J. Dubow2, B. Dzyngel2, T. Bilbault2,  
A. Giovinazzo3, A. Agro3
1Parkinson’s Disease and Movement Disorders Center of 
Boca Raton, Boca Raton, USA, 2Cynapsus Therapeutics, 
3Cynapsus Therapeutics, Toronto, Canada
Background and aims: Parkinson’s disease (PD) patients 
suffer from a variety of predictable and unpredictable OFF 
episodes throughout the disease duration. APL-130277 
(APL) is a soluble film strip that sub-lingually delivers 
apomorphine rapidly through absorption from the oral ca-
vity mucosa. This study evaluated the safety of single treat-
ments of APL-130277 for the management of OFF episo-
des in PD.
Methods: This was a phase 2, open-label, single-arm study. 
PD patients with at least one OFF episode per day and >2 
hours of total daily OFF time were included. Patients were 
initially administered APL 10 mg in the morning OFF state. 
If a satisfactory response was not seen, APL was increased 
in 5 mg increments until a clinically meaningful ON was 
achieved, to a maximum dose of 30 mg.
Results: 19 subjects received 77 total doses of APL 10-
30 mg. Overall, 13 (68.4%) patients experienced an AE, 
with most experiencing mild AEs (Table 1). The most com-
mon AEs were dizziness (7/19, 36.8%), somnolence (6/19, 
31.6%), nausea (4/19, 21.1%) and yawning (3/19, 15.8%) 
(Table 2). The most common AEs by dose are presented 
in Figure 1. One subject had an unrelated serious AE of 
dysphagia. 
Table 2: Treatment Emergent AEs in 2 or More Patients
Table 1: Overview of AEs with APL-130277
Figure 1: AEs in 2 or More Patients by Dose
Conclusion: APL was safe and well tolerated in PD pa-
tients with OFF episodes. The most common AEs were 
mild or moderate, and are commonly associated with dopa-
minergic medications and/or apomorphine. This trial sug-
gests sublingual APL-130277 has demonstrated tolerability 
and was safe in PD patients with OFF episodes. Longer 
phase 3 studies are planned to assess efficacy, tolerability, 
and safety.
Disclosure: SI was an investigator and has received com-
pensation from Cynapsus for research activities. JD, BD, 
TB, AG, and AA are employees of Cynapsus Therapeutics 
and hold stock or stock options. 
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Efficacy of apomorphine subcutaneous 
injections for the management of morning 
akinesia in Parkinson’s disease
S. Isaacson
Boca Raton, USA
Background and aims: Patients with Parkinson’s disease 
(PD) and motor fluctuations often have delayed time-to-on 
(TTO) after a dose of oral L-dopa. Delayed TTO can be due 
to gastrointestinal (GI) factors impairing L-dopa absorpti-
on. Delivery of non-oral (subcutaneous) medication may 
provide a more rapid and predictable response by avoiding 
the GI system. This open-label study assessed the effect of 
subcutaneous injection of apomorphine (APO) on first dose 
TTO in PD patients with morning akinesia.    
Methods: Subjects recorded their TTO following each 
morning dose of L-dopa for 7-days. Subjects who met in-
clusion criteria of >45 minute delay for ≥3 of 7 days were 
then titrated to an APO “optimal dose”. Subjects then re-
corded their TTO following each morning dose of APO 
for 7-days. Primary outcome: Mean TTO comparing APO 
treatment period versus baseline L-dopa period.    
Results: The full analysis set included 88 subjects. Mean 
TTO reduced from 60.86±18.11 minutes after L-dopa to 
23.72±14.55 minutes after APO (p<0.0001). Significant 
improvements were also found in PGI, CGI, & EQ-5L-3D 
scales. Dose failures (defined as >60min TTO) were repor-
ted for 144/310 (46%) completed diary entries during the 
L-dopa baseline week, but only 20/307 (7%) diary entries 
following APO. Most common AEs were nausea, dizziness 
and orthostatic hypotension (most AEs were mild/moderate 
and occurred during APO-titration).    
Conclusion: In patients with delayed TTO following their 
morning L-dopa dose, subcutaneous APO injections pro-
vided a robust motor improvement that was rapid, reliab-
le and safe. Dose failures were significantly reduced, and 
global impression and quality of life scales also improved.  
Disclosure: Study supported by US WorldMeds.
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Gabaergic and glutamatergic synaptic 
transmissions are altered after cuprizone 
exposure: implication for schizophrenia 
and demyelinating diseases.
C. Motta1, V. Studer1, D. Fresegna2, A. Gentile2, S. Bullitta2, 
E. Chiarello1, S. Gelibter1, D. Centonze1, S. Rossi1
1Tor Vergata University, Rome, Italy, 2IRCCS Santa Lucia, 
Rome, Italy
Background and aims: Growing evidence suggests the 
involvement of inflammatory and subtle demyelinating 
processes in the pathophysiology of schizophrenia. Beha-
vioral abnormalities relevant to some schizophrenia sym-
ptoms have been reported during exposure to cuprizone, a 
copper chelator agent selectively toxic to oligodendrocytes. 
While associating white matter damage to the behavioral 
abnormalities, these previous studies did not rule out the 
possible impairment in neuronal functions in cuprizone-
exposed mice.
Methods: After short-term exposure to cuprizone (0.2% 
for 1 week), behavioral tests, patch-clamp recordings from 
striatal neurons and Western blot analysis were performed.
Results: A profound derangement of spontaneous syn-
aptic activity was recorded at both pre- and post-synaptic 
level, differentially involving glutamatergic and GABAer-
gic transmission. The  amplitude of GABA-mediated in-
hibitory currents (sIPSCs) was significantly increased at 
post-synaptic level, whereas a pre-synaptic reduction of 
glutamate-mediated excitatory currents (sEPSCs) was ob-
served in corticostriatal slices of cuprizone mice, in par-
allel to psychotic behavior at the Marble Burying test. In-
creased GFAP and reduction of synapsin expression, with 
still normal level of myelin binding protein, APP and Tau 
protein, indicated early synaptopathy and astrogliosis inde-
pendent of demyelination and axonal damage. Caffeine, the 
most commonly self-administered psychoactive substance 
worldwide, increased sEPSC frequency and reduced sIPSC 
amplitude in vitro. Coadministration of caffeine prevented 
both synaptic and behavioral alterations in mice exposed 
to cuprizone.
Conclusion: Schizophrenia-like behavior is mediated by 
synaptic alterations and can be prevented by caffeine in cu-
prizone model.
Disclosure: Nothing to disclose
P2157
The evaluation of the burden on  
caregivers associated with relapsing- 
remitting (RRMS) and secondary  
progressive multiple sclerosis (SPMS)  
patients across Europe
S. Naoshy1, C. Watson1, J. Pike2, E. Jones2
1Biogen Idec, Cambridge, USA, 2Adelphi Real World,  
Manchester, United Kingdom
Background and aims: Multiple sclerosis (MS) is a chro-
nic inflammatory disease associated with substantial so-
cioeconomic burden on both patients and their caregivers. 
This study evaluates the burden on caregivers for RRMS 
and SPMS patients in Europe.
Methods: Data were identified from the Adelphi MS Di-
sease Specific Programme, a cross-sectional study with 
caregiver-reported data available for 359 RRMS and 106 
SPMS patients in Europe (France, Germany, Italy, Spain, 
UK). Fisher’s Exact or Chi-Squared (for categorical out-
comes) and Wilcoxon rank-sum test (for numerical outco-
mes) were used to determine differences between RRMS 
and SPMS patients.
Results: Caregivers for RRMS and SPMS patients differed 
significantly in their employment status (p<0.0001), as ca-
regivers for SPMS patients are less likely to be employed in 
full-time positions (34.62% vs 62.50%), more likely to be 
employed in part-time positions (23.08% vs 16.19%) and 
unemployed (42.31% vs 21.31%). When employed, a high-
er proportion of SPMS patient caregivers reported that their 
job has been affected by their role as a caregiver (58.33% 
vs 29.24% p<0.0001), and more caregivers for SPMS pa-
tients stopped work early to care for an MS patient than 
caregivers of RRMS patients (4.81% vs 0.28% p=0.0028).
Conclusion: Across Europe, caregivers for RRMS and 
SPMS patients experience a high socioeconomic burden as 
a result of their role as a caregiver. Caregivers for SPMS 
patients experience a more significant burden than those 
of RRMS patients, which is reflected in their ability to be 
employed full-time and effect of their role as a caregiver 
on their work.
Disclosure: Study sponsored by Biogen Idec.
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Disability and gray matter atrophy in  
multiple sclerosis patients with no  
evidence of disease activity: a one-year 
follow-up study
G. Nygaard1, E.G. Celius1, S.A.D.R. Benavent2, P. Sowa3,  
M.W. Gustavsen1, A.M. Fjell4, N.I. Landro4,  
K.B. Walhovd4, H.F. Harbo1
1Oslo University Hospital, Dept of Neurology, Oslo, Norway, 
2Oslo University Hospital, Dept of Ophthalmology, Oslo, 
Norway, 3Oslo Univsersity Hospital, Dept of Radiology, Oslo, 
Norway, 4Univserity of Oslo, Institute of Psychology, Oslo, 
Norway
Background and aims: New treatment options have made 
“no evidence of disease activity” (NEDA; no relapses or 
disability progression and no new or enlarging lesions on 
MRI) a potentially viable clinical goal in relapsing-remit-
ting multiple sclerosis (RRMS). We aimed to determine 
characteristics of NEDA patients in early RRMS and to 
study whether NEDA could be predicted from baseline ex-
aminations.
Methods: We performed a one-year follow-up study of 
RRMS patients (n=72, mean age 34.3 years, mean disease 
duration 2.2 years at baseline), treated according to natio-
nal guidelines, and evaluated neurologically, neuropsycho-
logically and with MRI, including gray matter volumetry. 
Differences between patients and matched healthy controls 
(HC; n=61); and between NEDA and non-NEDA patients 
were evaluated. Predictors for NEDA were assessed with 
logistic regression.
Results: NEDA was found in 54% of the RRMS pati-
ents after one year’s observation. Treatment assignment 
to second line medication (fingolimod or natalizumab) at 
baseline was the only predictor for NEDA. NEDA patients 
regressed in disability (EDSS: 2.0-1.7, p=0.003)), while 
non-NEDA progressed (EDSS: 1.8-2.2, p= 0.036). Cogni-
tion and gray matter characteristics were similar between 
the patient groups, which both had higher subcortical atro-
phy rates than HC (Annual percent change (standard devi-
ation): NEDA: -0.68(1.12), non-NEDA: -1.18(1.18), HC: 
-0.30±0.43, significance level of difference: p=0.022 and 
p<0.001 respectively).
Conclusion: Treatment assignment predicts NEDA in early 
RRMS, and NEDA patients experience a regression of disa-
bility. However, even in NEDA patients, subcortical atro-
phy rates are higher than in HC, indicating that pathological 
neurodegeneration takes place. This underlines the need for 
efficient treatment strategies in early RRMS.
Disclosure: We have received a grant for MRI aquisition 
and a grant for evaluation of fatigue in MS from Novartis.
P2159
Marital status after the diagnosis of  
multiple sclerosis
S. Ozkan, O. Ozdemir, D. O. Adapinar
Eskisehir Osmangazi University, Neurology, Eskisehir, Turkey
Background and aims: Multiple sclerosis is a life-limiting 
and social restrictive disease. Previous reports about mar-
ital status of relapsing remitting MS (RRMS) patients re-
ports an increased rate of divorce. This data can be affected 
by different cultural status.  We aimed to investigate the 
impact of MS on marital breakdown in Turkish RRMS pa-
tients.
Methods: 73 RRMS patients (37 women, 36 men) (mean 
age at diagnosis; 32±4.7 years) who were married during 
the diagnosis of MS were included the study. Marital sta-
tus, marriage duration and if divorced, time between the 
diagnosis and the divorce were questioned. Demographic 
data, disease status and clinical information were conduc-
ted from our records. Crude devorce rate (CDR) per year 
was calculated.
Results: The rate of divorce during the five years period 
was 18% and CDR per year was 2.6. Shorter period of mar-
riage before the diagnosis, higher EDSS scores at the divo-
rce date, having only one or no child, female gender were 
statistically significant risk factors for the divorce. Educa-
tional level, relaps rate, age at onset, age at diagnosis were 
no risk for the cessation of the marriage.
Conclusion: MS patients have a greater risk for divorce 
than the general population in Turkey (CDR per year for 
general populaton in 2012 reported by Turkish Statistic In-
stitute was 1.64) and males are more likely to discontinue 
marriage if their spouse has MS. More severe disability in-
creases the risk. These results suggest that MS patients and 
and their families need more detailed family counseling 
and social support than the normal population.
Disclosure: Nothing to disclose
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Cardiac safety and tolerability of  
fingolimod in relapsing MS patients from 
the FIRST study who transitioned into the 
LONGTERMS study
J.A. Palace1, R. Gold2, G. Comi3, Y. Chen4, D. Tomic5,  
L. Kappos6
1University of Oxford, Oxford, United Kingdom, 2St. Josef-
Hospital and Ruhr-University Bochum, Bochum, Germany, 
3University Vita-Salute, Scientific Institute San Raffaele, Mi-
lan, Italy, 4Novartis Pharmaceutical Corporation, East Hano-
ver, New Jersey, USA, 5Novartis Pharma AG, Basel, Switzer-
land, 6University Hospital Basel, Basel, Switzerland
Background and aims: FIRST, a 4-month, open-label, 
multi-centre study, explored short-term safety and tolerabi-
lity of fingolimod 0.5 mg in “real-world” relapsing MS pa-
tients (N=2417), including those with pre-existing cardiac 
conditions (PCC). Completers from FIRST were invited to 
participate in the LONGTERMS study.
Methods: Of 1997 patients transitioning into LONG-
TERMS, 812 patients were followed for ≥1 year (i.e., ≥365 
days) while on fingolimod treatment. Cardiac safety was 
evaluated in these patients (FIRST-cohort: n=812) and in 
FIRST-cohort patients with PCC (PCC-subgroup: n=68). 
Incidence rates (IR) of adverse events (AE) and serious 
AEs (SAE) per 100 patient-years are reported. 
Results: In the FIRST-cohort, 42 patients (IR 2.6) had 
cardiac AEs, most frequently palpitations (IR 1.3), brady-
cardia (IR 0.4) and angina pectoris (IR 0.3). Of those, 3 
patients (IR 2.2) were in the PCC-subgroup: 1 case each of 
angina pectoris, palpitation and bradycardia. Hypertension 
was reported for 49 patients (IR 3.1) in the FIRST-cohort, 
of which 5 were in the PCC-subgroup (IR 3.9). In total, 3 
cardiac SAEs were reported: 1 case each of bradycardia, 
cardiac disorder and hypertension. No cardiac SAE was re-
ported in the PCC-subgroup.  Additional analysis of AEs in 
early dropouts (<1 year exposure) will also be presented.
Conclusion: These results are in line with the established 
cardiovascular safety profile of fingolimod. Incidence rates 
of cardiac events were similar overall and in patients with 
pre-existing cardiac conditions. 
Disclosure: Jacqueline Palace has received support for 
scientific meetings and honoraria for advisory committees 
from Merck Serono, Biogen Idec, Novartis, Teva Phar-
maceutical Industries Ltd., Chugai Pharmaceutical Co. 
Ltd., Med-Immune, LLC, and Bayer Schering Pharma, and 
unrestricted grants from Merck Serono and Bayer Schering 
Pharma. 
P2161
Correlations of cognitive function,  
neuroimaging and everyday activities in 
multiple sclerosis
A. Papathanasiou1, L. Messinis1, V. Georgiou2, P. Zabakis3,  
P. Papathanasopoulos1
1University of Patras, Department of Neurology, Patras, 
Greece, 2Hellenic Open University, Patras, Patras, Greece, 
3University of Patras, Department of Radiology, Patras, 
Greece
Background and aims: Cognitive decline is present in 
40%-70% of MS patients, affects quality of life and corre-
lates with brain MRI markers
Methods: We evaluated clinically and neuropsychologi-
cally 80 patients with MS (50 RRMS, 30 SPMS). Every-
day activities were assessed with Instrumental Activities of 
Daily Living (IADL). Brain MR total lesion volume, thala-
mic, corpus callosum atrophy and 3rd ventricle width was 
calculated.
Results: We found 38% of RRMS and 80% of SPMS pati-
ents to have cognitive deficits. RRMS cognitively impaired 
patients had weak correlation with EDSS and MR lesion 
load (p<.05) and strong correlation with all MR atrophy 
measures (p<.001). IADL was highly correlated with psy-
chomotor speed, processing speed, memory and all MR 
atrophy measures (p<.001). SPMS cognitively impaired 
patients had only weak correlation with 3rd ventricle width 
(p<.05). Using MS patients as single group, regression 
analysis revealed that low psychomotor speed (p=.004) 
and poor performance on Trail Making Test B (TMT B) 
(p=.007) were the most sensitive predictors of increased 
physical disability, whereas psychomotor speed predicted 
impaired every day activities (p=.001). Thalamic atrophy 
was the most sensitive indicator for poor performance on 
TMT B (p=.000), while corpus callosum atrophy predicted 
slow psychomotor speed (p=.000).
Conclusion: We observed a global pattern of cognitive de-
cline, consisting of impairment in information processing 
speed, followed by executive dysfunction and memory de-
ficits. Psychomotor speed, composite memory and TMT B 
are the best predictors of physical disability. Thalamic and 
corpus callosum atrophy are the best predictors of cognitive 
decline in our patients
Disclosure: Nothing to disclose
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Action naming in multiple sclerosis
D. Passafiume1, N. Caputi1, A. Matrella1, M. Colantonio2,  
D. Di Giacomo2
1University of L’Aquila, Life,Health and Environmental Sci-
ence, L’Aquila, Italy, 2University of L’Aquila, Life, Health and 
Environmental Science, L’Aquila, Italy
Background and aims: Multiple Sclerosis (MS) is cha-
racterized by the demyelination of the fibres in the cen-
tral nervous system and has several motor and cognitive 
consequences, such as in speed of information processing, 
memory, attention, and executive functions. A recent study 
conducted in our laboratory showed MS patients are im-
paired in recognition of chimerical figures, compared to 
real objects or animals. Mental imagery and mental repre-
sentation of the movement are impaired in diseases invol-
ving motor system, such as Parkinson’s disease, as a conse-
quence of pathologies of the central nervous system.
Aim of the present study was to investigate the perfor-
mance of patients affected by relapsing/remitting MS in re-
cognizing and naming actions with high movement content 
compared  to actions with low movement content.
Methods: 20 patients affected by Relapsing/Remitting MS 
and 20 matched healthy subjects (HS), age range 20 to 50 
y, were tested with an experimental task composed by 100 
stimuli, 50 high-movement and 50 low-movement figures. 
Each stimulus consisted in the picture of an action; the sub-
jects were asked to name it. All subjects performed an ex-
tensive neuropsychological battery in order to assess their 
cognitive status.
Results: Preliminary analysis showed that MS patients 
have significantly worst performances in recognizing and 
naming actions with high movements contents compared to 
actions with low movements content, while no significative 
differences were HS group.
Conclusion: Our results seem to confirm our hypothesis: 
MS patients are impaired in naming high-moviment figu-
res. More analysis will be performed in order to explore the 
role of EDSS and of the years of illness.
Disclosure: Nothing to disclose
P2163
Patient-reported symptom burden among 
relapsing remitting multiple sclerosis 
(RRMS) vs secondary progressive multiple 
sclerosis patients (SPMS) in Europe
J. Pike1, C. Watson2, S. Naoshy2, E. Jones1
1Adelphi Real World, Manchester, United Kingdom, 2Biogen 
Idec, Cambridge, USA
Background and aims: This study evaluates patient-repor-
ted symptoms in RRMS and SPMS patients in Europe.
Methods: Data were identified from Adelphi MS Disease 
Specific Programme, a cross-sectional study in Europe 
(France, Germany, Italy, Spain and UK) with patient-repor-
ted data available from questionnaires for 881 RRMS and 
142 SPMS patients. The Wilcoxon rank-sum test was used 
to determine differences between RRMS and SPMS pati-
ents. Patients reported symptoms as either “mild”, “mode-
rate” or “severe” and symptoms that were reported as “mo-
derate” in at least 10% of either RRMS or SPMS patients 
have been included.
Results: A higher proportion of SPMS patients than RRMS 
patients reported the following symptoms as “moderate”:
Conclusion: There is a high symptom burden experienced 
by MS patients, with SPMS patients reporting a higher 
symptom burden than RRMS patients, highlighting the 
need to prevent patients from progressing from RRMS to 
SPMS.
Disclosure: Study sponsored by Biogen Idec.
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Durable effect of alemtuzumab on  
disease activity in patients with  
relapsing-remitting multiple sclerosis
H. Wiendl1, D.L. Arnold2, R.M. Hupperts3, G. Giovannoni4, 
D.H. Margolin5, L. Kasten6, E. Havrdova7
1Department of Neurology, University of Münster, Münster, 
Germany, 2NeuroRx Research, Montreal Neurological Insti-
tute, McGill University, Montreal, Canada, 3Orbis Medisch 
Centrum, Maastricht University Medical Center, Sittard, The 
Netherlands, 4Queen Mary University of London, Barts and 
The London School of Medicine, London, United Kingdom, 
5Genzyme, a Sanofi company, Cambridge, USA, 6PROMET-
RIKA LLC, Cambridge, USA, 7First Medical Faculty, Charles 
University in Prague, Prague, Czech Republic
Background and aims: In active relapsing-remitting mul-
tiple sclerosis patients who were treatment-naïve (CARE-
MS I; NCT00530348) or had inadequate efficacy response 
to prior therapy (CARE-MS II; NCT00548405), greater 
proportions of patients had no evidence of disease activity 
(NEDA) with alemtuzumab versus subcutaneous interferon 
beta-1a over 2 years. These proportions remained stable in 
year 3. This analysis examined NEDA in alemtuzumab-
treated patients during year 4 of CARE-MS studies.
Methods: In CARE-MS I (treatment-naive) and II (pati-
ents with ≥1 relapse after ≥6 months of prior therapy), the 
alemtuzumab 12-mg group received 2 annual treatment 
courses; in the extension study (NCT00930553), patients 
could receive as-needed alemtuzumab retreatment ≥1 year 
apart. NEDA definition: absence of relapse, 6-month sustai-
ned accumulation of disability (Expanded Disability Status 
Scale score increase from baseline of ≥1.0 [≥1.5 if baseline 
EDSS=0]), new/enlarging T2 lesions, and gadolinium-en-
hancing lesions.
Results: In CARE-MS I and II, 324 and 336 alemtuzumab 
patients were available for analysis in year 4, respectively; 
73% and 68% received only the initial 2 courses. Propor-
tion of alemtuzumab patients in CARE-MS I and II achie-
ving NEDA in year 4 was 60.2% and 54.5%, respectively 
(61.7% and 52.9% in year 3). Consistent with the overall 
study population, most patients achieving NEDA did not 
require alemtuzumab retreatment in years 3 and 4.
Conclusion: The proportion of alemtuzumab patients 
achieving NEDA remained stable in years 3 and 4 of 
CARE-MS studies, irrespective of treatment-naive status 
or inadequate efficacy response to prior therapy. This dura-
ble effect was observed despite most patients not receiving 
alemtuzumab during the last 3 years of observation.
Disclosure: Study supported by Genzyme, a Sanofi compa-
ny, and Bayer Healthcare Pharmaceuticals.
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Intermediate expansions in ataxia genes, 
ATXN2 and FMR1, associated with  
Parkinson’s disease
N. Abramycheva, E. Fedotova, M. Stepanova, A. Moroz,  
S. Klyushnikov, S. Illarioshkin
Research Center of Neurology, Neurogenetics, Moscow, Rus-
sian Federation
Background and aims: A full mutation of >34 CAG re-
peats in exon 1 of ATXN2 gene causes spinocerebellar ata-
xia type 2. A full mutation of >200 CGG repeats in 5’-un-
translated region of FMR1 gene causes fragile X syndrome, 
while a premutation of 55-200 repeats in the same gene re-
sults in fragile X-associated tremor/ataxia. Recently, sever-
al reports have suggested the association of the expansions 
in ATXN2 and FMR1 with another neurodegenerative dis-
order, Parkinson disease (PD). The aim of this study was to 
estimate the prevalence of ATXN2 and FMR1 expansions 
in a cohort of PD patients in Russian population.
Methods: Genetic analysis for expanded repeats in the 
ATXN2 gene was carried out in 445 Russian patients with 
PD and in 353 ethnically-matched healthy control subjects. 
The expansion in FMR1 gene was studied in 68 patients 
with PD and 95 control subjects. Both expansions were 
assessed by fragment analysis using ABI Prism 3130 (Ap-
plied Biosystems/HITACHI).
Results: The intermediate expansion of 28-32 repeats in 
ATXN2 was found in 18 (4.04%) cases with PD and 5 
(1.4%) control subjects (OR=2.93, 95% CI 1.01-9.12, 
p=0.046). The intermediate expansion of 39-43 repeats 
in FMR1 was identified in 11 (16.2%) PD patients and 3 
(3.2%) healthy controls (OR= 5.9, 95% CI 1.44-28.05, 
p=0.004).
Conclusion: Our study clearly showed that the intermedia-
te expansions in ataxia genes ATXN2 and FMR1 are asso-
ciated with PD in Russian population.
This study was supported by the Russian Foundation for 
Basic Research (grant # 13-04-01718а).
Disclosure: Nothing to disclose
P2166
Hereditary spastic paraplegias -  
characterization of a family with a SPG11 
mutation
J. Afonso Ribeiro, L. Almendra, C. Januário
Centro Hospitalar e Universitário de Coimbra, Neurology, 
Coimbra, Portugal
Background and aims: Hereditary Spastic Paraplegias 
(HSP) are a group of clinical and genetical heterogeneous di-
seases, with an European prevalence estimated in 3-10/100 
000 inhabitants. Mutations in SPG11 (chromosome 15q) re-
present one of the most common causes of AR-HSP in Me-
diterranean countries and are associated with a thin corpus 
callosum (TCC), mental retardation and early age at onset.
Methods: Case Report
Results: We report a Portuguese family with two male indi-
viduals affected, from a kindred of four children, with no his-
tory of consanguinity. They developed mental retardation and 
progressive changes in locomotion in their first decade of life. 
At first clinical observation, cognitive disabilities and spastic 
paraparesis were observed. Nowadays, with 20 years of di-
sease evolution, they present a phenotype of complex HSP, 
characterized by severe mental impairment, eye movement 
limitation, anarthria, cervical and upper limbs hypotonia, and 
marked atrophy of thenar and hypothenar muscles. There are 
no clinical or electrophysiologic signs of peripheral neuropa-
thy. Recent cerebral MRI shows TCC and marked cerebral 
atrophy, particularly of the frontoparietal cortex. The molecu-
lar study of the affected patients revealed two heterozygous 
mutations c.6206-?_6343+?del and c.733_734del, being the 
first described for the first time. The mother presents one of 
the mutant alleles, and one of the non-affected siblings is a 
carrier of one other allele.
MRI showing marked atrophy of parietal cortex
MRI showing TCC
Atrophy of thenar muscles of hand
Conclusion: Several mutations are nowadays recognized 
as a cause of HSP with mutations in SPG11. This family 
highlights the high degree of disability of this disease and 
enforces the need for early recognition of the pathology.
Disclosure: Nothing to disclose
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A novel mutation in the HTRA1 gene in a 
Turkish family with CARASIL
C.E. Bekircan-Kurt1, C. Koşukçu2, A.T. Kurne3,  
M.A. Topçuoğlu3, S. Erdem-Özdamar3, R. Göçmen4,  
N. Akarsu2
1Ankara, Turkey, 2Hacettepe University, Medical Genetics, 
Ankara, Turkey, 3Hacettepe University, Neurology, Ankara, 
Turkey, 4Hacettepe University, Radiology, Ankara, Turkey
Background and aims: CADASIL and CARASIL are au-
tosomal dominant and recessive types of small vessel di-
seases with subcortical infarcts and leukoencephalopathy. 
Clinical presentations are similar in both however, migrai-
ne followed by strokes are prominent in CADASIL where-
as gait disturbances, lumbago and alopecia are characteris-
tics of CARASIL. CARASIL associated with homozygous 
mutations in HTRA1 is rare and only few families have 
been reported. Heterozygous NOTCH3 mutations cause 
CADASIL. Here, we report an additional HTRA1 associa-
ted Turkish family. 
Methods: Direct sequencing of HTRA1 and NOTCH3 ge-
nes were performed in a consanguineous family with three 
affected and four normal sibs. The index case was a 39-ye-
ar-old female with migraine, hemiparesis, ataxia, cogniti-
ve decline and alopecia. MRI showed infarction in right 
frontal lobe, cerebellum, pons and medulla. Six years later, 
she had hematoma in right mesencephalon, pons and ce-
rebellum. Her 42-year-old sister experienced migraine and 
dysarthria. MRI depicted white matter hyperintensity. She 
has now severe dysarthria and never experienced stroke. 
The other 55-year-old sister had difficulty in speaking, left 
hemiparesis, memory dysfunction and white matter hyper-
intensity with lobar microbleedings in MRI.
Results: HTRA1 mutation analysis identified a homozy-
gote mutation that causes the substitution of a conserved 
proline by leucine at amino acid position 275 (Pro275Leu)/
(c.824C>T).  Two normal sibs who have migraine, depres-
sion and disc degeneration and parents were heterozygous 
for this mutation.  NOTCH3 mutation analysis was normal. 
Conclusion: Here we report a novel missense mutation of 
HTRA1 gene in CARASIL. Intrafamilial clinical variation 
is evident. Migraine and disc degenerations could be con-
founding factors on the diagnosis.      
Disclosure: Nothing to disclose
P2168
Novel PANK2 mutation in the first Greek 
case with pantothenate-kinase-associated 
neurodegeneration presenting with  
adult-onset progressive focal dystonia
A. Bougea1, C. Yapijakis2, G. Paraskevas2, E. Stamboulis2,  
E. Kapaki2
1Athens, Greece, 2National and Kapodistrian University  of 
Athens. Athens, Greece, 1st Department of Neurology, Medi-
cal School, Athens, Greece
Background and aims: Pantothenate kinase-associated 
neurodegeneration (PKAN) is the most common autosomal 
recessive form of neurodegeneration with brain iron accu-
mulation (NBIA). Less than ten mutations in PANK2 gene 
(20p13) are responsible for classic and atypical cases. We 
report here the first Greek case of atypical PKAN, confir-
med by molecular analysis that revealed two trans-acting 
mutations.
Case Report: We present a 25-year-old Greek male with 
a 3-year history of focal orobucal dystonia and dysarthria, 
who was diagnosed with atypical PKAN according the 
NBIA criteria of Dooling and Swaiman.  His brain MRI 
scan revealed the characteristic “eye-of-the-tiger” sign, 
but cognitive and laboratory evaluation were normal. The-
re was no positive family history and the patient’s parents 
originate from different parts of Greece. In the patient’s 
blood DNA sample the seven exons of PANK2, including 
the exon/ intron boundaries, were sequenced. The detected 
mutations were verified by combination of PCR and rec-
triction enzyme analysis in the patient and were also inves-
tigated in blood DNA samples of the patient’s mother and 
of 100 healthy Greeks.
Results: The patient had two mutations in combined he-
terozygosity (1424T>C, c.1583T>C), in exons 5 and 6 
of PANK2, respectively. His mother was a carrier of one 
mutation only (c.1583T>C) previously reported in PKAN 
patients. Both mutations were absent in the database of sin-
gle nucleotide polymorphisms of 1,000 genomes, and were 
not observed by restriction digestion analysis in the DNA 
samples of 100 healthy controls.
Conclusion: Our findings highlight the possible role of rare 
variants contributing to disease risk and possibly to variab-
le clinical phenotype. 
Disclosure: Nothing to disclose
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Chromosome 22q11 duplication and a 
novel NF1 gene mutation in a patient with 
Neurofibromatosis type 1
G.J. Braathen, A.K. Eek, K.O. Clausen, K. Tveten,  
Ø.L. Holla, Ø.L. Busk
Telemark Hospital, Department of Laboratory Medicine, 
Section of Medical Genetics, Skien, Norway
Background and aims: Neurofibromatosis type I (NF1) is 
characterized by café au lait spots, fibromatous tumors of 
the skin and there is an increased susceptibility to tumor 
development. NF1 is an autosomal dominant disorder with 
an incidence of about 1 in 3,000.
During the last 15 years several families with the chromo-
some 22q11 duplication syndrome have been described. 
The phenotypic features are diverse with mental retarda-
tion, learning difficulties, speech impairment, ADHD, 
hypotonia and the most frequent dysmorphic features are 
hypertelorism, broad flat nose, micrognathia and dysplastic 
ears. However, the phenotype may vary from mild to severe 
ranging from no abnormality or mild learning disabilities 
to severe mental retardation with multiple congenital mal-
formations.
Case Report: A patient with several neurofibromas, 6-8 
cafè au lait spots and mental retardation was investigated.
Results: Chromosomal analysis was normal while Array 
comparative genomic hybridization (ACGH) revealed the 
chromosome 22q11 duplication. Targeted High-Through-
put Sequencing (HTS) for NF genes identified the novel 
heterozygous NF1 missense mutation.
Conclusion: To our knowledge, this is the first case ever re-
ported with the chromosome 22q11 duplication syndrome 
and NF1 combined.
To our knowledge, the NF1 mutation is novel.
Disclosure: Nothing to disclose
P2170
Social cognition impairment in SPG4  
spastic paraplegia.
L. Chamard, S. Ferreira, M. Silvestre, E. Berger, E. Magnin
CHRU Jean Minjoz, Besançon, France
Background and aims: Mutations and deletions in the 
SPAST gene are known to cause cognitive impairment. A 
subtle decline is usually reported. However, few studies 
have used extensive cognitive assessments to measure it. 
The aim of our study was to describe neuropsychological 
profile of SPG4 subjects.
Methods: 6 affected and 1 asymptomatic subjects (carri-
ers of an identified mutation in the SPAST gene) from two 
families were included (figure 1). Two are monozygotic 
twins. Mean age at examination was 52.8 (±9.5). No dif-
ficulty in daily living activity was reported.
Systematic neurological and extensive neuropsychological 
assessments including the mini-Social cognition and Emo-
tional Assessment were performed. The disability stage (fi-
gure 2) was systematically fulfilled. We count the number 
of different cognitive domains.
Figure 1: Pedigrees
Figure 2: Disability Stage
Results: The mean score of the Mini-Mental State Exa-
mination at 26.6 (±3.8) was normal. However, all subjects 
had executive disorders, 86 % had social cognition impair-
ment, 71% apraxia, 57% episodic memory impairment. 
No language disorder, mental retardation or dementia was 
found. For the first time, social cognition impairment was 
reported. Patients with more impaired cognition had hig-
her disability. These patients had a longer disease course. 
The monozygotic twins had different neuropsychological 
profile that might be explained by epigenetic phenomena.
Conclusion: This study suggests that all SPG4 subjects, in-
cluding those who are asymptomatic for spastic paraplegia, 
have cognitive impairment. Social cognition impairment, 
reported for the first time, may be frequent. Therefore, this 
function must be systematically assessed. A neurodegene-
rative process may be involved in SPG4 relative disorders 
depending upon the duration of the disease.
Disclosure: Nothing to disclose
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CHCHD10 gene mutations in Italian  
sporadic and familial ALS patients
A. Chiò1, A. Calvo2, M. Barberis2, M. Brunetti3,  
G. Restagno4, G. Mora5, M. Sabatelli6, S. Battistini7,  
F. Conforti8, C. Caponnetto9, J. Mandrioli10, P. Mandich9,  
M. Zollino6, G. Borghero11, M.R. Murru11,  
M.R. Monsurrò12, P. Volanti13, I. Simone14, G. Logroscino14, 
F. Salvi15, F. Logullo16, S. Penco17, C. Lunetta18, B. Traynor19
1Turin, Italy, 2Univ of Torino, Turin, Italy, 3Univ of Torino, 
Univ of Torino, Italy, 4AOU Città della Salute e della Scienza, 
Turin, Italy, 5Fondazione Maugeri Milano, Milan, Italy, 6Univ 
Cattolica di Roma, Rome, Italy, 7Univ. of Siena, Sienna, Italy, 
8CNR Mangone, Mangone, Italy, 9Univ. of Genua, Genoa, 
Italy, 10Univ. of Modena, Modena, Italy, 11Univ. of Cagliari, 
Cagliari, Italy, 12Univ. of Naples, Naples, Italy, 13Fond Mau-
geri Mistretta, Mistretta, Italy, 14Univ. of Bari, Bari, Italy, 
15Univ. of Bologna, Bologna, Italy, 16Univ. of Ancona, Ancona, 
Italy, 17Ospedale Niguarda, Milan, Italy, 18Centro Clinico 
NEMO, Milan, Italy, 19NIA, NIH, Bethesda, USA
Background and aims: Missense mutations of the 
CHCHD10 gene have been recently reported to be related 
to familial amyotrophic lateral sclerosis and frontotemporal 
dementia in a large family of Spanish origin. No data on 
ALS Italian population have been reported so far. Our aim 
was to assess the frequency of CHCHD10 gene mutation in 
a large series of fALS and sALS of Italian origin.
Methods: 64 unrelated fALS patients and 224 apparent-
ly sALS patients, negative for C9ORF72, SOD1, TADBP 
and FUS mutations were assessed. A total of 165 healthy 
controls were also assessed. The 4 coding exons and flan-
king intronic regions of CHCHD10 were amplified by PCR 
and analyzed by DHPLC . PCR products with heteroduplex 
profiles were sequenced on an ABI 3130 sequencer.
Results: Three cases (1 fALS and 2 apparently sALS) 
(1.0%) carried a c.100C>T (p.Pro34Ser) heterozygous va-
riant in the exon 2 of the CHCHD10 gene. This mutation 
was not detected in the control population. The mutation 
resulted to be pathogenetic according to in silico analy-
ses. Two other aminoacidic substitutions (p.Ala92Thr and 
p.Pro96Thr) were also found in apparently sporadic pati-
ents. Both these substitution are likely to represent benign 
polymorphisms. Clinically, the cases are classical ALS, wi-
thout cognitive involvement or cerebellar signs.
Conclusion: CHCHD10 missense mutations have been 
found in about 1% of Italian ALS patients. The same mu-
tation has been recently described in 2 apparently sporadic 
French ALS patients (Chaussenot et al, 2014). CHCDH10 
mutations seem to be concentrated in exon 2 and can cause 
ALS with a classic phenotype.
Disclosure: Ministero della Salute (grant RF-2010-
2309849), European Community’s Health Seventh 
Framework Programme (grant agreement 259867), Joint 
Programme - Neurodegenerative Disease Research (Ita-
lian Ministry of Education and University) (Sophia and 
Strength projects)
P2172
A novel TOR1A mutation in a Serbian  
patient with cervical dystonia
V. Dobricic1, N.D. Kresojevic1, M. Zarkovic2, A. Tomic1,  
M. Svetel1, I. Novakovic2, V.S. Kostic1
1Neurology Clinic, Clinical Center of Serbia, School of Me-
dicine, University of Belgrade, Belgrade, Serbia, Belgrade, 
Serbia, 2Faculty of Medicine, University of Belgrade, Belgra-
de, Serbia
Background and aims: In addition to the most frequent 
TOR1A/DYT1 mutation (c.904_906delGAG), there is a 
growing number of rare TOR1A sequence variants that is 
being found in patients with dystonia. For most of them 
functional characterization demonstrated TOR1A func-
tional changes on different levels, implying that genetic 
testing of dystonia patients should not be limited only to 
screening for c.904_906delGAG.
Methods: We screened a total number of 519 Serbian pa-
tients with dystonia (463 isolated, 56 combined) for the 
changes in the TOR1A gene by direct DNA sequencing. 
Additionally, 110 neurologically healthy individuals were 
tested as control group.
Results: One novel likely pathogenic TOR1A substituti-
on (c.385G>A, p.V129I) was detected in a sporadic cer-
vical dystonia patient. Another four novel variants, two 
coding synonymous substitutions (c.795T>C, p.(Y265=); 
c.984T>C, p.(Y328=)) and two noncoding substitutions 
(c.-59T>C; c.-4G>C), were detected in a single patient 
each.
Conclusion: Our data expand the genotypic spectrum of 
TOR1A and highlight the importance of the whole TOR1A 
coding sequence analysis in establishing the molecular dia-
gnosis for patients with dystonia.
Disclosure: Nothing to disclose
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Anti-neurofilament antibodies and neu-
rofilament phosphoforms in two cases of 
anti-NMDAr encephalitis
P. Annunziata, C. Cioni, G. Masi
University of Siena, Medicine, Surgery and Neurosciences, 
Sienna, Italy
Background and aims: Anti-NMDAr encephalitis is an 
autoimmune neurological disorder involving the NMDA 
receptor. To test whether autoimmunity directed to other 
neural components is associated with anti-NMDAr antibo-
dies, anti-neurofilament (NFL) antibodies and NFL were 
measured in two cases of anti-NMDAr encephalitis.
Methods: Anti-heavy and light NFL IgG and heavy NFL 
phosphoforms were measured by ELISA in serum and ce-
rebrospinal fluid (CSF) from two women affected by anti-
NMDAr encephalitis, one associated with ovarian teratoma 
and one other with HSV-1 infection. Serum and CSF samp-
les were longitudinally collected during the disease course 
and clinical outcome was assessed with the modified Ran-
kin scale. As control groups, serum and CSF samples from 
6 subjects with clinically isolated syndrome, 5 with other 
viral encephalitis and 5 with dementias were included.
Results: Significantly higher serum and CSF levels of anti-
heavy and light NFL IgG as well as phosphorylated NFL 
were found as compared with control groups (P<0.001). A 
statistical trend towards a correlation of serum anti-heavy 
NFL IgG with the clinical outcome was found (r=0.79; 
p=0.058). Moreover, there was a very significant correla-
tion of serum anti-heavy NFL IgG with serum phospho-
rylated (r=0.96; p=0.0027) and hypophosphorylated NFL 
(r=0.93; p=0.007).
Conclusion: These findings demonstrate that, in these two 
cases of anti-NMDAr encephalitis, autoimmunity directed 
against heavy NFL correlating with clinical course occur-
red, raising the hypothesis that these antibodies may play 
a role in the disease pathogenesis in association with anti-
NMDAr autoimmunity.
Disclosure: Nothing to disclose
P2175
Extrapyramidal signs in patients with  
neurosarcoidosis
T. Drori1, O. S. Cohen2, G. Givaty1, A. Eldar-Hersalis1,  
M. Lidar3, P. Langevitz3, Y. Shoenfled4, A. Achiron5,  
J. Chapman1
1Department of Neurology, Sheba medical center, Tel Has-
homer, Israel, 2Parkinson’s disease amd movement disorders 
clnic, Tel Hashomer, Israel, 3- Rheumatology Unit. Sheba 
Medical Center, Tel Hashomer, Israel, 4Zabludowicz center for 
Autoimmune diseases, Tel Hashomer, Israel, 5Center of Multi-
ple Sclerosis, Sheba Medical Center, Tel-HaShomer, Israel
Background and aims: Sarcoidosis is a systemic autoim-
mune disease associated with a variety of neurological ma-
nifestations. 
Objectives: To systematically assess the frequency of ext-
rapyramidal signs (EPS) in patients with neurosarcoidosis 
(NS) and compare them to the prevalence in patients with 
multiple sclerosis (MS), as representative of an autoimmu-
ne disease mainly affecting the white matter.
Methods: A neurological exam was performed on patients 
diagnosed with MS or NS, with a special emphasis on extra-
pyramidal signs such as bradykinesia, rigidity, resting tremor 
and postural instability.
Results: 22 patients with NS and 22 patients with MS mat-
ched for age and gender were surveyed. Signs were gra-
ded according to severity, ranging from 0 to 3: 0- normal, 
1- Abnormal signs without functional disability, 2- Abnor-
mal signs with mild functional disability, 3- Major func-
tional disability. Brain MRI was assessed for focal lesions. 
In three out of 22 patients with NS we identified severe 
parkinsonism, fulfilling the criteria of Parkinson’s disease 
according to the “UK Brain Bank” criteria. None of the 
patients had lesions affecting basal ganglia or brain stem 
on MRI. Two patients were classified as having mild signs, 
and nine had abnormal signs on exam without functional 
disability. In the MS group, three patients had abnormal 
signs only, and the rest had no EPS (p=0.0011).
Conclusion: This is the the largest cohort of NS patients 
systematically assessed for EPS. In comparison to MS, we 
find a statistically significant increased frequency of extra-
pyramidal signs in NS. This finding raises the question of 
the relation between NS and Parkinson’s disease.
Disclosure: Nothing to disclose
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Treatment efficiency of immunoglobulins 
and therapeutic plasma exchange in 
neurology
M. Fernandez-Fournier, A. Tallon, C. Calle De Miguel,  
J. Rodríguez-Pardo, I. Puertas Muñoz,  
F.J. Rodríguez de Rivera, E. Diez Tejedor
Hospital Universitario La Paz, Neurology, Madrid, Spain
Background and aims: Intravenous immunoglobulins 
(IVIG) and Therapeutic Plasma Exchange (TPE) are ef-
fective treatments for certain neuroimmunological disea-
ses. Both are costly treatments administered in a hospital 
setting. According to current medical literature there are 
different degrees of evidence for each of these treatments 
depending on the disease. We aimed to determine the most 
efficient treatment option for neurological diseases.    
Methods: 1. Clinical guideline revision to determine equi-
valent indications for IVIG and TPE in Neurlogy. 2. Cost 
studies to determine the cost of a standard session of IVIG 
and TPE, and the cost of hospital stay in a Neurology De-
partment of a Spanish tertiary University Hospital. 3. Re-
trospective cost-benefit study of the use of IVIG and TPE 
between January 2008 and March 2014. 
Results: IVIG and TPE use is equivalent in acute Myas-
thenia Gravis (aMG) and Guillain-Barré Syndrome (GBS). 
The cost of a treatment session of IVIG was 5,023.90€ and 
of 2,465.06€ for TPE. In the study period, 48 patients were 
hospitalized for aMG, 17 were treated with IVIG and 4 
with TPE; and 39 patients were hospitalized for GBS, 28 
were treated with IVIG and 41with TPE. Hospital stay was 
9.5 days (±4.8) for aMG patients treated with en IVIG and 
12.0 days (±6.9) for those treated with TPE, p>0.05. 
Conclusion: For an equivalent indication, treatment with 
TPE entails a lower cost per process and is thus the most 
efficient treatment alternative. 
Disclosure: Nothing to disclose
P2177
Immunohistochemical screening for  
auto-antibodies in recent onset type 1  
narcolepsy and after H1N1 vaccination
A. van der Heide1, I.M. Hegeman-Kleinn1, E. Peeters2,  
G.J. Lammers1, R. Fronczek1
1Leiden University Medical Centre, Neurology, Leiden, The 
Netherlands, 2MCH Westeinde, Neurology, Den Haag, The 
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Background and aims: As a result of a selective loss of the 
hypocretin containing neurons in the hypothalamus, nar-
colepsy with cataplexy patients typically have undetectable 
hypocretin-1 levels in the CSF. Based on the tight HLA-
DQB1*06:02 association, an autoimmune attack targeting 
hypothalamic hypocretin (orexin) neurons is hypothesised. 
So far, no direct evidence for an autoimmune attack was 
found. One of the major limitations of previous studies was 
that none included patients close to disease onset. 
Methods: We screened serum of 21 narcolepsy type 1 pa-
tients (13 male, 8 female) close to disease onset (median 
duration of symptoms 11 months; range 2-48 months) for 
antibodies against hypocretin neurons using immunohisto-
chemistry. In 17 patients hypocretin-1 was measured, all 
were hypocretin-1 deficient. 20 patients were HLA-typed 
and were positive for DQB1*06:02. Six patients were 
vaccinated against H1N1 before onset of narcoleptic sym-
ptoms. Positive controls were a patient and a control sub-
ject that have autoantibodies against hypocretin neurons; 
described in our previous study. 
Results: No autoantibodies against hypocretin neurons 
could be detected, including the patients that were vacci-
nated against H1N1. The two positive controls were still 
positive.
Conclusion: No evidence was found for autoantibodies in 
serum of narcolepsy patients close to disease onset inclu-
ding patients vaccinated for H1N1. This finding not neces-
sarily contradicts the autoimmune hypothesis, nor does it 
implicate an absence of autoantibodies at any time in the 
development of the disease. For future studies, it could be 
of interest to screen CSF of patients as close as possible to 
disease onset for autoantibodies, or focus more on T-cell 
immunology.
Disclosure: Nothing to disclose
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The cytokine profile in CSF differentiates 
multifocal motor neuropathy from  
progressive muscular atrophy
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F. Shimizu3, K. Miyamoto4, Y. Takahashi5, T. Kanda6,  
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1Institute of Health Biosciences, Tokushima University, Toku-
shima, Japan, 2Insitute of Health Bioscience, Tokushima Uni-
versity, Tokushima, Japan, 3Yamaguchi University Graduate 
School of Medicine, Ube, Japan, 4Kinki University School of 
Medicine, Osaka, Japan, 5National Epilepsy Centor, Shizuoka 
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Japan, 6Yamaguchi University Graduate School of medicine, 
Ube, Japan, 7Institute of Health Bioscience, Tokushima Uni-
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Background and aims: Multifocal motor neuropathy 
(MMN) can occasionally mimic motor neuron disease, es-
pecially the lower motor neuron variant progressive muscu-
lar atrophy (PMA). We examined the cytokine and chemo-
kine profiles of MMN in comparison with those with PMA 
and amyotrophic lateral sclerosis (ALS) to investigate the 
immunological differences in the CNS.    
Methods: The CSF from 12 patients with MMN, 8 with 
PMA, 26 with sporadic ALS, and 10 with other non-in-
flammatory neurological disorders were analyzed for 27 
cytokines and chemokines using multiplex bead array. The 
cytokine titers of the four groups were compared, and the 
correlations between the titers of relevant cytokines and cli-
nical parameters were evaluated.    
Results: There were no obvious intrathecal changes in 
MMN except for IL-1ra. In contrast, the titers of IL-7, IL-
17, eotaxin/CCL11, FGF-2, G-CSF, and PDGF-BB were 
significantly elevated in both PMA and ALS. In ALS, IL-4 
and Eotaxin/CCL11 titers were higher in the patients with 
slowly progressive course, and IL-10 titers were higher in 
those with milder stage of the disease.
Conclusion: The CSF cytokine profile of MMN is distinct 
from those of PMA and ALS. On the other hand, the simi-
larity of cytokine profiles in PMA and ALS suggests that 
PMA, even without clinical evidence of upper motor neu-
ron involvement, shares common immunological features 
with ALS in the CNS.    
Disclosure: Supported by JSPS KAKENHI Grant-in-Aid 
for Young Scientists (B) 25870477; Grants-in-Aid from the 
Neuroimmunological Disease Research Committee and the 
Research Committee of CNS Degenerative Diseases, the 
Ministry of Health, Labor and Welfare of Japan.
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A study of Guillain Barré syndrome in Mal-
ta
J. Gauci1, M. Mifsud2, M. Vella2, M. Mallia2
1L-Msida MSD, Malta, 2Department of Neurology, Msida, 
Malta
Background and aims: Since the near global eradication 
of poliomyelitis, Guillain-Barré syndrome (GBS) has be-
come the commonest cause of acute neuromuscular para-
lysis.   Despite available treatment, GBS still results in a 
significant amount of morbidity and mortality.
Our aim was to conduct a retrospective analysis of the epi-
demiology and management of GBS in Malta.
Methods: All cases of GBS presenting between 2002 and 
2012 were identified through the Hospital Activity Analysis 
Register in Malta’s only public tertiary hospital (St. Luke’s 
/ Mater Dei Hospital). 
Results: A total of 53 patients were identified and studied. 
The incidence of GBS ranged from 0.25 to 3.58 per 100,000 
per year. The peak incidence was in spring and autumn 
months. Contrary to available European data, 74% of nerve 
conduction studies were of axonal subtype, while only 15% 
were of demyelinating subtype. Typical albuminocytologi-
cal dissociation in the cerebrospinal fluid was present in 
62%. Lung function tests were performed in only 4%.  87% 
of patients were treated with intravenous immunoglobulins, 
while 9% also received plasma exchange. 28% of patients 
required ITU/HDU admission. Autonomic involvement 
and neuropathic pain were observed in 26% and 36% res-
pectively. 74% of patients were discharged within 20 days; 
17% of these were transferred to a rehabilitation hospital. 
We report a mortality rate of 0%.
Conclusion: This is the first national study on GBS.  Most 
of our data is in concordance with international data, save 
for the predominance of the axonal subtype. This suggests 
the possibility of a specific aetiological agent with resultant 
cross-reactive antibody production and axonal damage.
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Depletion of CD11c positive dendritic cells 
is protective in a murine model of ische-
mic stroke
M. Gelderblom1, P. Ludewig1, P. Arunachalam1, A. Planas2, 
T. Magnus3
1University Hospital Hamburg-Eppendorf, Neurology, Ham-
burg, Germany, 2IDIBAPS, Barcelona, Spain, 3University 
Hospital Hamburg-Eppendorf, Hamburg, Germany
Background and aims: The devastating effect of ischemic 
stroke is attenuated in mice lacking conventional and un-
conventional T-cells, suggesting that inflammation enhan-
ces tissue damage in cerebral ischemia. Our goal was to 
explore the functional contribution of CD11c positive den-
dritic cells to the tissue damage following stroke    
Methods: In accordance with current quality guidelines, 
we characterized dendritic cells in a murine ischemic stro-
ke model. Depletion of CD11c positive dendritic cells was 
achieved in a transgenic mouse model in which the diphthe-
ria toxin receptor is expressed under the CD11c promoter 
(CD11c.DTR).
Results: Depletion of dendritic cells in the CD11c.DTR 
resulted in significantly decreased infarct size. Mechanisti-
cally, depletion of CD11c positive dendritic cells was asso-
ciated with an reduction of IL-17 in γδ T-cells. 
Conclusion: We propose that dendritic cells contribute to 
the postischemic tissue damage by induction of detrimental 
IL-17 in atypical T-cells. 
Disclosure: Dr. Gelderblom has received consulting fees 
from Merz pharmaceuticals and Allergan.
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CX3CR1 signalling important in maintai-
ning an immune barrier following S. aure-




Background and aims: Infection of the central nervous 
system causing encephalitis and meningitis via the olfacto-
ry pathway is relatively infrequent, suggesting the presence 
of effective endogenous innate defence mechanisms. This 
study investigates signaling between the neuroprotective 
chemokine CX3CL1 and its receptor CX3CR1 and regula-
tion of both nitric oxide production and cytokine expression 
levels in response to bacteria in the compromised olfactory 
pathway.
Methods: The olfactory epithelium of wild type C57/
BL6 and CX3CR1GFP/GFP mice was compromised using 
1% TritonX-100 solution. Fluorescently labeled S. aureus 
were introduced into the nasal cavity and the expression 
of inducible nitric oxide synthase (iNOS) and GFP or Iba1 
examined by immunofluorescence. Cytokine profiles and 
bacterial clearance were determined.
Results: CX3CR1 deficiency allowed increased numbers 
of bacteria to infiltrate the olfactory bulb. In CX3CR1 GFP/
GFP mice numbers of iNOS-expressing cells were signifi-
cantly reduced compared to WT mice. Macrophages were 
depleted by 50% in bacteria treated CX3CR1 GFP/GFP 
mice but were increased in WT mice.  Following S. aureus 
exposure in WT mice expression of  tumour necrosis factor-
alpha and interleukin-6 increased within 48h and interleu-
kin-10 and interleukin-1beta decreased.  In contrast there 
were no changes in the cytokine profile of CX3CR1GFP/
GFP mice.
Conclusion: The immune barrier was impaired in the CX-
3CR1GFP/GFP mice as shown by marked infiltration of S. 
aureus into the granule layer of the OB, reduced numbers of 
microglia and lack of cytokine and iNOS induction. Thus, 
CX3CR1/CX3CL1 signaling plays a key role in the innate 
immune response in the olfactory pathway.
Disclosure: Nothing to disclose
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Neurological manifestations of  
systemic disease 1
P2182
A case of Cerebrotendinous Xanthomato-
sis with two new heterozygous variants of 
the CYP27A1 gene
R. Araújo1, P. Correia1, A. Ribeiro2
1Centro Hospitalar e Universitário de Coimbra, Neurology, 
Coimbra, Portugal, 2Hospital Garcia da Orta, Neurologia, 
Lisbon, Portugal
Background and aims: Cerebrotendinous xanthomatosis 
(CTX) is a rare metabolic disorder caused by a defective 
mitochondrial enzyme affecting bile acid synthesis and 
cholestanol production. Its clinical manifestations include 
cataracts, tendinous xanthomathosis and progressive neu-
rological impairment. Diagnosis can be made biochemi-
cally (elevated serum cholestanol levels) and genetically 
(molecular defects in the sterol 27-hydroxylase gene). Ear-
ly diagnosis is mandatory due to the availability of disease-
modifying therapy that can halt disease progression.   
Case Report: A 48-year-old male presents with progressi-
ve gait impairment and falls.  His medical history included 
juvenile cataracts and a mild mental development delay. He 
had an elder brother that experienced sudden death at the 
age of 44 who “looked and walked the same”; his father 
died at age 61 of stroke, and his mother had an aterothrom-
botic stroke at the age of 65. On examination he displayed 
tendon xanthomata, bilateral limb ataxia, spastic parapare-
sis, mild cerebellar gait ataxia and reduced left arm swing 
with bradykinesia on motor tasks. 
Tendon xanthomata
Cerebral MRI findings; Heel X-Ray
Results: His MRI showed diffuse symmetrical white mat-
ter periventricular and cerebellar lesions with cortical atro-
phy. His blood cholestanol levels were high (60.6mmol/L). 
A heterozygous c.1016C>T mutation of the CYP27A1 
gene was detected as well as two new previously undescri-
bed heterozygous variants - C.545T>C (p.lle182Thr) and 
c.563G>C (p.Arg188Pro). Bioinformatic analysis indica-
tes that the latter likely bears pathogenicity. The diagnosis 
of CTX was made and he was started on atorvastatine and 
chenodeoxycholic acid.
Conclusion: We report a rare metabolic disease with a new 
compound heterozygous gene mutation. Prompt diagnosis 
is mandatory since treatment is available.
Disclosure: Nothing to disclose
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Neurological manifestations of Behçet’s 
disease: 161 cases in one Moroccan center
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Background and aims: Behçet’s disease (BD) is a chronic 
multisystemic inflammatory disease, predominant within 
the Mediterranean countries and characterized by oral, ge-
nital mucous ulcers and uveitis. Neurological involvement 
is one of the most serious complications of BD and repre-
sents a major cause of morbidity.
Methods: 161 Moroccan cases of neurobehçet disease 
(NBD) have been categorized into two main groups: “par-
enchymal” CNS involvement, which includes hemispheric, 
brain-stem, spinal, and multifocal presentations; and “non 
parenchymal” CNS involvement, which includes dural si-
nus thrombosis and arterial involvement.
Results: Parenchymal CNS pattern was observed in 74% 
of our cases with a predominance of symptoms related to 
brainstem involvement (30%) such ophthalmoparesis, bul-
bar and pseudobulbar palsy. Other symptoms have been 
present with varying frequencies: cerebellar signs (52%), 
headache (52%), psychiatric and cognitive symptoms 
(34%), sphincter disturbances (22%), epilepsy (9%). Some 
features are less common such as optic neuropathy (2%) 
or peripheral neuropathy (1%). Non-parenchymal form 
was noted in 26% of our series essentially represented by 
cerebral venous thrombosis (CVT). Only 4 of cases have 
cerebral arterial involvement, three with intracranial aneu-
rysm. All patients have cerebral imaging. Magnetic reso-
nance imaging showed a caracteristic lesion in one third of 
our patients, located at the mesodiencephalic junction and 
the pontobulbar region. Treatment was based on corticos-
teroids in the two categories. Long-term maintenance with 
immunosuppressive agents was administrated in patients 
with parenchymal CNS involvement and anticoagulants in 
case of CVT.
Conclusion: Neurological involvement represents a ma-
jor complication of BD which requires early diagnosis and 
long term management.
Disclosure: Nothing to disclose
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Anderson-Fabry disease and risk of  
misdiagnosis: an Italian family with late 
onset neurological manifestations.
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F. Crusco3, G. Savarese4, M. Zampolini5
1USL Umbria 2, Neurorahabilitation, Foligno, Italy, 2USL 
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Radiology, Foligno, Italy, 4USL Umbria 2, Cardiology, Folig-
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Background and aims: We describe two patients with iso-
lated neurological manifestation from an Italian family la-
ter diagnosed with Anderson-Fabry disease. Clinical exa-
mination, neuroimaging (MRI), biochemical and genetic 
analyses were carried out in all the patients.
Case Report: Case 1: A male patient of 49 years with histo-
ry of TIAs presented an ischemic vertebrobasilar stroke, re-
tinopathy and cardiomiopathy A contrats enhanced MR car-
diac imaging showed Left Ventricular Hypertrophy with 
patchy mid-wall abnormalities. Case 2: A female cousin, 
had diagnosis of probable primary progressive multiple sc-
lerosis twenty years before at the age of 30, and treated with 
periodical steroideal infusions. Both had absence of alpha-
galactosidase A activity detected by fluorimetric assay and 
genetic analysis by DNA sequencing demonstrated on exon 
7 a mutation gor gene GLA c 1025G>A (p.R342Q).
Results: In both cases enzyme replacement therapy was 
recommended. MRI was abnormal in all the patients and 
showed lacunar infarctions in the periventricular white 
matter. In patients with Anderson-Fabry disease, stroke-
like manifestations are frequent complications, and may be 
the first threatening clinical manifestation. 
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brain MRI FLAIR sequences with bilateral brain stem infarctions
CE cardiac MRI showing infero lateral enhancement
Conclusion: In young people with undefined stroke or 
neurological stroke-like conditions, even without signs of 
renal involvement, it is important to consider the diagnosis 
of Anderson-Fabry disease and so to perform clinical exa-
mination and biochemical analysis to avoid misdiagnosis.
Disclosure: Nothing to disclose
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The correlation between the neurological 
complications of rheumatoid arthritis with 
the disease activity and functional  
impairment (disability)
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M.I. Alfaki1, M. Alfaki3, R.A. Alsherif1, A.M. Hussein4
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Background and aims: To identify the impact and predic-
tors of the neurological complications of rheumatoid arth-
ritis (RA).
Methods: A case series study of 58 consecutive patients 
diagnosed as RA at Omdurman university hospital rheu-
matology clinic was done. Patients have another possible 
etiology for the neurological manifestations were excluded. 
The doctors of rheumatology clinic examined the patients 
and the Clinical Disease Activity Index (CDAI) was calcu-
lated. A senior consultant neurologist objectively assessed 
the neurological complications of RA. The patients were 
interviewed using the Health Assessment Questionnaire 
(HAQ) to evaluate the functional impairment. The rheu-
matoid factor status and the most recent ESR value were 
documented.
Results: 60.3% have neurological signs (pyramidal system 
signs 43.1%, extrapyramidal/cerebellar 0%, proximal wea-
kness 8.6%, sensorimotor neuropathy 5.2%, pure sensory 
neuropathy 1.7%). The mean HAQ scores for patients who 
have neurological signs and those who do not 1.34 and 1.40 
respectively without significant difference (P=0.778). The 
association between the neurological complications and di-
sease activity, ESR value, and rheumatoid factor status is 
not significant (P=0.701, 0.515, 0.299 respectively). There 
is not only a strong association between the disease activity 
(CDAI) of RA and functional status (HAQ) of the patient 
(P=0.0, R=0.56), but also 30% of variability of the functio-
nal impairment can be attributed exclusively to the variabi-
lity of the disease activity (R2=0.3).
Conclusion: The RA activity is the major determinant of 
disease morbidity. The functional impairment caused by the 
neurological complications of RA is negligible. The disease 
activity, ESR value, and rheumatoid factor status are poor 
predictors of the neurologic complications.
Disclosure: Nothing to disclose
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Clinico-radiological characteristics of  
primary and secondary neurological  
manifestations in a large cohort of HHT 
patients
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Background and aims: Hereditary hemorrhagic telan-
giectasie (HHT) is an autosomal dominant genetic disease 
with vascular malformations, including pulmonary arteri-
ovenous malformations (PAVMs), cerebral vascular mal-
formations (CVMs). Main neurological complications are 
cerebral abscess and cerebral ischemic events (secondary 
neurological complications) and cerebral hemorrhages se-
condary to CVMs (primary neurological manifestations). 
Objective: To precisely describe primary and secondary 
neurological manifestations in a large cohort of consecu-
tive patients with HHT and to evaluate gentype-phenotype 
correlations.
Methods: We performed a retrospective study of consecu-
tive patients from 2 French HHT specialized centers. Inclu-
sion criteria were: 1) a clinically definite diagnosis (Cura-
cao criteria) and/or a genetically established diagnosis of 
HHT, and 2) a cerebral MRI and/or CT scan and with a 
MR and/or CT angiography. In these patients, we identified 
“neurological patients” if a neurological manifestation was 
reported and/or if a parenchymal and/or vascular lesion was 
reported on radiological explorations.
Results: 337 patients were included. 225 neurological 
patients were identified. The estimed prevalence of neu-
rological complications is 10.1%. Primary neurological 
complications were reported in 113 patients (57% with 
Endogline mutation). Cerebral Arterio-veinous malforma-
tions (MAVc) were the most frequent of CVMs (26%). 
14 patients patients had a symptomatic haemorrhage. Se-
condary neurological complications were present in 124 
patients (35 with abscess and 100 with ischemic events), 
73% with Endogline mutation. 86% of patient had PAMVs, 
frequently multiple and with an afferent artery diameter 
>3mm. The clinical prognosis was very good.
Conclusion: Neurological complications were not rare in 
HHT patients. Ischemic events were the most frequent et 
were associated with PAMVs. CMVs were predominantly 
silent.
Disclosure: Nothing to disclose
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Severe cerebral involvement due to idiopa-
thic systemic capillary leak syndrome
A.R. Günes, R. Weber, M. Krämer, P. Berlit
Alfried Krupp Krankenhaus, Department of Neurology, Essen, 
Germany
Background and aims: The idiopathic systemic capillary 
leak syndrome (SCLS) is a rare and life-threatening disor-
der, characterized by recurrent attacks of hypotension, hyp-
albuminemia and hemoconcentration. Cerebral involve-
ment has been described in exceptional cases only.
Case Report: A 43-year-old woman presented with nau-
sea, vomiting, confusion and expressive aphasia following 
gastrointestinal complaints of 2 days duration. Laborato-
ry findings indicated hypoalbuminemia in the absence of 
albuminuria, hemoconcentration and a known monoclonal 
gammopathy. Serum electrolytes were normal. Lumbar 
puncture revealed normal CSF findings without cells, au-
toimmune antibodies or oligoclonal banding. The patient’s 
clinical condition worsened with the development of gene-
ralized edemas and coma. The initial MRI showed contrast 
enhancement of the right temporal lobe (Figure 1) and the 
posterior part of the corpus callosum. Within 1 week after 
symptom onset MRI demonstrated symmetrical T2-lesions 
and diffusion restriction in the brainstem (Fig. 2), cerebel-
lum, hippocampi, thalami and posterior part of the corpus 
callosum, respectively. We administered high-dose intrave-
nous immunoglobulin (IVIG) and were able to extubate the 
awake patient. The patient’s right hemiparesis and aphasia 
improved constantly and MRI findings were regressive 
(Fig. 3). With an IVIG prophylaxis every 4 weeks no more 
attacks occurred during follow up.
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Conclusion: To our knowledge, this is the first case report 
describing massive bilateral cerebral involvement of SCLS. 
IVIG is a rational therapeutic option during the acute phase 
as well as for prophylaxis.
Disclosure: Nothing to disclose
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Stroke induced by internal carotid artery 
dissection in a young patient with unk-
nown cystathionine beta-synthase (CBS) 
deficiency
A. Lopez, N. Giraldo, J.J. Bravo, A. Parralo, C. Valencia,  
J.P. Cabello, A. Hernandez
Ciudad Real, Spain
Background and aims: Homocysteine is a sulfur-contai-
ning amino acid generated during methionine metabolism. 
It’s known that hyperhomocysteinemia exerts toxic effects 
on endothelium and blood coagulation system. The most 
commonly involved enzyme in this process is CBS, which 
controls the transsulfuration of homocysteine to cystathio-
ne, and depends on vitamin B6 as a cofactor.
Commonly diagnosed during childhood, hyperhomocy-
steinemia is rarely uncovered in adults. We report a patient 
who presented a stroke due to an internal carotid occlusion. 
Etiological workup found CBS deficiency.
Case Report: A 35-year-old woman was admitted with 
right hemiparesis and mixed aphasia. Her only vascular risk 
factor was estroprogestative pill intake. Family medical 
history was unrevealing. Cranial Computed Tomography 
(CT) and Axial CT angiography confirmed a left internal 
carotid artery dissection, and ischemic stroke on the corre-
sponding territory. (Img. 1 and 2)
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Image1. Cranial TC.
Image2. Axial TC angyography.
Results: She was initially treated with aspirin, which 
was changed to acenocumarol after the acute stroke pha-
se. Blood sampling found major hyperhomocysteinemia, 
with total plasma homocysteine >200µmol/l (normal 
<15µmol/l). Urinary amino acids chromatography confir-
med high homocysteinuria and elevated methionin, compa-
tible with CBS deficiency. Plasmatic folate, vitamin B 12, 
and cardiac studies were normal.
Vitamin supplementation and acenocumarol were maintai-
ned at the discharge. During subsequent weeks the condi-
tion steadily improved.
Conclusion: Plasma homocysteine has been investigated 
as an independent risk factor for ischaemic stroke. There 
is a recent suggestion that hyperhomocisteynemia may be 
associated with spontaneous cervical artery dissection. We 
aim to emphasize the importance of plasmatic homocistein 
study in both stroke and carotid disection, specially among 
young patients.
Disclosure: Nothing to disclose
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Predicting poor functional outcome after 
acute ischemic supratentorial stroke using 
clinical parameters and parameters of 
quantitative electroencephalography
A. Kuznietsov, O. Kozyolkin
Zaporizhzhya State Medical University, Neurology, Zaporiz-
hzhya, Ukraine
Background and aims: Elaboration of statistical models 
to predict functional recovery after acute ischemic supra-
tentorial stroke (AISS) is a very important and relevant in 
modern angioneurology that can help the practicioners to 
improve treatment approaches. We therefore developed 
new model using clinical parameters and parameters of 
quantitative electroencephalography (QEEG).
Methods: 107 patients (mean age 67.9±0.8 years) were stu-
died within first 72 hours after clinical onset of AISS. Cli-
nical examination included evaluation by National Institute 
of Health Stroke Scale (NIHSS). Clinical and social out-
come was defined by modified Rankin Scale (mRS) on 21st 
day from AISS onset. Poor functional outcome (PFO) was 
clarified in case of 4-5 score by mRS on 21th day. Separa-
tely to affected and intact hemisphere (IH) the values of ab-
solute and relative spectrum rhythm power (RSRP), fronto-
occipital gradients (FOG) of δ-, θ-, α-, β-ranges, θlo-, θhi-, 
αlo-, αhi-, βlo-, βhi-subranges were detected. Development 
of prognostic model was made by logistic regression and 
ROC-analysis.
Results: Out of 107 stroke patients, 48 (44.9%) had PFO. 
Near 60 models were obtained. The model with the largest 
area under the curve=0.999 was: β=3,195*(NIHSS score on 
the 3rd day)+0.228*(RSRP of δ-range in IH)–0.29*(RSRP 
of θlo-subrange in IH)-19.989*(FOG of θlo-subrange in 
IH)-34.879. Significance level of Hosmer-Lemeshow-test 
for selected model p=0.989, Percent Concordant=99.9. Op-
timal cut-off value of β, which predicted PFO with sensiti-
vity=97.9% and specificity=98.3%, was determined. 
Conclusion: Developed prognostic model might be a pow-
erful tool for predicting PFO of AISS and improving effec-
tiveness of treatment.
Disclosure: Nothing to disclose
P2202
Clinical and radiological implication of 
incidental cerebral aneurysm in patients 
with cerebral infarction
S.-B. Kwon1, C.-Y. Lee1, S.-S. Hong2, Y.-K. Minn1, S. Jung1, 
S.-H. Hwang1
1Hallym University College of Medicine, Neurology, Seoul, 
Korea, Republic of, 2SoonChunHyang University Hospital, 
Radiology, Seoul, Korea, Republic of
Background and aims: Asymptomatic intracranial aneu-
rysms are frequently encountered among patients visiting 
neurology clinic. Since not every patient but those with 
cerebral infarction undergo MRI, a group of infarcted pa-
tient serves useful representative for incidental unruptured 
intracranial aneurysms (UIAs). Since rupture of asympto-
matic aneurysm brings catastrophic consequences, stratifi-
cation of patients according to the possibility of harboring 
UIA is important. The aim of this study is to analyze the 
clinical and radiological characteristics of patients diag-
nosed with UIA in order to wisely select patients who need 
imaging work up for aneurysm more strongly than others.
Methods: Consecutive adult (≥18 years old) patients diag-
nosed with cerebral infarction admitted to our clinic during 
a 17-month period from Jan 2013 through Jun 2014 were 
included. Based on MR angiography, we divided and ana-
lyzed patients into those with and without UIAs.
Results: Of 321 patients, there were significant differen-
ces in female sex (P=0.004), presence of concurrent cere-
bral stenosis (P=0.036) between groups with (20; 6.2%) 
and without (301; 93.8%) UIAs. Factors associated with 
aneurysm in cerebral infarction patients according to logi-
stic regression analysis were female gender (OR 4.37, 95% 
CI 1.537 – 12.394, P=0.006), and cerebral arterial stenosis 
(OR 2.87, 95% CI 1.004 – 8.18, P=0.049).
Conclusion: Incidental unruptured intracranial aneurysms 
found in acute cerebral infarction patients show sever-
al peculiar characteristics or tendencies including female 
predominance and cerebral stenosis. When treating fema-
le patients diagnosed with cerebral arterial stenosis, more 
cautions need to be paid to look for coexisting intracranial 
aneurysm.
Disclosure: Nothing to disclose
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High on-treatment platelet reactivity to 
acetylsalicylic acid used in the secondary 
prevention of stroke and its risk factors
B. Labuz-Roszak, K. Pierzchala
Medical University of Silesia in Katowice, Chair and Clinical 
Department of Neurology in Zabrze , Zabrze, Poland
Background and aims: The aim of the study was to eva-
luate the prevalence of high on-treatment platelet reactivity 
(HOPR) to acetylsalicylic acid (ASA), used for secondary 
prevention of stroke, and the assessment of risk factors as-
sociated with HOPR.
Materials and Methods: 215 patients after ischaemic stro-
ke taking ASA at the dose of 75-150 mg and 46 healthy 
volunteers were enrolled in the study. Platelet function was 
assessed by impedance aggregometry method in the who-
le blood using a multi-channel platelet function analyzer 
(Multiplate®, Dynabyte).
Results: HOPR (defined as AUC≥300 for arachidonic acid 
as agonist) was present in 85 (39.5%) of examined pati-
ents. The following risk factors for HOPR were determi-
ned: ASA dose ≤100mg/daily, heart rate > 70 beats/min, ta-
king nitrates, haematocrit >40%, platelet count >300x103, 
duration of diabetes mellitus (DM) >5 years. The degree 
of diabetes control did not significantly influence platelet 
function. Function of platelets in vitro was different in wo-
men and men after using other agonists than arachidonic 
acid. The probability of the critical event was higher but 
insignificantly for patients with HOPR.
Conclusion: The study confirmed the occurrence of HOPR 
in many patients taking ASA for secondary stroke preven-
tion. Risk factors for HOPR in the examined group were 
as follows: low ASA dose, higher heart rate, usage of some 
drugs, higher haematocrit and platelet count, long DM du-
ration. Sympathetic activity could influence reactivity of 
platelets in patients taking ASA. The laboratory HOPR es-
tablished by impedance aggregometry increases the risk for 
clinical aspirin resistance.
Disclosure: Nothing to disclose
P2204
Infratentorial variant of posterior reversib-
le encephalopathy syndrome complicated 
by bilateral ischemic stroke
F. Ladeira, A. Caetano, S. Calado, F. Sá
CHLO, Neurology, Lisbon, Portugal
Background and aims: Reversible posterior leukoence-
phalopathy syndrome (PRES) rarely presents with exclu-
sive infratentorial involvement. We report a case compli-
cated by bilateral lacunar infarcts involving the posterior 
circulation.
Case Report: A 53-year-old man was admitted to the 
emergency department with subacute complaints of wea-
kness and incoordination of the left limbs, diplopia, gait 
disturbance, and mild headache. He had a history of hy-
pertension and HCV infection. Examination showed high 
blood pressure (203/125mmHg), left hemiparesia with ex-
tensor plantar response and left limb cerebellar ataxia. His 
lab results showed a mild increase of C reactive protein (5.8 
mg/L) and cryoglobulinemia. CSF examination revealed a 
protein increase (79 mg/dL) with elevation of albumin quo-
tient. Citology and intratecal synthesis of immunoglobulin 
were negative. His CT scan was normal, but cerebral MRI 
showed hyperintense lesion in T2 and FLAIR, involving 
the pons, and cerebellar hemispheres with normal diffusion 
weighted imaging (DWI) and increased signal in apparent 
diffusion coefficient (ADC) map and bilateral thalamocap-
sular lesions with restricted diffusion in DWI suggesting 
acute ischemic lesions. MRI spectroscopy didn’t show any 
changes compatible with neoplasm. The patient was trea-
ted with methylprednisolone pulse and antihypertensive 
agents. After 1 week he showed no sign of paresia or ataxia 
although he maintained the Babinsky sign. The MRI after 
1 month revealed that the infratentorial lesion had subsided 
but the supratentorial lesions remained.
Conclusion: The MRI features of our patient were consis-
tent with infratentorial variant of PRES. Hypertension and 
cryoglobulinemia may have contributed to its development. 
Although infrequent, ischemic stroke is a potential compli-
cation.
Disclosure: Nothing to disclose
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Intraorbital fistula – a case report
E. Liaptsi1, F. Pico1, M. L. Chadenat1, J.M. Baud2,  
E. Houdart3
1Versailles Mignot Hospital, Neurology department and Stro-
ke Center, Versailles, France, 2Versailles Mignot Hospital, 
Angiology Department, Versailles, France, 3 Lariboisière 
Hospital, Neuroradiology Department, Paris, France
Background and aims: Arteriovenous fistulas (AVFs) of 
the cavernous sinus are high flow arteriovenous shunts, 
usually presented by a classical triad of symptoms (exoph-
thalmos, diplopia, chemosis).
Case Report: A 77-year-old woman presented with ptosis, 
vertical diplopia and left retro orbital headaches.The neuro-
logical examination reveals an isolated partial third nerve 
palsy: ptosis and vertical palsy without chemosis.
Results: An orbital MRI showed a T2 hypo-intense sig-
nal without opthalmic vein dilatation and motivated the re-
search of a dural fistula. The presence of an opthalmic vein 
AVF was confirmed by an orbital ultra sound. A diagnostic 
arteriography demonstrated a type IIa dural fistula of the 
cavernous sinus; drained to the left and right petrosal si-
nus, without drainage in the meningial veins. Three weeks 
later, a clinical aggravation marked by severe invalidating 
headaches, diplopia and trigeminal neuralgia motivated the 
performance of a therapeutic arteriography. During the pro-
cedure, we found a modification of the fistula which was 
now equally drained in the left superficial middle cereb-
ral vein, with a subsequent elevated central neurological 
risk. Successful obliteration of the fistulous connection was 
achieved by endovascular treatment, with restoration of 
normal arterial and venous flows, regression of headaches 
but persistence of the partial third nerve palsy.
Conclusion: The interests of this case are: i) the clinical 
presentation of an intraorbital arteriovenous fistula without 
chemosis ii) The diagnostic value of orbital ultrasound ex-
amination whereas orbital MRI was not conclusive. In such 
patients early diagnosis and treatment may prevent the high 
hemorrhage risk consequent to a possible cortical venous 
drainage.






Impact of the new ASCOD classification: 
shifting categories and reducing undeter-
mined strokes
L. Pereira, M. Rodrigues
Hospital Garcia de Orta, Neurology, Almada, Portugal
Background and aims: A useful stroke etiology classifica-
tion should not categorize many patients as undetermined. 
ASCOD updated ASCO with this purpose. We explored 
this potential advantage in shifting patients to higher grades 
of disease likelihood and reducing undetermined strokes.
Methods: In a hospital-based study, stroke patients were 
classified prospectively according to ASCO phenotyping 
before ASCOD was published. Afterwards cases were 
reclassified without new diagnostic workup. We present 
proportions and shifts between grades, and frequencies of 
undetermined causality (without grade 1-2 evidence in any 
category).
Results: We included 460 patients (64.3% male, medi-
an age 66), 20.9% thrombolysed. A1 went from 19.3% 
in ASCO to 22.0% in ASCOD. S categories’ proportions 
didn’t change significantly. C2 went from 1.5% to 5.2%. 
ASCO O1 comprised 5.0%, distributed to ASCOD O1 2.4% 
and D1 2.8%. Grade 9 proportions shifted from ASCO to 
ASCOD: A9 16.7% to 5.4%; S9 remained 0.2%; C9 5.4% 
to 5.0%; O9 remained similar (25.9%-24.8%); and D9 was 
2.8%. Patients with undetermined etiology were 28.9% in 
ASCO and 26.5% in ASCOD (p=0.46). Important category 
shifts were in: atherothrombosis 3.8% A3 to A1, and 66.2% 
A9 to A0; small-vessel disease 38.3% S3 to S0; cardioem-
bolism 4.6% C0, 6.1% C3 and 8.0% C9 to C2; and other 
etiologies O1 loses 52.2% of subjects to O0 due to new 
dissection category.
Conclusion: New ASCOD seems important in reclassify-
ing atherosclerotic stenosis severity, restricting the spect-
rum of small-vessel disease, and categorising multiterritori-
al infarcts as cardioembolic. While in individual categories 
the rate of incomplete workup lowers, the global number of 
undetermined strokes didn’t change significantly.
Disclosure: Nothing to disclose
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P2209
Utility of serial Holter ECG to detect  
paroxysmal atrial fibrillation in embolic 
stroke of undertermined source
J. Perez Lucas, P. Martínez Sánchez, B.E. Sanz Cuesta,  
J. Rodríguez Pardo de Donlebún, J. Díaz De Terán,  
I. Illán Gala, C.A. Calle de Miguel, E.M. Alba Suarez,  
B. Fuentes, E. Diez Tejedor
Hospital Universitario La Paz, Neurology, Madrid, Spain
Background and aims: To assess the utility serial 24-hours 
ECG Holter Monitoring (24h-HM) for the diagnosis of pa-
roxysmal atrial fibrillation (PAF) in patients with an embo-
lic stroke/transient ischemic attack of undetermined source 
(ESUS).
Methods: Observational study of patients with ESUS ad-
mitted at a Stroke Center (2009-2013). A first 24h-HM was 
performed in all cases and, if it was negative, a second or 
even a third HM was performed. Variables analysed: de-
mographic data, vascular risk factors (VRF), clinical data, 
presence of carotid plaques by duplex ultrasound, left atri-
al enlargement by echocardiography. Multivariate models 
were preformed to identify those factors associated with the 
PAF detection.
Results: A total of 507 patients were diagnosed with an 
ESUS, mean age 70.28 years old (SD 12.8), 58% of them 
male. Overall, serial 24hHM found PAF in 25% of the cases 
(130/513 patients). The first 24hHM detected PAF in 23.9% 
(121/507), the second in 10.3% (6/58) and the third in 50% 
(3/6) of patients. Results are shown in Figure 1. Multiva-
riate analysis showed that, for the first 24hHM, older age 
(OR 1.033, CI 95% 1.013-1,054) and LA enlargement (OR 
2.012; CI 95% 1.289-3.143) were the factors associated 
to the presence of AF. For the second and third 24hHM, 
the multivariate analysis showed that LA enlargement (OR 
13.333; CI 95% 1.539-115.548) was the only factor related 
to the PAF diagnosis.
FIGURE 1: PAF diagnosis by serial 24h Holter monitoring
Conclusion: Serial 24hHM detect PAF in more than 25% 
of patients with ESUS. Age and left atrial enlargement are 
the factors more strongly associated with the PAF diagno-
sis.
Disclosure: Nothing to disclose
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A six-month registration of iatrogenic neu-
romuscular injuries in an EMG Unit
R. Arca1, M. Morales1, J. Baron Sanchez2, C. Cabib1,  
J. Valls-Solé1
1Hospital Clinic Barcelona, Neurology, Barcelona, Spain, 
2Hospital Clinico de Valladolid, Neurology, Valladolid, Spain
Background and aims: The usefulness of electrodiag-
nostic testing (EDX) is widely recognized in the assess-
ment of neuromuscular injuries. It is often a resource for 
the assessment of iatrogenic neuromuscular injuries (INI). 
We evaluated the role of EMG examination in INI that 
came to our department between June and November 2014.
Methods or Materials or Case Report: We noted all INIs 
during six months routine EDX testing in our department. 
We revised patients’ history to identify if INIs were ful-
ly recognized before the EDX examination and, in case of 
newly identified cases, whether the diagnosis prompted a 
change in patient’s management.
Results: We identified 72 INI cases out of 654 studies 
(11%), 22 after chemotherapy, 32 after surgery, 9 after 
prolonged bed stay and 9 with other causes. In 10 cases 
(13.8%), no clinical suspicion of INI was found in patient’s 
history. In 7 of these 10 patients and 22 others, the EDX 
had an influence on clinical management but this was not 
the case for patients submitted to chemotherapy. An impro-
vement was seen in 37.5% of INI, 23 patients with focal 
nerve lesions (8 after prolonged bed stay, 15 for surgical 
procedures), 2 patients with polyneuropathy after toxicity 
and 2 patients with post-UCI neuromyopathy.
Conclusion: EDX may be useful in the diagnostic workup 
of potential INI. It is essential for diagnosis and evaluati-
on of nerve recovery especially in focal lesions that, in our 
sample, have the higher rate of improvement. Although it 
does not change the management of patients submitted to 
chemotherapy, it helps with their monitoring.
Disclosure: Nothing to disclose
P2211
Effect of short-term vibration on  
cutaneous silent period
S. Aydın, Y. Bakuy, M. Kızıltan
Istanbul University, Cerrahpasa Medical Faculty, Neurology, 
istanbul, Turkey
Background and aims: Suppression of ongoing electro-
myography activation following cutaneous nerve stimula-
tion is called cutaneous silent period (CuSP). CuSP is spi-
nal inhibitory reflex mediated by small diameter fibers (A 
delta fibers) and large diameter fibers (alpha motor axons). 
The role of muscle spindles afferents had not been studied. 
We aimed to evaluate whether there is a contribution of the-
se nerves during and after short–term vibration application.
Methods: The study group’s age was between 29 and 44 
(mean: 34.7±5.25), including healthy (6 male) volunteers. 
Right median nerve motor and sensory action potentials 
and CuSPs were recorded on abductor pollicis breves mu-
scle by stimulation of median nerve of index finger before, 
during and after appliance of vibration. Vibration frequen-
cy was 100 Hz and 1mm of amplitude and was applied to 
forearm for 2 minutes. Data gained and rectified from the 
recordings of 10 volunteers were examined for their initial 
and endpoint latency periods, CuSP intervals, and suppres-
sion of EMGs.
Results: Average latency and duration of CuSP before, during 
and after vibration period were (14.80±77.6/ 40.1±10.84), 
(84.46±4.27/ 34.53±4.47) and (75.94±13.33/ 35.66±6.15) 
respectively. Although our results is not statistically signi-
ficant, onset latency CuSP during vibration was prolonged, 
duration of CuSP was shortened.
Conclusion: Vibration is a potent stimulus for the primary 
muscle spindle endings and induce increased discharges of 
Ia afferents. Purpose of this study was to evaluate the con-
tribution of la afferents on CuSP, however our results did 
not demonstrate a significant effect of vibration on CuSP 
activity.
Disclosure: Nothing to disclose
276      Poster presentation with discussion
© 2015 European Journal of Neurology, 22 (Suppl. 1), 120–483
P2212
Slow right prefrontal repetitive  
transcranial magnetic stimulation for the 
treatment of resistant depressive 
symptoms in a progressive supranuclear 
palsy patient
S. Boulogne, F. Le Camus, R. Bation, F. Galvao,  
F. Haesebaert
Hopital Le Vinatier, Treatment-Resistant Depression Unit, 
Lyons, France
Background and aims: Repetitive Transcranial Magnetic 
Stimulation (rTMS) applied on Dorso Lateral Prefrontal 
Cortex (DLPFC) is increasingly used for treatment-resis-
tant depression but has never been evaluated for depressive 
symptoms associated with neurodegenerative diseases. 
Case Report: We report the case of a 62-year-old man 
diagnosed with progressive supranuclear palsy (PSP) pre-
senting a severe comorbid depression. PSP began with 
insidious personality change associated with mood distur-
bance and anxiety; vertical ophtalmoplegia, axial rigidity 
and dysarthria added up progressively. Ten years after on-
set, he was admitted to our treatment-resistant depression 
unit for a melancholic depression, the Montgomery-Asberg 
Depression Rating scale (MADRS) was rated 33/60. Due 
to significant side effects and inefficiency of several anti-
depressant drugs, a rTMS therapy targeting the right DLPC 
was performed: 20 daily sessions of 360 stimulations at 1 
Hz frequency and 120% resting motor threshold intensity.
Psychiatric symptoms and global functioning were evalua-
ted at baseline and after session 10 & 20 with the MADRS, 
the StateTrait Anxiety Inventory (STAI), the Lille Apathy 
Rating Scale (LARS) and the Global Assessment of Func-
tioning (GAF) Scale.
Results: A significant clinical response was obtained 
within 20 sessions with sustained effect. MADRS decre-
ased by 64% from 33/60 to 12/60, LARS by 180% from 
-10/36 to -28/36, STAI by 18% from 72/80 to 61/80. GAF 
scale increased by 75% from 40/100 to 70/100. No side ef-
fects were reported.
Conclusion: 1 Hz DLPFC rTMS is noninvasive and well 
tolerated and could be an interesting antidepressant therapy 
in parkinsonian syndromes. This first report in PSP has to 
be replicated in larger sample.
Disclosure: Nothing to disclose
P2213
Quantitative EEG in patients with 
Parkinson’s disease (PD) with and without 




Background and aims: We investigated how certain 
qEEG variables, particularly signal power in the alpha1 
(8-10Hz) and theta (4-8Hz) bands differed for MCI (mild 
cognitive impairment) and Non-MCI Parkinson patients in 
the different
Methods: High-resolution 256-channel EEG were recor-
ded in 43 PD patients (MCI/non-MCI: 18/25 | age: 68.1±7.9 
| female/male: 16/27). Semi-automatic processing of the 
data was done to calculate the relative power in alpha1 and 
theta bands across the different regions of the brain, apart 
from the global relative power. Follow-up recordings at 
four weeks (4W) and six months (6M) were collected for 
32 patients (MCI/non-MCI: 13/19). Permutation tests on 
t-statistics were carried out to correct for multiple compa-
risons and effect sizes were calculated. To test for the diffe-
rences in different regions of the brain, t-tests were carried 
out for both groups of patients.
Results: An increase (p=0.017; ES=0.789) in the theta and 
a decrease (p=0.042; ES=0.782) in the alpha1 signal power 
were associated with MCI in PD patients. Temporal, Occi-
pital and Frontal Right regions of the brain in Baseline stu-
dy patients were seen to significantly differ between MCI 
and Non-MCI patients. The Occipital Left region was also 
found to differ between the two groups of patients at the 
Follow-up recordings (4W and 6M).
Conclusion: Alpha1 and theta signals can be associated 
with MCI in PD patients. The signal differences in the ana-
tomical regions of the brain can be investigated further to 
be used for screening PD patients for early cognitive defi-
cits.
Disclosure: Nothing to disclose
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Deep repetitive transcranial magnetic 
stimulation with H-coil in Alzheimer’s di-
sease: a double-blind, placebo-controlled 
pilot study
E. Coppi1, L. Ferrari1, A. Nuara1, R. Chieffo1, E. Houdayer1, 
M. Bianco1, M.P. Bernasconi1, M. Falautano1, A. Zangen2,  
G. Comi1, G. Magnani1, L. Leocani1
1Neurological Dept. & Experimental Neurophysiology Unit 
- Institute of Experimental Neurology (INSPE); University 
Hospital-IRCCS San Raffaele, Milan, Italy, Neurology De-
partment, 2Ben-Gurion University, Department of Life Scien-
ces, Beer-Sheva, Israel
Background and aims: Repetitive transcranial magnetic 
stimulation (rTMS) applied with focal coils in Alzheimer’s 
disease (AD) revealed positive effects on cognition. The H-
coil is able to depolarize deeper and wider neuronal struc-
tures compared with focal coils. Our aim was to evaluate 
feasibility, safety and efficacy of excitatory rTMS with H-
coil in AD.
Methods: 30 AD subjects (age 70.21±8.66; MMSE 
17.31±5.77), randomized in real and sham group, under-
went 12 rTMS sessions within 4 weeks, then a 4-week 
maintenance (1/week), over the fronto-parieto-temporal 
lobes (10Hz; 120%RMT). Neuropsychological assess-
ment (Alzheimer’s Disease Assessment Scale cognitive 
- ADAS-cog, Mini-Mental State Examination-MMSE, 
Beck Depression Inventory-II, Clinical Global Impression-
Improvement, a word recognition task) were performed at 
baseline, 4 weeks from start of treatment (4w), end of treat-
ment (8w), follow-up (8 weeks after 8w).
Results: No serious side effects were reported and no pati-
ent dropped due to side effects. Four subjects were exclu-
ded from the analyses (1 acute myocardial infarction in the 
sham group, 1 misdiagnosis, 2 missing data). Comparing 
percent ADAS-cog change at 4w with a null hypothesis 
of 0 change, only the real group significantly improved 
(-7.22±10.49 %, p=0.046). To achieve 3-4 points group dif-
ference change ADAS-cog with 80% power, we calculated 
a sample size 16-22 per arm.
Conclusion: Our preliminary findings suggest that rTMS 
with H-coil is a safe and feasible procedure in AD, with 
good patients’ adherence. Our neuropsychological data will 
be used to plan phase II trials on a larger sample. Future 
studies should explore earlier disease phases and the com-
bination with cognitive training.
Disclosure: Nothing to disclose
P2215
Sensitivity and predictive value of OCT 
and VEP in multiple sclerosis
G. Di Maggio
Milan, Italy
Background and aims: To evaluate the role of optical co-
herence tomography (OCT) and visual evoked potentials 
(VEPs) in detecting visual involvement and monitoring 
multiple sclerosis (MS).
Methods: To study 121 consecutive subjects with MS. 
Of 242 eyes, 166 had no previous history of optic neuritis 
(ON), 22 had a single recent ON episode (<3 months); 54 
had chronic ON (at least 1 episode >3 months before). All 
patients underwent assessment of EDSS, OCT retinal ner-
ve fiber layer (RNFL) thickness and VEP (checkerboard, 
size 15’). 77  subjects underwent a second EDSS (EDSS2 ) 
evaluation after a mean time of 1.94 (+0.69) years (median 
EDSS 2, range 0-7).
Results: In eyes with recent ON, the sensitivity of OCT was 
38.9% with a higher sensitivity of VEP (77.3%; McNemar 
p<0.02). In eyes with chronic ON, no significant difference 
was found between OCT (68.5%) and VEP (81.5%) sensi-
tivity. In asymptomatic eyes, VEPs had a higher sensitivity 
(31.7%) vs OCT (19.9%; p=0.005); VEP/OCT combined 
detected abnormalities in 39.2%. In follow up evaluation, 
in patients without previous ON, basal OCT alterations 
(1 eye per patient) were associated with  disability after 2 
years (Mann-Whitney p=0.013), differently from VEP.
Conclusion: The present findings confirm that VEPs are 
more sensitive than OCT early after acute optic neuritis and 
in asymptomatic eyes. In eyes without previous optic neuri-
tis, basal asymptomatic OCT abnormalities was associated 
with disability development after 2 years.
Disclosure: Part of this work was financially supported by 
Merck Serono S.A., Geneva, Switzerland. Merck Serono 
is the biopharmaceutical division of Merck KGaA, Darm-
stadt, Germany.
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Variation of median nerve latency after 
long lasting phalen maneuver
H.M. D’Onofrio
Buenos Aires, Argentina
Background and aims: Carpal Tunnel Syndrome (CTS) is 
usually associated with risk occupational factors such as re-
petitiveness of single actions, prolonged postures or force-
ful work involving the wrist, so either muscle imbalance 
or nerve compression may act as biomechanical forces 
with a different effect on healthy individuals (HI) com-
pared with patients suffering entrapment nerve disorders. 
Phalen maneuver (PMT) is highly recommended to trig-
ger CTS symptoms because it provokes a reduced median 
nerve (MN) intraneural blood flow lasting one minute. To 
address whether a five minutes lasting PMT (5mPM) trig-
gers a more serious detrimental effect on MN latencies in 
CTS patients compared with responses found in HI, CTS 
patients and HI underwent to MN neuroconduction study. 
Methods: CTS: 24 arms/ HI 20 arms. MN motor distal la-
tency (MDL) and sensitive latency (SL) to I,II,III digit were 
analyzed at rest and after PM held for 5 minutes
Results: 5mPM increased MNMDL and MNSL, and re-
duced MN thenar amplitude response: HI DML mean 
increase 0.04ms/ mean amplitude reduction of 0.793 
mv compared to 0.272ms and 8.3mv found in CTS 
(p<0.05). HI SL mean increase of 0,05 ms to II/III digit 
compared to 0.125 and 0.118 ms found on CTS (p<0.05) 
Conclusion: 5mPM on CTS patients has shown a higher 
influence on MN latency values . These findings should be 
considered in CTS workers at risk activities to analyze the 
way they have to manage their usual exposure to long las-
ting biomechanical forces to avoid an increase on MN neu-
roconduction impairment.
Disclosure: Nothing to disclose
P2217
The effect of cerebellar degeneration on 
human sensori-motor plasticity
R. Dubbioso, F. Manganelli, A. Antenora, G. De Michele,  
A. Filla, L. Santoro
University of Naples “Federico II”, Department of Neurosci-
ences, Reproductive Sciences and Odontostomatology, Uni-
versity Federico II of Naples, Italy., Naples, Italy
Background and aims: Plasticity of the primary motor 
cortex (M1) has a critical role in motor control and lear-
ning. The cerebellum facilitates these functions using sen-
sory feedback. We investigated how cerebellar degenerati-
on influences the plasticity of the M1 by using PAS (paired 
associative plasticity) technique. PAS involves repeated 
pairs of electrical stimuli to the median nerve and transcra-
nial magnetic stimulation (TMS) of the motor cortex. If the 
interval between peripheral and TMS stimulation is around 
21–25ms, corticospinal excitability is increased via a long-
term potentiation (LTP)-like effect within M1. Our aims 
were: (i) to explore the presence of a time-specific influence 
of cerebellar degeneration on human associative plasticity; 
(ii) to evaluate the role of somatosensory pathway on cere-
bellar modulation of sensory-motor plasticity.
Figure 2  Schematic representation of the spino-cerebello-thalamo-
cortical circuit models controlling the peripheral afferent information 
flow to motor cortex (M1).   (A) Healthy subjects, (B) cerebellar pati-
ents. Afferent inputs are conveyed through infer
Figure 1  PAS 21.5 and 25 in healthy subjects (HS) and cerebellar pa-
tients (C) (A) Grand average of normalized MEPs at T0 and T30 to 
baseline in each session. Asterisks indicate significant differences from 
PAS 25 of cerebellar patients
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Methods: We studied 10 patients with pure cerebellar atro-
phy and 10 age-matched healthy subjects. Motor-evoked-
potentials amplitudes, short-afferent inhibition, motor 
thresholds, I/O curves, somatosensory-evoked-potentials 
(SEPs) were measured before, just after and 30 min after 
PAS at interstimulus-intervals of 21.5 and 25ms. 
Results: In cerebellar patients LTP-like effect induced by 
PAS was abolished at 25 but not at 21.5ms (figure 1). SEPs 
showed that the amplitude of P25 wave was markedly redu-
ced in patients with a more severe clinical and radiological 
impairment of cerebellum.
Conclusion: Cerebellar patients have an altered capabili-
ty of cerebellar filtering or processing of time-specific in-
coming sensory volleys, influencing the plasticity of M1 
(figure 2). These results have important implication for un-
derstanding the pathophysiology of neurological disorders 
in which cerebellar impairment is assumed.
Disclosure: Nothing to disclose
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P2218
The dementia of King Ferdinand VI of 
Spain.
S. Fernández Menéndez1, N. González1, L.B. Lara Lezama2, 
R. Garcia Santiago3, L. Redondo Robles2, A. Álvarez Noval4, 
B. Cabezas Delamare2, A. Ares-Luque2,  
J.M. González González5
1León, Spain, 2Complejo Asistencial Universitario de Leon, 
Leon, Spain, 3Leon, Spain, 4complejo asistencial universitario 
de leon, leon, Spain, 5autónomo, Oviedo, Spain
Background and aims: Ferdinand VI was king of Spain 
from 1746 until 1759. His last year of reign is known as 
“the year without a king” because the rapidly progressive 
deterioration of his mental health status. The clinical con-
dition has been always attributed to a pure psychiatric dis-
order by historians.
Methods: We reviewed the primary and secondary sour-
ces of information, mainly the manuscript written by the 
principal physician of King Ferdinand VI, Andres Piquer y 
Arrufat. We made an evaluation of the clinical situation and 
we tried to find out the cause of the royal illness.
Results: Ferdinand VI had prior depressive episodes and 
the clinical deterioration of his last year started with the 
death of his beloved wife. At first, the symptoms were simi-
lar to the symptoms of a major depressive disorder, but the 
King had a rapidly progressive deterioration, with severe 
changes in personality and behavior. Later on, Ferdinand 
VI suffered seizures, myoclonus and fell into a state of 
prostration. He died 1 year after his clinical deterioration 
was marked, although it is probable that the first symptoms 
appeared before reported or they were attributed to his pre-
vious depressive episodes.
Conclusion: The cause of the illness of King Ferdinand 
VI will never be discovered. Although it is possible that it 
could have been a pure psychiatric disorder, there is enough 
information to think about a rapidly progressive dementia 
as the main cause of his clinical worsening and death.
Disclosure: Nothing to disclose
P2219
Neurosyphilis and classical music: the 
great composers and “The Great Imitator”
M. Kahakura Franco Pedro1, F.M. Branco Germiniani1,  
H.A. Ghizoni Teive2
1Curitiba, Brazil, 2UFPR, Curitiba, Brazil
Background and aims: Neurosyphilis is one of the most 
devastating forms of the venereal disease; throughout his-
tory, many were victimized by it, including several classi-
cal composers, with a wide range of clinical presentations, 
whose cases we analysed.
Methods: Six articles with descriptions of composers with 
possible neurosyphilis were revised, as well as references 
in musicology.
Results: Usually a late manifestation of Treponema palli-
dum infection, neurosyphilis, whose manifestations include 
general paresis, tabes dorsalis and meningeal signs, among 
others, is a possible diagnosis for composers such as Beet-
hoven, whose progressive hearing loss greatly influenced 
his career, culminating in complete deafness. In his autop-
sy cochlear nerve atrophy and cochlear inflammation were 
described - findings coherent with neurosyphilis. Donizetti, 
who was treated at the Salpêtrière, developed behavioral 
changes that ended his career, as well as headaches, gene-
ral paresis and seizures. Both Schumann and Wolf suffered 
from personality changes, persecutory delusions and hal-
lucinations; they developed delirium and died in poverty. 
Delius and Joplin also suffered from symptoms that can be 
attributed to syphilis. Autopsy findings confirmed the diag-
nosis of Smetana, who described in his diary symptoms of 
primary and secondary syphilis; dementia, deafness and au-
ditory hallucinations with rapid progression. He developed 
tinnitus, which he represented musically in his First String 
Quartet.
Conclusion: Neurosyphilis victimized several notorious 
composers, often influencing their musical output. Alt-
hough they may have had composed more pieces if it were 
not for the disease, it can be argued that neurosyphilis was 
a major source of inspiration as well, playing a pivotal role 
in the very genesis of musical masterpieces.
Disclosure: Nothing to disclose
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P2220
Neurology in context of moral and political 
philosophy: support of UNO-agenda 21
E. Neu1, M.C. Michailov1, C. Lütge1, R. Neu1, M.-L. Gräfin 
von Brockdorff1, B. Lichterman2, G.-R. Stainov3, T. Bilbili1, 
G.-E. schulz1, P. Birkenbihl1, U. Welscher1, M. Holler4,  
M. Schratz5, G. Weber6
1Inst. Eco-Med., 2Inst. Eco-Med., Moscow, Russian Federati-
on, 3Inst. Eco-Med., Fulda, Germany, 4Inst. Eco-Med., Ham-
burg, Germany, 5Inst. Eco-Med., Innsbruck, Austria, 6Inst. 
Eco-Med. (=Inst. Umweltmed.) c/o ICSD/Int. Acad. Sci., 
POB 340316, 80100 Muenchen, Germany (Berlin-Bratislava-
Innsbruck-Muenchen-New Delhi-Paris-Sofia-Vienna), Vienna, 
Austria
Background and aims: Blood-circulation & neuroregula-
tion from cellular upto system-levels have central position 
in all animal organisms: This way angio-cardiology & neu-
rology are a-priori fundamental bio-medical disciplines, 
which have moral&scientific responsibility to support bet-
ter health. This is also political obligation.
References: Michailov-Neu-Welscher et-al.: Philoso-
phy: FISP (WorldCongrPhilos) 2013-Athens Congr.-
Book 464-5&503-4&766; 2008-Seoul DVD2010 
(ISBN-13:978-1-889680-835) Proc. Vol.4:101-
108&Vol.20:203-214&Vol.37:195-202&Vol.45:229-237; 
2003-Istanbul 279-280 Physiology: FEPS-2014-Budapest 
(FedEurPhysiolSci) Acta-Physiol 211:62-64 Psychology: 
IUPsyS-2012-Cape-Town PsycholPress/IntJPsychol 47/407.
Conception: In context of humanization, higher ef-
fectiveness (without stress) & internationalization of 
science&health-medicine has to be discussed: a. In-
tegration of ethics/scientific-theory in neurological 
education&research. b. Foundation of elementary units for 
philosophical neurology to some clinics for neurology=CN. 
c. Foundation of national-European-international-CN via 
network of clinics from selected countries in context of 
creation of international universities proposed by Bertrand 
Russell (British Nobel-Laureate) & Gustav MENSCHING 
as paradigm for better education-research-technology. d. 
Implication of neurological topics to intern. congresses for 
philosophy-FISP, psychology-IUPsyS, physiology-IUPS, 
biophysics-IUPAB, chemistry-IUPAC, also in clinical-
medicine (IUPHAR/FIGO/ISIM/SIU/etc). Fundamentals 
for a-d could be 1. Common educational/research program-
mes. 2. Common elementary administration & laborato-
ries. 3. Recognition of participants as intern./continental 
professors/doctors, etc. 4. Possibility for regular work (not 
only guests) to institutes/branches in Africa-America-Asia-
Australia-Europe. 5. Regular successive financial support 
for participants/projects by nat.-ministries/industry/Eur. 
Union/UNESCO,etc. 6. Possibility for whole-life-work 
after 60years as senior-scientists incl. honorary professors, 
institute-directors,etc
Conclusion: Implication of a-d&1-6 resp. in neurology will 
help UNO-Agenda21 by better health-education-therapy & 
prophylaxis in all countries. Social & political responsibili-
ty needs support of neurology-EAN incl. proposals a-d+1-6 
by governments, foundations, EU/UNESCO/WHO.
Disclosure: Nothing to disclose
P2221
Functional lesional neurosurgery in the 
treatment of movement disorders: history 
and perspective
S. Schreglmann1, R. Bauer2, S. Hägele-Link1, N. Wegener1, 
E. Martin3, G. Kägi1
1Kantonsspital St.Gallen, Department of Neurology, 
St.Gallen, Switzerland, 2Kantonsspital St.Gallen, Depart-
ment of Neurosurgery, St.Gallen, Switzerland, 3University 
Children’s Hospital Zurich, MR Centre , Zurich, Switzerland
Background and aims: Functional neurosurgery aims at 
changing the functionality of neuronal circuits involved e.g. 
in human motor control. Lesional treatment for movement 
disorders (MD) began in the mid 20th century and conti-
nuously evolved with the technology available. Its effects 
and side effects considerably advanced the understanding 
of basal ganglia function. We aim to trace major steps in the 
history of and perspectives for lesional treatment for MDs. 
Methods: PubMed Literature review.    
Results: From the first transventricular Caudate Nucleus 
resection, stereotaxy, chemopapillotomy, bipolar diathermy 
and radiofrequency ablation to the application of trajectory-
free techniques such as GammaKnife and MR-guided fo-
cused high intensity ultrasound, surgical technology and 
technique evolved dramatically. Anatomically, procedures 
centered at the pallidum and only later included thalamic 
and subthalamic targets. Chronologically, the lesional treat-
ment of MDs followed a bi-phasic pattern interrupted by 
the euphoric success of Levodopa treatment. Although in-
terpretation of early literature results needs to take targeting 
precision, reporting bias and the lack of outcome scales into 
consideration, important lessons can be learned. 
Table 1.: Chronological order of major clinical studies in the lesional 
neurosurgical treatment of movement disorders
Conclusion: In addition to deep brain stimulation (DBS), 
trajectory-free lesional approaches that spare the surroun-
ding tissue by using focused thermal or radiation energy 
are a major addition to the neurosurgical armamentarium. 
When combined with advanced real-time image guidance 
and omitting radiation, such as in MR-guided focused high 
intensity ultrasound, new levels of targeting precision and 
safety seem achievable. 
Disclosure: Nothing to disclose
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Neuroanatomical and neuro- 




Background and aims: Michelangelo’s work as a sculp-
tor and painter has attracted particular attention by physi-
cians. Some noted deviations from normal anatomy such 
as the unnatural form of the left breast of the Notte in San 
Lorenzo’s church (1), or blood filled veins in the sculpture 
of the dead Jesus in St. Peter (2). Others noted the lacking 
circumcision of David (3), or a multinodular goiter of the 
creator in the Separation of Light from Darkness in the Sis-
tine Chapel (4).
Methods: Search for neurological and neuro-ophthalmolo-
gical aspects in the works of Michealngelo.
Results: Previously, some authors thought that there is 
a hidden shape of the brain in the Creation of Adam (5), 
or the hidden shape of the brainstem in the Separation of 
Light from Darkness (6), or a horizontal eye deviation in 
the sculpture of David (7).
Own observations indicate a horizontal eye deviation in the 
Delphian Sybil, an ocular tilt reaction in the creator in The 
Creation of the Sun and Moon, and people with bilateral 
ptosis in the Last Judgement.
Conclusion: Any interpretation of art is exceedingly sub-
jective and depends on the experiences and interests of the 
interpreter. Obviously, Michelangelo’s work is of special 
interest for physicians to trace deviations from normal con-
ditions and to speculate on their hidden meanings. This 
quest will continue.
References
1. N Engl J Med 2000;343:1577-1578
2. JAMA 1972;219:1212
3. JAMA 1971;218:1304
4. J R Soc Med 2003;96:609-611
5. JAMA 1990;264:1837-1841
6. Neurosurgery 2010;66:851-861
7. J R Soc Med 2005;98:75-76
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P2223
An initial survey on neurological palliative 
care
L. Vanopdenbosch1, D. Oliver2
1Bruges, Belgium, 2Wisdom Hospice, Rochester, United King-
dom
Background and aims: Although the patients with pro-
gressive neurological disease may require palliative care 
there are often barriers between the specialties of neurology 
and palliative care in daily practice. To identify the barriers 
to overcome and close the gap between palliative care and 
neurology, we undertook a classical barriers analysis.
Methods: A cross sectional mixed methods study. Evident 
barriers were identified from a literature search and these 
were used to develop a semistructured interview. The in-
terviews were undertaken with a representative sample of 
healthcare providers in neurology until there was topic sa-
turation to identify emergent barriers. These barriers were 
quantified in a quantitative websurvey addressed to practi-
sing neurologists.
Results: We report the 50 initial replies of the first survey 
invitation to neurologists in Belgium. We found that moral, 
ethical, psychological or religious objections are not per-
ceived as barriers for palliative care in neurology. A seman-
tic barrier was identified: although much of the work of the 
neurologist can be classified as palliative care, neurologists 
would not use that term. There was disagreement whether 
time and money constraints pose a barrier. Intrinsic neuro-
logical aspects such as uncertain prognosis were seen as 
barriers. The greatest barrier for palliative care in neuro-
logy is lack of education and perceived lack of experience 
and exposure during training.
Conclusion: Moral, ethical, psychological, religious issues 
nor lack of time and funding seem to be the real reasons 
for the perceived lack of palliative care and neurology. We 
identified a semantic issue and an experience/education 
barrier.
Disclosure: Nothing to disclose
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Headache and pain 3
P2224
Allodynia and medication-overuse  
headache in Portuguese migraineurs:  
An exploratory study
M. Mendonça, A. Caetano, M. Pinto, R. Miguel, R. Pelejão, 
R. Barbosa, F. Ladeira, F. Sá, M. Viana-Baptista
Centro Hospitalar de Lisboa Ocidental - Hospital Egas  
Moniz, Neurology Department, Lisbon, Portugal
Background and aims: A troubling aspect of migraine 
therapy is that overuse of acute headache medication can 
lead to medication-overuse headache (MOH). MOH patho-
physiology remains largely unknown but some evidence 
suggests that it may be associated with central sensitization. 
Allodynia has been proposed as a manifestation of central 
sensitization so we assessed its presence in MOH patients.
Methods: 63 consecutive migraineurs were evaluated for 
the first-time. Demographic and diagnosis data was collec-
ted. Allodynia was assessed with 12-point Allodynia Sym-
ptom Checklist-12(ASC-12): No-to-mild-allodynia was 
defined as ASC-12 score 0-5 and moderate-to-severe-allo-
dynia as score >5. Severe allodynia was defined as score 
≥ 9. Hospital Anxiety and Depression Scale(HADS) was 
used. HADS and ASC-12 data was missing for one MOH 
and one non-MOH subject.
Results: 6 (6/63, 9.5%) of the patients fulfilled criteria for 
MOH and, when compared to non-MOH migraineurs, had a 
non-significantly higher age (41.5 versus 35.4 years), BMI 
(27.9 versus 24.5kg/m2), headache intensity (10 versus 
8) or HADS score(15 versus 14.4). Severe allodynia was 
present in all (5/5) MOH subjects and in 25.0% (14/56) of 
non-MOH (p=0.002; Fisher’s exact test). Lowering cut-off, 
moderate-to-severe-allodynia was present in 46.4% (26/56) 
of non-MOH (p=0.053; Fisher’s exact test).
Conclusion: Allodynia is common in MOH. This explora-
tory study supports the idea that central sensitization could 
be involved in MOH. Recommendations suggest withdra-
wal of the abused drugs and management of withdrawal 
headache. Acting on sensitization process could be helpful 
in the withdrawal. Future longitudinal studies are necessa-
ry to understand the relevance of addressing allodynia in 
MOH pathophysiology and treatment. 
Disclosure: Nothing to disclose
P2225
Resting state functional connectivity  
abnormalities in pediatric patients with 
migraine
R. Messina1, M.A. Rocca1, B. Colombo2, E. De Meo1,  
A. Falini3, G. Comi2, M. Filippi1
1San Raffaele Scientific Institute, Vita-Salute San Raffaele 
University, Neuroimaging Research Unit, Milan, Italy, 2San 
Raffaele Scientific Institute, Vita-Salute San Raffaele Univer-
sity, Department of Neurology, Milan, Italy, 3Università Vita-
Salute San Raffaele, Neuroradiology, Milan, Italy
Background and aims: Aim of this study was to explore 
abnormalities of resting state (RS) functional connectivity 
(FC) and functional interaction among networks in pediat-
ric patients with migraine.
Methods: Using a 3.0 Tesla scanner, RS functional ma-
gnetic resonance imaging scans were acquired from 13 
pediatric migraine patients and 15 age-matched controls. 
Independent component analysis and a template-matching 
procedure were used to identify the default mode (DMN), 
salience (SN), fronto-parietal attention (FPN), working 
memory (WMN), sensorimotor (SM), auditory and visual 
(VN) networks. Within-group and between-group RS FC 
comparisons were performed using SPM8. The FNC tool-
box was used to assess changes of interactions among RS 
networks. Correlations between RS FC abnormalities and 
patients’ clinical characteristics were also assessed.
Results: Compared to controls, pediatric migraine patients 
had an increased RS FC of the precuneus of the DMN and 
the dorsolateral prefrontal cortex of the right WMN. They 
also experienced a decreased RS FC of the anterior cin-
gulum of the SN and the temporo-parietal junction of the 
left WMN. FNC analysis detected a decreased FC between 
the DMN and right WMN, and an increased FC between 
the VN and FPN in migraine patients compared to controls. 
No significant correlation was found between intra- and 
inter-network RS FC abnormalities and patients’s clinical 
characteristics.
Conclusion: Significant RS FC abnormalities occur in 
pain-processing networks of pediatric migraine patients. 
Brain regions involved in cognition were selectively invol-
ved, suggesting that abnormalities of cognitive modulation 
of pain in migraine patients occur from an early stage of 
the disease.
Disclosure: Nothing to disclose
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Modulatory effect of L-kynurenine and 
probenecid on the trigeminal activation 
and sensitization in the rat
G. Nagy-Grócz1, A. Fejes-Szabó1, Z. Bohar2, L. Tar3,  
L. Vécsei2, Á. Párdutz1
1University of Szeged, Department of Neurology, Szeged, 
Hungary, 2University of Szeged, MTA-SZTE Neuroscience 
Research Group, Szeged, Hungary, 3University of Szeged, 
Department of Neurology, Ulm, Germany
Background and aims: Migraine is one of the com-
monest neurological diseases, affecting 16% of 
the population. Despite intensive research, the ex-
act pathomechanism of migraine is not fully un-
derstood, but the role of glutamate seems pivotal. 
Kynurenic acid (KYNA) is an endogenous antago-
nist of glutamate and α-7-nicotinic acethylcholine re-
ceptors. KYNA level in the central nervous system 
can be significantly increased by the administration of 
its precursor L-kynurenine (L-KYN) and the proben-
ecid (PROB) an inhibitor of organic acid transporter. 
One of the animal models of trigeminal activation is the 
orofacial formalin test, which leads to activation and sensi-
tization of the trigeminal system. We examined the effects 
of combined pretreatment of L-KYN and PROB on the 
formalin-induced changes in the second-order neurons in 
the trigeminal nucleus caudalis (TNC) of the rat.
Methods: Half of the animals received intraperitoneal L-
KYN+PROB injection, the remaining rats got the placebo. 
One hour later animals received formalin in the right upper 
lip. Four hours later the animals were perfused transcardi-
ally and the TNC was removed for immunohistochemistry.
Results: Four hours after the formalin injection of rats, 
the number of c-Fos immunoreactive and calcium/calmo-
dulin-dependent protein kinase II-alpha-immunoreactive 
neurons in the TNC was increased which reflect activation 
and sensitization of the trigeminal system respectively. The 
pretreatment with the combination of L-KYN and PROB 
significantly attenuated the formalin-induced changes in 
the TNC.
Conclusion: The manipulation of KYNA influences the ac-
tivation and sensitization of the trigeminal system possibly 
via glutamate and α-7-nicotinic acethylcholine receptors 
presenting a possible new target for future antinociceptive 
agents.
Disclosure: This work was supported by the Hungarian 
Brain Research Program (Grant No. KTIA_13_NAP-A-
III/9); the EUROHEADPAIN (FP7-Health 2013-Inno-
vation; Grant No. 602633); the TÁMOP-4.2.2.A-11/1/
KONV-2012-0052; and the European Union and the State 
of Hungary, co-financed by the European Social Fund in 
the framework of TÁMOP 4.2.4.A/2-11-1-2012-0052. Dr. 
Árpád Párdutz was supported by the Bolyai Scholarship 
Programme of the Hungarian Academy of Sciences.  
P2227
Spontaneous intracranial hypotension: 
definition of the serious form based on a 
series of 24 cases
S. Richard1, A. Lyoubi Idrissi1, G. Mione1, A.M. Enea1,  
E. Schmitt2, O. Klein3, X. Ducrocq1
1CHU Nancy, Neurology, Nancy, France, 2CHU Nancy, 
Neuroradiology, Nancy, France, 3CHU Nancy, Neurosurgery, 
Nancy, France
Background and aims: Recommended treatments for 
spontaneous intracranial hypotension (SIH) range from bed 
rest only for simple cases to neurosurgery for more serious 
forms. However, the serious form of SIH is poorly defined. 
A better description of the characteristics of patients with 
the serious form and their outcome may help define thera-
peutic options.
Methods: We reviewed 24 cases of patients with SIH and 
separated them into two groups according to whether or not 
they presented with signs of severity at admission: distur-
bance of consciousness, subdural hematomas and cerebral 
venous thrombosis (CVT).
Results: 9 patients (37%) were classified as having a seri-
ous form of SIH: 6 (25%) presented subdural hematomas; 
3 (12%) disturbance of consciousness; and 1 (4%) CVT. 
Bed rest and epidural blood patches (EBP) were sufficient 
to treat all patients in the non-serious form group and four 
patients in the serious form group. 2 patients (8%) had to 
undergo cerebrospinal fluid leak repair, and 3 others (12%) 
evacuation of subdural hematomas. Time to diagnosis was 
longer in the serious form group (63 vs. 36 days). Outcome 
was good in both groups, with only one (4%) death due to 
extensive subdural hematomas. Time to recovery was hig-
her in the serious form group (9 months vs. 4.8 months).
Table: Patients’ characteristics, treatment and outcome of both groups: 
with and without sign of severity. N/A: Not applicable
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Conclusion: The presence of subdural hematomas, dis-
turbance of consciousness and a longer time to diagnosis 
and recovery seem to define the serious form of SIH. The-
se patients may require neurosurgery, only after failure of 
conservative measures – bed rest and time – and EBP, with 
good outcome.
Disclosure: Nothing to disclose
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Cost-effectiveness of self-management 
education versus usual care for patients 
with migraine headache: a pilot rando-
mized controlled trial
L. Ridsdale1, B. Osumili2, P. McCrone3
1King’s College London, Institute of Psychiatry, Psychology 
& Neuroscience, Basic and Clinical Neuroscience, London, 
United Kingdom, 2King’s College London, Institute of Psych-
iatry, Psychology & Neuroscience, Psychological Medicine, 
London, United Kingdom, 3King’s College London, Institute 
of Psychiatry, Psychology & Neuroscience, Health Services & 
Population Research, London, United Kingdom
Background:  Headache is one of the common health 
conditions affecting society. In the context of high costs to 
patients, the health care system and society, the need for 
providing cost-effective care is apparent.  
Aim  To estimate the service and social costs of people with 
headache, and to compare the cost-effectiveness of partici-
pants randomised to receive minimal contact cognitive be-
haviour therapy (CBT) and relaxation with those receiving 
standard medical care (SMC) alone.  
Methods:  Participants recruited from specialist headache 
clinics across London were randomised to receive CBT and 
relaxation (plus SMC) or SMC alone. Service use over a 
four month period before and after randomisation was mea-
sured and lost employment recorded. These data were used 
to estimate economic costs. Predictors of cost were identi-
fied using regression and cost-effectiveness was compared 
by combining the costs with QALYs.
Results: The mean service and total costs were £858 and 
£6588 respectively. Service costs were significantly related 
to the number of days spent with headache and total costs 
were significantly related to the impact of headache. In the 
cost-effectiveness analysis, the ICER was £39,492 from the 
health care perspective. From the societal perspective, the 
intervention was dominant with 55.2% chance that it will 
results in lower costs and better outcomes at cost-effective-
ness threshold of £20,000 per QALY.
Conclusion: Costs of headache are high and associated 
with severity. The intervention was not cost-effective from 
a healthcare perspective but was from a societal one. 
Disclosure: Nothing to disclose
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“MyMigraines” community: improving 
communication between migraine patient 
and neurologist
Á.L. Guerrero Peral1, M. Ruiz Piñero2, J.R. Miralles3
1Clinical Universitary Hospital in Valladolid, Neurology, 
Valladolid, Spain, 2Valladolid, Spain, 3Labs Health Company, 
Vigo, Spain
Background and aims: Using of a diary is invaluable in 
the adjustment of therapeutic strategy in a migraine pati-
ent. Diaries or calendars are useful tools to identify pain 
characteristics, possible trigger factors, and the amount of 
symptomatic drugs needed. Electronic diaries are available 
at many websites. “MyMigraines” is an app designed as a 
headache diary available for mobile devices.
Methods: “MyMigraines” allows migraine patients to coll-
ect in an easy and intuitive way, and using their own mobi-
le devices, detailed information on their headache. Quality, 
intensity, location, duration and accompanying symptoms 
of headache episodes and their precipitating factors are so 
recorded. Symptomatic drugs used, and impact on daily li-
ving, including a possible visit to an emergency room are 
also collected. All this information is displayed in calen-
dars.
Results: Migraine patients can also be invited by 
their neurologists to join “MyMigraines” community. 
“MyMigrainesPRO” is an app complementary to 
“MyMigraines” that allows doctors to check, using their 
own mobile devices, the evolution of each of their patients. 
Furthermore, the neurologists can activate an alert system 
individualized for each patient in order to be aware of cer-
tain clinical settings which may require therapeutic chan-
ges. “MyMigrainesPRO” also allows doctors to send mes-
sages to their patients in order to suggest specific behaviors 
or set a new medical visit. 
Conclusion: Mobile technologies, along with its ecosys-
tem of apps as “MyMigraines” community, have created 
a new model for health care. “Mymigraines” and “MyMi-
grainesPRO” allows migraine patients and neurologists, 
through their mobile devices, to improve their communica-
tion achieving a personalized therapy.
Disclosure: Nothing to disclose
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Modulation of pain through cardio-visual 
stimulation in CRPS patients
M. Solcà1, R. Ronchi1, J. Bello Ruiz1, T. Schmidlin2,  
J.-Y. Beaulieu3, F. Luthi4, A. Schnider5, A. Guggisberg5,  
O. Blanke1
1Ecole Polytechnique Fédérale de Lausanne, Laboratory of 
Cognitive Neuroscience, Brain Mind Institute, School of Life 
Sciences,, Lausanne, Switzerland, 2Ecole Polytechnique Fédé-
rale de Lausanne, Center for Neuroprosthetics, Lausanne, 
Switzerland, 3University Hospitals of Geneva, Service of Or-
thopedic Surgery, Unit of Hand Surgery, Geneva, Switzerland, 
4Clinique romande de réadaptation suvacare, Department for 
Musculoskeletal Rehabilitation, Sion, Switzerland, 5Univer-
sity Hospital Geneva, Department of Clinical Neurosciences, 
Geneva, Switzerland
Background and aims: Complex regional pain syndrome 
(CRPS) is a painful condition that remains poorly under-
stood and difficult to treat. Pain perception in healthy sub-
jects has been found to be modulated by experimental ma-
nipulations of body ownership – leading to the experience 
of an artificial body or body part as belonging to their own 
body. Here we propose to use a similar illusion of bodily 
self-consciousness to relieve symptoms of CRPS.
Methods: 9 patients with CRPS following upper limb trau-
ma were tested. We used virtual reality to expose patients 
to a “cardio-visual hand illusion”, in which we presented to 
the participants a virtual hand flashing in synchrony (or in 
asynchrony in the control condition) with their own heart-
beat. Participants underwent both synchronous and asyn-
chronous conditions in a randomized order. Just before and 
after each condition, pain and grip strength were assessed 
using a visual analog scale (VAS) and a dynamometer, re-
spectively.
Results: Preliminary results demonstrated a tendency to-
wards a statistically significant reduction of pain percepti-
on selectively after exposure to the synchronous vs. asyn-
chronous condition. Moreover, grip strength increased after 
exposure to the synchronous condition but reduced after 
the asynchronous condition probably through the analgesic 
effect.
Conclusion: This study provides preliminary evidence 
that the exposure to a virtual hand illusion based on cardio-
visual integration can be used to treat CRPS symptoms. 
These findings could potentially lead to new non-invasive, 
analgesic rehabilitation approach for different pain condi-
tions.
Disclosure: Nothing to disclose
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An unusual presentation of herpes zoster 
ophthalmicus: unilateral ophthalmoplegia 
caused by orbital myositis
S.-R. Kim
DONG-GANG general hospital, Neurology, ULSAN, Korea, 
Republic of
Background and aims: We present a case of unilateral 
ophthalmoplegia caused by orbital myositis associated 
with herpes zoster ophthalmicus (HZO) preceding vesicu-
lar eruptions.
Case Report: A 31-year-old man was admitted to our hos-
pital with right ocular pain, proptosis, double vision, and a 
dull ahcy forehead pain on eye movement. One day later, 
he had a vesicular cutaneous rash in the distribution of the 
ophthalmic division of the right trigeminal nerve. Brain 
MRI revealed proptosis and swelling of right extraocular 
muscles. At that time, the level of creatinin phosphokinase 
was elevated.
Results: Treatment with antiviral agents and prednisolone 
resulted in a rapid improvement of the ophthalmoplegia.
Conclusion: HZO represents approximately 10 to 25 per-
cent of all case of herpes zoster. Several complications as-
sociated with HZO commonly include keratoconjunctivitis, 
scleritis, uveitis, secondary glaucoma, chronic postherpetic 
neuralgia, and ophthalmoplegia caused by cranial nerve III, 
IV, or VI palsies. Ophthalmoplegia associated with HZO is 
not uncommon. The majority were due to involvement of 
ocular cranial nerve. We suppose that the pathogenensis of 
extraocular myositis in this patient may be caused by direct 
affection of herpes zoster virus. So, orbital manifestation 
preceded the skin lesion, extraocular muscle palsies reco-
vered completely, and postherpetic neuralgia did not deve-
lop. HZO can present as unilateral myositis of the extraocu-
lar muscles with signs and symptoms of ophthalmoplegia, 
which are preceded by eruption of the classical skin rash. 
We have to consider the possibility of HZO in a patient of 
unilateral ophthalmoplegia in association with ipsilateral 
facial pain, even without skin rashes.
Disclosure: Nothing to disclose
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Acute myeloneuropathies as a result of 
Ebola virus infection
D. Labunskiy1, T. Fedotova2, V. Poleshchuk3
1Santa Rosa CA, USA, 2Tver State Medical Academy, Tver, 
Russian Federation, 3Research Center of Neurology, Moscow, 
Russian Federation
Background and aims: Hemorrhagic fevers caused by 
Ebola virus are febrile illnesses with abnormal vascular 
regulation and vascular damage.The disease begins with 
severe weakness, headache, muscle aches, diarrhea, abdo-
minal pain, sore throat. Macrophages participation in viral 
infections is widely reported. Microglial response and CNS 
involvement are also evident since syndrome, characterized 
by recurrent optic neuritis, cervical myelopathy from sy-
ringomyelia, paraparesis, amenorrhea-galactorrhea, and 
have other endocrine problems, has been described. Later, 
a dry cough and stabbing pains in the chest appears, deve-
loping signs of dehydration, vomiting, rash (about 50% of 
the patients), together with a decrease of liver and kidneys 
function. 
Methods or Materials or Case Report: Pro-inflammatory 
cytokines, IFN-γ, IL-10, IL-12-p70, IL-1, IL-8, TNF-α, and 
IL-6 were measured simultaneously in tissue culture super-
natants from primary brain derived macrophages, microg-
lia, harvested from the brain tissue of 3 Ebola infected and 
deceased patients. We tested the effects of RAL on markers 
of astrocytosis and neurite integrity in primary human neu-
roglial cultures.
Results: It was revealed reliable decrease of IFN-γ, IL-10, 
IL-12-p70 in macrophages. The levels of IL-8, TNF-α, and 
IL-6 were increase in microglial cells of Ebola patiens in 
comparison with these parameters in patients died from 
other diseases.
Conclusion: Cell culture obtained from patients infected 
with Ebola virus and demonstrated before their death sym-
ptoms of typically myeloneuropathy: difficulty walking 
(gait difficulty) caused by sensory ataxia (irregular muscle 
coordination) due to dorsal column dysfunction or dege-
neration of the spinal cord, showed different pattern of cy-
tokines change. Probably, these findings will contribute to 
more profound pathogenesis understanding of Ebola viral 
myeloneuropathy.
Disclosure: Nothing to disclose
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Intramedullary abscess;  
an epidemiological and clinical analysis
C. Legault1, S. Lapointe2, R. Altman3, D. Vinh4
1Montreal, Canada, 2Université de Montréal, Neurology, 
Montreal, Canada, 3McGill University, Neurology, Montreal, 
Canada, 4McGill University, Microbiology and Infectious 
diseases, Montreal, Canada
Background and aims: Spinal cord abscess is a potentially 
devastating infection of the central nervous system. How-
ever, little is known about this entity. We characterize cli-
nical, epidemiological and imaging features of spinal cord 
abscesses.
Methods: We performed a comprehensive literature review 
of reported intramedullary abscess and report a case of ab-
scess due to Nocardia. Data were identified by searches of 
papers published on Embase, Medline, Cinahl and EMB 
databases, spanning the years 1830 – 2014, using key words 
“spinal cord”, “intramedullary”, “abscesses”, “infection”. 
An “abscess” had to be confirmed by imaging, culture from 
pyogenic debris/cerebrospinal fluid or intraoperatively.
Results: We identified 197 cases of intramedullary abscess. 
We found a striking male predominance (71%). Almost half 
(44%) had acute presentations (0-7 days). Most common 
risk factors were dermal sinuses (30%; 54% under 12 yo), 
concomitant systemic infection (31%) and immunocom-
promised states (13%). The most common microorganisms 
were Staphyloccocus and Streptococcus, followed by poly-
microbial infections and Mycobacterium Tuberculosis. On 
imaging, the majority of abscesses showed multiple spinal 
segments extension (90%), gadolinium ring enhancement 
(68)%, and diffusion restriction (100%; n=3). CSF analysis 
was characterized by leukocytosis, proteinorachia (79%) 
and hypoglychoracchia (64%). Most patients were treated 
by tandem surgery and antibiotics (63%). Of the 107 out-
comes reported, 30% fully recovered and 4% died during 
course of illness.
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Nocardia intramedullary abscess case - Cervical MRI with T2 and Ga-
dolinium
Nocardia intramedullary abscess case - Cervical MRI Diffusion 
weighted image
Norcardia intramedullary abscess - Direct modified Acid fast stain 
from pus drained from the lesion showing Nocardia farcinica colonies
 
Conclusion: Intramedullary abscesses are rare and associ-
ated with poor outcomes. Rapid diagnosis is paramount to 
minimize morbidity. Clues to diagnosis include predispo-
sed host, pyogenic CSF, and gadolinium ring enhancement 
with diffusion restriction. Optimal treatment remains unde-
fined, however combined surgical drainage with appropria-
te antimicrobials appears most successful.
Disclosure: Nothing to disclose
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An outstanding and striking case of  
solitary cerebral toxoplasmosis mimicking 
glioblastoma as the first presentation of 
HIV
M. León Ruiz1, M. Alonso Riaño2, P. Gómez Iglesias3,  
S. Delis Gómez4, S. del Carmen Martínez5, J. Benito-León4, 
M.Á. García Soldevilla1, L. Izquierdo Esteban1,  
F. Cabrera Valdivia1, J. Tejeiro Martínez1,  
C.S. Abdelnour Ruiz1, M. Molina Sánchez1,  
M.H. Torregrosa Martínez1, P. Hernández Navarro1,  
E. García-Albea Ristol1, O. Toldos González2,  
A. Hernández Laín2
1Hospital Universitario Príncipe de Asturias, Neurology, 
Madrid, Spain, 2Hospital Universitario 12 de Octubre, Pa-
thology, Madrid, Spain, 3Hospital Universitario Fundación 
Alcorcón, Pathology, Madrid, Spain, 4Hospital Universitario 
12 de Octubre, Neurology, Madrid, Spain, 5Hospital Clínico 
Universitario de Salamanca, Pathology, Salamanca, Spain
Background and aims: To report an exceptional case of 
encephalic toxoplasmosis (ET) resembling glioblastoma as 
initial manifestation of HIV-infection.
Case Report: A 50-year-old man consulted for a 10 days 
long clinical picture of behavioral disturbances and phar-
maco-refractory headache. Past medical history was remar-
kable by 8 month-course of constitutional syndrome with 
normal blood test, thoraco-abdomino-pelvic CT-scan, and 
colonoscopy.
Results: Neurological examination only highlighted drow-
siness, but cranial CT-scan (and MRI later), showed a right 
fronto-parietal infiltrative mass, with annular enhancement, 
invading contralateral hemisphere through corpus callo-
sum, causing midline shift. After performing stereotactic 
lesion biopsy, immunohistopathology revealed Toxoplasma 
intracellular bradyzoites and extracellular tachyzoites, be-
sides HIV-antigen presence using anti-HIV p24-antibody. 
Laboratory analyses disclosed positive anti-toxoplasma-
IgG, 262 CD4/μL, and 747.604 copies/mL viral load. Anti-
Toxoplasma and antiretroviral therapies were initiated. Fi-
nally the patient achieved complete remission.
Cranial CT-scan (axial slice: after intravenous contrast application). It 
became apparent an extensive fronto-parietal hypodensity with mass 
effect, reaching the contralateral hemisphere in a “butterfly-like” 
mode, and producing midline displacement.
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Gadolinium-enhanced T1-weighted MRI (axial slice). The results of 
the MRI confirmed the findings on CT-scan, defining the lesion as a 
large intra-axial ring-enhancing mass and extensive surrounding ede-
ma, giving rise to subfalcine herniation.
Cerebral tissue sample. In optical microscope, free tachyzoites (blue 
arrows) and pseudocyst bradyzoites (green arrows) around necrotic 
lesions were observed (HE stain, x100). These formations tested posi-
tive for anti-Toxoplasma immunohistochemical stain.
Conclusion: Glioblastoma is the commonest primary brain 
neoplasm in adults. Furthermore, ET (AIDS-defining ill-
ness) is generally a late HIV-infection complication that 
usually results from latent infection reactivation. Common 
ET clinical presentations are cephalalgia and focal neuro-
logical deficit. Its onset rarely precedes HIV-infection dia-
gnosis. Only 14-25% of patients show a single lesion, mo-
reover, AIDS patients may have ET in abnormal locations. 
Definitive diagnosis procedure is brain biopsy which is 
justified in cases of atypical radiologic appearance for ET. 
To our knowledge, this is the first described case with the-
se neuroradiological features and >200 CD4/μL heralding 
AIDS. Consequently, clinicians must consider this possi-
bility before a ring-enhancing space-occupying cerebral 
lesion, even in patients without prior immunosuppression 
or HIV-infection history, in order to bring about early diag-
nosis and treatment administration.
Disclosure: Nothing to disclose
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Central nervous system tuberculosis:  
a three-decade analysis.
M.J. López-Martínez1, L. Martínez-García2, M. Bordallo2,  
E. Navas3, C. Quereda3, G. Garcia-Ribas1,  
E. Gómez-Mampaso2, Í. Corral1
1Hospital Universitario Ramón y Cajal, Neurology, Madrid, 
Spain, 2Hospital Universitario Ramón y Cajal, Microbiology, 
Madrid, Spain, 3Hospital Universitario Ramón y Cajal, Infec-
tious Diseases, Madrid, Spain
Background and aims: Tuberculous meningitis (TBM) is 
an uncommon but severe complication of tuberculous in-
fection, due to a high rate of morbidity and mortality de-
spite adequate treatment. Immunosuppression is the most 
important risk factor for the development of neurological 
tuberculous disease.
Methods: Retrospective review of epidemiology, clinical 
manifestations, laboratory features, neuroimaging, treat-
ment regimen and clinical outcome of patients with definite 
central nervous system (CNS) tuberculosis (Mycobacteri-
um identification in cerebrospinal fluid (CSF) or in biopsy 
material), in a tertiary hospital from 1979 to 2013. We com-
pare human immunodeficiency virus (HIV) infected and 
HIV-negative groups.
Results: A total of 63 subjects was included: 61 TBM (4 
associated with tuberculous brain abscess (TBA), 1 isolated 
TBA and 1 isolated tuberculoma. Among TBM cases: 61% 
were male, mean age was 43 years [32-66] and 59% had 
active extraneurological tuberculosis. Median CSF white 
blood cell count was 160 cells/µl [66-345], glucose 21 mg/
dl [19-41] and protein 1.7 mg/dl [1.1-2.5]. Neuroimaging 
was normal in 44%. Multidrug resistance was found in 3 
HIV-positive patients. Antituberculous treatment was ad-
ministered a mean of 6 days [2-23] after CSF analysis. Per-
manent neurological sequelae occurred in 38% and morta-
lity was 23%. HIV-positive patients (21) were younger, had 
extraneurological tuberculosis and developed TBA more 
frequently (4 of 5 TBA). They presented more neurologic 
sequelae, but mortality was similar to the HIV-negative 
group.
Conclusion: CNS tuberculosis is frequently associated to 
HIV infection, but this association does not affect mortality, 
clinical manifestations or ancillary tests results. TBA is a 
characteristic complication in HIV-positive patients.
Disclosure: Nothing to disclose
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Guillain-Barré syndrome following acute 
hepatitis E in a Western European man
P. Pérez Torre, F. Acebrón, E. Monreal, E. Viedma Guiard,  
P. Martinez Ulloa, C. Estévez Fraga, A. Alonso Cánovas,  
I. Avilés Olmo, J. Buisán Catevilla
Hospital Ramón y Cajal, Neurology, Madrid, Spain
Background and aims: In Europe and North America, 
hepatitis E is known as an acute disease in travellers re-
turning from tropical countries, but an endemic source of 
hepatitis E has always been suspected. Here, we report one 
of the few cases of GBS due to local acute hepatitis E vi-
rus (HEV) infection associated with the presence of anti-
ganglioside GM1 antibodies in immunocompetent male of 
Western Europe.
Case Report: A 54-year-old previously healthy man pre-
sented with Guillain-Barré syndrome (GBS) and elevated 
liver enzymes. As epidemiological data he had been bitten 
a month earlier by a dog and raised a pig in the backyard. 
The patient presented with tetraparesis. Further diagnostic 
investigations showed HEV acute infection confirmed se-
rologically and by polymerase chain reaction (PCR) from 
blood .
Results: The presence of an acute hepatitis E infection was 
associated with anti-ganglioside GM1 antibodies. After 
treatment with intravenous immunoglobulins, the patient 
made a rapid recovery.
Conclusion: The actual incidence of GBS associated with 
HEV infection is unknown because native hepatitis E is still 
underdiagnosed in Western Europe. Since the patient repor-
ted no travel history, it seems likely that the HEV infection 
was locally acquired. Despite having been bitten by a dog 
we consider it most probably resulted from touching an in-
fected pig since HEV infection is endemic in the Spanish 
swine population, not so in dogs. Therefore we strongly 
recommend that testing for HEV should be included routi-
nely even in Western Europe, in the diagnostic algorithm of 
GBS when liver function is altered. 
Disclosure: Nothing to disclose
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Effects of coenzyme Q10 in PSP, A  
multicenter, randomized, placebo- 
controlled, double-blind study
D. Apetauerova1, S. Scala1, D. Standaert2, R. Hamill3,  
D. Simon4, T. Yacoubian5
1Lahey Hospital and Medical Center, Neurology, Burlington, 
MA, USA, 2²University of Alabama at Birmingham, Neuro-
logy, Birmingham, USA, 3³University of Vermont College of 
Medicine, Neurological Sciences, Burlington, VT, USA, 4Beth 
Israel Deaconess Medical Center & Harvard Medical Center, 
Neurology, Boston, MA, USA, 5²University of Alabama at 
Birmingham, Neurology, Birmingham, AL, USA
Background and aims: Progressive Supranuclear Palsy 
(PSP) is a neurodegenerative disorder clinically classified 
as an atypical parkinsonian syndrome or neuropathologi-
cally as a tauopathy. Mitochondrial dysfunction is hypothe-
sized to play a role in the pathophysiology of PSP. CoQ10, 
a potent antioxidant found in humans, is the coenzyme for 
mitochondrial enzymes (complexes I, II & III) as well as 
other cellular enzymes. An investigator initiated, multi-
center, randomized, placebo-controlled, double-blind cli-
nical trial to determine whether Coenzyme Q10 (CoQ10) 
is safe, well tolerated, and effective in slowing functional 
decline in PSP.
Methods: 61 participants received CoQ10 (1200mg/day) 
or placebo for up to 12 months. The Progressive Supra-
nuclear Palsy Rating Scale (PSPRS), Unified Parkinson’s 
Disease Rating Scale (UPDRS), Activities of Daily Life 
(ADL), Mini Mental Status Exam (MMSE), Parkinsons 
Disease Quality of Life Scale (PDQ-39), and SF-36 were 
monitored at baseline and subsequently at months 3, 6, 9 
and 12. The safety profile of CoQ10 was determined by 
adverse events, vital signs, and clinical laboratory values. 
Primary outcome measures were change in PSPRS and UP-
DRS scores from baseline at month 12.
Results: CoQ10 was well tolerated. No statistically signifi-
cant differences were noted between the CoQ10 and place-
bo groups in the primary or secondary outcome measures. 
A non-significant trend toward slower clinical decline in 
the CoQ10 group was observed in total PSPRS among tho-
se participants who completed the trial. 
Conclusion: High doses of CoQ10 did not show statisti-
cally significant improvement of PSP symptoms or disease 
progression. The trend towards slower clinical decline in 
the total PSPRS in the CoQ10 groups is of uncertain sig-
nificance.
Disclosure: This study was supported by grants from the 
Society for PSP and the Robert E. Wise Research and Edu-
cation Institute.  The CoQ10 and matching placebo were 
formulated, manufactured and packaged with minimal cost 
by Vitaline® Formulas (Green Bay, WI) and Kaneka (Pasa-
dena, TX)
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Clinical aspect of botulinum treatment  
discontinuation in focal dystonia
M. Balaz1, E. Ehler2, M. Bares1
1Brno, Czech Republic, 2Pardubice Hospital, Pardubice, 
Czech Republic
Background and aims: Botulinum toxin (BoNT) therapy 
is considered to be a first-line, best and standard treatment 
of focal dystonia. Despite this fact, drop-out rates from the 
treatment appear to be quite high. Aim of our work was to 
compare reasons for BoNT discontinuation in focal hand 
dystonia (FHD) and cervical dystonia (CD).
Methods: We included 630 patients, 80 of them with FHD 
and 550 with CD examined in two movement disorders 
centers. We inititiated survey on effectivity of treatment 
and reasons for discontinuation of BoNT therapy where ap-
plicable. All patients with BoNT treatment were followed 
for at least 3 years.
Results: Of patients initiated with BoNT only about 60% 
continued with treatment for more than  5 treatment cycles. 
Main diference between the groups was the incidence of 
side effects, which was the most frequent cause (27%) of 
BoNT discontinuation in FHD. In CD group, only 13.4% 
of patients reported side effects  (p 0.047). Most relevant 
reported side effect in both groups was muscle weakness 
(85%).
Conclusion: Relatively high proportion (53%) of patients 
with FHD chose to discontinue the treatment with BT. This 
was not statistically different in comparison to CD (44%).
Our results imply that it is important to pay attention to 
occurrence especially of side effects in patients with FHD. 
Improvement of treatment procedure by adjusting a BoNT 
dose or improvement of the application is warranted.
Disclosure: Nothing to disclose
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Significant reduction of pain treatments 
with safinamide administered as add-
on therapy to levodopa in patients with 
Parkinson’s disease and fluctuations.
P. Barone1, C. Cattaneo2, R. La Ferla2, E. Bonizzoni3,  
M. Sardina4
1University of Salerno, Department of Medicine, Neurosci-
ence Section, Baronissi (Salerno), Italy, 2Zambon SpA, Medi-
cal Department, Bresso (Milan), Italy, 3University of Milan, 
Department of Clinical Science and Community, Section of 
Medical Statistics and Biometry “G.A. Maccacaro”, Milan, 
Italy, 4Zambon SpA, R&D Department, Bresso (Milan), Italy
Background and aims: Safinamide (Xadago™, Zambon 
SpA, Italy), a unique molecule with a novel mechanism of 
action (dopaminergic and non-dopaminergic), was studied 
in late-stage PD patients in  two double-blind, placebo-
controlled, 6-months trials (016 and SETTLE), showing 
an increase in “ON” time and a decrease in “OFF” time 
without increasing troublesome dyskinesia. The objective 
of this post-hoc analysis is to evaluate the efficacy of safi-
namide vs. placebo on pain in Parkinsonian patients with 
motor fluctuations.
Methods: The effects of safinamide on the reduction of 
concomitant pain treatments and on the bodily discomfort 
domain of the Parkinson’s Disease Quality of life question-
naire PDQ-39 were investigated using the pooled data from 
the pivotal Phase III trials 016 and SETTLE.
Results: The percentage of patients with no pain treatments 
at the end of the trials were significantly lower in the safi-
namide group compared to the placebo group (76.1 vs 70% 
respectively, p=0.03053). Moreover, safinamide showed 
significant improvements in the bodily discomfort domain 
(p=0.0007) of the PDQ-39 scale.
Conclusion: Safinamide, administered as add-on therapy 
to levodopa in mid- to late-stage fluctuating PD patients, 
contributed to reduce the number of concomitant pain treat-
ments and to improve the bodily discomfort domain of the 
PDQ-39 score, with a significant positive impact on the 
quality of life of the patients.  
Disclosure: Carlo Cattaneo, Roberto La Ferla and Marco 
Sardina are employees of Zambon Pharma SpA. Erminio 
Bonizzoni is a consultant for statistical analyses of Zambon 
SpA. Paolo Barone is consultant and member of the Scien-
tific Advisory Board of Zambon SpA.
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Exploring indexes of driving performance 
in cognitively intact drivers and drivers 
with Parkinson’s disease (PD)
I. Beratis1, N. Andronas1, E. Papadimitriou2, D. Pavlou2,  
M. Stamelou1, G. Tsivgoulis1, L. Stefanis1, S. Papageorgiou1
1Athens Medical School, “Attikon” University Hospital , 2nd 
Department of Neurology, Athens, Greece, 2National Techni-
cal University of Athens, School of Civil Engineering, Depart-
ment of Transportation Planning and Engineering, Athens, 
Greece
Background and aims: Previous research has provided 
evidence about the presence of driving difficulties in dri-
vers with Parkinson’s disease (PD). In the present research 
we explored in detail the driving profile of individuals with 
PD by applying a large driving simulation experiment.
Methods: Inclusion criteria required a valid driver’s license, 
regular car driving, a CDR score ≤0.5, and a Hoehn&Yahr 
score ≤3. 41 cognitively intact individuals (Age: 59.8±9.1 
years) and 19 individuals with PD (Age: 62.7±11.1 years) 
participated in the study. The data collection included a 
comprehensive neurological/neuropsychological assess-
ment and a driving simulation experiment. Drivers with PD 
were tested during the on-phase. Outcome measures were 
average driving speed, speed variation, wheel position va-
riation, number of crashes, reaction time in unexpected in-
cidents, lateral position, lateral position variation, average 
headway distance, and headway distance variation.
Results: Significant differences were found in average 
speed (p=.002), speed variation (p=.048), reaction time 
(p=.001), average headway distance (p<.001), headway 
distance variation (p=.004), and wheel position variation 
(p=.027). The cognitively intact group had greater average 
speed, speed variation and variation of the wheel position 
as compared to the group of drivers with PD. On the con-
trary, the clinical group had increased reaction time as well 
average headway distance and headway distance variation.
Conclusion: The results of the present study indicate that 
the driving patterns of individuals with PD differ signifi-
cantly from those of healthy individuals in indexes that 
may play an important role in overall driving performance 
and behaviour.
Disclosure: Nothing to disclose
294      Poster presentation with discussion
© 2015 European Journal of Neurology, 22 (Suppl. 1), 120–483
P2242
Marked intrafamilial variability of ataxia 
and hypogonadotropic hypogonadism 
cause by RNF216 mutation
S. Bohlega1, M. Alqwaifly2, H. Murad1, F. Alkuraya3
1Riyadh, Saudi Arabia, 2KFSH & RC, Neurosciences, Riyadh, 
Saudi Arabia, 3KFSH & RC, Genetics, Riyadh, Saudi Arabia
Background and aims: The syndrome of ataxia and hypo-
gonadism is a rare disorder initially described by Gordon 
Holmes and recently it was found to be caused by a mutati-
on in RNF2156, STUB1, or PNPLA6.   Many other clinical 
features are associated with these disorders.
Objective:  To describe the phenotype and genotype of a 
new family.
Methods: A positional cloning approach utilizing genome-
wide linkage, homozygozity mapping and whole exome 
sequencing was used.
Results: A native Saudi Arabian family with 2 out of 9 
siblings; parents are consanguineous. The first had poor 
development of secondary sexual characteristics but no 
ataxia. Cerebellar atrophy and mild white matter lesions 
were seen on brain MRI. In the second, progressive ata-
xia was noted at the age of 24 with feature hypogonadism 
and gynecomastia; moderate cognitive impairment and 
hyper reflexia were noted. Marked cerebellar atrophy and 
severe white matter involvement were noted. Serum testo-
sterone level were low but no other pituitary access were 
affected. Whole body x-ray indicated marked delay in cor-
responding bone age. Exome sequencing performed from 
both patients and showed homozygous splice mutation in 
RNF216,c.2061G>A.
Conclusion: The inheritance pattern in this family was 
autosomal recessive. There was marked clinical and radio-
logical variabilities among the affected members. The mu-
tation noted was novel and will add to the known mutation 
reported in this disorder.  
Disclosure: Nothing to disclose
P2243
Normal pressure hydrocephalus: increase 
of oVEMP/utricular input in responders to 
diagnostic lumbar puncture – evidence for 
otolith dysfunction?
N. Böttcher, T. Bremova, A.-M. Ruppert, C. Heinze,  
R. Schniepp, M. Strupp
University of Munich, Neurology, Munich, Germany
Background and aims: Normal pressure hydrocephalus 
(NPH) is characterized by an impairment of gait and retro-
pulsion. Similar symptoms are also found in patients with 
impaired otolith function. Therefore, we investigated oto-
lith function using vestibular evoked myogenic potentials 
(VEMP) (ocular VEMP (oVEMP) for utricular and cervi-
cal VEMP (cVEMP) for saccular function) in patients with 
probable NPH before and after spinal tap test (sTT).
The aim of this study is to investigate whether there is a 
change in o/cVEMP in responders versus non-responders 
to sTT in patients with suspected NPH.
Methods: In 25 patients (6 females, age 62-83yrs, mean 
76yrs) VEMPs were measured before and after sTT. Pa-
tients with an increase of >20% of preferred walking ve-
locity were classified as responders (n=10). As controls, 
VEMPs were also measured in 11 non-NPH patients before 
and after sTT.
Results: All patients had reproducible oVEMP; only 16 
out of the 25 patients (68%) had cVEMP. There was a si-
gnificant increase of the peak-to-peak oVEMP amplitude 
after sTT in responder from 8.5±2.7µV to 18.9±7.5µV 
(p=0.010). No significant changes were found in non-
responder (10.9±6.8µV vs 11.1±7.1µV), in controls 
(10.7±5.5µV vs 10.2µV±2.9) and for the cVEMP (res-
ponder: 41.5±17.5µV vs 49.4±10.4µV; non-responder: 
41.0±25.7µV vs 44.1±75.6µV).
Conclusion: 32% of patients with suspected NPH had im-
paired otolith function. Responders to sTT only had a si-
gnificant increase of oVEMP and thereby utricular input, 
probably due to decreased pressure. Both findings indica-
te that otolith dysfunction may contribute to imbalance in 
NPH and that an increased utricular function after sTT may 
be important for gait improvement.
Disclosure: Nothing to disclose
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Impulse control disorders and side of  
motor symptoms in Parkinson’s disease
M. Calejo1, A. Rua2, I. Moreira3, A. Gonçalves1, J. Damasio1, 
N.M.D.S. Vila-Chã2, A. Bastos Lima2, A. Mendes2,  
S. Cavaco1
1Centro Hospitalar do Porto - Hospital de Santo António, 
Neuropsychology Unit, Porto, Portugal, 2Centro Hospitalar 
do Porto - Hospital de Santo António , Neurology, Porto, 
Portugal, 3Centro Hospitalar do Porto - Hospital de Santo 
António, Neuropsychology, Porto, Portugal
Background and aims: Impulse control disorders (ICD) 
are frequent in Parkinson’s disease (PD) and have been 
linked to changes in the ventral striatum and ventromedial 
prefrontal cortex. The literature on ICDs association with 
side of motor symptoms in PD is scarce and inconsistent. 
We aimed to explore this association with a PD cohort.
Methods: We evaluated 299 consecutive patients diag-
nosed with PD from the movement disorders’ outpatient 
clinic [51% men; mean age=69±11; mean education=6±4; 
mean age at onset=60±12; 46% left and 54% right side mo-
tor symptoms at onset; mean disease duration=9±6; mean 
Unified Parkinson’s Disease Rating Scale-III (UPDRS-III) 
off=34±12 and on=23±10; mean levodopa equivalent dose 
(LED)=884±544mg; 40% were taking dopamine agonists]. 
Presence of ICD and/or related-behaviors (ICDRB) was 
screened using the Questionnaire for ICD in Parkinson’s 
Disease-Current-Short (QUIP). Chi-square test and multi-
ple logistic regression analysis were applied for data ana-
lysis.
Results: ICDRB were identified in 54 patients (18%). The 
presence of ICDRB was more frequent in patients with mo-
tor symptom onset on the right side than on the left side 
(23.5% vs 11.7%, p=0.008). This association remained sta-
tistically significant (adjusted odds=2.694, p=0.008), when 
controlled for sex, age at disease onset, UPDRS-III off, 
LED, and dopamine agonists.
Conclusion: PD patients with motor symptom onset on the 
right side of the body, which corresponds to greater dopa-
minergic denervation on the left hemisphere, have an in-
creased risk of developing ICDRB. This finding suggests 
that excessive pharmacologic stimulation of the preserved 
right mesocorticolimbic structures triggers the occurrence 
of ICDRB.
Disclosure: Nothing to disclose
P2246
Brain structural and functional  
abnormalities in Parkinson’s disease  
patients with freezing of gait
E. Canu1, F. Agosta1, E. Sarasso1, M.A. Volonté2, L. Sarro1,  
S. Galantucci1, S. Basaia1, R. Gatti3, A. Falini4, G. Comi2,  
M. Filippi1
1San Raffaele Scientific Institute, Vita-Salute San Raffaele 
University, Neuroimaging Research Unit, Milan, Italy, 2San 
Raffaele Scientific Institute, Vita-Salute San Raffaele Univer-
sity, Department of Neurology, Milan, Italy, 3San Raffaele 
Scientific Institute, Vita-Salute San Raffaele University, Labo-
ratory of Movement Analysis, Milan, Italy, 4Università Vita-
Salute San Raffaele, Neuroradiology, Milan, Italy
Background and aims: To assess brain functional and 
structural network alterations in Parkinson’s disease with 
freezing of gait (PD-FoG).
Methods: T1-weighted, diffusion tensor (DT) MRI and 
resting state (RS) fMRI were obtained from 23 PD-FoG 
patients and 36 controls. Subjects underwent clinical, mo-
tor-functional, and neuropsychological evaluations. Gray 
matter (GM) volume and white matter (WM) damage were 
assessed using voxel-wise approaches. RS fMRI data were 
analyzed using a model free approach investigating sen-
sorimotor, visual and cognitive brain networks. DT MRI 
measures were obtained from the main interhemispheric 
and long-associative WM tracts.
Results: Patients presented mild FoG. Compared with con-
trols, patients showed WM damage mainly of the locomo-
tor pathways, corpus callosum and cingulum. No GM atro-
phy was detected in patients relative to controls. RS fMRI 
analysis showed that PD-FoG was associated with a decre-
ased functional connectivity in the sensorimotor, associati-
ve-visual, default-mode, and ventral-attentive networks. In 
patients, reduced functional connectivity was related to the 
damage of the WM tracts passing through the networks. 
More severe FoG was associated with lower functional 
connectivity within the associative-visual network. Worse 
motor and cognitive performances were related with more 
severe WM damage and reduced functional connectivity.
Conclusion: PD-FoG patients showed disrupted structural 
and functional connectivity of the locomotor, associative-
visual, and cognitive-related brain networks, which was 
related to FoG, disease severity, executive and visuospatial 
deficits. These findings support the theory of FoG as the 
result of a poor integration between motor programming, 
visuospatial and attentional abilities.
Disclosure: Jacques and Gloria Gossweiler Foundation. 
296      Poster presentation with discussion
© 2015 European Journal of Neurology, 22 (Suppl. 1), 120–483
MS and related disorders 5
P2247
Quality of life and cognitive function in  
pediatric and young multiple sclerosis  
patients: a cross-sectional study
A. Carotenuto1, A. Chiodi1, V. Magri1, A. Napolitano1,  
T. Costabile1, C.V. Russo1, M. Moccia1, R. Liuzzi2,  
K. Piscopo1, L. Rosa1, M. Ottobre1, N. Rainone3,  
M.F. Freda3, P. Valerio1, V. Brescia Morra1, R. Lanzillo4
1Federico II University, Naples, Italy, Department of Neu-
rosciences, Reproductive Science and Odontostomatology, , 
Naples, Italy, 2Institute of Biostructure and Bioimaging, Nati-
onal Research Council, Naples, Italy, 3Federico II University, 
Naples, Italy, Department of Humanistic Study, Naples, Italy, 
4Naples, Italy
Background: Multiple sclerosis (MS) is a demyelinating 
disease of the CNS occurring in children or adolescents in 
approximately 5% of cases. It has been reported cogniti-
ve impairment (CI) in 40-54% of  early-onset MS patients 
(EO-MS) and lower health-related quality of life (QOL).
Objective: Assess the relationship between cognitive func-
tion and QoL in EO-MS.
Methods: This is a cross-sectional study carried out on 
59 EO-MS. Pediatric Quality of life inventory Version 
4.0,  Beck Depression Inventory II (BDI II)  and the Brief 
Repeatable Battery were performed.
Results: Demographic and clinical characteristics are sum-
marized in table 1. 39% had no CI, 61% had a borderline/
significant CI. No association was found between  CI and 
any socio-demographic and clinical data.
HR-QoL was higher in pediatric (age at onset <18y)  than 
young (age at onset  18<x<25) MS patients  (p=0.02), and it 
was inversely related to EDSS (p=0.0005) and Multiple Sc-
lerosis Severity score (MSSS) (p=0.0001). BDI was lower 
in pediatric than young MS patients and  it was directly re-
lated to EDSS and MSSS. HR-QoL total score is not related 
to CI nor to any domain-specific cognitive function even 
considering BDI as possible bias. CI was related to social , 
physical functioning score and  EDSS (p=0.01) at a logistic 
regression backward stepwise estimation.
Table 1.
Conclusion: We confirmed results of previous papers, 
pointing out, in addition, that cognition in EO-MS is influ-
enced by physical disability and  poor social involvement 
(school, education, work…). Social participation, affective 
relations and psychological flexibility could have  a protec-
tive function on CI. 
Disclosure: Nothing to disclose
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Differential recovery from relapse  
between treatment groups in the  
CONFIRM study of delayed-release  
dimethyl fumarate
A. Chan1, J.T. Phillips2, R.J. Fox3, A. Zhang4, J. Potts4,  
N.C. Kurukulasuriya4
1St. Josef Hospital, Ruhr University, Bochum, Germany, 
2Multiple Sclerosis Program, Baylor Institute for Immunology 
Research, Dallas, USA, 3Mellen Center for Multiple Sclerosis 
Treatment and Research, Cleveland Clinic, Cleveland, USA, 
4Biogen Idec, Cambridge, USA
Background and aims: Delayed-release dimethyl fumara-
te (DMF; also known as gastro-resistant DMF) demonstra-
ted significant efficacy and an acceptable safety profile in 
relapsing-remitting multiple sclerosis (RRMS) in the Phase 
3 DEFINE and CONFIRM studies. The objective of this 
analysis was to evaluate the association between relapse 
and disability progression, and between progression/relap-
se status and quality of life (QoL) outcomes, in a post-hoc 
analysis of data from CONFIRM.
Methods: Eligibility criteria included age 18−55 years, 
RRMS diagnosis, and Expanded Disability Status Scale 
(EDSS) score 0−5.0. Patients were randomized to receive 
placebo, DMF 240mg BID or TID, or glatiramer acetate 
(GA; reference comparator). Odds of relapse-led disability 
progression (12-week confirmed disability progression be-
ginning within 180 days after the start date of relapse) were 
assessed using logistic regression adjusted for baseline co-
variates. Changes from baseline in the Physical and Mental 
Component Summaries (PCS/MCS) of the Short Form-36 
and visual analog scale (VAS) were assessed. Results from 
patients receiving DMF BID (approved maintenance dose 
in all regions) are reported.
Results: The intent-to-treat population comprised 363, 
359, and 350 patients in the placebo, DMF BID, and GA 
groups, respectively. At 2 years, the proportion of patients 
with relapse-led disability progression was lowest in the 
DMF BID group (Figure 1). PCS, MCS, and VAS scores 
were significantly improved in patients with no progression 
and no relapse compared with patients with relapse and/or 
progression (Figure 2).
Conclusion: Results suggest that patients receiving DMF 
had reduced odds of relapse-led disability progression com-
pared with placebo, and that relapse and disability status 
impact QoL measures.
Disclosure: Study supported by Biogen Idec, Inc. 
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Efficacy of teriflunomide treatment in 
achieving no evidence of disease activity 
over a 2-year period: post hoc analysis of 
the TEMSO study
A. Chan1, J. de Seze2, P. Truffinet3, K. Thangavelu4, P. Rufi3, 
M. Comabella5
1St. Josef Hospital, Klinikum der RUB, Bochum, Germany, 
2Strasbourg University, Hôpital Civil, Strasbourg, France, 
3Genzyme, a Sanofi company, Chilly-Mazarin, France, 4Gen-
zyme, a Sanofi company, Cambridge, USA, 5Vall d’Hebron 
University Hospital, Barcelona, Spain
Background and aims: Teriflunomide is a once-daily oral 
immunomodulator approved for relapsing-remitting MS. 
This post hoc analysis evaluated the efficacy of terifluno-
mide in achieving no evidence of disease activity (NEDA) 
in TEMSO (NCT00134563), a pivotal phase 3 study vs 
placebo.
Methods: Patients with relapsing forms of MS (N=1088) 
were randomized to teriflunomide 14mg (n=359), 7mg 
(n=366), or placebo (n=363) for 108 weeks. For each year 
and over the full 2-year study period, the proportion of pa-
tients with a composite measure of NEDA (defined as no 
gadolinium-enhancing T1 lesions, no new/enlarging T2 le-
sions, no clinical relapse, and no 12-week sustained disabi-
lity progression) was reported using odds ratio (OR) and P 
value for teriflunomide 14mg and 7mg vs placebo.
Results: In year 1, NEDA was observed in 34.4% of pa-
tients receiving teriflunomide 14mg vs 22.0% receiving 
placebo (OR 1.85; P=0.0002) and in 28.8% receiving te-
riflunomide 7 mg (OR 1.43; P=0.0371). In year 2, NEDA 
was observed in 35.3% of patients receiving teriflunomide 
14mg vs 21.2% receiving placebo (OR 2.03; P=0.0002) 
and in 29.9% receiving teriflunomide 7mg (OR 1.59; 
P=0.0162). Over the complete 2-year study period, the pro-
portion of patients with NEDA was significantly higher in 
the 14mg group (22.9%; OR 1.78; P=0.0031) vs placebo 
(14.3%). The proportion with NEDA was also higher with 
teriflunomide 7mg (18.4%; OR 1.34) but not statistically 
significant.
Conclusion: Teriflunomide was associated with a signifi-
cant dose-dependent increase in the proportion of patients 
with NEDA in the first year that persisted in the second 
year.
Disclosure: Study supported by Genzyme, a Sanofi com-
pany.
P2250
Devenir: observational study of detection 
and assessment of demyelinating events 
in France
R. Colamarino1, J.-M. Visy2, J.-J. Pere3, I. Bourdeix4,  
G.L. Defer5
1Centre hospitalier Vichy, Neurology, Vichy, France, 2office 
based neurologist, Rheims, France, 3Novartis Pharma, Cli-
nical research, Rueil-malmaison, France, 4Novartis Pharma, 
Biometry, Rueil-Malmaison, France, 5CHU Côte de Nacre, 
Neurology, Caen, France
Background and aims: Detection and assessment of a first 
clinical demyelinating event (CSI) in routine practice are 
currently not well known
This prospective study assessed over 12 months proporti-
on of treated patients with an immunomodulatory (IMD) 
among those with a first clinical demyelinating event.
Methods: Observational study in France conducted by a 
representative sample of neurologists on patients for whom 
first clinical demyelinating event has been diagnosed and 
who will be followed over 12 months. Nature and frequen-
cy of diagnostic tools, decision factors of IMD treatment 
and use of optional tools evaluating fatigue (U-FIS), beha-
vioral disorders (HAD) and cognitive disorders have been 
recorded.
Results: Diagnosis tools were used with the following fre-
quency: MRI (100%), lumbar punction (69.3%), evoked 
potential (48.9%). Out of 137 patients analyzed, 66 (48.2%) 
have initiated IMD. The most frequent decision criteria 
for IMD treatment were MRI (77.3%), clinical symptoms 
(59.1%) and the estimated risk of relapse (45.5%). Fatigue 
(U-FIS)) and behavioral disorders (HAD) were evaluated 
for 59% of patients, but cognitive disorders were rarely as-
sessed.
Conclusion: Initiation of IMD treatment in multiple scle-
rosis for half of the patients within the year following the 
first clinical demyelinating event is mainly based on MRI 
criteria and/or the occurrence of a relapse. At MRI the first 
spatiotemporal dissemination criteria was satisfied for al-
most 75% of treated patients, but 40% of patients have not 
been treated despite the presence of this criteria. 
Disclosure: This study was granted by Novartis Pharma 
S.A.S.
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Endothelin-1 serum levels are increased in 
patients with multiple sclerosis
C. Criscuolo1, R. Lanzillo1, A. Cianflone1, E. Postiglione1,  
R. Liuzzi2, G. Vacca1, O. Caporale3, R. Palladino3,  
M. Triassi3, M. Vastola1, M. Moccia4, G. Puorro1, A. Marsili1, 
M. Incoronato5, M. Salvatore6, V. Brescia Morra1
1Federico II University, Neurosciences, Reproductive and 
Odontostomatological Sciences , Naples, Italy, 2Institute of 
Biostructure and Bioimaging, National Research Council, 
Naples, Italy, 3Federico II University, Department of Public 
Health, Naples, Italy, 4Naples, Italy, 5IRCSS SDN Foundation, 
Naples, Italy, 6Federico II University, Advanced Biomedical 
Sciences, Naples, Italy
Background: Clinical and experimental evidence suggests 
that endothelin-1 (ET-1) plays a role in cardiac and vascu-
lar disease. Patients with multiple sclerosis (MS) show glo-
bal cerebral hypoperfusion.
Objectives: To evaluate ET-1 in MS patients vs healthy 
subjects (HS) in the context of a larger study on the as-
sociation among MS, amyotrophic lateral sclerosis (ALS), 
and vascular changes at molecular, genetic, anatomic and 
functional level, over 3 years.
Methods: After two years, we recruited 300 MS patients, 
46 ALS patients and 178 HS. Serum ET-1 levels were 
coded and assayed with a commercially available ELISA 
kit in blinded fashion by a laboratory assistant (detection 
range 0.39–25 pg/mL; R&D Systems).
Results: ET-1 levels were performed in 120 MS patients 
(79 females, 41 males) and in 125 HS (68 females, 57 ma-
les). ET-1 median were significantly higher in MS compa-
red to HS (1.59 vs 1.50 pg/mL, p=0.03) at Mann-Whitney 
test. When stratified for gender, median ET-1 levels were 
significantly higher in females MS vs HS (1.58 vs 1.44 pg/
mL, p=0.03). ET-1 levels positively correlated with age in 
female MS vs HS (p<0.05) but not in males. ET-1 median 
were significantly higher in 23 SP vs 97 RR MS subtype 
(2.10 vs 1.57 pg/mL, p=0.003). 
Conclusion: We confirm that serum ET-1 levels are signifi-
cantly increased in MS patients, especially in women. This 
finding could help explaining the higher incidence of MS in 
females and the sex-associated differences in susceptibility 
to cardiovascular diseases. Correlation of ET-1 levels with 
SP subtype of disease opens new insights in MS pathoge-
nesis.
Disclosure: Nothing to disclose
P2252
Assessing pathological cutoffs of brain 
atrophy rates in patients with multiple  
sclerosis
N. De Stefano1, M.L. Stromillo1, A. Giorgio1,  
M.L. Bartolozzi2, M. Battaglini1, M. Baldini2, E. Portaccio3, 
M.P. Amato3, M.P. Sormani4
1University of Siena, Sienna, Italy, 2Hospital of Empoli, Em-
poli, Italy, 3University of Florence, Florence, Italy, 4Universi-
ty of Genoa, Genoa, Italy
Background and aims: Brain volume (BV) is a valid bio-
marker of clinical state and progression in neurology. We 
tried to assess the feasibility of establishing specific cutoff 
values able to discriminate “physiological” or “pathologi-
cal” rates of BV loss in multiple sclerosis (MS). 
Methods: We analyzed longitudinal MRI datasets of MS 
patients (n=206, 87% relapsing-remitting, 7% secondary 
progressive, 6% primary progressive) and healthy controls 
(HC) (n=35). Brain atrophy rates were computed over a 
mean follow-up of 7.5 years for MS patients and 6.3 years 
for HC with the SIENA software and expressed as annua-
lized percent BV change (PBVC/y). A weighted ROC ana-
lysis and the Area Under the Curve were used for statistics.
Results: The weighted PBVC/y was -0.51±0.27% in MS 
patients and -0.27±0.15% in HC (p<0.0001). There was a 
significant age-related difference in PBVC/y between HC 
older and younger than 35 years of age (p=0.02), but not in 
MS patients (p=0.8). The cutoff of PBVC/y that could ma-
ximize the accuracy in discriminating MS patients from HC 
was -0.37%, with 67% sensitivity and 80% specificity. Ac-
cording with the observed distribution, values of PBVC/y 
as measured by SIENA that could define a pathological ran-
ge were above -0.52% with 95% specificity, above -0.46% 
with 90% specificity and above -0.40% with 80% specifi-
city.
Conclusion: Our evidence-based criteria provide values 
able to discriminate presence or absence of “pathological” 
BV loss in MS with high specificity. Such results could be 
of great value in clinical setting, particularly in assessing 
treatment efficacy in MS.
Disclosure: Nothing to disclose
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Verbal fluencies are improved with  
fampridine treatment in multiple sclerosis
P. Decavel1, E. Magnin2, Y. Sagawa3, L. Chamard1,  
E. Berger4, T. Moulin1
1Besançon, France, 2CHRU J. Minjoz , Neurology, Besancon, 
France, 3CHU Jean Minjoz, Movement analysis, Besançon, 
France, 4CHRU Jean Minjoz, Besançon, France
Background: A recent study suggests an effect of famp-
ridine on cognition, especially on information-processing 
speed. The aims of this study were to evaluate the effects of 
fampridine on verbal fluencies in MS patients and to com-
pare the supposed cognitive effect with gait effect.
Methods: 31 MS patients were included with 42% of the 
patients with the primary progressive form, 45% with the 
secondary progressive form, and 13% with the relapsing 
remitting form. The mean EDSS was 5.43. Verbal phono-
logical and semantic fluencies were repeated two times (in 
one week) before fampridine treatment and two times after 
fampridine treatment. Gait velocity was measured before 
and after fampridine treatment. Post-hoc analyses were per-
formed in order to limit impact of the test-retest effect.
Results: Verbal fluencies were significantly improved by 
fampridine treatment (p<0.05). Phonological fluency show-
ed greater improvement than semantic fluency after fampri-
dine treatment. No significant difference on verbal fluency 
performance was observed between gait respondent and 
non-respondent groups.
Conclusion: Our results suggest that fampridine has an in-
dependent procognitive effect in MS, especially on executi-
ve functions and not only on information-processing speed.
Disclosure: Nothing to disclose
P2254
Five-year follow-up data from the French 
national Copaxone observatory
M. Clanet1, A. Moulignier2, C. Pierrot-Deseilligny3,  
C. Lebrun-Frenay4, T. Moreau5, A. Leizorovicz6, F. Boutitie7, 
P.-H. Depoortere8, F. Gueyffier9
1CHU Purpan, Toulouse, France, 2Fondation Ophtalmolo-
gique A. de Rothschild, Paris, France, 3Hôpital de la Salpêtri-
ère, Paris, France, 4Hôpital Pasteur, Nice, France, 5CHU, 
Dijon, France, 6Université Claude Bernard, Lyon I, France, 
7Université Claude Bernard, Lyon-Sud, France, 8Teva Labo-
ratoires, La Défense, France, 9Faculté de Médecine Laennec, 
Lyons, France
Background and aims: Information on outcome on pa-
tients with multiple sclerosis (MS) treated with immuno-
modulatory treatments in everyday practice is poorly do-
cumented. The objective of this naturalistic cohort study 
was to describe clinical outcome over time in MS patients 
starting treatment with glatiramer acetate (GA) in France.
Methods: A representative sample of hospital- and commu-
nity- based neurologists in France was invited to participate 
in the study. All adult patients with a diagnosis of relapsing-
remitting MS and starting treatment with GA for the first 
time were eligible. Patients were followed up according to 
the physician’s everyday practice. Data were documented 
at yearly study visits and included relapses, EDSS score, 
treatments, hospitalisations, consultations, sick leave and 
adverse events.
Results: 852 patients were enrolled between 2005 and 
2008. 594 (69.7%) were followed for at least 4.5 years, of 
whom 260 were still receiving GA. The median GA treat-
ment duration was 3.4 years. The principal reasons for 
treatment discontinuation were inadequate efficacy (38.9% 
of discontinuations) and poor tolerability (35.6%). 37.2% 
of patients did not experience a relapse during follow-up. 
The annualised relapse rate decreased from 0.64 relapses/
year at year 1 to 0.28 at year 5. Progression of disability oc-
curred in 31.9% of patients, and 7.9% evolved to secondary 
progressive MS. No unanticipated safety issue arose.
Conclusion: Treatment persistence in this real-life cohort 
was somewhat higher than anticipated from other obser-
vational studies. Clinical outcome was comparable to that 
seen in the long-term follow-up of the Phase III clinical 
study.
Disclosure: The research has been granted by Teva Labo-
ratoires
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The influence of age on the disease phe-
notype preceding the onset of progressive 
multiple sclerosis
A. Scalfari1, C. Lederer2, M. Daumer3, R. Nicholas4,  
G. Ebers5, P. Muraro6
1London, United Kingdom, 2Sylvia Lawry Centre, Munich, 
Germany, 3Silvia Lawry Centre, Munich, Germany, 4Imperial 
College, London, United Kingdom, 5Oxford University , Ox-
ford, United Kingdom, 6Imperial College , London, United 
Kingdom
Background and aims: Although primary (PP) and secon-
dary progressive (SP) multiple sclerosis (MS) patients start 
to progress at similar age, the clinical phenotype before 
progression is widely variable. We investigated the rela-
tionship between age and relapses before the progressive 
phase. 
Methods: By using the London Ontario database we as-
sessed, among 751 progressive MS patients (PP=217; 
SP=534): 1) the relationship of age with the relapses fre-
quency; 2) the impact of relapses on the age at onset of 
progression; 3) the influence of age on the evolution of the 
progressive phase.  
Results: Among SP patients, age at onset did not influ-
ence the early (first two years) attack frequency (r=-0.05; 
p=0.13). In contrast, being younger at onset was associated 
with a longer latency to progression and with a significantly 
larger number of total attacks before progression (≥4 re-
lapses=27.4 years; 2-3 relapses=31.0 years; 1 relapse=32.8 
years; p<0.001). Progressive MS subtypes with no attacks 
(PPMS) or 1, 2-3 and ≥4 relapses during the relapsing re-
mitting (RR) phase began to progress at similar age (38.6, 
41.3, 41.4, 39.2 mean years, respectively). However, the 
age at start of progressive disease did not affect its evolu-
tion. 
Conclusion: The age at onset of RRMS strongly influences 
the pre-progressive course, yet the age at onset of progres-
sion is unaffected by the relapses frequency. We suggest 
redefining progressive MS as a unified disorder, with initi-
ally different phenotypes that converge into a progressive 
course under the dominant influence of age-related mecha-
nisms.
Disclosure: This research was supported by the UK MS 
Society 
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Functional connectivity alterations and 
executive and social skills in  
Neurofibromatosis Type 1
M. Loitfelder1, I. Veer2, S. Rombouts2, H. Swaab2,  
M. Van Buchem3, B. Verbist3, E. Arkink3, E. Arkink3,  
R. Schmidt1, S. Huijbregts2
1Department of Neurology, Graz, Austria, 2Leiden University, 
Leiden, The Netherlands, 3Department of Radiology, Leiden, 
The Netherlands
Background and aims: Neurofibromatosis Type 1 (NF1) 
has regularly been associated with cognitive, social and be-
havioral problems. The fact that many different cognitive 
and behavioral impairments have been observed in NF1 
suggests that networks of brain regions are involved rather 
than specific brain regions. Here, we examined whether 
functional connectivity (FC) was different in NF1 and, if 
so, whether associations were present with cognitive, social 
and behavioral outcomes. 
Methods: 14 NF1 patients (8 male, age: M=12.49, 
SD=2.65) and 30 healthy controls (HC; 23 male, age: 
M=12.30, SD=2.94; p=.835) were included. FC was as-
sessed using functional resting state scanning. We analyzed 
brain regions that have been associated specifically with 
cognitive and social functions. For NF1-patients, connec-
tion strengths between brain regions showing HC-NF1 dif-
ferences were correlated with parent-reports of cognitive, 
social and behavioral functioning.  
Results: Compared to HC, patients showed differences in 
FC between the left vACC and the frontal cortex, insula, 
and subcortical areas (caudate, putamen), between the left 
amygdala and the frontal cortex, insula, supramarginal 
gyrus and PCC/precuneus, and between the left OFC and 
frontal and subcortical areas (caudate, pallidum). In pati-
ents, indications were found for associations between in-
creased fronto-frontal and temporo-frontal FC with cogni-
tive, social and behavioral deficits (r-range=0.536-0.851).
Conclusion: NF1 patients showed differences in FC bet-
ween areas associated with cognitive and social functioning 
when compared to controls. This, plus the fact that con-
nectivity strengths in these networks were associated with 
worse cognitive, social, and behavioral outcomes suggests 
a neuro-pathological basis for the widespread deficits ob-
served in NF1.
Disclosure: Nothing to disclose
P2257
Cognitive and social correlates of  
cerebral volumetric abnormalities in  
Neurofibromatosis Type 1
M. Loitfelder1, I. Veer2, S. Rombouts2, H. Swaab2,  
R. Schmidt1, M. Van Buchem3, S. Huijbregts2
1Department of Neurology, Graz, Austria, 2Leiden University, 
Leiden, The Netherlands, 3Department of Radiology, Leiden, 
The Netherlands
Background and aims: Neurofibromatosis Type 1 (NF1) 
is characterized by social and cognitive problems. MRI-
studies have shown focal T2-hyperintensities in white mat-
ter and deep grey matter and larger white and grey matter 
volumes in NF1. This study aimed to elucidate associations 
between abnormalities observed with MRI and cognitive 
and social outcomes. 
Methods: 15 NF1-patients (mean age 12.9 years, SD 2.6) 
and 18 healthy controls (HC, mean age 13.8 years, SD 3.6) 
underwent 3T MRI-scanning. Segmentation of grey and 
white matter, as well as a range of subcortical nuclei, was 
carried out. Voxel-based morphometry was performed to 
assess differences in grey matter density. Correlations were 
calculated between MRI-parameters and cognitive and so-
cial outcomes.
Results: After correction for age, sex, and intracranial vo-
lume, larger volumes of all segmented subcortical regions 
were found in NF1-patients compared to controls. Patients 
further showed decreased grey matter density in midline re-
gions of the frontal and parietal lobes, and larger total white 
matter volume. NF1-patients showed more social problems 
and autistic mannerisms, and poorer executive functioning 
than HC. In NF1-patients larger left putamen volume and 
larger total WM-volume were associated with more soci-
al problems and poorer executive functioning, larger right 
amygdala volume with poorer executive functioning and 
autistic mannerisms, and smaller precentral gyrus GM-den-
sity was associated with more social problems. Presence 
of T2-hyperintensities was not associated with cognitive or 
social outcomes.
Conclusion: Extensive differences between patients and 
controls were found in white matter, cortical, and subcorti-
cal brain regions, which could be associated with social and 
executive problems in NF1. 
Disclosure: Nothing to disclose
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Microstructural white matter alteration in 
Neurofibromatosis Type 1 and its  
association with executive functioning
M. Loitfelder1, S. Huijbregts2, I. Veer2, M. Van Buchem3,  
R. Schmidt1, H. Swaab2, S. Rombouts2
1Department of Neurology, Graz, Austria, 2Leiden University, 
Leiden, The Netherlands, 3Department of Radiology, Leiden, 
The Netherlands
Background and aims: Neurofibromatosis Type 1 (NF1) 
is characterized by brain volumetric increases and cognitive 
deficits (particularly executive dysfunction). Moreover, wi-
despread microstructural white matter changes (WM) have 
been reported, but their relation to executive function has 
not been investigated so far. We here seek to examine the 
relation between micro-structural alterations and executive 
functions in patients and highlight WM group differences.
Methods: We performed diffusion tensor imaging analyses 
using tract-based spatial statistics in 16 NF1 patients and 
32 controls and used a whole brain as well as a region of 
interest based approach (using bilateral anterior thalamic 
radiation, ATR), to determine micro-structural group dif-
ferences. Sub-scores of the Memory-Search-2-Dimensions 
(MS2D, one of the Amsterdam Neuropsychological Tasks) 
were correlated with diffusion-parameters. 
Results: Bilateral fractional anisotropy (FA), an index 
of general WM integrity, and the right-hemispheric axi-
al diffusivity (DA), a measure of axonal integrity, of the 
ATR correlated with MS2D correct responses (FA: right: 
r=.695, p=0.008; left: r=.615, p=0.025, DA: right: r=.513, 
p=0.037). In line with previous literature, we identified de-
creases in FA, and increases in mean diffusivity, radial dif-
fusivity and axial diffusivity in NF1 patients disseminated 
over the whole brain. Group differences were found signi-
ficant within ATR for all four measures (p-range: <0.001-
0.004). 
Conclusion: We here report for the first time on the associ-
ation between aberrant WM-microstructure within the ATR 
and executive function in NF1. However, its association 
with increased WM needs to be further determined.
Disclosure: Nothing to disclose
P2259
Brain atrophy evaluation in multiple  
sclerosis: change over time of corpus  
callosum area is more sensitive and  
reproducible than whole brain volume.
L. Bandieri1, L. Vuolo1, A.  M. Repice2, M. Grammatico1,  
C. Mechi2, L. Massacesi2
1University of Florence, Neurosciences Drugs and Child 
Health, Florence, Italy, 2Careggi University Hospital-Univer-
sity of Florence, Neurology 2, Florence, Italy
Background and aims: Measurement by MRI of whole 
brain volume (BV) changes over time is commonly used 
as an in vivo marker of brain atrophy, but its sensitivity and 
reproducibility is limited, even within individuals.  Corpus 
Callosum (CC) measurement may represent an alternative, 
but its efficacy has never been compared to BV. In this stu-
dy longitudinal changes of BV and of CC area and their 
correlation to disability were compared in multiple sclero-
sis (MS) patients.
Methods: Relapsing Remitting MS patients (n= 40) were 
included. Brain MRI were carried out at baseline (T0) and 
after 5 years (T5). CC area was measured with a semiauto-
matic method (MIPAV) in the central slice of T2w sagittal 
MRI scans; in the same patients BV was evaluated with an 
automated method (SIENA/SIENAX) in T1w scans.
Results: T0 CC area= 549.52mm2, T5 CC area=505.83mm2; 
CC area reduction between T0-T5=7.8%+6.8% (43.7mm2 
+37.6;); CC area correlation between T0 and T5, r=0.96. T0 
BV=1,587cm3, T5 BV= 1,552cm3; BV reduction between 
T0-T5=2.2%+4.0 (35.0cm3+68.3); BV correlation between 
T0 and T5, r=0.80.  CC area but not BV changes resulted 
correlated to disability progression  (OR=0.9; p<0.04).
Conclusion: CC area is a marker of brain atrophy more 
sensitive, reproducible and closely associated to disability 
changes than BV. CC area used as an outcome measure can 
improve both power of clinical trials and individual patient 
follow up of clinical practice.
Disclosure: Nothing to disclose
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Differential diagnosis of  
neurodegenerative parkinsonism using 
magnetic resonance imaging at 1.5 and 3.0 
Tesla
C. Müller1, J. Tashiro1, A. Hussl1, M. Schocke2, C. Scherfler1, 
E. Gizewski3, W. Poewe1, K. Seppi1
1Medical University of Innsbruck, Neurology, Innsbruck,  
Austria, 2Medical University of Innsbruck, Radiology,  
Innsbruck, Austria, 3Medical University of Innsbruck,  
Neuroradiology, Innsbruck, Austria
Background and aims: While magnetic resonance ima-
ging (MRI) at 3.0 Tesla (T) is increasingly used in the dia-
gnostic work-up of parkinsonian disorders, no studies have 
assessed its diagnostic potential for differential diagnosis 
of neurodegenerative parkinsonism in comparison to 1.5T 
MRI. Our aim is to assess the diagnostic value of 3.0T MRI 
for the differential diagnosis of Parkinson’s disease (PD), 
multiple system atrophy (MSA) and progressive supranu-
clear palsy (PSP).    
Methods: Patients with PD (HY stages <3), MSA, PSP and 
healthy controls (HC) underwent brain MRI at 1.5 and 3.0T. 
Blinded to diagnosis and MR field strength, semiquantita-
tive and -qualitative rating of different brain regions was 
performed. Abnormalities rated as indicative for MSA in-
cluded putaminal atrophy, T2 putaminal hypointensity, T2 
hyperintense putaminal rim, hot-cross-bun sign, MCP atro-
phy, T2 MCP hyperintensity and cerebellar atrophy, while 
midbrain atrophy, hummingbird sign and SCP atrophy were 
rated as signs for PSP. 
Demographical characteristics of study participants (mean ± standard 
deviation).
Results: Scans positive for MSA at 1.5T revealed good 
discriminatory power between groups. Sensitivity at 3.0T 
was 90.5% in distinguishing MSA from PD, PSP and HC, 
whereas specificity was poor, but improved by excluding 
putaminal signal changes. MRI scans indicative for PSP 
showed similar diagnostic accuracies at 1.5 and 3.0T in di-
stinguishing PSP from MSA, PD and HC.
Sensitivity and specificity of scans indicative for MSA in patients with 
neurodegenerative parkinsonism and HC.
Sensitivity and specificity of scans indicative for PSP in patients with 
neurodegenerative parkinsonism and HC.
Conclusion: Rater-based assessment of structural abnor-
malities in MRI at 3.0T does not seem to yield greater 
diagnostic accuracy as compared to 1.5T.  Evaluation of 
putaminal signal abnormalities on 3.0T carries a high rate 
of false positive rates for MSA.
Disclosure: Supported by funds of the Oesterreichische 
Nationalbank (Austrian Central Bank, Anniversary Fund, 
project number: 14171).
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Translational imaging in diagnostic  
workup of neurodegenerative  
parkinsonian syndrome
C. Paschetta1, A. Skanjeti1, F. Buttari1, M. Iudicello2,  
D. Gned3, V. Podio1
1S. Luigi Hospital, Nuclear Medicine, Orbassano, Italy,  
2S. Luigi Hospital, Neurology, Orbassano, Italy, 3S. Luigi 
Hospital, Radiology, Orbassano, Italy
Background and aims: Movement disorders are common, 
and neuroimaging plays a pivotal role in diagnosis. Aim 
of this study was the evaluation of diagnostic accuracy in 
neurodegenerative parkinsonian syndrome (NPS) of an up-
to-date analysis of FP-CIT SPECT and MRI images.
Methods: 62 patients with Parkinson’s disease suspicion 
(age 66±11, 33 M) underwent FP-CIT SPECT and brain 
MRI within 2 years. Later, neurologist established diagno-
sis on a clinical base and NPS was confirmed in 31 patients. 
From the two imaging modalities, images were normalized 
(with our FP-CIT template and built-in T1 template, res-
pectively) and analyzed by SPM; volume-of-interest data 
for each modality were extracted with MarsBaR software. 
Multivariate logistic regression was used to evaluate the 
correlation of both SPECT and MRI semi-quantitative data 
with diagnosis.
Results: At SPECT, basal ganglia uptake was significantly 
lower in NPS compared to NPS-free (p=0.00001). In T1 
images, SPM detected difference between the two groups 
in thalami and in anterior cingulate (p=0.005 and p=0.04, 
respectively): in both occurrences MR accuracy was lower 
than SPECT accuracy. Multivariate analysis showed that 
MRI data of thalami were independently and significantly 
correlated with diagnosis and improve accuracy from 77% 
of SPECT alone to 87% (SPECT + MRI). Cingulate data 
showed to be non significant (probably variable dependent 
from thalami).
Conclusion: SPECT is mandatory when NPS is suspected; 
an integrated voxel-based analysis of MR and SPECT by 
SPM showed to increase accuracy. Translational imaging 
should be encouraged in order to fully develop the strength 
of both structural and functional imaging in patients with 
suspected NPS.
Disclosure: Nothing to disclose
P2262
“Corpus callosum fibers rupture sign” as 
a neuroimaging biomarker of dementia in 
Parkinson’s disease
K. Mazurenka1, V. Ponomarev2, R. Sakovich3
1Belarusian Medical Academy of Postgraduate Education, 
Department of Neurology and Neurosurgery, Minsk, Belarus, 
2Belarusian Medical Academy of Postgraduate Education, 
Head of Department of Neurology and Neurosurgery of Bel-
MAPGE, Minsk, Belarus, 3Minsk City Clinical Hospital №2, 
Radiology Department, Minsk, Belarus
Background and aims: Dementia is a common complica-
tion of Parkinson’s disease (PD), but the specific neuroima-
ging criteria of dementia in PD (PDD) remain undefined.
Methods: 40 patients with PD (9 demented, 31 non-demen-
ted) and 30 healthy controls underwent DTI at 1.5T MRI 
scanner. Diffusion tensor tractography (DTT) of the cor-
pus callosum (CC) was performed using multiple regions 
of interest (ROIs). ROIs were drawn at the caudal, middle 
and ventral substantia nigra (SN), anterior and posterior 
quadrants of both hemispheres, fractional anisotropy (FA) 
and apparent diffusion coefficient (ADC) were extracted. 
Neuropsychological evaluation included MMSE, Frontal 
Assessment Battery (FAB), Parkinson’s Disease-Cognitive 
Rating Scale (PD-CRS).
Results: PD patients scored lower on the MMSE (27.5+2.2 
vs. 28.3+1.5), FAB (15.3+2.5 vs. 16.9+1.3) and PD-CRS 
(85.5+17.2 vs. 96.8+10.9) than controls. PD patients have 
shown an increased ADC at the ventral SN (p=0.008) com-
pared to control patients. PDD patients had significantly 
higher total ADC of all quadrants of the brain (p=0.02), 
especially posterior quadrants (p=0.001) and the CC 
(p=0.0006). Using DTT of CC we found “corpus callosum 
fibers rupture sign” or “hood” sign. Most of the CC fibers in 
PDD patients had a downward direction, creating a charac-
teristic “hood” sign with depletion of its tractography pat-
tern. The sensitivity of PDD diagnostics using DTT “hood” 
sign was 88.9%, specificity 77.4%, the diagnostic accuracy 
of 80%.
Conclusion: Our study using DTT demonstrates that 
“hood” sign could be a promising biomarker of PDD. We 
also found that ADC values in the ventral SN can help to 
discriminate PD patients and healthy subjects.
Disclosure: Nothing to disclose
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Transient global amnesia (TGA). Study of 
functional connectivity in the memory  
networks using resting state functional 
MRI (rsfMRI) during the acute phase
E. Rigal1, P. Peran2, B. Lemesle1, E. Barbeau3,  
F. Bonneville4, J. Pariente5
1Toulouse Univesrity Hospital, Neurology, 2INSERM u825, 
neurologie, 3Toulouse Univesrity Hospital, Reasearch, 4CHU 
Purpan, Neuroradiologie, 5CHU Purpan, neurologie, Tou-
louse, France
Background and aims: The transient global amnesia 
(TGA) is a sudden onset of a anterograde and retrograde 
amnesia that last up to 24 hours. Use of structural high re-
solution MRI can detect a focal and selective lesion loca-
ted on the CA1 part of the hippocampus observed only 72h 
after onset of the episode (day 3). In this study we inves-
tigated a functional impairment during the acute phase of 
TGA patients. The aim of this study is to identify functio-
nal connectivity impairment using resting state functionnal 
MRI (rsfMRI) and specify cognitive impairment during the 
acute phase of TGA.
Methods: 11 patients were included during the acute phase 
of TGA and matched to 14 control subjects at the Toulouse 
University Hospital. All subjects were evaluated during two 
successive visits, acute phase and 3 days after (Day 3). At 
each visit a neuropsychological assessment, and structural 
MRI and rsfMRI (seed-to-voxel method) were performed.
Results: Impairment of episodic memory (d=2.89; 
p<0.0001) and executive functions (d=1.72; p<0.0001) was 
observed in acute phase in the atient group. Hippocampal 
lesion (CA1) was found in all patients at Day3. A reduc-
tion in functional connectivity between the hippocampus, 
the left polar temporal area and the lower left prefrontal 
gyrus was found during the acute phase of TGA relative to 
controls (p=0.001). No difference with controls was found 
at day 3 in rsfMRI.
Conclusion: These data suggest that memory impairment 
observed during the acute phase of TGA correspond to a 
reversible functional dysconnexion between the medial 
temporal structures and frontal regions.
Disclosure: Funding by Appel d’Offre Local du CHU de 
Toulouse 2013 and Institut des Sciences et du Cerveau de 
Toulouse (ISCT) 2013
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Recovery of language comprehension in 
the minimally conscious state studied by 
FDG-PET
S. Wannez1, A. Thibaut1, C. Di Perri1, G. Vitali Roscini1,  
M.-A. Bruno1, C. Chatelle1, C. Bernard2, R. Hustinx2,  
P. Maquet3, S. Majerus4, S. Laureys1
1Coma Science Group, Liege, Belgium, 2University Hospital 
of Liège, Liege, Belgium, 3University of Liège, Cyclotron Re-
search Centre, University Hospital of Liège, Liege, Belgium, 
4University of Liège, Departement of Psychology, Cognition 
and Behaviour, Liege, Belgium
Background and aims: The minimally conscious state 
(MCS) can be subcategorized in MCS minus (i.e., pati-
ents showing non-reflex behaviour such as visual pursuit, 
localization to pain or to objects or contingent behaviour 
to emotional stimuli) and MCS plus (i.e., the presence of 
command following) (1). We here aim to assess changes 
in brain metabolism related to the recovery of language 
understanding and command following in severely brain-
damaged patients with chronic MCS.
Methods: Brain metabolism was assessed using [18F]-
fluorodeoxyglucose-positron emission tomography (FDG-
PET) in 32 patients with chronic MCS minus. 5 patients 
were reassessed by FDG-PET after clinical recovery of lan-
guage comprehension (i.e., evolved to MCS plus according 
to Coma Recovery Scale Revised assessments (2)). One pa-
tient was excluded because of left-handedness. Demogra-
phic data are reported in table 1. Data were pre-processed 
and analysed by means of statistical parametric mapping 
(SPM8). 
Table 1: Demographic data of severely brain damaged patients in mi-
nimally conscious state who recover functional language comprehen-
sion.
Results: Compared to age-matched control subjects, pati-
ents in MCS minus showed significant hypometabolism in 
the left dominant hemisphere encompassing the language 
network (Figure 1). Recovery to MCS plus was paralleled by 
recovery of metabolism in the right temporo-occipital areas, 
including hippocampus and parahippocampus (Figure 2).
Figure 1: Significant cerebral hypometabolism, as compared to mat-
ched controls, in patients with signs of consciousness without langua-
ge comprehension (i.e., minimally conscious state minus).
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Figure 2: Areas with an increased brain metabolism after recovery of 
language comprehension and response to command (right temporo-
occipital areas, including hippocampus and parahippocampus).
Conclusion: Recovery of language understanding and 
command following in severe massive left-hemispheric 
brain-damaged patients with MCS minus seems to corre-
late with an increase in contralateral right hemispheric me-
tabolic activity rather than in peri-lesional areas as can be 
observed in aphasia and focal stroke lesions (3).  Bruno et 
al. (2011). Journal of Neurology. Giacino et al. (2004). Ar-
chives of Physical Medicine and Rehabilitation. Heiss et al. 
(2003). Neuroimage. 
Disclosure: Nothing to disclose
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systemic disease 2
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Brucellosis and inflammatory cerebral  
lesions: a diagnostic challenge
C. Machado, S. Rocha, J. Cruz Araújo, J. Pinho, E. Lourenço
Braga, Portugal
Background and aims: Human brucellosis remains a com-
mon zoonotic infection and Portugal is one of the countries 
where it is endemic. 
Case Report: A 62-year-old man was admitted for a 4-day 
history of isolated gait distrurbance. Neurological examina-
tion revealed right-sided hemiparesis and pyramidal signs. 
Brain MRI showed a left corona radiata pseudotumoral le-
sion.Wright agglutination test (WAT) was positive in blood 
(Brucella abortus 1/640) and negative in CSF. Additional 
extensive etiological investigation was negative. After a 
6-week course of rifampicin and doxycycline, the patient 
improved and WAT was negative 7 months later.Two years 
after treatment, the patient was admitted with nausea, vo-
miting and vertigo for 3 days. Neurological examination re-
vealed right ataxic hemiparesis and right sixth nerve palsy. 
General physical examination was normal. MRI revealed 
lesions in the dorsal part of the midbrain and in the superior 
cerebellar peduncle. WAT was positive (Brucella abortus 
1/320) and further complete basic and immunological ana-
lysis and serological studies were normal. CSF study show-
ed mildly elevated protein content (0.53g/L), nine white 
cells and normal glucose; positive unmatched oligoclonal 
bands and WAT and culture were negative. He started treat-
ment with rifampin, doxycycline and co-trimoxazole. Four 
months after treatment, he presented clinical improvement, 
WAT was negative and the MRI lesions were smaller.
Conclusion: There is no consensus in literature regarding 
diagnostic criteria and treatment for NB. Despite absence 
of definite confirmation of NB in our patient, exclusion of 
other etiologies and clinical and imagiological improve-
ment after more prolonged treatment is suggestive of NB.
Disclosure: Nothing to disclose
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Epilepsy and celiac disease
S. Makhlouf, M. Messelmani, E. Mabrouk, I. Bedoui,  
J. Zaouali, R. Mrissa
Military Hospital of Tunis, Neurology department, Tunis, 
Tunisia
Background and aims: Celiac disease (CD) is a chronic 
inflammatory entheropathy of variable severity, induced by 
the ingestion of dietary gluten . CD may be associated with 
a number of neurological disorders, and the prevalence of 
epilepsy is reported to be increased in patients with CD
Case Report: We report the case of a patient with CD as-
sociated to epilepsy.
Results: We report the case of a 37-year-old woman,who 
has 5 years of generalized seizures resistant to antiepileptic 
treatment. The patient also reported a weight loss associ-
ated with a diarrhea. Neurological examination and EEG 
were normal. Biology has shown signs of malabsorption 
who were related to celiac disease.The brain MRI was nor-
mal. A gluten-free diet has been associated with antiepi-
leptic drugs. The evolution was marked by the control of 
seizures
Conclusion: A high prevalence of epilepsy has been re-
ported in patients with CD compared with controls .This 
is from the existence of a currently well defined syndrome 
involving seizures, parieto-occipital calcifications and celi-
ac disease (CEC). The calcifications could be lacking in 5% 
of cases because of the early age of diagnosis of CD. Since 
it is known that some CEC patients with initial normal CT 
Scan may develop bilateral parieto-occipital calcifications 
later during the evolution. The institution of gluten-free-
diet helps to control the seizures, due to a better absorp-
tion of the antiepileptic drug and correction of metabolic 
disorders. It is important to search for celiac disease when 
investigating the etiology of epilepsy in refractory patients, 
because of the potential curability of the disease.
Disclosure: Nothing to disclose
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Chronic lymphocytic inflammation with 
pontine perivascular enhancement  
responsive to steroids (CLIPPERS) –  
primary or secondary?
S. Moreira1, L. Ruano1, J. Roriz2, C. Veira2
1Santa Maria da Feira, Portugal, 2CHEDV, Neurology, Santa 
Maria da Feira, Portugal
Background and aims: CLIPPERS is an inflammatory 
CNS disorder of unknown etiology, with characteristic but 
unspecific radiologic findings and diverse pathological as-
sociated findings. It is still a matter of debate whether it 
represents an independent disorder or a manifestation of an 
heterogeneous group of diseases.
Methods: Revision of a clinical case.
Results: 39-year-old man, ex-smoker, with a history of 
granuloma excision from the left foot. Presented with per-
sistent low-fever, malaise, weight loss and symptoms of 
respiratory tract infection, refractory to several consecuti-
ve antibiotics. Thoracic CT showed diffuse interstitial lung 
infiltrates, with negative bronchial aspirate cultures – in-
itially suggestive of Bronchiolitis Obliterans Organizing 
Pneumonia (BOOP). Six weeks after initial symptoms, he 
started complaining of imbalance and right hypoesthesia. 
Brain MRI revealed T2-hiperintense lesions of the pons 
and cerebellar peduncles, with discrete local edema and 
unusual curvilinear patchy gadolinium enhancement – sug-
gestive of CLIPPERS. Blood analysis showed only mild 
leucocytosis, with negative HIV and self-immunity tests. 
CSF cytochemical, microbiological and serological analy-
sis was unremarkable. He was discharged with uncertain 
neurological diagnosis and medicated with corticosteroids, 
with respiratory improvement but neurological worsening 
- with left VIth nerve palsy, right central facial palsy, and 
aggravated ataxia, dysarthria and limb dysmetria. Control 
MRI showed increased local mass effect and contrast en-
hancement. Lung biopsy revealed several non-necrotizing 
granulomatous structures. He was diagnosed with multi-
system sarcoidosis and medicated with increased dose of 




Brain MRI gadolinium enhanced
Conclusion: The present case reinforces the idea that 
CLIPPERS may constitute a neurological manifestation of 
different systemic diseases, namely sarcoidosis.
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Delay in the diagnosis of acute intermit-
tent porphyria: case presentation.
B. Pelok
Municipal Hospital, Neurology, Odorheiu Secuiesc, Romania
Background and aims: Acute intermittent porphyria is a 
rare, but underdiagnosed condition, due to its unusual and 
complex symptomatology. 
Case Report: Our 33-year-old female patient was operated 
at the age of 21 with cerebellar medulloblastoma, followed 
by radiotherapy and oncologic follow-up, and she was de-
clared in remission after a few years.
From the age of 24, she presented recurrent episodes of 
abdominal pain, with repeated admissions to medical and 
surgical wards, including explorative laparoscopy, without 
positive diagnosis. She developed psychiatric signs in time, 
i.e. depressive and paranoid elements, for which she was 
admitted to a number of psychiatric services. A few times 
she was checked for supposed relapse of the cerebellar tu-
mour by CT-scans of the head.
At the age of 32 she presented progressive, generalized 
weakness of the limbs, difficulty in walking, and respirato-
ry infections (i.e. pneumonias). The neurological condition 
was identified as a severe polyneuropathy. The corrobora-
tion of clinical data suggested acute intermittent porphyria, 
confirmed by laboratory findings.
Results: Cessation of psychotropics, administration of 
hemin-based medicines (outside the country), and carbo-
hydrate-based diet led to a slow recovery in all of her syn-
dromes.
Conclusion: The complex semiology, the apparently un-
related symptoms may delay substantially the diagnosis 
of acute intermittent porphyria. Usual psychotropic drugs, 
such as clonazepam, may contribute to the alteration of the 
clinical picture. In our opinion, the remitted cerebellar tu-
mour is unlikely to have causal relationship with the meta-
bolic disease, but was important in delaying the diagnosis 
of the later.
Disclosure: Nothing to disclose
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Acute intermittent porphyria: axonal or de-
myelinating peripheral neuropathy ?
M. Philibert1, P. Sahuc2, S. Attarian1, P. Alla2
1CHU La TIMONE Marseille, Neurophysiology, Marseilles, 
France, 2Army Instruction Hospital Sainte Anne, Toulon, Neu-
rology, Toulon, France
Background and aims: Acute Intermittent Porphyria 
(AIP) is an autosomal dominant disease due to porphobili-
nogen (PBG) deaminase enzyme deficiency, characterized 
by acute life-threatening attacks of non specific neurovis-
ceral symptoms.
Case Report: We report a patient who developed acute 
tetraplegia due to AIP with electromyography conduction 
anomalies.
Results: A 20-year-old woman was admitted for acute tetra 
paresis occurring after a trip on India. She had no medical 
or familial history and did not use any treatment. Symp-
toms began with fever, headache, myalgia and abdominal 
pain without diarrhea. Then, she complained about abdomi-
nal pain explored by normal tomography. Her initial exami-
nation revealed severe tetraparesis  predominantly in pro-
ximal limbs that started one week before by lower limbs, 
facial diplegia, distal lower limbs hypoesthesia, areflexia, 
tachycardia, abdominal pain and constipation. Paraclinical 
investigations showed hepatic cytolysis and hyponatre-
mia. Cerebrospinal fluid (CSF) revealed immunoglobulins 
synthesis without high protein level. Electromyography 
showed motor and sensory axonal loss associated with 
conduction blocs and temporal dispersion. Infectious blood 
analysis and anti ganglioside antibodies were negative. She 
was diagnosed Guillain Barré syndrome (GBS) and treated 
by intra-veinous immunoglobulins. She worsened under 
treatment presenting complete quadriplegia, dyspnea, swal-
lowing difficulties, neuropathic pain in lower limbs, major 
anxiety and hallucination. EEG revealed fronto-temporal 
epilepsy; cerebral and spinal MRI were normal. Qualita-
tive urine porphobilinogen and aminolevulinic acid were 
elevated. She was finally diagnosed with AIP and received 
Hemin infusions.
Conclusion: AIP must be considered in atypic GBS; es-
pecially if associated with abdominal pain, psychiatric 
symptoms and hyponatremia. We describe a rare case with 
demyelinating electromyography anomalies.
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© 2015 European Journal of Neurology, 22 (Suppl. 1), 120–483
Poster presentation with discussion      311
P2270
Radiological investigations in Takayashu 
disease with stroke: report of two cases 
and review of the literature
A. Riahi1, A. Arous2, L. Rzigui3, C. Drissi2,  
M. Ben Mahmoud2, N. Hammami2, R. Sebai2, S. Nagi2,  
M. Ben Hammouda2
1Tunis, Tunisia, 2National Institute of Neurology, Neuroradio-
logy department, Tunis, Tunisia, 3National Institute of Neuro-
logy, Neurology department, Tunis, Tunisia
Background and aims: Takayashu disease (TD) is a chro-
nic inflammatory arteritis of unknown etiology. It affects 
principally the aorta and its chief branches. Strokes are 
rare complications in TD. We report here two cases of TD 
revealed by ischemic stroke in two young women and we 
discuss its clinical and radiologic features.
Methods: Two women aged 26 and 30 years, respectively, 
presented with right hemiplegia and aphasia. Both patients 
had presented upper limbs pulse asymmetry and cervical 
murmur on auscultation. They underwent brain CT-scan 
and MRI, angioscanner of supra-aortic vessels and Willis 
cycle, and echography and Doppler.
Results: Brain imaging showed left middle cerebral artery 
(MCA) infraction in the first case and left carotidal territory 
(middle and anterior territories) infraction in the second. 
Angioscanner exploration of supra-aortic vessels showed a 
complete thrombosis of the left primitive carotid expanding 
to the internal carotid and the MCA in the first patient, and 
90% stenosis of the left carotid with vertebral arteries occlu-
sion at their origins in the second. Both patients showed a 
diffuse vessel wall poorly echogenic thickening at echogra-
phy with hyperemia at Doppler. A complement of thoraco-
abdominal angioscanner showed abdominal aorta lesions 
in the first patient. Diagnosis of TD was made according 
to the Ishikawa criteria. Radiologic criteria are preponde-
rant with 7 out of 13 criteria. Our observation reminds that 
Doppler-echography and angioscanner are sufficient and 
can supplement the arteriography. Our patients were put on 
corticosteroids in addition to anticoagulant treatment.
Conclusion: While stroke represents a rare complication 
of TD, this diagnosis must be suspected in young women.
Disclosure: Nothing to disclose
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Association between asymmetric  
dimethylarginine and diabetic neuropathy
Y. Tamam1, E. Uzar1, A. Tay2
1Diyarbakir, Turkey, 2Diyabakir, Turkey
Background and aims: Asymmetric dimethylarginine 
(ADMA) as an endothelial nitric oxide synthase inhibitor is 
an important marker of endothelial dysfunction. There 
are a few studies focusing on relationshp between blood 
ADMA and  diabetic neuropathy. The aim of this study was 
to evaluate the relationship between serum ADMA levels 
among diabetic neuropathy cases
Methods: 141 patients with diabetic neuropathy and  91 
healthy subjects were included in the study. All type-2 dia-
betic patients underwent electrophysiological and neurolo-
gical examination. Serum ADMA levels were determined 
by using the ELISA method.
Results: The serum ADMA levels in diabetic neuropathy 
patients were found to be statistically significantly lower 
than those of the control group (p=0.005). There were no 
significant differences among patient groups in terms of di-
sease course, age and sex.
Conclusion: Changes in blood ADMA levels in the dia-
betic neuropathy patients may be an indicator of oxidati-
ve stress and endothelial dysfunction in the pathogenesis 
of diabetic neuropathy. It could be used as a marker in the 
severity of diabetic neuropathy. 
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Three non-alcoholic Wernicke  
encephalopathy cases
I. Tatlidil, H. Uluğut Erkoyun, H.S. Türe, T. Kurt İncesu,  
Y. Secil
Katip Celebi University, Atatürk Training and Research Hos-
pital,, Izmir, Turkey
Background and aims: Wernicke encephalopathy is a me-
dical emergency secondary to thiamine deficiency. Suspici-
on of diagnosis in patients having remarkable history and 
clinical symptoms are important. We describe three cases of 
Wernicke Encephalopathy having non-alcoholic etiology.
Case Reports: Our three cases are male patients aged 49 
to 66. All three cases had no history of use of alcohol and 
all of them had gastrointestinal disease causing impairment 
of thiamin uptake. Common characteristics of history were 
impairment of nutrition, history of having total parenteral 
nutrition, impairment of consciousness state, nausea and 
vomiting. All three patients had history of hospitalization 
in internal medicine related clinics. All of them had nystag-
mus in neurological examination; none of them had classi-
cal clinical triad of Wernicke Encephalopathy.
Results: Two of the cases had response to thiamin treat-
ment and two of cases, including the case where thiamin 
treatment could not be assessed, had typical lesions in Ma-
gnetic Resonance Imaging involving brainstem and dience-
phalon. Finally, all three cases were diagnosed as Wernicke 
encephalopathy.
Conclusion: Patients having alcoholic background alert 
the clinician for the diagnosis of Wernicke encephalopathy. 
However, autopsy series of hospital show most of non-
alcoholic Wernicke encephalopathy cases are underdiag-
nosed. Rarity of presentation of classical clinical triad and 
limited neurological evaluation due to coma state are the 
other challenges of diagnosis of Wernicke encephalopathy. 
All three cases are demonstrative to emphasize the clinical 
evidence of Wernicke encephalopathy other than alcohol 
usage.
Disclosure: Nothing to disclose
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Multiple Sclerosis and systemic Behçet 
syndrome as comorbid disorders
B. Zeydan, U. Uygunoğlu, S. Saip, A. Siva
Istanbul University Cerrahpaşa School of Medicine, Neurolo-
gy, Istanbul, Turkey
Background and aims: Although it is less frequently seen, 
Behçet Syndrome (BS) is often included in the differential 
diagnosis of Multiple Sclerosis (MS). In young individuals 
with subacute/insidious central nervous system(CNS) sym-
ptoms/signs, since neurological presentations have resem-
blances, CNS involvement of BS, neuro-Behçet’s syndro-
me (NBS) is considered commonly as an alternative to MS. 
But MS and systemic BS may rarely seen together. The aim 
of this study is to examine clinical-radiological courses of 
patients, diagnosed both as MS and BS.
Methods: We retrospectively examined 10 patients 
(Male:4/Female:6) with both MS and BS, who attended our 
clinical neuroimmunology and MS clinic between 1994 
and 2014. 
Results: BS and MS mean ages at time of diagnosis are 
30.4±8.7 and 33.3±9.9 respectively. All patients had syste-
mic involvement (such as mucocutaneus, eye, musculoskel-
etal), which is essential for BS, whereas in MS it is atypical. 
All patients had typical MS lesions (all patients: supraten-
torial periventricular-subcortical-juxtacortical lesions, 5 
patients: spinal cord lesions, 1 patient: small brainstem 
and cerebellar lesions, 1 patient: optic nerve involvement), 
while 2 patients also had a history of large diencephalic/
brainstem lesions, which are characteristic of NBS. In 3 of 
5 patients with cerebrospinal fluid examination performed, 
oligoclonal bands were positive and 4 of them had neutro-
philic pleocytosis. Follow-up duration is 7±6.6 years and 
the last EDSS is 1.7±2.3.
Conclusion: Both NBS and MS have distinctive features 
and they are unlikely to be confused when clinical, radio-
logical and cerebrospinal fluid analysis evaluated carefully. 
However MS and systemic BS may rarely seen together as 
comorbid disorders.    
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Cisplatin inhibits the expression and  
transport of mitochondrial dynamic  
factors in mice
I. Bobylev1, A. Joshi1, M. Barham2, W. Neiss2,  
H.C. Lehmann1
1University Hospital of Cologne, Neurology, Cologne,  
Germany, 2University of Cologne, Department of Anatomy I, 
Cologne, Germany
Background and aims: Sensory neuropathy is a common 
adverse effect of the antineoplastic agent cisplatin. There is 
increasing experimental evidence that dysfunctional mito-
chondria play a crucial role for the development of cisplatin 
induced neuropathy. We explored the role of axonal mito-
chondria in a murine model of cisplatin induced sensory 
neuropathy.
Methods: We assessed the morphology and function of 
axonal mitochondria in different models of cisplatin indu-
ced neuropathy including transgenic mice with cyan fluo-
rescent protein labeled mitochondria. Neuropathy was as-
sessed by nerve conduction studies, electron microscopic 
and histological analysis of distal nerve segments and skin 
sections. In addition, we determined mRNA transport of 
nuclear encoded mitochondrial proteins in axons.
Results: We found that high doses of cisplatin induced neu-
ropathic changes primarily affecting sensory fibres. These 
morphological changes were accompanied by mitochondri-
al damage as revealed by electron microscopy. In addition 
we found an impaired expression and axonal transport of 
nuclear encoded mitochondrial fusion / fission GTPases 
that correlated with the degree of mitochondrial damage.
Conclusion: Our results support the notion that the dyna-
mics of axonal mitochondria are affected by systemic ci-
splatin treatment.
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Primary intracranial Rosai-Dorfman  
disease (RDD) mimicking meningiomatosis
L. Boccara Girardstein1, J. Capron1, F. Bielle1, M. Peyre2,  
N. Martin-Duverneuil1, K. Hoang-Xuan1, A. Idbaih1
11-APHP, Groupe Hospitalier Pitié-Salpêtrière,Paris, France. 
2-2Institut du Cerveau et de la Moelle épinière (ICM), IN-
SERM U 1127, CNRS, UMR 7225, Paris, France. 3-UPMC 
University Paris 6, UM 75, Paris, France., Service de Neuro-
logie 2 , Paris, France, 2GH Pitié-Salpétrière, Neurochirur-
gie, Paris, France
Background and aims: Rosai-Dorfman is a rare non 
Langerhans histiocytosis occurring in young adults. It is 
a multisystemic disease mainly affecting cervical lymph 
nodes. Extranodal sites include skin, orbits, upper respira-
tory tract, testes and central nervous system (CNS). CNS 
involvement is rare, reported in 5% of cases. Histological 
and immunochemical examination show, in one hand, infil-
tration of histiocytes, lymphocyte and plasma cells and in 
the other hand, a typical emperipolesis.
Case Report: We present the case of a 39-year-old man 
who presented with partial epileptic seizures and right-
sided headaches. Brain MRI showed multiple extra-axial 
lesions at the skull convexity mimicking diffuse nodular 
pachymeningitis or diffuse meningiomatosis. Meningeal 
lesions induced mass effect on brain structures and impor-
tant oedema within the contiguous brain parenchyma on 
T2-weighted images. After contrast infusion, the lesions 
were homogeneously and strongly enhanced.
No systemic lesions or inflammation were detected on PET 
scan and on blood examinations.
Results: The pathological examination, after surgical bi-
opsy, revealed S100+/CD68+/CD1a- histiocytes, lympho-
cytes, plasma cells and emperipolesis, in favour of RDD.
Conclusion: Although it is rare, primary intracranial RDD 
disease should be discussed faced to meningioma-like, 
meningiomatosis-like or pachymeningitis-like isolated le-
sions.
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From Trousseau syndrome to CoaGlio IV: 
the translational journey from our patients 
via glioblastoma biology back to a  
randomized, controlled multicenter trial
S. Kuhn1, T. Kratzsch2, L. Handel3, R. Kalff3, U.-K. Hanisch4, 
P. Vajkoczy2
1Potsdam, Germany, 2Charité - Universitätsmedizin Berlin, 
Neurosurgery, Berlin, Germany, 3University Hospital Jena, 
Neurosurgery, Jena, Germany, 4Universitätsmedizin Göttin-
gen, Neuropathology, Göttingen, Germany
Background and aims: Venous thromboembolism (VTE) 
is a paraneoplastic monitor of aggressive glioblastomas. 
Prophylaxis could not only prevent VTE, but could genera-
te additional anti-tumor therapy.
Methods: Clinical file review, prospective cohort study, tu-
mor immunohistochemistry, cell assays, and animal models 
were performed. Target for VTE prevention was identified. 
Clinical study protocol for anticoagulation was developed.
Results: One third of patients experience VTE. They show 
activated coagulation factors II-XII in their circulation. 
Those with VTE show correlation with multiple factor dys-
regulations (p=0.018). Further, patients with preoperative 
co-activation of antithrombin III survive longer; patients 
with normal or low antithrombin III survive shorter. Glio-
blastoma tissue expresses all coagulation factors of the in-
trinsic as well as the common final pathway (p<0.05), and 
the coagulation factor receptors PAR-1/PAR-4 (p<0.05). 
The activation of receptors with increases DNA synthe-
sis, proliferation, and migration (p<0.05). Thrombin and 
PAR-1 inhibitors, like hirudin, unfractionated heparin, anti-
thrombin III, PPACK, low molecular weight heparins, and 
the PAR-1 specific antagonist FLLRN inhibit proliferation 
of tumor cells (p<0.01). Consequently, VTE prophylaxis 
by LMWH reduces sizes of human glioblastomas in xeno-
grafts (p<0.05). The randomized, controlled, multinational 
CoaGlio-IV trial includes operated patients from their first 
postoperative day to receive the factor Xa inhibitor apixa-
ban for a 12-month-period accompanying standard treat-
ment. FXa inhibition should not only prevent VTE and re-
lated short-term deaths, but also should improve long-term 
prognosis by tumor inhibition.
Conclusion: Transfer of symptoms into the lab and trans-
lation back into clinical trials is necessary, as VTE is a 
dangerous complication, and glioblastoma is still a deadly 
disease.
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Brainstem gliomas in adult patients.
J.R.L.D.M. Marques1, M. Fernandes1, J. Passos1,  
A.L. Azevedo1, I. Costa1, J.M.D.A. Nunes1, T. Pimentel2,  
D.M.C. Salgado1, J.M.T.B. Marques1
1Instituto Português de Oncologia de Lisboa, Neurology, Lis-
bon, Portugal, 2Instituto Português de Oncologia de Lisboa, 
Lisbon, Portugal
Background and aims: Brainstem gliomas are uncommon 
in adults (only 1%–2% of intracranial gliomas), represen-
ting nonetheless a very heterogeneous oncological enti-
ty. Although the clinical, imaging and prognosis of brains-
tem gliomas is well characterized in children, in the adult 
population it has not been as thoroughly evaluated.
Methods: Demographic, clinical, treatment and survival 
characterization of adult patients with brainstem glioma 
(histological and/or clinical-radiological diagnosis). Medi-
cal charts from patients followed between 1998 and 2012 in 
a Portuguese oncological hospital were reviewed.
Results: 22 patients were included, 10 female patients, 
mean age at diagnosis 33.5±9.4 years. The mean time to 
diagnosis was 10.3 months. The most common earlier sym-
ptoms/signs were cranial nerve dysfunction (17), motor 
dysfunction (8) or ataxia (5). On imaging (MRI), brainstem 
gliomas were classified as diffuse intrinsic in 17 patients, 
cystic/necrotic in 2 and exophytic in 3. There was gadoli-
nium-enhancement in 7 patients. Only ten patients were bi-
opsied (open or stereotactic biopsy): 6 of them were diffuse 
tumors, 2 were cystic/necrotic and 2 were exophytic. His-
tological diagnosis were varied: pylocytic astrocytoma (1); 
grade II (3) and grade III (3) astrocytomas; glioblastoma 
(1); grade II (1) and grade III (1) oligodendrogliomas. All 
but one patient were treated with radiotherapy; 17 patients 
were also treated with chemotherapy. There were 11 deaths; 
4 patients were lost to follow-up.
Conclusion: Our series is similar to previous studies in 
adult patients with brainstem gliomas, documenting a 
marked clinical and radiological heterogeneity. We high-
light the importance of a histological diagnosis in this rare 
tumor, with important implications in treatment and prog-
nosis. 
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Nitrous oxide recreational use and  
subacute combined degeneration
A. Papathanasiou1, T. Ham1, T. Cope1, S. Chawda2,  
A. Chaudhuri1
1Department of Neurology, Essex Centre for Neurological Sci-
ences, Queen’s Hospital, Romford, UK, Neurology, London, 
United Kingdom, 2Department of Radiology, Essex Centre 
for Neurological Sciences, Queen’s  Hospital, Romford, UK, 
Radiology, London, United Kingdom
Background and aims: Nitrous oxide is a widely used 
anaesthetic gas though also recreationally misused quite 
commonly. It is a potential neurotoxic agent due to functio-
nal disruption of cobalamin (vit B12), which serves as an 
active cofactor for methionine synthase, a critical enzyme 
in the methylation of myelin sheath phospholipids.
Methods: We report two cases of young males, presented 
with subacute onset and progressive course of gait difficul-
ties. On examination both had spastic paraparesis and pro-
prioception deficits resulting in spasticoataxic gait. One pa-
tient had significant low vitamin B12 (160 ng/l), while the 
other had borderline (248ng/l). Both reported recreational 
use of nitrous oxide for couple of years. MRI on both cases 
revealed hyperintense signal in the posterior columns of 
cervical spine. Intramuscular injections of B12 were com-
menced and after 6 months one patient was significantly 
improved with corresponding improvement on MRI, while 
the other was quite stable clinically and radiologically.
Saggital STIR cord MR image demonstrates hyperintense signal in the 
cervical spine
Axial MR image of cervical spine level demonstrates hyperintense 
signal
Conclusion: Nitrous oxide or laughing gas has been incre-
asingly misused for recreational purposes, due to its wide 
commercial availability, causing subacute combined dege-
neration. Low or borderline levels of vitamin B12 can be 
found, therefore it is useful to measure methylmalonic acid 
and homocysteine levels to detect early B12 deficiency. 
Edema secondary to demyelination and eventual gliosis re-
sult in the typical MR findings of increased T2 signal in the 
dorsal and to a lesser extend in lateral and anterior columns 
of the cervical and occasionally thoracic cord. Functional 
recovery is variable and difficult to predict in relation to 
serum vitamin B12 levels.
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Guillain-Barré syndrome induced by  
platin-based chemotherapy
B. Herlin1, E. Pappa2, D. Ricard2, T. Lenglet3,  
T. Maisonobe1, D. Psimaras4
1Pitié-Salpêtrière, Paris, France, 2Paris, France, 3Pitié -
-Salpêtrière Hospital, Service Explorations Fonctionnelle 
Neurologie, Paris, France, 4University René Descartes, De-
partment of Neurology Mazarin, Hôpital Pitié-Salpêtrière, 
Paris, France
Background and aims: Platin-based chemotherapy has 
essentially been associated with acute neuro-muscular hy-
perexcitability and a sensory axonal delayed dose-related 
neuropathy. We report a series of patients presenting Guil-
lain-Barré Syndrome (GBS) short after the administration 
of platin analogs for a solid tumor treatment.
Methods: Our 4 patients, 1 man and 3 women, aged from 
53 to 62 years, were treated for various carcinomas and de-
veloped symptoms of GBS (3 demyelinating and 1 axonal 
form) starting a few days after chemotherapy (2 to 7 days). 
None of our patients had any history or paraclinical exami-
nation evoking usual causes of GBS. 
Results: All patients had a complete clinical recovery after 
an intravenous immunoglobulines (IVIg) treatment.
Conclusion: Guillain-Barré syndrome is classically associ-
ated with hematological malignancies and only rarely with 
solid tumours, with the exception of paraneoplastic condi-
tions or induced by chemotherapy. To date, only platinum 
analogues have been associated with GBS, as it is the case 
with our patients. We propose that it is important to estab-
lish if the development of GBS is a consequence of plati-
num analogues in order to suspend chemotherapy treatment 
and propose IVIg therapy.




Evaluation of relationship between  
overactive bladder syndrome and use of 
antidepressant drugs in female patients
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M.C. Nacar5, F. Erdemir3
1Bozok unıversty medical faculty, urology, yozgat, Turkey, 
2Turkey, Turkey, 3Gazıosmanpasa unıversty medical faculty, 
urology, Tokat, Turkey, 4Tokat, Turkey, 5Tokay state hospital, 
obstretric and gynecology, tokat, Turkey
Background and aims: Overactive bladder (OAB) is defi-
ned by the International Continence Society as a symptom 
complex of urinary urgency, generally accompanied by fre-
quency and nocturia with (OAB wet) or without (OAB dry) 
urinary urgency incontinence (UUI). The objective of this 
study was to investigate the relationship between OAB and 
use of antidepressant in women.    
Methods: Of the 205 women who were invited, patients 
were then divided into two groups: group 1: 113 patients 
with use of antidepressant due to various cases and group 2: 
92 healthy controls. Patients were performed OAB-V8 
questionnaire. In order to collect clinical and demographic 
variables, a medical history was conducted with questions 
regarding age, weight, and height, number of pregnancies. 
In the present study we compared women using antidepres-
sants and healthy control group according to prevalence of 
OAB. Prevalence of OAB between two groups was com-
pared. İn addition prevalence of OAB was compared also 
according to antidepressant types    
Results: The mean age of the attendees was 38 years (range 
25-82).  In groups demographic datas were similar. In cor-
relation analysis of datas ICIQ-SF, BDI scores, and patient 
age was positively correlated with OAB-V8 (r=0.379**, 
r=0.318**, r=0.247**) (respectively). Patient age, and BDI 
scores was positively correlated with ICIQ-SF (r=0.187**, 
r=0.129*) (respectively) (*p<0.05, **p<0.01). Results are 
shown in Table 1. The highest prevalence in group of fluo-
xetine (63.6%), and lowest prevalence in group of sertraline 
was determined. Likewise this difference was statistically 
significant between the antidepressant groups (P=0.038). 
Conclusion: In current study we found that overactive 
bladder syndrome was associated with the use of antide-
pressant.    
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The role of mTOR and PI3K/Akt in the  
pathogenesis of different types of gliomas
S. Szlufik1, W. Grajkowska2, D. Perek3, B. Dembowska-
Bagińska3, I. Filipek3, P. Daszkiewicz4, M. Sidor1, J. Jozwiak1
1Center for Biostructure Research, Medical University of 
Warsaw, Department of Histology and Embryology, Warsaw, 
Poland, 2The Children’s Memorial Health Institute, Depart-
ment of Pathology, Warsaw, Poland, 3The Children’s Memori-
al Health Institute, Department of Oncology, Warsaw, Poland, 
4The Children’s Memorial Health Institute, Department of 
Neurosurgery, Warsaw, Poland
Background and aims: The most frequent molecular al-
terations found in different types of gliomas belong to two 
groups of signaling proteins: cell cycle and the growth fac-
tor-regulated signaling pathways. The aim of this study was 
to detect changes in expression of the tumour suppressor 
PTEN, and the phosporylated forms of mTOR and PI3K/
Akt pathway, which may lead to the formation of gliomas.
Methods: To characterize hyperactivation of mTOR and 
PI3K/Akt pathway in gliomas, we analyzed astrocytoma, 
oligodendroglioma and mixed glioma tissue samples from 
50 patients operated in the Department of Neurosurgery of 
the Childrens’ Memorial Health Institute. Monoclonal an-
tibodies against pAkt, PI3K, PTEN, pS6, pMTOR, pErk, 
pMek, pRSK1, PRAS40 were used and detected by stan-
dard Western Blot method.
Results: We detected hyperactivation of phosphorylated 
mTOR, Erk and Akt in the majority of glioma samples 
(90%). The expression of pS6, pMek, pRSK1 was found in 
roughly the same proportion. We also observed an insigni-
ficant overexpression of pPRAS40. PTEN was not found in 
most of astrocytomas, especially in higher-grade tumours.
Conclusion: Gliomas are genetically complex tumours. In 
the majority of gliomas, mTOR and PI3K/Akt pathways 
are hyperactivated, while the activity of tumor suppressor 
PTEN is decreased. Loss of PTEN function can lead to hy-
peractivation of Akt, which promotes phosphorylation of 
other particular proteins of Akt/mTOR pathway, like p70 
S6 kinase or S6 protein. This co-activation of mTOR and 
PI3K/Akt pathways can play an important role in the proli-
feration and differentiation of low- and high-grade gliomas.
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Paraplegia after spinal anesthesia due to 
adhesive arachnoiditis
R. Barbosa, F. Ladeira, L. Alves, F. Sá, E. Medeiros
Hospital Egas Moniz, Centro Hospitalar Lisboa Ocidental, 
Neurology Department, Lisbon, Portugal
Background and aims: Acute flaccid paraparesis fol-
lowing spinal anesthesia is a rare neurological complication 
and multiple causes need to be considered. Direct effects of 
topic anaesthetics can be responsible through a neurotoxic 
reaction leading to axonal degeneration of nerve roots or 
by  inducing a leptomeningeal inflammatory reaction with 
subsequent adhesive arachnoiditis. 
Case Report: An 88-year-old woman who underwent he-
miarthroplasty of left femoral head under spinal anesthesia 
with levobupivacaine two days earlier, develops back pain 
and acute paraplegia. On neurologic examination she had 
flaccid paraplegia, lower limb hyporeflexia and asymmetric 
hyposthesia with T12 and L1 level (right and left respec-
tively), apalesthesia  and impairment of position sense on 
the lower limbs, urinary and fecal incontinence.  Dorso-
lumbo-sacral MRI showed conglomeration of cauda equi-
ne roots with gadolinium enhancement, compatible with 
arachnoiditis, and degenerative alterations of the lumbar 
canal. Electromyography (EMG) revealed absence of sen-
sitive and motor action potentials in the lower limbs. We 
assumed chemical arachnoiditis and started two, 3-day long 
cycles of IV methylprednisolone as well as physiotherapy 
without improvement. She was discharged 2 months later, 
without any change in the admission neurological exam. 
She has a urinary catheter and uses a wheel chair. A new 
EMG, three months later showed, additionally, fibrillation 
potentials in the lower limbs. 
Conclusion: Close temporal relation between the onset of 
the neurologic deficits and spinal anesthesia and sugges-
tive MRI findings allowed the diagnosis of arachnoiditis 
by local anesthetic neurotoxicity.  Although not yet proved, 
a stenotic spinal canal appears to be a risk factor for this 
complication.
Disclosure: Nothing to disclose
P2284
Idiopathic spinal cord herniation
Y. Beckmann1, F. Gelal2, N. Gürgör3, G. Güvenç4
1Izmir, Turkey, 2Katip Çelebi University Atatürk Research and 
Training Hospital, Radiology, Izmir, Turkey, 3Katip Çelebi 
University Atatürk Training and Research Hospital, , Neuro-
logy, Izmir, Turkey, 4Katip Çelebi University Atatürk Training 
and Research Hospital, Neurosurgery, Izmir, Turkey
Background and aims: Dorsal herniation of the spinal 
cord through the dura is a very uncommon phenomenon 
that results in progressive myelopathy. Idiopathic spinal 
cord herniation is not usually recognized in neurology 
practice. Although it is a treatable condition, misdiagnosis 
and delayed diagnosis remain a major concern. We report 
two cases with idiopathic spinal cord herniation who had 
full recovery after the surgery.
Case Report: A 62-year-old previously well male presen-
ted with progressive spastic paraparesis that was exacer-
bated by walking for 5 years. He was diagnosed as having 
transverse myelitis and treated by corticosteroids at a dif-
ferent institution. His symptoms persisted. A 58-year-old 
previously well male presented with a 3-year history of 
thoracic back pain and spastic progressive paraparesis.
Results: Imaging revealed a dorsal dural defect with her-
niation of the spinal cord at T7 in both cases (Figur 1). The 
patients underwent a T7-T8 laminoplasty to repair the dural 
defect (Figure2). At 1-year follow-up, both patients noted 
a significant improvement in strength and back spasticity.
preoperative spinal cord herniation
postoperative spinal cord herniation
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Conclusion: Misdiagnosis is reported in a number of spi-
nal cord herniation case reports. MRI is the investigation 
of choice for the diagnosis of spinal cord herniation. Sa-
gittal sections often demonstrate enlargement of the dor-
sal subarachnoid space, with ventral displacement of the 
thoracic spinal cord. On axial imaging, the cord herniation 
is attached to the anterior dura mater. Treatment consists 
of either conservative management or surgery, but owing 
to the unclear natural history of the condition. Surgery is 
generally recommended for patients with motor function 
deficit or progressive neurological symptoms.




Progressive weakness of lower limbs -  
a case of tuberculous radiculomyelitis
I.-H. Cioriceanu1, M.R. Mărceanu1, R.D. Ionescu2,  
D.M. Gabor3
1Psychiatry and Neurology Hospital, Brasov, Romania, 2In-
fectious Diseases Hospital, Brasov, Romania, 3County Pneu-
mology Hospital, Brasov, Romania
Background and aims: Intramedullary involvement of 
Mycobacterium tuberculosis (MT) is a rare condition and 
may be present as a transverse myelitis, radiculomyelitis or 
pial arteritis with spinal cord infarction and the diagnosis 
can be neglect and difficult.
Case Report: We present a case of a 78-year-old male 
admitted with a history of urinary retention, singultus and 
acute-onset progressive weakness of right lower limb for 
the past 7 days. He had no history of trauma, fever, back or 
root pain. A detailed neurological examination was made 
with evaluation of the motor, sensory and sphincter sys-
tems. The next days, his condition continues to deteriorate 
and the patient develops flaccid paraplegia, despite recei-
ving intravenous corticosteroids treatment.
Results: The involvement of MT was suspected after we 
excluded other known causes of radiculomyelopathy. Ce-
rebrospinal fluid (CSF) examination revealed high protein 
content based on Pandy’s reaction, elevated level of glu-
cose, positive Polymerase Chain Reaction (PCR) for MT 
and isoniazid resistance based on Genotype Mycobacteria 
Direct Test. Magnetic Resonance Imaging (MRI) of the spi-
ne revealed altered cervical, thoracic and lumbar medullar 
signal intensity appearing isointense on T1W and hyperin-
tense on T2W images, no swelling and with leptomeningeal 
enhancement.
Conclusion: Following the result of the CSF and the MRI 
of the spinal cord we initiated combined antituberculous 
treatment and the patient neurological condition gradually 
improved over the next 10 months, almost with full reco-
very. Despite it is a rare etiological agent for spinal cord 
infections, MT must be considered even if we deal with a 
negative contact or manifest disease in anamnesis.
Disclosure: Nothing to disclose
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Back pain and radiculopathy secondary to 
Intracranial Hypertension Syndrome (IHS)
N. Giraldo Restrepo1, A. Hernandez2, A. Lopez Garcis1,  
J.J. Bravo1, A. Parralo2, C. Valencia Guadalajara1,  
S. Carrasco García de León3
1Ciudad Real, Spain, 2University General Hospital of Ciudad 
Real, Neurology, Ciudad Real, Spain, 3Hospital General, 
Neurology, Ciudad Real, Spain
Background and aims: HIS is typically characterized by 
headache, vomiting, visual disturbance, diplopia, tinnitus 
and hearing loss. Moreover, associated back pain and radi-
culopathy have been scarcely reported in the literature. We 
present three cases with lumbar symptomatology related to 
IHS caused by different etiologies.
Methods: Case 1: A 70-year-old female, with headache, 
vomiting, bilateral papilledema, hearing loss, arterial hy-
pertension, drowsiness and severe back pain. Compute-
rized Tomography (CT) and Magnetic Resonance Imaging 
(MRI) showed triventricular hydrocephalus.
Case 2: A 19-year-old male with history of familiar spastic 
paraparesis, presented with headache, vomiting, ophthal-
moparesis, visual loss, papilledema, and worsening of te-
traparesis, areflexia, radicular and back pain. Brain CT and 
MRI were normal. Electrodiagnostic testing revealed acute 
radicular affectation.
Case 3: A 70-year-old female, with headache, ophthalmo-
paresis, blindness, papilledema, tetraparesis and areflexia. 
CT and MRI showed hydrocephalus. Spinal MRI was nor-
mal. Severe acute multiradicular affectation was diagnosed 
by electrodiagnostic tests.
Results: In all cases the opening pressure of CSF was very 
elevated (60, 50, and up to 100cm H2O, respectively). CSF 
in case 3 showed hypoglycorrhachia and malignant cells. 
Lumbar symptoms improved after CSF shunt, including 
back pain in case 3 (with meningeal carcinomatosis).
Conclusion: It has been described that back pain associ-
ated with HIS may be present in half of cases, and may 
associate paresis and hypoesthesia that improve after CSF 
derivation. The main challenge in differential diagnosis 
could be Guillain Barré syndrome with papilledema. We 
remark that back pain and radiculopathy can be distracting 
symptoms evaluating patients with IHS.
Disclosure: Nothing to disclose
P2289
Endovascular treatment for dural  
arteriovenous fistula – clinical experience
A. Bazina1, Z. Hucika2, A. Mišmaš1, M. Krbot Skoric1,  
D. Ozretić3, Z. Poljaković4
1Zagreb, Croatia, 2Zabok, Croatia, 3Zagreb University Hos-
pital Centre, Department of Diagnostic and Interventional 
Radiology, Zagreb, Croatia, 4Zagreb University Hospital 
Centre, Neurology, Zagreb, Croatia
Background and aims: The aim of this study was to eva-
luate clinical improvement after endovascular treatment in 
patients with spinal dural arteriovenous fistula (dAVF).
Methods: We reviewed data on 26 patients with spinal 
dAVF referred for endovascular treatment to University 
Hospital Centre Zagreb, University Department of Neuro-
logy in a period between August 2008 and June 2014
Results: Study included 26 patients; 18 (69.2%) males and 
8 (3.8%) females; mean age 56.29±12.14. History of minor 
back trauma was positive in 6 (23.1%) patients. The dAVF 
were localized in cervical 3 (11.54%), thoracic 15 (57.7%), 
thoraco-lumbar 7 (26.92%) and 1 (3.84%) in sacral level. 
The most common presenting symptom was paraparesis 18 
(69.2%). In 23 (88.46%) patients endovascular treatment 
was possible, while 3 (11.54%) patients were referred for 
neurosurgical procedure after spinal digital subtraction an-
giography. Second endovascular procedure was indicated 
in 7 (30.43%) patients, while 2 (8.7%) patients who were 
treated with two endovascular procedures were finally re-
ferred for neurosurgical procedure. Among patients who 
were endovascularly treated 15 (65.22%) showed clinical 
improvement.
Conclusion: Endovascular treatment for dAVF can be suc-
cessful as a primary treatment for the majority of patients 
with this pathology.
Disclosure: Nothing to disclose
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Acute flaccid paralysis subsequent to  
acute aortoliac occlusion: a case report
O. Jugurt, S. Plesca, M. Sangheli, I. Andronati
INN, Neurology, Chisinau, Moldova
Background and aims: Acute flaccid paralysis is a clini-
cal syndrome with a broad array of potential etiologies, in-
frequently occurred after ischemic pathology of the spinal 
cord. Spinal cord ischemia has been reported after thoracic 
and abdominal aorta surgery, and rarely after interruption 
of the cord blood supply by embolism at the aortic bifurca-
tion (saddle embolus). Acute aortoiliac occlusion (AAO) 
is a catastrophic event with high incidence of neurological 
complications and it is frequently accompanied by myocar-
dial dysfunction.
Case Report: We report a case of a 57-year-old man who 
developed severe back pain with acute lower extremities 
paralysis, coldness and pallor in the lower limb (march 
2014). There was no weakness in the upper extremities, 
sphincter muscles of bladder and bowel. His past medical 
history included a myocardial infarct (2007).
Results: A CT-angiography revealed a segmental occlusion 
of the distal infrarenal aorta and bilateral common iliac ar-
teries. The transthoracic echocardiography demonstrated a 
left ventricular aneurysm with mural thrombus, which was 
the source of this acute spinal cord ischemia. The patient 
underwent aorto-bifemoral by-pass surgery. Despite this 
intervention, the paralysis persisted.
Conclusion: Sudden onset of flaccid paralysis should im-
mediately alert the physician, because this cardinal sym-
ptom can denote an AAO. This case highligts that AAO 
needs early recognition, prompt diagnosis and immediate 
intervention.
Disclosure: Nothing to disclose
P2291
Hyperacute presentation of encephalomy-
elitis 10 days after onset of mycoplasma 
pneumoniae infection
V. Keereman, A. Meurs, J. De Bleecker
Ghent University Hospital, Neurology, Ghent, Belgium
Background and aims: Mycoplasma-associated encepha-
lomyelitis is a known entity. The pathophysiological basis 
is not well understood, but either neurotoxic or autoimmu-
ne reactions, or direct invasion of the CNS by the organism 
are suspected.
Case Report: A 29-year-old male presented to the emer-
gency department, with rapidly ascending paralysis. At the 
time of presentation, there was tetraplegia, a global sensory 
level at C5, complete areflexia and increasing respiratory 
distress. He experienced paresthesias in both arms from 12 
hours before, but leg symptoms had only started 2 hours 
before. Approximately 10 days before, he experienced 
bronchitis for 1 week. After examination, the patient was 
sedated and intubated.
Results: Cerebrospinal fluid showed 900 leukocytes/µL 
and a total protein of 373 mg/dL. Treatment was started 
with IV corticosteroids, immunoglobulin, acyclovir, ceft-
riaxone and doxycycline. MRI showed a T2 hyperintense 
myelum from the conus medullaris to the pons and bilateral 
supratentorial FLAIR hyperintense white matter lesions. 
A positive PCR for M. pneumoniae in pulmonary aspira-
te confirmed an active pulmonary infection. Cerebrospinal 
fluid M. pneumoniae PCR was negative. After stopping se-
dation, the patient was conscious and respirator-dependent, 
with tetraplegia and paralysis of the tongue and inferior 
division of the facial nerve. After 3 months, he showed 
limited recuperation and remained completely respirator-
dependent. MRI after 1 month showed reduced intracere-
bral lesions but spontaneous T1 hyperintense signal in the 
spinal cord, indicating hemorraghic transformation.    
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Brain FLAIR image on the day after admission showing bilateral hy-
perintense white matter lesions.
Full spine T2w MRI on the day after admission showing hyperintense 
T2w signal in the entire spinal cord up to the pons, most extensively in 
the lower cervical cord.
Full spine T2w MRI on the day after admission showing hyperintense 
T2w signal in the entire spinal cord up to the pons, most expressively 
in the lower cervical cord. Cervical and thoracic spine T1w MRI one 
month after admission
Conclusion: This patient presented with a hyperacute ence-
phalomyelitis, probably due to a dramatic immune respon-
se to a M. pneumoniae infection. Intrathecal infection with 
M. pneumoniae is unlikely, as the CSF PCR was negative. 
Disclosure: Nothing to disclose
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Cervical spondylotic myelopathy causing 
cerebellar type subacute ataxia
A.D. Magalhães1, M. Oliveira Santos1, L.P. Faria de Abreu1, 
J. Teixeira2, N. Simas2, M. Coelho1
1Hospital de Santa Maria, Neurology Department, Lisbon, 
Portugal, 2Hospital de Santa Maria, Neurosurgery Depart-
ment, Lisbon, Portugal
Background and aims: Classically, cervical spondylotic 
myelopathy (CSM) causes motor weakness, sensory loss, 
sensory ataxia, spasticity, increased deep tendon reflexes, 
extensor plantar response and dynamic Hoffman sign. On 
the other hand, it is not a common cause of cerebellar type 
ataxia.
Case Report: An 81-year-old diabetic male was admitted 
for imbalance and numb and clumsy hands. On neurologi-
cal examination there was normal muscle tone, predomi-
nantly distal limb tetraparesis, weak upper limb deep ten-
don reflexes, left patellar reflex with contralateral response, 
absent Achilles reflex, flexor plantar reflex, mild decreased 
vibration sense up to the knee level, maintained joint po-
sition sense, dysmetria on nose-finger and heel-knee-shin 
tests, intention tremor, truncal ataxia, inability to stand un-
aided with multidirectional oscillations, widened base, un-
stable gait and inability to tandem walk.
Results: Brain MRI was unremarkable, CSF analysis 
showed elevated protein level, anti-neuronal antibodies 
were negative, detection EMG showed minor demyelina-
ting sensorimotor polyneuropathy and chronic neurogenic 
right C5 and bilateral C6-C7-C8-D1 lesions due to radi-
culopathy. Cervical spine MRI showed spinal stenosis of 
the C3-C6 vertebral level cervical canal with marked spinal 
cord compression on C3-C4 level. The patient underwent 
C3-C6 decompressive laminectomy with marked progres-
sive improvement with autonomous walking without ataxia 
after 1 month.
Conclusion: Despite the minor vibration sense deficit, the 
patient’s severe ataxia was of cerebellar type. We propo-
se that, in rare cases, cervical spondylotic myelopathy can 
cause ataxia of cerebellar type due to compression of the 
spinocerebellar tracts.
Disclosure: Nothing to disclose
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Hemodynamic changes after successful 
stent retrievers’ thrombectomy in acute 
stroke: a sign of vessel wall injury?
F. Perren1, J.-M. Pignat2, V. Mendes Pereira3
1Geneva, Switzerland, 2CHUV, University Hospital , Neurology, 
Lausanne, Switzerland, 3University of Toronto  University 
Health Network, Interventional Neuroradiology, Toronto, 
Canada
Background and aims: Stent retrievers with rapid recana-
lization and acceptable safety have revolutionized intracra-
nial endovascular treatment of acute ischemic stroke. How-
ever, animal studies showed that mechanical thrombectomy 
may cause endothelial injury leading to myointimal hyper-
plasia. Using transcranial duplex sonography (TDS) moni-
toring, we observed post-procedural hemodynamic chan-
ges in the treated vessel.    
Methods: We studied acute ischemic stroke patients 
with single large intracranial artery occlusion in whom 
mechanical thrombectomy using stent retrievers was 
performed. Only those with complete vessel recana-
lization (modified TICI 2b or 3) as assessed by post-
procedural DSA and MRA and in whom early control 
TDS was performed were retained. Patients treated with 
intra-arterial thrombolysis or stenting were excluded. 
Results: In 28 patients (26 MCA, 2 BA), post acute MRA 
confirmed complete recanalization without residual ste-
nosis or vasospasm. However, in 24 (17 men; mean age 
66.8 yrs) of them TDS (mean 3.4 days after thrombectomy) 
showed very segmental acceleration of blood flow veloci-
ties in the affected arteries (MCA PSVmax at least > 35%) 
as compared with the contralateral side at same depth; BA 
PSVmax > 40% as compared to velocities measured in the 
same vessel). None showed clinical deterioration. Follow-
up TDS (mean 20 days) showed normalization in 11/14. 
Conclusion: This is the first TDS study showing focal ac-
celeration of blood flow velocities after stent retrievers’ 
thrombectomy. Without residual stenosis, thrombosis or 
vasospasms, this may be a sign of intimal injury in hu-
mans. Whether this is due to local inflammatory agents, 
neothrombosis or myointimal hyperplasia is yet not clear. 
Disclosure: Nothing to disclose
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Florbetapir imaging in cerebral amyloid 
angiopathy-related hemorrhages
N. Raposo1, M. Planton1, P. Péran1, P. Payoux1,  
F. Bonneville1, A. Lyoubi2, J.-F. Albucher1, B. Acket1,  
A.S. Salabert1, J.M. Olivot1, A. Hitzel1, F. Chollet1,  
J. Pariente1
1TOULOUSE, France, 2CHU, neurologie, Paris, France
Background and aims: Several studies have suggested 
that positron emission tomography (PET) amyloid ima-
ging could help to diagnose cerebral amyloid angiopathy 
(CAA). We investigated the yield of florbetapir, a PET 
amyloid ligand, for the diagnosis of CAA among patients 
with intracerebral hemorrhage (ICH).
Methods: Consecutive patients with acute ICH were pro-
spectively enrolled. They were categorized into lobar or 
deep ICH. Lobar ICH were further divided in two sub-
groups according to CAA Boston criteria: probable CAA 
and other lobar ICH. Cortical florbetapir standard uptake 
value ratios (SUVr) were calculated using the whole cere-
bellum as a reference. Patients with lobar versus deep ICH, 
then patients with probable CAA versus other lobar ICH 
versus deep ICH, were compared for mean cortical florbe-
tapir SUVr values.
Results: 39 patients (mean age = 65.5±11 years) with pri-
mary ICH were enrolled:  21 deep and 18 lobar ICH (10 
with probable CAA). Mean cortical florbetapir SUVr was 
significantly higher among patients with lobar ICH than 
among patients with deep ICH (1.22±0.12 vs. 1.13±0.08; 
p=0.006). Patients with probable CAA had a higher cor-
tical florbetapir SUVr than patients with other lobar ICH 
(1.28±0.08 vs. 1.13±0.11; p=0.008) or deep ICH (1.28±0.08 
vs. 1.13±0.08; p<0.001). No difference was found between 
patients with other lobar ICH and deep ICH.
Conclusion: Cortical florbetapir uptake is increased among 
patients with lobar ICH, especially those with probable 
CAA. Florbetapir PET appears to be a promising tool for 
diagnosing CAA-related ICH.
Disclosure: This study was funded by Avid Radiophar-
maceuticals, Toulouse Teaching Hospital (CHU) and the 
Institut des Sciences et du Cerveau de Toulouse. 
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Correlation between nitric oxide and  
cholinesterase levels in blood serum of 
patients with acute ischemic stroke
K. Rasulova
Tashkent, Uzbekistan
Background and aims: This study investigated the relati-
onship between serum markers of endothelial dysfunction 
(the levels of NO metabolites) and cholinergic system (ace-
tylcholinesterase activity) in atherothrombotic, lacunar, and 
cardioembolic strokes.
Methods: 100 ischemic stroke (IS) patients were recruited 
and divided into three groups: 42 with atherothrombotic 
stroke, 41 with lacunar stroke, 17 with cardioembolic stro-
ke. In blood serum we determined NO2 and NO3 levels 
using Griss reactant, acetylcholinesterase (ACE) level by 
spectrophotometer method. Control group consisted of 20 
patients without stroke.
Results: In IS the levels of NO metabolites significantly 
decreased on 37.3%. The most significant decrease of NO 
level was noted in cardioembolic stroke (on 40.4%). Se-
rum level of acetylcholinesterase decreased on 24% that 
is evidence of cholinergic system deficit in IS, the most 
significant decrease was revealed in cardioembolic stroke 
(on 31.5%). Correlation analysis showed that NO level was 
straightly proportionally dependent on acetylcholinesterase 
level. This may indicate decreased stimulation of endothe-
lial relaxation factor (NO) in stroke. We could find straight 
correlative interrelation of deficits of these substances in 
stroke subtypes, which was stronger in cardioembolic 
(r=0.79) and lacunar (r=0.72) and weaker in atherothrom-
botic stroke (r=0.68).
Conclusion: Endothelial dysfunction, characterized by 
endothelial NO reduction, and cholinergic neuromediati-
on deficit, conditioned by decrease in cholinesterase level 
in blood serum of patients with IS, are considered to play 
the important role in the development of IS. NO reduction 
was found to be significantly correlated with serum level of 
cholinesterase and severity of ischemic stroke, especially in 
cardioembolic and lacunar strokes.
Disclosure: Nothing to disclose
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Predictive factors of brain death in severe 
stroke patients identified by organ  
procurement and transplant coordination 
in Lorrain, France
S. Richard1, L. Humbertjean1, R. Fay1, L. Durin2, G. Mione1, 
A.M. Enea1, X. Ducrocq1
1CHU Nancy, Neurology, Nancy, France, 2Agence de la Bio-
médecine, Direction Prélèvement Greffe organes - tissus, SRA 
Nord-Est, Nancy, France
Background and aims: Severe strokes are now the leading 
cause of brain death (BD). Potential donors require inten-
sive care unit (ICU) management to protect organs while 
waiting for possible progression to BD. There are no esta-
blished predictive factors to identify patients with a high 
probability of presenting BD. 
Methods: We retrospectively collected clinical and para-
clinical data of consecutive severe stroke patients with a 
potential progression to BD through the hospital organ pro-
curement and transplant coordination system in five centers 
in Lorrain (France) between 1st January 2012 to 31st De-
cember 2013. Final endpoint was adjudicated BD. Statisti-
cal comparison of each factor was made between patients 
with and without BD. A prognostic score was made based 
on factors significantly associated with BD.
Results: Of 400 included patients 91 (23%) presented 
adjudicated BD. Initial Glasgow score ≤6 (p<0.0001), 
stroke volume >65 mL (p=0.040), herniation (p=0.038), 
hydrocephalus (p<0.0001), initial systolic blood pressure 
>150 mmHg (p=0.034) and past history of alcohol abuse 
(p=0.002) were significantly associated with BD progres-
sion (figure 1). In patients with quantifiable stoke volume 
the likelihood of presenting BD was 28 times greater for 
a score of 4 to 6 vs. 0 to 1 (p<0.0001) (table 1) (figure 2). 
Figure 1: Factors significantly associated in multivariate analysis with 
brain death evolution for model 1 (a) and 2 (b). Model 1: model for 
stroke with non quantifiable volume, model 2: model for stroke with 
quantifiable volume
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Table 1: Risk of brain death evolution according to model and number 
of predictive factors. Model 1: model for stroke with non quantifiable 
volume, model 2: model for stroke with quantifiable volume,
Figure 2: Percentage of patients with brain death evolution according 
to predictive score for model 1 and 2. Model 1: model for stroke with 
non quantifiable volume, model 2: model for stroke with quantifiable 
volume.
Conclusion: This is the first study to determine predicti-
ve factors for BD progression in severe stroke patients. It 
could be the basis of a simple tool of 6 criteria to help neu-
rologists make the difficult decision of ICU management to 
preserve organs in potential organ donors.




Predictors of early neurological  
deterioration in acute ischemic stroke
A.F. Santos1, J. Mota2, L. Oliveira3, L.M. Afonso4,  
C. Machado1, J.N. Alves1, J. Pinho1, C. Ferreira1
1Hospital de Braga, Neurology, Braga, Portugal, 2Hospital de 
Santa Maria Maior - Barcelos, Internal Medicine, Barcelos, 
Portugal, 3Centro Hospitalar do Médio Ave - Famalicão,  
Internal Medicine, Famalicão, Portugal, 4Unidade Local de 
Saúde de Matosinhos, Internal Medicine, Matosinhos, Portu-
gal
Background: Mild stroke symptoms are cited as the reason 
for not using rtPA in 29-43% of time-eligible patients. It is 
unknown whether the reversal of this decision, during hos-
pital stay, changes the outcome. 
Objective: Determination of early neurological deteriora-
tion predictors in acute ischemic stroke and outcome at 3 
months.
Methods: Case control study. From a registry of rtPA tre-
ated patients (February 2007–September 2014) were iden-
tified 30 with NIHSS≤ 4 at admission and neurological 
worsening within the time window, subsequently submitted 
to thrombolysis. Risk factors, OCSP, TOAST and mRS at 
3 months were noted. Control patients were 29, admitted 
during 2013, with NIHSS≤4, without worsening in the first 
day. Statistical analysis used SPSS Statistics 22.0.
Results: Mean age 67; 53% men. 20 had high blood pres-
sure, 6 diabetics. 7 were on antiplatelets. One third PACI. 
Median NIHSS at the beginning of the infusion 9 (IQR = 
7-10). ASPECT score 10 in 25; 4 had hyperdense middle 
cerebral artery (MCA). Mean time onset-to-needle: 198 mi-
nutes (SD = 75.8). Cardioembolic etiology in 30%. Patients 
with neurological deterioration had higher glycemia at ad-
mission than the control group (p<0.05). No other predic-
tors of deterioration, including age, gender, OCSP, TOAST, 
ASPECTS, hyperdense MCA. Outcome was similar in both 
groups.
Conclusion: While waiting for scientific evidence to per-
form thrombolysis in patients with minor stroke, it is essen-
tial to maintain surveillance, particularly until 4,5 hours, 
namely in those with high glycemia. This treatment rever-
sed the deleterious effect of neurological worsening in the 
acute phase.
Disclosure: Nothing to disclose
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Influence of left ventricular dysfunction 
and related echocardiographic findings in 
ischemic stroke outcome
B.E. Sanz Cuesta1, B. Fuentes Gimeno1,  
P. Martínez Sánchez1, M.T. López Fernández2,  
J.J. Arévalo Manso1, J. Díaz De Terán1, I. Illán Gala1,  
J. Rodríguez Pardo De Donlenbún1, E.M. Alba Suarez1,  
C. Calle De Miguel1, J. Pérez Lucas1, J. Máñez Miró1,  
E. Miñano Guillamón1, E. Díez Tejedor1
1Hospital Universitario La Paz, Neurology, Madrid, Spain, 
2Hospital Universitario La Paz, Cardiology, Madrid, Spain
Background and aims: Severe left ventricular systolic 
dysfunction (LVSD) is associated with increased morbidi-
ty and mortality in stroke. However, it is unknown whe-
ther left ventricular dysfunction (LVD) including mild to 
moderate LVSD and left ventricular diastolic dysfunction 
(LVDD) could influence ischemic stroke (IS) outcome. In-
creased left ventricular filling pressure (iLVFP) is a typical 
echocardiographic finding, which is present in both types 
of LVD of any severity, less known in IS. Our objective 
was to analyse LVD frequences and factors associated with 
unfavourable outcome including some LVD related echo-
cardiographic findings.
Methods and Materials: Retrospective observational 
study in IS patients (Study period: 2010-2014). Demo-
graphics, vascular risk factors, results of diagnostic tests, 
reperfusion treatments and outcome at 3 months were coll-
ected (unfavourable if mRS≥3). The results of transthoracic 
echocardiography (TTE) including some of the most LVD 
related findings like left atrial enlargement >34 ml (LAE), 
left ventricular ejection fraction <35% (LVEF<35%) and 
iLVFP, were recorded. A predictive model of factors asso-
ciated with unfavourable outcome was generated.
Results: 459 IS patients with TTE with LVD parameters 
measured. Mean age 67.8 years, 60.3% male. 70 (15.2%) 
had mRS≥3 at 3 months. 211 patients (46%) with LVD and 
141 (30.7%) with iLVFP. 38 (8.3%) with LVSD and 191 
(41.6%) with LVDD. iLVFP was associated with unfavou-
rable outcome (OR 2.209, 95% CI 1.135- 4.299, p<0.020) 
after adjustment for diabetes mellitus, stroke severity and 
hospital complications.
Conclusion: Left ventricular dysfunction was present in 
almost half of the ischemic stroke patients. Increased left 
ventricular filling pressure was the only LVD related echo-
cardiographic finding associated with poor outcome.
Disclosure: Nothing to disclose
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The functional of the MnSOD Ala16Val, oxi-
dative stress and markers of apoptosis as 
biomarkers in patients with stroke
A.E. Flores1, E.T. Pascotini1, A.L. Prado1, A. Kegler1,  
I.B. da Cruz1, M.M. Duarte1, R.S. Scalco2, M.R. Fighera3
1Universidade Federal de Santa Maria, Santa Maria, Brazil, 
2University College London, London, United Kingdom, 3Uni-
versidade Federal de Santa Maria, Neurology, Santa Maria, 
Brazil
Background and aims: The VV genotype associated with 
the Ala16Val polymorphism (MnSOD gene) has been asso-
ciated with different health conditions including neurolo-
gical disorders. Here we investigated the oxidative stress, 
apoptotic biomarkers and the Ala16Val polymorphism in 
patients with chronic stroke (CS).    
Methods: A cross-sectional study of 40 CS patients and a 
control group of 40 healthy people was performed. Inclusi-
on criteria included CS (>6 months after initial symptom). 
Clinical features were assessed by a standardized questi-
onnaire and physical exam. Blood analysis included serum 
glucose (GLU), glycated hemoglobin (HBA1C), choleste-
rol (CHO), urea, phosphatase (PHO), acetylcholinesterase 
(AChE), low-density lipoprotein cholesterol (LDL), Prote-
in Carbonyl (PC), caspase-1, caspase-3 and caspase-8. Sta-
tistical analyses were carried out using the SPSS statistical 
software, version 18.0 (SPSS Inc., Chicago, IL). Ala16Val 
genotype was presented in mean (%). T  test was used to 
compare serum PC levels and serum caspase (1, 3 and 8) 
levels with clinical features ( significance level was set at 
5%).    
Results: Patients with CS presented a higher frequency of 
the VV genotype (AA(32.5%), AV (27.5%) e VV(40%)) 
comparing to the control group ((AA 55% AV35% e VV 
10%)). The serum PC (t=7.5 nmol/mg proteins), caspase-
1(t=6.9 U/mg protein), caspase-3 (t=6.8 U/mg protein) and 
caspase-8 (t=6.7 U/mg protein) levels were increased in 
patients with CS compared to the control group. Other fea-
tures of the CS group included GLU t=3.9mg/dL, HBA1C 
t=2.8%, CHO t=5.0mg/dL, LDL t=4.1mg/dL.
Conclusion: Our data suggest that the VV genotype may 
influence the oxidative stress response resulting in increa-
sed apoptotic markers in patients with CS. 
Disclosure: Nothing to disclose
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Combination of statin and inosine  
pranobex decreases the total rate of  
serum infectious pathogens  
immunoglobulins M and the incidence  
of post-stroke infections
E. Sidorovich1, T. Amvrosieva2, S. Likchachev3,  
Z. Bogush4, Y. Shabalina5, I. Petrovich5, B. Piskun5
1“National Research and Clinical Center Of Neurology and 
Neurosurgery, neurological, Minsk, Belarus, 2 The Repub-
lican Research and Practical Center for Epidemiology and 
Microbiology, Laboratory infections with natural reservoir, 
Minsk, Belarus, 3National Research and Clinical Center Of 
Neurology and Neurosurgery, neurological, Minsk, Belarus, 
4The Republican Research and Practical Center for Epide-
miology and Microbiology, Laboratory infections with natural 
reservoir, Minsk, Belarus, 5Minsk city emergency hospital, 
neurological, Minsk, Belarus
Background and aims: Post-stroke infections being the 
result of the stroke-induced immunodepression worsen the 
ischemic stroke (IS) prognosis.
Methods: 148 patients with IS were randomly divided into 
3 groups. The first group patients (n=54) received routine 
treatment including antiplatelet and symptomatic therapy. 
Excepting this treatment the second group patients (n = 
45) received simvastatin 40mg/d or atorvastatin 20 mg/d. 
Adding to this therapy the third group patients (n = 49) re-
ceived inosine pranobex (IP) 1000 mg thrise daily. Cyto-
megalovirus (CMV), herpes simplex virus (HSV), varicella 
zoster virus, Helicobacter pylori, Mycoplasma pneumoni-
ae, Chlamydia pneumoniaе serum immunoglobulins (Ig) 
M were determined in IS patients using an enzyme-linked 
immunosorbent assay.
Results: The rates of infectious pathogens IgM in three 
IS groups were 27/54, 14/45 and 25/49 at the stroke on-
set. After 14 days of treatment the decrease in the rate of 
infectious pathogens serum IgM in the third group (22/25 - 
84.0%) was higher than in the first (3/27-11.1%, P<0.0001) 
and in the second (4/14 – 28.6%, P<0.001) ones. In the 
third group the elimination of HSV and CMV IgM was no-
ted in the majority of cases (17 from 22). The number of 
cases with poststroke infections in the third group (2.04%) 
was significantly lower than in the first (35.2%) and in the 
second (15.5%) groups of IS patients, P<0.05.
Conclusion: The results of the pilot study suggest that the 
combination of statin and IP having immunomodulatory as 
well as direct antiviral effect may prevent reactivation of 
latent infections and reduce the incidence of post-stroke 
infections.
Disclosure: Nothing to disclose
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FMRI correlates of sustained attention in 
pediatric multiple sclerosis
E. De Meo1, M.A. Rocca1, L. Moiola2, A. Ghezzi3,  
P. Veggiotti4, R. Capra5, M.P. Amato6, A. Fiorino2,  
L. Pippolo3, M.C. Pera4, G. Comi2, A. Falini7, M. Filippi1
1San Raffaele Scientific Institute, Vita-Salute San Raffaele 
University, Neuroimaging Research Unit, Milan, Italy, 2San 
Raffaele Scientific Institute, Vita-Salute San Raffaele Uni-
versity, Department of Neurology, Milan, Italy, 3Ospedale di 
Gallarate, Centro Studi Sclerosi Multipla, Gallarate, Italy, 
4C. Mondino National Neurological Institute, Department of 
Child Neurology and Psychiatry, Pavia, Italy, 5Spedali Civili 
of Brescia, Regional Referring Center for Multiple Sclerosis, 
Brescia, Italy, 6University of Florence, Department of NEU-
ROFARBA, Florence, Italy, 7Università Vita-Salute San Raffa-
ele, Neuroradiology, Milan, Italy
Background and aims: To assess fMRI abnormalities 
during a sustained attention task in pediatric multiple sc-
lerosis (MS) patients and their correlations with cognitive 
dysfunction.
Methods: fMRI scans were acquired in 58 pediatric MS 
patients and 14 matched healthy controls (HCs) during the 
Conners’ Continuous Performance Test (CPT). Patients 
with > 2 abnormal tests at neuropsychological evaluation 
were classified as cognitively impaired (CI).
Results: 20 patients were CI. With increasing task demand, 
all participants showed activations of bilateral parietal re-
gions, middle frontal gyrus, supplementary motor area 
(SMA), right lingual gyrus and precuneus. Compared to 
HC, MS patients had an increased activation of left insula, 
anterior cingulate cortex and right inferior frontal gyrus, 
and a reduced activation of right precuneus and paracentral 
lobule. Compared to HC and CI, CP MS patients showed 
increased activation of left thalamus, inferior temporal and 
lingual gyri. Compared to the other two groups, CI MS 
patients had increased recruitment of the bilateral superi-
or medial frontal gyrus, left SMA and right inferior frontal 
gyrus and cerebellum. They also experienced a reduced ac-
tivation of the right postcentral gyrus (PCG). Better perfor-
mance during CPT correlated with increased activity if the 
right precuneus and PCG, while worse CPT performance 
correlated with increased activity in frontal regions.
Conclusion: During and attentive task, CI and CP pediatric 
MS patients recruited different brain area with increasing 
task demand. The increased fMRI activity in frontal regions 
seen in CI MS patients is likely to be a maladaptive mecha-
nism, associated with cognitive impairment.
Disclosure: Partially supported by a grant from Italian Mi-
nistry of Health (GR-2009-1529671).
P3111
Hand-foot-mouth disease neurologic com-
plications: clinical features and  
parameters
T.-H. Eom
Seoul, Korea, Republic of
Background and aims: Hand-foot-mouth disease (HFMD) 
is a common childhood illness. Enterovirus 71 (EV71) 
epidemics have recently been associated with HFMD-
based neurologic complications in the Asia-Pacific region. 
This study described HFMD clinical features, and investi-
gated clinical parameters in patients presenting with acute 
neurologic complications associated with HFMD.
Methods: We retrospectively reviewed medical records 
from 235 hospitalized patients who developed HFMD with 
or without neurologic complications (22 and 213 cases, res-
pectively) in Uijengbu, Korea between 2010 and 2013. Cli-
nical manifestations, radiologic findings, cerebrospinal flu-
id analyses, virological analyses, and treatment regimens 
were summarized. Additionally, routinely collected base-
line data from 235 patients were retrospectively analyzed 
to identify clinical parameters associated with neurologic 
complications.
Results: Brainstem encephalitis was the most frequent 
neurologic complication (11 cases), followed by aseptic 
meningitis (seven cases). We also found acute dissemi-
nated encephalomyelitis and meningitis retention syndro-
me. Both have rarely been reported in EV71-associated 
HFMD. Virological analyses were performed for 15 ca-
ses, and 14 demonstrated EV71 infection, while one pa-
tient demonstrated Coxsackievirus B3 infection. Multiva-
riate logistic regression analysis indicated patients were 
more likely to develop neurologic complications if they 
experienced nausea/vomiting (OR=13.65, P<0.001) and 
lethargy (OR=10.68, P=0.003). Males were more likely 
to develop neurologic complications compared to females 
(OR=2.12, P=0.005). In addition, neurologic complications 
were associated with a higher peak heart rate (OR=1.13, 
P=0.001).
Conclusion: This study revealed usual and unusual fin-
dings of HFMD-associated neurologic complications. Male 
gender, nausea/vomiting, lethargy, and peak heart rate pre-
dicted HFMD-associated neurologic complications. How-
ever, laboratory findings did not reliably predict HFMD-
associated neurologic complications. 
Disclosure: Nothing to disclose
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Cognitive outcomes of children with fetal 
antiepileptic drug exposure at the age of 
3-6 years – preliminary data.
N. Gogatishvili1, T. Ediberidze1, S. Mamukadze1,  
G. Lomidze2, N. Tatishvili3, S. Kasradze2
1Tbilisi, Georgia, 2Institute of Neurology and Neurophsycho-
logy, neurology, Tbilisi, Georgia, 32Department of Neurosci-
ence. M.Iashvili Children Central Hospital. Tbilisi. Georgia, 
Tbilisi, Georgia
Background and aims: Data on effects of intra-uterine 
exposure to antiepileptic drugs (AEDs) on cognitive func-
tioning are limited and conflicting. Our aim was to assess 
the effects of fetal AEDs on cognitive outcomes in children.
Methods: In this retrospective cohort study children aged 
3-6 years with fetal exposure to AEDs registered in the 
Georgian National AED-Pregnancy Registry of the Euro-
pean Registry of Antiepileptic Drugs (EURAP) were in-
cluded. Neuropsychological assessments were performed 
in all using the Wechsler Preschool and Primary Scale of 
Intelligence (WPPSI – IV), and Wide Range Assessment of 
Visual Motor Abilities (WRAVMA) tests. Statistical analy-
sis was done using SPSS version 20 (SPSS Inc, Chicago, 
Illinois)
Results: So far 23 children were evaluated. 12 (52%) were 
exposed to valporate (VPA), 5 (22%) to carbamazepine 
(CBZ), 1 (4%) to lamotrigine (LTG), 3 (13%) to Phenobar-
bital (PB) and 2 (9%) to polytherapy with carbamazepine 
and levetiracetam (LEV). IQ scores were average (91-110) 
in 8 cases (35%), low (81-90) in 7 (30%), borderline (71-80) 
in 4 (17%) and extremely low (<71) in 4 (17%) children. 
6 of 8 children with borderline and extremely low IQ were 
exposed to VPA mono-therapy. The 2 remaining were ex-
posed to CBZ and PB, respectively. 
Conclusion: These preliminary results indicate that 2/3 of 
children exposed to AEDs had reduced cognitive abilities, 
and most of them had been exposed to VPA monotherapy. 
More data are needed to establish significant conclusions. 
Disclosure: The study was performed within the scientific 





Diffusion tensor imaging of the auditory 
neural pathway for clinical outcome of 
cochlear implantation (CI) of pediatric  
congenital sensorineural hearing loss  
patients
L. Huang1, W. Zheng1, C. Wu2, X. Wu3
1The Second Affiliated Hospital, Medical College of Shantou 
University, Radiology, Shantou, China, 2The Second Affiliated 
Hospital, Medical College of Shantou University, Radiology, 
Shantou, China, 3The Second Affiliated Hospital, Medical 
College of Shantou University, E.N.T, Shantou, China
Background and aims: To evaluate possible changes in 
microstructure in auditory neural pathway of children with 
profound congenital sensorineural hearing loss (SNHL) 
and the possible difference between good and poor clini-
cal outcome of cochlear implantation (CI) patients by using 
diffusion tensor imaging (DTI).
Methods: 30 patients (mean age, 4.6 years) with SNHL and 
20 age-matched healthy controls underwent conventional 
MR imaging and DTI examination. Fractional anisotropy 
(FA) of six regions of interest (ROIs) positioned along the 
auditory pathwaythe trapezoid body (TB), the superior oli-
vary nucleus (SON), the inferior colliculus (IC), the medial 
geniculate body (MGB), the auditory radiation (AR) and 
the white matter of Heschl’s gyrus (WHG)  were measured 
bilaterally in all subjects. Among the 30 patients, 17 pati-
ents with categories of auditory performance (CAP) score 
over 6 were classified into the good outcome group and 13 
patients with CAP score below 6 were classified into the 
poor outcome group.
Results: FA values were significantly reduced at the six 
ROIs positioned along the auditory neural pathway of pati-
ents with SNHL compared with healthy controls, compared 
to good outcome subjects, poor outcome subjects displayed 
decreased FA values at all of the ROIs investigated in this 
study. Correlation analyses revealed strong correlations 
between FA values at all of the ROIs and CAP scores deter-
mined 12 months after CI.
Conclusion:  Preoperative DTI imaging can be used to 
evaluate microstructural alterations in the auditory neural 
pathway that are not detectable by conventional MR ima-
ging, and may play an important role in the evaluation of 
the outcome of the surgery.
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Correlations between FA values and CAP scores at the selected brain 
regions(ROI); The lines are the result of a linear regression.
Disclosure: This study was supported by the Natural Sci-
ence Foundation of Guangdong Province, China (2014), 
and was sponsored by Shantou University Medical College 
Clinical Research Enhancement Initiative(2014), Shantou 
China, Science and Technology Planning Project of Shan-
tou City, China (grant No.201424260), Shantou China.
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Visual evoked potentials and retinal  
optical coherence tomography in optic 
neuropathy
N. El Ayoubi1, H. Sawaya2, R. Sawaya1
1Beirut, Lebanon, 2American University Medical Center, 
Beirut, Lebanon
Background and aims: Flash (fVEP) and pattern reversal 
visual evoked potentials (PRVEP) study the physiological 
changes in the retinal neurons and axons, while retinal fi-
ber layer (RNFL) and ganglion cell/internal plexiform layer 
(GCIPL) seen on optical coherence tomography (OCT) re-
flect the size of the respective layers. The aim of this study 
is to correlate these different variables in normal eyes and 
patients with chronic optic neuropathy (ON).
Methods: We studied 14 normal eyes and 13 eyes with op-
tic neuropathy. All eyes were stimulated with intermittent 
light and pattern reversal stimulation, monocularly with 
high-contrast checkerboard pattern, at a reversal rate of 2 
Hz, with a check size of 30’, and an average of 150 stimula-
tions. OCT was performed using Spectral-Domain Cirrus® 
OCT Device. RNFL and GCIPL were measured. Multiple 
statistical methods were used.
Results: The mean and standard deviation of fVEP, 
PRVEP, RNFL, GCIPL was calculated for controls and pa-
tients with ON (table 1). We found a negative correlation 
between PRVEP and RNFL in the control group (fig 1), and 
a negative correlation between fVEP and GCIPL in the ON 
eyes (fig 2).
Fig.1: Mean and SD of fVEP, PRVEP, RNFL and GCIPL in normal 
and ON eyes.
Fig.2: PRVEP latencies and RNFL in controls.
Fig.3: fVEP latenices and GCIPL in ON eyes.
Conclusion: In controls PRVEP is shorter and less varia-
ble than fVEP. It correlates with RFNL size, but does not 
reflect changes in the GCIPL. In ON PRVEP is delayed 
while fVEP is shorter and more variable than in controls. 
Furthermore, in ON fVEP reflects GCIPL thickness more 
than PRVEP.
Disclosure: Nothing to disclose
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The VEMP score: a promising marker of 
disability progression in patients with mul-
tiple sclerosis
T. Gabelic1, M. Krbot Skoric1, I. Adamec1, M. Habek2
1Zagreb, Croatia, 2University Hospital Center Zagreb, Neuro-
logy, Zagreb, Croatia
Background and aims: Vestibular evoked myogenic po-
tentials (VEMP) have been recognized as a reliable method 
in detection of symptomatic and asymptomatic brainstem 
involvement in multiple sclerosis (MS). Recently develo-
ped VEMP score showed significant correlation with EDSS 
and disease duration in MS patients in a cross-sectional 
study.
The aim of this study was to evaluate the VEMP score as a 
marker of disability progression in MS patients.
Methods: 26 patients with definitive diagnosis of relap-
sing-remitting MS underwent clinical, neuroradiological 
and neurophysiological work up at the study entry consis-
ting of expanded disability status scale (EDSS), brainstem 
functional system (BSFS), presence of brainstem lesions on 
the brain MRI and ocular and cervical VEMPs. For these 
26 patients second complete clinical and neuroradiologi-
cal analysis with additional data about number of relapses, 
number of total new T2 lesions and new gadolinium en-
hancing lesions was done after three years and results were 
correlated with the VEMP score value at the study entry.  
Results: EDSS at follow-up was significantly correlated 
with values of the VEMP score at the study entry (p=0.048; 
R=0.392). Significance with the VEMP score was also ob-
served for follow-up values of BSFS (p=0.050; R=0.389). 
No statistically significant correlation was found between 
VEMP score and number of gadolinium enhancing lesions 
or number of clinical relapses.
Conclusion: The VEMP score shows promise as a marker 
of future disability development in patients with relapsing- 
remitting MS. 
Disclosure: Nothing to disclose
P3118
Optical coherence tomography and multi-
focal visual evoked potentials can be use-
ful in clinical practice when full-field visual 
evoked potentials fail in identifying visual 
pathway abnormalities.
S. Guerrieri1, G. Di Maggio1, F. Vitali2, R. Santangelo1,  
S. Medaglini1, L. Moiola1, U. Del Carro1, V. Martinelli1,  
G. Comi1, L. Leocani1
1San Raffaele Scientific Institute, Vita-Salute San Raffaele 
University, Department of Neurology, Milan, Italy, 2San 
Raffaele Scientific Institute, Department of Neurophysiology, 
Milan, Italy
Background and aims: Full-field visual evoked potenti-
als (ff-VEP) are fundamental in neurological practice, for 
detecting and defining the nature of visual disturbances or 
to identify subclinical involvement of the visual pathway. 
We explored whether, in case of normal ff-VEP and suspec-
ted organic visual pathway involvement, multifocal  visual 
evoked potentials (mf-VEP) and optical coherence tomo-
graphy (OCT) can be useful in the diagnostic workup.   
Methods: Observational case reports.  
Results: We described the cases of three patients arrived 
at our Neurology department for visual disturbances. Two 
patients had relapsing optic neuritis (ON) and visual acuity 
(VA) loss, with normal or not significant ff-VEP outside 
acute clinical episodes. In both cases OCT scan showed a 
reduction of global retinal nerve fiber layer (RNFL) thick-
ness, allowing visual pathway damage identification. Ano-
ther patient with left frontal basal meningioma involving 
the left optic nerve arrived at our department complaining 
of blurred vision in the nasal visual field of the left eye as 
confirmed by computerized perimetry (CP). While ff-VEP 
showed a normal latency and a non significant amplitude 
reduction in the left eye, mf-VEP showed an important am-
plitude reduction in the whole lower left eye visual field. 
OCT scan confirmed axonal damage showing left global 
and sectoral RNFL thinning. 
Conclusion: Sometimes ff-VEP fails in identifying abnor-
malities in patients with organic pathological processes 
involving the visual pathway, particularly in cases with 
axonal or sectoral optic nerve involvement. We suggest the 
importance of a multimodal instrumental evaluation, inclu-
ding OCT and mf-VEP.  
Disclosure: Part of this work was supported by Merck 
Serono S.A., Geneva, Switzerland. Merck Serono is the 
biopharmaceutical division of Merck KGaA, Darmstadt, 
Germany.
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Pattern reversal visual evoked potentials 
variability with age
R. Sawaya1, S. Hammoud1, H. Sawaya2, W. Radwan1
1Beirut, Lebanon, 2American University Medical Center, 
Beirut, Lebanon
Background and aims: Pattern reversal visual evoked po-
tential (PRVEP) is an electrophysiological test to study the 
optic nerves and tracts. This study aims at evaluating the 
changes in the latencies and amplitudes of the PRVEP ac-
ross the different age groups in normal subjects to standar-
dize this technique, produce average results for the different 
decades, and to evaluate the changes across age groups.
Methods: We studied 81 healthy participants (162 total 
eyes), between the ages of 20 and 92 divided into decades. 
Stimulation was performed monocularly with high-contrast 
(>50%) black-white checkerboard pattern, at a reversal rate 
of 2 Hz, with a check size of 30’, a band-pass of 1-100 Hz, 
a sweep of 250 msec, and an average of 150 stimulations. 
Multiple statistical methods were used.
Results: We define the mean and standard deviations for 
the latencies and amplitude for each decade (table 1). Trend 
analyses showed that there was a significant linear trend 
by age for all three latencies, indicating that the higher age 
groups had longer latencies We found that the latencies dip 
at the 4th decade before increasing in the older age groups 
(fig 1). The amplitude of N75-P100 decreases with age (fig 
2).
Fig. 1: Latencies vs amplitude a cross age categories. 
Fig. 2: P100 latencies across age categories.
Table1: Means and standard deviations of prVEP N75, P100 and N145 
Latencies (ms) and N75 – P100 Amplitude (µv) for the different age 
groups
Conclusion: We define the N75, P100 and N145 latencies 
across the different age groups and conclude that the la-
tencies increase with age while the N75-P100 amplitude 
decreases. Latencies are shortest in the 4th decade.
Disclosure: Nothing to disclose
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Age-related changes in neurophysiology 
according to gender
I. Gomes1, A.C. Siviero2, L.E. Hauck3, R. Siciliani Scalco4,  
J. Becker5
1PUCRS, Neurology, Porto Alegre, Brazil, 2ULBRA, Porto 
Alegre, Brazil, 3Plau, Germany, 4Porto Alegre, Brazil, 5PU-
CRS and ULBRA, Neurology, Porto Alegre, Brazil
Background and aims: Age and gender related physio-
logical changes are common and are to be expected. It is 
however not clearly standardized how these factors can 
affect normal neurophysiological reference limits and fre-
quently a common average reference is generally used to 
report neurophysiological studies of the peripheral nervous 
system in both male and female patients
Methods: We retrospectively analysed 4,622 upper limb 
and 3,896 lower limb neurophysiological reports with re-
sults within the normal limits to identify age-related chan-
ges according to gender.    
Results: Both sensory and motor conduction studies show-
ed age-related amplitude and conduction velocity decrea-
ses and distal latency increases (motor conduction studies). 
These findings were even seen in younger age groups and 
progressively changed over life in different ways according 
to gender.    
Conclusion: Understanding the expected normal range of 
neurophysiological results according to age group and gen-
der may have an important practical application as it may 
improve diagnostic criteria of normality.    
Disclosure: Nothing to disclose
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Mystery beneath the abductor pollicis  
brevis atrophy: a case series
B. Bastan1, P. Kahraman Koytak2, H. Alibas2, K. Uluç2
1Haseki Educational and Research Hospital, Neurology, 
Istanbul, Turkey, 2Marmara Univercity Faculy of Medicine, 
Neurology, Istanbul, Turkey
Background and aims: Atrophy of the abductor pollicis 
brevis (APB) muscle is a well-known presentation of severe 
carpal tunnel syndrome (CTS) and motor neuron disorders 
(MND). However, it may be seen in other disorders. The 
purpose of this case series is to document the different etio-
logies causing thenar atrophy other than CTS and MND.
Methods: We prospectively evaluated 15 patients presen-
ting to our clinic with atrophy of the abductor pollicis brevis 
muscle, without clinical and electrophysiological evidence 
of CTS and/or MND between January and December 2013. 
All of the patients underwent electrophysiological investi-
gation, magnetic resonance imaging (MRI) of the cervical 
spine and MRI of the hand muscles, when necessary.
Results: 7 patients had electrophysiological and radiolo-
gical evidence of cervical radiculopathy, with 6 of them 
showing isolated involvement of C8-T1 roots. One patient 
had C8-T1 root avulsion. 3 of the cases had brachial plexo-
pathy, in which 2 of them revealed typical features of neu-
rogenic thoracic outlet syndrome. 1 patient had syringomy-
elia and another patient had proximal median neuropathy. 2 
of the patients were found to have agenesis of APB muscle 
which was confirmed by hand MRI. Needle electromyogra-
phy of these patients showed no acute denervation poten-
tials or motor unit potentials in the APB muscle whereas 
needle examination of the other median innervated muscles 
and other C8-T1 root innervated muscles was normal.
Conclusion: Cervical radiculopathy is the most common 
cause of thenar atrophy in patients without signs of CTS 
and/or MND. Although it is a very rare condition, agenesis 
of APB muscle should be included the differential diagno-
sis.
Disclosure: Nothing to disclose
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Two cases of lipoatrophy after local  
steroid injection
I. Kim, S. Lee
Korea, Republic of
Background and aims: Local corticosteroid injections are 
frequently included as treatment option in clinical guideli-
nes in the field of musculoskeletal disorders. Adverse ef-
fects of systemic steroid medication are well known to the 
public, whereas the side effects of local steroid injections, 
were not known to even clinicians and there is a potenti-
al threat to misdiagnosis. We report two cases of localized 
lipoatrophy and depigmentation following local steroid in-
jection.
Case Reports: A 43-year-old woman was referred to our 
clinic with a 4-month history of depressed skin and numb-
ness in back of the hand. She underwent a local triamci-
nolone injection around the right first metacarpal joint 
to alleviate the pain of radial collateral ligament injury 4 
months ago. Examination revealed atrophy of the skin, hy-
popigmentation, and hypoesthesia in the right first dorsal 
interosseous area (Figure 1) without weakness. An 18-ye-
ar-old female visited our clinic with a 3-month history of 
depression in her left medial foot. Four months ago, she 
had been treated for a presumed plantar fasciitis with local 
steroid injection. Examination revealed a prominent tissue 
atrophy and depigmentation between navicular prominence 
and instep (Figure 2). Electrodiagnostic studies of the two 
cases showed no abnormalities
Figure 1
Figure 2
Conclusion: Although the incidence of soft tissue atrophy 
after local steroid injection is reported less than 1%, it will 
increase in proportion to the frequency of the procedure. 
Many practitioners classify these adverse effects as ‘trivial’ 
and leave out of consideration. However, even clinicians, 
who do not perform the injection, should be aware of the 
occurrence of this cosmetically disturbing side effect.
Disclosure: Nothing to disclose
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A 5-year follow-up of visual evoked  
potentials and nerve conduction study in 
adolescents with type 1 diabetes mellitus
S. Lee1, H. Kim2, H.-S. Han3
1, Korea, Republic of, 2Chungbuk National University School 
of Medicine, Preventive Medicine, Cheongju-si, Korea, Repu-
blic of, 3Chungbuk National University School of Medicine, 
Paediatrics, Cheongju-si, Korea, Republic of
Background and aims: Central nervous system impair-
ment is common in diabetic patients, even in the early sta-
ges of the disease, and could be associated with periphe-
ral neuropathy. The aim of the study was to prospectively 
investigate central nerve conduction changes in adolescent 
with type 1 diabetes using pattern-reversal visual evoked 
potentials (PRVEP) and to determine how those results 
were related to clinical risk factors and parameters of peri-
pheral nerve conduction studies (NCS).
Methods: A total of 36 type 1 diabetic patients (15 males), 
5-24 years of age (mean 14.5±4.7), underwent PRVEP and 
NCS annually for five years. For comparison, 39 healthy 
adolescents (mean 14.8±5.0) were studied.
Results: The P100 latencies of PRVEP were prolonged at 
the study entry when compared with controls (P<0.001). 
Significant correlations were not found between the para-
meters of PRVEP and HbA1C levels, but on the other hand 
the parameters of peripheral NCS were well correlated to 
the metabolic control. The latency and amplitude values of 
P100 were not related to any parameter of NCS.
Conclusion: Prolonged PRVEP latency may be a sign of 
optic pathway dysfunction which begins before the appa-
rent diabetic retinopathy. Poor glycemic control proved to 
be an important risk factor as related to the development of 
peripheral neural pathway abnormalities. However, central 
conduction changes were poorly related with diabetic con-
trol and attributes of peripheral nerve conduction studies 
over the 5 year follow-up. There was no significant change 
in the parameters of PRVEP in adolescents with type 1 di-
abetes mellitus during the relatively early stage of the di-
sease.
Disclosure: Nothing to disclose
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Predictors of Quality of Life in patients 
with multiple sclerosis
I. Moreira1, R. Samoes1, E. Santos1, C. Pinto2, A. Gonçalves2, 
S. Cavaco2, A. Martins Silva1
1Centro Hospitalar do Porto - Hospital Santo António, Neuro-
logy, Porto, Portugal, 2Centro Hospitalar do Porto - Hospital 
de Santo António, Neuropsychology Unit, Porto, Portugal
Background and aims: Quality of life (QoL) is common-
ly affected in patients with Multiple Sclerosis (MS) and is 
considered an important outcome measure in clinical tri-
als. Our aim was to explore associations between patients’ 
demographic, clinical, psychopathological and cognitive 
features and indicators of QoL in MS.
Methods: In a population of 419 patients with MS, 270 
patients (62% women; age=39±11; education=12±5 years; 
EDSS=3±2; disease duration=10±9 years; 85% relapsing-
remitting course, 8% secondary progressive, 7% primarily 
progressive) answered the Functional Assessment of Mul-
tiple Sclerosis Scale (FAMS) and the Hospital Anxiety and 
Depression Scale (cut off > 11 for anxiety and depression), 
and underwent a neuropsychological assessment (cogniti-
ve impairment was defined as >25% neuropsychological 
measures <5th percentile). Mann-Whitney test, Pearson’s r, 
and multiple linear regressions (without variable selection) 
were used for statistical analysis.
Results: Negative associations (p<0.05) were found bet-
ween QoL scores (FAMS) and female gender, increasing 
age, longer disease duration, higher EDSS, progressive 
course of disease, anxiety, depression, and cognitive im-
pairment. QoL increased with education (p<0.05). Multiple 
linear regression analysis showed that EDSS (β adjusted = 
-5.375), anxiety (β adjusted = -17.781), depression (β ad-
justed = -31.789), and cognitive impairment (β adjusted = 
-7.861) remained statistically associated with FAMS total 
score when controlling for demographic characteristics sex, 
age and education.
Conclusion: Neurological disability, psychopathological 
symptoms, and cognitive functioning were robust predic-
tors of QoL in this population with MS. The study results 
are consistent with the literature and underscore the impor-
tance of addressing mood and cognition in the clinical ma-
nagement of MS patients.
Disclosure: Nothing to disclose
P3125
Cognitive evolution inTysabri treated  
multiple sclerosis patients
F. Jacques1, B. Harel2, A. Schembri3, C. Paquette1,  
B. Bilodeau1, P. Kalinowski3
1Clinique Neuro-Outaouais, Gatineau, Canada, 2Cogstate, 
New Haven, USA, 3Cogstate, Melbourne, Australia
Background and aims: Cognitive dysfunction affects up 
to 65% of MS patients and progresses over time. 
The objectives of this study are to understand the impact of 
natalizumab on cognition beyond two years of therapy and 
to investigate whether baseline characteristics are predicti-
ve of clinical response. 
Methods: This is a single-center, 24-month, observational 
study. 63 patients treated with natalizumab were assessed 
prior to monthly infusions using a Cogstate battery and the 
SDMT.  A linear mixed model was conducted with durati-
on of natalizumab therapy as a between-subjects factor (≤2 
or >2 years), assessment as a within-subjects factor, and 
MSSS as a covariate. All patients in the ≤2 years group 
were treated with natalizumab for less than two years prior 
to baseline. All patients in the >2 years group were treated 
with natalizumab for at least two years prior to the baseline 
(mean 3.6 years). 
Results: There were no statistically significant differences 
between the key demographic variables aside for the MSSS 
(p=.0074). No patient showed evidence of sustained cog-
nitive deterioration over the 24 month period. Irrespective 
of time on natalizumab, significant improvements were ob-
served at the group level in executive function, verbal me-
mory and working memory, whereas processing speed and 
attention remained unchanged. Impaired cognition or any 
other baseline parameter did not influence the trajectory of 
cognitive change over 24 months. 
Conclusion: Our results suggest that natalizumab preser-
ves cognitive function, including the ability to learn, for 4 
years and beyond of continuous therapy. This occurs irres-
pective of baseline characteristics. 
Disclosure: The research has been financed by an unre-
stricted grant from Biogen Idec.
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Brain on Track: development of a self- 
administered web-based test for  
longitudinal cognitive assessment
L. Ruano1, A. Sousa2, M. Severo1, I. Alves2, M. Colunas3,  
R. Barreto2, C. Mateus2, S. Moreira2, E. Conde3, V. Bento4,  
N. Lunet1, J. Pais2, V. Tedim Cruz2
1University of Porto Medical School, Department of Clinical 
Epidemiology, Predictive Medicine and Public Health, Porto, 
Portugal, 2Entre Douro e Vouga Hospital Center, Neurology, 
Santa Maria Da Feira, Portugal, 3University of Aveiro, Cli-
nical Research Office, Health Sciences Department, , Aveiro, 
Portugal, 4University Institute of Maia – ISMAI, Maia, Por-
tugal
Background and aims: Follow-up testing has been recom-
mended to improve the diagnostic reliability of cognitive 
screening and patient monitoring strategies. However, few 
brief asessement tools have been validated for this purpose. 
Our objective is to develop a web-based self-administered 
test intended for repeatable cognitive assessment  (Brain 
on Track).
Methods: A team of neuropsychologists and neurologists 
designed several computerized subtests, expected to evalu-
ate different cognitive domains. An initial (Test A) and a re-
fined subtest battery (Test B) were applied to patients with 
mild cognitive impairment or early stage dementia (n=88) 
and matched controls (Study I). Principal component and 
internal consistency analysis were performed. The area 
under the Receiver Operating Characteristic (ROC) curve 
and the Smallest Real Difference (SDR) were estimated. A 
subsample of a population-based cohort (n=113) performed 
Test B from home every 3 months (Study II). Test-retest 
reliability was evaluated using two-way mixed single intra-
class consistency correlation coefficient (ICC). 
Results: Cronbach’s alpha was 0.91 for Test A and 0.90 for 
Test B. For both tests A and B, the total scores were signifi-
cantly different between patients and controls (p = 0.001), 
with the SDR (3.74 and 4.18) being lower than the clinical 
relevant difference (4.00 and 4.82). The area under ROC 
curve was 0.66 and 0.73. In a 3 trial analysis of test-retest 
reliability, 9/10 subtests showed high ICC (≥0.74).    
Conclusion: The Brain on Track test showed good inter-
nal consistency, discriminative ability and reliability when 
performed from home. Undergoing clinical and population-
based prospective studies will allow for further refinement 
and validation for longitudinal clinical use.
Disclosure: Nothing to disclose
P3127
Hemiprosopometamorphopsia as the  
presenting symptom of Marchiafava-Big-
nami disease
M. Tábuas-Pereira, J. Parra, D. Duro, A.M.C. Maduro,  
M.I.J. Santana
Coimbra, Portugal
Background and aims: Cognitive deficits that compro-
mise the perception and recognition of faces are related to 
fusiform area, especially the right fusiform gyrus, which 
is central in prosopagnosia. Hemiprosopometamorphopsia 
is a rare deficit in perception of face configuration, related 
mainly with ischemic lesions (located in the retrosplenic or 
unilateral temporoocipital regions). Marchiafava-Bignami 
is a rare toxic disease seen mostly in chronic alcoholics that 
results in progressive demyelination and necrosis of the 
corpus callosum.
Case Report: A 59-year-old right-handed man, presented 
with changes in the perception of the right half of the hu-
man faces, which seemed deformed and somehow longer. 
These changes have been progressively developing for 
some days/weeks. He did not show neither signs of alexia/
dyslexia, colour anomia, optic aphasia, apraxia, agraphia 
nor other cognitive or neurological deficits. The changes 
were restricted to the faces. MRI showed a lesion in the 
left side of the splenium of the corpus callosum. OCT and 
Hess-Lancaster found no changes. Blood and CSF analysis 
showed only a reduction of folic acid levels. The patient 
reported subjective feeling of improvement with vitamin 
supplementation. MRI performed six months later showed 
central necrosis of the lesion, with no enlargement.
Conclusion: Hemiprosopometamorphopsia is a rare sym-
ptom (less than 15 cases reported) but with a high loca-
lization value. It is associated with disconnection of the 
occipital lobe with the contralateral fusiform area. Being 
bizarre, it may be overlooked as of psychiatric nature. Here, 
we present the first report of hemiprosopometamorphopsia 
as a presenting sign of a patient with Marchiafava-Bignami 
syndrome.
Disclosure: Nothing to disclose
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Hippocampal-DMN disconnectivity in MS 
is related to WM lesions and contributes 
to depression
L. Vacchi1, M.A. Rocca1, E. Pravatà2, P. Valsasina1,  
M. Radaelli3, B. Colombo3, C. Gobbi4, G. Comi3, A. Falini5, 
M. Filippi1
1San Raffaele Scientific Institute, Vita-Salute San Raffaele 
University, Neuroimaging Research Unit, Milan, Italy, 2Neu-
rocenter of Southern Switzerland, Department of Neuroradio-
logy , Lugano, Switzerland, 3San Raffaele Scientific Institute, 
Vita-Salute San Raffaele University, Department of Neuro-
logy, Milan, Italy, 4Neurocenter of Southern Switzerland, 
Department of Neurology, Lugano, Switzerland, 5Università 
Vita-Salute San Raffaele, Neuroradiology, Milan, Italy
Background and aims: The hippocampus is part of the 
default-mode network (DMN) and is functionally hit early 
in the course of multiple sclerosis (MS). We hypothesized 
that white matter focal lesions may contribute, through a 
disconnection mechanism, to hippocampal dysfunction 
and hippocampal-related clinical deficits. To test this, we 
assessed the relationship between abnormalities of hippo-
campal resting state (RS) functional connectivity (FC) with 
brain T2 lesion volumes and presence and severity of de-
pression.
Methods: Structural and RS fMRI images were acquired 
from 69 cognitively intact MS patients and 42 matched 
healthy controls (HC). In patients, depression was quanti-
fied using the Montgomery-Asberg Depression Rating Sca-
le. Hippocampal RS FC was assessed using a seed-voxel 
approach. SPM8 was used for between-group comparisons 
and analysis of correlation between RS FC abnormalities 
with clinical and structural MRI variables.
Results: Compared to HC, MS patients experienced a si-
gnificant atrophy of the whole brain and left hippocampus 
(p<0.001) as well as a distributed pattern of decreased RS 
FC between the hippocampi and several cortical-subcorti-
cal regions. Reduced hippocampal RS FC with the DMN 
was strongly correlated to higher T2 lesion volume as well 
as to disease duration, severity of depression and disability.
Conclusion: In cognitively preserved MS patients, brain 
focal WM lesions influence the functional integration of the 
hippocampus to other brain regions of the DMN, leading to 
a disconnection syndrome. Such a disruption of hippocam-
pal RS FC contributes to the occurrence of depression and 
to clinical disability.
Disclosure: This work has been supported by a grant from 
Italian Ministry of Health (GR-2008-1138784) and Fonda-
zione Italiana Sclerosi Multipla (FISM2012/R/8).
P3129
Does fast titration of topiramate reveal the 
early detection of patients who will  
experience negative cognitive side  
effects?
G. Widman, J.A. Witt, C.E. Elger, C. Helmstaedter
Universität Bonn, Klinik für Epileptologie, Bonn, Germany
Background and aims: Topiramate (TPM) is effective 
for migraine-prophylaxis, treatment of epilepsy, obesity, 
neuropathic pain, and alcohol-dependence. Executive dys-
function, however, is a common adverse side effect, which 
may significantly affect daily functioning. Additionally, an-
osognosia for these changes has been suggested, when they 
develop slowly under normal titration.
For treatment of refractory status epilepticus, however, a 
titration up to 400mg within one day was reported without 
severe non-cognitive side effects.
Methods: Executive functions before and after fast (n=10 
with 50mg /day) versus slow titration (n=15 as recommen-
ded) were compared using the screening tool EpiTrack®. 
End doses were comparable with 215mg/day and 220mg/
day respectively
Results: With fast titration, objective deficits in executive 
functions increased from 50% at baseline to 80% at follow-
up, and 70% experienced a significant decline. With slow 
titration deficits increased from 53% to 73% with signifi-
cant declines in 47% of the patients.
Conclusion: Faster titration of TPM may help to avoid 
disastrous numbness after dismissal, but 23% more pati-
ents than with low titration experience decline in executive 
functions. A controlled study with longer follow up will be 
necessary in order to evaluate whether patients with fast ti-
tration habituate and have outcomes as observed with slow 
titration.
Disclosure: Nothing to disclose
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Spatial attention and the feeling of bodily 
self in the elderly
D. Zeller, M. Hullin
Univ. of Würzburg, Dept. of Neurology, Würzburg, Germany
Background and aims: In young adults, a right-hemisphe-
ric specificity has been suggested for spatial attention and 
for the feeling of body-ownership. Here, we aimed at as-
sessing these neuropsychological functions, which may be 
modulated by age, in the elderly.
Methods: 65 subjects with median age of 75 (60-90) ye-
ars without a neurological history were included. Spatial 
attention was assessed by the Milner landmark task, which 
requires a judgment of asymmetry of centrally pre-bisected 
lines. The spontaneous feeling of limb ownership was in-
quired by a questionnaire. To experimentally manipulate 
this feeling, we used the “rubber hand illusion” (RHI) pa-
radigm. Synchronous or asynchronous brushstrokes were 
applied to the subjects’ hidden real hand and an aligned 
plastic hand. The occurrence of the illusion was assessed 
by subjective (questionnaire) and objective (proprioceptive 
drift) measures.
Results: Spatial attention was asymmetric, with 63±26% 
(p<0.001) overestimation of the right segment of the mid-
bisected line. In all subjects except for one, the spontane-
ous feeling of limb-ownership was unimpaired. Subjective 
responses indicated an experience of the RHI during syn-
chronous, but not asynchronous stimulation, without late-
ralization. The proprioceptive drift towards the plastic hand 
following synchronous stroking was comparable between 
sides (1.4±2.0/1.7±2.7cm, right/left). At the left hand, how-
ever, the proprioceptive drift correlated significantly with 
the rightward bias of spatial attention.
Conclusion: In the healthy elderly, neither subjective nor 
objective RHI measures were lateralized on group level. 
However, asymmetric spatial attention may influence the 
multisensory process of „embodiment“ of an artificial 
hand, as indicated by correlation. Further studies will as-
sess body-related multisensory integration in neurological 
conditions.
Disclosure: Nothing to disclose
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AD8 informant screening questionnaire for 
cognitive impairment: pragmatic  
diagnostic test accuracy study
B. Ziso1, B. Stagg2, M. Rawle1, A. Larner1
1Walton Centre Neurology and Neurosurgery, Neurology, 
Liverpool, United Kingdom, 2Alzheimer’s Society, Liverpool, 
United Kingdom
Background and aims: To report the diagnostic accuracy 
of AD8, a brief informant screening questionnaire for the 
detection of dementia and cognitive impairment.
Methods: Prospective observational study, Cognitive 
Function Clinic.
Results: Of 334 consecutive patients seen between July 
2013 and July 2014, 212 (M:F = 106:106; age range 
16-92 years, median 64.5 years) attended with a suitable 
informant. No informant declined when invited to perform 
AD8. Of the 212 patients, 69 were diagnosed with demen-
tia (DSM-IV-TR criteria), 62 had MCI (Petersen criteria). 
Using the cut off ≥2/8 (“cognitive impairment is likely to 
be present”; higher AD8 scores are worse) as defined in the 
index paper (Galvin et al. 2005), AD8 score was sensiti-
ve (0.97) but not specific (0.17) for cognitive impairment. 
Looking at all AD8 scores, the most accurate cut off (0.67) 
was ≥2/8. Area under the ROC curve was 0.67. AD8 scores 
showed no correlation with patient age (r=0.019) and low 
correlations with cognitive screening instrument scores 
(MMSE and 6CIT: r = -0.23 and 0.37, respectively).
Conclusion: AD8 is simple to administer and score. In this 
pragmatic diagnostic test accuracy study AD8 was sensiti-
ve but not specific for identifying patients with cognitive 
impairment.
Disclosure: Nothing to disclose
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Neuroprotective effects of  
allopregnanolone in a pilocarpine-induced 
status epilepticus mouse model
W.-J. Kim, I. Cho, H.-J. Kim, H.-W. Kim
Yonsei University, College of Medicine, Neurology, Seoul, 
Korea, Republic of
Background and aims: Oxidative stress released by seizu-
re is related to the epileptogenesis. The SOD is responsible 
for destroying free radicals, thereby keeping normal condi-
tion between ROS and antioxidant defense system. Some 
of neurosteroids are known to show wide anticonvulsant 
effects and alter neuronal excitability through interaction 
with GABAA receptor. We investigated the role of ROS 
in prolonged seizure-induced neuronal death and the pos-
sible mechanism of neuronal protection underlying allop-
regnanolone, one of neurosteroids, thereby detecting SOD 
expression in pilocarpine-induced status epilepticus mouse 
model.
Methods: Adult male C57BL/6 mice were given injec-
tions of pilocarpine 30 min after scopolamine treatment. In 
allopregnanolone group, we treated with several dosages 
of allopregnanolone after SE. Hippocampal cell death was 
assessed by cresyl violet and TUNEL staining. The ROS 
was assessed using in situ detection of oxidized hydroethi-
dine (HEt) administered intravenously after SE. SOD level 
was analyzed by both western blotting analysis and immu-
nofluorescent staining in hippocampus.
Results: A decrease in the number of neuronal cells was 
clearly observed and TUNEL positive cells were significantly 
increased in hippocampal CA1 and CA3 regions, except 
for the region of DG, 3 days after SE. In allopregnanolone 
group, the ROS of production, TUNEL positive cells, and 
oxidative DNA damage were significantly decreased com-
pared to vehicle-injected group. SOD expression, mean-
while, was increased in hippocampus both Western blot 
and immunestaining analysis in allopregnanolone-treated 
group.
Conclusion: Excessive ROS clearly induces neuronal 
death through neuronal DNA damage in a hippocampus, 
and allopregnanolone has a neuroprotective effect in re-
sponse to oxidative stress by altering the SOD level in 
brain.
Disclosure: Nothing to disclose
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Congruency of MR imaging and  
histopathologic diagnosis in surgically  
treated patients with epilepsy
M. Kovacevic1, S. Raicevic2, D. Damjanovic3, I. Nikolic3,  
V. Bascarevic4, A. Ristic1, N. Vojvodic1, S. Jankovic1,  
J. Milin Lazovic5, D. Sokic1
1Clinical Center of Serbia, Center for Epilepsy and Sleep Dis-
orders, Neurology Clinic, Belgrade, Serbia, 2Clinical Center 
of Serbia, Pathohistology Department, Belgrade, Serbia, 3Cli-
nical Center of Serbia, Radiology and Magnetic Resonance 
Imaging Center, Belgrade, Serbia, 4Clinical Center of Serbia, 
Institute for Neurosurgery, Belgrade, Serbia, 5Medical School, 
University of Belgrade, Institute for Medical Statistics and 
Informatics, Belgrade, Serbia
Background and aims: Underlying pathology of focal 
epilepsy is an important predictor of seizure outcome after 
surgery. While histopathologic (HP) findings are the gold-
standard, brain magnetic resonance imaging (MRI) is an 
important tool in preoperative assessment of underlying 
pathology. The aim of our study was to evaluate the con-
gruency of MRI diagnosis of epileptogenic lesions with 
histopathologic findings in surgically treated patients with 
focal epilepsy.
Patients and methods: We identified 88 surgically treated 
patients with lesional focal epilepsy evaluated at the Neu-
rology Clinic, Clinical Center of Serbia. 10 patients were 
eliminated due to insufficient data. 3 patients had normal 
HP findings. The remaining 75 patients (33 male, 34.6±9.9 
years) were classified according to HP as hippocampal 
sclerosis (HS), 2) malformations of cortical development 
(MCD), 3) tumors, 4) vascular malformations (VM) and 
5) other pathologies. MRI of operated patients were post 
hoc analyzed by two radiologist blinded to surgical and PH 
outcome and compared to PH diagnosis.
Results: Congruency existed in 39/41 (95.1%) patients 
with HS (three with undetected FCD type IIIa); 4/12 
(33.3%) with MCD; 11/14 (68.8%) with tumors (two with 
undetected FCD type IIIb); 4/4 (100.0%) with VM and 2/4 
(50.0%) with other pathologies. Overall, MRI correctly 
identified the diagnosis in 60/75 (80.0%) patients.
Conclusion: In most patients with lesional focal epilepsy, 
MRI can correctly identify the underlying pathology, espe-
cially in patients with HS, VM and tumors. A provisional 
MRI diagnosis is important for presurgical planning and 
may have prognostic implications.
Disclosure: Nothing to disclose
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Pro-inflammatory cytokines in patients 
with mesial temporal lobe epilepsy with 
and without co-morbid depression
O. Kukhlenko
Danylo Halytsky Lviv National Medical University, Depart-
ment of Neurology and Neurosurgery , Lviv, Ukraine
Background and aims: Depression is a frequent psychiat-
ric disorder in patients with temporal lobe epilepsy (TLE). 
Nowadays it is established that major endogenous depres-
sion is associated with inflammation. However, genesis or 
maintenance of depression in patients TLE has to be better 
understood. The aim of our study was to evaluate the state 
of pro-inflammatory cytokines profile in blood plasma of 
patients with mesial temporal lobe epilepsy with and wit-
hout co-morbid depression.
Methods: Concentrations of interleukin-1β (IL-1β), inter-
leukin-6 (IL-6), interleukin-17 (IL-17) and C-reactive pro-
tein (CRP) were evaluated in blood plasma by the ELISA 
method. Hamilton depression rating scale and DSM-IV cri-
teria were used for the diagnosis of co-morbid depression. 
We examined 26 patients with mesial TLE and hippocam-
pal sclerosis signs on MRI. All the patients took carbama-
zepine as antiepileptic monotherapy and had similar rate of 
seizures frequency.
Results: Received data revealed increase in plasma IL-6 
concentration in patients with TLE and major depression 
21.4±1.4pg/ml while compared with MTLE patients wit-
hout major depression – 12.5±1.1pg/ml (p<0.05). Concen-
tration of IL-1β in patients with co-morbid depression was 
higher, but did not differ reliably (p>0.05). There was reli-
ably higher mean concentration of IL-17 in patients with 
major depression – 12.6±1.2pg/ml, while in non-depressed 
patients – 8.6±1.0pg/ml (p<0.05). No reliable differences 
between both studied groups in concentration of C-reactive 
protein were found.
Conclusion: There is an evidence that hyperproduction of 
pro-inflammatory cytokines IL-6, IL-17 may be involved in 
the pathogenesis of major depression in TLE.
Disclosure: Nothing to disclose
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ABCB1/MDR1 gene polymorphisms and 
the level of apoptotic factors in epilepsy 
patients treated with antiepileptic drugs
U. Lagan-Jedrzejczyk1, A. Oczkowska2, A. Florczak3,  
J. Florczak-Wyspianska1, J. Karczewski4, A. Swiejkowska4, 
K. Wiktorowicz4, E. Przedpelska-Ober1, W. Kozubski1,  
J. Dorszewska5
1Chair and Department of  Neurology, Poznan, Poland, 
22Laboratory of  Neurobiology, Department of  Neurology, 
Poznan, Poland, 3Laboratory of  Neurobiology, Department 
of  Neurology, Poznan, Poland, 4Department of Biology and 
Environmental Studies, Poznan, Poland, 5Laboratory of  Neu-
robiology, Department of  Neurology,Poznan University of 
Medical Sciences, Poznan, Poland
Background and aims: The antiepileptic drug (AED) the-
rapy besides its clinical side effects may also induce plenty 
of molecular changes including the level of apoptotic fac-
tors. The ABCB1/MDR1 gene may modulate the pathways 
of suicidal cell death.
The aim of the study was to analyze the frequency of 
C3435T and C1236T polymorphisms of ABCB1/MDR1 
gene, homocysteine (Hcy) and methionine (Met) concen-
tration, the level of apoptotic proteins (p53, Bax, Bcl-2) 
and apoptotic cells in epilepsy patients, before and during 
AEDs treatment and in controls.
Methods: The study involved 57 epilepsy patients (18 – 69 
aged) and 24 controls (22 – 61 aged). Genetic study was 
conducted using PCR-RFLP, plasma biothiols concentra-
tion was analyzed by HPLC/EC, the levels of apoptotic 
proteins in peripheral lymphocytes by Western blotting me-
thod and the level of lymphocyte apoptotic cells by active 
caspase-3 detection by flow cytometry.
Results: The study has shown that AEDs therapy in epi-
lepsy patients leads to changes in plasma biothiols concen-
tration and the level of apoptotic factors. The frequency of 
CC genotype of ABCB1/MDR1 C1236T and beneficial for 
treatment TT C3435T of this gene was higher in epilepsy 
patients than in control group. Epilepsy patients with ge-
notype TT C3435T in combination with CC C1236T well 
responded to older AEDs in monotherapy and with CT 
C1236T to newer anticonvulsants.
Conclusion: It seems that in epilepsy patients treated with 
AEDs only ABCB1/MDR1 C3435T polymorphism is con-
nected with regulation of the apoptotic cells level.
Genetic analysis of ABCB1 gene polymorphisms in epi-
lepsy patients may lead to the more successful therapy.
Disclosure: Nothing to disclose
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Effectiveness of eslicarbazepine acetate 
as add-on treatment to antiepileptic mo-
notherapy in adults with partial-onset sei-
zures (EPOS study): analysis by baseline 
antiepileptic drug
C. Lawthom1, R. McMurray2, R. Sousa3, M. Holtkamp4
1Royal Gwent Hospital, Newport, Wales, United Kingdom, 
2Eisai Europe Ltd, Hatfield, United Kingdom, 3Bial -Portela 
& Cª, S.A., S. Mamede do Coronado, Portugal, 4Charité - 
Universitätsmedizin Berlin, Berlin, Germany
Background and aims: Eslicarbazepine acetate (ESL) is 
approved as a once-daily adjunctive therapy for adults with 
partial-onset seizures (POS), with or without secondary 
generalisation. The prospective, non-interventional Esli-
carbazepine acetate in Partial-Onset Seizures (EPOS) study 
investigated the effectiveness and safety/tolerability of ESL 
as add-on to antiepileptic monotherapy in everyday clinical 
practice across eight European countries. Here we present 
an analysis of ESL’s effectiveness by baseline antiepileptic 
drug.
Methods: Adult patients with uncontrolled POS under an-
tiepileptic monotherapy, whose clinician had previously 
and independently decided to initiate ESL add-on therapy, 
were included if they provided informed consent. Retenti-
on rate at 6 months (primary endpoint), time to ESL dis-
continuation and responder rate (response defined as ≥50% 
seizure frequency reduction from baseline) were assessed 
according to the most frequent baseline monotherapies 
(>10% of patients).
Results: Of 219 patients included in the study, 83, 54 and 30 
received baseline monotherapy with levetiracetam (LEV), 
lamotrigine (LTG) and valproate (VAL), respectively. Re-
tention rates (95% confidence intervals) at 6 months were 
85.5% (76.1–92.3%) for LEV, 75.9% (62.4–86.5%) for 
LTG and 80.0% (61.4–92.3%) for VAL. Mean times to ESL 
discontinuation were 96.9 days (LEV), 90.8 days (LTG) 
and 88.8 days (VAL). Responder rates at 6 months ranged 
from 69.8% (LTG) to 88.5% (VAL) (Table 1).
Conclusion: ESL as add-on to antiepileptic monotherapy 
was effective independently of the type of monotherapy 
to which it was added. These findings must be interpreted 
with caution due to low subgroup patient numbers.
Disclosure: Study Supported by Eisai.
P3137
Genetic variation in GRIN2B and clinical 
characteristics of mesial temporal lobe 
epilepsy with hippocampal sclerosis
B. Leal1, J.M.M. Chaves1, D. Boleixa2, C. Carvalho3,  
A. Bettencourt3, J. Freitas1, J.M.C.F. Lopes1,  
J.E.D.P. Ramalheira1, R. Rangel4, P. Pinho Costa5,  
A. Martins da Silva6, B. Martins da Silva7
1Porto, Portugal, 2Abel Salazar Institute of Biomedical Sci-
ences, University of Porto – ICBAS/UP, Unit for Multidisci-
plinary Research in Biomedicine (UMIB), Porto, Portugal, 
3Autoimmu and NeuroScien,  Unidade Multidisciplinar Invest 
Biomed, Inst Ciencias Biomed Abel Salazar, UPorto, Porto, 
Portugal, 4hospital santo antónio - centro hospitalar do por-
to, Porto, Portugal, 5Instituto nacional de saúde Dr. Ricardo 
Jorge, Porto, Portugal, 6Hospital Santo António - Centro 
Hospitalar do Porto, Porto, Portugal, 7Autoimmu and NeuroS-
cien,  Unidade Multidisciplinar Invest Biomed, Inst Ciencias 
Biomed Abel Salaza, Porto, Portugal
Background and aims: Mesial Temporal Lobe Epilepsy 
with Hippocampal Sclerosis (MTLE-HS) is the most fre-
quent pharmaco-resistant epilepsy. Some authors claim that 
up to 80% of MTLE-HS patients have antecedents of com-
plex FS and the existence of a genetic basis that underlie 
both conditions has been postulated. Several studies have 
demonstrated that glutamate receptor NMDA, particular-
ly its subunit NR2B, has lower gene expression in brain 
tissue from epileptic patients. Function and expression of 
this subunit may be influenced by several polymorphisms 
in GRIN2B gene. Our aim was to analyse the association 
between rs7301328 and MTLE-HS development and clini-
cal characteristics in a Portuguese population.d. 
Methods:  A cohort of 163 MTLE-HS patients (91F, 72M, 
mean age= 44.1±11.7 years, age of onset= 13.5±10.6 years, 
82 with febrile seizures antecedents) was compared with 
a cohort of 272 healthy individuals (HI) in a case-control 
genetic association study. rs7301328 was genotyped by 
Taqman PCR methodology. 
Results: Genotypic and allelic frequencies were similar 
between patients and controls., independently of FS ante-
cedents. 
Conclusion: Our results show that disease predisposition 
is not dependent of rs7301328, at least, in the population 
studied. 
Disclosure: Nothing to disclose
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Efficacy of adjunctive perampanel in  
idiopathic generalised epilepsy: Subgroup 
analysis of patients with absence and 
myoclonic seizures in a double-blind  
placebo-controlled Phase 3 trial
T.J.O’Brien1, B.J. Steinhoff2, H. Yang3, A. Laurenza3,  
A. Patten4, F. Bibbiani3
1Royal Melbourne Hospital, Melbourne, Australia, 2Kork 
Epilepsy Centre, Kehl-Kork, Germany, 3Eisai Neuroscience 
Product Creation Unit, Woodcliff Lake, NJ, USA, 4Eisai Neu-
roscience Product Creation Unit, Hatfield, Hertfordshire, 
United Kingdom
Background and aims: Adjunctive perampanel was 
shown to be efficacious in reducing primary generalised 
tonic-clonic seizures (PGTCS) in patients with idiopathic 
generalised epilepsy (IGE) (French et al., AES 2014). We 
assess the effects of adjunctive perampanel on absence and 
myoclonic seizures in these patients.
Methods: Patients ≥12 years with ≥3 PGTCS in the 8 
weeks before randomisation, receiving 1–3 concomitant 
anti-epileptic drugs for ≥30 days before baseline were eli-
gible to enrol. The study had pre-randomisation (4-week 
screening, 4–8-week baseline) and randomisation (4-week 
titration, 13-week maintenance, 4-week follow-up) phases. 
Perampanel was increased weekly by 2 mg to 8 mg/day 
or individual optimal dose. Secondary endpoints included 
median percent change from baseline and 50% responder 
rate for absence and myoclonic seizures.
Results: The full analysis set comprised 162 patients (81 
placebo; 81 perampanel). 37.0% of patients experienced 
absence seizures and 29.0% experienced myoclonic seizu-
res during pre-randomisation. The study was not powered 
to detect differences in these seizure types, however, there 
was a numerical reduction in absence seizures with peram-
panel versus placebo. Myoclonic seizures were reduced in 
both treatment arms, but the decrease was greater in place-
bo patients (Table 1). Similar proportions of perampanel 
and placebo patients experienced an increase in myoclo-
nic seizures (Table 2). Overall, perampanel did not worsen 
myoclonic seizures. Seizure freedom across all seizures for 
perampanel versus placebo was 23.5% versus 4.9%.
Conclusion: Adjunctive perampanel reduces PGTCS in 
patients with IGE. When assessing other generalised sei-
zure types, compared with placebo, adjunctive perampanel 
improved absence seizures and did not aggravate myoclo-
nic seizures.
Disclosure: Study funding: Eisai Inc. Medical writing sup-
port: Choice Healthcare Solutions, funded by Eisai Ltd.
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Functional movement disorders:  
diagnostic and management patterns in  
a Portuguese cohort
R. Barreto, V.T. Cruz
CHEDV, Neurology, Feira, Portugal
Background and aims: Functional movement disorders 
(FMD) are frequent in specialized and non-specialized cli-
nical practice and often entail significant loss of quality of 
life. Their heterogeneity and link to psychiatric problems 
complicate diagnosis and appropriate treatment. We aim to 
review all FMD cases and follow-up presented to our de-
partment until September 2014.
Methods: Review of hospital database for episodes com-
patible with DMF (according to Fahn-Williams criteria). 
Excluded other functional pathologies such as pseudoepi-
leptic seizures.
Results: 36 patients were selected (67% female). Symp-
toms began between the age of 6 and 80 (mean = 52 years), 
the average duration of symptoms at first observation was 
3.3 years. One-third of the cases did not present psychiatric 
backgrounds. The most frequent phenomenon was tremor 
(56%), followed by myoclonus (17%) and dystonia (8%). 
The average time of follow-up was 15 months, 28% of pa-
tients were still in follow-up, 81% initiated or maintained 
psychotropic drugs, 44% were referred to psychiatry and 
8% to physical therapy. Half of the patients underwent one 
or more tests due to FMD: neuro-radiological (39%), neu-
rophysiological (22%) and genetic testing (8 percent). Cur-
rently, after a mean period of 7 years (range: 1-30 years), 
42% of patients still show symptoms of FMD.
Conclusion: In our study, FMD occurred in all age groups, 
being that most patients obtained a late diagnosis, which is 
known to carry a worse prognosis. The use of psychoactive 
drugs was more common than multidisciplinary referral. 
The high chronicity rate reflects the complexities of treat-
ment in FMD. Future prospective population-based studies 
can be very important.
Disclosure: Nothing to disclose
P3141
Quantitative finger tapping assessment 
based on inertial sensors - assistance in 
differential diagnostics of parkinsonism
M. Djuric-Jovicic1, M. Ječmenica-Lukić2, I. Petrović3,  
S. Radovanović4, N. Dragasevic2, V. Bobić5, M. Belić1,  
V.S. Kostic2
1University of Belgrade, School of Electrical Engineering, 
Innovation center, Belgrade, Serbia, 2University of Belgrade, 
Medical faculty, Clinical centre of Serbia, Neurology Clinic, 
Belgrade, Serbia, 3Belgrade, Serbia, 4University of Belgrade, 
Institute for Medical Research, Belgrade, Serbia, 5University 
of Belgrade, School of Electrical Engineering, Belgrade, 
Serbia
Background and aims: In clinical practice, the finger tap-
ping movement is often validated visually, thus resulting 
in a coarse diagnostic resolution. However, using the ap-
propriate instrumentation, finger tapping performance can 
be quantified, allowing objective assessment of specific 
characteristics or changes in the finger tapping pattern over 
time. 
Methods: By using miniature inertial sensors, mounted on 
fingertips on index finger and thumb, various parameters 
such as cadence, tapping duration, opening and closing 
speed, tapping angle were extracted for detailed analysis of 
patients’ motor performance. Besides listed kinematic para-
meters, acquired data were preprocessed using continuous 
wavelet transformation (CWT), and their coefficients were 
used in further analysis of spectral content. Based on cross-
sections of CWT in time and frequency, we introduced 
parameters describing characteristic tapping frequencies 
and vigor of the performed movements. The study inclu-
ded 16 patients with Parkinson’s disease (PD), 18 patients 
with progressive supranuclear palsy (PSP), 18 patients with 
multiple system atrophy (MSA), and 14 age and gender 
matched healthy subjects.
Results:  In this way, characteristic frequency areas, high 
activity sequences, motor blocks and decrement in time can 
be identified and observed. These parameters were further 
used in classification for distinction between the four 
groups, achieving more than 85% classification accuracy 
among groups, offering support for differential diagnostics.
Conclusion: Using the proposed sensors and methodolo-
gy, quantitative assessment of repetitive finger tapping per-
formance can be obtained thus providing support in moni-
toring the patient’s state, response to therapy as well as in 
differential diagnostics of parkinsonism.
Disclosure: The work on this study was supported by the 
Serbian Ministry of Education, Science and Technologi-
cal Development under Grant No. 175090, and Grant No. 
175016.
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Phosphorylated α-synuclein biomarker in 
skin nerves is differently expressed in  
pure autonomic failure and idiopathic  
Parkinson’s disease
V. Donadio1, A. Incensi1, C. Piccinini1, P. Cortelli2,  
M.P. Giannoccaro1, A. Baruzzi1, R. Liguori1
1IRCCS Istituto Scienze Neurologiche Bologna, UOC Clinica 
Neurologica, Bologna, Italy, 2University of Bologna, Depart-
ment of Biomedical and Neuromotor Sciences, Bologna, Italy
Background and aims: This study defines the expressi-
on in skin nerves of native and misfolded (phosphorylated) 
α-synucleins in pure autonomic failure (PAF) and idiopa-
thic Parkinson disease (IPD), two synucleinopathies with 
different clinical phenotypes and pathogenesis. The spe-
cific aims were to: 1) define the importance of native (n-
syn) and phosphorylated (p-syn) α-synucleins as disease 
biomarkers; 2) ascertain differences in abnormal skin nerve 
deposits that may justify a different pathogenesis.
Methods: We studied 30 patients including 16 well-charac-
terized IPD patients and 14 patients fulfilling the diagnostic 
criteria for PAF. 30 age-matched healthy subjects served 
as controls. Subjects underwent skin biopsy from proximal 
(i.e. cervical) and distal (i.e. thigh and leg) sites to study 
small nerve fiber and intraneural n-syn and p-syn.    
Results: PAF and IPD patients showed a length-dependent 
small fiber neuropathy, more severely expressed in patients 
with higher p-syn load. N-syn was similarly expressed in 
both groups of patients and controls. By contrast, p-syn was 
not found in any skin sample of controls but was found in 
all PAF and IPD patients. Nevertheless, abnormal p-syn de-
posits differed between IPD and PAF both in spatial distri-
bution and pattern of innervation.
Conclusion: 1) p-syn was a reliable in vivo marker of IPD 
and PAF whereas n-syn should not be considered a disease 
marker; 2) neuritic p-syn inclusions differed in IPD and 
PAF suggesting a different underlying pathogenesis; but 3) 
they were associated with a length-dependent small fiber 
neuropathy in both disorders suggesting a similar effect on 
peripheral nerve fiber dysfunction. 
Disclosure: Nothing to disclose
P3143
Botulinum toxin injections are effective to 
treat foot dystonia and pain associated in 
Parkinson’s disease
F. Durif1, I. Rieu2, E. Durand3, B. Pereira4,  
M. Simonetta Moreau5, F. Ory-Magne5, S. Sangla6,  
D. Guehl7, S. Soulayrol8, F. Fluchère9, T. Rouaud10,  
D. Gayraud11, C. Geny12, B. Degos13, C. Vial14,  
G. Castelnovo15, P. Derost3
1Clérmont-Ferrand, France, 2CHU , Clermont-Ferrand, 
France, 3CHU Clermont-Ferrand, Neurology, Clermont-
Ferrand, France, 4CHU Clermont-Ferrand, Biostatistic Unit, 
Clermont-Ferrand, France, 5TOULOUSE, France, 6AP-HP, 
Paris, France, 7Pessac, France, 8Aubagne, France, 9AP-HM, 
Marseilles, France, 10Hopital Laënnec, Neurology, Nantes, 
France, 11CH Aix en Provence, Aix en provence, France, 
12CHU Montpellier, neurology, Montpellier, France, 13AP-HP, 
neurology, Paris, France, 14Hospices Civils de Lyon, Service 
d‘ENMG et pathologies neuromusculaires, Lyons, France, 
15CHU Nimes, Neurology, Nimes, France
Background and aims: Botulinum toxin (Btx) injections 
seem to be effective to treat foot dystonia. However studies 
on this topic are few and very imprecise. This double bind 
randomized study was undertaken to evaluate if intramus-
cular injections of Btx in Flexor Digitorum Longus (FDL) 
or Flexor Digitorum Brevis (FDB) are beneficial to reduce 
dystonia and associated pain in parkinsonian patients with 
foot dystonia (vs placebo injections) and determinate which 
site of injection is the most efficient.
Methods: 45 patients were randomized in 3 groups: 
“FDB”group (1 injection of placebo in FDL/1 injection 
of Btx (100U- Xeomin) in FDB), “FDL”group (1 injec-
tion of placebo in FDB/1 injection of Btx in FDL) and the 
“PL”group (1 injection of placebo in FDB and FDL). Pati-
ents were injected 2 times spaced in 3 months. Six weeks 
after each injection, clinical state improvement, duration 
and severity of dystonia, pain and quality of life were eva-
luated.
Results: The 3 groups were not significantly different 
in terms of age, disease duration, treatment and dystonia 
(duration/severity/pain). Patients treated by Btx groups 
(FDB+FDL) showed an improvement of the clinical state 
and a reduction of pain and dystonia (p<0.05 vs J0) with 
no difference in quality of life. Clinical state and pain im-
provement was significantly higher in Btx groups vs PL 
group (p<0.05). Considering the injection site, clinical state 
tended to be more improved in FDL group vs FDB group 
(p=0.08).
Conclusion: Btx injections are effective to treat foot dysto-
nia and pain associated. Injection in FDL muscle tended to 
be more beneficial.
Disclosure: Financial support : MERZ society
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Diagnostic value of 24h urinary copper  
excretion after 48h of d-penicillamine 
cessation in compliance assessment in 
Wilson’s disease patients
K. Dziezyc1, T. Litwin2, G. Chabik2, A. Członkowska2
1Warsaw, Poland, 2Institute of Psychiatry and Neurology, 2nd 
Department of Neurology, Warsaw, Poland
Background and aims: Wilson’s disease (WD) is an inhe-
rited autosomal recessive disorder of copper metabolism. 
Treatment with anti-copper agents is effective in most cases. 
However, compliance is essential. Urinary copper excreti-
on is an important parameter for diagnosis and treatment 
monitoring. During long-term treatment with chelating 
agents, a two-day interruption in treatment should result in 
normal values of urinary copper concentration (<50µg/dl). 
The aim of this study was to establish the usefulness of this 
method in compliance assessments in these patients.
Methods: We examined consecutive patients treated with 
d-penicillamine (DPA) for a minimum of one year under-
going routine follow-up studies at our center. We assessed 
copper metabolism parameters, neurological examinations, 
hepatic status, and compliance. We performed 24-h urinary 
copper excretion analysis 48h after an interruption in che-
lating therapy.
Results: 33 patients were enrolled. The mean treatment du-
ration was 11.78±11.75 years. After 48h of DPA cessation, 
normalization (<50µg/24h) in copper excretion was obser-
ved in 20 (87%) of 23 compliant patients. Ten patients were 
non-compliant and copper excretion was above 50µg/24h 
in 7 (70%) of them after cessation of DPA. The specificity 
and sensitivity of this test was 87% and 70%, respectively. 
Receiver operator curve analysis found an optimal cut-off 
of urinary copper excretion of 62µg/dl for compliant pati-
ents.
Conclusion: Measurement of 24-h urinary copper excreti-
on after a 48-h interruption in DPA therapy in patients with 
WD is a reliable method for confirming patients’ compli-
ance and may be helpful for further treatment decisions.
Disclosure: Nothing to disclose
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Frequencies of initial gait disturbances 
and falls in 100 Wilson’s disease patients
K. Dziezyc1, T. Litwin2, G. Chabik2, A. Członkowska2
1Warsaw, Poland, 2Institute of Psychiatry and Neurology, 2nd 
Department of Neurology, Warsaw, Poland
Background and aims: Wilson’s disease (WD) is an inhe-
rited disorder of copper metabolism. Gait disturbances may 
present with both extrapyramidal and cerebellar patterns. 
However, so far frequency of particular types of gait abnor-
malities were not established. Thus, the aim of our study 
was to establish the frequency of initial gait disturbances 
among our neurological WD patients.
Methods: We analyzed gait disturbances at the time of di-
agnosis in neurologic feature WD patients diagnosed bet-
ween 2005 and 2014. Assessment was based on Unified 
Wilson’s Disease Score Scale (UWDRS). In UWDRS, gait 
abnormalities are divided into three main patterns: dysto-
nic, ataxic, parkinsonian. All type of gait impairment were 
assessed with four stages of severity (0-normal, 4-severe). 
History of falls also was obtained.
Results: 103 patients were diagnosed between 2005 and 
2014. 3 patients with severe neurological impairment, un-
able to walk were excluded from analysis. Gait abnormali-
ties were observed in 59% of patients. The most frequent 
(45%) was ataxic gait which manifests mainly as impaired 
tandem. Parkinsonian gait was noted in 18% (11/59), and 
dystonic gait in 10% (6/59) of patients. Mixed type of gait 
impairment was observed in 25% (15/59) of patients (ata-
xic, dystonic, and parkinsonian n=8, ataxic and parkinsoni-
an n=7). Falls were noted in 35% patients, but in most cases 
were occasionally observed.
Conclusion: Gait disturbances in WD are frequent.The 
most common is ataxic gait and mixed disturbances. Com-
plex gait abnormalities in WD reflect involvement of many 
brain structures.
Disclosure: Nothing to disclose
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Does “Botox” make stupid? – The effect of 
botulinum toxin on cognition
K. Elwischger, M. Schmöger, U. Willinger, C. Abdel-Aziz,  
J. Alger, S. Pretscherer, E. Auff, T. Sycha, G. Kranz
Medical University of Vienna, Department of Neurology, 
Vienna, Austria
Background and aims: Recent work has indicated chan-
ges of emotional processing after cosmetic botulinum toxin 
(BoNT) therapy. Thereby, proprioceptice afferences from 
facial muscles have been proposed to boost emotional pro-
cessing via facial feedback loops. In this study, we inves-
tigated the effect of BoNT on higher cognitive functions. 
Methods: 84 subjects, 19 patients with cranial dystonia and 
hemifacial spasm, 32 patients with cervical dystonia and 33 
matched healthy control subjects were recruited. All pati-
ents had been injected repeatedly before and were recruited 
from our BoNT outpatient clinic. At baseline, all subjects 
performed the „verbal analogies test“ for verbal reasoning, 
and the subtest „matrices“ of the Intelligence Structure Test 
2000-R for non-verbal reasoning. All patients received 
their routine BoNT treatment after baseline testing. Three 
weeks after baseline, the tests were repeated.
Results: The intelligence scores revealed no differences at 
baseline between the three groups. Three weeks after base-
line, patients with injections in facial muscles scored worse 
(p=0.022 in the non-verbal subtest; p=0.051 in the verbal 
test), whereas patients with cervical injections and controls 
remained unchanged. We found no correlation between 
BoNT-dose and intelligence scores. 
Conclusion: Our data suggest a reversible negative short 
term-effect on non-verbal intelligence scores (and trend 
wise in verbal scores) when facial muscles are treated with 
BoNT. Similar to emotional processing, proprioceptive 
feedback loops from facial muscles might have a positive 
effect on concentration and cognition.
Disclosure: Nothing to disclose
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Evaluation of gait and posture in essential 
tremor before and after unilateral Gamma 
knife thalamotomy
B. Emmanuelle1, T. Witjas1, R. Carron2, J. Regis2,  
J.-P. Azulay1, M. Vaugoyeau3, A. Eusebio1
1Marseilles, France, 2CHU La Timone, Marseilles, France, 
3CNRS, Marseilles, France
Background and aims: Essential tremor (ET) is characte-
rized by a progressive postural and kinetic tremor affecting 
the arms, responsible for a functional impairment in daily 
activities. Its pathophysiology remains poorly understood 
and therapeutic options are limited. Some clinical and ex-
perimental data suggest a cerebellar involvement. Howe-
ver, few data exist regarding gait and posture impairment in 
ET. The aim of our study was to describe specific features 
of gait disorders and postural instability in patients with se-
vere ET, and to evaluate the effect on these motor skills of a 
unilateral Gamma Knife thalamotomy (GKT).
Methods: 19 patients with severe ET were included; we 
analysed gait and posture before and one year after unila-
teral GKT, using a multiparametric automatized movement 
analysis system.
Results: Our results show a significant decrease of step 
length, cadence and velocity in ET compared to age-mat-
ched controls. Patients with head and upper limb tremor 
had a higher impairment of gait than patients with isolated 
upper limb tremor. Posturo-locomotor skills were compa-
red for each patient before and after radiosurgery, and sta-
tistical analyses reveal no effect of unilateral GKT on gait 
and posture.
Conclusion: This study confirms postural instability and 
gait impairment in ET, which may be related to a dysfunc-
tion of cerebello-thalamo-cortical pathway. Our results 
suggest that head tremor could be correlated with a more 
severe gait impairment. Specific involvement of cerebel-
lum, or alteration of visuo-vestibular input caused by head 
movements, could deteriorate postural control. Our work 
shows no deleterious effect of unilateral GKT on posture 
and gait, requiring confirmation on larger population.
Disclosure: Nothing to disclose
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Case series: post-operative edema  
associated with delayed delirium after 
DBS surgery in Parkinson’s disease
C. Fricke1, J.-J. Rumpf1, T. Woost1, D. Weise2, D. Winkler2,  
J. Meixensberger2, J. Classen1
1Universitätsklinikum Leipzig, Neurology, Leipzig, Germany, 
2Universitätsklinikum Leipzig, Neurosurgery, Leipzig, Ger-
many
Background and aims: Deep brain stimulation (DBS) has 
been used to treat advanced stages of Parkinson’s disease 
(PD) in patients without major cognitive deficits. Some 
studies suggest that cognitive function may decline after 
DBS. We here investigated whether delayed post-operative 
delirium is associated with edema surrounding DBS leads. 
Methods: We evaluated patients who were implanted with 
DBS for PD in 2013 and 2014 at the university hospital of 
Leipzig. Each subject received a cranial CT following sur-
gery; the majority of patients additionally received an MRI 
several days later. We analyzed the frequency of postope-
rative edema and its association with documented deliria 
occurring during the postoperative period.
Results: 18 subjects (8 f., 10 m., age 64.2±6.5y) receiving 
DBS for treatment of PD were included. 8 patients show-
ed psychiatric symptoms starting a few days following 
the procedure. Edema was absent in all CT scans obtai-
ned immediately postoperatively. 14 subjects received an 
MRI between day 3 and 14 (mean 8.3). Edema surrounding 
leads was present in 9 cases, of whom 7 showed psychiatric 
symptoms. Chi-quadrat test shows that the association bet-
ween edema and psychiatric symptoms was above chance 
(p=0.036). 
Conclusion: These findings suggest that edema may be 
more common than expected and associated with delirium 
following surgery. As delirium is a known factor promoting 
later cognitive impairment, identification of risk factors 
may hold promise in reducing these deficits. This data may 
help guiding preparations of a multi-centre study addres-
sing associations between postoperative edema, delirum 
and long-term cognitive deficits in DBS patients.
Disclosure: Nothing to disclose
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Optical coherence tomography and visual 
evoked potentials in assessing MS  
evolution
M. Pisa, G. Di Maggio, S. Guerrieri, R. Santangelo,  
S. Medaglini, M. Rodegher, B. Colombo, L. Moiola,  
U. Del Carro, V. Martinelli, G. Comi, L. Leocani
San Raffaele Scientific Institute, Vita-Salute San Raffaele 
University, Department of Neurology, Milan, Italy
Background and aims: The availability of instrumental 
markers of myelin and axonal damage to monitor and pre-
dict disability progression in MS is fundamental to assess 
the efficacy of therapeutic interventions. The visual pa-
thway is receiving increasing attention as a putative win-
dow into brain neurodegeneration.    
Methods: We performed VEPs, OCT with measurement 
of retinal nerve fiber layer (RNFL) and clinical and neuro-
radiological assessment at baseline and after an average 
follow-up of 2 years in 75 subjects with MS of whom 59 
were analysed, excluding patients with acute optic neuritis 
(ON) within 6 months from baseline assessment.    
Results: Reduction of binocular mean RNFL thickness was 
significantly correlated (Spearmann rho - 0.587, p<0.0001) 
with increased rate of the expanded disability status scale 
(EDSS) regardless of baseline disability, and was greater 
in subjects with neuroradiological or clinical activity of 
the disease (p<0.0001, test T). The rate of RNFL reduc-
tion was similar in eyes with or without previous ON. Alt-
hough baseline RNFL was correlated with EDSS change at 
follow-up, this correlation lost significance after correcting 
for baseline EDSS.    
Conclusion: Progressive reduction of RNFL can occur in 
relation with disease activity along the visual pathway, as 
detected by VEPs, or as part of the global neurodegenerati-
on process characterizing MS, even with clinical or neuro-
logical activity not manifesting with visual symptoms. The 
association between atrophy of the RNFL and the formati-
on of new inflammatory lesions in the brain could be exp-
lained by trans-synaptic degeneration. OCT may be more 
useful for monitoring neurodegeneration rather than as a 
prognostic indicator.    
Disclosure: Nothing to disclose
P3150
Different MRI measures predict clinical 
deterioration and cognitive impairment in 
MS: a 5-year longitudinal study
P. Preziosa1, M.A. Rocca1, S. Mesaros2, M. Copetti3,  
M. Petrolini1, J. Drulovic2, E. Pagani1, M. Filippi1
1San Raffaele Scientific Institute, Vita-Salute San Raffaele 
University, Neuroimaging Research Unit, Milan, Italy, 2Uni-
versity of Belgrade, Clinic of Neurology, Faculty of Medicine, 
Belgrade, Serbia, 3IRCCS-Ospedale Casa Sollievo della Sof-
ferenza, Biostatistics Unit, San Giovanni Rotondo, Italy
Background and aims: To assess the value of conventio-
nal and quantitative brain and spinal cord MRI measures in 
predicting disability and cognitive worsening in multiple 
sclerosis (MS) patients after 5 years.
Methods : Brain dual-echo, 3DT1-weighted and diffusion-
tensor (DT) MRI scans and cervical cord T2-weighted, 
3DT1-weighted and magnetization transfer (MT) MRI 
scans were obtained at baseline and after 5 years (Y5) in 
76 MS patients and 7 controls, followed clinically (EDSS 
and phenotype changes) and neuropsychologically (Rao’s 
battery). At baseline and Y5, measures of lesion load, brain 
and cord atrophy were obtained. Brain DT MRI measures 
of white matter (WM) tracts, normal-appearing WM and 
gray matter (GM), and cord MT ratio were also assessed. 
Predictors of clinical and cognitive worsening at Y5 were 
identified using random forest (RF) analysis.
Results: At Y5, 46/76 patients showed a significant disa-
bility worsening (death=9/76), 23/76 evolved to a worse 
phenotype and 15/61 had a cognitive decline. At Y5, a si-
gnificant accumulation of brain T2 lesions, brain atrophy 
(especially for GM), WM tract diffusivity abnormalities 
and spinal cord atrophy occurred. At RF analysis, baseline 
WM tract diffusivity measures predicted worsening of cli-
nical disability (classification [C]-index=70%) and pheno-
type modification (C-index=78%), whereas baseline brain 
volume, GM diffusivity and cognitive-related WM tract 
diffusivity abnormalities predicted cognitive worsening 
(C-index=78%).
Conclusion: Different mechanisms contribute to clini-
cal and cognitive worsening in MS patients after 5 years. 
While disability deterioration seems mainly due to disrup-
tion of WM integrity, cognitive dysfunction is likely due to 
a complex interplay between WM and GM damage.
Disclosure: Nothing to disclose
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Instrumented gait analysis reveals walking 
pattern adaptation in patients with  
primary progressive multiple sclerosis:  
a hierarchical clustering approach
I. Pulido-Valdeolivas1, D. Gómez  Andrés1,  
I. González-Suárez2, J.A. Martín-Gonzalo3,  
I. Rodríguez-Andonaegui3, C. Oreja-Guevara2, E. Rausell1
1Universidad Autónoma de Madrid, Anatomy, Histology and 
Neuroscience, Madrid, Spain, 2Hospital Universitario Clí-
nico San Carlos, Neurology, Madrid, Spain, 3Physiotherapy 
School. ONCE-UAM, Madrid, Spain
Background and aims: Weight support and translation du-
ring gait is poorly managed by patients with primary pro-
gressive multiple sclerosis (PPMS), causing disability and 
dependency. Understanding the way their CNS configures 
different gait strategies as adaptations to lesion in is essen-
tial to design a care plan and to evaluate therapeutic approa-
ches. Our aim is to investigate and describe gait patterns 
in PPMS patients by means of instrumented gait analysis 
(IGA) and multivariate statistical approaches.
Methods: 97 kinematic flexion-extension gait cycle graphs 
of pelvis, hip, knee, and ankle joints were acquired from 10 
PPMS patients (48left/49right of each joint). Cycles were 
classified by hierarchical clustering analysis (dynamic time 
warping Euclidean distance as dissimilarity measure and 
average as grouping criterium). The resulting patterns were 
then compared with graphs obtained from 13 healthy vo-
lunteers.
Results: Hierarchical clustering analysis revealed five 
abnormal walking joint configurations which we named 
PPMS sagittal patterns I to V. They differ in several degrees 
of joint adaptation (Figure) in comparison to normalcy 
(grey lines). Thus, the pelvis tends to be more anteverted, 
the hip extension tends to deteriorate, the knee joint tends 
to be more flexed and its maximum flexion in the swing 
tends to be delayed, or heel strike degrades towards planti-
grade or equinus. PPMS patients tend to use invariably the 
same combination of one or two patterns.
Gait patterns in PPMS patients
Conclusion: The CNS of PMMS patients implements a 
specific combination of at least five kinematic joint strate-
gies to keep effective walking. Each strategy could emerge 
from different causal chains that should lead to tailored the-
rapeutic management.
Disclosure: Nothing to disclose
P3152
Switching MS patients from natalizumab 
to fingolimod therapy: comparison of 
short and prolonged washout periods
D. Raciborska1, B. Turner2, K. Schmierer3
1Barts and The London School of Medicine and Dentistry, 
London, United Kingdom, 2Barts Health NHS Trust, Neurolo-
gy, London, United Kingdom, 3Barts and the London School 
of Medicine and Dentistry, Blizard Institute, Centre for Neu-
roscience and Trauma, London, United Kingdom
Background and aims: This retrospective study compared 
clinical outcomes in two groups of MS patients switching 
from natalizumab to fingolimod. Group 1 had a short inter-
val (SIG) and Group 2 a prolonged interval (PIG) between 
treatments. 
Methods: The total population was 25 patients, the durati-
on of follow-up after the cessation of natalizumab was 17.4 
months. The meantime on treatment with fingolimod was 
12.8 months (range: 6 to 41 months). The population was 
divided into SIG (n=15) and PIG (n=10). In SIG the mean 
treatment interval period was 30 (14-46) days, in PIG it was 
179 (76-460) days.
Results: Comparing the two groups over the study peri-
od there were more relapses in the PIG group (3 relapses) 
compared to the SIG group (1 relapse). However no patient 
had relapses within 6 months in either group and only 1 pa-
tient in the PIG had a relapse within 12 months (9 months). 
None of these differences were significant. There were no 
significant differences in adverse events between the two 
groups. 
Conclusion: Whilst this is a small study over an 18-month 
follow-up there was no evidence of any harmful effects of 
a short interval between natalizumab and fingolimod and a 
suggestion of fewer relapses. In addition in the whole group 
the observed ‘relapse’ or ‘rebound’ activity after stopping 
natalizumab is less than published studies. In summary, this 
study supports the method of rapid initiation of fingolimod 
treatment following the cessation of natalizumab.
Disclosure: Barts Health and individuals presenting this 
abstract have received honoraria from Novartis and Biogen.
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Neuromyelitis optica spectrum disorders: 
long-term safety and efficacy of  
rituximab in caucasian patients
M. Radaelli1, F. Sangalli1, L. Moiola1, M. Rodegher1,  
B. Colombo1, F. Esposito2, R. Fazio1, V. Martinelli1,  
G. Comi1
1San Raffaele Scientific Institute, Vita-Salute San Raffaele 
University, Department of Neurology, Milan, Italy, 2Scientific 
Institute San Raffaele, Department of Neurology, Milan, Italy
Background and aims: Neuromyelitis optica (NMO) is an 
inflammatory demyelinating disease of the central nervous 
system that generally involves the optic nerve and the spi-
nal cord. Despite the severe prognosis of the disease the-
re are no approved treatments for NMO. The aim of our 
study was to evaluate the long term safety and efficacy of 
Rituximab (RTX) in patients affected by NMO and NMO 
spectrum disorder (NMOsd)
Methods: We evaluated the safety and efficacy of RTX in 
NMOsd patients who underwent at least one cycle of the 
drug and with at least 2 years of follow-up. 
Results: 21 patients (18 females) were included in the stu-
dy.  At a mean follow-up of 48 months we observed a sig-
nificant reduction of ARR from  2.0 to 0.16 (p<0.01) and 
of the median EDSS from 5.5 to 4.0 (p<0.013). A complete 
control of the disease was obtained in 57% of patients.  5 
patients (24%) reported haematological adverse events 
consistent with a persistent grade II leucopoenia. Serious 
infective adverse events were reported by 5 patients. They 
had leucopoenia and hypogammaglobulinemia, and they 
all, but one, were wheelchair bound at the beginning of 
RTX .
Conclusion: In a real world clinical practice a fixed treat-
ment scheme of rituximab with re-treatment  every six 
months is an efficacious treatment for NMO and related 
disorders with a relative good safety profile. However to as-
sess the best risk-benefit ratio a close monitoring of CD19+ 
B cells should be performed before re-treatment in patients 
with high disability and concomitant leucopenia and hypo-
gammaglobulinemia.
Disclosure: Nothing to disclose
P3154
Fampridine modulates thalamic resting 
state functional connectivity and  
ameliorates fatigue in multiple sclerosis 
patients
M.A. Rocca1, P. Valsasina2, B. Colombo3, P. Preziosa1,  
V. Martinelli3, A. Falini4, G. Comi3, M. Filippi1
1San Raffaele Scientific Institute, Vita-Salute San Raffaele 
University, Neuroimaging Research Unit, Milan, Italy, 2San 
Raffaele Scientific Institute, Vita-Salute San Raffaele Univer-
sity, 1Neuroimaging Research Unit, Milan, Italy, 3San Raffaele 
Scientific Institute, Vita-Salute San Raffaele University, De-
partment of Neurology, Milan, Italy, 4Università Vita-Salute 
San Raffaele, Neuroradiology, Milan, Italy
Background and aims: To investigate the effects of famp-
ridine and amantadine on thalamic resting state (RS) func-
tional connectivity (FC) in patients with multiple sclerosis 
(MS) and fatigue.
Methods: 45 fatigued MS patients were randomly, blind-
ly assigned to undergo treatment with fampridine (n=15), 
amantadine (n=15) or placebo (n=15) and underwent clini-
cal, neuropsychological (including fatigue assessment) and 
3T RS fMRI at baseline (T0) and after four weeks (W4) of 
treatment. 15 matched healthy controls were also studied. 
RS FC analysis was done using the left thalamus as seed 
region and SPM8.
Results: At T0, compared with controls, MS patients 
showed decreased thalamic RS FC with temporal, occipital, 
frontal and cerebellar regions. At W4, fampridine patients 
showed significantly increased global, physical and cogni-
tive MFIS (p=0.003/0.004/0.02), while no significant MFIS 
changes were observed in amantadine patients. Placebo pa-
tients showed improved global, physical and psycho-social 
MFIS (p=0.02/0.01/0.02). In fampridine patients, increased 
thalamic RS FC at W4 was detected with bilateral tempo-
ral, frontal and parahippocampal regions, while amantadine 
patients and healthy controls showed no significant RS FC 
modifications. In placebo patients, small clusters of incre-
ased thalamic FC with frontal and parietal regions were 
identified.
Compared to the other groups, fampridine patients showed 
a significant RS FC increase over time in the left insula 
and fusiform gyrus, and right precentral and hyppocampal 
gyrus. Physical MFIS improvements were associated with 
increased thalamo-cerebellar FC, while cognitive MFIS 
improvements were associated with increased thalamo-
frontal FC.
Conclusion: Treatment with fampridine ameliorates fa-
tigue in MS patients possibly through a modulation of tha-
lamic functional connections.
Disclosure: Partially supported by a grant from Italian Mi-
nistry of Health (GR-2008-1138784).
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Potassium channel Kir4.1: a novel target 
for neuromyelitis optica autoantibodies?
A. Ruiz, C. Benetollo, S. Cavagna, S. Vukusic, P. Giraudon,  
R. Marignier
Lyon Neuroscience Research Centre, Lyons, France
Background and aims: Autoantibodies directed against 
the potassium channel Kir4.1 have been recently identified 
in the sera of multiple sclerosis (MS) patients. As Kir4.1 is 
mainly expressed by astrocyte and associated to aquaporin4 
at the membrane, we hypothesized that such autoantibodies 
could also be present in neuromyelitis optica (NMO) pa-
tients. Our objectives were to develop a new method for 
Kir4.1 autoantibodies detection to identify conformational 
epitopes and to test their interest in a cohort of MS and 
NMO patients.
Methods and Materials: We set up an in-house method for 
the detection of Kir4.1 autoantibodies by cell-based assay 
with live HEK cells transiently transfected with His-Kir4.1. 
We then tested sera from 56 NMO and 171 MS patients 
and 19 healthy donors. A proportion of samples were also 
tested for: i) binding on deglycosylated form of Kir4.1 after 
Tunikamicin exposure ii) Kir4.1 expression in Western blot 
after exposure to rat astrocyte primary culture.
Results: A relatively high proportion of NMO patients 
tested positive for Kir4.1 autoantibodies (16/56, 28.5%), 
mainly in the AQP4-IgG positive group (13/36, 36%). By 
contrast, only 3/171 MS sera (1.75 %) were positive. None 
of the control samples were positive. Deglycosylation 
did not modify sera binding on Kir4.1. Purified IgG from 
Kir4.1 autoantibodies positive NMO sera downregulate 
Kir4.1 astrocyte expression, suggesting a pathogenic effect.
Conclusion: Using a new method for Kir4.1 autoantibo-
dies detection, even though we cannot reproduce the fin-
dings on MS, we demonstrated a potential high interest of 
such autoantibodies in NMO.
Disclosure: Nothing to disclose
P3156
Fatigue during multiple sclerosis relapse: 
relation to relapse severity
S. Sabanagic-Hajric, E. Suljic, N. Subasic
Clinical Center University of Sarajevo, Department of Neuro-
logy, Sarajevo, Bosnia and Herzegovina
Background and aims: Fatigue is defined as subjective 
lack of physical and/or mental energy perceived by indivi-
dual. The objective was to investigate presence of fatigue 
in multiple sclerosis (MS) patients during relapse and its 
relation to relapse severity. 
Methods: This cross sectional study included 120 MS pati-
ents during relapse treated at the Department of Neurology, 
Clinical Center University of  Sarajevo. Fatigue was mea-
sured by fatigue severity scale (FSS).
Results: Mean FSS score was 4.83±1.49. 45% patients 
with FSS score≥5.0 were clasiffied as fatigue (MSF) group 
while 40% patients with FSS≤4.0 were classified as non-
fatigue (MSNF) group. There were significant differences 
in FSS scores between mild (Me=3.7; IQR=2.6 to 5.8) and 
severe relapse (Me=6.5; IQR=5.0 to 7.0) (p=0.013) and 
moderate (Me=3.8; IQR=3.2 to 6.1) and severe relapse 
(p=0.002) (figure 1). There were also significant differences 
in FSS scores between MSNF (Me=2.7; IQR=2.5 to 3.5) 
and MSF groups (Me=6.0; IQR=5.0 to 7.0) (P=0.002) in 
patients with mild relaps; MSNF (Me=3.3; IQR=3.0 to 3.5) 
and MSF groups (Me=6.1; IQR=5.5 to 6.5) (p<0.001) in 
patients with moderate relaps; MSNF (Me=3.5; IQR=2.8 to 
4.0) and MSF groups (Me=7.0; IQR=5.8 to 7.0) (p=0.002) 
in patients with severe relapse (figure 2). Regression analy-
sis showed that relaps severity didn‘t independently predict 
fatigue severity (table 1).
Figure 1.
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Figure 2.
Table 1.
Conclusion: Fatigue is a frequent symptom during mul-
tiple sclerosis relapse. It should be recognized and treated 
as other disabling symptoms of multiple sclerosis. Higher 
fatigue severity relation to higher relapse severity is par-
tially due to influence of other factors such as disability, 
depression and patient’s age. 
Disclosure: Nothing to disclose
P3157
RETURN II: Investigation of clinical di-
sease and safety outcomes in RMS-pati-
ents receiving subcutaneous (sc) interfe-
ron (IFN) beta-1a following discontinuation 
of natalizumab
R. Weissert1, K. Jendroska2, T. Wagner3
1Klinik und Poliklinik für Neurologie, Regensburg, Germany, 
2Facharzt für Neurologie, Berlin, Germany, 3Merck Serono 
GmbH, Darmstadt, Germany
Background and aims: After discontinuation of an escala-
tion therapy, limited data are available regarding switches 
to first-line therapies. Therefore this non-interventional 
study focused on patients with relapsing multiple sclerosis 
(RMS) receiving subcutaneous (sc) interferon (IFN) beta-
1a after treatment with natalizumab.
Methods: Patients with RMS who had been treated with 
natalizumab and switched to sc IFN beta-1a treatment were 
observed for 24 months. Seven follow-up visits were sche-
duled following the baseline visit. The primary endpoint 
was annualized relapse rate (ARR) over 24 months. Tole-
rability of sc IFN beta-1a was rated on a 4-point scale by 
physicians at the final visit.
Results: Evaluable data were available for 21 patients 
from nine centres. All patients had received first-line di-
sease-modifying drugs prior to starting natalizumab. In 15 
(71.4%) patients, high relapse rate was cited as the reason 
to start natalizumab. The mean duration of natalizumab 
therapy was 24.4 months. 14 (66.7%) patients discontinu-
ed study treatment with sc IFN beta-1a (mean treatment 
duration: 8.7 months). During the observation period, 15 
(71.4%) patients experienced at least one relapse; the mean 
ARR for the whole cohort was 1.1. 15 patients had at least 
one adverse drug reaction. ‘Headache’ was the most com-
mon preferred term. No serious adverse events were repor-
ted. Tolerability was rated as ‘very good’ or ‘good’ for 16 
(76.2%) patients and ‘not satisfactory‘ in 3 (14.3%) who 
also discontinued treatment prematurely.
Conclusion: Disease activity was stabilized on a moderate 
inflammatory level after natalizumab treatment, especially 
compared to the inflammatory level before escalation the-
rapy.
Disclosure: Study supported by: Merck Serono GmbH, 
Darmstadt, Germany
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Novel SEPT9 mutation underlying  
Hereditary Neuralgic Amyotrophy:  
multigenerational evaluation and  
phenotypic variability
S.P. Iyadurai1, J. Roggenbuck2, J. Kissel1
1OSU, Neurology, Columbus, USA, 2OSU, Genetics, Colum-
bus, USA
Three mutations in SEPT9 have been described to date that 
underlie HNA.  Here, we report a novel SEPT9 mutation 
and the variability of expression of hereditary neuralgic 
amyotrophy (HNA) in a multi-generational family.
Methods: Case Series
Results: The proband, a 54-year-old man presented 
with right arm weakness preceded by pain approximate-
ly 2 weeks prior. He reported that many of his fami-
ly members had had a similar episode at variable ages, 
and with varying degrees of weakness. Some of them 
had experienced sequential and/or recurrent asymme-
tric weakness in the upper extremities. Neurological 
examination revealed normal cranial nerves, scapular 
winging, asymmetric proximal weakness, hyporeflexia 
and normal lower extremity examination. MRI of brachial 
plexus revealed enhancement of the T1 nerve root. EMG/
NCS revealed bilateral brachial plexopathy. Gene testing 
revealed a novel aberration in the SEPT9 gene (38 Kb 
duplication with a proximal breakpoint in the exon 2 of 
SEPT9). Clinical evaluation and medical history of family 
members revealed varying ages on onset, different patterns 
of muscle involvement and recurrence and hypotelorism in 
all the affected members.
Conclusion: We report a novel SEPT9 mutation in a mul-
tigenerational family with HNA and its clinical variability. 
Hypotelorism and recurrent painful brachial plexopathy 
seem to be invariant features associated with this novel mu-
tation.
Disclosure: Nothing to disclose
P3159
Identification of novel mutations in LRRK2 
gene in patients with Parkinson’s disease
M. Janković, N.D. Kresojevic, V. Dobricic, V. Marković,  
I. Petrović, I. Novakovic, V.S. Kostic
Neurology Clinic, Clinical Center of Serbia, School of Me-
dicine, University of Belgrade, Belgrade, Serbia, Belgrade, 
Serbia
Background and aims: Mutations in LRRK2 (leucine - 
rich repeat kinase 2) are the most common cause of auto-
somal dominant Parkinson’s disease (PD). Large interna-
tional studies have revealed that pathogenic mutations are 
clustered in several exons coding for functional domains of 
LRRK2 protein, but the mutation frequency differs among 
populations. Systematic study of LRRK2 mutation preva-
lence and phenotype in Serbian population has not been 
performed.
Methods: Comprehensive mutation screening of selected 
exons of LRRK2 gene, harboring proven and potential 
pathogenic mutations, was performed in 486 Serbian PD 
patients. 
Results: Previously reported LRRK2 mutations I1371V 
and G2019S were identified in a single patient each, and 
c.4536+3A>G substitution in two patients. G2019S is the 
most common, proven pathogenic mutation, while pathoge-
nic roles for recurrent variants I1371V and c.4536+3A>G 
are possible, but not confirmed. Two novel LRRK2 muta-
tions S1508G and I1991V were also discovered in 2 unre-
lated patients. These mutations are considered as disease 
causing according to software predictions, but additional 
segregation and functional analyses are required.
Conclusion: Mutation frequency in our study (1.23%) was 
similar to other European populations, although the most 
common mutations were underestimated and novel variants 
were detected. In most cases, symptoms of LRRK2-PD are 
similar to sporadic PD, so estimation of frequency and pe-
netrance of mutations in different populations is important 
for efficient genetic testing strategy and counseling.
Disclosure: This study was supported by grants from the 
Ministry of Education and Science of Republic of Serbia 
(ON175090 and ON175091).
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Strong HLA-DPB1*03:01 association with 
multiple sclerosis risk in patients of a  
Hellenic cohort study.
M. Anagnostouli1, S. Katsavos1, A. Artemiadis2
1Medical School, Athens National and Kapodistrian Univer-
sity, Aeginition Hospital, Immunogenetics Laboratory, of 1st 
Dept of Neurology, Athens, Greece, 2417 General  
military hospital nimts, neurology, Athens, Greece
Background and aims: Multiple Sclerosis (MS) is an 
autoimmune and degenerative disease, mainly affecting 
young adults. There are multiple, independent correlations 
with MS risk across the Major Histocompatibility Com-
plex, with predominant the Human Leucocyte Antigen 
(HLA) DRB1*15:01 allele association, already confirmed 
in many Caucasian populations, the Hellenic included. Ne-
vertheless, the DP region has not been investigated as tho-
roughly as the DR/DQ region in this context. Aim of this 
study was to perform, for the first time, DPB1* genotyping 
for MS patients of Hellenic origin.
Methods: 70 patients suffering from MS, followed in our 
Outpatient Clinic, and 246 healthy controls were included 
in this study. HLA-genotyping was performed by Sequence 
Specific Oligonucleotide (SSO) technique. Statistical pro-
cessing included univariate analyses with chi-squared tests 
(level of significance set at p=0.05).
Results: Our patients were predominantly women (64.3%), 
with mean age 38.1 years, and mean age of MS onset 29.6 
years. DPB1*03:01 allele frequency was significantly in-
creased in MS patients compared to controls (p=0.001). 
There were also trends towards increase of the DPB1*10 
and DPB1*14 alleles and towards reduction of DPB1*13 
and DPB1*17 alleles. Interestingly, no coexistence of 
DRB1*15:01 and DPB1*03:01 was found in any patient 
of our sample.
Conclusion: Although DRB1*15:01 allele has an establis-
hed role in MS, there is inadequate information concerning 
the impact of DPB1* region in MS genetic burden. Our 
observations are in accordance with recent studies, regar-
ding increased DPB1*03:01 frequency in Caucasian MS 
patients. Its effects are probably independent of these attri-
buted by other susceptibility alleles, like the predominant 
DRB1*15:01.
Disclosure: Nothing to disclose
P3161
Connecting genes to pathways and  
networks in neurodegenerative diseases
P. Kuru, P.H. Ozdinler
Northwestern University Feinberg School of Medicine,  
Department of Neurology, Chicago, USA
Background and aims: The goal of this study is to inves-
tigate the link between genes, proteins, and networks in 
an effort to understand the cellular and molecular basis of 
selective vulnerability in neurodegenerative diseases. To 
identify the networks and cellular pathways that are affec-
ted we focus on the binding partners of the proteins that are 
encoded by the mutated genes. Our studies will reveal both 
the canonical pathways and cellular networks that are parti-
cularly significant for different neurodegenerative diseases.
Methods: Using genes that lead to Alzheimer’s disease 
(AD), Amyotrophic lateral sclerosis (ALS) and Fronto-
temporal dementia (FTD) when mutated, we first identified 
their binding partners and performed systems analysis to 
reveal the canonical pathways and cellular networks they 
are critically important.
Results: Glucocorticoid Receptor Signaling is the main ca-
nonical pathway in AD, ALS and FTD. HNF4A interacts 
with 11 different proteins in the ALS, whereas it interacts 
with only 3 proteins in the AD connectivity map. Likewise, 
APP interacts with 17 proteins in the AD, but with only 2 
proteins in the ALS domain. Such differences are excepti-
onally important to suggest the protein connectome and to 
reveal potential candidate molecules/genes/targets for the 
initiation of neuronal vulnerability and for selective neuron 
death. Investigation of protein-protein interactions reveal 
the potential pathways that are affected in distinct neurode-
generative diseases.
Conclusion: Selective gene expression profile in neurons 
inform us about their potential vulnerability and the pa-
thways that are particularly important for their function and 
connectivity. This information will shed light onto the com-
mon and unique mechanisms involved for different neuro-
degenerative diseases.
Disclosure: Nothing to disclose
356      Poster presentation with discussion
© 2015 European Journal of Neurology, 22 (Suppl. 1), 120–483
P3162
Autosomal recessive ataxia due to ADCK 3 
mutation – a series of 3 cases from 2  
families.
S. Little, J. Flowers, M. McEntagart, S. Omer
St Georges Hospital, London, UK, Atkinson Morley Neurosci-
ences centre, London, United Kingdom
Background and aims: Autosomal recessive cerebellar 
ataxias (ARCAs) are clinically and genetically heterogene-
ous. They lead to a progressive cerebellar dysfunction, of-
ten in association with a variety of other neurological sym-
ptoms and signs. Recently, a new genetic locus has been 
discovered for ARCAs in a gene responsible for Co-enzyme 
Q10 synthesis, namely the AarF domain containing kinase 
3 gene (ADCK3). This gene is responsible for encoding a 
membrane protein involved in electron transfer within the 
mitochondrial respiratory chain complex. Importantly, this 
condition can potentially respond to Co-enzyme Q10 sup-
plementation, making its recognition amongst the ARCAs 
particularly important. However, clinical identification is 
complicated by the wide range of phenotypic presentations 
that can occur.
Methods: Here we describe a case series of 3 patients with 
cerebellar ataxia and genetically proven ADCK3 mutations 
from our centre.
Results: Two siblings presented with highly similar pheno-
types of childhood onset cerebellar ataxia, myoclonus and 
bradykinesia are compared with a further case characte-
rised by cerebellar ataxia, seizures and a different ADCK3 
mutation.
Conclusion: The clinical identification, diagnostic work 
up, genetic testing and management of this condition is dis-
cussed.
Disclosure: Nothing to disclose
P3163
Cerebral folate deficiency (CFD) in adult 
patients: a treatable non-specific  
syndrome associated with various  
diseases.
M. Masingue1, J.-F. Benoist2, F. Sedel3, E. Roze1, Y. Nadjar3
1Hôpital Pitié-Salpêtrière, Department for Diseases of the 
Nervous System, Paris, France, 2Hôpital Robert Debré, De-
partment of Biochemistry and Hormonology, Paris, France, 
3Hôpital Pitié-Salpêtrière, Department for Diseases of the 
Nervous System, UF Neuro-metabolic, Paris, France
Background and aims: Cerebral folate deficiency (CFD) 
is characterized as any neuro-psychiatric condition associ-
ated with low cerebrospinal fluid (CSF) level of 5-methyl-
tetrahydrofolate (5MTHF).  Mainly described in children, 
it can be associated with numerous diseases. We describe 
clinical and radiological data in adult patients with CFD, as 
well as evolution after folinic acid supplementation.
Methods: A retrospective study was conducted in pati-
ents for whom 5MTHF was examined in CSF. Demogra-
phic, clinical, biological, radiological and treatment data 
were recorded. CFD was defined as a 5MTHF level below 
41mmol/L in CSF.
Results: Among 224 patients, 69 had CFD (31%), with a 
mean 5MTHF level of 21 nmol/L (±11, 2-40) and a mean 
age at onset of 24 years (±21, 0-65). 35% of CFD patients 
had a defined underlying condition. Fahr disease (n=7), 
CAFSA (Cerebellar Ataxia with elevated cerebrospinal 
Free Sialic Acid) syndrome (n=4), and hepatic encepha-
lopathy (n=16) were associated with the lowest 5MTHF 
levels. In CFD patients, cognitive impairment was more 
common (44.6% vs 28.8%, p= 0.024), as was hearing loss 
(18.5% vs 6.9%, p=0.011). Calcifications and T2 hypersi-
gnals in posterior fossa were more frequent (respectively 
29% vs 2.2%, p= 0.014 and 16.3% vs 4.8%, p=0.021). 25 
patients received folinic supplementation and 13 showed 
clinical improvement, mostly on gait disturbance (n=7), 
movement (n=7) and behavior (n=5) disorders. 5MTHF in 
CSF had normalized after treatment in 8 over 9 cases.
Conclusion: CFD has a large clinical and radiological 
spectrum in adult patients, and is associated with various 
diseases. In severe CFD, folinic acid treatment may drama-
tically improve clinical condition.
Disclosure: Nothing to disclose
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Mutations in the genes of the 
α-ketoglutarate dehydrogenase may  
predispone to Alzheimer’s disease
M.J. Molnár1, E. Bányász2, K. Pentelényi2, V. Hársfalvi2,  
M. Palkovits3, V. Ádám-Vizi4
1Semmelweis University, 3Department of Genomic Medicine 
and Rare Disorders, Budapest, Hungary, 2Semmelweis Uni-
versity, Institute of Genomic Medicine and Rare Disorders, 
Budapest, Hungary, 3Laboratory of Neuromorphology, De-
partment of Anatomy, Histology and Embryology, Budapest, 
Hungary, 4Semmelweis University, Department of Medical 
Biochemistry, Budapest, Hungary
Background and aims: The αKGDH enzyme is a key en-
zyme of the Krebs cycle and its mutations are known to 
result in extensive oxidative stress and cell damage. The 
hereditary mutations lead to a variety of phenotypes, exten-
ding from the lethal infant-type enzyme defect, to the el-
derlys’ chronic diseases. Reduced enzyme activity has been 
reported in Alzheimer’s patients’ fibroblasts. Our objective 
was the analysis of the enzyme’s genetic code and the inci-
dence of SNP-s in Alzheimer patients.
Methods: In 22 Alzheimer cases DNA from blood samples, 
in 11 cases from post mortem brain tissue and in 2 control 
brain samples the E2 and E3 components of the αKGDH: 
dihydrolipoamide S-succinyltransferase (DLST) and dihy-
drolipoyl dehydrogenase (DLD) genes were sequenced. 
Results: 4 pathogenic mutations were present in 3 of 11 
Alzheimer patient’s brains: Arg263His missense mutation 
in DLD gene, Pro204Leu, Leu394Met and Leu453His mis-
sense mutations in DLST gene. No mutations were present 
in the blood samples.
Conclusion: The presence of the 4 pathogenic mutations 
in the aKGDH may indicate that this enzyme is a keyplayer 
in the pathogenesis of the Alzheimer’s disease. Further stu-
dies are needed to support our hypothesis.
Disclosure: Nothing to disclose
P3165
A clinical multimodal approach in a large 
Italian cohort with Hereditary Spastic  
Paraplegia (HSP) looking for  
neurophysiological biomarkers
O. Musumeci1, V. Rizzo1, M.T. Bassi2, M. Marino1,  
F. Montagnese1, A. Quartarone1, A. Toscano1
1University of Messina, Messina, Italy, 2IRCCS Medea, Bosi-
sio Parini, Italy
Background and aims: Hereditary spastic paraplegias 
(HSP) are a group of neurodegenerative disorders charac-
therized by an extreme clinical and genetic variability. A 
growing number of testable genes, associated with HSP, 
offers very large opportunities for their genetic definition 
but complicates the diagnostic workout. Aim of this study 
was to present the clinical and electrophysiological data in 
a cohort of HSP patients to identify possible neurophysiolo-
gical markers capable to better address diagnosis.   
Methods: Since 2009, we have recruited over 160 patients 
with suspected HSP. All patients were evaluated with a 
standardized clinical protocol. For the molecular definiti-
on, 10 genes associated with the more common HSPs were 
tested. A multimodal electrophysiological protocol,   inclu-
ding electromyography (EMG) and nerve conduction study 
(NCS), motor-evoked potentials (MEPs) and somatosenso-
ry evoked potentials (SEPs) at four limbs, visual (VEPs) 
and brainstem evoked potentials (BAEPs) was applied
Results:  A wide variation in age of onset and disease seve-
rity was observed among pure and complicated cases and, 
even,  within families. Molecular definition was obtained in 
33 patients (21%) (22 SPG4, 4 SPG5,2 SPG10, 3 SPG11, 1 
SPG7, 1 SPG15). The common neurophysiological finding 
was the increased central motor and sensory conduction 
time at lower limbs. Alterations in VEPs/BAEPs were ob-
served in few cases of SPG4, 5, 11 and 15. Axonal polyn-
europathy was detected in SPG5, 10, 11. 
Conclusion: Our data confirm the clinical heterogeneity 
of these disorders. Electrophysiological evaluation in dif-
ferent SPGs showed a various CNS and PNS involvement 
either in pure or in complicated forms that could be useful 
to address the molecular diagnos
Disclosure: Nothing to disclose
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Natural history of cerebrotendinous  
xanthomatosis: a pediatric disease  
diagnosed in adults.
Y. Nadjar1, P. Couvert2, F. Lamari3, M.D.M. Amador1,  
E. Flammand-Roze1, B. Degos1, F. Mochel4
1Hôpital Pitié Salpétrière, Département des maladies du 
Système Nerveux Central, UF Neurométabolique, Paris, 
France, 2Hôpital Pitié Salpétrière, Laboratoire de Biochimie 
Endocrinienne et Oncologique,, Paris, France, 3Hôpital Pitié 
Salpétrière, Biochimie Métabolique, UF Neurométabolique, 
Paris, France, 4Hôpital Pitié Salpétrière, Département de 
Génétique, UF Neurométabolique, Paris, France
Background and aims: Cerebrotendinous xanthomatosis 
(CTX) is a treatable inborn error of metabolism for which 
the onset of neurological symptoms usually occurs in young 
adults. Elevated plasma cholestanol is a specific biomarker 
of the disease. Here we describe the natural history of CTX 
in our population. We aimed at identifying  early clinical 
markers allowing treatment initiation before the occurrence 
of irreversible neurological disability.
Methods: We conducted a retrospective clinical study on 
17 French patients with CTX.  We collected demographic, 
clinical, electrophysiological and radiological data.
Results: Neurological symptoms occurred at a mean age 
of 28 years (15-50), and consisted of gait abnormalities 
(61%), cognitive and/or behavioral disorder (25%, exclu-
ding learning difficulties), or both (14%). Gait abnormali-
ties comprised mixed cerebellar and pyramidal dysfunction 
(43%), isolated cerebellar ataxia (28%), isolated pyramidal 
dysfunction (14%), or peripheral nerve impairment (14%). 
Cognitive and psychiatric symptoms consisted mainly of 
frontal syndrome with disinhibition and aggressive behavi-
or. 47% of patients had juvenile bilateral cataract preceding 
the occurrence of neurological symptoms, 64% had chronic 
diarrhea in early childhood, and 80% had learning difficul-
ties in childhood or adolescence.
Conclusion: Overall, 88% of patients had early clinical 
markers of the disease (cataract and/or chronic diarrhea 
and/or learning difficulties) during childhood. However, 
CTX was mainly diagnosed when patients were adults. 
Therefore, the identification of early clinical markers of 
CTX, as described here, should prompt the dosage of plas-
ma cholestanol. The early initiation of CTX treatment ( 
CDCA : chenodeoxycholic acid) could indeed prevent or 
delay the occurrence of neurological symptoms.
Disclosure: Nothing to disclose
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Optical coherence tomography in patients 
with radiologically isolated syndrome
R. Karabudak1, A. Vural1, N.P. Acar1, M.A. Tuncer1,  
G. Sayat1, S. Kadayifcilar2, A. Kurne1
1Hacettepe University, Neurology, Ankara, Turkey, 2Hacettepe 
University, Opthalmology, Ankara, Turkey
Background and aims: Incidental detection of white mat-
ter lesions is named as radiologically isolated syndrome 
(RIS). Some of these patients develop multiple sclerosis 
(MS) in time. In MS brains, axonal injury was observed 
in normal appearing white matter and retinal nerve fiber 
layer (RNFL) of the unaffected eye. Retinal axonal loss be-
gins early in the course of MS. In the absence of clinically 
evident optic neuritis, RNFL thinning was detected in pati-
ents with clinically isolated syndrome. There is no study of 
acknowledged axonal injury in RIS subjects. In this study, 
we investigated whether axonal trans-section occurred in 
retinal layer of the RIS subjects. 
Methods: We present the preliminary data of an ongo-
ing, prospective study. Spectral-domain optical coherence 
tomography (SD-OCT) is performed to measure RNFL 
thickness and macular volume (MV) in individuals fulfil-
ling 2009 Okuda Criteria and healthy controls. 
Results: SD-OCT has been done in both eyes of 12 RIS 
subjects (7 female, 5 male) and 12 controls. Overall RNFL 
thickness and MV were not statistically different between 
groups. When taken individually, atrophy of RNFL was de-
tected in one subject and borderline RNFL thickness was 
detected in retina of 6 more subjects compared to the gene-
ral population, whereas in the control group the measure-
ments were between normal limits. 
Conclusion: These data suggest that axonal transection 
in retina might be elicited in RIS subjects. SD-OCT may 
reveal subclinical retinal axonal loss at the earliest stages 
of MS. Whether there might be an apparent consistency 
between brain MRI -DTI and retinal OCT will be the next 
analysis of this study. 
Disclosure: This study is supported by Merck-Serono.
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Multiparameter autoantibody screening in 
the diagnosis of neurological autoimmune 
diseases
W. Stöcker, C. Probst, B. Teegen, K. Rentzsch,  
W. Schlumberger, J. Fraune, L. Komorowski
Institute of Experimental Immunology, Euroimmun AG,  
Lübeck, Germany
Background and aims: The aspect of autoimmunity in 
neurological disorders attracts a steadily growing interest. 
Identified autoantibodies include those against intracellular 
antigens (biomarkers of paraneoplastic neurological syn-
dromes) and newly, those against neuronal cell surface pro-
teins, many of them being pathogenic in several forms of 
autoimmune encephalitis. However, differential diagnosis 
of the clinical conditions is challenging due to similar sym-
ptomatic appearances and often requires consideration of 
a broad range of anti-neuronal antibodies. Here, we report 
on diagnostic benefits of determining a comprehensive an-
tibody profile by multiparametric testing during requested 
sample analyses.
Methods: 16,741 samples were sent to the Clinical Immu-
nological Laboratory (Lübeck) from April 1st 2012 until 
March 31st 2013. Irrespective of the parameter requested, 
all samples were tested for multiple parameters using in-
direct immunofluorescence on BIOCHIP-mosaics (com-
bining various substrates in one reaction field) and immu-
noblot.
Results: 14.1% of the samples were positive for at least 
one neurological parameter. About half of the detected au-
toantibodies (52.1%) were of the IgG class. Among these, 
antibodies against extracellular antigens were twice as fre-
quent as antibodies against intracellular antigens. 53.4% 
of the samples were positive for the requested parameter 
whereas 46.6% of the samples were positive for another but 
requested parameter.
Table 1: Results of multiparametric screening, samples with request on 
analyses of one or more neurological autoantibodies, n = 16,741 (April 
1st, 2012 – March 31st, 2013).
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Figure 1: Composition of detected autoantibodies of class IgG in sam-
ples which have been sent with request on analyses of neurological 
parameters.
Conclusion: Our results reveal that multiparametric scree-
ning of samples can increase the hit rate of positive and 
diagnostically relevant findings by 87% compared to single 
testing of requested parameters. This may also accelerate 
the diagnostic process. Both aspects significantly support 
correct and rapid diagnoses of neurological autoimmune 
diseases, which is crucial to initiate appropriate and often 
life-saving therapies.
Disclosure: Research has been performed at the Clinical 
Immunological Laboratory Prof. Dr. med. Winfried Stö-
cker, Lübeck in research cooperation with EUROIMMUN 
AG.
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Prevalence of autoreactive antibodies 
(ARAB) in patiens with relapsing-remitting 
multiple sclerosis (RRMS) under interferon 
beta treatment.
C. Papastergios1, E. Karamouzos1, I. Markakis1, C. Kaliouli2, 
E. Pappa2, G. Gekas1
1“St. Panteleimon” General State Hospital of Piraeus, Neu-
rology, Piraeus, Greece, 2“St. Panteleimon” General State 
Hospital of Piraeus, Immunology, Athens, Greece
Background and aims: Interferon beta is widely used as 
a first line immunomodulatory medication for patients with 
RRMS. However, interferon treatment has been implicated 
in the development of autoimmune disorders. Our objective 
was to evaluate the impact of interferon beta-1a and beta-
1b treatment on the serum autoantibody profile of patients 
with RRMS.
Methods: 61 patients with newly diagnosed RRMS were 
followed-up during a 2 year period, after the initiation of 
immunomodulatory treatment with interferon (interferon 
beta-1a: 37, interferon beta-1b: 24). Patients were tested for 
an extensive panel of ARAB including antinuclear (ANA), 
thyroid microsomal (anti-TPO), human thyroglobulin (anti-
TG), smooth muscle (ASMA), anticardiolipin (aCL), anti-
beta2-glycoprotein-1 (anti-beta2-GP1) and anti-neutrophil 
cytoplasmic antibodies (ANCA). Serological tests were 
performed at baseline and at the end of the 2-year follow-up
Results: Interferon beta-1a treatment was associated with 
a statistically significant increase in ARAB positivity for 
ANA, ASMA, aCL, ANCA; alterations of anti-TPO, anti-
TG, anti-beta2-GP1 and anti-Ro were not statistically sig-
nificant. Moreover, patients having positive ANA at base-
line, showed a statistically significant rise of serum titers 
following treatment (p<0.01). Interferon beta-1b treatment, 
was not associated with significant induction of any ARAB, 
nor with significant alterations of ARAB titers in patients 
that were positive at baseline.
Conclusion: Interferon beta-1a may induce ARAB forma-
tion in patients with RRMS and thus seems to have a grea-
ter risk of autoimmunity induction.
Disclosure: Nothing to disclose
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Expression of the quiescence marker, 
TOB-1, in T-cells of CIS patients at high 
risk of rapid conversion to clinically  
definite MS
S. Basdeo1, S. Kelly2, K. O‘Connell2, N. Tubridy2,  
M. Hutchinson2, J. Fletcher1, C. McGuigan2
1Trinity College Dublin, Schools of Medicine and Bioche-
mistry & Immunology, Dublin, Ireland, 2St Vincent’s Universi-
ty Hospital, Department of Neurology, Dublin, Ireland
Background and aims: There are no laboratory biomar-
kers to accurately identify patients at risk of rapid conver-
sion to clinically definite multiple sclerosis (CDMS) fol-
lowing a clinically isolated syndrome (CIS). CD4+ T-cells 
play a central role in the pathogenesis of MS. A recent stu-
dy identified a pattern of gene expression that distinguis-
hed CIS patients with rapid conversion to CDMS. TOB-1, 
which plays a crucial role in maintaining T-cell quiescence, 
was reduced in patients with rapid conversion whilst CD44, 
the osteopontin receptor, was over-expressed in this group. 
Methods: Expression of TOB-1 and CD44 in total and na-
ive CD4+ T-cell from PBMC was examined by RT-PCR 
in patients converting from CIS to CDMS within 1 year 
(n=10), those not converting within 1 year (n=10) and pati-
ents with an aggressive course on Tysabri (n=5), compared 
with healthy controls (n=10). 
Results: No significant difference in expression of TOB-
1 or CD44 was seen between groups. There was a trend 
towards reduced TOB-1 expression in total CD4+ T-cells 
from patients converting to CDMS within 1 year compared 
with those not converting. Naive CD4+ T-cells from pati-
ents with aggressive MS exhibited reduced TOB-1 expres-
sion compared with the other groups analysed, however, 
this was not statistically significant. 
Conclusion: CD4+ T-cell expression of TOB-1 was not si-
gnificantly reduced in patients who progressed from CIS to 
CDMS within 1 year in this study. TOB-1 with other mar-
kers of T cell quiescence may predict a cohort of patients at 
risk of a more aggressive disease course. 
Disclosure: Nothing to disclose
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Limbic encephalitis and intrathecal  
immunoglobulin A and G antibodies to  
Synapsin, a neuron-specific synaptic  
vesicle-associated protein
J. Piepgras1, M. Höltje2, C. Otto3, H. Harms3, F. Benfenati4,  
A. Pich5, D. Gitler6, G. Ahnert-Hilger2, K. Ruprecht1
1Charité Universitätsmedizin Berlin, Department of Neuro-
logy, Berlin, Germany, 2Charité Universitätsmedizin Berlin, 
Institute for Integrative Neuroanatomy, Berlin, Germany, 3St. 
Josefs-Krankenhaus, Klinik für Neurologie, Potsdam, Ger-
many, 4Istituto Italiano di Tecnologia, Department of Neu-
roscience and Neurotechnologies, Genoa, Italy, 5Hannover 
Medical School, Institute for Toxicology, Hanover, Germany, 
6Ben-Gurion University of the Negev, Department of Physio-
logy and Cell Biology, Beer-Sheva, Israel
Background: Limbic encephalitis (LE) is characterized 
by memory dysfunction, seizures, behaviour changes, and 
mesiotemporal involvement on imaging studies, and is as-
sociated with antibodies to neuronal autoantigens. Here we 
report the identification of the synaptic vesicle-associated 
protein Synapsin as a novel autoantigen in a patient with 
LE.
Methods: Methods included indirect immunofluorescence, 
immunoprecipitation, mass spectrometry, cell-based assays 
with Synapsins Ia, Ib, and IIa plasmids, and immunoblots 
of wild-type and Synapsin I/II/III null mice.
Results: A 70-year-old patient presented with seizures, 
short-term memory deficits, and left hippocampal hyper-
intensities on T2-weighted magnetic resonance imaging. 
Cerebrospinal fluid (CSF) studies revealed a strong intrat-
hecal synthesis of immunoglobulin (Ig)A and IgG. Except 
for low-titre IgG antibodies to voltage-gated potassium 
channels in CSF, testing for known neuronal autoantibo-
dies was negative. However, indirect immunofluorescence 
on murine brain sections showed prominent staining of the 
mossy fibre tract, amygdala, and the cerebellar molecular 
and granular layer by IgA antibodies in the patient’s CSF 
and serum. Immunoprecipitation with CSF IgA and sub-
sequent mass spectrometry identified the neuron-specific 
synaptic vesicle-associated protein Synapsin as the anti-
genic target. Knockout studies and cell-based assays un-
ambiguously confirmed Synapsin Ia/Ib and Synapsin IIa as 
autoantigens detected by intrathecally synthesized IgA and 
IgG antibodies.
Conclusion: Synapsin is a novel autoantigen in LE. Re-
markably, in addition to IgG, Synapsin is targeted by intrat-
hecally produced IgA, suggesting that also IgA antibodies 
could play a role in antineuronal autoimmunity. Future stu-
dies should clarify the prevalence and pathogenic relevance 
of IgA and IgG antibodies to Synapsin in patients with LE.
Disclosure: Nothing to disclose
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Neuropsychiatry and onconeuronal  
antibodies: An observational cohort  
study of 585 patients admitted to acute 
psychiatric care
S.G. Saether1, M. Schou1, A.E. Vaaler1, K. Borowski2,  
B. Teegen2, D. Kondziella3, W. Stoecker2, S.K. Reitan1
1St Olavs University Hospital, Department of Psychiatry, 
Trondheim, Norway, 2Institute for Experimental Immunology, 
Affiliated to EUROIMMUN AG, Lübeck, Germany, 3Rigshos-
pitalet, Copenhagen University Hospital, Department of Neu-
rology, Copenhagen, Denmark
Background and aims: Paraneoplastic limbic encephalitis 
frequently presents with prominent psychiatric symptoms. 
Onconeuronal antibodies are used as serum markers of pa-
raneoplastic limbic encephalitis. The significance of these 
antibodies in patients with psychiatric syndromes but wit-
hout a limbic encephalitis is unknown. We aimed at exami-
ning the prevalence of onconeuronal antibodies in patients 
acutely admitted to psychiatric care. We hypothesized that 
onconeuronal antibodies are frequent in this population and 
that different antibodies are associated with distinct neuro-
psychiatric profiles.
Methods: Serum collected from 585 consecutive patients 
admitted to acute psychiatric care was assessed for the pre-
sence of Immunoglobulin (Ig)G, IgM and IgA onconeuro-
nal antibodies. Analysis was performed with an indirect 
immunofluorescence test (Euroimmun; Lübeck, Germany).
Results: We identified 31 patients (5.3%) with positive on-
coneuronal antibody titres. 19 patients (3.2%) had anti-Ma2 
antibodies (6 IgM, 6 IgA and 7 IgG), and 9 patients (1.4%) 
had anti-Ma1 antibodies (0 IgM, 2 IgA and 7 IgG). Anti-Yo 
(n=3 patients), anti-Amphiphysin (n=2) and Rho GTPase 
(n=1) antibodies were less frequent. We found a trend to-
wards a higher prevalence of high titres of anti-Ma2 anti-
bodies in the ICD 10 F20 diagnostic group (schizophrenia, 
schizotypal and delusional disorder) as compared with the 
other diagnostic groups (p=0.019).
Conclusion: Compared to healthy blood donors (Dahm 
et al. 2014), we identified a relatively high prevalence of 
anti-Ma2 antibodies in patients with acute psychiatric sym-
ptoms, in particular in those with psychotic syndromes. The 
present results suggest that further research into the signifi-
cance of onconeuronal antibodies for neuropsychiatry phe-
nomenology is warranted.
Disclosure: W.S. is shareholder of Euroimmun AG and 
member of the Board of Euroimmun AG. K.B. and B.T. are 
employees of Euroimmun AG.
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Serum prevalence of N-methyl d-aspartate 
receptor (NMDAR) antibodies in an  
unselected cohort of patients with acute 
psychiatric symptoms
M. Schou1, S.G. Saether1, S.K. Reitan1, K. Borowski2,  
B. Teegen2, D. Kondziella3, W. Stoecker2, A.E. Vaaler1
1St Olavs University Hospital, Department of Psychiatry, 
Trondheim, Norway, 2Institute for Experimental Immunology, 
Affiliated to EUROIMMUN AG, Lübeck, Germany, 3Rigshos-
pitalet, Copenhagen University Hospital, Department of Neu-
rology, Copenhagen, Denmark
Background and aims: Patients with NMDAR encephali-
tis typically present with prominent psychiatric symptoms, 
especially psychosis, before they develop neurological 
symptoms. In an unselected cohort of patients admitted 
to acute psychiatric care we hypothesized that patients 
with psychotic disorders had a higher prevalence of serum 
NMDAR antibodies compared to other patients. 
Methods: Serum collected from an unselected cohort of 
926 patients admitted to acute psychiatric care at the De-
partment of Psychiatry, St Olavs Hospital, Trondheim, Nor-
way were used. Patients with ICD-10 diagnosis F20-F29, 
psychotic disorders, were compared to the other patients, 
see table 1. Antibody analysis was performed with an indi-
rect immunofluorescence test (Euroimmun; Lübeck, Ger-
many).
Results: 70 patients (7.6%)  had NMDAR antibodies of Im-
munoglobulin (Ig)G, IgM or IgA  subtype. 5 patients were 
positive for Ig G, 38 for Ig M and 34 for  Ig A NMDAR 
antibodies.  The prevalence of NMDAR antibodies in pati-
ents with psychotic disorders were 6.3% and    did not dif-
fer significantly from patients with other diagnosis leading 
to acute psychiatric admissions (7.8% (Chi square 0.226 
p=0.64)). Including only high antibody titers (1:100 and 
above) in our analysis, the prevalence still did not differ in 
the two groups (2.1% and 3.1%,  respectively. Fisher exact 
p=0.78). 
Table 1 Prevalence of NMDAR antibodies in patients with psychotic 
and non-psychotic disorders
Conclusion: We did not find any significant differences 
in serum prevalence of NMDAR antibodies between pa-
tients with psychotic disorders and other patients. Positi-
ve NMDAR IgG antibody titre status was rare. However, 
further studies on whether or not the antibodies are of cli-
nical significance in patients with psychiatric disorders are 
needed. 
Disclosure: K.B and B.T. are employees of Euroimmun 
AG. W.S. is shareholder and member of the Board of Eu-
roimmun AG.
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Association of a FAS/APO-1 promoter SNP 
with multiple sclerosis in the Altai region
I. Smagina
Altai State Medical University, Barnaul, Russian Federation
Background and aims: Violation of peripheral immune 
tolerance is involved in the pathogenesis of multiple scle-
rosis (MS). Binding of Fas/APO-1 receptors of autoreacti-
ve lymphocytes with Fas-ligand plays a critical role in the 
initiation of apoptosis. Object of study is to investigate the 
association of the SNP rs2234767 (1377G> A) in the pro-
moter region of Fas/APO-1 gene with the MS.
Methods: 100 patients with relapsing-remitting MS, Rus-
sian, living in the Altai Region, and 100 volunteers without 
MS and other autoimmune diseases (control group) were 
participated in the study. Genotyping was performed by 
TaqMan allelic discrimination.
Results: The distribution of genotypes were not deviate 
from Hardy-Weinberg equilibrium (p=0.84; p=0.79, MS 
group and control respectively). We found significant as-
sociations between MS and genotype G/A (OR-1.74; 95% 
CI 1.07-2.82; p = 0.02), and the A allele (OR-2.94; 95% CI 
1.25- 6.92; p = 0.01) of the SNP rs2234767 (1377G> A) of 
Fas/APO-1.
Conclusion: The findings suggest that the SNP rs2234767 
(1377G> A) in the promoter region of Fas/APO-1 is associ-
ated with MS in the Altai region.
Disclosure: Nothing to disclose
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Intravenous dexamethasone in acute  
management of vestibular neuritis:  
a randomized, placebo-controlled, single 
blind trial
I. Adamec1, M. Krbot Skoric1, T. Gabelic1, B. Barun1,  
J. Ljevak2, A. Bujan Kovac1, I. Jurjevic3, M. Habek3
1Zagreb, Croatia, 2Zagreb University Hospital Centre, Neu-
rology, Zagreb, Croatia, 3University Hospital Center Zagreb, 
Neurology, Zagreb, Croatia
Background and aims: Aim of this study was to evaluate 
the role of intravenous dexamethasone in relieving symp-
toms and signs of vestibular neuritis (VN) in the emergency 
department setting.
Methods: This was a randomized, placebo-controlled; 
single-blind study. Patients were randomized either to in-
travenous dexamethasone (group A) or placebo (group 
B) with all of the patients receiving symptomatic therapy. 
Primary outcome of the study was defined as necessity to 
hospitalize patients who present with VN in the emergency 
department. Secondary outcomes were: 1) improvement of 
nystagmus, 2) improvement of postural instability, 3) lesse-
ning of nausea, 4) lessening of vomiting, and 5) recovery of 
subjective symptoms.
Results: Altogether 100 patients were randomized, 51 into 
group A and 49 into group B. There was no difference in 
hospitalizations between groups (p=0.284). In both groups 
there was a statistically significant difference in values of 
all measured variables two hours after therapy intervention 
compared to baseline. In group A significantly less patients 
had 3rd degree nystagmus two hours after therapy inter-
vention (p=0.000) while the difference in group B did not 
reach statistical significance (p=0.063). After therapy more 
patients had 1st degree nystagmus in group A (p=0.004) as 
well as in group B (p=0.0016) than before the intervention. 
There was a significantly greater absolute difference in Eu-
ropean Evaluation of Vertigo scale results in group A when 
compared to group B (p=0.025).
Conclusion: Intravenous dexamethasone provides modest 
benefit in clinical recovery of VN. There is evidence of effi-
cacy of antihistamines and benzodiazepines as symptoma-
tic therapy in VN.
Disclosure: Nothing to disclose
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Clinical recovery after acute vestibular 
neuritis
S. Cousins, D. Kaski, N. Cutfield, H. Ahmad, Q. Arshad,  
B. Seemungal, J. Golding, M. Gresty, A. Bronstein
Imperial College, London, United Kingdom
Background and aims: Clinical recovery after acute ves-
tibular neuritis (VN) is variable and many patients report 
chronic symptoms. Symptoms correlate poorly with traditi-
onal vestibular-ocular reflex assessments. Accordingly, we 
prospectively assessed perceptual visuo-vestibular function 
and clinical outcome in patients presenting with acute ves-
tibular neuritis. 
Methods: 40 vestibular neuritis patients were studied in the 
acute (median 2 days), short (median 10 weeks; n=32) and 
long (>6 months; n=26) term recovery stages. Vestibular-
ocular (VO) and vestibular-perceptual (VP) responses were 
measured at threshold and supra-threshold (90deg/s velo-
city step rotations) levels. Measures of visual dependency 
(Rod-and-disk test), clinical recovery (Dizziness Handicap 
Inventory) and psychological factors (HADS, BSQ and 
VSS-autonomic arousal) were obtained at each stage. 
Results: Acutely, VO and VP vestibular thresholds were 
asymmetrically raised. Vestibular-ocular supra-threshold 
responses were asymmetric and reduced. However, VP sup-
ra-threshold responses were symmetrically reduced. There 
was no significant change in clinical recovery (DHI) after 
the short term recovery stage. Acutely increased visual de-
pendency (p=0.006), autonomic anxiety (p=0.002) and fear 
of bodily sensations (p=0.05) predicted poor symptomatic 
recovery. Factor Analysis with DHI at short term recovery 
stage as dependent variable, showed a strong association 
between clinical recovery, visual dependency and psycho-
logical variables (HADS, VSS-AA and BSQ), all loading 
on a single component (49.21% of variance). 
Conclusion: Vestibular-perceptual mechanisms exist that 
serve to suppress vertiginous sensations acutely, shown 
currently in the bilateral suppression of supra-threshold 
vestibular perception. Rather than being dependent on re-
covery of peripheral vestibular function, clinical outcome 
from acute VN is mediated by centrally modulated sensory 
integration mechanisms and psychological processing. 
Disclosure: This work was supported by the Medical Re-
search Council of the U.K.
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White matter abnormalities in dizzy  
patients: retrospective cohort multi –  
centre study
H. Ahmad1, N. Cerchiai2, M. Mancuso3, A.P.  Casani2,  
A. Bronstein1
1Imperial College London, London, United Kingdom,  
2Department of Medical and Surgical Pathology, Otorhinola-
ryngology Unit, Pisa University Hospital, Pisa, Italy, 3 Uni-
versity of Pisa, Neurological Clinic, Pisa, Italy
Background and aims: Although cerebral small vessel di-
sease is a significant contributor to the development of im-
balance and falls in the elderly, whether it also contributes 
to the development of dizziness is not known.  
Methods: A retrospective case analysis was conducted 
for 125 dizzy patients referred to two neuro-otology terti-
ary  centres in London and Pisa.  Specific search criteria of 
“white matter disease”   was applied to patient databases. 
Case notes were reviewed by a neuro-otologist and patients 
were divided into ‘explained’ causes of dizziness (ie beni-
gn vertigo ,orthostatic hypotension, cerebellar ataxias)  and 
‘unexplained’ causes of dizziness.  Brain imaging was 
reviewed by a neurologist in conjunction with the neuro-
radiologist report.  WM hyperintensities in MRI (T2 weigh-
ted and FLAIR) were rated according to the Fazekas scale. 
Results: There were 61 patients (mean age=72,SD=7.95) 
in the ‘unexplained’ group and 64 (mean age=72.01, 
SD=8.28) in the ‘explained’ group. The overall frequency 
of lesions (Fazekas 1-3) differed between the unexplained 
and explained dizziness groups (p=0.015).  The frequency 
of severe lesions (Fazekas 3) was significantly higher in the 
unexplained group (21%) than in the explained group (5%); 
chi squared test, p=0.005.  Gait and postural abnormalities 
were more frequent in the unexplained group (44%) as 
compared to the explained group (25%).
Conclusion: The increased severity of WM abnormali-
ties in cases of unexplained dizziness suggests that such 
abnormalities are contributory to the development of the 
dizziness.  We postulate that WM lesions may induce diz-
ziness either because patients perceive a degree of objecti-
ve unsteadiness or by a cortical-subcortical disconnection 
syndrome. 
Disclosure: This work was supported by the Medical Re-
search Council of the U.K.
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Central paroxysmal positional nystagmus: 
characteristics and possible mechanisms
J.-Y. Choi1, M.H. Song2, J.H. Kim3, H.J. Kim4,  
S. Glasauer5, J.S. Kim6
1Ansan-si, Gyeonggi-do KP, Korea, Republic of, 2SM Chris-
tiainity Hospital, Neurology, Pohang, Korea, Republic of, 
3Korea University College of Medicine, Neurology, Seoul, 
Korea, Republic of, 4Kyungdong University, Goseong, Korea, 
Republic of, 5University of Munich, Center for Sensorimotor 
Research, Munich, Germany, 6Seoul National University 
Bundang Hospital, Seoul, Korea, Republic of
Background and aims: The diagnosis of central paro-
xysmal positional nystagmus (CPPN) is still challenging, 
and the mechanisms require further elucidation. This study 
aimed to determine the characteristics and mechanisms of 
CPPN. 
Methods: 17 patients with CPPN were subjected to analy-
ses of their clinical findings, MRI lesions, and oculographic 
data on spontaneous and positional nystagmus.
Results: The direction of CPPN was mostly aligned with 
that of the head motion during the positioning, and three 
types of CPPN were identified: downbeat nystagmus on 
straight-head hanging, upbeat nystagmus on up-righting, 
and apogeotropic nystagmus during supine head roll test. 
The direction of CPPN was aligned with the vector sum 
of the rotational axes of the semicircular canals that were 
normally inhibited during the positioning. The intensity of 
evoked nystagmus was at its peak initially and then decre-
ased exponentially over time. The time constants (TC) of 
the vertical CPPN ranged from 3 to 8 seconds, which corre-
sponds to the TC of the vertical rotational vestibulo-ocular 
reflex. Sixteen patients (94.1%) showed more than one type 
of CPPN. Furthermore, persistent downbeat or apogeo-
tropic positional nystagmus was associated in 11 patients 
(64.7%). Most patients with CPPN from a circumscribed 
brain lesion showed an involvement of the cerebellar no-
dulus or uvula. 
Conclusion: CPPN may be ascribed to enhanced responses 
of the vestibular afferents due to lesions involving the no-
dulus and uvula. CPPN could be differentiated from benign 
paroxysmal positional nystagmus by positional nystagmus 
induced in multiple planes, temporal patterns of nystagmus 
intensity, and associated neurological findings suggestive 
of central pathologies.
Disclosure: Dr. J.-S. Kim serves as an Associate Editor 
of Frontiers in Neuro-otology and on the editorial boards 
of the Journal of Clinical Neurology, Frontiers in Neuro-
ophthalmology, the Journal of Neuro-ophthalmology, the 
Journal of Vestibular Research, and the Journal of Neurolo-
gy; in addition, he received research support from SK Che-
micals, Co. Ltd.; Dr. S. Glasauer receives research support 
from the German Research Foundation and the German 
Federal Ministry of Education and Research and has served 
as a reviewer for the European Commission. He is a share-
holder of EyeSeeTec GmbH.; Others report no disclosures.
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Retinal involvement in fronto-temporal  
dementia: role of optical coherence  
tomography and clinical implications
L. Ferrari, E. Coppi, F. Vitali, G. Magnani, G. Comi,  
L. Leocani
San Raffaele Scientific Institute, Vita-Salute San Raffaele 
University, Department of Neurology, Milan, Italy
Background and aims: Frontotemporal dementia (FTD) 
is a clinical syndrome subtending a neurodegenerative 
process that involves mainly frontal and temporal lobes. 
Optical coherence tomography (OCT) is a non-invasive 
imaging technology that provides high-resolution cross-
sectional images of retinal nerve fiber layer (RNFL).
Retinal neurodegeneration has been recently identified as a 
disease-phenotype in carriers of progranulin mutations be-
fore clinical onset of dementia.
The aim of our study was to investigate RNFL thickness 
in FTD patients compared to healthy controls (HC), also 
considering clinical and neuropsychological aspects.
Methods: 10 FTD patients (5 F, mean age 65+7 years) and 
49 HC (26 F, mean age 68+7 years) underwent RNFL ex-
amination by spectral domain OCT. The two groups were 
compared through T-test, then a Pearson test was done to 
explore correlation between RNFL and age at OCT exa-
mination,  disease duration, mini-mental state examination, 
proteins total-tau, phosphorylated-tau and amyloid-beta 
I-42.
Results: RNFL was significantly reduced as for global, su-
perior and inferior quadrant, in patients compared to HC 
(p= 0.05): average 89.60+4.95 mm vs  98.37+7.46 mm; 
superior 111.20+10.62 mm vs 121.06+11.55 mm; inferior 
112.40+9.93 mm vs 125.22+12.35 mm. RNFL thickness of 
FTD patients inversely correlated with disease duration. No 
significant correlations appeared  between RNFL thickness 
and clinical-neuropsychological data.
Conclusion: Our data confirm the hypothesis of RNFL in-
volvement in FTD. Future studies on larger samples will be 
needed to further explore neuropsychological and biomar-
kers correlations and to define the value of OCT as a rapid 
and high reproducible tool to monitor FTD evolution.
Disclosure: Nothing to disclose
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Vestibulo-ocular reflex (VOR) deficit in 
spinocerebellar ataxia type 3: a possible 
disease biomarker?
C. Gordon1, A. Zivotofsky2, A. Caspi3
1Kfar-Saba, Israel, 2Bar Ilan University, Brain Science, Ra-
mat Gan, Israel, 3Sami Shamoon College, Engineering, Ash-
dod, Israel
Background and aims: Spinocerebellar Ataxia Type 3 
(SCA-3) is an autosomal dominant neurodegenerative dis-
order for which genetic testing can reveal those at risk for 
developing the disease. Quantitative measures that would 
identify pre-symptomatic gene carriers at the threshold of 
clinical diagnosis would be extremely valuable in early 
diagnosis, tracking disease progression, and assessing the 
efficacy of new treatments. Our objective was to investigate 
if eye movements can be used as biomarkers to quantify 
the appearance and progress of the disease even pre-sym-
ptomatically.
Methods: Using the magnetic search coil technique we 
recorded saccades, smooth pursuit, and VOR of 10 sym-
ptomatic SCA-3 patients and 4 subjects at risk for deve-
loping SCA-3. 3 of at risk subjects were genetically tested 
and found to have expanded “CAG” repeats in the ATXN3 
gene. The fourth is a sibling of a symptomatic MJD patient 
who has declined genetic testing. 
Results: 4 at risk subjects have a reduction in the gain of 
the VOR as measured using the head impulse test. No-
netheless, we did not find any deficit in either their saccades 
or smooth pursuit. In contrast, all of the symptomatic pati-
ents had saccadic and smooth pursuit deficits, in addition to 
impaired VOR. There was a trend of a negative correlation 
between VOR gain of the symptomatic patients and their 
ataxia score. 
Conclusion: Individuals at risk for developing SCA-3 can 
be asymptomatic for years before receiving formal clinical 
diagnosis. Our preliminary results suggest that the VOR 
changes may serve as a biomarker of the disease.
Disclosure: Nothing to disclose
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Glucorcorticoids improve dizziness  
symptoms following acute vestibular  
neuronitis
A. Batuecas-Caletrio1, R. Yañez1, C. Sanchez2,  
S. Santa Cruz Ruiz2, E. Gonzalez2, L. Guardado Sanchez2,  
D. Kaski3
1Universidad de Salamanca, Salamanca, Spain, 2Hospital 
clinico universitario de Salamanca, Salamanca, Spain, 3Impe-
rial College London, London, United Kingdom
Background and aims: Vestibular neuronitis (VN) is cha-
racterized by acute vertigo, nausea, and imbalance without 
neurological deficits or auditory symptomatology. The 
symptoms of VN gradually improve over time as a result of 
a process of vestibular compensation in a majority of pati-
ents, but a significant proportion go on to develop chronic 
dizziness. The aim of this study was to explore the effect of 
glucocorticoid treatment on the degree of canal paresis in 
patients with acute VN, and critically, to establish its relati-
onship with dizziness symptom recovery.     
Methods and Materials: We recruited consecutive pati-
ents with VN who were assigned to one of two groups ac-
cording to whether they received steroid treatment (n=32) 
or not (n=44). All patients underwent pure-tone audiomet-
ry, bithermal caloric testing, MRI brain imaging, and were 
asked to complete a dizziness handicap inventory at base-
line and just prior to hospital discharge.
Results: In the steroid group, canal paresis was significant-
ly lower than the control group (mean±SD %: 38.04±21.57 
versus 82.79±21.51, p<0.001). Similarly, patients trea-
ted with steroids acutely had less severe nystagmus upon 
leaving hospital (p=0.03). Subjective dizziness scores 
were significantly lower in the steroid group at discharge 
(mean±SD %: 23.15±12.40 versus 64.07±12.87, p<0.001).
Conclusion: Patients who received steroid treatment show-
ed greater symptomatic improvement, reduced hospital 
stay, and reduced canal paresis, than those treated conser-
vatively. The results suggest that steroids may facilitate 
central vestibular compensation and thus reduce long-term 
morbidity.
Disclosure: Nothing to disclose
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Head jolting nystagmus: head-shaking-
induced occlusion of the horizontal  
semicircular canal
A. Bronstein1, D. Kaski1, N. Cutfield2, D. Buckwell1,  
R. Banga3, J. Ray4, S. Chavda3, R. Irving3
1Imperial College London, London, United Kingdom, 2Uni-
versity of Otago, Otago, New Zealand, 3University Hospital 
Birmingham, Birmingham, United Kingdom, 4Sheffield 
Teaching Hospitals, Sheffield, United Kingdom
Background and aims: We report a new syndrome (head 
jolting nystagmus, HJN) that expands the differential diag-
nosis of head-movement induced paroxysmal vertigo.
Case Report: Two male patients (65 and 58yrs).    
Results: The patients described rotational vertigo after vi-
olent and brief (1-2s) oscillations of the head (head jolting) 
that triggered intense horizontal nystagmus lasting 45s. 
Accelerations of the head required to induce these episo-
des could only be achieved by the patients themselves. In 
Patient 1 the episodes gradually disappeared over a 6-year 
period. In Patient 2, 3-Tesla MRI suggested a filling defect 
in the left horizontal semicircular canal. He underwent sur-
gical canal plugging that resolved the symptoms. 
Conclusion: We attribute HJN to dislodged material within 
the horizontal semicircular canal, and provide a mechanis-
tic model to explain its origin.
Disclosure: Nothing to disclose
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Cryoglobulinaemic neuropathy and  
peripheral neurotoxicity of interferon- 
alpha treatment: a retrospective study.
I. Allegri1, L. Manneschi2, L. Sacchelli3, E. Montanari2,  
G. Pavesi4, F. Gemignani4
1A.O. di Parma, U.O. Neurologia, Parma, Italy, 2AUSL Parma, 
U.O. Neurologia, Fidenza (PR), Italy, 3A.O. di Parma, U.O. 
Malattie Infettive, Parma, Italy, 4Università di Parma, Istituto 
di Scienze Neurologiche, Parma, Italy
Background and aims: Neuropathy related to interferon-
alpha (IFNa) treatment for hepatitis C virus (HCV) infec-
tion has been occasionally reported, mainly in patients with 
mixed cryoglobulinaemia, as new onset neuropathy or as 
worsening of pre-existing (cryoglobulinaemic) neuropathy.
Methods: Retrospectively, we evaluated patients affected 
by cryoglobulinaemic neuropathy, examined at our Neuro-
muscular Service during the period 1998-2013, who under-
went treatment with IFNa.
Results: Among 29 patients affected by cryoglobulinaemic 
neuropathy treated with IFNa, possible neurotoxicity was 
observed in 10 patients (9 women). Apparently, in 6 ca-
ses a painful neuropathy developed during the treatment. 
4 patients had multiple mononeuropathy with sensorimo-
tor involvement: in two patients a relapse occurred during 
treatment several years after neuropathy onset, whereas in 
two patients multiple mononeuropathy appeared during the 
last months of therapy with pegylated IFNa and ribavirin. 
In the remaining 19 patients neuropathy was unchanged or 
slightly improved after IFNa therapy.
Conclusion: The reported patients had either distal poly-
neuropathy or multiple mononeuropathy, variously rela-
ted to IFNa treatment as triggering or exacerbating factor. 
Likely, clinical heterogeneity reflects different underlying 
mechanism, such as direct IFNa neurotoxicity or vasa ner-
vorum damage mediated by modification of cryocrit and 
circulating immune complexes. Although our retrospective 
study did not consent epidemiological conclusions, it is in-
triguing that worsening or new onset of neuropathy occur-
red in about one third of patients with HCV-related cryo-
globulinemia treated with IFNa. Potentials or actual IFNa 
neurotoxicity should be considere in patients with HCV in-
fection, particularly if associated with cryoglobulinaemia, 
evaluating the opportunity to utilize, in alternative, newer 
antiviral therapies.
Disclosure: Nothing to disclose
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Doppler ultrasonography findings in carpal 
tunnel syndrome: comparison of  
ultrasonographic findings with  
electrophysiological severity
N. Kutlar1, A.O. Bayrak1, I.K. Bayrak2, S. Canbaz3,  
H. Turker1
1Ondokuz mayıs university, Neurology, Samsun, Turkey, 2On-
dokuz mayıs university, Radiology, Samsun, Turkey, 3Ondokuz 
mayıs university, Public Health, Samsun, Turkey
Background and aims: Carpal tunnel syndrome    (CTS) 
is the most common entrapment neuropathy. The diagnosis 
is based on history, clinical findings, physical examination 
and electrophysiological studies. Imaging techniques are 
reserved for cases that are difficult to diagnose and also in-
formative about the morphology of the median nerve. More 
recently, it has been shown that Doppler ultrasonography 
can detect increased intraneural blood flow in CTS.  The 
aim of our study is to evaluate the relationship between the 
severity of CTS and hypervascularization and cross sectio-
nal area (CSA); and to determine the diagnostic value of 
Doppler ultrasonography for CTS. 
Methods: The patient group consisted of 125 wrists of 75 
patients who were diagnosed with CTS, both clinically and 
electrophysiologically. The control group consisted of 100 
wrists of 50 healthy volunteers. The hands were classified 
into five stages according to the electrophysiologic studies. 
A radiologist examined the groups blindly with gray scale 
and doppler ultrasonography and evaluated CSA and hy-
pervascularization.
Results:  A total of 121 wrists  were included in the study. 
The CTS stage was found to be minimal in 28 hands, mild 
in 36 hands, moderate in 36 hands, and severe in 21 hands. 
The sensitivity and specifity of CSA and hypervasculari-
zation in detecting CTS was 90.9, 94.0, 93.4 and 90.0 % 
respectively.   There was a significant correlation between 
severity of CTS and hypervascularization (p <0.05) for all 
stages of CTS.    
Conclusion: Our study suggests that the severity of CTS 
significantly correlates with Doppler sonography findings 
and this method is a useful complementary tool in identify-
ing CTS patients. 
Disclosure: Nothing to disclose
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Recurring brachial neuralgic amyotrophy 
and facial dysmorphism
S. Beltran1, B. De Toffol1, A.-M. Guennoc1, J. Laulan2,  
P. Latour3, P. Corcia1
1CHRU Bretonneau, Neurology, Tours, France, 2CHRU Trous-
seau, Orthopedic & traumatic surgery, Tours, France, 3Labo-
ratory of medical biology, multisite of Lyon, Neurobiology, 
Bron, France
Background and aims: The hereditary neuralgic amyotro-
phy is difficult to diagnose because of its clinical hetero-
geneity. We report a case linked to a SEPT9 gene mutation.
Case Report: A patient of 16 years consulted for a sharp 
pain in the left arm occurring 10 days after a trauma and 
followed three weeks later by significant difficulties in 
using his arm. Clinically, there was a motor impairment of 
the entire left arm. The amyotrophy dominated in the pro-
ximal part. The deep tendon reflexes were abolished. The 
Electroneuromyography (EMG) examination pointed to a 
bilateral brachial plexopathy that dominated in the territo-
ries of radial and circumflex nerves (and median for motor 
impairment). There were also signs of chronic denervation 
and reinnervation. The cervical spinal MRI was normal. 
The existence of a similar episode at the age of 4 years in 
the right arm, without a triggering event, associated with 
an hypotelorism, led to evoke an hereditary brachial ple-
xopathy linked to the mutation of SEPT9 gene. This diag-
nosis was confirmed by molecular biology that showed the 
p.R88W mutation.
Results: The recurring forms of brachial plexopathies are 
associated to 2 genes and 2 loci. The types related to the 
deletion of PMP-22 are associated with distal demyelina-
tion. The forms linked to SEPT9 are associated with facial 
dysmorphism that need to be searched for because of its 
association with mutation p.R88W.
Conclusion: The co-existence of painful, recurring and 
amyotrophying attack of the brachial plexus with an hy-
potelorism should lead systematically to seek the SEPT9 
mutation.
Disclosure: Nothing to disclose
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Relation between blood pressure profiles 
and functional status of Guillain-Barré 
syndrome
H.S. Lee, H.E. Lee, H.Y. Shin, S.M. Kim
Severance hospital, neurology, Seoul, Korea, Republic of
Background and aims: Autonomic dysregulation is not 
uncommon in Guillain-Barré syndrome (GBS). There is a 
paucity of information about the relation of blood pressure 
(BP) profiles and functional status of GBS patients. We ai-
med to study labile BP profiles in the early phase of GBS 
are correlated with poor functional status of plateau phase 
in GBS.
Methods: From January 2013 to August 2014, 37 patients 
with GBS were included. We analyzed BP profiles during 
initial 7 days as follows: mean BP, maximum BP, maxi-
mum BP – minimum BP, standard deviation (SD) of systo-
lic blood pressure (SBP), and coefficient of variation (CV) 
of SBP, and that of diastolic blood pressure (DBP) and heart 
rate (HR). We serially checked GBS functional status by 
GBS disability score at base line, 1 week and 1 month from 
admission. The group with poor status was defined who has 
GBS disability score as high as 4, which corresponds with 
the inability to walk. 
Results: 14 of 37 were poor status and this group had a sig-
nificantly higher maximum, maximum-minimum, SD, CV 
of SBP and HR. The analysis by tertile categorization of 
SBP, HR parameters showed a dose-response relationship 
between most of the BP parameters and functional poor 
status.
Patients demographics
Correlations between blood pressure parameters and functional status 
of GBS
Conclusion: Autonomic dysfunction occurs in approxi-
mately two-thirds of patients. Although it is still matter of 
a debate on relationship between autonomic dysregulation 
and functional status of GBS patients, this study highlight 
that variability of SBP and HR in the early phase of GBS 
is associated with functional status during plateau phase in 
GBS patients.
Disclosure: Nothing to disclose
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Leflunomide-induced painful neuropathy. 
Report of three cases with small fibre  
involvement
L. Manneschi1, V. Pietrini2, I. Allegri3, D. Santilli4,  
F. Gemignani2, E. Montanari1
1AUSL Parma, U.O. Neurologia, Fidenza (PR), Italy, 2Univer-
sità di Parma, Istituto di Scienze Neurologiche, Parma, Italy, 
3A.O. di Parma, U.O. Neurologia, Parma, Italy, 4A.O. di Par-
ma, U.O. Reumatologia, Parma, Italy
Background and aims: Leflunomide is an immunosup-
pressive drug used in rheumatoid and psoriatic arthritis. 
Occurance of polyneuropathy, usually of sensorimotor axo-
nal type, has been reported in association with leflunomide, 
ranging from 1 to 10% of treated patients.
Methods: Case reports of 3 patients with leflunomide-in-
duced neuropathy with features of painful small fibre type.
Results: Three men, aged 55, 54 and 52 years, affected 
by seronegative rheumatoid arthritis (two patients) and 
psoriatic arthritis, manifested neuropathic pain, replacing 
previous symptoms of arthritic pain, during leflunomide 
treatment at months 14, 3 and 10, respectively. Pain was 
deemed neuropathic by a clinical judgement, based upon 
the distribution of pain symptoms and the quality of sym-
ptoms, and  confirmed by a total score of at least 4/10 (the 
cut-off value for the diagnosis of neuropathic pain) in the 
DN4 questionnaire. Small fibre neuropathy was diagnosed 
in 2 patients according to clinical criteria only, i.e. presence 
of both symptoms and signs related to small fibre involve-
ment, and in one patient by skin biopsy showing decreased 
intraepidermal nerve fibre density in a non-lenght depen-
dent distribution. Nerve conduction studies were negative.
Conclusion: Small fibre neuropathy has not been previous-
ly reported in association with leflunomide, but most stu-
dies were based upon electroneurographic findings, which 
do not individuate small fibre involvement. The neuroto-
xic risk of leflunomide therapy could be underestimated, 
as symptoms related to arthritis can confound the clinical 
picture obscuring neuropathic manifestations. A focused 
clinical evaluation considering subtle sensory symptoms 
and signs, using pain instruments, should be appropiate to 
define the occurence of leflunomide neuropathy.
Disclosure: Nothing to disclose
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Genetic epidemiology of Charcot-  
Marie- Tooth disease in Hungary.
G.M. Milley1, A. Gal1, B. Bereznai1, E.T. Varga1,  
P. Balicza1, Z. Aranyi2, J. Boczan3, P.D. Dioszeghy4,  
M.J. Molnár1
1Semmelweis University, Institute of Genomic Medicine and 
Rare Disorders, Budapest, Hungary, 2Semmelweis University, 
Department of Neurology, Budapest, Hungary, 3Department 
of Neurology, Medical and Health Centre of the University of 
Debrecen, Debrecen, Hungary, 4Andras Josa Hospital, De-
partment of Neurology, Nyíregyháza, Hungary
Background and aims: Charcot-Marie-Tooth neuropathies 
(CMT) are clinically and genetically heterogeneous disor-
ders and belong to the most common hereditary neuromu-
scular diseases. This study aims to estimate the mutational 
frequency of the most common CMT gene (PMP22 MPZ, 
MFN2, Connexin 32 and EGR2) mutations among 550 
Hungarian CMT patients (249 female and 301 male, mean 
age: 40,56±16.98) and to detect two founder mutations 
(NDRG1-R148X, CCFDN-IVS6+389C>T) in 15 Roma 
patients (11 female and 4 male, mean age: 39.88±14.87). 
Methods: We performed mutational screening with MLPA, 
real-time PCR, PCR-RFLP and Sanger sequencing.
Results: The quantitative analysis of the PMP22 gene 
found 120 duplications and 77 deletions. Pathogenic mu-
tations were detected in the MPZ gene in 19, in the Cx32 
gene in 14, in MFN2 gene 5, in EGR2 gene in 3 cases and 
in PMP22 gene in 1 cases. In Roma patients LOM type 
neuropathy was present in 8, CCFDN mutation was found 
in 4 cases. In 1 family PMP22 duplication and EGR2 muta-
tion coexisted. The genetic background of neuropathy was 
clarified in 45.6% of the patients.
Conclusion: In our presentation we would like to emphasi-
ze that mutation analysis of clinically and electrophysiolo-
gically well-characterized neuropathic patients reveals the 
genetic aetiology in a relatively large percent of cases.
Disclosure: Nothing to disclose
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Electrodiagnostic criteria for Guillain- 
Barré syndrome: a need for reappraisal?
D. Parisis, G. Papadopoulos, E. Koufou, D. Karakostas
AHEPA University Hospital, 2nd Neurology Department, 
Thessaloniki, Greece
Background and aims: It has been suggested that serial 
electrophysiology is essential for the reliable differentiati-
on between acute inflammatory demyelinating polyradicu-
loneuropathy (AIDP) and acute motor axonal neuropathy 
(AMAN). However, Rayabally Y et al. recently proposed a 
modified set of neurophysiological criteria that could make 
accurate diagnosis possible with a single nerve conduction 
study. We aimed to further clarify the influence of this set 
of criteria on the classification of Guillain Barré syndrome 
(GBS) subtypes.
Methods: We retrospectively reviewed records of 37 con-
secutive patients with GBS from Thessaloniki, Greece, 
admitted to our Department between 2006 and 2013. Elec-
trophysiology was analyzed using existing criteria (Hadden 
et al. Ann Neurol. 1998) as well as the above mentioned 
criteria based on Van den Bergh criteria for AIDP (Muscle 
Nerve 2004) and incorporating new knowledge on electro-
physiology of axonal GBS. For that purpose, exclusive pre-
sence of conduction blocks or isolated F-wave absence in 
two nerves were indicative of axonopathy. 
Results: With existing criteria, patients were classified as 
having AIDP (65%), or AMAN (19%), or equivocal forms 
(16%). With modified criteria, AIDP was diagnosed in 54% 
and AMAN in 46% of patients. We observed a similar shift 
from AIDP to axonal GBS with modified criteria as that 
reported from studies that used serial nerve conduction stu-
dies (Uncini A et al., JNNP 2010)(20.8%vs 18.5%; p=0.7). 
Conclusion: These data further support the utility of these 
criteria in the diagnosis of GBS subtypes, whereas pros-
pective studies are clearly needed to verify these findings. 
Disclosure: Nothing to disclose
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A semi-automated method to assess 
IENFD in human skin biopsies
S. Seger1, M. Stritt2, K. Doppler3, C. Sommer3, A. Panaite4,  
T. Kuntzer5, A. Steck6, A. Pagenstecher7, A. Stalder1
1Allschwil, Switzerland, 2Actelion Pharmaceutical, Allschwil, 
Switzerland, 3Würzburg, Germany, 4CHUV, Neurology, Lau-
sanne, Switzerland, 5CHUV, neurology, Lausanne, Switzer-
land, 6University Hospital Basel, Department of Neurology, 
Basel, Switzerland, 7Universitat Marburg, Marburg, Germany
Background and aims: The density of Intra-Epidermal 
Nerve Fibers (IENF) in skin biopsies is increasingly used 
as support for the diagnosis of peripheral neuropathies. The 
number of IENF is counted manually under a microscope in 
most histopathology labs. Unless the images are digitized, 
there is no documentation, and the method has an inter-
rater and inter-lab variability of about 25%. Our aim was 
to develop a standardized, reproducible and documented 
semi-automated quantification of IENF density.
Methods: We analyzed samples from 4 different Universi-
ty Centers (Neuropathology/Neurology Basel, Neuropatho-
logy Marburg, Neurology Würzburg, Neurology Lausanne) 
stained according to local protocols. Images were acquired 
through the Z-plane using a whole slide scanner. ORBIT 
image analysis software was used to create an analyzable 
image and develop a reliable algorithm for IENF detection.
Results: The obtained rebuilt images revealed well-cont-
rasted nerves allowing a reliable detection of fibers cros-
sing the basal membrane (automated part). The software 
presents these nerves for quality check (manual part). Com-
pared to the conventional count performed by histo-patho-
logists (2 independent University Centers), the presented 
semi-automated method achieved a correlation coefficient 
of 0.99 and 0.96 (Spearman r-test), and an inter-facility va-
riability of 19% and 23%, respectively.  We found a better 
reproducibility for fluorescence-stained specimens. 
Conclusion: The new semi-automated method has a high 
experimenter-independent reproducibility when based on 
fluorescent nerve detection. This method is easy to handle 
even by untrained users. The IENF counting is electroni-
cally well documented 
Disclosure: Nothing to disclose
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Spontaneous intracerebral haemorrhages 
in the posterior fossa: characteristics, 
associated factors, short and long-term 
outcome
C. Rossi1, D. Strbian2, N. Samarasekera3, Y. Béjot4,  
R. Al-Shahi Salman3, M. Giroud4, T. Tatlisumak2,  
C. Cordonnier1
1University of Lille, UDSL, Inserm U1171, CHU Lille, Depart-
ment of Neurology, Lille, France, 2Helsinki University Central 
Hospital, Department of Neurology and Stroke unit , Helsinki, 
Finland, 3University of Edinburgh,, Division of Clinical Neu-
rosciences, Center for Clinical Brain Sciences,, Edinburgh, 
United Kingdom, 4University Hospital of Dijon, Department 
of Neurology, Dijon, France
Aims: To compare brainstem and cerebellar intracerebral 
haemorrhages (ICH) regarding baseline characteristics and 
outcome.
Methods: We selected patients with exclusively posterior 
fossa ICH from a cohort of 2,005 spontaneous ICH cases 
[two hospital-based cohorts (Lille, France, n=562; Hel-
sinki, Finland, n=928) and two community-based studies 
(Lothian, Scotland, n=137, Dijon, France, n=378)]. We 
performed bivariate and multivariable logistic regression 
to investigate demographic, clinical, and radiographic as-
sociations.
Results: Posterior fossa ICH was present in 208 [10%; 
95% confidence interval (CI) 9 to 11] patients; 39% were 
located in the brainstem and 61% in the cerebellum. In mul-
tivariable analysis, patients with brainstem ICH were more 
likely to have an excessive alcohol consumption (OR 7.2, 
95%CI 2.5 to 21.4) and less likely to be treated with anti-
hypertensive medications (OR=0.2; 95%CI 0.07 to 0.66). 
In-hospital case fatality rate was 43%, and was associated 
with the National Institute of Health Stroke Scale (NIHSS) 
score at presentation (OR 1.2; 95%CI 1.2 to 1.2), brainstem 
vs. cerebellar location (OR 19.8; 95%CI 2.0 to 193.2) and 
ICH volume (OR 1.1, 95%CI 1.0 to 1.2 per 1 ml increase). 
During one year of follow-up, no recurrent ICH occurred 
and survival did not differ between brainstem and cerebel-
lar ICH.
Conclusion: Brainstem ICH differed from cerebellar ICH 
regarding risk factors and early outcome, but not longer-
term outcome.
Disclosure: Nothing to disclose
P3202
Intervention versus aggressive medical 
management in carotid artery  
atherosclerosis: experience from a  
University Hospital in Hyderabad, India
K. Subhash, S. Alladi, S. Deepika, G. Sandeep
Nizam’s Institute of Medical Sciences, Hyderabad, India
Background and aims: Based on the current guideli-
nes,  interventional (surgical or endovascular)  revasculari-
zation of carotid artery stenosis is considered  superior to 
medical therapy for secondary  prevention of stroke. How-
ever, these guidelines are based on the  studies  done before 
the era of aggressive medical management. To investigate 
whether interventional (surgical or endovascular) revascu-
larization  is superior to the aggressive medical manage-
ment.
Methods: Patients of ischemic stroke and transient ische-
mic attacks due to significant carotid artery stenosis 
(>50%) were given the option of medical or interventional 
treatment in the first 3 months following the stroke. Patients 
were followed up at 3 months, 6 months and 1 year after 
stroke.
Results: Out of 53 symptomatic patients, 40 preferred 
medical management and 13 opted for interventional  ma-
nagement.  Among these,  7 patients presented with TIA 
(13.3%) and 46 patients (86.7%) with stroke. The most 
common presenting symptom was left hemiplegia in 20 
(37.7%) followed by right hemiplegia in 15 (28.3%) pa-
tients. Retinal symptoms were noted in 4 (7.5%) patients. 
Recurrence within one year was noted in 5 patients (12.5%) 
in medical management group  and 2 (15.4%) patients of 
interventional  group. One patient with recurrence  in me-
dical  group  and one patient with recurrence in surgical 
group  had poor compliance to drugs.
Conclusion: There was no statistically significant diffe-
rence in recurrence rate in medically or surgically managed 
group upto one year.   
Disclosure: Nothing to disclose
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New ultrasound ischemic leukoaraiosis 
indices, increased carotid artery stiffness 
and characteristics of cerebral  
hemodynamics in patients with ischemic 
leukoaraiosis
M. Turk1, M. Zaletel2, M. Zupan2, J. Pretnar-Oblak1,  
J. Kobal3, B. Zvan2
1University Medical Centre Ljubljana, Department of Vascu-
lar Neurology and Intensive Neurological Therapy, Ljubljana, 
Slovenia, 2University Medical Centre Ljubljana, Department 
of Vascular Neurology and Intensive Neurological Therapy, 
Ljubljana, Slovenia, 3University Medical Centre Ljubljana, 
Department of Vascular Neurology and Intensive Neurologi-
cal Therapy,, Ljubljana, Slovenia
Background and aims: The pathophysiology of ischemic 
leukoaraiosis (ILA) is unknown, but there are growing 
studies about increased arterial stiffness and changed he-
modynamic parametersof intra and extracranial arteries in 
ILA patients. However, the diagnosis so far is still based on 
head MRI and exclusion of other causes appearing radio-
logically similar.  Therefore we aimed to find vascular re-
liable markers of ILA using non-invasive widely available 
colour-coded duplex ultrasound and Trans Cerebral Dopp-
ler sonography (TCD).
Methods: We compared local carotid stiffness parameters 
and different hemodynamic parameters in the middle cere-
bral artery (MCA) in 53 LA patients to 40 gender and risk 
factor matched controls with normal MRI of the head. The 
ILA diagnosis was based on head MRI and the exclusion 
of other causes of  white matter hyperintensities.  We int-
roduced new ILA indices (ILAi) that are ration of carotid 
stiffness parameters and MCA mean blood flow velocity. 
The associations between ILAi and ILA and diagnostic si-
gnificance of ILAi for the prediction of ILA were analysed 
by SPSS 20.0 
Results: We found significantly higher values of pulse 
wave velocity beta (PWVb, m/s), pressure-strain elastici-
ty modulus (Ep, kPa) and beta index and lower diastolic, 
systolic and mean MCA blood flow velocities in the ILA 
group (p≤0.05). All ILAi significantly differed between the 
groups (p<0.05) and were significantly associated with ILA 
(p<0.01) The ROC curves showed that ILAi are sensitive 
and specific for predicting ILA (p<0.05).
Conclusion: New ILA indices are significant predictors of 
ILA and they have potentially diagnostic value in ILA pa-
tients.
Disclosure: Nothing to disclose
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Assessment and frequency of cerebral 
microbleeds in the VMCI -Tuscany Study* 
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G. Orlandi4, M. Cosottini5, A. Chiti4, U. Bonucelli4,  
D. Inzitari1, L. Pantoni1
1Florence, Italy, 2University of Florence, Department of 
Neurological and Psychiatric Sciences, Florence, Italy, 3Uni-
verstiy of Bologna, Department of Electrical, Electronic and 
Information Engineering „Guglielmo Marconi“, Cesena, 
Italy, 4University of Pisa, Department of Neurosciences, Pisa, 
Italy, 5Department of Translational Research and New Tech-
nologies in Medicine and Surgery, Pisa, Italy, Department of 
Translational Research and New Technologies in Medicine 
and Surgery, Pisa, Italy
Background and aims: Cerebral microbleeds (MBs) are 
one of the neuroimaging expressions of small vessel di-
sease. The aims of our study were to assess the reliability 
and feasibility of the Microbleed Anatomical Rating Scale 
(MARS) and describe presence and location of MBs in a 
cohort of patients with mild cognitive impairment (MCI) 
and leukoencephalopathy.
Methods: The VMCI Tuscany Study is a multicenter, ob-
servational study investigating predictors of transition from 
vascular MCI to dementia. MARS was used to assess the 
presence, number, and location of MBs. Detection of MBs 
was performed by consensus by 3 blinded raters. 20 MRI 
scans were independently reassessed by the three raters to 
evaluate inter-rater agreement (Landis and Koch, weighted 
kappa). 
Results: MRI T2*-weighted gradient-echo sequences were 
available for 152 patients. Inter-rater agreement ranged 
good-very good (weighted kappa: 0.76-1.00). 41 patients 
(27%) had at least 1 MB (mean number: 3.7±4.8; range 
1-18. MBs were located in infratentorial regions in 44% 
of patients, in deep regions in 51%, and in lobar regions in 
56%. Analyzing the possible relationship between MBs and 
other expressions of SVD, the presence of lacunar infarcts 
was associated with higher number of total MBs (p=0.008), 
particularly with those in infratentorial and deep locations 
(p=0.003 and p=0.045, respectively).
Conclusion: The MARS scale proved to be a reliable and 
feasible instrument for the assessment of MBs. Inter-rater 
agreement was good to very good. Nearly one third of our 
patients had at least one MBs, and these were associated 
with the presence of lacunar infarcts.
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Uric acid in acute ischemic stroke: the 
URICIS study
S. Vidale1, G. Carbotta2, R. Condurso3, A. Consoli4,  
F. Galati5, P. Postorino5, M. Arnaboldi1, S. Ricci3, D. Consoli5
1Sant‘Anna Hospital, Como, Italy, 2La Sapienza University, 
Rome, Italy, 3USL1 Umbria, Città di Castello, Italy, 4Univer-
sity of Florence, Florence, Italy, 5Jazzolino Hospital, Vibo 
Valentia, Italy
Background and aims: Uric acid is a potent antioxidant 
agent. However, its role in the etiology and clinical out-
come after an acute ischemic stroke is still unclear and de-
batable. Aim of this study was to evaluate the role of uric 
acid in a group of ischemic stroke patients. 
Methods: Consecutive patients admitted to two Italian 
stroke units between 2012 and 2013 have been studied. 
Demographical data, vascular risk factors, admission and 
follow-up clinical features have been registered. Uric acid, 
creatinine, glomerular filtration rate (GFR), blood urea ni-
trogen and glucose have been tested for each patient. Sta-
tistical analysis was performed using chi-square and t-test 
for univariate analysis. A conditional logistic regression 
was applied to determine the significant prognostic nega-
tive factors.    
Results: A total of 1,132 patients have been enrolled. Me-
dian age was 73 years and males were prevalent (602 ca-
ses). High blood pressure was the principal vascular risk 
factor (69%). Mean uric acid value was 5.9±4.2mg/dL and 
hyperuricemia was present in 404 patients. Hyperurice-
mia was associated to age, blood urea nitrogen and GFR 
(p>0.001). Hyperuricemic patients were mostly male and 
hypertensive (p<0.05). 
Conclusion: Hyperuricemia was present mostly in elder-
ly, hypertensive and altered renal function ischemic stroke 
patients.
Disclosure: Nothing to disclose
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Cortical venous thrombosis due to int-
racranial hypotension after an epidural 
anesthesia
E. Viedma-Guiard1, L. Crespo Araico1, P. Agüero Rabes1,  
C. Estévez Fraga1, A. De Felipe Mimbrera2,  
C. Matute Lozano1, A. Alonso Cánovas1
1Hospital Ramón y Cajal, Neurology, Madrid, Spain, 2Hospi-
tal Universitario Ramón y Cajal, Neurology, Madrid, Spain
Background and aims: Isolated cortical venous thrombo-
sis is an infrequent subtype of cerebral venous thrombosis. 
Although large sinuses thrombosis may occurr in intracra-
nial hypotension, isolated cortical venous thrombosis  are 
extremely rare in this clinical condition.
Results: A previously healthy 20-year-old woman, in her 
fourth postpartum week, was admitted because of new on-
set persistent headache. Epidural anesthesia (wet tap) was 
performed before the delivery. Since then, she referred a 
daily pulsatile holocraneal orthostatic headache (with in-
creased intensity when upright and decreased intensity 
when lying down). In addition, she had had several short 
episodes of right sided hypoesthesia during the week before 
admission. Neurologic examination, including funduscopy, 
was normal and meningeal signs were negative. Contrast-
enhanced CT scan was normal while MRI scan showed a 
cortical venous thrombosis on the left parietal convexity, 
without abnormalities in parenchyma or large venous sinu-
ses. Signs of decreased intracranial pressure were noticed, 
with descended cerebellar tonsils and generalised dural hy-
perintensity after gadolinium administration. Hypercoagu-
lability screening tests were negative and extensive ancil-
lary tests did not show any evidence of systemic disease.
Result: Clinical improvement with complete remission 
was achieved with conservative management (hydration 
and recumbent position resting).
Fig. 1. MRI: Isolated cortical venous thrombosis in the left parietal 
convexity
Fig- 2. MRI: a. Meningeal enhancement after gadolinium administration. 
b. Cerebellar tonsils descent.
Fig. 3. MRI: Reconstruction of central nervous system venous sinuses.
Conclusion: We present an unusual case of cortical venous 
thrombosis due to cerebrospinal fluid hypotension in the 
prothrombotic context of puerperium. Wet epidural punc-
tures should be closely monitored because of the risk of 
developing such complications, as our case illustrates.
Disclosure: Nothing to disclose
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Etiological and clinical features of  
hemorrhagic stroke in young adults in 
northeastern China
L. Yin, Q. Fu, C. Ma
2nd Hospital of Dalian Medical University, Department of 
Neurology, Dalian, China
Background and aims: To investigate etiological and 
clinical features of hemorrhagic stroke in young adults in 
northeastern China.
Methods: 415 hemorrhagic stroke in young adults were 
collected which were admitted to our single center over the 
past 14 years. All cases were verified by imaging exami-
nations. 201 cases received DSA. A retrospective analysis 
method was used.
Results: Of 415 cases, 263 were intracerebral hemorrhage 
and 152 subarachnoid hemorrhage (SAH). 313 cases had 
the onset in winter and spring  while 102 cases in summer 
and autumn.  Bleeding location include subarachnoid space 
in 152 cases, basal ganglion in 84 cases, cerebral lobes in 
59 cases, thalamus in 45 cases, cerebellum in 29 cases, 
brainstem in 14 cases, multiple sites in 27 cases and others 
in 5 cases. DSA demonstrated brain arteriovenous malfor-
mation (AVM) in 76 cases, intracranial aneurysm (ICN) 
in 59 cases, Moyamoya disease (MMD) in 19 cases, dural 
arteriovenous fistula (DAVF) in 3 cases and cerebral venous 
thrombosis (CVT) in 2 cases.  DSA was normal in the 
remaining 42 cases. 330 cases had a definite cause including 
essential hypertension, cerebral AVM, ICN, blood system 
diseases, MMD, perimesencephalic non-aneurysmal SAH, 
cavernous hemangioma, tumor stroke, puerperal stroke, 
DAVF, CVT, and connective tissue disease that were seen 
in 99, 76, 59, 28, 19, 15, 13, 11, 4, 3, 2 and 1 cases, res-
pectively. However, the etiology in 85 cases (20.48%) was 
unknown .
Conclusion: Hemorrhagic stroke in young adults is beco-
ming more common in northeastern China.  Essential hy-
pertension is the first cause followed by cerebral AVMs and 
ICNs. The etiology is unclear in around one-fifth cases.
Disclosure: Nothing to disclose
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Background and aims: Few studies have comprehensi-
vely assessed the characteristics of ischaemic stroke (IS) 
in young adults.     
Methods: We have prospectively studied a hospital-based 
series of 336 young adults (<45 years)  between 2005 and 
2014 with an acute IS confirmed by MRI. The patients were 
investigated by a standardized  protocol including biolo-
gical and toxicological screenings, cardiac and vascular 
check up.    
Results: Mean age was 36.8±5.5, and the sex ratio was 
1.2. As to the modifiable risk factors: tobacco use 48.5%, 
cannabis use 16.3%, and alcohol consumption 14.5%; po-
tentially modifiable risk factors: dyslipidemia 41.3%, mi-
graine 23.5%, oral contraceptive use for women 21.7%, hy-
pertension 15.7%, history of stroke 5.9%, atrial fibrillation 
and diabetes less than 5% each. 8 women out of 149 were 
pregnant having stroke. Aetiologies by frequency were the 
following: cardioembolism 27%, intracranial arterial steno-
sis 18%, cervical dissection 12.2%, isolated patent foramen 
ovale 6%, haematologic in 4%, small vessel disease and 
aneurysm less than 1% for each. In 23.5% the aetiology 
remained undetermined. Clinical outcome was favourable 
with a mean discharge NIH scale score of 2.0±2.1. At 3 
months, the mRS was inferior to 2 for 77% of patients.     
Conclusion:  We provide a description of the risk factors, 
aetiologies, clinical outcome characteristics of IS in a pros-
pective series of young patients. The distribution of aetiolo-
gies among these young adults is different from those in the 
elderly which could be explained by the higher prevalence 
of lifestyle risk factors in this population.    
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Safety of pre-operative aggressive  
antiplatelet treatment in patients with 
symptomatic carotid artery stenosis  
treated with early carotid endarterectomy.
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K. Vadikolias7, M. Lazarides3, S. Vasdekis8, G. Tsivgoulis7
1Vrilissia - Athens, Greece, 2Athens, Greece, 3Department of 
Vascular Surgery, Democritus University of Thrace, School of 
Medicine, Alexandroupolis, Greece, Alexandroupolis, Greece, 
4LOUTRAKI CORINTHIAS, Greece, 5Chaidari-Athens, 
Greece, 6Department of Vascular Surgery, “Attikon” Hospital, 
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Background and aims: The association of pre-operative 
double antiplatelet therapy with neck haematoma (NH) 
complicating early carotid endarterectomy (CEA) in pa-
tients with symptomatic carotid artery stenosis (sCAS). 
Conversely, aggressive antiplatetel therapy (AAT) has been 
shown to decrease both asymptomatic microembolization 
and recurrent cerebrovascular events during the first days 
of ictus. The aim of this prospective, multicenter study was 
to evaluate the safety of pre-operative AAT in patients with 
sCAS treated with early CEA.
Methods: Consecutive patients with non-disabling acute 
ischemic stroke (AIS) or Transient Ischemic Attack (TIA) 
due to sCAS (≥70%) were treated with clopidogrel load 
(300mg) at hospital admission followed by the combination 
of clopidogrel (75mg) and aspirin (100mg) for 1 month. All 
patients underwent early CEA during the first two weeks of 
ictus. Bleeding complications and recurrent strokes during 
the first 30 days following stroke onset were prospectively 
recorded.
Results: A total of 97 patients with sCAS [mean age 67±9 
years; 79% men; 58% AIS] underwent early CEA (median 
elapsed time from stroke onset to CEA 6 days, interquarti-
le range 4-9). The only bleeding complications that were 
documented were 6 cases of NH (6.2%, 95%CI: 2.6%-
13.1%). Re-exploration of the neck wound was required in 
two patients, while blood transfusions were administered 
in one. The rate of recurrent stroke prior to CEA was low 
(2.1%, 95%CI: 0%-7.7%). Recurrent strokes occurred du-
ring the hyperacute stroke stage (≤12 hours) in all cases.
Conclusion: Our findings underscore the safety profile of 
pre-operative AAT in patients with sCAS who are treated 
with early CEA.
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Validation of the cube test - a cognitive 
screening tool - preliminary data
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1CHEDV, Neurology, Feira, Portugal, 2Utopia, Projectos  
de Arquitectura, Porto, Portugal, 3Santa Maria da Feira,  
Portugal
Background and aims: The cube test consists of assem-
bling six identical four sided indented pieces to reprodu-
ce that geometric form in the shortest period of time. The 
task relies on visuo-constructive, executive and processing 
speed abilities, frequently impaired in the initial forms of 
the most prevalent degenerative disorders. We report the in-
itial validation of this cognitive test and relation with scores 
of other cognitive screening tests.
Methods: The test was applied in a large population-based 
cohort (EpiPorto) living in Oporto, Portugal. Time-to-first 
vertex, time-to-cube completion and number of correctly 
assembled pieces were recorded. Mini Mental state Exa-
mination (MMSE) and Montreal Cognitive Assessment 
(MoCA) were also performed.
Results: We evaluated 845 individuals (mean age 62.8 ye-
ars old; mean education 10.2 years, sd 5.6). The task was 
completed correctly by 86% of the participants. Mean time-
to-first vertex was 45 seconds (sd 42.8s) and the mean time-
to-cube completion was 97.6 seconds (sd 70.2s). Completi-
on of task, time-to-first vertex and time-to-cube completion 
were significantly associated (p<0.001) with age, education 
level, MMSE and MoCA scores. Individuals with MoCA 
scores below age/education adjusted cutoffs for the Por-
tuguese population were 15.6s slower to complete the cube 
than individuals performing above cutoffs (p<0.05). 
Conclusion: The cube test showed good usability in a po-
pulation-based cohort and the test parameters were signifi-
cantly associated with validated cognitive assessment sca-
les. Further test development and validation will be pursued 
in clinical studies to assess its feasibility as a screening tool 
for the most prevalent neurodegenerative diseases.
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Stigma of Alzheimer’s disease: what do 
professionals perceive?
L. Cartz Piver1, B. Calvet1, N. Dumoitier2, J.P. Clement1,  
P. Couratier1
1University Memory Clinic, Limoges, France, 2University of 
Medicin, Limoges, France
Background and aims: Alzheimer’s disease (AD) is a pro-
gressive neurological disorder leading to memory and cog-
nitive decline and disability. Stigma against AD contributes 
to the burden of patients and families, and adds to the strain 
of professionals involved in the management of the disease. 
Methods: Professionals of the COGLIM memory network 
of Limousin (France) filled out the STIG-MA questionnaire 
anonymously. The STIG-MA questionnaire is 10 questions 
from the EMIC (Explanatory Model Interview Catalogue, 
1992): each is scored from 0 (signifying the least stigma) to 
3 (signifying the most stigma). The sum of all the questions 
is the STIG-MA score. 
Results: 243 professionals completed the STIG-MA ques-
tionnaire. 75% were women, the average age was 48. They 
were general practicioners (GP) (14%), pharmacists (PH) 
(13%), nurses (NU) (31%), psychologists (PS) (10%) and 
others (32%). The global STIG-MA score was 9.9 (±4.8): 
the lowest stigma was expressed by the PS (8.5). Emotional 
impact (loss of self-esteem, shame) was strongly expressed 
by all the professionals, but less by GPs. Working in a re-
tirement home or training in gerontology-geriatrics did not 
influence stigma. Professionals aged over 50 expressed 
more stigma. 
Conclusion: This study shows differences in stigma of pro-
fessionals who care for AD patients. The main factor that 
seems to influence stigma is age. Further studies are neces-
sary to address this issue and to define strategies to help 
professionals in their work.
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The effects of age-related brain changes 
on mental state attribution using the  
standardized version of the story-based 
empathy task
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S. Iannaccone4, A. Marcone4, A. Falini5, D. Perani1, S. Cappa3
1Vita-Salute San Raffaele University, Milan, Italy, 2San Raf-
faele Scientific Institute, Vita-Salute San Raffaele University, 
Department of Clinical Neurosciences, Milan, Italy, 3San 
Raffaele Scientific Institute, Milan, Italy, 4San Raffaele Hospi-
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Background and aims: Normal aging is characterized by 
progressive brain volumetric reduction, mainly involving 
prefrontal, temporal and parietal regions. Since mentalizing 
partially relies on the same regions involved in age-related 
neurodegeneration, these observations suggest that a decli-
ne in the ability to understand other minds may reflect con-
comitant grey matter (GM) changes associated with aging.
Methods: To test this hypothesis we evaluated the effect 
of aging on mentalizing abilities in 34 middle-aged and 
elderly subjects (age range 43-76 years), who underwent 
a voxel-based morphometry (VBM) magnetic resonance 
imaging study and performed a task (i.e., the story-based 
empathy task) assessing the ability to infer others’ inten-
tions and emotions.
Results: VBM provided evidence of an age-related GM 
volume reduction in the frontal lobe, including the inferior 
frontal gyrus (IFG), and in temporal regions (hippocampus, 
temporal pole (TP) and superior/middle temporal gyrus). 
Moreover, while global performance was positively related 
to GM volume in the precuneus, GM volume in the left 
IFG, right superior/middle temporal gyrus and bilateral TP 
positively correlated with mentalizing performance based 
on affective cues.
Conclusion: The study shows an association between age-
related brain shrinkage in frontal and temporal structures 
and mentalizing, measured through the standardized versi-
on of a simple, non-verbal task assessing both intention and 
emotion attribution skills.
Disclosure: This work has been partially supported by the 
MIUR grant “I meccanismi neurocognitivi alla base delle 
interazioni sociali” (PRIN2010XPMFW4_008), and by the 
Università degli Studi di Milano-Bicocca CARIPLO grant 
„Dottorato ad alta Formazione in Psicologia Sperimenta-
le, Linguistica e Neuroscienze Cognitive“. Dr. Cerami was 
funded by Fondazione Eli-Lilly (Eli-Lilly grant 2011 „Ima-
ging of neuroinflammation and neurodegeneration in pro-
dromal and presymptomatic Alzheimer’s disease phases“).
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Patterns of impaired cognitive and  
affective Theory of Mind in bvFTD and  
AD patients
A. Dodich1, C. Cerami2, C. Crespi1, G. Lettieri1, N. Canessa3, 
S. Iannaccone4, A. Marcone4, D. Perani1, S. Cappa3
1Vita-Salute San Raffaele University, Milan, Italy, 2San Raf-
faele Scientific Institute, Vita-Salute San Raffaele University, 
Department of Clinical Neurosciences, Milan, Italy, 3San 
Raffaele Scientific Institute, Milan, Italy, 4San Raffaele Hospi-
tal, Milan, Italy
Background and aims: Theory of mind (ToM) can be dif-
ferently impaired in course of neurodegeneration. In this 
study, we assessed affective and cognitive ToM in a sample 
of dementia (i.e. Alzheimer’s disease (AD) and behavioral 
variant of frontotemporal dementia (bvFTD)) and prede-
mentia (i.e. amnestic mild cognitive impairment, aMCI) 
patients. The relationship between ToM sub-conditions and 
an executive control task condition was evaluated.
Methods: We enrolled 35 patients (i.e.,12 AD, 20 bvFTD 
and 15 aMCI fulfilling IWG criteria for AD in predementia 
phase) and 35 healthy controls (HC). Subjects performed 
the Story-based Empathy task (SET), a non-verbal task 
measuring the ability to infer others’ intentions (IA) and 
emotions (EA) compared to a control condition (causal 
inferences, CI). Global and single sub-condition scores as 
well as the balance between the two ToM sub-conditions 
and the control condition were evaluated with a vectorial 
approach.
Results: While dementia patients showed impaired per-
formances on all SET sub-conditions, aMCI presented no 
significant difference compared to HC. Additional analyses 
highlighted a specific impairment in the balance between 
EA and CI conditions in bvFTD.
Conclusion: Our study showed impaired intention and 
emotion attribution in AD and bvFTD with comparable 
global performances on the task. Nevertheless, the vectori-
al analysis supports a pure ToM deficit in the attribution of 
mental states based on affective cues in the bvFTD group. 
In contrast, the overall deficit in the task in AD appears to 
be related to the severity of dementia. This latter finding is 
further supported by the normal performance of the aMCI 
group.
Disclosure: This work has been partially supported by the 
MIUR grant “I meccanismi neurocognitivi alla base delle 
interazioni sociali” (PRIN2010XPMFW4_008), and by the 
Università degli Studi di Milano-Bicocca CARIPLO grant 
„Dottorato ad alta Formazione in Psicologia Sperimenta-
le, Linguistica e Neuroscienze Cognitive“. Dr. Cerami was 
funded by Fondazione Eli-Lilly (Eli-Lilly grant 2011 „Ima-
ging of neuroinflammation and neurodegeneration in pro-
dromal and presymptomatic Alzheimer’s disease phases“).
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Near-death experiences in patients with 
locked-in syndrome (LIS): not always a 
blissful journey
V. Charland1, Z. Lugo1, J.-P. Jourdan2, A.-F. Donneau3,  
V. Blandin4, F. Pellas5, S. Laureys1
1Coma Science Group, Cyclotron Research Center and Neu-
rology Department, University and University Hospital of 
Liège, Liege, Belgium, 2International Association For Near 
Death Studies, Oraison, France, 3University of Liège, Liège, 
Belgium, Department of Public Health, Liege, Belgium, 4ALIS 
- Association du Locked-In Syndrome, Boulogne-Billancourt, 
France, 5Médecine Rééducative, Hôpital Caremeau, CHU Nî-
mes, Nîmes and Association for Locked-in Syndrome (ALIS), 
Nîmes, France
Background and aims: We here aimed at retrospectively 
characterizing the content of NDEs in patients with LIS 
having suffered from an acute brainstem lesion (cerebro-
vascular accident (CVA) or trauma; i.e., “LIS NDEs”) and 
to compare these experiences to those collected in a cohort 
of NDE experiencers after coma with supratentorial lesions 
(CVA or trauma; i.e., “classical NDEs”).    
Methods: Differences between groups were assessed using 
Student’s t-test and a Pearson’s chi square test or Fisher’s 
exact test using SPSS (Chicago, IL, USA). Results were 
considered to be significant at the 5% critical level (p<0.05) 
and were expressed as mean ± standard deviation (SD) for 
quantitative variables and as counts and proportions (%) for 
categorical variables. 
Table 1- Demographical information
Results: 14 patients with LIS recalled having had memo-
ries of their coma period. 8 (57%) qualified as a NDE ac-
cording to the Greyson NDE scale criteria (i.e., total score 
≥7).  “LIS NDEs” reported less frequently feelings of 
peacefulness (96% vs. 38%, respectively, p<0.001) and joy 
(70% vs. 25%; p=0.028) and more frequently experienced 
life review during the NDE (26% vs. 75%; p=0.032).
Figure 1- Comparison of reported features according to the Greyson 
NDE scale
Conclusion: Patients with LIS who retrospectively report 
an NDE subsequent to an acute brainstem lesion of ischemic 
or traumatic origin, experience this event as less positive as 
compared to “classical” NDEs following coma after sup-
ratentorial brain damage. Less positive NDEs might have 
a specific neuroanatomical substrate related to impaired 
pontine/paralimbic connectivity or alternatively might be 
related to the emotional distress caused by the presence of 
conscious awareness in a paralyzed body.  
Disclosure: Nothing to disclose
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Memory impairment in thalamic stroke  
patients: implication of the mamillo- 
thalamic tract
L. Danet1, E. Barbeau2, P. Eustache3, N. Raposo4, I. Sibon5, 
J.-F. Albucher6, F. Bonneville7, P. Peran8, J. Pariente7
1Inserm U825 - CerCo CNRS - CHU Purpan, Toulouse, 
France, 2CerCo CNRS - CHU Purpan, Toulouse, France, 
3Inserm U825, Toulouse, France, 4CHU Purpan, neurologie, 
toulouse, France, 5CHU Pellegrin, Bordeaux, France, 6CHU 
Purpan, Neurologie, Toulouse, France, 7CHU Purpan - In-
serm U825, Toulouse, France, 8INSERM U825, neurologie, 
Toulouse, France
Background: Thalamic amnesia has been described but 
mechanisms underlying memory impairment remain equi-
vocal. It is unclear if thalamic amnesia is directly related 
to damage of some specific nuclei or indirectly related to 
mamillothalamic tract (MTT) lesion. The present study ai-
med to better understand mechanisms of thalamic amnesia.
Methods: We assessed 12 subjects with a left thalamic in-
farction. They were matched for age and education level 
to 25 controls. Subjects underwent a neuropsychological 
assessment including verbal and visual memory, executive 
functions, language and behaviour. Participants received a 
volumetric MRI scan. Patients’ lesions were manually seg-
mented and localized within the thalamus using an innova-
tive method. We then segregated the patient group in two 
subgroups: iMTT and dMTT (intact/damaged) according to 
damage of the MTT intact (iMTT) and damaged (dMTT). 
Cognitive performance was compared between patients 
and controls. We then compared cognitive performance 
between the two subgroups: iMTT and dMTT. Correlation 
between memory performance and MTT volume and medi-
odorsal volume loss were assessed.
Results: Most of the lesions were located in the mediodor-
sal and in the intralaminar nuclei. Six patients presented a 
lesion of the MTT. Patients performed worse than controls 
in verbal memory. Patients’ performance was also lower in 
executive functions. iMTT group and dMTT group differ 
in verbal recall only. A significant correlation was found 
between recall and MTT volume in the patients’ group. No 
correlation was found for mediodorsal volume loss.
Overlap of left thalamus lesions (% of patients, N=12) on axial view 
(upper, A: anterior, P: posterior). PuT: putamen, GPe: globus pallidus 
external, ic: internal capsule, R: reticular nucleus, VA: ventral-anterior, 
mtt: mamillothalamic tract, CeM: centra
Conclusion: This study shows that MTT damage play an 
important role in amnesia occurrence after a thalamic stro-
ke.
Disclosure: Nothing to disclose
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Diagnostic utility of the Clock Drawing Test 
and relationship with Alzheimer’s disease 
CSF biomarkers
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I. Santana6
1Coimbra, Portugal, 2Centro Hospitalar e Universitário de 
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3Faculty of Psychology, University of Coimbra, Coimbra, 
Portugal, 4Centro Hospitalar e Universitário de Coimbra, 
Neurology Department, Coimbra, Portugal, 5CHUC, Neurolo-
gy, Coimbra, Portugal, 6Centro Hospitalar e Universitário de 
Coimbra, Neurology, Coimbra, Portugal
Background and aims: Mild Cognitive Impairment 
(MCI) is a recognized entity representing patients with a 
significantly higher probability of developing Alzheimer’s 
disease (AD). Several neuropsychological measures have 
been studied in trying to establish the best tool to predict 
progression to AD in individuals with MCI. The diagnostic 
utility of the Clock Drawing Test (CDT) has been studied 
rather extensively but its relationship with specific AD bio-
markers remains unclear. We explored the relationship bet-
ween common cognitive screening instruments, the CDT 
and AD CSF biomarkers in a sample of MCI subjects.
Methods: 81 MCI subjects were assessed with the Mini-
Mental State Examination (MMSE), Montreal Cognitive 
Assessment (MoCA), the Alzheimer’s Disease Assessment 
Scale (ADAS) and the CDT (Rouleau, Cahn and Babins 
scoring systems). CSF parameters analyzed included Aβ42, 
Tau, phosphorylated-tau and an index which classified MCI 
patients in MCI or MCI-due to AD (according to the 2011 
McKhann criteria).
Results: 46 (56.8%) patients were classified as MCI-due to 
AD. We found significant moderate correlations between 
the all CSF parameters, except Aβ42, and the MMSE, and 
less significant correlations with the MoCA and ADAS. 
There was no correlation between the CDT and CSF bio-
markers. The MCI-due to AD group had a significantly lo-
wer performance in all tests, but there were no differences 
in CDT scores between the two groups.
Conclusion: Our results support the higher adequacy of 
specific cognitive screening instruments for the detection of 
MCI patients at higher risk for developing AD, confirming 
the low utility of the CDT in milder forms of cognitive im-
pairment where memory is the primary deficit.
Disclosure: Nothing to disclose
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Modulation of GABAA receptor signaling 
increases neurogenesis and suppresses 
anxiety through NFATc4
M. Elnaggar1, G. Quadrato2, C. Duman2
1Tübingen, Germany, 2Hertie institute for clinical brain re-
search, Tübingen, Germany
Background and aims: Correlative evidence suggests 
that GABAergic signalling plays an important role in the 
regulation of activity-dependent hippocampal neurogenesis 
as well as of emotional behaviour in adult mice.  Howe-
ver whether these are causally linked at the molecular le-
vel remains elusive. NFAT proteins are activity-dependent 
transcription factors that respond to environmental stimuli 
in different cells types, including hippocampal newborn 
neurons. 
Methods: Here we identify NFATc4 as a key activity-de-
pendent transcriptional regulator of GABA signalling in 
hippocampal progenitor cells via an unbiased high through-
put genome wide study.
Results: Next, we demonstrate that GABAA receptor si-
gnalling modulates hippocampal neurogenesis through 
NFATc4 activity, which in turn regulates GABRA2 and 
GABRA4 subunit expression via binding to specific promo-
ter responsive elements as assessed by ChIP and luciferase 
assays. Furthermore, we show that selective pharmacolo-
gical enhancement of GABAA receptor activity promotes 
hippocampal neurogenesis via calcineurin/NFATc4 axis. 
Importantly, NFATc4 dependent increase in hippocampal 
neurogenesis following GABAA receptors stimulation 
is required for the suppression of the anxiety response in 
mice.
Conclusion: Taken together, these data provide a novel 
molecular insight into the regulation of the anxiety respon-
se in mice suggesting GABAAR/NFATc4 axis as a drug-
gable target for the therapy of emotional disorders.
Disclosure: This research have been performed by grants 
from DFG and Fortune grant from the University of Tü-
bingen.
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Continuous electrodermal activity in  
comatose survivors after a cardiac arrest: 
a potential new biomarker for prognosis?
V. Alvarez1, C. Reinsberger2, B. Scirica3, M. O‘Brien3,  
K. Avery4, G. Henderson5, J. W. Lee6
1Sion, Switzerland, 2Universität Paderborn, Sportmedizini-
sches Institut, Paderborn, Germany, 3Brigham and Women’s 
Hospital, Department of Cardiology, Boston, USA, 4Brigham 
and Women’s Hospital, Department of Nursing, Boston, USA, 
5Brigham and Women’s Hospital, Department of Neurology, 
Boston, USA, 6Brigham and Women’s Hospital, Neurology, 
Boston, USA
Background and aims: Electroneurophysiology is impor-
tant for prognostication after cardiac arrest (CA). While it 
is possible to identify accurately patients with bad outco-
mes, it is still difficult to predict who will recover. Autono-
mic dysfunction measured by electrodermal activity (EDA) 
may reflect the depth of coma and could represent a new 
biomarker. Continuous EDA recording through is investi-
gated in this setting.    
Methods: In this prospective study, EDA was recorded 
continuously, during therapeutic hypothermia and normo-
thermia, in comatose adult patients after cardiac arrest.  A 
novel wrist-worn skin conductance biosensor incliding two 
silver coated electrodes applied on the wirst was used. As-
sociation between EDA parameters and later signs of awa-
kening from coma were assessed. 
Results: 18 patients were enrolled. Recordings started at 
a median of 18.4 hours (range: 8 - 41) after CA and lasted 
43.45 hours (0.3 – 68.3) (see example in Figure 1). All pha-
sic EDA parameters, also know as “electrodermal respon-
ses” (EDR), during TH were associated with outcome. A 
higher number of EDR and higher median amplitudes were 
seen in patients with later awakening from coma (see Table 
1 and Figure 2). The tonic parameter, or the base line, was 
similar in both groups.    
Figure 1: A: View of the complete display with the 24 hours record on 
the bottom and the “zoom” widow on the top right (2 min/page) show-
ing two electrodermal responses during endotracheal tube aspiration 
and their measurement. 
Figure 2: Comparison of patients who remained comatose with the 
ones with signs of awakening from coma using boxplots of EDA para-
meters during therapeutic hypothermia. The first line displays the 
number of electrodermal response / 24 hours and the second 
Table 1: Comparison of patients that remained comatose and dose that 
showed signs of awakening from coma regarding electrophysiology 
(EEG and EDA) during hypothermia and normothermia
Conclusion: Continuous electrodermal recording may be a 
new neurophysiologic biomarker of awakening from coma 
after CA, with many EDA features being different between 
patients with signs of awakening from coma from and those 
remaining comatose. Because this technology is conveni-
ent to implement in the intensive care unit, it may open a 
new field in brain function monitoring in neuro-critically 
ill patients.    
Disclosure: I was funded by the Swiss National science 
Foundation, grant: P2GEP3_148510 and the Gottfried und 
Julia Bangerter-Rhyner Foundation
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Predictors of cognitive outcome in  
traumatic coma patients
N. Khizanishvili, M. Khaburzania, T. Kherkheulidze,  
M. Beridze
Tbilisi State Medical University, Neuromedicine, Tbilisi, 
Georgia
Background and aims: To investigate the possible predic-
tors of cognitive outcome in patients recovered from trau-
matic coma. 
Methods: Totally 75 traumatic coma patients investigated. 
Consciousness rated by Glasgow Coma Scale (GCS). Vege-
tative state (VS) and minimally conscious state (MCS) dia-
gnosed according to international criteria. Coma recovered 
patients accessed by Disability Rating Scale (DRS).  Cog-
nitive status evaluated by Mini Mental Examination Scale 
(MMSE).  Patterns of EEG background activity detected 
by 16 channel EEG. Brain conventional CT or MRI (1.5 
T) was done in all patients. Auditory long latency evoked 
potentials (ALLEP) were studied by 16 channel EEG with 
regime for evoked potentials. Statistical analysis performed 
by SPSS 11.0.
Results: At one month 26 coma patients (GCS= 4-7) with 
alpha and delta EEG patterns died, 24 patients (GCS=5-8) 
with beta (33.4%), delta (25%) and theta (41.6%) coma de-
veloped VS.  Among them14patients detected to have MCS 
and 11patients  showed ALLEP (GCS=4-8) with theta EEG.
Another 25 (GCS=5-8) patients with beta (28%), theta 
(54%) and delta (18%) background EEG recovered with 
different DRS (2-14) and MMSE (14-20). Positive correla-
tion established between MCS patients with high amplitude 
frontal and temporal lobe theta frequencies and ALLEP (P-
300) (r=+0.47; p<0.01). Logistic regression (entered step-
wise model including patients’ age, brain lesion size and 
site, EEG pattern, GCS, DRS) toward MMSE revealed the 
significance of high amplitude theta EEG (p<0.00) after
adjustment with ALLEP (P-300).
Conclusion: The high amplitude theta background EEG 
with positive ALLEP is significant for favorable cognitive 
outcome in traumatic coma patients.
Disclosure: Nothing to disclose
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Active and passive paradigms of  




Background and aims: Active and passive paradigms 
based on functional Magnetic Resonance Imaging (fMRI) 
and electroencephalography (EEG) may reveal conscious-
ness in vegetative (VS) or minimal conscious states (MCS). 
Whereas active paradigms suggest a higher degree of cer-
tainty, passive paradigms may allow detecting signs of 
consciousness in patients who are unable to cooperate in 
cognitive tasks. A meta-analysis was performed in order to 
assess whether the clinical diagnosis is accurately reflec-
ted by signs of consciousness revealed by fMRI and EEG, 
including command following (active paradigms) and pre-
served cognitive event-related potentials and/or relevant 
cortical activation (passive paradigms).
Methods: Eligible studies were selected from multiple in-
dexing databases through December 2014 and evaluated 
using standardized systemic review methods.
Results: 31 studies were identified, including data from 913 
patients (mean age 43 years, range 16 to 89; male/female 
2.1:1; 39.5% traumatic brain injuries). MCS patients were 
more likely than VS patients to follow commands during 
active paradigms (32% versus 15%; odds ratio 2.68 (95% 
CI 1.76-4.07; p<0.0001)) and to show preserved cortical 
connectivity during passive paradigms (68% versus 26%; 
odds ratio 5.9 (95% CI 4.0-8.66; p<0.0001)).
Conclusion: In non-communicating patients, active para-
digms may underestimate the degree of consciousness as 
compared to passive paradigms. While MCS patients are 
more likely to show signs of preserved consciousness in 
both paradigms, a significant number of VS patients are 
able to follow commands by modifying their brain activity. 
However, there are important limitations at the single-sub-
ject level; for instance, patients from both categories may 
show command following although passive paradigms are 
negative.
Disclosure: Nothing to disclose
384      Poster presentation with discussion
© 2015 European Journal of Neurology, 22 (Suppl. 1), 120–483
P3221
Predictive risk factors for delayed  
neurologic sequelae after carbon  
monoxide poisoning
H. Kuroda1, K. Fujihara2, S. Kushimoto3, M. Aoki1
1Tohoku University Graduate School of Medicine, Department 
of Neurology, Sendai, Japan, 2Tohoku University Graduate 
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Background and aims: Delayed neurologic sequelae 
(DNS) is a relapse of neurologic deficits after carbon mon-
oxide (CO) poisoning. Although several studies mentioned 
the risk factors associated with DNS, reliable predictive 
risk factors have not been established. We aimed to reveal 
predictive risk factors for DNS.
Methods: This study was designed as a prospective, ob-
servational study. We analysed clinical and laboratory data 
of patients experiencing acute CO poisoning. The patients 
were followed until 3 months after acute poisoning. We ca-
tegorised patients showing a relapse of neurologic deficits 
as patients with DNS, and patients showing no deficits as 
patients without DNS.
Results: Of 93 patients experiencing acute CO poisoning 
[median, 46 years; 72% male], 16 patients (17%) develo-
ped DNS, and 77 (83%) did not. By univariate analyses, 
predictive risk factors for DNS were the lowest score of 
Glasgow Coma Scale <10, duration of CO exposure >6.25 
hours, duration of consciousness disturbance >24.5 hours, 
globus pallidus lesion on brain CT, white blood cell count 
>11,900, CRP >0.15, CK >514, serum bilirubin index, de-
fined as [(bilirubin at 24-48 hours after acute poisoning) / 
(bilirubin within 12 hours after acute poisoning)], <1.056. 
By logistic regression analyses, [odds ratio, 95% confident 
interval, P-value] were globus pallidus lesion [17.8, 2.13-
238, 0.0069], CRP >0.15 [16.8, 2.32-347, 0.0039], and se-
rum bilirubin index <1.056 [19.4, 3.24-173, 0.0009].
Conclusion: The knowledge about the predictive risk fac-
tors for DNS will be useful for risk stratification of patients 
experiencing acute CO poisoning.
Disclosure: This study was supported by Grants-in-Aid 
for scientific research (grant number 24592728) from The 
Ministry of Education, Science, and Technology of Japan.
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Air bubbles in the air: cerebral air  
embolism in commercial flights
B. Oyanguren1, A. Alonso Cánovas2,  
A. De Felipe Mimbrera3, I. Hernández Medrano3,  
V. Sánchez González4, I. Prieto5, J.C. Martinez Castrillo3,  
J. Martínez San Millán6, I. Corral Corral3,  
J. Masjuan Vallejo2, A. Escobar-Villalba2
1Hospital Universitario de Torrejón, Neurology, Madrid, 
Spain, 2Hospital Ramón y Cajal, Neurology, Madrid, Spain, 
3Hospital Universitario Ramón y Cajal, Neurology, Madrid, 
Spain, 4Hospital General Virgen de La Luz, Neurology, Cuen-
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Background and aims: Cerebral air embolism (CAE) may 
exceptionally occur in patients with thoracic lesions during 
air travelling. The risk for this complication and prognostic 
factors are unknown.
Methods: We present 3 new cases of CAE during commer-
cial flights and a review of literature.
Results: 3 patients with CAE have been admitted to our 
Emergency Department: two males (B, C), one female (A). 
All experienced loss of consciousness (LOC) early in the 
course of a commercial flight with subsequent seizures. 
Chest radiograph showed thoracic bullae in all cases. Brain 
computed tomography (CT) scan showed subarachnoid 
bubbles in A, several intraparenchymal bubbles in B, and 
global hypoperfusion on multimodal CT in C. Magnetic 
resonance imaging was normal in A, showed bilateral in-
farctions and edema in B, and diffuse edema with posterior 
ischemic lesions in C. All received supportive treatment. A 
and C survived, B died. Including ours, 14 cases (7 female, 
mean age 55, 19-71) of CAE associated with commercial 
flights have been reported. LOC and dyspnea early in the 
flight were common. Thoracic cysts (7) and bullae (7) were 
found. 5 received hyperbaric oxygen therapy. 9 died, 2 re-
mained moderate-severely disabled. In the 3 patients with 
complete recovery, infarction, edema and intraparenchymal 
bubbles were absent in basal neuroimaging. 5 patients had 
previously experienced neurological problems onboard.
Conclusion: CAE is an infrequent but serious complication 
of air travelling increasingly recognized. Neuroimaging 
findings may constitute a prognostic factor.
Thoracic cystic lesions bear a risk for CAE which has not 
been estimated.
Diagnosing non fatal CAE may help prevention.
Disclosure: Nothing to disclose
© 2015 European Journal of Neurology, 22 (Suppl. 1), 120–483
Poster presentation with discussion      385
P3223
Comparison of interrater reliability and 
predictive validity of FOUR score and 
Glasgow Coma Scale in multi traumatic 
patients
F. Seifar1, S. Shams Vahdati2
1students research committee,Tabriz University of medical 
Sciences, Tabriz, Iran, 2Tabriz, Iran
Background and aims: Multi traumatic injuries impo-
se health care concern and major burden for society. The 
Glasgow Coma Scale (GCS) is a routine scale for assessing 
levels of consciousness and prognosis of traumatic patients. 
The Full Outline of UnResponsiveness (FOUR) score is a 
new coma scale developed to overcome the limitations of 
GCS. In this prospective study we aimed to compare the 
predicting outcomes and inter-rater reliability of the GCS 
and FOUR score in a group of multi traumatic patients. 
Methods: 96 consecutive muti traumatic patients admitted 
emergency department were enrolled in the study. GCS and 
FOUR score were documented on arrival to emergency 
room. Their correlation with patients ‘outcomes was ana-
lysed. Inter-rater reliability was also assessed using κ score.
Results: In terms of predictive power for in-hospital mor-
tality, calculated mortality rate was 33.1 for FOUR score 
and 30.21 for GCS. Mean value of GCS and FOUR score 
were 14.83 and 13.68, respectively. Mortality rate was de-
termined 9.3% and mean duration of hospitalisation was 
7.86±8.73 days. In addition, inter-rater reliability was de-
termined κ=0.84±0.01 for GCS score and κ=0.86±0.01for 
FOUR score rating. Inter-rater reliability and outcome pre-
dictability for FOUR score was superior to the GCS in this 
study, therefore FOUR score can be considered as a viable 
alternative to the GCS in emergency department by accura-
tely predicting outcome and improving the quality of ma-
nagement in traumatic patients.
Disclosure: Nothing to disclose
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Background and aims: We have quantified usage of am-
plitude integrated electroencephalography (aEEG and neu-
rosonography (NS) in newborns  treated with moderate 
hypothermia (during 72 hours) after sever asphyxia for 
short-term outcome prediction in newborns.
Methods: 40 term neonates with severe perinatal asphy-
xia were cooled in NICU of City Children’s Hospital 
(Sept. 2011 – Oct. 2012). All children were monitored by 
one-channel aEEG: after arrival at NICU, 24-48 hours of 
life, 3-5 days of life (70% of newborns). NS was made for 
all patients on 3-5, 7-10 and 28 days of life. Outcomes was 
estimated on 28-30 d of life. Spearman rank correlation and 
line regression analysis were developed to assess NS and 
aEEG at 3-6 hours, 24 and 72 after asphyxia as predictors 
of short-term outcome.
Results: Apgar score was 1 and 4 (median) at 1 and 5 mi-
nutes, respectively. Duration of mechanical ventilation was 
10.1±1.8 days, length of hospital stay was 32.6±3.4 days. 
10 patients (25%) by the end of the neonatal period had 
unfavorable outcome (death(5%)/ vegetative state/ forming 
spastic tetraparesis + somnolence). Correlation of severity 
of hypoxic-ischemic encephalopathy (HIE) and pattern of 
aEEG conducted at the age of 1 day (р<0.0001; r=0.70) 
and 3-5days (р=0.01; r=0.52) was found. For aEEG con-
ducted on admission correlation with clinical severity is 
not revealed. The most predictive indicator for NS was the 
presence of ischemia of the basal ganglia(3-5days of life) 
(р=0.03; r=0.40).
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Conclusion: Using NS (evaluating “status marmoratus”) 
and aEEG after 24 hours of life can help to predict unfavo-
rable outcome in the end of neonatal period of term new-
borns with HIE treated with hypothermia. Moderate hypo-
thermia is safe and effective.
Disclosure: Nothing to disclose
P3225
The electroencephalogram as a predictor 
of somatosensory evoked potentials in  
patients with impaired consciousness
J. Vynckier1, M. Schrooten2
1Scherpenheuvel, Belgium, 2University Hospitals Leuven, 
Neurophysiology, Leuven, Belgium
Background: To identify a correlation between the pattern 
on electroencephalography (EEG) and the presence or ab-
sence of the N20 response on somatosensory evoked poten-
tials (SEP) in coma patients.
Methods: We conducted a retrospective analysis to iden-
tify all patients who were admitted to an ICU and received 
both EEG and SEP for prognostic evaluation. EEGs were 
categorized according to Young’s classification, SEPs were 
divided into three categories according to the presence or 
absence of the N20 response. Functional outcome at six 
months was categorized according to the Glasgow Out-
come Scale. Primary outcome was the correlation between 
the EEG and SEP category. Secondary outcomes were cor-
relation between the results of electrophysiological investi-
gations and the functional outcome.
Results: We identified 2380 patients over a period of 16 
years. For practical reasons, the 120 patients who were ad-
mitted in the last two years were the subject of our study. 
Overall mortality at six months was high in our populati-
on with 85%. Inter-rater variability for the EEG readings 
was excellent with a kappa value of 0.76. Correlation of 
EEG and SEP category was significant with rs of 0.519 
(P<0.001). Negative predictive value for unilaterally as 
well as bilaterally absent N20 response was 100%.
Conclusion:  For coma patients who receive predictive 
evaluation with both EEG and SEP, a strong correlation 
exists between the EEG pattern and the N20 response. The 
unilateral absence of an N20 response is almost as robust 
a predictor of poor functional outcome as bilaterally absent 
N20 responses. 
Disclosure: Nothing to disclose
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A long-term experience of monotherapy 
in a tertiary epilepsy center: comparison 
between oxcarbazepine and levetiracetam
B.S. Kang, S.K. Lee
Seoul, Korea, Republic of
Background and aims: To evaluate and compare the long-
term efficacy and safety of oxcarbazepine (OCB) and leve-
tiracetam (LEV) based on a large population of patients at a 
tertiary epilepsy center.
Methods: All patients who were using OCB or LEV at the 
Seoul National University Hospital between January 2007 
and March 2009 were recruited. Patients who had received 
brain surgery for seizure control or who had associated pro-
gressive disease were excluded from this study.
Results: A total of 307 patients were recruited. 158 of the 
177 patients treated with OCB and 58 of the 130 patients 
treated with LEV had localization-related epilepsy (LRE). 
In the LRE subgroup, 86 patients (54.4%) with OCB and 
36 patients (52.9%) with LEV remained seizure free during 
the follow-up period (P=0.837). LEV was also effective 
for juvenile myoclonic epilepsy (57.1% seizure-free rate) 
and epilepsy with generalized tonic–clonic seizure (62.5% 
seizure-free rate). The 3-year retention rates in patients tre-
ated with OCB and LEV were not significantly different 
(81.4% vs 72.1%; P=0.781). General weakness (11.9% vs 
4.6%; P=0.027) and skin rash (4.0% vs 0%; P=0.022) were 
more frequent in the OCB group, whereas irritability (0.6% 
vs 33.8%; P<0.001) was more frequent in the LEV group. 
Conclusion: OCB and LEV were effective and safe as a 
monotherapy for partial epilepsy. LEV was also effective 
for the treatment of generalized epilepsy. 
Disclosure: Nothing to disclose
P3227
Ictal cardio-respiratory depression:  
a real risk for SUDEP?
E. Pasini1, F. Provini1, L. Volpi2, R. Michelucci2
1Department of Biomedical and Neuromotor Sciences, Alma 
Mater Studiorum, University of Bologna, Bologna, Italy, 
Bologna, Italy, 2IRCCS of Neurological Sciences of Bologna, 
Bellaria Hospital, Bologna, Italy
Background and aims: Cardio-respiratory dysfunctions 
during epileptic seizures have been extensively investiga-
ted during the last years as a possible risk factor for SUDEP 
(Sudden Unexpected Death in Epilepsy).
Here we report a 60-year-old woman affected by focal 
cryptogenetic left fronto-temporal lobe epilepsy associated 
with ictal asystole and central apnea.
Case Report: The patient underwent prolonged video-
polygraphic (EEG-ECG-respiratory) monitoring in the te-
lemetry unit because of a 58-year history of hypermotor 
nocturnal seizures preceded by epigastric discomfort and 
associated, in the last 25 years, with choking sensation.  
Results: We recorded several sleep-related seizures ari-
sing from the left fronto-temporal regions complicated by 
asystole (max 12s) and prolonged central apnea (more than 
30s). The patient was rapidly implanted with pace-maker 
(PM). Repeat post-implant monitoring demonstrated the 
persistence of ictal apnea concomitant to the activation of 
PM, in the absence of significant hypoventilation.
Conclusion: Our case highlights the possibility of huge 
cardio-respiratory dyscontrol during ictal discharges, 
which might be fatal in some patients. However the life-
long history of dysautonomic ictal symptoms in our patient 
seems to challenge the usefulness of PM implant and assis-
ted ventilation in such conditions. 
Disclosure: Nothing to disclose
388      Poster presentation with discussion
© 2015 European Journal of Neurology, 22 (Suppl. 1), 120–483
P3228
Two-year real-world experience of  
perampanel in elderly patients with  
refractory focal epilepsy
A. Rohracher, I. Deak, J. Dobesberger, J. Höfler, G. Kalss,  
G. Kuchukhidze, M. Leitinger, E. Trinka
Paracelsu Medical University Salzburg, Department of Neu-
rology, Salzburg, Austria
Background and aims: Elderly adults >60 years have a 
high incidence of epilepsy and seizure recurrence. Choice 
of antiepileptic drug (AED) in this group is influenced by 
seizure type, tolerability and comorbidities. Real-life data 
were used to investigate treatment response and adver-
se events (AEs) with perampanel in the elderly versus a 
younger population.
Methods: Clinical registry data for elderly patients (>60 
years) were compared with those <60 years from a cohort 
of 85 adults with focal onset epilepsy who have received 
perampanel since 09/2012. Treatment response and AEs 
are reported according to age group, while controlling 
for perampanel dose and concomitant anti-epileptic drugs 
(AEDs).
Results: 20 elderly patients (7 female; mean age 69.8 ye-
ars, SD 11.5) and 65 younger patients (39 female; mean 
age 36.8 years; SD 11.5) were included. Over 57 months, 
75% (15/20) elderly patients and 53.8% [35/65] younger 
patients were still taking perampanel. 35% (7/20) elderly 
patients were seizure free compared with 13.8% (9/65) 
younger patients (p=0.009). 35% (7/20) of elderly patients 
experienced AEs compared with 55.4% (36/65) younger 
patients (p=0.563). Speech effects (30%) and fatigue (20%) 
were the most common adverse effects in the elderly group, 
while vertigo (40%) and psychiatric effects (9.2%) were 
most common in younger patients.
Conclusion: Perampanel efficacy and tolerability in the 
elderly population mirrors that seen in younger patients. 
These real-life data suggest a broad patient base for whom 
perampanel may be a useful add-on treatment, potentially 
leading to improved safety, independence and quality of 
life in elderly patients. 
Disclosure: A. Rohracher received travel support from EI-
SAI.
P3229
Familial cerebral cavernomas:  
identification of a novel KRIT1 gene  
mutation
I. Rosário Marques, F. Antunes, N.E.T. Ferreira,  
M.D. Grunho
Almada, Portugal
Background: Cerebral cavernomas are vascular malfor-
mations that may occur in sporadic or familial forms. Fa-
milial forms have autosomal dominant inheritance, wherein 
three genes have been identified: KRIT1/CCM1, CCM2 
and PDCD10/CCM3.
Case Report: A 31-year-old previously healthy female 
presented with a three years’ duration epileptic disorder, 
with daily complex focal seizures characterized by altered 
consciousness, manual and oromandibular automatisms, 
and automatic speech. Subsequent brain MRI revealed nu-
merous bilateral cortical cavernomas, and the EEG docu-
mented right temporal focal paroxysmal activity. Seizure 
control was achieved with antiepileptic duotherapy. The 
proband’s 50-year-old mother was found to have a history 
of focal seizures initiated at age 13 and surgical excision of 
a cortical cavernoma at age 27, with a subsequent seizure- 
and medication-free period of 8 years. Seizures, characte-
rized by disturbance of consciousness and right upper limb 
dystonic posturing, restarted at age 35 and fully remitted 
with carbamazepine. Brain MRI showed multiple encepha-
lic cavernomas. The genetic testing for familial forms of 
cerebral cavernomas detected, in both patients, a heterozy-
gous mutation in KRIT1 gene, consistent with the diagno-
sis of Hereditary Cerebral Cavernous Malformation type 
1. This mutation, c.947_948insAC(p.Leu317Argfs*2)-
exon10, is not yet described in the literature.
Conclusion: The pathogenic KRIT1 mutation identified in 
this family is not yet described in the literature. The careful 
and thorough follow-up of patients, and respective families, 
with multiple cerebral cavernomas is essential for the cli-
nical, imaging and genetic characterization of this disease, 
particularly while trying to identify the factors that influ-
ence its treatment and prognosis.
Disclosure: Nothing to disclose
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Inflammation and apoptotic markers in 
adult patients with epilepsy: is there any 
link?
A. Kegler1, R.S. Scalco2, C. Almeida1, D. Santana1,  
E.T. Pascotini1, J. Arend1, P. Gabbi1, I.B. da Cruz1,  
M.M. Duarte1, L.F. Royes1, M.R. Fighera1
1Universidade Federal de Santa Maria, Santa Maria, Brazil, 
2University College London, London, United Kingdom
Background and aims: Epilepsy in adult people is gene-
rally a chronic disorder frequently associated with a variety 
of factors. We aimed to investigate if there is a link between 
neuroinflammation, apoptotic markers and oxidative mar-
kers in epilepsy pathophysiology.
Methods: A cross-sectional study of 43 patients presen-
ting with epilepsy and a control group of 41 healthy people 
was performed. Inflammatory markers, apoptotic markers 
and DNA damage were evaluated and included TNF-alpha 
(TNF-α), caspase-3 (CASP-3) and PicoGreen (PG). A cor-
relation between inflammatory and apoptotic markers were 
analysed.
Results: Statistical analyses showed that patients with epi-
lepsy presented higher levels of TNF-α (p<0.001) as com-
pared to the control group. We observed that patients with 
epilepsy had significantly higher serum CASP-3 (p<0.001) 
and PG (p<0.001) than the control group. Statistical analy-
sis revealed a significant correlation between inflammatory 
and apoptotic markers in the epilepsy group (p<0.05).
Conclusion: These findings suggest an important link bet-
ween inflammatory and apoptotic markers and epilepsy in 
the studied sample.
Disclosure: Nothing to disclose
P3231
Prescribing for epilepsy in adult patients 
with an intellectual disability and/or  
pervasive developmental disorder:  
a systematic review
Z. Doran1, R. Shankar1, L.J. Sander2, W. Lee3, C. Dale4,  
M. Kerr5, L. Richard6, B.N. McLean7, J. Devapriam8,  
K. Wilson9, J. Craig10, M.C. Walker2, R. Hillier11, D. Cox9, 
M.J. Sadler12, M. Mohan13
1Cornwall Partnership NHS Foundation Trust, Neuropsych-
iatry, Truro, United Kingdom, 2London, 3Plymouth Univer-
sity, Peninsula Schools of Medicine & Dentistry, Plymouth, 
United Kingdom, 4Cornwall Partnership NHS Foundation 
Trust, Research, Truro, United Kingdom, 5Cardiff University, 
Psychological Medicine and Clinical Neurosciences, Cardiff, 
United Kingdom, 6Cornwall Partnership NHS Foundation 
Trust, Psychiatry, Truro, United Kingdom, 7Truro, 8Leices-
tershire Partnership NHS Trust, Acute & Low Secure Mental 
Health Services, Leicestershire, United Kingdom, 9Cornwall 
Partnership NHS Foundation Trust, Truro, United Kingdom, 
10Belfast, 11United Kingdom, 12Plymouth, 13North Bristol NHS 
Trust, Bristol, United Kingdom
Background and aims: About a quarter of people with epi-
lepsy (PWE) have intellectual disability (ID) and/or Perva-
sive Developmental Disorders (PDD) such as autism. This 
group has higher mortality, significant communication is-
sues, difficulties making informed choices and greater risks 
of chronic physical and mental health co-morbidities. There 
is no specific prescribing guidance for this cohort of PWE 
and ID. We aimed to systematically review the literature 
on Anti Epilepsy Drug (AED) prescribing in this group, in 
particular examining different needs of the ID population.
Methods: We undertook a literature review using the 
search engines PubMed/Medline, EMBASE, PsychINFO 
and Google-scholar to identify a current evidence base for 
AED prescribing in PWE and ID, PDD and associated ge-
netic syndromes.
Results: The search strategy returned 224,817 results. Of 
these 45 were included for analysis. 17 were systematic re-
views, 16 cohort studies, 6 randomised control trials and 4 
case control studies. 224, 772 were excluded due to small 
sample size or irrelevance.
Conclusion: PWE and ID/PDD tend to have various men-
tal health and physical health co-morbidities and as a re-
sult can respond differently to medications when compared 
with the general population. The review identified very few 
studies which looked systemically at the influence of AEDs 
in PWE and ID/PDD. In the last 15 years there is no major 
research looking at the influence of the newer AEDs in this 
vulnerable population. In addition to the lack of research, 
no structured method exists for safely and effectively exa-
mining the safety of new AEDs in populations with an ID/
PDD.
Disclosure: Nothing to disclose
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P3234
Help-seeking for mood problems in  
people with Parkinson’s disease:  
A qualitative analysis
A. Simpson1, M. Samuel2, R. Brown1
1King’s College London, Institute of Psychiatry, Psychology 
& Neuroscience, Psychology, London, United Kingdom, 2East 
Kent University Hospitals NHS Foundation Trust/King’s Col-
lege Hospital, Neurology, Ashford/London, United Kingdom
Background and aims: Mood problems in Parkinson’s di-
sease (PD) are often as, if not more, disabling than motor 
symptoms and can affect between approximately 30-50% 
of patients. However, patients with these problems often 
do not receive effective treatment. Reasons for this include: 
patients not reporting such problems, and issues surround-
ing illness beliefs and treatment preferences. Help-seeking, 
or actively seeking help for a problem, is influenced by 
these factors. Currently, there is little understanding of the 
help-seeking behaviour of people with Parkinson’s (PwP) 
for mood problems. The objective of this study is to un-
derstand the factors associated with help-seeking for mood 
problems in PwP, from the patient and carer perspective.
Methods: In-depth qualitative interviews were conducted 
with 10 PwP and 10 carers of PwP, and analysed using the-
matic analysis. Demographic, mood and PD related infor-
mation was also collected to characterise the sample.
Results: Six major themes relating to help-seeking were 
identified in the sample: 1) causes of mood problems, 2) the 
meaning of depression and anxiety, 3) the source of help, 
4) attitudes about treatment, 5) coping strategies, and 6) re-
lationship with the clinician. Thematic differences between 
help seekers and non help seekers were identified.
Conclusion: Specific attitudes, knowledge and preferences 
to mood problems and treatment thereof were identified in 
this sample. Understanding how these factors facilitate or 
hinder help-seeking will allow us to develop interventions 
to encourage help-seeking behaviour and ultimately impro-
ve mood problems in these patients.
Disclosure: This research is supported by an East Kent 
Hospitals University NHS Foundation Trust R&D grant 
scheme.
P3235
Look, don’t look, look close:  
video-oculographic abnormalities in  
functional movement disorders
M. Slovak1, T. Serranova1, T. Sieger2, C. Bonnet3,  
O. Ulmanova1, J. Hanuska1, E. Ruzicka1
1Charles University, First Faculty of Medicine and General 
University Hospital, Department of Neurology, Prague, Czech 
Republic, 2Czech Technical University, Faculty of Electrical 
Engineering, Department of Cybernetics, Prague, Czech 
Republic, 3Pierre and Marie Curie University, Paris, France
Background and aims: Convergence spasm (transient 
ocular convergence, miosis and accommodation associa-
ted with disconjugate gaze) was reported as a common eye 
movement (EM) abnormality in patients with functional 
(psychogenic) movement disorders (FMD). Our aim was 
to verify the incidence of convergence spasm and to further 
analyze EM abnormalities in FMD using videooculography 
(VOG). Additionally, we hypothesized that the antisaccade 
task may reveal a specific deficit in motor response inhibi-
tion in FMD.
Method: 8 female patients with FMD and 9 matched con-
trols underwent VOG with tasks for prosaccades (rapid 
reflexive EM to the target point), antisaccades (rapid voliti-
onal EM to the opposite site from the target point) and ver-
gence (alternation of convergence and divergence tracking 
proximal and distal target point). Latencies and mean sac-
cade velocities were analyzed in prosaccades and vergence. 
In antisaccades, error rate (percentage of errors from total 
number of antisaccades) was evaluated.
Results: Only 1 out of 8 patients presented a convergence 
spasm during the EM examination. However, in compari-
son with controls, FMD patients showed prolonged laten-
cies in both convergence and divergence (P<0.05), but no 
alterations in velocities in the vergence task, and higher 
error rate (44% vs 27%, P<0.001) in antisaccades. No dif-
ferences in prosaccades were found.
Conclusion: Despite a low incidence of an overt conver-
gence spasm, VOG revealed subclinical abnormalities in 
vergence EM along with normal reflexive EM in FMD. 
Consistently with current hypothesis of attention deficit and 
response inhibition disorders in FMD, we found an increa-
sed error rate in antisaccades in FMD.
Disclosure: Supported by Charles University in Prague, 
CZ, PRVOUK P26/LF1/4.
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Psychiatric burden in patients with initial 
stage Parkinson’s disease and early mild 
cognitive impairment
I. Stanković1, A. Tomic1, M. Ječmenica Lukić1,  
N.D. Kresojevic1, V. Marković1, G. Mandic Stojmenovic2,  
T. Stojkovic2, N. Dragasevic1, I. Petrović1, M. Svetel1,  
E. Stefanova2, V. Kostic1
1Clinic of Neurology, Neurodegenerative diseases, Belgrade, 
Serbia, 2Neurology Clinic, Clinical Centre of Serbia, Centre 
for memory disorders, Belgrade, Serbia
Background and aims: Psychiatric manifestations and 
mild cognitive impairment (MCI) became increasingly re-
cognized in the early stage of Parkinson’s disease (PD). We 
report a baseline cross-sectional assessment of psychiatric 
symptoms derived from a prospective cohort study of year-
ly followed-up PD patients recruited in the initial stage of 
PD (Hoehn and Yahr stage 1; HY1).
Methods: Non-demented PD outpatients in the HY1 stage 
(n=117) and sex and age-matched healthy controls (HC) 
(n=109) underwent detailed clinical, psychiatric and neu-
ropsychological testing. Psychiatric evaluation consisted of 
depression, anxiety, apathy, perceptive problems and sleep 
and wakefulness assessments. MCI was diagnosed accor-
ding to the level 2 of the Movement Disorders Society Task 
Force criteria.
Results: Initial-stage PD patients were more frequent-
ly depressed (p<0.01), anxious (p<0.01) and apathetic 
(p<0.01), with more cognitive (p<0.01) and sleep problems 
(p=0.003) compared to HC. Higher caregiver burden was 
associated with symptoms of depression (p<0.01), anxie-
ty (p<0.01), apathy (p<0.01), sleep problems (p<0.01) and 
agitation (p=0.039). Criteria for MCI associated with PD 
(PD-MCI) were fulfilled in 24% of PD patients at the -1.5 
SD, in contrast to 7% of MCI in HC group. PD-MCI pati-
ents at early disease endorsed depression (p=0.014) and an-
xiety (p=0.022) more frequently compared to PD-nonMCI 
patients. Sleep problems, including vivid dreams (p=0.019) 
and frequent waking (p=0.036), were more prevalent in 
MCI-PD group (p=0.018) compared to PD-nonMCI pati-
ents.
Conclusion: The major psychiatric burden in initial-stage 
PD-MCI patients are depression and sleep distrubances.
Disclosure: This study was supported by a grant from the 
Ministry of Education and Science, Republic of Serbia 
(projects No#175090).  
P3237
Acetyl-dl-leucine for treatment of  
Niemann-Pick type C: a case series
T. Bremova1, V. Malinova2, Y. Amraoui3, E. Mengel4,  
J. Reinke4, M. Kolnikova5, M. Strupp1
1University Munich, Department of Neurology, Munich, Ger-
many, 2First Faculty of Medicine, Charles University, General 
University Hospital Prague, Department of Pediatrics and 
Adolescence Medicine, Prague, Czech Republic, 3Center for 
Paediatric and Adolescent Medicine, University Medical 
Center of the Johannes Gutenberg University Mainz, 4De-
partment of Lysosomal Storage Disorder, Mainz, Germany, 44 
Department of Lysosomal Storage Disorder, Center for Paedi-
atric and Adolescent Medicine, University Medical Center of 
the Johannes Gutenberg University Mainz, Mainz, Germany, 
55 Department of Child Neurology, Comenius University 
Children’s Hospital, Bratislava, Bratislava, Slovakia
Background and aims: Niemann-Pick type C disease (NP-
C) is a rare lysosomal storage disorder characterized by a 
combination of systemic, neurological and psychiatrical 
symptoms. The most prominent neurological sign is cere-
bellar ataxia. The current disease-specific therapy approved 
for NP-C miglustat slows the progression of the disease, 
however, additional symptomatic therapies are needed to 
improve the function and quality of life of NP-C patients. 
Acetyl-DL-leucine (AL), an amino acid, ameliorates cere-
bellar symptoms in patients with cerebellar ataxia. We eva-
luated the AL efficacy in NP-C patients.
Methods: 12 NP-C patients were treated with AL 3g/day 
for 1 and 5g/day for 3 weeks. The Scale for the Assess-
ment and Rating of Ataxia (SARA), Spinocerebellar Ataxia 
Functional Index (SCAFI), modified Disability Rating Sca-
le (mDRS), EuroQol 5Q-5D-5L and Visual Analog Scale 
(VAS) were administrated. Measurements took place at 
baseline, after 1 month of therapy, and after 1 month of 
wash-out.
Results: SARA significantly changed from baseline of 10.8 
(8 to 24.6) to 7.0 (5.6 to 19.6) (median (IQR)) under medi-
cation and 10.5 (7.1 to 23.9) after wash-out (p=0.000412; 
post hoc p=0.003 between baseline and on medication, on 
medication and wash-out p=0.005). SCAFI subscore 9-Ho-
le-Peg-Test (9HPT) for dominant hand, mDRS and VAS 
significantly improved under medication. No side effects 
in 11 patients, but intermittent vertigo in 1 patient were re-
ported.
Conclusion: The treatment with AL significantly improved 
ataxic symptoms in NP-C patients without persistent side 
effects showing a good risk-benefit profile.
Disclosure: This study was supported by the BMBF to the 
IFB (grant code 01 EO 0901). 
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Dopa-responsive dystonia in the Serbian  
population: clinical and genetical  
characteristics
M. Svetel1, A. Tomic1, V. Dobricic2, I. Novakovic2,  
N. Dragasevic Miskovic1, I. Petrović1, V. Kostic1
1Institute of Neurology, Faculty of Medicine, University of 
Belgrade, Movement Disorders Department, Belgrade, Ser-
bia, 2Institute of Neurology, Faculty of Medicine, University 
of Belgrade, Laboratory for Molecular Genetic Diagnostic of 
Neurological Diseases, Belgrade, Serbia
Background and aims: Dopa-responsive dystonia (DRD) 
is inborn neuromethabolic disorders which could be inheri-
ted as an autosomal-dominant (AD) disease with  heterozy-
gous mutations in GPT-cyclohydrolase 1 gene (GCH1-DY-
T5a) and autosomal-recessive (AR) one with homozygous 
or compound heterozygous mutations in genes for  thy-
rosin-hydrolase (TH) (DYT5b) or sepiapterin-reductase 
(SPR).  AD form is characterized by reduced penetrance 
and excellent and permanent response to levodopa, while 
AR form is more severe, with developmental delay and 
cognitive impairment. The objecitve was to assess genetic 
and clinical characteristics of GCH1 mutations carriers in 
patients with dystonia-plus syndrome in Serbia. 
Methods: The study comprised 66 patients with dystonia-
plus syndrome and 60 healthy controls matched by age and 
gender. Genetical analysis was performed by direct sequen-
cing of coding exones of GCH1 gene, and MLPA analysis 
for detection of large duplications/deletions. 
Results: We found 5 point mutations (c.209delA, 
c.470T>C, c.541+1G>C, c.550C>T, c.608G>A) and one 
deletion of whole exon 2 in GCH1 gene in 10 carriers. The 
most frequent mutation (c.470T>C) was demonstrated in a 
family with 5 affected members, all with spastic parapare-
sis as initial presentation and excellent levodopa responsi-
veness. Phenotype spectrum was wide in our group of pati-
ents, from lower extremities dystonia to hemiparkinsonim, 
dystonia-parkinsonism complex and spastic paraparesis. 
All patients were on continuous levodopa treatment. 
Conclusion: Our results showed GCH1 mutations in 15% 
of patients with dystonia-plus syndrome. It is important to 
stress phenotypic heterogeneity of the disease with wide 
spectrum of clinical expressions in forms of dystonia, par-
kinsonism and spastic paraparesis.




Botulinum toxin treatment of freezing of 
gait in Parkinson’s disease patients as  
reflected in functional magnetic resonance 
imaging of leg movement
M. Vaštík1, P. Hok1, P. Hlustik2, P. Otruba3, Z. Tüdös4,  
P. Kanovsky5
1 Palacky University Medical School and University Hospi-
tal, Olomouc, Department of Neurology, Olomouc, Czech 
Republic, 2Olomouc, Czech Republic, 3University Hospital 
Olomouc, Neurology, Olomouc, Czech Republic, 4Palacky 
University Medical School and University Hospital, Olo-
mouc, Department of Radiology, Olomouc, Czech Republic, 
5University Hospital and Faculty of Medicine and Dentistry, 
Palacky University Olomouc, Neurology, Olomouc, Czech 
Republic
Background and aims: Freezing of gait (FOG) is a com-
mon disabling symptom in Parkinson’s disease (PD). The 
mechanism of FOG in not clearly understood. We inves-
tigated the clinical effect and changes of the activity of 
the sensorimotor system using repeated functional MRI 
(fMRI) before and after application of botulinum toxin in 
Parkinson’s disease patients with FOG.
Methods: We investigated 20 patients with PD, 10 with 
FOG and 10 without FOG. PD patients with FOG were 
treated with intramuscular application of botulinum toxin 
type A into the tensor fasciae latae muscle bilaterally. The 
clinical effect of treatment was assessed using FOG ques-
tionnaire, “Time up and go” test, UPDRS, Hoehn and Yahr 
staging, Clinical global impression scale. Activation of the 
sensorimotor system was studied using BOLD fMRI of the 
whole brain during repetitive abduction – adduction of each 
leg interleaved with rest. The clinical (in the FOG group) 
and imaging (in both groups) examination was repeated af-
ter a four-week interval.
Results: In the FOG group, the FOG questionnaire has 
shown a decline of scores after application of botulinum 
toxin that suggests possible effect of botulinum toxin on 
freezing of gait. In fMRI results, both groups manifested 
reduction of the sensorimotor network activated with leg 
movement, however, the FOG group also showed increased 
activation in cerebellar vermis and nuclei, in dorsal pons 
and in medulla after treatment.
Conclusion: Alleviation of the FOG in PD patients by bo-
tulinum toxin seems to be reflected in the functional par-
ticipation of the cerebellum and its projections as seen by 
fMRI.
Disclosure: Supported by IGAMZ13575
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Characterization of cognitive function and 
change of function in a population-based 
cohort to study non-motor-symptoms of 
Parkinson’s disease
E.-J. Vollstedt1, J. Graf2, J. Hampf2, S. Tunc2, E. Warrlich2,  
C. Bibergeil2, C. Klein2, M. Kasten3
1Institute of Neurogenetics, Lübeck, Germany, 2University of 
Lübeck, Institute of Neurogenetics, Lübeck, Germany, 3Uni-
versity of Lübeck, Clinic for Psychiatry and Psychotherapy, 
Lübeck, Germany
Background and aims: Cognitive function influences in-
dependency and is closely related to Parkinson’s disease 
(PD). Various determinants have been indicated. We descri-
be cognitive function and change in performance, compa-
ring control groups and PD patients longitudinally.
Methods: After a population screening and baseline exa-
mination of 736 subjects including 119 PD patients, we re-
examined 199 subjects, 61 PD patients and 41 subjects with 
mild Parkinsonian signs (MPS). Examination included the 
Montreal Cognitive Assessment (MoCA) with subscores 
for visuospatial, naming, recall, attention, language, abs-
traction, and orientation. Relative contribution of MoCA-
subscores was defined as ratio subscore/summary score.
Results: At baseline, we analyzed determinants of MoCAs-
cores in PD patients and subscore profiles across groups. 
We saw moderate correlation between MoCAscore and 
current age (r=-0.279, p<0.001), Hoehn&Yahr (r=-0.274, 
p=0.005), age at onset (r=-0.251, p=0.009), and disease du-
ration (r=-0.172, p=0.076). Linear regression identified age 
at onset and disease duration as independent determinants 
(R2=23.8%). Relative contribution of MoCA subscores dif-
fered between groups for naming (highest in PD), visuospa-
tial (lowest in PD), recall (lowest in PD; p<0.001).
Longitudinally, change in MoCA summary scores diffe-
red between groups, with declining scores in PD and MPS 
(ANOVA p=0.024). Specifically, MoCAsubscores showed 
a decline in abstraction (p=0.079) and recall (p=0.033) for 
PD and MPS.
Conclusion: PD characteristics only partially explain Mo-
CAscores. Despite its brevity the MoCA seems sensitive 
for differences between domains. Interestingly, even the 
MPS group had more cognitive decline than the control 
groups and showed similar development of subscores as 
the PD group.
Disclosure: This work was supported by DFG grant KA 
3179/2-1.
P3242
Levodopa response in paroxysmal  
exercise-induced dystonia without GLUT1 
deficiency
B. Ziso, A. Larner
Walton Centre Neurology and Neurosurgery, Neurology,  
Liverpool, United Kingdom
Background and aims: To report a patient with paroxys-
mal exercise-induced dystonia complicated by severe in-
tention upper limb and head tremor, and the tremor respon-
se to levodopa.
Methods: A prospective observational study, Cognitive 
Function Clinic.
Results: Episodes of painless flaccid limb weakness after 
exercise, accompanied with bending truncal movements 
and dystonic hand movements lasting for hours, began 
at age 18 months but became infrequent by age 30 years. 
From age 5 years, bilateral optic atrophy and pendular nys-
tagmus developed, and as a teenager typical migraine with 
aura. In her mid-thirties she developed upper limb intention 
tremor and head tremor making it difficult to feed herself. 
Intellect was preserved (6CIT = 0/28).
Genetic testing showed no pathogenic sequence variant or 
copy number change in the SLC2A1 gene, hence there was 
no evidence for GLUT1 deficiency.  Mitochondrial point 
mutations associated with MELAS, MERFF, NARP, and 
LHON (3243, 8344, 8993; 3460, 11778, 14484) were all 
negative, as was Friedreich’s ataxia triplet expansion. Le-
vodopa (300 mg/day) improved her limb tremor, such that 
she was able to feed herself.
Conclusion: Some cases of paroxysmal exercise-induced 
dystonia without GLUT1 deficiency may show a partial re-
sponse to levodopa therapy.
Disclosure: Nothing to disclose
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Demography, clinical characteristics and 
socioeconomic status of the Portuguese 
patients with multiple sclerosis in 2014 
– results of the national cross-sectional 
PORT-MS study
J. Tomás1, J. Dias Ferreira2, J. Sequeira3, M. Grilo4,  
R. Samoes5, S. Varanda6, J. Morgado3, J. Guimaraes4,  
C. Nunes1, J.J.F.C.A. Cerqueira6, J.M. Vale Santos7,  
M.J. Sá8, A.A.D.M. Silva5, L.M.A.F.D. Sousa1,  
R.M.G. Pedrosa3, J. de Sa2, P. Alegria7
1Centro Hospitalar Universitário de Coimbra, Neurology, 
Coimbra, Portugal, 2Centro Hospitalar de Lisboa Norte 
– Hospital de Santa Maria, Neurology, Lisbon, Portugal, 
3Centro Hospitalar de Lisboa Central – Hospital de Santo 
António dos Capuchos, Neurology, Lisbon, Portugal, 4Centro 
Hospitalar de São João, Neurology, Porto, Portugal, 5Centro 
Hospitalar do Porto – Hospital de Santo António, Neurology, 
Porto, Portugal, 6Hospital de Braga, Neurology, Braga, Portu-
gal, 7Hospital Beatriz Ângelo, Neurology , Loures, Portugal, 
8Centro Hospitalar de São João, Neurology , Porto, Portugal
Background and aims: In Portugal, there did not exist a 
multicentric study on the general characteristics (demo-
graphy, disease milestones, disease modifying treatment 
(DMT), socioeconomic status) of multiple sclerosis (MS) 
patients.
Methods: Patients fulfilling McDonald 2010 criteria were 
sequentially recruited from May to November 2014 in 7 
centers and data was systematically collected.
Results: 561 patients included: first symptoms occur-
red at 30.2±10.5 years old (Relapsing Remitting (RR) 
MS 29.2±10, Primary Progressive (PP) MS 39.4±11.7, 
p<0.001); diagnosis 3.2±5.3 years later (RRMS 3.0±5.1, 
PPMS 4.9±2.5, p=0.002); 9.4±7.2 years elapsed since di-
agnosis (similar RRMS and PPMS); current age 42.9±12.4 
years-old (RRMS at diagnosis 42.0±12.1, PPMS 52.5±11.3, 
p<0.001); current EDSS 2.5 (RRMS 2.0, PPMS 6.0); fema-
les to males 2.5:1 (RRMS similar, PPMS 1.1:1, p<0.05); at 
diagnosis RRMS 90.6%, SPMS 0.9%, PPMS 8.6%; 9.5% 
of RRMS reached SP at inclusion (those older at diagnosis, 
in actuality, or with longer follow-up); proportion on DMT 
90.4% of currently in RRMS; Economically active 61.5% 
of all, unemployment 13.5%; females pregnant after diag-
nosis 15%; positive family cases in 7.8%. Analysis by age 
at diagnosis: PPMS more frequent at older ages (p<0.001), 
also slight increase in females. Analysis by diagnosis at 
each of the last decades: stable proportions of gender and 
disease types.
See Table for additional data.
Table: additional data. 
Conclusion: 10% of the national MS population was coll-
ected. Data generally consistent with international reports. 
Proportion under DMT relatively high in all disease types, 
but second line therapies underrepresented. Young patients 
with mild disease have an active economic life. Those not 
active are essentially retired due to disease.
Disclosure: This research had institucional support from 
Biogen Idec and the GEEM (Grupo de Estudos de Esclero-
se Múltipla, the Portuguese medical society for MS)
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Cognition in neuromyelitis optica:  
a systematic review
F. Trew1, K. Murray2, S. Pal2
1University of Edinburgh, Edinburgh, United Kingdom, 2Anne 
Rowling Regenerative Neurology Clinic, University of Edin-
burgh, Edinburgh, United Kingdom
Background and aims: Neuromyelitis Optica (NMO) is 
an antibody-mediated central nervous system disorder cha-
racterised by optic neuritis and longitudinally extensive 
transverse myelitis. Whilst clinically similar to multiple sc-
lerosis (MS), it has been widely assumed cognition is spa-
red.  However, recent case series have reported deficits in 
attention, information processing speed and memory. This 
systematic review and narrative analysis evaluates cog-
nitive performance in NMO, and compares profiles with 
healthy controls and patients with MS. 
Methods: A wide-ranging literature search was conducted 
using the Medical Subject Headings Neuromyelitis Optica, 
Cognition, Cognitive Disorders and Memory from 2004-
2014.
Results: 6 studies fulfilled inclusion criteria, including 129 
patients with NMO, 61 with MS, and 158 healthy controls. 
Neuropsychological tests used included the Brief Repeata-
ble Battery of Neuropsychological Tests and the California 
Verbal Learning Test. Patients were matched for age, edu-
cation, disease course and severity. All studies demonstra-
ted significant cognitive impairment in patients with NMO 
compared to controls. Profiles of deficit varied, but memory 
impairment was uniformly identified. Impaired information 
processing speed and attention were present in most, and 
impaired executive function, learning and verbal fluency in 
individual studies. There was no significant difference bet-
ween NMO and MS.
Conclusion: Patients with NMO demonstrate significant 
cognitive impairment similar in severity to MS. This is po-
tentially functionally impairing, under-recognised, and in-
completely evaluated suggesting that NMO patients should 
be counselled accordingly and symptoms screened for. 
Larger studies are warranted using more versatile cognitive 
tests and controlling for common confounders, to assess if 
clinical phenotype or MRI changes predict cognitive defi-
cits.
Disclosure: Nothing to disclose
P3245
The MS@Work study – predictors of  
employment status and work absenteeism 
in relapsing-remitting Multiple Sclerosis
D. van Gorp1, K. van der Hiele2, M. Heerings1, P. Jongen3,  
I. van Lieshout4, F. Vosman5, M. Reneman6, J. van der Klink7, 
H. Middelkoop2, L. Visser8
1National MS Foundation, Maassluis, The Netherlands, 2Lei-
den University, Leiden, The Netherlands, 3MS 4 Research 
Institute, Nijmegen, The Netherlands, 4Van Lieshout Arbo 
Advies, Uden, The Netherlands, 5University of Humanistic 
Studies, Utrecht, The Netherlands, 6University Medical Cen-
ter Groningen, Haren, The Netherlands, 7Tilburg University, 
Tilburg, The Netherlands, 8St. Elisabeth Hospital, Tilburg, The 
Netherlands
Background and aims: The majority of Multiple Sclero-
sis (MS) patients are unable to retain employment within 
10 years from disease onset. Cross-sectional studies have 
identified factors associated with decreased employment 
status and work absenteeism in MS, including cognitive, 
physical and psychological problems, work factors and 
type of treatment. Prospective studies are rare, or take into 
account a limited number of factors. The main aim of this 
study is to examine predictors of (changes in) employment 
status and work absenteeism in relapsing-remitting MS 
(RRMS) patients over a period of three years. In a sub study 
20 semi-structured interviews will be conducted to examine 
patient perspectives on what can be done to improve work 
participation.
Methods: The MS@Work study is an observational, pros-
pective cohort study in 400 patients with RRMS recruited 
from 15 outpatient clinics in the Netherlands. We plan to 
include RRMS patients who are 18 years and older, and 
either currently employed or within three years since their 
last employment. At baseline and after 6 months, 1, 2 and 3 
years, participants will be asked to complete occupational 
and psychological questionnaires, and undergo neurologi-
cal and neuropsychological examinations. 
Results: At abstract submission, 63 patients have been rec-
ruited. Baseline characteristics will be presented. Final data 
are expected in 2018.
Conclusion: The study will provide more insight in the 
predisposing factors resulting in decreased work participa-
tion in patients with MS. Possible factors, like (perceived) 
cognitive problems, fatigue, depression, coping style and 
physical disability are factors which could be addressed by 
healthcare professionals working in occupational health.
Disclosure: This research is financially supported by the 
National Multiple Sclerosis Foundation, the Netherlands, 
Teva Pharma BV and by a ZonMw TopZorg grant.
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InMS: Chronic Insomnia Disorder in  
Multiple Sclerosis – a Portuguese  
multicentre study on prevalence,  
subtypes, associated factors and impact 
on quality of life
P. Viana1, E. Rodrigues2, C. Fernandes3, A. Matas4,  
R. Barreto5, M. Mendonça6, R. Peralta7, R. Geraldes8
1Lisbon, Portugal, 2Centro Hospitalar do Funchal, Neurology 
Department, Funchal, Portugal, 3Hospital Garcia de Orta, 
Neurology Department, Almada, Portugal, 4Centro Hospitalar 
Trás-os-Montes e Alto Douro, Neurology Department, Vila 
Real, Portugal, 5Centro Hospitalar Entre-o-Douro e Vouga, 
Neurology Department, Santa Maria da Feira, Portugal, 
6Centro Hospitalar Lisboa Ocidental, Neurology Depart-
ment, Lisbon, Portugal, 7Hospital de Santa Maria, Neurology 
Department, Lisbon, Portugal, 8Oxford University Hospital, 
Nuffield Department of Clinical Neurosciences, Oxford, Uni-
ted Kingdom
Background: Patients with Multiple Sclerosis (MS) have 
under-recognized sleep disorders and frequent sleep comp-
laints. Few studies have addressed insomnia using standard 
diagnostic criteria in MS patients.
Objectives: To determine the prevalence of chronic in-
somnia disorder (CID) in a population of MS patients, the 
frequency of CID subtypes, identify associated factors and 
assess impact on quality of life (QoL).
Methods: Hospital-based, multicentre, cross-sectional 
study of an MS population, in order to assess CID, as de-
fined by the 3rd Edition of the International Classification 
of Sleep Disorders, using an adapted version of the Brief 
Insomnia Questionnaire. This instrument was also used to 
classify CID subtypes. A comprehensive questionnaire was 
used to evaluate demographic, MS-related features as well 
as other possible contributors to CID. Fatigue was evalua-
ted by the Fatigue Severity Scale. QoL was assessed by the 
EQ-5D scale.
Results: Of 206 patients, 39.3% complained of frequent 
insomnia symptoms, while 22.3% fulfilled criteria for CID. 
Initial insomnia was found in 11.7%, maintenance insomnia 
in 11.2% and terminal insomnia in 10.2% of patients. CID 
was significantly more common in female patients, those 
with nocturnal symptoms and other medical comorbidities, 
and correlated with higher levels of anxiety, depression 
and fatigue. Multivariate analysis identified female sex, 
medical comorbidities, anxiety and fatigue as independent 
factors for CID. CID patients had a significantly lower self-
reported QoL.
Conclusion: CID is prevalent in MS patients and highly as-
sociated with potentially treatable psychiatric and medical 
comorbidities. It is also associated with fatigue and has a 
negative impact on QoL.
Disclosure: Nothing to disclose
P3247
Investigating the spectrum of cognitive 
impairment in multiple sclerosis using 
touchscreen cognitive testing
N. Vithanage1, K. Murray2, S. Colville2, D. Lyle2,  
D. Cranley2, F. Cormack3, J. Barnett3, S. Pal2
1University of Edinburgh, Edinburgh, United Kingdom, 2Anne 
Rowling Regenerative Neurology Clinic, University of Edin-
burgh, Edinburgh, United Kingdom, 3Cambridge Cognition, 
Cambridge, United Kingdom
Background and aims: Multiple sclerosis (MS) is a CNS 
demyelinating syndrome characterised by physically disab-
ling symptoms.  Cognitive impairment, which potentially 
impact on quality of life, is generally under-recognised and 
incompletely evaluated but has been reported in up to 70% 
of patients when specifically assessed.
The aims were to investigate the spectrum of cognitive 
impairment, and potential confounding factors for deficits, 
in patients with MS reviewed in an outpatient clinic using 
validated Cantab neuropsychological tests administered by 
touchscreen. 
Methods: 105 consecutive patients presenting to a speci-
alist MS clinic were assessed. Working Memory (WM), 
Executive Functioning (EF), Processing Speed (EF), At-
tention (AT) and Episodic Memory (EM) were evaluated 
using the Cantab mobile test. Performance was adjusted for 
age, sex and educational level based on a large normative 
database. Disease duration, type of MS, severity of disease, 
sedating medications, and severity of depression were cor-
related with the presence and severity of cognitive deficits.
Results: The most frequent cognitive domain affected 
was EF (in 25%), followed by WM (23%), PS (17%), EM 
(18%) and AT (6%). Single domain cognitive impairment 
was identified in 24% of patients and multi-domain defi-
cits in 26%. Disease severity was associated with impaired 
WM, EF, PS and AT. Severity of depression correlated with 
diminished EF, WM and PS. 
Conclusion: Results from this study confirm cognitive im-
pairment is common in MS patients. Furthermore, impair-
ment occurs across a range of domains, and correlates with 
disease duration although is independent of factors such as 
age and type of MS. Routine testing is recommended as 
part of holistic patient assessment.
Disclosure: Nothing to disclose
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Cerebrospinal fluid free light chains are 
elevated in clinically isolated syndrome 
and multiple sclerosis and correlate with 
lesion load and cortical thinning
M. Voortman, T. Stojakovic, M. Jehna, H. Scharnagl,  
S. Ropele, T. Seifert-Held, J.J. Archelos-Garcia, S. Fuchs,  
C. Enzinger, F. Fazekas, M. Khalil
Medical University of Graz, Graz, Austria
Background and aims: It has been shown that cerebrospi-
nal fluid (CSF) immunoglobulin free light chains (FLC) are 
increased in multiple sclerosis (MS). However, only scarce 
information exists regarding their relation to MRI metrics, 
in particular measures of brain changes in regions with di-
rect contact to CSF.
We thus aimed to compare FLC kappa (KFLC) and FLC 
lambda (LFLC) levels in CSF and serum between MS pa-
tients and controls, and to investigate their relation to MRI 
based measures of cortical thinning and periventricular le-
sion load.
Methods: FLC in CSF and serum were measured by nephe-
lometry in 61 patients (clinically isolated syndrome (CIS) 
n=48, relapsing-remitting MS n=13) and 60 non-inflamm-
atory neurologic controls. We then calculated CSF/serum 
FLC quotients and determined FLC indices by correcting 
for the albumin quotient. CIS/MS patients underwent MRI 
at 3T to determine the extent of cortical thinning (FreeSur-
fer software) and periventricular lesion load.
Results: In MS we found increased CSF KFLC and LFLC 
levels, quotient and indices compared to controls (p<0.001). 
CSF LFLC correlated with the percentage of periventri-
cular lesion load (r=-0.356, p=0.005) and the CSF KFLC 
index correlated with mean cortical thickness (r=0.274, 
p=0.036). No correlation emerged between CSF FLC and 
physical disability.
Conclusion: Our study demonstrates increased intrathecal 
synthesis of KFLC and LFLC in MS emphasizing an al-
tered B-cell response. The correlation of FLC with MRI 
based measures of cortical and periventricular tissue dama-
ge suggests an etiologic association. Further studies with 
longitudinal clinical and MRI data are necessary to confirm 
our findings.
Disclosure: Nothing to disclose
P3249
Economic costs of an MS relapse  
(PEARL Study)
S. Vormfelde1, T. Ziemssen2
1Novartis Pharma GmbH, TA Neuroscience, Nuremberg, 
Germany, 2Carl Gustav Carus University Hospital, Center for 
Clinical Neurosciences, Dresden, Germany
Background and aims: There is an ongoing discussion, 
whether medical, patient and healthcare cost caused by re-
lapses warrant early escalation of pharmacotherapy. Here 
we focus on healthcare cost.
Methods: The PEARL study (ProspEctive phArmacoeco-
nomic cohoRt evaLuation) is a 24-month, German non-in-
terventional study in 1705 patients with relapsing remitting 
multiple sclerosis (RRMS). Patients were treated office-
based, 1214 with beta-interferons, 491 with glatiramer ace-
tate. To describe the costs of a relapse, we compare patients 
with a relapse in the first study year (ACTIVE group) to 
those without (INACTIVE group).
Results: In the first study year, 411 patients relapsed at 
least once (ACTIVE group, “A”); 1294 patients did not re-
lapse (INACTIVE group, “I”). Mean MS-duration was 5.1 
and 5.2 years in ACTIVE and INACTIVE patients, respec-
tively. The mean annual relapse rates over the two year pe-
riod were A=1.4 and I=0.1 relapses/year. Employment dec-
lined only in the ACTIVE group during the two year period 
(A:58%→53%, I:61%→61%). Also more ACTIVE pati-
ents were permanently part-time employed (A: 7%→5%, 
I:6%→2%), with lower fractions of full employment at stu-
dy end (A:50%→35%, I:53%→56%). Only ACTIVE pa-
tients continuously felt their work productivity suppressed 
by MS (A:2.2→2.3, I:2.1→1.7, 0-10 rating scale). More 
ACTIVE patients took sick leaves at baseline as well as 
at the end of the study (A: 33%→18%, I: 18%→8%, [of 
patients/quarter]), were hospitalized (A:7.1%→3.3%, 
I:4.0%→1.2%, [of patients/quarter]) or stayed in rehabili-
tation (A:2.7%→1.4%, I:1.8%→1.0%, [of patients/year]).
Conclusion: MS patients are less productive in the year 
following a relapse.
Disclosure: The PEARL study was supported by Novartis 
Pharma GmbH, Nuremberg, Germany; Stefan Vormfelde 
ist employee of Novartis; Tjalf Ziemssen has served on sci-
entific advisory boards, and has received scientific grants 
and  speaker honoraria from Bayer, Biogen Idec, Genzyme, 
TEVA, Merck Serono, and Novartis.
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Disability, health status and estimation of 
treatment effectiveness with versus  
without an MS relapse (PEARL Study)
S. Vormfelde1, T. Ziemssen2
1Novartis Pharma GmbH, TA Neuroscience, Nuremberg, 
Germany, 2Carl Gustav Carus University Hospital, Center for 
Clinical Neurosciences, Dresden, Germany
Background and aims: There is an ongoing discussion, 
whether medical, patient and healthcare costs caused by re-
lapses warrant early escalation of pharmacotherapy. Here 
we focus on the medical perspective.
Methods: The PEARL study (ProspEctive phArmacoeco-
nomic cohoRt evaLuation) is a 24-month, German non-in-
terventional study in 1705 patients with relapsing remitting 
multiple sclerosis (RRMS). Patients were treated office-
based, 1214 with beta-interferons, 491 with glatiramer ace-
tate. To describe the costs of a relapse, we compare patients 
with a relapse in the first study year (ACTIVE group) to 
those without (INACTIVE group).
Results: In the first study year, 411 patients relapsed at 
least once (ACTIVE group, “A”); 1294 patients did not 
relapse (INACTIVE group, “I”). Mean MS-duration was 
5.1 and 5.2 years in ACTIVE and INACTIVE patients, re-
spectively. The mean annual relapse rate was 1.4 and 0.1 
relapses/year over the two year period, respectively.
Disability, measured by the Expanded Disability Status 
Scale (EDSS), was worse in ACTIVE patients at baseline 
and deteriorated further during the 24 months (A:2.5→3.0, 
I:2.2→2.4).
Health worsening peaked in ACTIVE patients in the first 
study year and then remained elevated (CGI improvement 
scale, fraction who reportedly worsened minimally, much 
or very much compared to the previous year at baseline/
peak/24 months: A:23%/32%/16%, I:6%/8%/10%).
ACTIVE patients switched drug more often (A:30%, 
I:12%). Physicians and patients deemed treatment similar-
ly effective; except those INACTIVE patients, who later 
discontinued treatment, more often thatn their physicians 
deemed treatment insufficient (30% vs 19%).
Conclusion: Patients remain worsened after a relapse. In-
tensifying therapy may reduce such worsening.
Disclosure: The PEARL study was supported by Novartis 
Pharma GmbH, Nuremberg, Germany; Stefan Vormfelde 
ist employee of Novartis; Tjalf Ziemssen has served on sci-
entific advisory boards, and has received scientific grants 
and  speaker honoraria from Bayer, Biogen Idec, Genzyme, 
TEVA, Merck Serono, and Novartis.
P3251
The Patient’s subjective consequences of 
an MS relapse (PEARL Study)
S. Vormfelde1, T. Ziemssen2
1Novartis Pharma GmbH, TA Neuroscience, Nuremberg, 
Germany, 2Carl Gustav Carus University Hospital, Center for 
Clinical Neurosciences, Dresden, Germany
Background and aims: There is an ongoing discussion, 
whether medical, patient and healthcare costs caused by re-
lapses warrant early escalation of pharmacotherapy. Here 
we focus on the patient perspective.
Methods: The PEARL study (ProspEctive phArmacoeco-
nomic cohoRt evaLuation) is a 24-month, German non-in-
terventional study in 1705 patients with relapsing remitting 
multiple sclerosis (RRMS). Patients were treated office-
based, 1214 with beta-interferons, 491 with glatiramer ace-
tate. To describe the costs of a relapse, we compare patients 
with a relapse in the first study year (ACTIVE group) to 
those without (INACTIVE group).
Results: In the first study year, 411 patients relapsed at 
least once (ACTIVE group, “A”); 1294 patients did not 
relapse (INACTIVE group, “I”). Mean MS-duration was 
5.1 and 5.2 years in ACTIVE and INACTIVE patients, re-
spectively. The mean annual relapse rate was 1.4 and 0.1 
relapses/year over the two year period, respectively. Over 
the 24-month study period, treatment satisfaction declined 
only in ACTIVE patients (A:54%→36%, I:52%→55%). 
Subjective health state as measured by the EQ-5D sca-
le deteriorated only in ACTIVE patients (A:69.9→68.0, 
I:72.0→73.2). ACTIVE patients were worse off after 24 
months in all five EQ-5D dimensions. E.g. 55% ACTIVE 
and 41% INACTIVE patients had pain or discomfort af-
ter 24 months (baseline 52%/49%). MS-specific subjective 
quality of life impairment was greater and declined less in 
ACTIVE patients (A:8.7→7.8, I:8.3→6.8). MS-specific 
subjective activity impairment was greater and worsened 
more in ACTIVE patients (A:4.7→5.0, I:4.0→4.1).
Conclusion: Activity and QoL worsen with a relapse. Es-
calating therapy may prevent such worsening.
Disclosure: The PEARL study was supported by Novartis 
Pharma GmbH, Nuremberg, Germany; Stefan Vormfelde 
ist employee of Novartis; Tjalf Ziemssen has served on sci-
entific advisory boards, and has received scientific grants 
and  speaker honoraria from Bayer, Biogen Idec, Genzyme, 
TEVA, Merck Serono, and Novartis.
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Reduced activation of frontal and midline 
brain structures: new insight in the brain 
of myotonic dystrophy type 1 (DM1)
S. Baldanzi1, C. Simoncini2, G. Ricci3, L. Volpi2, P. Cecchi4, 
S. Fabbri4, G. Migaleddu4, M. Cosottini5, R. Lorio6,  
F. Bevilacqua6, A. Petrucci7, C. Angelini8, G. Siciliano1
1Pisa, Italy, 2University of Pisa, Department of Clinical and 
Experimental Medicine, Pisa, Italy, 3University of Pisa, Pisa, 
Italy, Department of Clinical and Experimental Medicine, 
Neurological Clinic, , Pisa, Italy, 4Pisa Hospital, Neuroradio-
logy Unit, Pisa, Italy, 5Department of Translational Research 
and New Technologies in Medicine and Surgery, Pisa, Italy, 
Department of Translational Research and New Technologies 
in Medicine and Surgery, Pisa, Italy, Pisa, Italy, 6IRCCS San 
Camillo, Neurology Unit, Lido Venice, Italy, 7San Camillo 
Forlanini Hospital, Neurology Unit, Rome, Italy, 8San Camil-
lo Forlanini Hospital, Neurology Unit, Lido Venice, Italy
Background and aims: DM1 is a genetic multisystemic 
disorder due to polynucleotide expansions, characterized 
by functional/morphological brain abnormalities to diffe-
rent extents beyond muscular involvement. 
Methods: 46 patients with established clinical-genetic di-
agnosis were enrolled in the frame of a larger study and 
underwent complete neurological assessment including 
psychological and neuropsychological evaluation, with the 
administration of  quality of life interview to both, patient 
and main caregiver; 27 patients underwent brainMRI with 
3T-scanner and a subgroup of 19 patients underwent func-
tional MRI investigation during a validated self-awareness 
task based on self or semantic word attribution.
Results: Neurological examination showed mild to severe 
muscle involvement (MIRS mean2.98±0.92). Frontal and 
visuo-spatial abilities were reduced respectively in 61% and 
66% of our patients; patients’ behavior  was characterized 
by anxiety, depression, apathy and by variable sets of pa-
thological personality traits; illness-unawareness, assessed 
by the comparison between patient’s and main caregiver’s 
reports on quality of life, was found in 52.1% and was 
smoothly correlated with executive impairment (p=0.075). 
Parietal lobe white matter changes correlated with reduced 
spatial memory performances (Fisher-Exact-Test p<0.05). 
fMRI analysis revealed frontal and midline brain regions 
hypoactivation in patients with reduced illness-unaware-
ness (Z-threshold>5.3,cluster p threshold <0.001).
Conclusion: In our study DM1 brain changes were both 
structural and functional, with functional impairment cha-
racterized by typical cognitive-behavioural disorders, with 
heterogeneous associations with clinical features. The as-
sociation between illness-unawareness and  specific brain 
regions hypoactivation may be a persistent deficit in sub-
jects with DM1, thus representing a distinctive feature of 
this complex disease.
Disclosure: AFM (Association Francaise contre les Myo-
pathies) research grant in 2012
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DNAJB6 myopathy in a Saudi family with 
cytoplasmic and nuclear inclusions
S. Alfawaz1, H. AlHindi2, D. Monies3, H. Murad4,  
S. Bohlega4
1KFSH & RC, Neurosciences, Riyadh, Saudi Arabia, 2KFSH 
& RC, Pathology & Laboratory Medicine, Riyadh, Saudi Ara-
bia, 3KFSH & RC, Genetics, Riyadh, Saudi Arabia, 4Riyadh, 
Saudi Arabia
Background and aims: Limb Girdle Muscular Dystro-
phy (LGMD) is a clinically and genetically heterogeneous 
group of disorders. Recently a mutation in the DNAJB6 
gene has been described in patient with LGMD1D. This is 
a rare disorder only recently described.
Objective: To describe the clinical feature, pathological 
finding and genetic results of a native Saudi family with 
LGMD1D.
Methods: Sixty-six (66) Saudi Arabian families with 
LGMD were recruited and the causative underlying genes 
were studied utilizing a genome wide linkage, homozygo-
sity mapping, and whole exome sequencing.
Results: A Bedouin (nomads) native Saudi family: the 
father and one of his sons were affected. Progressive pro-
ximal weakness was noted at the age of 25 and at 17 in 
the son. The weakness led to being wheel-chaired at age of 
40 with dysphagia and dysphonia requiring permanent tra-
cheostomy in the father. The creatinine kinase levels were 2 
to 3 times normal. Muscle biopsy showed marked variation 
in myofiber size with scattered angular atrophic fiber, ni-
cotic fibers and myophagocytocis, and red-rimmed vacuo-
les depicting a sarcoplasmic bodies on trichrome-stained 
section. Heterozygous mutation in the exome 5 of DNA-
JB6, c. C287T predicting P96L were found in all affected.
Conclusion: DNABJ6 myopathy or LGMD1D is rarely 
identified in a large cohort from Arabic descent. The phe-
notype and the mutation described are different than those 
seen in other ethnic groups and our findings will expand the 
phenotype and genotype of this disorder.    
Disclosure: Nothing to disclose
P3254
Mutations causing limb-girdle muscular 
dystrophy in the Polish population
J.P. Fichna1, A. Macias2, M. Szymczyk2, A. Kaminska2,  
C. Zekanowski1
1Mossakowski Medical Research Centre, Department of Neu-
rodegenerative Disorders, Warsaw, Poland, 2Medical Univer-
sity of Warsaw, Department of Neurology, Warsaw, Poland
Background and aims: Limb-girdle muscular dystrophy 
(LGMD) is a heterogeneous group of genetically determi-
ned disorders, characterized by primary or predominant-
ly proximal distribution of muscle weakness. Individual 
LGMD subtypes are classified on the basis of genetics and 
so far 25 different loci associated with the disease have 
been identified. However, a large overlap of phenotypic 
manifestations resulting from different gene mutations po-
ses a challenge for determination of the exact type of the 
muscular disease.
Methods: To accelerate molecular diagnosis and to widen 
spectrum of analysed genes we determined sequence of the 
exome, using Whole Exome Sequencing method.
Results: So far we have analysed genomic DNA samples 
from 21 LGMD patients, and in 15 cases (71%) we found 
mutations in the genes already associated with the di-
sease. Homozygous or compound heterozygous mutations 
were detected in the following genes: CAPN3 (33% of all 
LGMD cases), DYSF (19%), FKRP (9.5%), ANO5 (9.5%), 
and PLEC1 (4%). 2 patients had more than one known gene 
affected. In total we have found 19 variants (both novel and 
already described) in LGMD associated genes with CAPN3 
c.550delA being the most common (2 homozygotes and 4 
heterozygotes). Apart from causative mutations also ad-
ditional variants in genes related to muscle diseases were 
found: SGCA, TTN, DES, COL6A2, COL6A3, LDB3/
ZASP, RYR1, LMNA, LARGE, NEB, FLNC. Those muta-
tions could be modifiers of the clinical phenotype.
Conclusion: Genetic etiology of patients without muta-
tions in already known LGMD genes is being further in-
vestigated.
Disclosure: The research was supported by the KNOW-
MMRC project (JPF). 
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Long-term prognostic factors in ocular 
myasthenia gravis (OMG)
M. Mazzoli1, A. Ariatti1, M. Tondelli2, F. Benuzzi3,  
F. Valzania1, P. Nichelli3, G. Galassi1
1University of Modena, Biomedical,metabolic,neural sci-
ences, Modena, Italy, 2Universityof Modena, Biomedical, 
metabolic,neural sciences, Modena, Italy, 3University of Mo-
dena, Biomedical, metabolic,neural sciences, Modena, Italy
Background and aims: Clinical expressions of Myasthe-
nia Gravis (MG) ranges from limited ocular involvement 
to respiratory failure. Purpose of our study was to identify 
prognostic factors in our prospective cohort of 200 patients 
affected by ocular MG (OMG) evaluated during a follow-up 
period of 15 years.
Methods: Myastenia Gravis Foundation of America classi-
fication was used to grade disease severity every 6 months. 
Prognostic factors were gender, age at onset, electrophysio-
logical results, presence of antibodies against acetylcholine 
receptors (AChR-Abs), treatment, thymic abnormalities. 
As outcome measures, we considered variations in ocu-
lar (O-QMG) or total (T-QMG) subscores, progression to 
generalizatio, changes in mental (MCS), physical (PCS) 
scores of SF-36.
Results: 115 cases were males, 85 females. Median age 
was 65 y. Patients with onset before 50 were considered 
early onset, the remaining 162 patients (81.0%) had late on-
set. Electrophysiological tests were positive in 66%.Anti-
AChR-Abs were found in 39%. 11 patients had thymoma, 
10 underwent thymectomy, 11% had hyperplastic thymus. 
83% of patients received treatment. Generalization occur-
red within median time of 34 months in 20% of cases.
Conclusion: Among ocular scores, ptosis significantly 
worsened (p=0.004). No statistically significant changes 
were observed in MCS and PCS (p=0.71 0.42 respectively).
Survival analyses showed that factors influencing generali-
zation were age of onset and treatment (longer stability in 
younger treated patients, p=0.01).Patients with anti-AChR-
Abs above  mean value of 29.5 pmol/ml had high risk of 
generalization (p=0.001)confirmed on multivariate analysis 
(HR 3.67, 95%CI 1.35-9.9).Patients aged more than 50 had 
higher risk of worsening (HR 3.00, 95% CI 1.2-7.1) than 
younger subjects.
Disclosure: Nothing to disclose
P3256
LMNA-related congenital muscular  
dystrophy whole-body MRI fingerprint:  
description and comparison with  
SEPN1-related myopathy
D. Gómez Andrés1, K. Hankiewicz2, A. Felter3, B. Doré3,  
I. Dabaj2, B. Estournet2, P. Richard4, R.Y. Carlier3,  
S. Quijano-Roy2
1Hospital Universitario La Paz, Pediatric Neurology, Mad-
rid, Spain, 2Hôpital Raymond Poincaré, Centre de Référence 
Maladies Neuromusculaires GNMH. Service de Pédiatrie, 
Garches, France, 3Hôpital Raymond Poincaré, Service de 
Radiologie, Garches, France, 4GH Pitié-Salpêtrière, Inserm, 
UMRS_974, 4) U.F. Cardiogénétique et Myogénétique, Ser-
vice de Biochimie Métabolique, Paris, France
Background and aims: Congenital muscular dystrophies 
(CMD) are genetically heterogeneous disorders. Molecular 
diagnosis is important for genetic counselling and clinical 
care but it may be difficult to establish due to overlap-
ping clinical and histological features. Whole-body MRI 
(WBMRI) could be a complementary test to orientate dia-
gnosis. We aim to define the fingerprint of muscle affection 
in LMNA-related CMD (L-CMD) and to compare it with 
the pattern described in SEPN1-related myopathy (SEPN-
RM).
Methods: Signal abnormality and atrophy in 109 muscles 
using T1 weighthed WBMRI technique were scored by se-
miquantitative scales in 8 L-CMD patients. Heatmaps were 
used to represent the muscle involvement. Comparison 
with the pattern shown by 9 SEPN1-RM patients was made 
using conventional and regularized random forests.
Results: LMNA patients showed predominant signal ab-
normalities in the erector spinae, serratus anterior, subsca-
pularis, gluteii medius and minimum, vastii, adductor ma-
gnus and longus, semimembranosus, medial gastrocnemius 
and soleus muscles.
In addition, atrophy was observed in the glutei medius and 
minimum muscles as well as the scapular girdle and tensor 
fascia latae. Head muscles, flexor digitorum longus, and ti-
bialis posterior muscles tended to be spared. Psoas, sterno-
cleidomastoid, gracilis and sartorius muscles were often 
preserved from infiltration although sometimes atrophied.
Random forest revealed that atrophy and infiltration of glu-
teus minimum, atrophy of sternocleidomastoid and particu-
larly, atrophy of semimembranosus were the most relevant 
muscles to distinguish between L-CMD and SEPN1-RM.
Conclusion: WBMRI shows a selective pattern in children 
with L-CMD. Artificial intelligence techniques identified a 
reduced number of muscles of interest in the differential 
diagnosis between this entity and SEPN1-RM.
Disclosure: This work was financially supported by the As-
sistance Publique des Hôpitaux de Paris (APHP), Institute 
Nationale de la Santé (INSERM), Université de Versailles 
Saint Quentin-en-Yvelines (UVSQ) and Ministerio de Sa-
nidad (España).
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Single referral center study in Serbia: a 
case series of 41 patients with congenital 
myasthenic syndromes
A. Kosac1, V. Milic Rasic2, J. Mladenovic1, S. Todorovic3,  
G. Vlahovic4, V. Rakocevic Stojanovic5, D. Savic Pavicevic6, 
H. Lochmuller7
1Clinic for neurology and psychiatry for children and youth, 
Belgrade, Serbia, 2Clinic for neurology and psychiatry for 
children and youth, Faculty of Medicine, University of Bel-
grade, Belgrade, Serbia, 3Clinic for neurology and psychi-
atry for children and youth, Belgrade, Serbia, 4Mother and 
Child Health Care Institute, Belgrade, Serbia, Department of 
Neurology, Belgrade, Serbia, 5Clinic of neurology, Clinical 
Center of Serbia, Faculty of Medicine, University of Belgrade, 
Belgrade, Serbia, 6Faculty of Biology, University of Belgrade, 
Belgrade, Serbia, 7Institute of Genetic Medicine, Newcastle 
University, Newcastle, United Kingdom
Background and aims: Congenital myasthenic syndromes 
(CMS) are rare, heterogeneous group of disorders which 
are caused by inborn defect of the structure/ function of the 
neuromuscular junction. The aim of this study was to pre-
sent both clinical and genetic characteristics of the series of 
patients with CMS.
Methods: A retrospective study based on the patient’s me-
dical records examined and treated in the clinic under sus-
picion of CMS in the period between 2000 and 2014. Diag-
nosis of CMS was established after carrying out necessary 
clinical and electrophysiological examinations. All patients 
were analyzed at the genetic level. The descriptive statistical 
model was applied.
Results: 41 patients (21 male and 20 female), from 28 fa-
milies, were diagnosed with CMS. Diagnosis of CMS was 
defined at the genetic level in 32 (78%), out of which 31 
with postsynaptic CMS, 1 with synaptic CMS and no pati-
ents with presynaptic CMS. Positive neostigmine test was 
observed in 38 out of 40 patients. Repetitive nerve stimula-
tion test was positive in 18 out of 29 tested patients. Among 
patients with postsynaptic CMS, 26 were diagnosed with 
CHRNE (1267delG), 3 with RAPSN and 2 patients with 
CHRNB1. All patients with 1267delG mutation were gypsi-
es, and had ptosis, ophthalmoparesis and pathological fati-
gability; delayed psychomotor development had 42%; non/
slowly progressive course of the disease 92% and 77% of 
patients showed good clinical response to pyridostigmine.
Conclusion: Results suggest possible algorithm when di-
agnosing CMS in Balkan region: with predominance of 
postsynaptic CMS in the first place mutation in CHRNE, 
which should be considered first.
Disclosure: Nothing to disclose
P3258
Long-term follow-up in patients with the 
Lambert-Eaton myasthenic syndrome
A.F. Lipka1, M.J. Titulaer2, J.J. Verschuuren1
1Leiden, The Netherlands, 2Erasmus Medical Center, Neurolo-
gy, Rotterdam, The Netherlands
Background and aims: Lambert-Eaton myasthenic syn-
drome (LEMS) is an autoimmune disorder causing fluctu-
ating muscle weakness and autonomic dysfunction. Symp-
toms usually progress over the first months. After diagnosis, 
symptoms can vary between long-lasting remission upon 
treatment, frequent fluctuations, and permanent disability. 
Few, small studies have characterized functional impair-
ments of LEMS patients over a longer period of time.
Methods: Disease course in LEMS patients was recorded 
retrospectively, using a structured interview combined with 
medical records. We used modified Rankin Scale (mRS) 
and Karnofsky performance scales (KPS) to grade functio-
nal impairment. 
Results: 23 LEMS patients (including 6 with lung cancer) 
were included, with a median follow-up of 63 months (ran-
ge 3 months – 29 years). 2 patients died 16 and 20 months 
after onset because of lung cancer. 21 patients (91%) repor-
ted secondary progression after initial onset, before LEMS 
was diagnosed. At diagnosis, 8 patients (35%) were depen-
dent for self-care (KPS<70), decreasing to 19% at 1 year 
afterwards. 16 patients were only treated symptomatically, 
7 with immunosuppressive drugs. Distribution of KPS and 
mRS over the disease course and at maximum severity are 
detailed in Fig 1 and 2. Exacerbations after diagnosis were 
present in a minority of 10/23 (43%) patients. 
Conclusion: A majority of LEMS patients in our study re-
port a stable disease course after diagnosis and treatment. 
Most patients either remain or become independent for 
self-care over time, after appropriate treatment. 
Disclosure: Nothing to disclose
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Malonyl-CoA inhibits not only carnitine 
palmitoyltransferase II but even more  
pronounced the S113L variant of this  
enzyme
L. Motlagh1, R. Golbik2, W. Sippl3, S. Zierz4
1Halle, Germany, 2Martin Luther University Halle-Witten-
berg, Institute of Biochemistry and Biotechnology, Halle, 
Germany, 3Martin Luther University Halle-Wittenberg, Insti-
tute of Pharmacy, Halle, Germany, 4Martin Luther University 
Halle-Wittenberg, Department of Neurology, Halle, Germany
Background and aims: It is still the prevailing view that 
only carnitine palmitoyltransferase (CPT) I but not CPT II 
is inhibited by malonyl-CoA. The almost complete inhibi-
tion of total CPT activity (i.e. CPT I and CPT II) by malo-
nyl-CoA in muscle homogenates from patients with CPT II 
deficiency has been interpreted either as a lack of an active 
enzyme or an abnormal sensitivity of the mutated CPT II to 
malonyl-CoA. Muscle CPT II deficiency is the most com-
mon defect of lipid metabolism in skeletal muscle. In about 
90% of patients the underlying defect is a S113L mutation 
in the CPT II gene.
Methods: Recombinant His6-N-hCPT2 and His6-N-
hCPT2/S113L were produced and characterized according 
to their functional and regulatory properties. A model of 
malonyl-CoA binding to wild type and mutated CPT II is 
suggested by docking studies.
Results: The wild type and its variant S113L showed the 
same enzymatic activity. Both enzymes were inhibited by 
malonyl-CoA. This inhibition was, however, significantly 
more pronounced for the mutated enzyme.
The mutated enzyme revealed an abnormal thermal de-
stabilization at 40°C. This temperature might simulate the 
fever situation, which is known to provoke attacks of myo-
globinuria in CPT II-deficient patients. 
Conclusion: Thus, the problems of CPT II-deficient pati-
ents are not due to a loss of catalytically active enzyme but 
rather might be due to the impaired thermal stability and an 
abnormal regulation.
These results clearly indicate that CPT II can also be inhi-
bited by malonyl-CoA. This inhibition is, however, signifi-
cantly more pronounced in CPT II-deficient patients.
Disclosure: Nothing to disclose
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Longitudinal white matter alteration in  
patients with moderate to severe  
consciousness disorder due to traffic 
accident-related brain injury
H. Abe1, K. Shimoji2, T. Kondo3, T. Kochiyama4, T. Chiba5, 
Y. Nagamine6, S. Fujiwara7, Y. Oouchida8, S.-I. Izumi9
1Kohnan Hospital Tohoku Ryogo center, Department of Reha-
bilitation Medicine, Sendai, Japan, 2Tokyo Metropolitan Ger-
iatric Hospital, Department of Diagnostic Radiology, Tokyo, 
Japan, 3Graduate School of Medicine, Tohoku University, 
Department of Physical Medicine and Rehabilitation, Sendai, 
Japan, 4Brain Activity Imaging Center, Advanced Telecommu-
nications Research Institute, Kyoto, Japan, 5Kohnan Hospital, 
Department of Radiology, Sendai, Japan, 6Kohnan Hospital 
Tohoku Ryogo center, Department of Neurosurgery, Sendai, 
Japan, 7Kohnan Hospital, Department of Nerurosugery, 
Sendai, Japan, 8 Graduate School of Medicine, Tohoku Uni-
versity, Department of Physical Medicine and Rehabilitation, 
Sendai, Japan, 9Graduate School of Biomedical Engineering, 
Tohoku University, Department of Physical Medicine and 
Rehabilitation, Sendai, Japan
Background and aims: We analysed the longitudinal 
white matter (WM) alteration using whole brain and regio-
nal brain diffusion tensor imaging analysis in patients with 
consciousness disorder (CD). Furthermore, we investigated 
whether WM alteration was correlated with the degree of 
CD.    
Methods: 7 patients with CD due to traffic accident-related 
brain injury underwent diffusion tensor imaging with a 3T 
magnetic resonance imaging. First and second scans were 
performed at 135–400 days and 288–849 days after insults, 
respectively. The severity of CD was measured using the 
Kohnan score, which measures the recovery from severe 
persistent vegetative state. We analysed the fractional an-
isotropy (FA) value using the tract-based spatial statistics 
technique (whole-brain analysis). We subsequently focused 
on measuring the mean FA value of the forceps minor (FM) 
of all subjects by tract-specific analysis (regional brain ana-
lysis). We used Pearson correlation coefficients to evaluate 
the relationship between FA value and the degree of impro-
vement from CD.
Results: In the whole-brain analysis, FA values significant-
ly decreased in part of FM at second scan p<0.05, family-
wise error corrected). Further, in the regional brain analy-
sis, mean FA value significantly decreased at second scan 
(0.57±0.4 at first, 0.53±0.3 at second scan). A significant 
positive correlation was observed between the improving 
CD and the number of voxels with a FA value >0.5 in whole 
brain (r=0.78, P<0.05). 
Result of TBSS(tract-based spatial statistics technique)
Results of TSA(tract-specific analysis) at first scan (one patient).
Result of TSA at second scan (one patient)
Conclusion: Our results show that microstructural WM 
changes occur in patients with CD. FA values may be useful 
indices of WM alterations in patients with CD.
Disclosure: This study was supported by a medical research 
grant on traffic accident from the General Insurance Asso-
ciation of Japan. This study is supported by a Grant-in-Aid 
for scientific research in innovative areas (Comprehensive 
Brain Science Network) from the Ministry of Education, 
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Promotion of axonal collateral branching 
as potential mechanism underlying  
erythropoietin-induced poststroke  
plasticity
D.M. Hermann, E. Sanchez
Essen, Germany
Background and aims: We have previously demonstrated 
that erythropoietin (Epo) induces contralesional pyrami-
dal plasticity after transient middle cerebral artery occlu-
sion (t-MCAO), thereby enhancing neurological recovery.
Methods: To elucidate mechanisms underlying this pro-
cess we exposed embryonic cortical neurons to increasing 
concentrations of Epo for 24h during the polarization phase 
in vitro.
Results: Contrary to what was expected, we found that 
high concentrations of Epo (50 I.U./mL) did not change the 
length of the axon but reduced the number of branches at 20 
µm from the soma as measured by Scholl analysis (8.0±1.5 
(control) vs. 6.0±0.5 (Epo treated); P<0.01). However the 
density of small collateral sprouts was significantly increa-
sed when compared to control (1.3±1.3 (control) vs 3.0±1.7 
(Epo treated) collaterals/ 20µm; P<0.001). Interestingly, 
this increase in collateral branching was accompanied by an 
overall increase in the ratio of tubulin acetylation (+50% in 
Epo treated; P<0.001) and a decrease of actin signal (-50% 
in Epo treated; P<0.001) at the tip of the growth cone.
Conclusion: The balance of tyrosylated and acetylated tu-
bulin determines the dynamics of polymerization of micro-
tubuli. High levels of tyrosylated tubulin are necessary for 
axonal growth whereas acetylated tubulin is a more stable 
form of tubulin which enhances the mobility of kinesin-1 
and axonal specification. Our data provide important in-
sight into how Epo influences brain plasticity poststroke, 
identifying axonal collateral formation as potential thera-
peutic target.
Disclosure: Nothing to disclose
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Simple prognostic scale for traumatic 
brain injury patients: 5-year prospective 
population study
A. Korchut, S. Szklener, K. Rejdak
Lublin, Poland
Background and aims: Traumatic brain injury (TBI) is a 
major global public health issue so that searching for new 
prognostic tools can be useful to create optimal strategy for 
neuroprotection of patients after TBI. We focused on deve-
loping of prognostic scale based on admission characteris-
tics which would allow for application of the model before 
in-hospital therapeutic interventions.
Methods: In this paper we present the prognostic value 
of factors on admission after TBI by using univariate and 
multivariable analysis. The test group comprised of 208 
patients after TBI (24 excluded from the study) who were 
admitted to Neurology Department of Lublin Medical Uni-
versity. In the tested group were patients with full recovery 
outcome and unfavorable outcome, based on the Glasgow 
Outcome Scale (GOS) at 6 months after injury.
Results: The independent factors on admission after TBI 
include: age, Glasgow Coma Scale (GCS), systolic blood 
pressure (SBP), Marshall CT classification. The four cate-
gories create simple prognostic scale in TBI. The scale pro-
vides a score in the range from 0 to 6 points. Patients with a 
score ≤2 achieved usually full recovery and with a score >2 
points were assessed as unfavorable outcome. The scale as 
a prognostic background to assess full recovery of patients 
after TBI is characterised by high sensitivity 97.22% and 
specificity 75.00%, positive predictive value 93.30% and 
negative predictive value 88.20%. Youden index for the 
scale was 0.7222.
Conclusion: Prognostic Scale in TBI could be a useful cli-
nical tool for easy and fast assessing of patients after trau-
matic brain injury. 
Disclosure: Nothing to disclose
P3265
An exploratory intervention study  
suggests clinical benefits of training in 
chronic stroke to be paralleled by changes 
in brain activity using repeated fMRI
B. Landsmann1, D. Pinter1, E. Pirker1, E. Wallack2,  
G. Pichler2, W. Schippinger3, S. Ropele1, T. Gattringer1,  
F. Fazekas1, C. Enzinger1
1Medical University of Graz, Neurology, Graz, Austria,  
2Albert Schweitzer Clinic Graz, Neurology, Graz, Austria,  
3Albert Schweitzer Clinic Graz, Internal Medicine, Graz, 
Austria
Background and aims: Previous studies demonstrated 
changes in sensorimotor network activation after stroke 
that have been interpreted as partly compensatory. Mobili-
ty trainings may improve both mobility and cognition and 
normalise cerebral activation. We here aimed to test these 
assumptions in an exploratory study to inform future larger 
intervention studies.
Methods: 8 patients (73.3±4.4 yrs) with chronic (mean 
interval 3.7 yrs) ischemic hemispheric stroke and residu-
al gait disturbance received a dedicated five week training. 
Before and afterwards, they underwent neuropsychological 
and gait assessments and MRI of the brain at 3T including 
a functional ankle movement paradigm. 16 healthy controls 
(HC; 68.8±5.4 yrs) followed the same protocol without in-
tervention.
Results: After training, patients showed improved mobi-
lity, memory and partly processing speed. While cerebral 
activations in HC remained constant, at baseline, patients 
compared to HC demonstrated increased activation in the 
contralesional precuneus and pre- and postcentral gyri with 
movement of the right foot. After training, these differences 
disappeared, suggesting a normalisation of brain activation 
in the patients. 
Conclusion: The present study documents the feasibility of 
a complex study including repeated MRI and outpatient re-
habilitation through close collaboration. These preliminary 
data also suggest that a training intervention focussing on 
mobility, endurance and coordination may improve cogni-
tion and induce neuronal plasticity. Future studies need to 
test the specificity and sustainability of these findings.
Disclosure: Our study has been granted by Land Steier-
mark.
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Neurorehabiliation outcome in  
hypoglycaemic encephalopathy:  
a case series
K. Lange, W. Nager, E. Walther
Schön Clinic Hamburg Eilbek, Neurocentre, Neurology and 
neurological rehabilitation, Hamburg, Germany
Background and aims: Hypoglycaemic encephalopathy 
(HE) can be defined as an unique metabolic brain insult 
[Auer, 2004], which presents as coma/stupor and blood glu-
cose levels <50mg/dl on admission, persistence of coma/
stupor for ≥24h despite normalization of blood glucose 
levels, and exclusion of any other cause of coma/stupor 
[Witsch et al., 2012]. Data on the clinical rehabilitation out-
come after the acute phase of HE is currently very limited.
Methods: Retrospective case study: patients admitted bet-
ween January 2010 and April 2014 with principal or secon-
dary diagnosis G93 (‘Other disorders of brain’). Data of 
patients with confirmed HE (apparative diagnostics; phy-
sio-, ergotherapeutical, logopedical and neuropsychologi-
cal records) were examined.
Results: Of all 311 patients with G93, 5 (1 male, 4 fema-
le) matched with the diagnosis of HE. The mean age was 
44 years (range 35-64 y.), mean initial blood glucose level 
14,2 mg/dl. Diabetes mellitus was known in one patient, 
four had attempted suicide.
The mean duration of phase B neurorehabilitation was 106 
days (range 46-177 d.). One patient was dismissed in mi-
nimally conscious state. All 4 post-suicidal patients achie-
ved alertness with relatively well preserved motor abilities 
whereas psychomotor agitation, disorientation and distinct 
cognitive restrictions remained.
The patient with poor outcome showed no cortical respon-
se in sensible evoked potentials. We found no additional 
relations between cCT/cMRT, EEG and clinical outcome.
Conclusion: In 4 of 5 patients we saw distinct cognitive 
impairments by well preserved motor abilities after the 
multimodal neurorehabilitation. This demonstrates the ne-
cessity for further, directed studies.
Disclosure: Nothing to disclose
P3267
Controlled clinical trial of repeated left 
prefrontal tDCS in patients with chronic 
minimally conscious state
C. Martial1, A. Thibaut1, M.-A. Bruno1, S. Wannez1,  
C. Chatelle2, D. Anne-Françoise3, P. Maquet4, S. Laureys1
1ULg, Cyclotron Research Centre, 2Harvard Medical School, 
Rehabilitation Hospital, 3University of Liège, Biostatistics 
Department, 4University of Liège, Cyclotron Research Centre, 
University Hospital of Liège, Liege, Belgium
Background and aims: A recent study showed that sin-
gle-session anodal transcranial direct current stimulation 
(tDCS) applied to the left dorsolateral prefrontal cortex 
(LDLPF) transiently improves consciousness in 43% of pa-
tients in minimally conscious state (MCS) (1). We here test 
the potential effects and safety of repeated tDCS in severely 
brain-damaged patients with MCS. 1. Thibaut A, Bruno 
MA, Ledoux D, Demertzi A, Laureys S. tDCS in patients 
with disorders of consciousness: sham-controlled rando-
mized double-blind study. Neurology. 2014 Apr 1;82(13): 
p. 1112-8.
Methods: In this double-blind cross-over sham-controlled 
experimental design, we delivered two sessions of repeated 
(5 days of stimulation) tDCS, either anodal or sham in a 
randomized order. We stimulated the LDLPF cortex (Figu-
re1) during twenty minutes in 20 MCS patients (12men, 
48±16 years, time since onset 78±95 months, 12 post-trau-
matic). Consciousness was assessed by the French adapta-
tion of the Coma Recovery Scale Revised (CRS-R) before 
and after each stimulation (Figure2).
Fig. 1 Left Dorsolateral Prefrontal Cortex (LDLPF)
Fig. 2 Protocol
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Results: A treatment effect was observed for the compari-
son between CRS-R total scores at baseline and after 5 days 
of real tDCS (p<0.01). Behaviorally, 10/20 patients showed 
a tDCS-related improvement; 5 patients responded after the 
first stimulation and 5 other patients responded after 2, 3 
or 4 days of stimulation (Figure3). No side effect (e.g. epi-
lepsy) was reported.
Fig. 3 Graphique
Conclusion: Our results demonstrate that repeated (5 days) 
anodal LDLPF tDCS is safe and might improve signs of 
consciousness in about half of patients in MCS. It is impor-
tant to note that the first session is not predictive for a future 
positive effect of the efficacy of the non-invasive electrical 
stimulation.
Disclosure: Nothing to disclose
P3268
Fatigue after traumatic brain injury
B. Carlan1, M. Moarcas2, R. Mircea3, A. Voina3, S. Paripas3, 
S. Diaconu4, C. Falup Pecurariu4
1Faculty of Medicine, Transilvania University Brasov, Brasov, 
Romania, 2Emergency County Hospital Brasov, Neurology, 
Brasov, Romania, 3Emergency County Hospital Brasov, Neu-
rosurgery, Brasov, Romania, 4Brasov, Romania
Background: Fatigue may appear as a consequence of 
traumatic brain injury (TBI). It can interfere with daily life 
functioning, duties at work and can also alter quality of life. 
It is  subjectively defined, but can be assesed with specific 
scales.
Objectives: To evaluate the prevalence of fatigue among 
patients with traumatic brain injury and the impact of this 
symptom on general quality of life.
Methods: We conducted a prospective study on 41 patients 
with mild and moderate TBI in a period of 6 months. The 
instruments we used to evaluate fatigue were Fatigue Sym-
ptom Inventory (FSI) and Fatigue Severity Scale (FSS).
Results: The study group included 28 men (68.29%), with 
a mean age of 43.5±17.26 years. Following traumatic brain 
injury, 69.69% of the patients experienced fatigue, of which 
27%, reported very severe and 17%  severe symptoms. 
19.51% of patients totally agreed that fatigue is among their 
three most disabling symptoms and has a negative impact 
on their  work, family or social life. Less than a quarter of 
the patients identified physical activity as a cause of their 
fatigue.
Conclusion: Fatigue is a frequent symptom reported by 
patients with traumatic brain injury. It impacts the quality 
of life and standardized methods aid the clinician in iden-
tifying it.  
Disclosure: Nothing to disclose
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Characteristics of focused and sustained 
attention and EEG of soccer players with 
recurring mild head injuries
P. Radić1, B. Radić2, M. Mišigoj-Duraković3, D. Vukleta3,  
D. Milanović3
1University of Zagreb, School of Medicine, Zagreb, Croatia, 
2University Hospital Center Zagreb, Department of Neurolo-
gy, Zagreb, Croatia, 3University of Zagreb, Faculty of Kine-
siology, Zagreb, Croatia
Background and aims: The soccer players with head inju-
ry contribution ranging from 4 to 22%. Attentional and ce-
rebral electrical activity impairments as the consequences 
of mild recurring traumatic brain injury (TBI) caused by 
heading the ball and blows to the head. 
Methods: The study included the experimental sample of 
70 male amateur soccer players, competing in a veteran 
league, with previous senior competition experience, and 
70 control subjects with no soccer experience. Cognitive 
tests were applied on the groups as well as EEG recordings 
together with spectral analysis. 
Results: Comparison between the groups revealed signi-
ficant attention deficits in experimental group (EG) in the 
tasks requiring simple reaction time (SRT) and attention 
sustained through a longer time interval. Soccer playing 
experience affected all the tests’ scores except for the de-
cision response time (DRT). In EG certain EEG changes 
were found in the frontotemporal region
Conclusion: The findings of the research that compared the 
group of soccer players and the controls indicate significant 
attention deficits in footballers when they were performing 
tasks requiring simple reaction and attention maintenance 
over a longer time interval. In the group of footballers EEG 
changes were found in the cerebral frontotemporal region. 
The found EEG changes can be related to the existent co-
gnitive deficits, but they are not cognitive disorder specific 
on their own. 
Disclosure: Nothing to disclose
P3270
Barriers to recovery from concussion
T. Shetty1, K. Cummings1, K. Halvorsen2, M. Singer3, 
J. Nguyen4
1Hospital for Special Surgery, Neurology , New York, USA, 
2Williams College, Williamstown, USA, 3Princeton University, 
Princeton, USA, 4Hospital for Special Surgery, Biostatistics 
Core, New York, USA
Background and aims: The prescribed treatment for con-
cussion is physical and cognitive rest. Physicians and pa-
tients struggle with defining the prescription of ‘rest’ and 
understanding the consequences of compliance. This study 
attempts to determine factors influencing recovery from a 
concussion and investigate the correlation between durati-
on and quality of rest and recovery time.
Methods: Patients between the ages 10 and 50 years seen 
for a concussion were asked to complete a questionnaire 
regarding their activity during their recovery period. A total 
of 220 patients were asked to participate from November 
2011- May 2014 and 45 completed it by this time.
Results: On average, females had a longer recovery time 
compared to males (116 verses 97 days, respectively). 
Alcohol (p=0.126), cigarette (p=0.037), and marijuana 
(p=0.003) consumers/users had a far greater recovery time. 
While many activities were associated with longer recovery 
times, only reading (p=0.028) and listening to audio books/
talk-radio/podcasts (p<0.001) were statistically significant. 
Patients who played video/phone/computer games had ne-
arly double the recovery time compared to those who did 
not play those games. Patients who had previous concus-
sions had a recovery length 3.5 times longer than first time 
concussion patients (p=0.011).
Participates who answered “yes” to questions regarding reading, liste-
ning to audio books, talk radio, or podcasts, or playing video, phone, 
or computer games, had  longer recoveries than those who answered 
“no”.
Conclusion: Gender, pastimes, alcohol and substance con-
sumption during recovery, and prior concussion history 
have a significant impact on recovery time. Females have a 
more difficult time recovering than males and suffer sym-
ptoms for greater lengths of time. Simple activities, such 
as reading or audiobooks, may in fact impede recovery. A 
history of multiple concussions poses greater challenges 
during recovery.
Disclosure: Dr. Shetty has a grant from GE and the NFL to 
research imaging in mild traumatic brain injury. This is a 
separate research project from the abstract above. 
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Autosomal Recessive Charcot-Marie-
Tooth disease: Clinical, electrophysiolo-
gical and genetic spectrum in a Tunisian 
series
I. Kacem1, A. Nasri1, Y. Sidhom1, L. Sellami1, Y. Hizem1,  
M. Ben Djebara1, A. Gargouri1, E. Leguern2, R. Gouider1
1Razi Hospital, Tunis, Department of Neurology/ Research 
Unit UR12SP21, Tunis, Tunisia, 2La Pitié Salpêtrière Hospi-
tal, Department of Genetics and Cytogenetics, Paris, France
Background and aims: Autosomal Recessive Charcot-
Marie-Tooth (AR-CMT) disease is a genetically heteroge-
neous group of hereditary neuropathies. It is considered as 
a rare form of CMT in European countries. Our goal is to 
report clinical, electrophysiological and genetic characte-
ristics of a Tunisian AR- CMT series.
Methods: We performed a prospective study of a cohort 
of AR-CMT Tunisian patients followed in the neurology 
department of Razi Hospital, Tunisia from 2002 to Sep-
tember 2014. Clinical and electrophysiological data were 
analyzed. Genetic screening, including most of the known 
genes involved in this form of disease, was performed and 
analyzed.
Results: Among 100 patients with CMT, we included 39 
patients belonging to19 families. Consanguinity was found 
in 94% of families. Mean age of onset was 4.2 years, mean 
Over Neuropathy limitations Scale (ONLS) was 4.7; mean 
Charcot Marie Tooth Neuropathy Score (CMTNS) of 20. 
Electrophysiological data showed demyelinating forms in 
51.5% and axonal ones in 48.5%. These later were asso-
ciated to an early onset (90.9%) (p<0.001), and a severe 
ONLS score (p=0.04). Molecular diagnosis was perfor-
med in all families; gene mutations were identified in 08 
families. The mutations in the GDAP1 gene were the most 
frequent (50%), followed by MPZ gene (25%).Four novel 
mutations were detected and characterized phenotypically.
Conclusion: ARCMT are more frequent in our country 
because of high consanguinity rate. They are characterized 
by an early onset with a severe phenotype. GDAP1 gene 
mutations still the most frequent mutation in these cases.
Disclosure: Nothing to disclose
P3272
Hypereosinophilia and vasculitic  
neuropathy without lung manifestation. 
An atypical presentation of Churg-Strauss 
syndrome.
A. Grisold1, C. Weber1, H. Kiener2, G. Kovacs3, P. Schnider4, 
E. Auff1, F. Zimprich1
1Medical University of Vienna, Department of Neurology, 
Vienna, Austria, 2Medical University of Vienna, Department 
of Internal Medicine, Vienna, Austria, 3Medical University of 
Vienna, Clinical Institute of Neurology, Vienna, Austria, 4Lan-
desklinikum Hochegg, Department of Neurology, Hochegg, 
Austria
Background and aims: Churg-Strauss syndrome (CSS) is 
a rare form of eosinophilic vasculitis associated with asth-
ma. In 20 to 50% peripheral neuropathies occur and may be 
the initial manifestation. The neuropathy is often asymme-
tric, presenting as mononeuritis multiplex. CNS involve-
ment is rare. Systemic organ manifestation is frequent. 
Hypereosinophilia and elevated p-ANCA are indicative. 
In NCV an asymmetric distribution of axonal neuropathy 
is found, EMG shows denervation depending on the stage 
of the disease. Nerve biopsies show necrotizing vasculitis 
or microvasculitis with perivascular infiltrates. Treatment 
consists of corticosteroids or cyclophosphamide.
Results: A 71-year old male patient presented with back-
pain followed by paraesthesias in all extremities. Within 3 
weeks he developed an asymmetric quadriparesis, accen-
tuated in the legs. Initially a Guillain-Barré syndrome was 
suspected and the patient received intravenous immuno-
globulins with only minor and temporary improvement. 
In the course of further evaluations a striking eosinophilia, 
elevated P-ANCA titers and CRP in combination with the 
findings of an asymmetric axonal neuropathy (mononeu-
ritis multiplex) suggested a CSS, though in the absence of 
typical lung lesions and without clinical evidence of asth-
ma the diagnostic criteria were not fully met. Nerve biopsy 
showed an axonal neuropathy with microvasculitic chan-
ges, but no evidence of necrotizing vasculitis. The patient 
responded well to steroids, followed by cyclophosphamide. 
Subsequently strength and mobility improved and sensory 
symptoms and pain diminished.
Conclusion: The combination of mononeuritis multiplex 
with hypereosinophilia is very suggestive of CSS. Despite 
the criteria were not completed, a therapeutic trial with ste-
roids is warranted as this case demonstrates.
Disclosure: Nothing to disclose
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Small fiber neuropathy associated with 
copper deficiency
M.J. Ibanez, M. Frasquet Carrera, R. Vílchez, N. Muelas,  
T. Sevilla, J.J. Vilchez
Valencia, Spain
Background and aims: Copper deficiency is a rare cause 
of myelopathy mimicking vitamin B12 deficiency subacu-
te combined degeneration. Neuropathy has been less fre-
quently described as an axonal large fiber neuropathy. To 
our knowledge, no cases of small fiber neuropathy due to 
copper deficiency have been reported. 
Methods: We report a retrospective series of 8 patients 
with copper deficiency and clinical evidence of small or 
mixed fiber neuropathy. Skin biopsy samples were taken 
at distal leg and proximal thigh levels and were analysed 
with bright-field immunohistochemistry protocol and quan-
tification of intraepidermal nerve fiber (IENF) density. Six 
muscle biopsies were also analysed by conventional histo-
logical and histochemical techniques.
Results: 5 patients showed copper deficiency and three 
other presented with both copper and B12 deficiency. 5 
patients expressed a mixed large and small fiber neuropa-
thy profile while the other three subjects only had clinical 
evidence of small fiber neuropathy with no large fiber  in-
volvement in electrophysiological studies. Half of the pati-
ent series combined myelopathic  features  with impaired 
somatosensory evoked potentials and normal spinal mag-
netic resonance imaging (MRI) Low distal IENF density 
and less pronounced proximal INF depletion was observed 
in all patients suggesting a length dependent small fiber 
neuropathy. Many muscle fibres showed absent or reduced 
COX staining. After copper supplementation myelopathic 
symptoms remain stable but dysesthesia and pain have im-
proved considerably in all cases.
Conclusion: Copper deficiency is a rare cause of small fi-
ber neuropathy and it should be included in the differential 
diagnosis. Additionally, copper supplementation may stabi-
lize or even improves the clinical symptoms.
Disclosure: Nothing to disclose
P3274
Chronic inflammatory demyelinating  
polyneuropathy (CIDP) sera reduce the 
ability of Schwann cells to support axonal 
regeneration
A. Joshi, I. Bobylev, H.C. Lehmann
University Hospital of Cologne, Neurology, Cologne, Germany
Aims: To explore the role of Schwann cell (SC) regulators 
in the pathogenesis of CIDP.
Background: Despite immunosuppressive treatment, a 
signi ficant proportion of CIDP patients experiences pro-
gressive impairment or incomplete improvement after a 
relapse, which can be attributed to the degree of axonal 
injury and incomplete regeneration. After nerve injury SC 
usually proliferate and dedifferentiate from a myelinating 
to an axon growth supporting non-myelinating phenotype. 
This phenotypic switch is controlled by a set of transcrip-
tion factors including c-Jun and p57kip2. We hypothesized 
that inflammatory mediators could alter transcriptional pro-
gram and diminish the pro-regenerative function of Sch-
wann cells in CIDP which may account for the axonal loss.
Methods: In an in vivo model of delayed nerve repair we 
explored the effects of transplanted SCs treated with va-
rious control and CIDP sera. In vitro, SC cultures were 
treated with sera from CIDP patients or non-inflammatory 
disease controls (NIC). 
Results: After chronic denervation, transplanted SCs tre-
ated with CIDP sera were much less supportive for axonal 
regeneration than those exposed to controls. In vitro, treat-
ment with CIDP sera significantly decreased the expressi-
on of c-Jun and p57kip2 and significantly altered SC mor-
phology. IgG fractions from CIDP patients did not induce 
any morphological changes. A comparative cytokine array 
revealed that CIDP sera contained significantly less gra-
nulocyte monocyte colony stimulating factor (GM-CSF) 
compared to control sera. 
Conclusion: Our data implicate that the altered inflamm-
atory cytokine network in CIDP influences regulators of SC 
differentiation, which results in suboptimal support of SC 
for axonal regeneration. 
Disclosure: Nothing to disclose
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Tafamidis reduces disease progression in 
patients with transthyretin familial amyloid 
polyneuropathy: supportive post-hoc  
analyses of a pivotal trial
D. Keohane1, J. Schwartz1, B. Gundapaneni2, M. Stewart1,  
L. Amass1
1Pfizer Inc., NY, USA, 2Inventiv Health, MA, USA
Background and aims: Safety and efficacy of once-daily 
20 mg tafamidis, a transthyretin (TTR) stabilizer, was eva-
luated in an 18-month, multicenter, randomized, double-
blind, placebo-controlled study in 128 patients with early 
symptomatic V30M TTR familial amyloid polyneuropathy 
(TTR-FAP). In the intent-to-treat population, a responder 
analysis for Neuropathy Impairment Score-Lower Limb 
(NIS-LL) (co-primary with Norfolk Quality of Life-Di-
abetic Neuropathy) favored tafamidis (p=0.07). A pre-
specified, key secondary analysis of change from baseline 
to Month 18 in NIS-LL continuous scores was significant 
(p=0.04). Additional post-hoc analyses supporting tafami-
dis for delaying progression of TTR-FAP are reported here.
Methods: Change from baseline in NIS-LL over time was 
analyzed with the addition of baseline as a covariate in a 
repeated measures model. A sensitivity multiple imputation 
analysis with imputed values based on assigned treatment 
group was also performed. Additionally, change in NIS-
LL+Σ7 (neurophysiological function composite endpoint) 
over time was assessed.
Results: When adjusted for baseline NIS-LL disease se-
verity, statistical significance in change from baseline to 
Month 18 NIS-LL was retained. The magnitude of separati-
on between placebo and tafamidis was consistent across the 
full range of baseline values (Figure 1). Treatment effect 
estimates from the multiple imputation analysis, although 
reduced, were similar to those from the analysis of change 
from baseline to Month 18 as a continuous variable, and 
remained significant (Table 1). Significant differences bet-
ween treatment groups were observed for NIS-LL+Σ7 at 
Months 12 and 18 (Figure 2).
Figure 1. Baseline-adjusted change from baseline in NIS-LL at month 
18
Table 1. Imputation results for NIS-LL change from baseline to month 
18 analysis 
Figure 2. NIS-LL +Σ7 change from baseline at months 6, 12, and 18
Conclusion: The beneficial effects of tafamidis in delaying 
neurological impairment in TTR-FAP are further supported 
by these post-hoc analyses.
Disclosure: This study was funded by Pfizer Inc. 
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Validation of mEGOS score as a predictor 
of outcome among Guillain Barré  
syndrome patients in Thailand
K. Kulkantrakorn, P. Sukphulloprat
Thammasat University, Internal Medicine, Pathumthani, 
Thailand
Background and aims: Survivors from Guillain Barré 
syndrome (GBS) often had longterm disability. Data about 
prognostic factors are sparse in Thailand. The objective of 
this study is to validate the well recognized clinical pro-
gnostic scoring system, modified Erasmus outcome score 
(mEGOS) among GBS patients in Thailand.
Methods: Retrospective study of GBS patients who were 
at least 15 years old, admitted to Thammasat University 
Hospital and Bangkok Hospital between 1st January 2009 
and 30th November 2014. Correlation and regression analy-
sis between mEGOS at admission and severe motor disabi-
lity at last follow up was performed.
Results: 30 patients were recruited. Demographic data 
are as follows; 60% male; average age 54 years; Asian 
60%, European 20%, others 10%. Clinical subtypes are 
classic GBS 83.3%, PCB 3.3%, acute pharyngeal weak-
ness 3.3%, bifacial weakness with paresthesia 3.3%, clas-
sic MFS 3.3%, acute opthalmoparesis 3.3%. Average GBS 
disability score at admission was 2.9. Immunotherapy was 
IVIg 83.3%, plasma exchange 3.3%, steroid 3.3%. Average 
length of stay was 14.2 days, assisted ventilation rate was 
13.3%. After one-year follow-up, average GBS disability 
score was 2, good outcome (score <3) was 63.3% and no 
death. Significant correlation between mEGOS and seve-
re motor disability was observed (correlation coefficient 
0.409, p-value 0.025). Optimal cut-off value for mEGOS 
was estimated by logistic regression analysis to be 4 (AUC 
0.72)
Conclusion: mEGOS has a good performance for predic-
tion of severe motor disability among GBS patients in Thai-
land
Disclosure: Nothing to disclose
P3277
Carpal tunnel neuropathy: a study of  
1600 successive cases according to  
gender, age and severity
P. Lebrun-Grandie1, L. Letenneur2
1Périgieux, France, 2INSERM U897, ISPED case 11, 146 rue 
Léo Saignat, 33076 Bordeaux Cedex, Bordeaux, France
Background and aims: The Carpal Tunnel Syndrome 
(CTS) is the most frequent focal neuropathy. Diagnosing 
a CTS is a clinical approach and ENMG performs a car-
pal tunnel neuropathy (CTN) diagnosis.  We developed a 
CTN electrodiagnosis (EDX) approach presented at the 
AAN 2010 that gives a semi-quantitative estimation with 
the measurement of the potential amplitude and of the mu-
scle denervation. The objective is to describe the severity of 
CTN according to age and gender.    
Methods: Patients were recruited in private practice, con-
secutively included in 2009-2014 when EDX of CTN iden-
tified incident cases. Paresthesias associated with radiculo-
pathy, arthropathy or other origin were excluded. Severity 
of CTN is the critical point for surgical decision and was 
evaluated in 2 levels according to the sensitive amplitude 
of the median nerve.    
Results: Of the 1600 patients, 1117 (70%) were women. 
Severe CTN was observed in 740 subjects (46.2%). Men 
showed more severe CTN than women (55% vs 42%). Se-
verity increased with age: in men, 63% had severe CTN at 
55-75 years and 89% after age 75. In women, it was 45% 
and 85% respectively.      
Conclusion: The diagnostic of CTN, more than CTS, and 
the definition of a severe stage is a key for the decision of 
surgery treatment. Severe CTN occurs frequently in pati-
ents examined in a private doctor setting and is more pre-
valent in men. Severe CTN increases with age and appears 
early in men.
Disclosure: Nothing to disclose
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Defining central nervous system  
involvement in patients with acquired  
demyelinating peripheral neuropathies
L. Vacchi1, M.A. Rocca1, N. Riva2, R. Fazio3, E. Pagani1,  
M. Comola3, A. Falini4, G. Comi3, M. Filippi1
1San Raffaele Scientific Institute, Vita-Salute San Raffaele 
University, Neuroimaging Research Unit, Milan, Italy, 2San 
Raffaele Hospital, Milan, Italy, 3San Raffaele Scientific In-
stitute, Vita-Salute San Raffaele University, Department of 
Neurology, Milan, Italy, 4Università Vita-Salute San Raffaele, 
Neuroradiology, Milan, Italy
Background and aims: Polyneuropathies (PNP) include 
heterogeneous conditions in term of aetiology, clinical pre-
sentation, prognosis and treatment. We explored the pre-
sence and distribution of brain white matter (WM) and gray 
matter (GM) structural abnormalities in patients with chro-
nic acquired demyelinating PNP.
Methods: We recruited 16 demyelinating neuropathy as-
sociated with IgM antibodies against myelin-associated 
glycoprotein (antiMAG-PNP), 16 chronic inflammatory 
demyelinating polyneuropathy (CIDP) patients, and 32 
age- and gender-matched healthy controls (HC). Voxel-
wise methods were used to define the regional distribution 
of damage in the brain GM and WM.
Results: Compared to HC, both PNP groups had increased 
right cerebellar volume. CIDP patients had significant atro-
phy of the left middle-inferior temporal gyrus and left in-
ferior frontal gyrus. Moreover, a distributed pattern of WM 
atrophy and reduced fractional anisotropy (FA) was detec-
ted, involving the bilateral corona radiata, corpus callosum, 
external capsule, cingulum, left superior longitudinal fasci-
culum and right internal capsulae. AntiMAG-PNP patients 
had decreased mean diffusivity (MD) in posterior thalamic 
radiations and left sagittal stratum, as well as decreased 
axial diffusivity (AD) in bilateral corona radiata, internal 
capsule, sagittal stratum, corticospinal tracts, thalamic ra-
diations, left corpus callosum, external capsule and fornix. 
Similar AD abnormalities were detected in antiMAG vs 
CIDP patients.
Conclusion: Distributed CNS abnormalities occur in PNP 
patients. Increased cerebellar volume could be an index of 
a compensatory mechanism, while WM alterations in CIDP 
support the occurrence of central myelin involvement. The 
different behaviour of FA, MD and AD indices may sug-
gests different pathogenetic mechanisms, which may con-
tribute to explain differences in clinical profiles.
Disclosure: Nothing to disclose
416      Poster presentation with discussion
© 2015 European Journal of Neurology, 22 (Suppl. 1), 120–483
Spinal cord and root disorders 2
P3279
A rare cause of cervical myelopathy with 
cutaneous diagnostic clues
I. McGurgan, R. Lonergan, C. McGuigan
St Vincent’s University Hospital, Department of Neurology, 
Dublin, Ireland
Background and aims: Spinal vascular malformations re-
present a rare, treatable cause of myelopathy and frequently 
provide a diagnostic challenge. Spinal dural AVF (DAVF) 
is the most commonly detected malformation, accounting 
for 70%. DAVFs originate predominantly in the thoraco-
lumbar spine and typically affect middle-aged men. Repor-
ted is a rare case of a DAVF involving the cervical cord 
diagnosed in a patient with progressive myelopathy and an 
associated medical condition.
Case Report: A 55-year-old man presented with a three-
month history of progressive, bilateral lower limb weak-
ness. Examination demonstrated a spastic paraparesis and 
multiple cutaneous telangiectasias. Subsequent develop-
ment of upper limb weakness, acute urinary retention and 
eventually respiratory compromise resulted in requirement 
for ventilatory support. MR imaging of spine revealed dif-
fuse T2 hyperintensity in the cervical cord with gadolinium 
enhancement and cord expansion. Immunomodulatory the-
rapy for a presumed diagnosis of transverse myelitis yiel-
ded no response so a vascular aetiology was suspected.
Results: Spinal angiography demonstrated a DAVF invol-
ving the upper cervical cord. Endovascular embolisation 
was successfully performed and a marked clinical impro-
vement was acheived. A clinical diagnosis of hereditary 
haemorrhagic telangiectasia (Osler-Weber-Rendu syndro-
me [OWR]) was also made and DAVF has been reported as 
a rare association with OWR.
Conclusion: Cervical DAVFs can cause progressive my-
elopathy, radiculopathy, brainstem dysfunction and sub-
arachnoid haemorrhage. Management typically comprises 
either endovascular embolisation or surgical interruption. 
A clinical association with hereditary haemorrhagic telan-
giectasia (Osler-Weber-Rendu syndrome) was made in this 
case, and to our knowledge this represents only the second 
such reported case in the international literature.
Disclosure: Nothing to disclose
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Uncommon extradural lesion causing  
spinal canal compression – juxtafacet cyst
P. Orosz1, I. Szőcs1, G. Varallyay2, I. Zsigmond2, G. Rudas2, 
D. Bereczki1, I. Vastagh1
1Semmelweis University, Department of Neurology, Budapest, 
Hungary, 2Semmelweis University, MR Research Center, Bu-
dapest, Hungary
Background and aims: Juxtafacet cysts are uncommon 
degenerative lesions of the joints, they can present with 
nerve root, myelon and cauda equina compressive syn-
dromes. Lumbar (L) 4 and 5 levels of the spine are most 
commonly affected, cervical (C) cysts are extremely rare. 
Several cases of hemorrhage into juxtafacet cysts causing 
acute symptoms have been reported, but chronic progres-
sive outcome can be present as well. Magnetic resonance 
(MR) imaging is the first choice diagnostic technique. Sur-
gical resection of the cyst is indicated in case of significant 
neurologic deficits and pain. 
Case Report: We report two cases of chronic progressive 
synovial cysts resulting in myelon compressive symptoms. 
A 51-year-old male patient was presenting with cervical 
and upper back pain. His examination revealed mild spas-
tic paraparesis with left dominance and hypaesthesia distal 
from thoracal (Th) 10 segment. Cervicothoracal comput-
ed tomography (CT) and MR imaging showed a synovial 
cyst at the  CVII and ThI level of the spine. A 46-year-old 
female patient was complaining about left sided lumbar 
back pain, paresthesia and weakness of her left foot. Her 
neurological examination proved palsy of foot extensors 
and Achilles areflexia on the affected side. Two distinct sy-
novial cysts causing spinal canal stenosis and nerve root 
compression at the LIV and V segments were detected by 
lumbar MR imaging.
Results: Cysts were neurosurgically removed, histopatho-
logical examinations confirmed the diagnosis of synovial 
cyst. Post-operatively both patients became pain free and 
had complete resolution of their symptoms.
Conclusion: The possibility of juxtafacet cysts has to be 
considered in the differential diagnosis of epidural com-
pressive syndromes.
Disclosure: Nothing to disclose
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Spinal pathology in girls with anorectal 
malformations
F. Otamurodov, Y.N. Madjidova, N. Ergasheva
Tashkent, Uzbekistan
Background and aims: To study incidence rate and clini-
cal events of the associated disorders of the pelvic organ 
functions in the girls with anorectal malformations.
Methods and Materials: The investigation included 185 
girls with anorectal malformations. The age of patients 
fluctuated from the first day of life to 15 years. For iden-
tification of the accompanying  defects of the other organs 
and systems the patients were performed complex clinical, 
ultrasound, X-Ray, MSCT (multi-slice computer tomogra-
phy) and MRI (Magnetic resonance imaging) procedures.
Results: After performance of reconstructive surgeries in 
spite of good anatomic form in the patients there was noted 
complication looking-like chronic constipation or  inconti-
nence. In these patients were performed MSCT and MRI 
investigations of the sacrococcygeal area. The associated 
malformations of the spinal cord were found in 30 patients. 
Of them in 18 girls there was revealed Spina bifida of the 
sacrococcygeal site, in 7 – coccygeal agnesia, of them 4 
with deformation of the of the sacral vertebrates. The de-
formation of the spinal cord due to additional vertebrates 
in the various sites – in 4 patients. Meningocele of the 
lumbosacral site was found in one patient. As a rule in the 
malformations of the sacrococcygeal part of the spine the 
development of the sacral plexus is affected the branches of 
which innervate the sphincter apparatus of the bladder and 
rectum that may contribute to decrease in tactile sensitivity 
of perineum and functional disorders.
Conclusion: Thus, the treatment of associated anomalies 
of the spinal cord development in children with anorectal 
anomalies  should be performed parallel with team of adja-
cent specialists.
Disclosure: Nothing to disclose
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Vertebral Artery Dissection (VAD)  
presenting as a Brown Sequard syndrome: 
a case report and literature review
S. Qureshi, S. Omer
St George’s Hospital, Neurology, London, United Kingdom
Background and aims: We report a case of atraumatic 
spontaneous vertebral artery dissection in a middle aged 
lady resulting in cervical cord lesion presenting as Brown 
Sequard Syndrome. Vertebral artery dissection commonly 
presents as posterior headache or neck pain accompanied or 
followed by posterior circulation transient ischemic attack 
or stroke. Rare clinical features include isolated headache 
or neck pain, cervical spinal cord ischemia and cervical 
root impairment. Isolated ischemia of the cervical spinal 
cord is an uncommon but increasingly recognized compli-
cation of vertebral artery dissection (VAD).To the best of 
our knowledge, this is the fourth case in literature reporting 
Brown Sequard as a clinical presentation of VAD.
Case Report: A 41-year-old lady of Asian origin working 
as a part time administrator, presented with right upper arm 
pain, weakness and tingling in hand with impaired tempe-
rature sensations on left side of her body. Eight days before 
presentation she developed nausea and vertigo of sudden 
onset in morning. There was no history of trauma, mani-
pulation of neck, preceding headache or neck pain. All po-
tential causes for vertebral artery occlusion were ruled out 
and we therefore think dissection is the most likely cause.
Conclusion: Vertebral artery dissection is a serious and po-
tentially life-threatening conditon. The diagnosis should be 
considered in patients presenting with Brown Sequard syn-
drome as a result of acute cervical spinal cord ischaemia.
Disclosure: Nothing to disclose
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Background and aims: Spinal tuberculosis (ST) is a de-
structive form of tuberculosis (TB) with increasing global 
incidence. Here we present a retrospective database review 
of reported cases of ST in the Emilia Romagna Region 
(RER, northern Italy), between 1996 and 2006. 
Methods: Data for incident TB cases (1996-2006, n=5,377 
cases) in RER were retrieved from a centralized database, 
focusing on ST (i.e. ICD9=015.0x). Categorical variables 
were analyzed through chi-square test and logistic regressi-
on. Continuous variables were evaluated through Student’s 
t-test/ANOVA.    
Results: Notification rate (NR) of TB was 11.4 ca-
ses/100,000 inhabitant/year. In total, 97 ST patients (1.8% 
of total TB cases; M/F=56/41=1.37) were identified, with 
a NR=0.21 cases/100,000/year. Italian-born people (IBP) 
were 56 (57.3%): among foreign-born people (FBP), 23 
were from AFR-WHO (23.7%) and 11 from EMR-WHO 
region (11.3%). ST FBP cases were significantly younger 
than ST IBP and non-ST TB cases (respectively: 32.3±11.07, 
58.1±23.66, 51.4±22.37 years; ANOVA p<0.0001). Taking 
into account IBP as referent group, AFR patients had a 
significantly higher risk for ST (OR=2.945 IC95%:1.624-
5.342). Active TB of other sites was infrequent (Table 1). 
Alcohol abuse (n=1), diabetes (n=2), HIV+ status (n=1), 
previous diagnosis of neoplasia (n=5) were not associa-
ted with ST diagnosis; also previous history of TB (n=3, 
0.57%) was infrequent (non-ST cases=1.98%, p=0.024).    
Figure 1. Cumulative risk of ST diagnosis in IBP and FBP. The latter 
had a higher risk for earlier diagnosis (Cox regression: OR 7.08 95%CI 
4.27-11.73).
Table 1. Characteristics of ST patients in confront with non ST TB 
cases.
Table 2. ST cases by age groups and geographical origin. Multinomial 
logistic regression taking in account sex and geophical origin (for age 
distribution) and age distribution (for geographical origin).
Conclusion: ST is an important public health issue, but 
remains infrequent in the RER. Its incidence was not sig-
nificantly influenced by commonly recognized risk factors. 
Moreover, the typical patient was younger than in previous 
reports, with a lower prevalence of previously untreated or 
inadequately treated TB among cases.     
Disclosure: Nothing to disclose
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Unilateral calf enlargement: an atypical 
sign of S1 radiculopathy
T. Santos1, J. Nunes2, H. Felgueiras1, A. Martins-Campos1,  
H. Morais1
1Centro Hospitalar Vila Nova de Gaia/Espinho, Neurology, 
Vila Nova de Gaia, Portugal, 2Centro Hospitalar Vila Nova de 
Gaia/Espinho, Imaging, Vila Nova de Gaia, Portugal
Background and aims: The approach to unilateral calf 
enlargement represent a diagnostic challenge, particularly 
when the diagnosis remain inconclusive after excluding 
tumoral and vascular etiologies. The cardinal signs of lo-
wer motor neuron (LMN) dysfunction include amyotrophy. 
However, some LMN disorders may rarely cause muscle 
hypertrophy.
Case Report: A 58-year-old women complained of right 
inferior limb claudication and calf hypertrophy for four ye-
ars. She was thoughtfully studied by ortopedics, vascular 
surgery and rheumatology. Medical history of dislipide-
mia (suspended statins due to mild CK elevation two years 
ago). Physical examination showed a right calf circumfe-
rence of 43cm versus 39cm on the left. Neurologic exami-
nation revealed a bilateral decrease in Achilles reflex and 
hypoesthesia involving the right S1 dermatome, without 
other abnormalities.
Results: Laboratory screening was normal. Electromyo-
graphy: nerve conduction studies revealed decreased am-
plitude of right tibial compound motor action potentials; 
needle-electromyography disclosed moderate active den-
nervation and chronic neurogenic features of right medial/
lateral gastrocnemius and biceps femoris muscles. Lumbar-
MRI revealed lumbar canal stenosis with bulging of inter-
vertebral discs and hypertrophy of facet joints and ligamen-
tum flavum justifying radiculopathy secondary to right S1 
root compression.
Conclusion: The approach to radiculopathies might be 
complex, particularly when the clinical manifestations op-
pose the neurologic cardinal signs. Calf enlargement is an 
uncommon phenomenon associated with S1 radiculopathy. 
The pathophysiology remains unclear with literature sug-
gesting the hypertrophy of nondenervated fibers, abnormal 
stretching of muscle fibers and abnormal electrical activity 
as three possible mechanisms. S1 radiculopathy should be 
considered in the differential diagnosis of unilateral calf 
enlargement, particularly after excluding the most frequent 
causes.
Disclosure: Nothing to disclose
P3285
Case of delayed radiation thoracic  
myelopathy with diagnosis of multiple  
myeloma having history of autologous 
bone marrow transplant
S. Duman, M. Celebisoy, I. Tatlidil
Izmir Katip Celebi University Ataturk Research and Training 
Hospital, Neurology, Izmir, Turkey
Background and aims: Delayed Radiation Myelopathy 
(DRM) is a rare long term progressive and serious com-
plication of radiotherapy. Differential diagnosis of DRM is 
challenging due to various complications of malignancies. 
On the other hand there is no curative treatment for DRM 
which makes defining risk factors and protection of suscep-
tible subjects more important. We describe a case of thora-
cic delayed radiation myelopathy who has history having 
multiple myeloma with history of autologous bone marrow 
transplant (ABMT) and treated with irradiation to thoracic 
spinal cord due to osteolytic metastasis of spine. 
Case Report: A 60-year-old-female patient presented with 
progressive paraparesis, sensory deficit below T10. Upon 
admission she was bound to bed. Laboratory test results 
were unremarkable. Lumbar puncture revealed normal ce-
rebrospinal fluid test results. No sign of infection and pri-
mary complication of malignancy were found. Spinal Ma-
gnetic Resonance Imaging (MRI) view revealed thickening 
of distal part of spinal cord with heterogeneous T2 hyperin-
tensity. The patient had history of 2000 rad radiotherapy to 
inferior thoracic area 14 months before admission. 
Results: She was diagnosed as DRM. Pulse steroid therapy 
was initiated.  She was not responsive 10-day-pulse-steoid 
therapy. 
Conclusion: Delayed radiation myelopathy in thoracic 
segment is rare compared to cervical myelopathy.  Most of 
radiotherapy regimens are tolerable for most of the compli-
cations of radiation therapy with low risk of DRM. Howe-
ver, case reports from literature showed that chemotherapy 
and ABMT reduce the threshold of tolerance for susceptib-
le subjects. Our case is demonstrative to show the relevance 
of accompanying factors increasing the risk of DRM.
Disclosure: Nothing to disclose
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A rare case of the extensive thoracic and 
lumbar spinal cord ischemic stroke with 
fatal outcome
M. Waliszewska-Prosół1, M. Koszewicz1, S. Budrewicz1,  
M. Ejma1, P. Szewczyk2, R. Podemski1
1Wrocław Medical University, Neurology, Wroclaw, Poland, 
2Wrocław Medical University, General Radiology, Interventi-
onal Radiology and Neuroradiology, Wroclaw, Poland
Background and aims: Spinal cord infarctions are diag-
nostic challenges. They occur infrequently, constitute ap-
proximately only 1% of all strokes and may have diverse 
causes. 
Case Report: An 87-year-old man, without past medical 
history, was admitted to the Neurology Department because 
of a sudden onset (1 day) lower limbs palsy and loss of 
sphincter control. The neurological examination revealed: 
flaccid paraparesis of the lower limbs with areflexia, ne-
gative Babinski signs. There were no  abdominal reflexes. 
Pinprick and temperature sensation were absent below the 
L1 dermatome. Proprioception and vibration sense were 
intact. Patient was catheterized. MRI of the thoracic and 
lumbar spine revealed in T2WI images hyperintense area 
covering the majority of the cross section of the spinal cord 
from level Th9 to the conus medullaris. In the late follow 
up MRI this area regressed, only slight spinal cord atrophy 
was observed. Routine laboratory tests showed elevated D-
dimers, but the other tests of blood coagulation were nor-
mal as well as CSF. Tumor markers, ANA, anty ds DNA, 
cANCA, pANCA, antibodies against beta2 glykoprotein 
and anticardiolipin were within normal limits. He was tre-
ated with an osmotic diuretics, steroids and low-molecule 
weight heparin, with no clinical and radiological improve-
ment. He died 1 month after recognition, because of a pul-
monary thrombosis.
Conclusion: We report a fatal case of spinal ischaemic 
stroke. Clinical observation and atypical extensive chan-
ges in MRI, allowed us to make a diagnosis of spontaneous 
ischemic spinal cord stroke. Because of many diverse cau-
ses is should be differentiated from post-traumatic stroke, 
postoperative damage, myelitis, vasculitis and blood co-
agulation disorders. 
Disclosure: Nothing to disclose
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Secondary resistance to botulinum  
toxin-A in urinary incontinence caused  
by spinal cord injury: diagnosis and  
management
C. Zuliani1, C. Fattorello Salimbeni1, F. Cavallari2,  
E. Andretta3
1Department of Neurology, Mirano (Ve), Italy, 2Department 
of Surgery, Mirano (Ve), Italy, 3Department of Urology, Dolo 
(Ve), Italy
Background and aims: Bladder botulinum toxin-A (BTX-
A) injections are routinely used in subjects with neurogenic 
overactive bladder resistant/intolerant to anticholinergics. 
This treatment needs to be repeated periodically. Some pa-
tients may develop resistance due to neutralizing antibo-
dies formation against the neurotoxin. We evaluated the 
incidence of secondary non-responder to BTX-A in our 
Spinal Cord Injury (SCI) casuistry and the usefulness of 
the Extensor Digitorum Brevis Test (EDB-T) to detect their 
immunoresistance.
Methods: From 2006 to nowadays, at least 10 out of 63 
thoracic SCI patients became completely or partially - 
mean benefit of 45 days - unresponsive to BTX-A after a 
mean of 2.5 treatments (range 1-4). 8 out of 10 (6 males 
and 2 females, mean age 46.5 years) underwent the EDB-T 
and 7 among them were switched to IncobotulinumtoxinA, 
a free of complexing protein BTX-A, maintaining the same 
dose (200 Units). All underwent urodynamic monitoring.
Results: All the patients had detrusor-sphincter dyssiner-
gia. EDB-T confirmed immunoresistance in 7 cases, par-
tial in 3 (although 1 was clinically resistant). The switch 
to IncobotulinumtoxinA has been effective in the patient 
resulted responsive to BTX-A at the EDB-T and maintai-
ned the same shorter benefit in 2 out of the 3 resulted partial 
resistant at the EDB-T.
Conclusion: In our experience about 16% of SCI patients 
become unresponsive to BTX-A. The EDB-T, the initial in-
vestigation to confirm secondary immunoresistance, show-
ed its reliability, absolute in 7 cases, relative in 1. Switching 
therapy to a less immunogenic BTX-A has shown a clinical 
advantage only in the patient not-resistant at EDB-T.
Disclosure: Nothing to disclose
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Is it true that the combination therapy with 
aminoglycoside antibiotics enhance the 
risk of systemic neurotoxic effect of  
Botulinum toxin A?
C. Zuliani1, M. Balladelli2, G. Artuso3, E. Andretta3
1Department of Neurology, Mirano (Ve), Italy, 2Microbiology 
Unit, Dolo (Ve), Italy, 3Department of Urology, Dolo (Ve), 
Italy
Background and aims: Intravesical injections of Botuli-
num toxin-A (BTX-A) are an effective, safe and well tole-
rated therapy for neurogenic bladder overactivity refracto-
ry/intolerant to antimuscarinics. Their commonest adverse 
event is Urinary Tract Infection (UTI) thus, especially in 
recurrent UTIs due to multiresistant bacteria, it is sometime 
necessary to pre-treat with antibiotics. In these cases Ami-
noglycosides, even though in some cases they represent the 
more suitable antibiotic treatment, should be used with cau-
tion, as they may interfere with the neuromuscular trans-
mission, and thusenhance the neuromuscular block caused 
by BTX-A. We report our experience about the assocation 
iBTX-A and Am used as short therapy.
Methods: From 03/2013 to 02/2014, 23 spinal cord injured 
(SCI) patients underwent combination therapy with BTX-
A (Onabotulinum 200 Units) and Gentamycin (3-5 mg/Kg/
once a day intravenously for 5 days) chosen according to 
the antibiogram and started on average 2 days before BTX-
A injections. Patients had regular follow-up examinations 
and were also checked by phone daily for 21 days after 
BTX-A.
Results: No neurological complications were reported. 
One patient developed UTI with hyperpyrexia, caused by 
multiresistant Klebsiella Pneumoniae, 2 days after BTX-A 
and 1 day after suspension of Gentamycin.
Conclusion: The fear that the combination therapy with 
aminoglycoside antibiotics can enhance the neuromuscular 
block caused by BTX-A comes from literature of 70s-’80s, 
where cases of botulism had been reported. Our results do 
not support these data, probably because BTX-A starts to 
work when Aminoglycosides has been already eliminated. 
The combination therapy with BTX-A and Aminoglycosi-
des can therefore be considered feasible and effective to 
avoid UTI.
Disclosure: Nothing to disclose
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Clinical, functional and behavioural  
correlates of isolated, subjective memory 
complaints in rural community-dwelling 
older adults: data from the Zabùt Aging 
Project
M. Conticelli1, A. Aronica1, A.B. Cefalù2, R. Monastero1
1Università di Palermo, Dipartimento Biomedicina Speri-
mentale e Neuroscienze Cliniche, Palermo, Italy, 2Università 
di Palermo, Dipartimento Biomedico di Medicina Interna e 
Specialistica, Palermo, Italy
Background and aims: Subjective Memory Complaint 
(SMC) is an issue of growing interest in the study of mild 
cognitive impairment and dementia. We describe clinical, 
functional and behavioural correlates of isolated SMC 
(iSMC) in an Italian community-based sample.
Methods: Subjects were drawn from a 10-year follow-up 
cohort study of nondemented subjects conducted in an Ita-
lian rural village in southern Italy: the Zabùt Aging Pro-
ject. iSMC was measured using the Memory Assessment 
Clinic-Questionnaire. Covariates includes: multimorbidity 
(≥3 disease requiring treatment), number of activities lost 
in the basic (ADL-l) and instrumental activities of daily li-
ving (IADL-l), and the presence of depressive symptoms 
using the Center for Epidemiological Studies-Depression 
Scale (CES-D).
Results: 457 subjects (266 controls and 191 iSMC), aged 
≥60 years, were included in the study. Cases and cont-
rols did not significantly differ regarding demographics 
and multimorbidity. Contrarily, respondents who reported 
iSMC showed higher scores in ADL-l (p<0.001), IADL-l 
(p<0.001), and CES-D (p<0.0001) than those without. Af-
ter adjustment for demographics, iSMC was independently 
associated with ADL-l (OR=1.4, 95% CI=1.0-1.8), IADL-l 
(OR=1.7, 95% CI=1.1-2.7), and with the presence of de-
pressive symptoms (OR=2.4, 95% CI=1.5-3.8). Further ad-
justment for the apolipoprotein E4 genotype did not modify 
results. 
Conclusion: iSMC independently correlates with functio-
nal disability and depression in our population. Prospective 
analyses from the Zabùt cohort as well as data from other 
longitudinal, population-based, cohorts would be useful in 
examining the prognostic role of iSMC in nondemented 
subjects.
Disclosure: This study was supported by the Italian Minis-
try of Health, grant Giovani Ricercatori 2007 to RM (GR-
2007-686973).
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Posterior cortical atrophy: a clinical case 
series and literature review
A. Nelson1, S. Pal2
1University of Edinburgh, University of Edinburgh Medical 
School, College of Medicine and Veterinary Medicine, Edin-
burgh, United Kingdom, 2Anne Rowling Regenerative Neu-
rology Clinic, University of Edinburgh, Edinburgh, United 
Kingdom
Background and aims: Posterior Cortical Atrophy (PCA) 
is a striking neurodegenerative syndrome characterised by 
visuoperceptual impairment with eventual decline in wider 
cognition and occipitoparietal abnormalities identified on 
neuroimaging. Debilitating visual symptoms including loss 
of facial recognition, impaired depth perception, difficulty 
reading and loss of writing ability occur, with heterogene-
ous underlying pathology including Alzheimer’s Disease 
(AD) identified at post-mortem. Despite being characte-
rised 25 years ago, no validated diagnostic criteria incor-
porating clinical phenotypic and biomarker findings exist. 
We present a case series of patients with review of the li-
terature.
Methods: Patients with PCA were identified clinico-radio-
logically and details of their clinical progression, including 
history, cognitive examination, neuroimaging, including 
MRI (T1 volume, T2 and FLAIR) and 99mTc-HMPAO 
SPECT scans, and CSF, extracted from patient records.
Results: Patients were referred from various services. Vi-
suospatial deficits were common including inability to see 
movement, impaired object recognition, night blindness, 
face blindness, visual hallucinations and impaired depth 
perception. Other common deficits included loss of reading, 
writing and calculation ability, reduced fluency, impaired 
working memory and eye movement incoordination. Neu-
roimaging identified occipitoparietal abnormalities. CSF 
examination revealed changes in beta amyloid and phos-
phorylated tau suggestive of AD in 50%. Cholinesterase 
inhibitors yielded subjective symptomatic benefit in 71%.
Conclusion: PCA diagnosis is based on occipitoparietal 
symptoms, supported by imaging findings. In our series, 
HMPAO-SPECT was more sensitive than MRI in diag-
nosing PCA and more commonly detected laterality and 
frontal lobe involvement. Anti-cholinesterase treatment re-
sulted in subjective benefit suggesting the need for future 
prospective randomised controlled trials of symptomatic 
treatments.
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Mechanisms of glutamate recycling and 
replenishment at mammalian synapses
N. Senaratne1, B. Billups2
1University of Cambridge, School of Clinical Medicine, Cam-
bridge, United Kingdom, 2University of Cambridge, Depart-
ment of Pharmacology, Cambridge, United Kingdom
Background and aims: The glutamate-glutamine cycle is 
disrupted in a variety of neurodegenerative conditions such 
as Alzheimer’s disease and Huntington’s chorea. Electro-
physiological evidence that this cycle is important during 
synaptic transmission has been inconsistent. We assessed 
the physiological importance of astrocytic recycling at the 
cerebellar mossy fibre-granule cell synapse by inhibiting 
the glutamate-glutamine cycle pharmacologically and as-
sessing its effect on neurotransmitter pools.
Methods: Cerebellar slices were taken from Wistar rats 
16-21 days old. We extracellularly stimulated mossy fibres 
at 50Hz using thick-walled glass pipettes. mEPSCs from 
whole-cell voltage-clamped granule cells were identified 
using a threshold of 7mV. We inhibited presynaptic gluta-
mine uptake with 20mM of either the system A antagonist 
α-(methylamino)isobutyric acid (MeAIB) or the multi-sys-
tem inhibitor histidine.
Results: 6 cells were patched from 6 animals. mEPSC am-
plitudes were stable over time, varying by 1.0±1.13 pA over 
10 mins (7±8% change; n=7 cells; p=0.40). Neither MeAIB 
or histidine significantly reduced mean mEPSC amplitudes 
(Fig 1A): 9.9±9.6% reduction for MeAIB (p=0.38, n=4 
cells); 12±9% reduction for histidine (n=2 cells).
Figure 1: A: Mean granule cell EPSC amplitudes. B + C: Example time 
courses for single patched cells. 
Conclusion: A functional glutamate-glutamine cycle is not 
necessary for neurotransmission at the cerebellar mossy fib-
re-granule cell synapse. This contrasts with studies of cor-
tical, hippocampal and brainstem synapses and highlights 
how neurotransmitter recycling mechanisms vary across 
the mammalian brain. These results hint that disruption of 
the cycle may only contribute to neuropathology at specific 
neuronal locations, a novel concept for neurodegenerative 
conditions such as Alzheimer’s disease and Huntington’s 
chorea.
Disclosure: Nothing to disclose
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Zarit Burden Interview: a possible  
informant-based diagnostic test for  
dementia?
B. Stagg1, A.J. Larner2
1Alzheimer’s Society, Liverpool, United Kingdom, 2Walton 
Centre for Neurology and Neurosurgery, Cognitive Function 
Clinic, Liverpool, United Kingdom
Background and aims: To report the diagnostic accura-
cy of the Zarit Burden Interview (ZBI) used as an infor-
mant screening questionnaire for the detection of dementia 
and cognitive impairment, and its comparison with patient 
performance measures, Mini-Mental State Examination 
(MMSE) and mini-Addenbrooke’s Cognitive Examination 
(m-ACE).
Methods: Prospective observational study, Cognitive 
Function Clinic.
Results: In 37 consecutive patient-spouse dyads seen over 
a 5-month period (July-December 2014; patient F:M = 
10:27; age range 30-85 years, median 67 years), 14 patients 
were diagnosed with dementia, 14 with MCI, and 9 with 
subjective memory impairment (SMI) only.  Full, short, and 
screening ZBI versions (22, 12, and 4-items respectively) 
showed overlapping scores for each diagnosis, and no cor-
relation with patient age, MMSE, or m-ACE scores.  Mean 
ZBI scores did not differ significantly between dementia 
and no dementia (= MCI + SMI) groups, or between cogni-
tive impairment (= dementia + MCI) and no cognitive im-
pairment (SMI) groups.  Mean MMSE and m-ACE scores 
differed significantly between cognitive impairment and no 
cognitive impairment groups.
Conclusion: ZBI is simple to administer and acceptable 
to informants, but did not prove effective as an informant-
based measure for dementia diagnosis.  Caregiver burden 
appears to be largely independent of degree of cognitive 
impairment, and hence requires dedicated assessment to 
plan appropriate interventions.
Disclosure: Nothing to disclose
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What is the current practice of cognitive 
and motor screening in dementia clinics? 
A world-wide on-line survey.
A. Symonds, T. Bak
University of Edinburgh, Edinburgh, United Kingdom
Background and aims: Motor dysfunction is increasingly 
recognised as an important feature of dementias and other 
cognitive disorders. However, in contrast to cognitive as-
sessment the practice of motor examination is less consis-
tent.
Methods or Materials or Case Report: In order to de-
termine the current practice regarding cognitive and motor 
examination in dementia clinics, we distributed a brief 10 
question on-line survey in 10 different languages to demen-
tia clinics across the world.
Results: We have received 317 responses from 31 coun-
tries, mostly from neurologists, psychiatrists and geriat-
ricians. Most clinicians estimated the frequency of motor 
symptoms in dementia clinic patients as 0-20%, lower than 
that reported in the literature. Non-disease specific cogniti-
ve screening tools (most commonly the Mini Mental State 
Examination (MMSE) were used by 98% of clinicians. De-
pending on specialty, only 35–75% of clinicians routinely 
performed a motor exam and only 30% used a motor scree-
ning test. All motor screening tests were disease-specific; 
the most widely used was Unified Parkinson’s Disease Ra-
tings Scale (UPDRS) -III.
Conclusion: Cognitive screening, most often using valida-
ted tools such as MMSE, forms an integral part of demen-
tia assessment across the world. In contrast, the practice of 
motor examination varies depending on specialty and the 
frequency of motor symptoms tends to be underestimated. 
While the cognitive screening tests can be applied to many 
forms of dementia, the motor screening tools are disease-
specific (e.g. UPDRS-III). We argue that the development 
of a generally applicable motor screening tool could incre-
ase the frequency of motor examination and enhance the 
awareness of motor symptoms in dementia. 
Disclosure: Nothing to disclose
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Evidence of diffusion-weighted MRI  
abnormalities one year prior to the onset 
of sporadic Creutzfeldt-Jakob disease
F. Verde1, N. Ticozzi1, S. Messina1, N. Calcagno1, E. Scola2, 
F. Girotti1, A. Falini3, F. Tagliavini4, V. Silani1
1Istituto Auxologico Italiano, Neurology, Milan, Italy, 2Fon-
dazione IRCCS Ospedale Maggiore Ca’ Granda, Neurora-
diology, Milan, Italy, 3Università Vita-Salute San Raffaele, 
Neuroradiology, Milan, Italy, 4IRCCS Istituto Neurologico C. 
Besta, Neuropathology, Milan, Italy
Background and aims: We describe a case of sporadic 
Creutzfeldt-Jakob disease (sCJD) with restricted diffusion 
on magnetic resonance imaging (MRI) one year prior to 
clinical onset.    
Case Report: A 65-year-old woman with headache un-
derwent brain MRI showing diffusion-weighted imaging 
(DWI) hyperintensity in the right basal temporo-occipital 
cortex (figure 1). A diagnosis of ischaemic lesions was 
made. After 12 uneventful months, she began to develop 
rapidly progressive mental deterioration. Almost concomi-
tantly, she was diagnosed with breast cancer, which was 
surgically removed. Two months later, she was admitted to 
our neurology unit.     
Fig. 1 Diffusion-weighted image from the MRI performed in June, 
2013, showing hyperintensity of the right basal temporo-occipital cor-
tex (3 Tesla scan)
Results: Neurological examination was notable for redu-
ced initiative, impairment of memory and abstract thinking, 
ideomotor apraxia, and visual agnosia. Neuropsychological 
evaluation demonstrated severe multidomain deterioration. 
Brain MRI showed extension and contralateral spread of 
the previous abnormalities (figure 2). Electroencephalo-
gram (EEG) displayed delta-wave slowing on the right he-
misphere. Cerebrospinal fluid (CSF) analysis demonstrated 
normal protein, glucose, and cells, and absence of autoanti-
bodies, but raised tau protein and detectable 14-3-3 protein. 
A diagnosis of sCJD was made.
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Fig. 2 Diffusion-weighted image from the MRI performed in Septem-
ber, 2014, demonstrating extension of the previously documented sig-
nal abnormalities, with bilateral involvement of basal temporo-occipi-
tal and parietal cortices, more marked on the right (1.5 Tesla)
Conclusion: Our case demonstrates that cortical restricted 
diffusion can be detectable on MRI up to one year before 
clinical onset of CJD, implying that prion protein deposi-
tion is an early event. Our findings could also suggest a 
possible role of DWI in predicting disease onset in familial 
cases. From a clinical standpoint, this case highlights that 
CJD should be considered not only in the contex of rapidly 
progressive dementia, but also when compatible MRI ab-
normalities are found incidentally in a cognitively normal 
person.
Disclosure: Nothing to disclose
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Characteristics of depressive symptoms 
in patients with early-onset Alzheimer’s 
disease by disease severity
B. Yoon1, K.O. Lee1, Y.S. Shim2, H.J. Kwag3
1Konyang University Hospital, Department of Neurology, 
Daejeon, Korea, Republic of, 2Bucheon St. Mary’s Hospital, 
Department of Neurology, Bucheon, Korea, Republic of, 
3Daejeon Veterans Hospital, Department of Neurology, Daeje-
on, Korea, Republic of
Background and aims: Depression shows higher inci-
dence in early-onset Alzheimer’s disease (EOAD). Howe-
ver, it is uncertain whether they change by disease severity 
and which depressive symptoms are more frequent in each 
disease stage. We investigated the differences in incidence 
and characteristics of depressive symptoms by dementia se-
verity in EOAD patients.
Methods: We enrolled 412 EOAD patients. The 15-item 
Korean version Geriatric Depression Scale (GDS-15) was 
administered to participants. We subdivided into 3 groups 
by disease severity: very mild (CDR 0.5, 191) vs mild 
(CDR 1, 180) vs moderate (CDR 2, 41). We compared indi-
vidual GDS-15 items among 3 groups.
Results: The incidence of depression by cut-off value ap-
peared relatively lower in moderate group (23.1%) than 
other groups (very mild 37.2%, mild 44.4%) (P=0.026). 
Three factors were generated, which were hopelessness/
negative thoughts(items 6,8,12,14,15), unhappiness/unsa-
tisfaction (items 1,3,5,7,11), and monotony/lack of ener-
gy (items 2,4,9,10,13). Except for memory complaints 
(10), monotony/lack of energy (2,13) were reported most 
frequently regardless of severity. Very mild and mild 
groups complained more memory problems than modera-
te group(P=0.001). Moderate group complained statisti-
cally less about unhappiness/unsatisfaction (1, P=0.048; 5, 
P=0.049; 11, P=0.036). Mild group showed tendency for 
more hopelessness/negative thoughts (12, P=0.054; 14, 
P=0.067). 
Conclusion: Symptoms by monotony/lack of energy were 
highest in all groups, however, depressive symptoms by un-
happiness/unsatisfaction significantly decreased at modera-
te stage. Moreover, mild group demonstrated tendency to 
feel hopelessness/negative thoughts higher. In conclusion, 
disease severity itself influenced incidence of depression 
and different characteristics according to disease severity 
in EOAD. 
Disclosure: Nothing to disclose
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Contralateral aberrant reinnervation in  
patients with pudendal nerve injury
J. Baron Sanchez1, G. Lacima2, R. Arca3, M. Morales3,  
C. Cabib3, J. Valls-Solé3
1Hospital Clinico de Valladolid, Neurology, Valladolid, Spain, 
2Hospital Clinic Barcelona, Gastroenterology, Barcelona, 
Spain, 3Hospital Clinic Barcelona, Neurology, Barcelona, 
Spain
Background and aims: Reinnervation after peripheral 
nerve injuries implies abnormal branching of regenerating 
axons, modification of the original distribution of muscle 
innervation and compensatory activity in neighbouring 
nerves. These may lead to an abnormal function in musc-
les that require fine motor control, such as sphincters. We 
investigated if external anal sphincter (EAS) dysfunction 
leading to incontinence was related to pudendal nerve rein-
nervation abnormalities.
Methods: In 10 patients with fecal incontinence and 3 con-
trols, we applied focal electrical stimuli with a monopolar 
needle inserted into one side and recorded responses in the 
other side. We hypothesized that the size of the contralate-
ral responses would be an indirect measure of the amount 
of abnormal contralateral reinnervation. We also recorded 
EAS needle EMG activity and pudendal nerve latency.
Results: 8 patients had abnormal needle EMG findings 
(denervation or significant jitter/blocking). Mean pudendal 
nerve latency was 2.9 ms, with absent responses in 2 ca-
ses. Patients had significantly larger contralateral responses 
that occurred at a shorter latency than in controls (response 
area of 625 µVxms in patients vs 14 µVxms in controls, 
and response latency of 11.7 ms in patients and 19.5 ms in 
controls).
Conclusion: Abnormal reinnervation of sphincter muscles 
after pudendal nerve lesion is a likely cause of anal sphinc-
ter dysfunction in patients with faecal incontinence.




Computer-assisted thermal threshold  
testing - our experience and normative 
data
V. Potockova1, R. Mazanec1, J. Schlenker2
1Charles University in Prague, 2nd Faculty of Medicine, Mo-
tol University Hospital , Department of Neurology, Prague, 
Czech Republic, 2Czech Technical University in Prague, Fa-
culty of Biomedical Engineering, Prague, Czech Republic
Background and aims: Computer-assisted thermal 
threshold testing (TTT) is a quantitative psychophysical 
method that allows to test small nerve fibers (type Aδ and 
C). It is an integral part of diagnostics of small fiber neu-
ropathy (SFN) which is undetectable using standard elec-
trophysiological techniques (conduction studies, needle 
electromyography). The most common cause of SFN is 
diabetes mellitus (DM), already in preclinical stage, i.e. 
impaired glucose tolerance. The aim was to create our own 
normative data and compare it with previously published 
papers.
Methodst: We tested 50 healthy subjects (25 F + 25 M, 
5 persons in each decade from 20 to 70 years). We deter-
mined cold and warm detection threshold (CDT, WDT) 
on both extremities and body sides (thenar, tibia, dorsum). 
We examined by means of a Peltier-based thermal stimu-
lator (SENSELab - TERMOTEST MSA, contact probe 
25x50mm, Somedic, Sweden). As an investigative algo-
rithm we used a non-randomized method of limits (reaction 
time inclusive technique). Exclusion criteria included the 
absence of the most frequent causes of SFN (DM, hyper-
lipidemia, chronic alcohol abusus) and other symptoms of 
peripheral or central nervous system impairment (cerebro-
vascular, autoimmune, infectious, metabolic or toxic).
Results: CDT, WDT (Table 1). We found a statistically si-
gnificant decrease of CDT and increase of WDT values in 
lower against upper extremities. We did not prove statisti-
cally significant influence of gender and age on the values 
of thresholds.
Table 1. Values of CDT (cold detection threshold) and WDT (warm 
detection threshold)
Conclusion: Thermal threshold testing is an important tool 
of diagnostics of SFN. This method is relatively time-sa-
ving and non-invasive, but requires a training of medical 
staff and appropriate laboratory conditions. 
Disclosure: Nothing to disclose
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Neurophysiological follow-up of patients 
with celiac disease on gluten-free diet:  
a TMS study
V. Puglist1, L. Vinciguerra1, R. Ricceri1, M. Cantone1,  
G. Lanza2, M. Pennisi3, C.C.D’Agate1, R. Ferri2,  
S. Giuffrida1, R. Bella1
1University of Catania, Catania, Italy, 2Sleep Research Cen-
tre, Department of Neurology, I.C., Oasi Institute (IRCCS), 
Troina, Italy, 3Emergency Hospital “Cannizzaro”, Catania, 
Italy
Background and aims: A recent investigation showed that 
Transcranial Magnetic Stimulation (TMS) might disclose a 
subclinical neurological involvement in patients with celi-
ac disease (CD). Here we aim to compare TMS measures 
before and after the gluten-free diet in order to monitor the 
observed changes and to assess the impact on the diet cor-
tical excitability.
Methods: A sample of 13 patients from the original cohort 
of 20 was re-evaluated after approximately 2 years of an 
adequate course of gluten-free diet. Antibodies were still 
present in 3 and were borderline in 2. A screening for cog-
nitive and neuropsychiatric symptoms was repeated as well 
as the evaluation of cortical excitability by means of sing-
le and paired-pulse TMS from the first dorsal interosseous 
muscle of the dominant hand.
Results: Compared to baseline, patients showed a signifi-
cant decrease of the median resting motor threshold (34 vs 
35%, p<0.01) and a shorter central motor conduction time 
(3.8 vs 4.8 ms, p<0.01). Depressive symptoms, quantified 
with the Hamilton Depression Rating Scale, improved (2.8 
vs 5.6, p<0.01). 
Conclusion: A global increase of cortical excitability to-
gether with a faster conductivity along the cortico-spinal 
tract was observed in gluten-free diet patients, without sig-
nificant changes of the other TMS measures found at base-
line. These findings may represent a neurophysiological 
evidence that immune system dysregulation might persist 
despite the alimentary therapy, although the diet seems to 
enhance the excitability and conductivity of the central mo-
tor pathways. The impact of the gluten-free diet on subclini-
cal neurological abnormalities needs to be further explored.
Disclosure: Nothing to disclose
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Epidermal recordings can be used for  
preclinical functional assessment of visual 
pathways.
R. Santangelo1, V. Castoldi1, M. Cursi1, L. Chaabane1,  
G. Comi2, L. Leocani3
1Scientific Institute and University San Raffaele Hospital, 
Department of Neurology and INSPE-Institute of Experimen-
tal Neurology, Milan, Italy, 2University Vita-Salute, Scientific 
Institute San Raffaele, Milan, Italy, 3Scientific Institute San 
Raffaele, Department of Neurology, Milan, Italy
Background and aims: Visual Evoked Potentials (VEPs) 
are a powerful tool to evaluate the electrical conduction 
along the visual pathways, both in humans and in precli-
nical models.Traditionally, epidural screw electrodes are 
used to record VEPs in preclinical research. Here we tested 
the feasibility, in rat models, of the same technique used for 
VEPs in humans, i.e. epidermal cup electrode recording, 
avoiding invasive surgical procedures
Methods: 7 Dark Agouti (DA) rats underwent VEP recor-
ding through epidermal 6mm Ø Ag/Cl cup electrodes (cup 
recorded, CR). Flash VEPs from both eyes were recorded 
under sevoflurane volatile anesthesia once a week for 6 
weeks, measuring P1 latency from N1-P1-N2 complex. P1 
latencies from CR rats were compared to P1 latencies from 
7 age-matched DA rats which underwent epidural VEP re-
cordings through stainless screw electrodes (screw recor-
ded, SR) at the same time points. P1 latency mean values 
were compared using the ANOVA for repeated measures or 
the Conover’s free distribution method, a non-parametric 
ANOVA based on ranks in case of data not normally dis-
tributed.
Results: Morphologically, VEP traces obtained with screw 
and cup electrodes were comparable and P1 wave was 
clearly detectable. Neither significant effects nor interac-
tions of the main factors “time” and “type of electrode” 
were found on VEP latencies. 
Conclusion: Epidermal electrodes can provide VEP waves 
comparable with traditional more invasive epidural recor-
dings. Further studis are needed to compare their value in 
assessing and monitoring preclinical models of neurologi-
cal diseases
Disclosure: Part of this work was financially supported by 
Merck Serono S.A., Geneva, Switzerland. Merck Serono 
is the biopharmaceutical division of Merck KGaA, Darm-
stadt, Germany.
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Frequency of accessory deep peroneal 
nerve: electrophysiological study
O. Sinanovic, S. Zukic, N. Piric
University Clinical Center Tuzla, Neurology, Tuzla, Bosnia 
and Herzegovina
Background and aims: The different anatomical anoma-
lies of peripheral nerves occur with various frequencies in 
the population. ADPN nerve has been regarded as an ano-
malous, derived from the superficial peroneal nerve or its 
branch and supplies motor innervations for extensor digi-
torum brevis (EDB). The EDB is usually innervated exclu-
sively by the deep peroneal nerve, however, one or both of 
the EDB muscles are (partially or exclusively) innervated 
by the ADPN. Electromyography lab is the best environ-
ment for detecting presence and prevalence of this nerve, 
so present study enrolled. 
Methods: In this ongoing cross sectional descriptive stu-
dy 138 cases comprising 276 legs referred for electrodia-
gnostic studies to Electromyography Lab, Department of 
Neurology, University Clinical Center Tuzla participated in 
the study. Compound muscle action potential (CMAP) and 
Nerve conduction Velocity (NCV) of Deep Peroneal Nerve 
(DPN) were measured using EMG machine by stimulating 
DPN at knee, ankle and lateral malleolus areas accordingly, 
with recording from extensor digitorum brevis muscle.
Results: The study included 75 females (54.3%) and 63 
(45.7%) males with mean age of 46.8±17.0. ADPN was de-
tected in 27 (19.50%) patients. Among them, 6 (22.2%) had 
bilateral ADPN and in remaining 21 (77.8%) ADPN was 
unilateral (6/22.2% on right, and 15/55.5% on left side). 
Conclusion: The frequency of ADPN in this electrophy-
siological study was 19.50% (22.2% bilateral and 77.8% 
unilateral). This common anatomical variation has to be 
known in order to avoid errors in interpreting the peroneal 
NCV with detection on the EDB.
Disclosure: Nothing to disclose
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A neurophysiological investigation of a 
large population of patients affected with 
Kennedy’s disease (SBMA) confirms  
diffuse neurological involvement
M. Volpe1, G. Zara2, G. Querin1, C. Bertolin1, F. Zoccarato1,  
E. da Re1, E. Volpato1, D. Pareyson3, M. Ermani1, G. Sorarù1
1Università di Padova, Neuroscienze, Padua, Italy, 2Azienda 
Ospedaliera di Padova, Neuroscienze, Padua, Italy, 3Istituto 
Neurologico C. Besta, Milan, Italy
Background and aims: Spinal and Bulbar Muscular Atro-
phy (SBMA) is a rare motor neuron disease due to a CAG 
repeat expansion in the androgen receptor gene. Growing 
evidence suggest a diffuse neurological involvement, other 
than motorneuron, such as muscular primitive damage and 
autonomic impairment, moreover respiratory involvement 
is considered negligible by some authors. There are no data 
in literature about phrenic nerve conduction study (NCS) 
and Sympathetic Skin Response (SSR), very few about 
Blink Reflex (BR) and there is a lack of detailed descrip-
tions of needle electromyography (EMG) features in diffe-
rent muscular districts.
Methods and Materials: 69 genetically confirmed SBMA 
patients underwent phrenic NCS, SSR, BR and EMG of 
cranial district, upper and lower limb.
Results: Distal latency of the phrenic nerve compound mu-
scle action potential (cMAP) was abnormally prolonged in 
61.2% of the right side and 52.2% of the left side studies. 
Nor distal latency or amplitude of cMAP correlated with 
forced vital capacity or CAG repeat size. Average laten-
cy of the SSR is significantly longer in our patients group 
when compared with normal subjects. BR showed a pro-
longed latency of R1 response in 9 cases, who also show-
ed altered sensory NCS of median, ulnar and sural nerves. 
EMG confirmed a chronic neurogenic pattern, but medial 
gastrocnemius showed low amplitude motor unit action 
potentials in 44.9% patients and a pattern suggestive for 
fibroadipose substitution.
Conclusion: Our pure neurophysiologic data from an un-
usually numerous population of patients seem to confirm 
subclinical diffuse neurological involvement and question 
the real entity of the respiratory disturbance in SBMA.
Disclosure: Nothing to disclose
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Non-convulsive status epilepticus in the 
elderly
H.M. Delgado1, V. Silva2, R. Pinto2, N.M.M. Canas2
1CHLO, Neurology, Lisbon, Portugal, 2HBA, Neurology,  
Loures, Portugal
Background and aims: The incidence of epilepsy is high-
est in the elderly, frequently presenting with non-convulsi-
ve status epilepticus (NCSE); the early recognition of the 
clinical manifestations and etiologies of NCSE can directly 
influence its associated morbidity/mortality. We describe 
the clinical features, etiology and outcome at discharge of a 
cohort of elderly patients with NCSE.
Methods: Retrospective study of patients ≥65 years old 
and EEG criteria for EMNC diagnosed in our hospital 
(2012-2014).
Results: We identified 31 patients (17 women), mean age 
79 years-old (65-90), 71% without history of epilepsy; 
55% had a diagnosis of dementia or motors deficits prior 
to admission. Although 33% patients had “de novo” focal 
neurologic signs, 90% presented with behavior/conscious-
ness changes. NCSE was provoked in 74.2% of patients 
(mostly metabolic/infectious causes), a third of them with 
remote structural damage in neuroimaging studies (stro-
ke, post-trauma). In only 22.6% the clinical diagnosis of 
NCSE was considered before EEG confirmation, mostly in 
the sequence of an isolated seizure with motor features; in 
the great majority of the others, the clinical features were 
attributed to the underlying dementia/ encephalopathy due 
to medical causes. In 35.5% of patients, NCSE was cont-
rolled with one antiepileptic, with levetiracetam the most 
widely used. 22.6% died and 16.1% had new or worsening 
of previous deficits.
Conclusion: In the elderly, the high prevalence of dementia 
and medical comorbidities may obscure the recognition of 
NCSE. This diagnosis should be suspected in patients with 
behavior/awareness changes, especially if they present a 
seizure with motor component or lesions with cortical in-
volvement.
Disclosure: Nothing to disclose
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A multicenter survey of clinical experience 
with perampanel in Spain - study of 187 
patients.
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C. Arcos Sánchez8, E. Muñoz Farjas9, S. Santos Lasaosa10, 
J.A. Olivan Usieto11, L. Diaz de Cerio Julian12,  
V. Bertol Alegre10
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Background and aims: Perampanel (PER) has been re-
cently approved for adjunctive treatment of partial-onset 
seizures from age 12 years on. This study was focused on 
evaluating the response to treatment with PER as adjunc-
tive therapy in patients with drug-resistant focal epilepsy.
Methods: We recorded and retrospectively analysed 187 
patients treated with PER from eight different Spanish cen-
tres. Patients should be monitored at least 6 months. Back-
ground characteristics of different variables were com-
pared with the improvement in seizure frequency, using 
chi-square test for heterogeneity, or T-student or variance 
analysis for quantitative variables.
Results: There were 59% women and 41% male with a me-
dian age of 40 years (P25-75:33-49) and median duration of 
epilepsy of 26 years (P25-75:13-36). Etiology was sympto-
matic in 58% of the cases. Median prior antiepileptic drugs 
(AED) was 8 (P25-75:4-9) and median number of AED at 
time of PER association was 2 (inductor 41%, partially in-
ductor 23%). Median time on treatment with PER was 9.2 
months (P25-75:6.6-10.2). Responder rate was 45% (6.5% 
seizure-free). 33% of patients experienced side effects; 
most frequent were dizziness (9%), somnolence (9%) and 
irritability (8%). Retention rate was 71% (discontinuation: 
12% inefficiency, 8% adverse effects and both 9%). The pa-
tients group with secondary generalization showed a 16% 
(IC:2-30) more improvement than those without generali-
zation (p 0.03). No other variables studied showed signifi-
cant correlation with the degree of improvement.
Conclusion: The adjunctive treatment with PER may lead 
to at least temporary freedom of seizures in difficult-to-treat 
partial epilepsy. However, adverse events are not unusual.
Disclosure: Nothing to disclose
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Research of CYP2C9 and CYP2C19 gene 
polymorphism in evaluation of treatment 
effectiveness in children with epilepsy
V.I. Guzeva1, V. Guzeva2, O. Guzeva2
1Saint Petersburg, Russian Federation, 2Saint-Petersburg 
State Pediatric Medical University, Neurological Department, 
Saint-Petersburg, Russian Federation
Background and aims: It is proved that the genetic po-
lymorphism is the basis of individual sensitivity to drugs 
and established the important role of gene polymorphisms 
of cytochromes P450 system in metabolism of anticonvul-
sants.
Methods: We studied genes CYP2C9 and CYP2C19 sys-
tem P450 in 86 children with severe forms of epilepsy: 
46 (53.49%) were boys and 40 (46.51%)- girls, age was 3 
months till 17 years.
Results: As a result of comprehensive survey found that 
26 (30.23%) of children had generalized symptomatic epi-
lepsy, 9 (10.47%) children- epileptic encephalopathy (West 
syndrome and Lennox-Gastaut syndrome), 47 (54.65%) 
children – symptomatic focal epilepsy (with secondary 
generalization and without it) and 4 (4.65%) children – 
idiopathic forms of epilepsy (generalized and focal). We 
identified 36 children with treatment-resistant epilepsy, 
children with non-resistant forms of epilepsy, accompa-
nied  by complications from taking antiepileptic drugs and 
43 (50%) children with polymorphic genes CYP2C9 and 
CYP2C19. The study showed that the average daily dose of 
valproate in all children with polymorphic genes to gene-
tic testing exceeded the average daily dose of valproate in 
children who do not have polymorphic genes.
Conclusion: In 50% of children with severe epilepsy iden-
tified gene polymorphism CYP2C9 and CYP2C19 system 
P450 and in 41.86% cases of rare genotypes established in 
children with resistant forms of disease. Therefore, treat-
ment of these children should be based on result of genetic 
research, which determines the presence or absence of po-
lymorphic genes of system P450.




Seizure recurrence after AED  
discontinuation in children
M. Impellizzeri, M. Maione, G. Fanelli, E. Leopizzi,  
G. Comi, F. Minicucci
Scientific Institute Vita-Salute University San Raffaele, Neuro-
logy, Milan, Italy
Background and aims: The discontinuation of antiepilep-
tic drugs (AED) is a challenging issue in epileptic children. 
The percentage of children who are undergoing AED with-
drawal is higher than that of adult patients, and the period 
of seizure remission before considering treatment withdra-
wal is shorter. Although the literature on AED withdrawal 
is focused on the pediatric population, few guidelines are 
actually provided. The aim of this study is to assess factors 
that can predict seizure recurrence after AED discontinuati-
on in pediatric patients.
Methods: 42 children, with age of onset of seizures <14 
years, were evaluated. Variables analyzed were: family his-
tory of epilepsy,  type of epilepsy, duration of disease, type 
and number of AED at time of discontinuation, neuroima-
ging and electroencephalographic features. These patients 
achieved complete seizure control for a minimum period 
of 2 years, and therefore discontinued antiepileptic therapy. 
The follow-up lasted 2 years.
Results: 35.7% of children relapsed within 2 years. The 
highest frequencies of recurrence were observed in patients 
with epilepsy of unknown cause (recurrence rate 63.6%) 
compared to other forms of epilepsy (recurrence rate 
20.7%; OR 0.199). Moreover, the recurrence rate was dou-
bled in children with focal seizures with secondary gene-
ralization (recurrence rate 60%) if compared to those with 
focal seizures without secondary generalization (recurrence 
rate 29.4%).
Conclusion: These results provide more information to the 
literature about seizure recurrence in pediatric patients af-
ter AED discontinuation. Due to the small sample, a larger 
cohort of patients should be analyzed in order to increase 
validity and better understand these variables.
Disclosure: Nothing to disclose
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Non-hyperammonemic reversible valpro-
ate-induced encephalopathy after long 
term treatment
J. Devianne1, I. Raynouard1, D. Buch1, B. Crepon2, F. Pico1
1hopital de versailles, neurology, 2RadiNeurology Depart-
ment, Versailles Mignot Hospital, Versailles, France
Background and aims: Encephalopathy is an unusual but 
severe adverse effect of valproate, a widely-prescribed drug 
in neurology and psychiatrics. Its mechanisms have not 
been fully understood yet, although its frequent associati-
on with hyperammonemia makes it the most often quoted 
cause.
Case Report: We report a patient with Valproate-induced 
encephalopathy (VIE) and normal ammoniemia level after 
long term treatment.
Results: This 62-year-old patient, with type 2 diabetes and 
hypertension, had a 25 years treatment by valproate (1g 
twice a day) and phenobarbital (100mg twice a day), in the 
setting of post traumatic epilepsy. He presented with acu-
te confusion and cognitive decline. The electroencephalo-
gram showed slow rhythms with an anterior maximum that 
were compatible with a nonconvulsive status epilepticus. A 
treatment by clonazepam and phenytoin was not associated 
with any improvement. The following exams were normal: 
liver and kidney function, blood tests, plasmatic ammone-
mia, valproate and phenobarbital plasma levels. Follow up 
encephalogram showed an increase of slow rhythms and 
triphasic waves appearance, associated with gradual deteri-
oration over a week. Valproate treatment was stopped, and 
there was a dramatic improvement of the patient’s neuro-
logic status. He could be discharged home, with levetira-
cetam in place of valproate.
Conclusion: The possible occurrence of VIE even after a 
long-term treatment should be well known by physicians, 
and should not be dismissed if ammonemia normal. This 
case could suggests that hyperammonemia is not the only 
mechanism of VIE.
Disclosure: Nothing to disclose
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nical neuroscience: outcome of epilepsy 
surgery in a cohort of Slovenian patients 
treated in collaboration between Ljubljana 
and Erlangen, Germany
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H. Stefan3, M. Buchfelder4, D.B. Vodušek1, E. Pauli3,  
B. Lorber1
1University Medical Centre, Ljubljana, Department of Neu-
rology, Ljubljana, Slovenia, 2University Medical Centre, 
Ljubljana, Department of Pediatric Neurology, Ljubljana, 
Slovenia, 3Neurologie, Epileptologie, Erlangen, Germany, 
4University Hospital Erlangen, Department of Neurosurgery, 
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Background and aims: For patients with medically in-
tractable epilepsy, neurosurgery is suggested as a treatment 
option, providing long-term seizure freedom in two thirds 
of temporal lobe resections and lower success rates in ext-
ratemporal resections (Téllez-Zenteno et al. 2005). In small 
countries functional neurosurgery programs are faced with 
limited potential for intraoperative diagnostic procedures 
and neurosurgical expertise because of lack of adequate 
“high volume” of patients necessary for clinical excellence. 
To overcome such limitation, the Department of Neurology 
at University Medical Centre in Ljubljana, Slovenia has es-
tablished collaboration with the Epilepsy Centre at Univer-
sity Hospital in Erlangen, Germany. In order to evaluate the 
surgical treatment of Slovenian epilepsy patients abroad, 
we performed a long-term follow-up study.
Methods: Data were obtained from medical records and an 
additional follow-up assessment was performed. We evalu-
ated seizure and medication outcome, psychiatric comor-
bidity, neuropsychological and psychosocial outcome and 
patient satisfaction.
Results: Between 2001 and 2012 a total of 53 Slovenian 
adult patients underwent surgical treatment in Erlangen. 
Nearly 90% suffered from temporal lobe epilepsy. 61% 
of patients were completely seizure-free and an additional 
28% were free of disabling seizures. Cognitive decline af-
ter surgery was rare and de novo mood disturbances were 
mostly of a transient nature. Surgical treatment did not im-
pact employment status. The majority of patients (89%) felt 
that the surgical treatment largely fulfilled their expecta-
tions.
Conclusion: This study demonstrates that cross-border 
collaboration in epilepsy surgery can be a very effective 
way to treat epilepsy patients even if important differences 
in native languages exist between the treating institutions.
Disclosure: Nothing to disclose
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Structural neural correlates of cognitive 
and behavioural impairment in motor  
neuron disease
F. Agosta1, P.M. Ferraro1, E.G. Spinelli1, E. Canu1, N. Riva2, 
M. Copetti3, E. Prudente4, A. Chiò5, S. Iannaccone6,  
A. Falini7, G. Comi2, M. Filippi1
1San Raffaele Scientific Institute, Vita-Salute San Raffaele 
University, Neuroimaging Research Unit, Milan, Italy, 2San 
Raffaele Scientific Institute, Vita-Salute San Raffaele Univer-
sity, Department of Neurology, Milan, Italy, 3IRCCS-Ospedale 
Casa Sollievo della Sofferenza, Biostatistics Unit, San 
Giovanni Rotondo, Italy, 4San Raffaele Scientific Institute, 
Vita-Salute San Raffaele University, Department of Neuro-
radiology, Milan, Italy, 5University of Turin, Department of 
Neuroscience, Turin, Italy, 6San Raffaele Scientific Institute, 
Vita-Salute San Raffaele University, Department of Clinical 
Neurosciences, Milan, Italy, 7Università Vita-Salute San Raf-
faele, Neuroradiology, Milan, Italy
Background and aims: To assess the structural neural 
correlates of cognitive and behavioral impairment in motor 
neuron disease (MND).
Methods: 101 patients with sporadic MND (56 classic 
amyotrophic lateral sclerosis, 31 predominantly upper 
MND, and 14 predominantly lower MND) and 51 controls 
were enrolled. Patients were classified into MND with a 
pure motor syndrome (MND-motor) and with cognitive/
behavioural symptoms (MND-plus). Cortical thickness 
measures and diffusion tensor (DT) metrics of WM tracts 
were assessed. A Random Forest (RF) approach explored 
the independent role of cortical and WM abnormalities in 
explaining major cognitive and behavioral symptoms.
Results: There were 48 MND-motor and 53 MND-plus pa-
tients. Relative to controls, both patient groups showed dis-
tributed cortical thinning of the bilateral precentral gyrus, 
cingulate cortex, and frontotemporal regions. In all regions, 
there was a trend towards a more severe involvement in 
MND-plus cases, particularly in the temporal lobes. Both 
patient groups showed a damage of the motor callosal 
fibers, which was greater in MND-plus. MND-plus pati-
ents showed a severe involvement of the extra-motor WM 
tracts. According to RF, the best predictors of executive and 
non-executive deficits and behavioural symptoms in MND 
were the DT MRI metrics of frontotemporal tracts.
Conclusion: Cortical thinning and WM degeneration are 
highly dependent upon neuropsychological and behavi-
oural symptoms in patients with MND. WM tract damage 
contributes to the severity of selective cognitive and beha-
vioural manifestations more than cortical thinning.
Disclosure: Italian Ministry of Health (#RF-2010-
2313220).
P4125
MRI as biomarker in G-CSF mediated  
clinical ALS stabilization
D. Baldaranov1, A. Khomenko1, J.  Blume1, J. Kassubek2,  
H.-P. Müller2, S. Johannesen1, I. Kobor1, J. Grassinger3,  
T. Bruun1, G. Schuierer4, W. Schulte-Mattler1, A. Schneider5, 
M. Deppe6, U. Bogdahn1
1University of Regensburg, Neurology, Regensburg, Germany, 
2University of Ulm, Neurology, Ulm, Germany, 3University of 
Regensburg, Hematology and Oncology, Regensburg, Germa-
ny, 4University of Regensburg, Neuroradiology, Regensburg, 
Germany, 5Sygnis, Heidelberg, Germany, 6University of Mu-
enster, Neurology, Muenster, Germany
Background and aims: G-CSF (Granulocyte Colony 
Stimulating Factor) may modulate clinical progression of 
patients with motor neuron disease. To elucidate potential 
mechanisms of action long term individual follow-up DTI 
(diffusion tensor imaging) was applied in ALS patients tre-
ated with G-CSF in an open label compassionate use pro-
gram.
Methods: 23 patients (15 male, 8 female, mean age 51,4) 
received individual G-CSF long-term continuous treatment 
up to 48 months in outpatient regimens after informed con-
sent. To prove safety and feasibility, DTI and other clinical 
biomarkers were prospectively obtained every 3 months. 
Between 2 and 16 image-datasets per patient were obtained 
and retrospectively analyzed, two consecutive 1.5 Tesla 
Siemens scanners were employed. Results were referenced 
to neurophysiological i-MUNIX (improved Motor Unit 
Number Index), hematological and clinical (ALS-FRS-r) 
parameters.
Results: Decreased FA (Fractional Anisotropy) in the cor-
ticospinal tract and frontal white matter are consistent with 
Braak’s ALS stages: clinical progression correlates with 
bilateral axonal integrity of fimbria fornix (p<0.01) as hip-
pocampal connectivity. There was a trend in correlating FA 
data to clinical progression and a significant correlation 
to i-MUNIX (p<0.038) as marker of lower motor neuron 
function.
Conclusion: FA is a promising biomarker in ALS: it is hel-
pful in staging, evaluation of clinical progression, treatment 
efficacy, safety, as well as in understanding G-CSF’s mode 
of action. FA - unaffected by individual pathophysiology - 
needs to be validated as a robust independent biomarker to 
help accelerate clinical trials in ALS.
Disclosure: Nothing to disclose
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A new therapeutic approach for  
amyotrophic lateral sclerosis:  
iPSC-derived CD15+CXCR4+VLA4+  
neural stem cell transplantation
S. Brajkovic, C. Simone, M. Nizzardo, F. Rizzo, M. Bucchia, 
A. Ramirez, N. Bresolin, G.P. Comi, S. Corti
IRCCS Foundation Ca‘ Granda Ospedale Maggiore Policli-
nico, Dino Ferrari Center, Neuroscience Section, Department 
of Pathophysiology and Transplantation, University of Milan, 
Milan, Italy., Milan, Italy
Background and aims: Amyotrophic lateral sclerosis 
(ALS) is a fatal disease characterized by the selective loss 
of motor neurons. No effective therapies are available. The 
transplantation of iPSC-derived neural stem cells (NCS) in 
ALS mice resulted in a significant improvement of the di-
sease phenotype (Nizzardo et al., 2014). In this study, we 
identified a novel subpopulation of NSCs that displays an 
increased ability to engraft central nervous system (CNS).
Methods: We differentiated iPS cells from human so-
matic cells through a non-viral non-integrating protocol 
of transfection and we directed iPSCs fate into NSCs. 
Preliminary injections were performed in pups in or-
der to optimize the protocol of injection. The isolation of 
CD15+CXCR4+VLA4+ NSC subpopulation was obtained 
by FACS selection. The phenotype of these cells was as-
sessed by morphologic, gene expression, and protein pro-
file analyses. iPSC-purified NSCs were administered by 
intrathecal injections into SOD1G93A mice and neuropa-
thological assays and functional tests were performed to 
evaluate any modifications of disease hallmarks.
Results: CD15+CXCR4+VLA4+ NSCs were demonstra-
ted to proliferate and differentiate into the three neuroec-
todermal lineages, both in vitro and in vivo. We analyzed 
their ability to migrate into the CNS after minimally invasi-
ve injection, and to engraft into the host spinal cord. Trans-
planted NSCs migrated into the CNS and differentiated into 
the three neuroectodermal lineages.
Conclusion: Our study showed a significant enhanced 
survival of host motor neurons after iPSC-derived NSC 
transplantation by reducing macrogliosis. Finally, we can 
suggest that the selection of NSC subpopulations can con-
tribute to the development of promising cell-based thera-
pies for ALS and other neurodegenerative disorders.
Disclosure: Nothing to disclose
P4127
Extrapyramidal signs in amyotrophic  
lateral sclerosis: EXTRALS study
A. Calvo, F. Dematteis, S. Cammarosano, C. Moglia,  
C.A. Artusi, A. Romagnolo, S. Angrisano, A. Bernardini,  
A. Ilardi, L. Lopiano, A. Chiò, M.G. Rizzone
University of Torino, ‚Rita Levi Montalcini‘ Department of 
Neuroscience, Turin, Italy
Background: Recent data suggested that different pheno-
typic expression in ALS patients, in particular the presence 
of frontotemporal, parkinsonian and psychiatric symptoms, 
may represent the manifestation of a spectrum of diseases.
Objectives To determine the presence of extrapyramidal 
signs in a prospective series of ALS patients.
Methods: 112 consecutive patients with a diagnosis of 
ALS (July 2012-December 2013) at Torino ALS centre ac-
cording to El Escorial-Rev criteria were included (58 M, 35 
F; mean age 66 years). To detect the presence of extrapyra-
midal signs, all patients were evaluated by neurologists ex-
pert in movement disorders and scored by MDS-UPDRS. 
Patients with parkinsonian signs underwent 123I-Ioflupane 
SPECT, genetic analysis for SNCA, parkin, PINK1, DJ-1, 
LRRK2 and GBA genes.
Results: At baseline 26 patients (9 classic, 10 bulbar, 4 flail 
leg, 2 flail arm, 1 upper motor neuron) showed parkinso-
nian signs (UPDRS I mean score 13.0, UPDRS II mean 
score 18.3, UPDRS III mean score 39.2). Bradykinesia was 
present in 100%, rigidity in 78.5%, rest tremor in 18.0%, 
postural tremor in 35.7%, kinetic tremor in 32.0%, gait dis-
turbances in 82.0% and postural instability in 50.0%. 20 
patients underwent 123I-Ioflupane SPECT. Only 3 patients 
showed a reduction of putaminal dopamine transporter bin-
ding. A mutation in LRRK2 gen was found in one patient.
Conclusion: Presence of extrapyramidal signs in ALS pati-
ents is a frequent clinical feature. Despite a relevant percen-
tage of new diagnosed ALS patients showed parkinsonian 
signs (28.0%), a nigrostriatal damage was observed only in 
a low percentage (13.6%) of patients who underwent 123I-
Ioflupane SPECT. 
Disclosure: Nothing to disclose
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Amyotrophic lateral sclerosis with  
cognitive Impairment: a role for cognitive 
reserve?
A. Canosa1, M. Pagani2, A. Calvo1, A. Ilardi1, A. Montuschi1, 
B. Iazzolino1, M. Barberis3, M. Brunetti3, G. Restagno4,  
A. Chio1
1University of Torino, Turin, Italy, 2CNR Rome, Rome, Italy, 
3Univ of Torino, Turin, Italy, 4AOU Città della Salute e della 
Scienza, Turin, Italy
Background and aims: 50% of ALS cases display cog-
nitive decline, from frontotemporal dementia (ALS-FTD), 
to executive (ALS-ECI), non-executive (ALS-NECI) and 
behavioral impairment (ALS-Bi). A protective role of cog-
nitive reserve (CR) is known in Alzheimer’s disease (AD) 
and FTD. We aimed to verify the CR hypothesis in ALS-
related cognitive impairment.
Methods: Our discovery cohort (DC) included 183 in-
cident cases from Piemonte (January 2009 - December 
2011).  A validation cohort (VC) (n=113) included patients 
from other regions diagnosed in such period and incident 
cases from Piemonte (January 2012 - June 2013). Patients 
underwent neuropsychological and genetic testing. In the 
DC 49.7% were cognitively normal, 12.6% ALS-FTD, 
19.7% ALS-ECI, 5.5% ALS-NECI, 6.0% ALS-Bi, 6.0% 
non-classifiable (ALS-NCCI). In the VC 50.5% were cog-
nitively normal, 15.9% ALS-FTD, 18.6% ALS-ECI, 3.5% 
ALS-NECI, 6.2% ALS-Bi, 5.3% ALS-NCCI. A Reserve 
Index (RI) (2-12) was calculated from education and oc-
cupation.
Results: In the DC ALS-FTD patients showed lower edu-
cation (4.7 years, SD 1.9) and RI (4.9, SD 1.3) than other 
groups (p=0.0001). In the VC ALS-FTD patients (7.0 ye-
ars, SD 2.6) had the same education of ALS-NECI (7.0, SD 
1.4), that was lower than other categories (p=0.003). ALS-
FTD patients had lower RI (5.7, SD 1.6) than other groups 
but ALS-NECI (p=0.003). Results were confirmed among 
c9orf72 mutation carriers (p=0.012). TMT B, TMT B-A, 
Stroop Colour-Word Interference Test, WAIS-R Block 
Design, WMS-R-Form 2, FAB (p=0.0001) and CPM total 
score (p=0.001) were related to RI.      
Conclusion: CR may have a role in ALS-related cognitive 
impairment, primarily frank FTD, including c9orf72 muta-
tion carriers, mainly due to frontal dysfunction.
Disclosure: Nothing to disclose
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Altered secretion of exosomes by muscle 
cells: role in ALS pathogenesis
S. Duguez1, L. Le Gall1, W.J. Duddy1, C. Martinat2,  
M. Thorley1, G. Ouandaogo1, J.P. Loeffler3,  
J.-L. Gonzales De Aguilar3, G. Butler Brown1, V. Mouly1,  
P.F. Pradat4
1Sorbonne Universités, UPMC Univ Paris 06, INSERM 
UMRS974, CNRS FRE3617, Center for research in Myology, 
Paris, France, 2INSERM/UEVE UMR 861, I-STEM, AFM, 
Evry, France, 3Université de Strasbourg / INSERM U1118, 
Mécanismes Centraux et Périphériques de la Neurodégéné-
rescence, Strasbourg, France, 4Departement des Maladies du 
Systeme Nerveux, AP-HP Pitié Salpétrière, Paris, France
Background and aims: The potential involvement of exo-
some trafficking is implicated in ALS by the aggregation 
of lysosomally-directed proteins in the cytosol of patient 
cells (both sporadic and familial cases), and by mutations 
in genes involved in autophagy and multivesicular biogene-
sis pathways in familial cases. Exosomes are small vesicles 
shown to export functional proteins, mRNA and miRNA 
from different cell types including muscle cells. Several 
studies suggest an involvement of skeletal muscle in ALS. 
Our purpose was to determine whether exosome secretion 
is altered in ALS muscle cells, and could alter the intercel-
lular communication between muscle and nerves.
Methods: To explore disruption of vesicle trafficking and 
secretion in ALS muscle, immunostains, Western blots, and 
RTq-PCR were performed on samples from sporadic ALS 
patients and aged-matched healthy subjects (n=10/group). 
Transcriptomic analysis was carried out for secretome pre-
diction and gene set enrichment.
Results: We observed a consistently striking and previous-
ly unnoticed accumulation of exosomal vesicles in patient 
myotubes, and confirmed this in vivo on muscle biopsies 
from sporadic ALS patients. In silico secretome prediction 
suggested a mechanistic basis of this, showing a signifi-
cant enrichment in both endosomal and lysosomal com-
partments, indicating disruption of exosome genesis and 
secretion, which was consistent with gene set enrichment 
analysis showing disrupted vesicle trafficking.
Conclusion: We hypothesise that altered exosome secreti-
on influences the intercellular communication between the 
muscle and its environment, including motor neurons. This 
phenomenon occurs independently of muscle denervation 
and could be a key element in the disease progression.
Disclosure: This work was financed by INSERM  and  Di-
rection Generale de l’Organisation des Soins (DGOS), and 
by the Association Française contre les myopathies (AFM). 
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Quantifying spinal cord atrophy: an MRI 
tool to investigate the selectivity of muscle 
weakness in SMA
M.-M. El Mendili1, T. Lenglet2, S. Lehericy3, H. Benali1,  
P.F. Pradat4
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vice Explorations Fonctionnelle Neurologie, Paris, France, 
3Pitié-Salpêtrière Hospital, Centre de Recherche de l‘Institut 
du Cerveau et de la Moelle épinière, INSERM UMRS_1127, 
Paris Cedex 13, France 75651; Pitié-Salpêtrière Hospital, 
Centre de Neuroimagerie de Recherche, Paris Cedex 13, 
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Background and aims: Spinal muscular atrophy (SMA) 
is characterized by lower motor neuron (LMN) loss that 
leads to proximal muscle wasting and paralysis. In this stu-
dy, we investigated the link between spinal cord atrophy 
profile and the proximal muscles deficits in spinal muscular 
atrophy.
Methods and Materials: 18 patients with type III/V SMN1-
linked SMA and 18 age-matched controls were recruited. 
Patients were scored using manual muscle testing (MMT) 
(Table 1). Subjects were scanned at 3T MRI system (Tim 
Trio, Siemens Healthcare). Spinal cord was imaged using 
a T2-weighted sequence (52 sagittal slices, FOV=280mm, 
TE/TR=1500/120ms, voxel size = 0.9x0.9x0.9mm3). Data 
were segmented. Cord cross-sectional area (CSA) was com-
puted along the cervical spinal cord. The difference in CSA 
between SMA patients and controls was assessed using per-
mutation test (one side). Spearman’s rank correlation coef-
ficient was used to investigate correlations between CSA 
and MMT. A supra-significance level alpha=10-3 was used.
Results: CSA showed a significant atrophy gradient main-
ly located between C3 and C6 vertebral levels with a cord 
atrophy rate ranging from 5.4% to 23% (Figure 1). There 
were no correlations between CSA and MMT nor between 
CSA and disease duration.
Conclusion: Atrophy predominates in the spinal segments 
innervating the proximal muscles. The missing correlations 
between CSA and MMT as well as the clear distal deficit 
showed by MMT in our SMA population; suggest that the 
loss of motor neuron cell bodies may not recapitulate all the 
mechanisms responsible for clinical deficits.
Disclosure: This study was supported by the Association 
Française contre les Myopathies (AFM) and the Institut 
pour la Recherche sur la Moelle épinière et l‘Encéphale 
(IRME). The research leading to these results has also recei-
ved funding from the program “Investissements d’avenir” 
ANR-10-IAIHU-06.
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Discriminatory performance of a  
suspicion index in identifying Niemann-
Pick disease Type C among patients with 
complex early-onset ataxias
M. Synofzik1, Z. Fleszar2, L. Schöls1, J. Müller vom Hagen2, 
P. Bauer3, J.V. Torres Martin4, S. Kolb5
1Tübingen, Germany, 2Hertie-Institute for Clinical Brain 
Research, University of Tübingen, Department of Neurodege-
nerative Diseases, Tübingen, Germany, 3Institute of Medical 
Genetics and Applied Genomics, University of Tübingen, Tü-
bingen, Germany, 4Syntax for Science SL, Basel, Switzerland, 
5Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
Background and aims: Despite recent progress in gene-
tics a notable proportion of patients with early-onset ataxia 
(EOA: onset <40 years) still remain without molecular dia-
gnosis, which highlights the need for easily applicable cli-
nical tools to identify treatable cases among subjects with 
unexplained EOA. Niemann-Pick disease type C (NP-C) 
suspicion index (SI) helps to identify NP-C in patients with 
unexplained neurological disease, but its discriminatory 
performance in EOA has been questioned. We evaluated 
the ability of the NPC-SI to discriminate between EOA 
cases with confirmed NP-C (n=53) and EOA cases (n=86) 
negative for NP-C mutations.
Methods: NP-C signs and symptoms were compared bet-
ween both groups by systematic phenotyping according to 
the SI protocol (Wijburg et al, Neurology 2012;78:1–1). 
NP-C SI risk prediction scores (RPS) were calculated for 
all patients and SI discriminatory performance was evalu-
ated.
Results: Of the most frequent NP-C signs/symptoms, verti-
cal supranuclear gaze palsy, cognitive impairment, spleno-
megaly and dystonia were less frequent in non-NP-C EOA 
cases vs. NP-C EOA cases (Fig. 1). Dysarthria/dysphagia 
was observed at a similar frequency in both groups. Spasti-
city was more frequent in non-NP-C EOA cases. Although 
moderate (40–69 points) and high (≥70 points) RPS were 
seen in 16/86 (19%) and 8/86 (9%) non-NP-C EOA cases 
(Fig. 2), the SI had excellent discriminatory power (AUC 
0.980). Discriminatory performance was not affected by 
patient age.
Fig 1. Symptom frequency in NP-C and non-NP-C EOA
Fig 2. Total RPS by patient age
Conclusion: The NP-C SI distinguished well between 
NP-C and non-NPC EOA cases, is easy to apply, and will 
reliably aid identification/diagnostics of patients with com-
plex EOAs who warrant further investigation for NP-C.
Disclosure: This abstract was supported by Actelion Phar-
maceuticals Ltd. MS and JMvH received honoraria from 
Actelion Pharmaceuticals Ltd. ZF and LS have no conflicts 
of interest to declare. PB has carried out paid consultancy 
work for, and received travel expenses and presentation ho-
noraria from, Actelion Pharmaceuticals Ltd. SK is an em-
ployee of Actelion Pharmaceuticals Ltd. JVTM conducted 
statistical analyses, paid for by Actelion Pharmaceuticals 
Ltd. 
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Deep brain stimulation can preserve  
working abilities in Parkinson’s disease
N. Kovacs1, I. Balás2, S. Komoly2, T. Dóczi1, J. Janszky1,  
Z. Aschermann2, A. Makkos2, G. Deli2
1MTA-PTE Clinical Neuroimaging MR Research Group, Pécs, 
Hungary, 2University of Pécs, Pécs, Hungary
Background and aims: There is a debate on the potential 
advantageous effects of bilateral subthalamic deep brain sti-
mulation (DBS) in the treatment of Parkinson’s disease with 
early fluctuations. Our investigation aimed to evaluate if 
DBS therapy was able to preserve the working capabilities.
Methods: We reviewed the data of 40 young (<60 year-old) 
PD patients who underwent DBS implantation at Universi-
ty of Pécs and had an at least 2 years follow-up. Patients 
were categorized into two groups based on their working 
capabilities at time of surgery: ‘Active job’ group (n=20) 
and ’No job’ group (n=20). Baseline characteristics were 
comparable. Severity of motor symptoms (UPDRS-3), qua-
lity of life (EQ-5D) and presence of active job were evalua-
ted preoperatively and 2 years postoperatively.
Results: Although similar (approximately 50%) improve-
ment was achieved in the severity of motor and major non-
motor symptoms in both groups, the postoperative quality 
of life was significantly better in the ‘Active job’ group 
(0.687 vs. 0.587, medians, p<0.05). Majority (80%) of ‘Ac-
tive job’ group members were able to preserve their job 2 
years after the operation. However, only a minimal portion 
(5%) of the ‘No job’ group members was able to return to 
the world of active employees (p<0,01).
Conclusion: Although our study has several limitations, 
our results fits well with the conclusions of EarlyStim study. 
In patients with active job the appropriately ‘early’ usage of 
DBS might help preserve working abilities in a two-year 
time-frame and gain higher improvement in quality of life.
Disclosure: Our study was supported by the Bolyai 
Scholarship of Hungarian Academy of Sciences, OTKA 
PD103964, TÁMOP-4.2.2.A-11/1/KONV-2012-0017 and 
Hungarian Brain Research Program (KTIA_13_NAP-A-
II/10) government-based funds. The present scientific con-
tribution is also dedicated to the 650th anniversary of the 
foundation of the University of Pécs, Hungary.
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Presenting symptoms of GBA-related 
Parkinson’s disease
N.D. Kresojevic1, M. Janković1, I. Petrović1, K. Kumar2,  
N. Dragasevic1, V. Dobricic1, I. Novakovic1, M. Svetel1,  
C. Klein3, T. Pekmezovic4, V. Kostic1
1Neurology Clinic, Clinical Center of Serbia, School of  
Medicine, University of Belgrade, Belgrade, Serbia, Belgrade, 
Serbia, 2Kolling Institute of Medical Research, Royal North 
Shore Hospital, University of Sydney, Department of Neuro-
gentics, Sidney, Australia, 3University of Lübeck, Institute of 
Neurogenetics, Lübeck, Germany, 4Clinic of neurology, Neu-
roepidemiology, Belgrade, Serbia
Background and aims: Mutations in the Glucocerebrosi-
dase gene (GBA) are associated with Parkinson’s disease 
(PD). It has been shown that GBA-related PD (PD-GBA) 
patients had an earlier age at PD onset and more prevalent 
non-motor symptoms when compared to “sporadic” PD pa-
tients without such mutations (sPD). Aim of our research 
was to explore whether presenting symptoms differ bet-
ween PD-GBA and sPD patients.
Methods: Demographic and clinical features (including 
presenting symptoms) were collected for 578 PD patients. 
Sequence analysis was performed for exons 8-11 of the 
GBA gene for all participants.
Results: 39 PD patients (6.7%) with GBA mutations were 
compared to 539 PD patients without them. No statistically 
significant differences were found regarding presenting 
symptoms (bradykinesia, rigidity, tremor, writing difficul-
ties, gait problems) with the exception of pain which was 
more frequently reported in the PD-GBA (10.3%; all with 
severe mutation) than in the sPD group (3.0%) (p=0.039).
Conclusion: PD patients with severe GBA mutations might 
have more frequently pain as a presenting symptom when 
compared with PD patients without such mutations.
Disclosure: This study was supported by a grant from the 
Ministry of Education and Science, Republic of Serbia 
(projects #ON175090 to VK).
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Evaluating the efficacy and safety of opi-
capone in patients over 70 years with 
Parkinson’s disease and motor  
fluctuations
A. Lees1, J. Ferreira2, N. Lopes3, R. Costa3, A. Santos3,  
C. Oliveira3, R. Pinto3, T. Nunes3, J.F. Rocha3,  
P. Soares-da-silva3
1National Hospital for Neurology and Neurosurgery, London, 
United Kingdom, 2Instituto de Medicina Molecular, Neu-
rological Clinical Research Unit, Lisbon, Portugal, 3BIAL 
– Portela & Cª – S.A., Dept. R&D, S. Mamede do Coronado, 
Portugal
Background and aims: Opicapone (OPC) is a novel 
once-daily peripheral COMT inhibitor shown to be safe 
and effective in reducing OFF-time in Parkinson’s disease 
(PD) patients with motor fluctuations. PD mainly affects 
the elderly and the incidence increases with age, being the 
second most prevalent neurodegenerative disease among 
older subjects.
Methods: Data from two multicentre, double-blind, rando-
mised, placebo- and active-controlled studies (BIPARK I 
and II) was pooled and evaluated by age (<70 and ≥70 ye-
ars). Efficacy outcome measures included the change from 
baseline to endpoint in absolute OFF-time and the OFF- 
and ON-time responder rates (≥1 hour). Safety was evalua-
ted by analysis of reported adverse events (AEs).
Results: 221 patients ≥70 years were included in the ana-
lysis (N=69, 66 and 86 for placebo, 25mg- and 50mg-OPC, 
respectively). Mean daily OFF-time decreased by 1.41h 
for placebo, 1.77h (p=0.4086) for 25mg-OPC and -2.26h 
(p=0.0384) for 50mg-OPC. Consistently, a higher proporti-
on of patients receiving either 25mg- or 50mg-OPC achie-
ved the OFF- and ON-time responders endpoint (p<0.05 
for 50mg-OPC). AEs occurring more frequently in the el-
derly (adjusted for placebo) included hallucinations (4.6% 
vs. 0.1%), visual hallucinations (3.8% vs. 0.1%) and weight 
decreased (4.6% vs. 1.1%). The incidence of serious AEs 
was lower in OPC treated patients than placebo.
Conclusion: OPC is effective and well tolerated by PD pa-
tients over 70 years old.
Disclosure: Nothing to disclose
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Safety of opicapone in patients with 
Parkinson’s disease and motor  
fluctuations: 1-year follow-up
A. Lees1, J. Ferreira2, R. Costa3, C. Oliveira3, R. Pinto3,  
N. Lopes3, T. Nunes3, J.F. Rocha3, P. Soares-da-silva3
1National Hospital for Neurology and Neurosurgery, London, 
United Kingdom, 2Instituto de Medicina Molecular, Neu-
rological Clinical Research Unit, Lisbon, Portugal, 3BIAL 
– Portela & Cª – S.A., Dept. R&D, S. Mamede do Coronado, 
Portugal
Background and aims: Opicapone (OPC) is a novel once-
daily peripheral COMT-inhibitor shown to be safe and ef-
fective in reducing OFF-time in Parkinson’s disease (PD) 
patients with motor fluctuations. The aim of this study was 
to evaluate the safety of OPC as add-on to levodopa over 
1-year of treatment.
Methods: Subjects that completed the double-blind (DB) 
part of a randomized, placebo-controlled study (BIPARK 
II) were enrolled into an open-label 1-year extension. Sub-
jects started with 25mg-OPC irrespective of prior DB treat-
ment. One week after, either OPC (25 or 50mg), levodopa 
or anti-PD drugs could be adjusted based on individual 
response. Safety was assessed by adverse events (AEs), 
laboratory, vital-signs, ECG, physical and neurological 
examinations, modified Minnesota Impulsive Disorders 
Interview (mMIDI) and Columbia Suicide Severity Rating 
Scale (C-SSRS).
Results: 286 (81%) subjects completed the 1-year treat-
ment. The most commonly reported AEs were dyskinesia 
(21.5%), (worsening) PD (17.0%), falls (9.1%), blood CPK 
increased (7.4%), insomnia (5.7%) and orthostatic hypo-
tension (5.4%). The majority of AEs were mild to moderate 
in intensity. Serious AEs were reported for 11.3% of the pa-
tients. Five deaths occurred, all but one (cerebral hemorrha-
ge after traumatic brain injury) were considered unrelated 
to treatment. There were no reports of urine discoloration, 
severe diarrhea, myocardial infarction, prostate cancer or 
any serious hepatic event. Melanoma was confirmed in 1 
patient. C-SSRS showed no effect on suicidality. Impulsi-
ve disorders, as screened by mMIDI, were reported in few 
subjects (4.0%).
Conclusion: OPC long-term use was safe and well tole-
rated.
Disclosure: Nothing to disclose
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Evaluation of hepatic safety of opicapone 
in patients with Parkinson’s disease
N. Lopes1, J. Ferreira2, A. Lees3, H. Gama1, A. Santos1,  
C. Oliveira1, R. Costa1, T. Nunes1, J.F. Rocha1,  
P. Soares-da-Silva1
1BIAL – Portela & Cª – S.A., Dept. R&D, S. Mamede do 
Coronado, Portugal, 2Instituto de Medicina Molecular, Neu-
rological Clinical Research Unit, Lisbon, Portugal, 3National 
Hospital for Neurology and Neurosurgery, London, United 
Kingdom
Background and aims: Opicapone (OPC) is a novel once-
daily peripheral COMT-inhibitor shown to be safe and ef-
fective in reducing OFF-time in Parkinson’s disease (PD) 
patients with motor fluctuations. Here we evaluate the ef-
fects of OPC on hepatobiliary function.
Methods: The safety data of 2 multicentre, double-blind, 
randomised, placebo- and active-controlled studies (BI-
PARK I and II) was pooled. Hepatic-related adverse events 
and changes from baseline in hepatic laboratory parameters 
were evaluated.
Results: A total of 509 subjects treated with OPC (25 or 
50mg) and 257 with placebo were analyzed. No relevant 
changes from baseline to endpoint in mean values for he-
patic laboratory parameters in any treatment group were 
observed. The incidence of potential clinically important 
values (alanine aminotransferase ≥ 3xULN, aspartate ami-
notransferase ≥ 3xULN, total bilirubin ≥ 2xULN, alkaline 
phosphatase ≥ 1.5xULN) was similar for placebo and OPC 
groups. Hepatic-related adverse events were reported by 
2.0% of patients in OPC groups compared to 3.5% in pla-
cebo. There were no cases of potential Hy’s law, hepatitis, 
hepatic failure or other severe hepatic injuries reported in 
OPC groups.
Conclusion: OPC was not associated with clinically rele-
vant effects on hepatobiliary function.
Disclosure: Nothing to disclose
P4137
Efficacy of opicapone in combination with 
dopamine agonists or MAO-B inhibitors 
on the treatment of motor fluctuations in 
Parkinson’s disease.
N. Lopes1, J. Ferreira2, A. Lees3, R. Costa1, A. Santos1,  
C. Oliveira1, R. Pinto1, T. Nunes1, J.F. Rocha1,  
P. Soares-da-Silva1
1BIAL – Portela & Cª – S.A., Dept. R&D, S. Mamede do 
Coronado, Portugal, 2Instituto de Medicina Molecular, Neu-
rological Clinical Research Unit, Lisbon, Portugal, 3National 
Hospital for Neurology and Neurosurgery, London, United 
Kingdom
Background and aims: Opicapone (OPC) is a novel once-
daily peripheral COMT inhibitor shown to be safe and ef-
fective in reducing OFF-time in Parkinson’s disease (PD) 
patients with motor fluctuations. PD patients are commonly 
treated with dopamine agonists (DA) or MAO-B inhibitors 
(MAO-Bi) in association with levodopa.
Methods: Data from two multicentre, double-blind, rando-
mised, placebo- and active-controlled studies (BIPARK I 
and II) was pooled and analyzed by concurrent use of DA 
or MAO-Bi at baseline (yes/no). Efficacy outcome measu-
res included the change from baseline to endpoint in abso-
lute OFF-time and the OFF- and ON-time responder rates 
(≥1 hour).
Results: 521 (69%) patients were using DA (N=185, 158 
and 178 for placebo, 25mg- and 50mg-OPC, respectively) 
and 151 (20%) were using MAO-Bi (N=49, 46 and 56, 
for placebo, 25mg- and 50mg-OPC, respectively). The 
mean placebo-adjusted OFF-time reduction was -35.5 min 
(p=0.0329) and -25.7 min (p=0.4120) for 25mg-OPC plus 
DA or MAO-Bi, respectively; -54.6 min (p=0.0007) and 
63.7 min (p=0.0326) for 50mg-OPC plus DA or MAO-Bi, 
respectively. Consistently, a higher proportion of patients 
receiving either 25mg- or 50mg-OPC achieved the OFF- 
and ON-time responders endpoint (p<0.05 for 50mg-OPC).
Conclusion: OPC was effective in reducing OFF-time re-
gardless the concomitant use of DA or MAO-Bi.
Disclosure: Nothing to disclose
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First-time deep brain stimulation of ventral 
and dorsal parts of the substantia nigra 
and its therapeutic effect on axial motor 
symptoms in Parkinson’s disease: a case 
report.
P. Ludewig1, C. Moll2, A. Gulberti2, U. Hidding1,  
J. Koeppen3, W. Hamel3, C. Gerloff1, C. Buhmann1,  
M. Poetter-Nerger1, M. Geldesblom1
1Universitätsklinikum Hamburg-Eppendorf, Neurology, Ham-
burg, Germany, 2Universitätsklinikum Hamburg-Eppendorf, 
Neurophysiology, Hamburg, Germany, 3Universitätsklinikum 
Hamburg-Eppendorf, Neurosurgery, Hamburg, Germany
Background and aims: Therapeutic options of axial mo-
tor impairment in Parkinson’s disease are limited due to 
variable treatment success rates of drugs and deep brain 
stimulation (DBS). Recently, positive effects of simulta-
neous stimulation of the substantia nigra (SNr) und nuc-
leus subthalamicus (STN) on „freezing of gait“ (FOG) 
were reported (Weiss,Walach et al. 2013). It is unknown 
which parts of the SNr are relevant for gait disturbances. 
We present a case report of a Parkinson’s patient with DBS 
stimulated at different heights in the SNr. We aimed to in-
vestigate whether ventral stimulation of the SNr might be 
beneficial for gait disturbances in Parkinson’s disease.
Case Report: A 68-year-old patient with preoperative FOG 
underwent DBS with deep implantation of 8-pole electro-
des covering different region of the SNr with four contacts. 
12 months after operation, we evaluated the effect of of 
nigral stimulation at each contact (1.5mA, 119Hz, 60µs) 
in combination with a standard STN stimulation (monopo-
lar stimulation, 119Hz, 60µs). Outcome measures included 
changes in the MDS-UPDRS Scores, FOG Score, Berg-
Balance-Score, and neuropsychiatric side effects.
Results: Whereas stimulation in the STN improved all 
scores, additional ventral or dorsal SNr stimulation did not 
improve scores beyond the effects STN stimulation. How-
ever, severe neuropsychiatric adverse effects occurred re-
sulting in the abortion of chronic stimulation of the ventral 
parts of the SNr.
Conclusion: This is the first report of deep brain stimula-
tion in different parts of the SNr. We did not observe bene-
ficial effects on axial motor symptoms in Parkinson’s di-
sease, but severe neuropsychiatric side effects, which have 
not been reported before.
Disclosure: Nothing to disclose
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Exposure-response analyses of  
CD56bright NK cell expansion and  
regulatory T-cells reduction by  
daclizumab high-yield process (HYP) in 
subjects with multiple sclerosis
L. Diao1, Y. Hang1, A.A. Othman2, D. Mehta1,  
L. Amaravadi1, I. Nestorov1, J. Tran1
1Biogen Idec, Cambridge, MA, USA, 2AbbVie, North Chicago, 
IL, USA
Background and aims: Daclizumab HYP is a humanized 
IgG1 monoclonal antibody specific for CD25, the high-
affinity interleukin 2 receptor alpha subunit. In registration 
studies in subjects with relapsing-remitting multiple scle-
rosis (RRMS), daclizumab HYP demonstrated efficacy on 
clinical endpoints and resulted in expansion of CD56bright 
natural killer (NK) cells and reduction of regulatory T-cells 
(Tregs). This analysis characterized the quantitative relati-
onship between daclizumab HYP exposure and biomarker 
effects.
Methods: More than 7000 observations for each biomarker 
from 1400 subjects with RRMS in SELECT/SELECTION, 
OBSERVE and DECIDE studies were included in the ana-
lyses using non-linear mixed-effects modelling.
Results: CD56bright NK cell expansion was characterized 
by an indirect response model with daclizumab HYP stimu-
lating the zero-order rate constant (Kin) for the increase in 
cell number. Estimated maximum expansion ratio of CD-
56bright NK cells induced by daclizumab HYP treatment 
was ~5 with an EC50 of 18.0µg/mL. After the last dose at 
steady state, CD56bright NK cells returned to baseline le-
vels within 24 weeks. Daclizumab HYP induced reduction 
of Tregs was characterized by a direct Emax model. Esti-
mated maximum Treg decline was ~60% with IC50 value 
3.97µg/mL and a Hill coefficient of 2. After the last dose at 
steady-state, Tregs returned to baseline levels in approxi-
mately 20 weeks.
Conclusion: The developed models quantitatively charac-
terized the relationship between daclizumab HYP exposu-
re and magnitude/time course of its effects on CD56bright 
NK cells and Tregs. Effects of daclizumab HYP on these 
two biomarkers at clinically efficacious exposures were si-
gnificant and reversible in parallel with daclizumab HYP 
clearance from the body.
Disclosure: Studies supported by Biogen Idec and AbbVie 
Biotherapeutics Inc. 
P4140
Population pharmacokinetics of  
daclizumab high-yield process (HYP) in 
subjects with multiple sclerosis
L. Diao1, Y. Hang1, A.A. Othman2, I. Nestorov1, J. Tran1
1Biogen Idec, Cambridge, MA, USA, 2AbbVie, North Chicago, 
IL, USA
Background and aims: In Phase 2 and 3 trials, daclizumab 
HYP demonstrated efficacy in reducing disease activity in 
relapsing-remitting multiple sclerosis (RRMS). This ana-
lysis characterized the population pharmacokinetics for 
daclizumab HYP and identified factors correlating with 
exposures using combined data from Phase 1–3 studies in 
healthy subjects and MS patients.
Methods: Daclizumab HYP measurable serum concen-
trations (n=17,139) from 1,670 subjects (71 healthy; 
1,599 MS) were analysed using a non-linear mixed-ef-
fects modelling approach. Evaluated doses ranged from 
50–300mg with subcutaneous and 200–400mg with intra-
venous administration.
Results: A two-compartment model with first-order absorp-
tion and elimination adequately described the pharmacoki-
netics of daclizumab HYP in healthy volunteers and RRMS 
patients. Clearance was 0.212 L/day and central volume of 
distribution was 3.92 L, scaled by body weight, with ex-
ponents of 0.87 and 1.12, respectively. Peripheral volume 
of distribution was 2.42 L. Absorption lag time, mean ab-
sorption time, and absolute bioavailability (100–300mg) 
for subcutaneous administration were 1.61 h, 7.2 days and 
88%, respectively. Terminal half-life was 21 days. Body 
weight explained 37% and 27% of the inter-individual vari-
ability for clearance and central volume of distribution, res-
pectively. Neutralizing antibody positive status (0.8% in all 
pharmacokinetic records) increased the daclizumab HYP 
clearance by 19%. Daclizumab HYP exposure was not im-
pacted by gender, age, or baseline CD4+CD25+ T-cells.
Conclusion: In subjects with MS, daclizumab HYP is cha-
racterized by low clearance, small volume of distribution, 
and high subcutaneous bioavailability, similar to observa-
tions in healthy volunteers. The impact of the covariates 
on daclizumab HYP pharmacokinetics was not clinically 
relevant.
Disclosure: Studies supported by Biogen Idec and AbbVie 
Biotherapeutics Inc. 
442      Poster presentation with discussion
© 2015 European Journal of Neurology, 22 (Suppl. 1), 120–483
P4141
Impact of early treatment of MS with  
interferon beta-1b: Patient-reported  
outcomes at the 11-year follow-up of  
BENEFIT (BENEFIT 11)
G. Edan1, M. Freedman2, X. Montalban3, H.-P. Hartung4,  
B. Hemmer5, E. Fox6, F. Barkhof7, S. Schippling8,  
I.-K. Penner9, F. Foley10, A. Schulze11, D. Pleimes12,  
C. Pohl13, R. Sandbrink14, G. Suarez15, E.-M. Wicklein16,  
L. Kappos17
1CHU-Hopital Pontchaillou, Rennes, France, 2University 
of Ottawa and Ottawa Hospital Research Institute, Ottawa, 
Canada, 3Department of Neurology-Neuroimmunology, Vall 
d’Hebron University Hospital, Barcelona, Spain, 4Heinrich-
Heine Universität, Neurology, Düsseldorf, Germany, 5Tech-
nische Universität München and Munich Cluster for Systems 
Neurology (SyNergy), Munich, Germany, 6University of Texas 
Medical Branch, Austin, USA, 7VU University Medical Cen-
ter, Amsterdam, The Netherlands, 8University Hospital Zurich, 
Zurich, Switzerland, 9University of Basel and University Hos-
pital Basel, Basel, Switzerland, 10Yeshiva University, School 
of Psychology, New York, USA, 11PAREXEL International, 
Berlin, Germany, 12Myelo Therapeutics GmbH, Berlin, Ger-
many, 13Bayer Pharma AG and University Hospital of Bonn, 
Berlin, Germany, 14Bayer Pharma AG and Heinrich-Heine 
Universität, Berlin, Germany, 15Bayer HealthCare Phar-
maceuticals, Whippany, USA, 16Bayer Pharma AG, Berlin, 
Germany, 17University Hospital Basel, Basel, Switzerland
Background and aims: Long-term follow up in the BE-
NEFIT trial showed that patients treated with interferon be-
ta-1b immediately after CIS had significantly better clinical 
and MRI outcomes compared with delayed treatment. Data 
on patient-reported outcomes (PROs) will further describe 
the impact of early treatment on long-term quality of life 
(QoL) for these patients.
Methods: Patients with CIS were randomly assigned 
to receive interferon beta-1b 250 μg (early treatment) or 
placebo (delayed treatment). After 2 years or conversion 
to CDMS, patients receiving placebo were offered active 
treatment. Eleven years after the initial randomization, all 
patients from participating study centers were approached 
to complete a comprehensive reassessment, including EQ-
5D, FAMS, CES-D, and FSMC.
Results: 278 patients (of the original 468) were enrolled 
(71.3% of patients from sites participating in BENEFIT11). 
At Year 11, median EDSS was 2.0 in both treatment arms. 
Results from both arms combined showed (median [Q1, 
Q3]): EQ-5D VAS change from baseline score, 0.0 (-10.0, 
8.0); EQ-5D HRQoL change from baseline score, 0.00 
(-0.19, 0.02); FAMS TOI, 117.10 (92.85, 134.00); CES-D 
total score, 9.00 (4.00, 19.00); and FSMC total score, 45.00 
(26.00, 66.00). 143/278 patients (51.4%) reported fatigue 
(defined as FSMC total score >42) and 84/278 patients 
(30.2%) reported depressive symptoms (defined as >15 on 
CES-D). There was little difference between the two treat-
ment arms for these variables.
Conclusion: Measures of QoL over 11 years remained sta-
ble and may reflect the beneficial impact of treatment early 
in the disease on the clinical course of MS.
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Systemically administered exosomes  
mediate recovery in the Theiler’s Mourine 
Ecephalomyelitis Virus animal model of 
multiple sclerosis.
J. Ramos Cejudo1, M. Fernandez-Fournier1, M. Gutierrez-
Fernandez2, B. Rodriguez-Frutos2, L. Otero-Ortega2,  
C. Guaza3, T. Navarro4, S. Cerdan4, E. Díez-Tejedor5
1Madrid, Spain, 2IdiPAZ, La Paz University Hospital, Neuros-
cience Labarotary, Madrid, Spain, 3Cajal Research Institute, 
Neuroimmunology, Madrid, Spain, 4Alberto Sols Biomedical 
Research Institute, Imaging, Madrid, Spain, 5Hospital Uni-
versitario la Paz, Neurology department and Stroke centerde-
partment and Stroke center, Madrid, Spain
Background and aims: Exosomes (EXO) are small vesic-
les of 40 to 150nm released by different cell types, media-
ting intercellular communication. An animal model that has 
recently gained relevance in the study of Multiple Sclerosis 
is Theiler’s Mourine Encephalomyelitis Virus (TMEV). We 
aimed to study if the administration of exosomes derived 
from mesenchymal stem cells could mediate recovery in 
the TMEV model.
Methods: Exosomes purified from human adipose tissue-
derive mesenchymal stem cells were intravenously admi-
nistered (25ug/Kg,i.v.) to mice undergoing demyelinating 
disease induced by TMEV injection (2x10^6 viral units) at 
Cajal Institute, Madrid. Animals, n=27 were randomly divi-
ded into 3 groups (Sham, n=7; TMEV, n=10; TMEV-EXO, 
n=10). Animals were evaluated clinically and by Magnetic 
Resonance Imaging (MRI). 
Results: Fifteen days post-exosome administration mo-
tor activity and memory improved in treated animals; and 
7-tesla MRI analysis showed partial resolution of both brain 
connectivity and ventricular atrophy. Myelin basic protein 
staining in vehicle treated mice showed higher demyelina-
tion in subcortical white matter and KI-67 cell proliferati-
on and the levels of Oligodendrocyte precursors’ markers 
PDGFR and CC1 were higher in the Subventricular Zone 
of TMEV-EXO animals. Proteomic content of exosomes in 
cell supernants was analyzed by Orbitrap identifying over 
1,300 proteins, including a number of trophic factors and 
signaling molecules not previously identified in the litera-
ture. 
Conclusion: Our results suggest that mesenchymal stem 
cells derived exosomes have the potential to mediate reco-
very after central nervous system demyelination and might 
provide a novel approach to treat autoimmune diseases 
such as multiple sclerosis.
Disclosure: Nothing to disclose
P4144
“Number Needed to Treat” analysis to  
assess the comparative outcomes from 
teriflunomide and dimethyl fumarate  
studies in relapsing multiple sclerosis
M.S. Freedman1, X. Montalban2, A.E. Miller3,  
C. Dive-Pouletty4, T.P. Leist5
1University of Ottawa and the Ottawa Hospital Research 
Institute, Ottawa, Canada, 2Department of Neurology-Neu-
roimmunology, Vall d’Hebron University Hospital, Barcelona, 
Spain, 3Icahn School of Medicine at Mount Sinai, New York, 
USA, 4Genzyme, a Sanofi company, Chilly-Mazarin, France, 
5Comprehensive Multiple Sclerosis Center, Thomas Jefferson 
University Hospital, Philadelphia, USA
Background and aims: Teriflunomide and dimethyl fu-
marate (DMF) have demonstrated efficacy in clinical tri-
als in patients with relapsing-remitting multiple sclerosis. 
Exploratory analyses of treatment effects can be compared 
informally using relative reductions in a specific endpoint. 
The number needed to treat (NNT) to prevent an event was 
assessed for outcomes in studies with teriflunomide and 
DMF.
Methods: NNTs were derived using data from studies 
with teriflunomide (TEMSO, NCT00134563; TOWER, 
NCT00751881) or DMF (DEFINE, NCT00420212; CON-
FIRM, NCT00451451) based on the inverse of absolute 
differences between treatment and placebo groups.
Results: Teriflunomide and DMF significantly reduced 
risk of relapse (all studies). NNTs to prevent 1 relapse were 
similar across studies (5.9 [TEMSO], 5.6 [TOWER], 5.3 
[DEFINE], 5.6 [CONFIRM]). Risk of disability progres-
sion sustained for 12 weeks was significantly reduced in 
TEMSO, TOWER, and DEFINE but not CONFIRM. Cor-
responding NNTs to prevent disability progression were 
13.8, 17.4, 10.8, and 30.2. Risk of relapse leading to hos-
pitalization was significantly reduced in TEMSO and TO-
WER but not in DEFINE and CONFIRM. Corresponding 
NNTs were lower in TEMSO (12.5) and TOWER (20) than 
in DEFINE (50) and CONFIRM (50). Safety data and cor-
ticosteroid use will be presented.
Conclusion: A comparable effect size for teriflunomide 
and DMF on relapse was demonstrated using the NNT ap-
proach. NNTs to prevent disability progression with teriflu-
nomide showed a consistent significant reduction in risk vs 
placebo in both TEMSO and TOWER, whereas for DMF, 
comparable NNTs were observed in DEFINE, but not in 
CONFIRM. Reduction of risk for relapse leading to hospi-
talization was significant only for teriflunomide.
Disclosure: Study supported by Genzyme, a Sanofi com-
pany.
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Do patients with multiple sclerosis  
understand quantitative health  
information? Comparison of a  
natalizumab-treated cohort from the  
German PERCEPT study with a  
probabilistic national sample
W. Gaissmaier1, M. Galesic2, R. Garcia-Retamero2, 
I. Kleiter3, S. Meuth4, S. Koepke5, C. Heesen6
1Universitaet Konstanz, Fachbereich Psychologie, Sozialpsy-
chologie und Entscheidungsforschung, Konstanz, Germany, 
2Max-Planck-Institut für Bildungsforschung, Berlin, Germany, 
3St. Josef Hospital, Neurologie, Bochum, Germany, 4Univer-
sitaetsklinikum, Klinik für Allgemeine Neurologie und Institut 
für Physiologie I - Neuropathophysiologie, Muenster, Germa-
ny, 5Universitaetsklinikum Schleswig-Holstein, Forschung und 
Lehre in der Pflege, Lübeck, Germany, 6Universitaetsklinikum 
Hamburg-Eppendorf, MS Day Hospital and Outpatient Unit 
Institute of Neuroimmunology and Clinical MS Research, 
Hamburg, Germany
Background and aims: Natalizumab (NAT) is a highly 
effective therapy in relapsing multiple sclerosis (MS), yet 
bears the risk of a progressive multifocal leukoencephalo-
pathy as a rare but severe side effect. To understand quan-
titative information about its benefits and risks and make 
informed treatment decisions, patients require statistical 
numeracy. It is unknown, however, whether MS affects 
numeracy, which is why we compared numeracy between 
NAT treated MS patients and a probabilistic national sam-
ple.
Methods: The prospective, observational, multicentre 
study PERCEPT investigated NAT patients’ and neurolo-
gists’ benefit/risk perception and knowledge in Germany. 
Numeracy of NAT patients was assessed as the proportion 
of correct answers on a standard test (1). Patients (N=344) 
were compared to published numeracy data from a German 
probabilistic sample (N=1,001; (1)) with an analysis of va-
riance also including sex, age, and education as predictors.
(1) Galesic M, Garcia-Retamero R. Arch Intern Med. 
2010;170(5): 462-8
Results: Preliminary analyses showed that MS patients 
had the same numeracy as the probabilistic national sample 
(71.6% vs. 69.2% correct answers, p=.142). In both pati-
ents and controls, higher numeracy was related to being 
male (p<.001), younger age (p=.037), and higher education 
(p<.001), see Table 1.
Conclusion: MS patients had the same numeracy as a nati-
onal probabilistic sample and the same demographic varia-
bles predicted numeracy in controls and patients. These re-
sults imply that MS patients understand quantitative health 
information as well as the general population and may be 
capable of understanding the benefits and risks of treatment 
with NAT.
Disclosure: Study sponsored by Biogen Idec GmbH.
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Switching from subcutaneous interferon 
Beta-1a to alemtuzumab improves  
relapse outcomes in CARE-MS I
B. Kieseier1, J. Lycke2, A.N. Boyko3, X. Montalban4,  
D.H. Margolin5, L. Kasten6, E.J. Fox7
1Heinrich-Heine-University Düsseldorf, Düsseldorf, Germa-
ny, 2University of Gothenburg, Gothenburg, Sweden, 3Russian 
Science and Research Medical University named after N. 
I. Pirogov and Moscow Multiple Sclerosis Center, Moscow, 
Russian Federation, 4Vall d’Hebron University Hospital and 
Research Institute, Barcelona, Spain, 5Genzyme, a Sanofi 
company, Cambridge, USA, 6PROMETRIKA LLC, Cam-
bridge, USA, 7Central Texas Neurology Consultants, Round 
Rock, USA
Background and aims: In the 2-year, phase 3 CARE-MS I 
study (NCT00530348), alemtuzumab significantly reduced 
annualised relapse rate (ARR) in treatment-naive patients 
with active relapsing-remitting multiple sclerosis, compa-
red with subcutaneous interferon beta-1a (SC IFNB-1a). 
This analysis investigated alemtuzumab’s effects on relapse 
in patients who received SC IFNB-1a in CARE-MS I and 
switched to alemtuzumab.
Methods: In CARE-MS I, SC IFNB-1a-treated patients 
received 44μg 3 times/week for 2 years during the core 
study and 2 annual courses of alemtuzumab 12mg in the 
first 2 years of the extension (NCT00930553). Relapse 
events were assessed by raters blinded to patients’ earlier 
treatment assignment. Evaluated endpoints included ARR, 
proportions relapse-free, and relapse outcomes over 2 years 
in all SC IFNB-1a-treated patients and in the subgroup who 
relapsed during the core study.
Results: The extension enrolled 144 (83%) SC IFNB-1a-
treated patients from CARE-MS I. ARR decreased by 69% 
after switching to alemtuzumab (0.39 vs 0.12). The pro-
portion of relapse-free patients increased after switching 
(79%), compared with core study SC IFNB-1a treatment 
(59%). In the patient subset who relapsed on SC IFNB-1a 
during the core study (n=60), ARR decreased after swit-
ching to alemtuzumab (0.82 vs 0.29) and 58% were relap-
se-free 2 years after switching. Similar results were obser-
ved in SC IFNB-1a patients who relapsed in Year 2 (n=32; 
ARR 1.04 vs 0.36 [47% relapse-free]).
Conclusion: Alemtuzumab treatment further decreased 
ARR in patients who received SC IFNB-1a in CARE-MS 
I. These findings highlight its superior efficacy, as shown in 
that randomised, head-to-head study, and demonstrate the 
benefits of switching to alemtuzumab.
Disclosure: Study supported by Genzyme, a Sanofi compa-
ny, and Bayer Healthcare Pharmaceuticals.
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First results of a prospective cohort study 
in clinically isolated syndromes and early 
multiple sclerosis of the German  
Competence Network Multiple Sclerosis
A. Salmen1, G. Antony2, A. Ziegler3, F. Zipp4,  
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H. Wiendl20, B. Hemmer21, R. Gold1
1St. Josef Hospital, Bochum, Germany, 2Philipps-University 
Marburg, Central Information Office (CIO), Marburg, 
Germany, 3University of Lübeck, Institute of Medical Bio-
metry and Statistics (IMBS), Lübeck, Germany, 4University 
Medicine Mainz, Johannes Gutenberg University Mainz, 
Neurology, Mainz, Germany, 5Philipps-Universität und Uni-
versitätsklinikum Gießen und Marburg, Klinik für Neurologie, 
Marburg, Germany, 6University of Leipzig, Neurology, Leip-
zig, Germany, 7University of Ulm, Neurology, Ulm, Germa-
ny, 8Ludwig-Maximilians-Universität, Institute of Clinical 
Neuroimmunology, Munich, Germany, 9Hannover Medical 
School, Neurology, Hanover, Germany, 10University Hospi-
tal Hamburg-Eppendorf, Neurology, Hamburg, Germany, 
11University of Heidelberg, Neurology, Heidelberg, Germany, 
12Charité – University Medicine Berlin, NeuroCure Clinical 
Research Center, Berlin, Germany, 13Klinikum Augsburg, 
Neurology, Augsburg, Germany, 14Heinrich-Heine-University, 
Neurology, Düsseldorf, Germany, 15Max-Planck-Institute of 
Psychiatry, Neurology, Munich, Germany, 16University Hos-
pital Erlangen, Neurology, Erlangen, Germany, 17University 
Hospital, Eberhard-Karls-Universität Tübingen, Neurology, 
Tübingen, Germany, 18University of Rostock, Neurology, 
Rostock, Germany, 19Hospital Köln-Merheim, Neurology, 
Cologne, Germany, 20University Hospital Münster, Neurology, 
Münster, Germany, 21Klinikum rechts der Isar, Technische 
Universität München, Neurology, Munich, Germany
Background and aims: Recent epidemiological data on 
course and treatment of early Multiple Sclerosis (MS) in 
Germany is widely lacking. Other countries are hardly 
comparable due to differences in respective environmen-
tal and genetic factors. The German Competence Network 
Multiple Sclerosis (KKNMS) initiated a nationwide cohort 
study in clinically isolated syndrome (CIS) and early MS.
Methods: This prospective cohort study (Ruhr-University 
Bochum, Ethics committee reg.-no. 3714-10) recruited 
adult CIS and early MS patients at 22 sites in Germany. 
Inclusion criteria comprised newly established diagnosis of 
CIS with high probability of conversion to MS or relap-
sing-remitting MS according to current diagnostic criteria 
within the past two years. Therapy-naïve status for disease-
modifying drugs (DMDs) was a prerequisite. Patients with 
progressive forms of MS or interfering neurological disea-
ses were excluded. Clinical, MRI data and biomaterial were 
collected following standardized protocols and quality con-
trol with yearly visits over the first three years and every 
other year consecutively for another three visits.
Results: The recruitment period was Aug-2010 to Dec-
2014. As of Dec-31-2014, 1208 patients were enrolled, 67 
of 1208 (5.5%) had to be excluded (inclusion criteria not 
fulfilled, major data missing); of resulting 1141 patients, 
133 (11.7%) were lost to follow-up. Analyses of baseline 
data and data clearing are ongoing and will be presented at 
the meeting.
Conclusion: This first description of a German cohort of 
more than 1000 newly diagnosed CIS and MS patients will 
allow for numerous investigations of MS disease course, 
usage of modern DMDs, environmental and genetic factors.
Disclosure: The KKNMS is supported by the German Fe-
deral Ministry for Education and Research, BMBF, grant 
no. 01GI0914.
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P4148
Modeling dose-PK-lymphocytes  
relationship under siponimod (BAF312) 
treatment to infer time to immune  
reconstitution
C. Sarr, M. Savelieva, G. Ette, C. Petry, E. Legangneux,  
E. Wallstroem
Novartis Pharma AG, Basel, Switzerland
Background and aims: Siponimod (BAF312), a selective 
sphingosine 1-phosphate 1 and 5 receptor modulator targets 
multiple sclerosis (MS) by preventing circulating effector 
lymphocyte infiltration to central nervous system. We con-
ducted a modeling analysis to characterize the relationship 
between siponimod PK exposure and lymphocyte dyna-
mics, using clinical data from phase I and phase II studies.
Methods: Several indirect response models, including mo-
dels with a feedback loop, were tested to characterize the 
interaction between siponimod concentrations and lympho-
cyte dynamics (Figure). Data from 6 phase I studies and 1 
phase II study were split into: model-building dataset (5 
studies) and qualification dataset (2 studies; Table 1). Co-
variates tested were weight, gender, MS (yes/no) and eth-
nicity. Simulations were performed to assess the time to 
lymphocyte recovery.
Figure: PKPD model for siponimod concentrations and absolute lym-
phocyte count
Table 1: Siponimod clinical trials pooled for analysis
Results: An indirect response model combined with an 
Imax model adequately characterized the relationship bet-
ween siponimod PK exposure and lymphocyte dynamics. 
The maximal effect on lymphocyte reduction was estimated 
to be 84%. The IC50 on lymphocyte reduction was estima-
ted at 4.55 ng/mL (inter-individual variability around 40%). 
Statistically significant covariates were: Gender on ‘IC50’, 
weight on ‘Imax’ and ‘PK clearance’, baseline on ‘Kout’, 
and disease status on ‘baseline’. Table 2 summarizes medi-
an time required for lymphocyte recovery following conti-
nuous treatment with siponimod 2mg or 1mg daily.
Table 2: Time in days needed to recover at different thresholds func-
tion of siponimod treatment and categories of MS patients (residual 
variability taken into account)
Conclusion: For the first time, the relationship between si-
ponimod doses and their impact on lymphocytes dynamic 
was characterized in healthy volunteers and MS patients. 
Lymphocyte recovery time may be relevant for vaccina-
tions, severe infections, therapy switch and other situations 
requiring reversal of pharmacodynamic effects. 
Disclosure: Study supported by: Novartis Pharma AG.  C 
Sarr, M Savelieva, G Ette, C Petry, E Legangneux and E 
Wallström are paid employees of Novartis Pharma AG, Ba-
sel, Switzerland.
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Epidemiological study to evaluate the 
course of disease and therapy decisions 
in relapsing-remitting multiple sclerosis 
patients with long-term first-line disease 
modifying treatment
S. Schmidt1, J. Koehler2, C. Winterstein3, P. Schicklmaier3,  
C. Wernsdoerfer3, B. Kallmann4
1Neurologische Gemeinschaftspraxis, Bonn, Germany, 2Be-
handlungszentrum Kempfenhausen für Multiple Sklerose 
Kranke gemeinnützige GmbH, Berg, Germany, 3Biogen Idec 
GmbH, Ismaning, Germany, 4multiple sklerose zentrum bam-
berg - msbz, Bamberg, Germany
Background and aims: A previous analysis has demons-
trated that about 25% of RRMS patients treated with first-
line DMT would have qualified for second-line treatment 
based on clinical and subclinical disease activity (Mäurer 
M. et al. Eur J Neurol 2011). It is unknown whether this 
situation has changed in the context of new therapeutic op-
tions and risk stratification tools.
Methods: This non-interventional multicenter study retros-
pectively evaluated the clinical course of disease, MRI, and 
QoL of 4215 RRMS patients treated with first line DMTs 
for ≥ 24 months from October 2010-June 2014. The assess-
ment of the clinical disease course by the treating neurolo-
gists and the resulting treatment decisions were analyzed.
Results: Baseline demographics: mean age 44.8 years, 
73.1% females, median disease duration 9.6 years, mean 
EDSS 2.3. In 1594 patients, EDSS, MRI, relapse rate, judg-
ment of disease course by the treating neurologists as well 
as treatment decisions were available. Although evidence 
of clinical and/or MRI activity was detectable in 50.8% of 
these patients, 64.8% were rated as “stable”, 2.3% even as 
“improved” and only 31.9% as “worsened”. Treatment op-
timization was considered for only 24.7% of these patients.
Conclusion: The treating physicians considered the majo-
rity of patients as „stable“ despite evidence of clinical and/
or subclinical disease activity. Therefore only a minority 
was considered suitable for treatment optimization. This 
study underlines the importance to understand and develop 
clinical and subclinical measures of disease activity in MS 
in order to improve the monitoring of treatment responses 
to DMTs and to optimize treatment decisions.
Disclosure: Study sponsored by Biogen Idec GmbH.
P4150
Exosomal RNA sequences as biomarkers 
of MS
I. Selmaj, K. Selmaj, M. Mariasiewicz, M. Mycko
Medical University of Lodz, Department of Neurology, Labo-
ratory of Neuroimmunology, Lodz, Poland
Background and aims: Exosomes are a membrane vesic-
les released from the endocytic compartment of live cells 
that play an important role in cell-to-cell communication. 
The major contents of the exosomes are short RNAs that 
can interfere with the function of the acceptor cells.
Methods: To analyze the role of exosomes in the relapsing 
remitting multiple sclerosis (MS) we have isolated exoso-
mes and exosomal RNA from serum and urine of the MS 
patients and control subjects. Subsequently we have gene-
rated exosomal RNA libraries and process them for the next 
generation sequencing analysis.
Results: We have found that both serum and urine exoso-
mes are a reach source of the shortRNA (<300 nt) in MS 
patients. RNA-seq yielded an average of 4019 different 
annotated sequences in serum exosomes of MS patients 
during relapse, whereas 2877 sequences in the MS during 
remission and 3075 sequences in control subjects. The uri-
ne exosomal RNA analysis have demonstrated presence of 
4480 different annotated RNA sequences in material from 
MS patients during relapse whereas only 1093 different se-
quences in material from controls. All the sequences have 
been grouped into 14 different RNA categories: CDBox, 
HAcaBox, RefSeq_antisense, lincRNA, lincRNA_anti-
sense, miRNA, other_ncRNA, other_ncRNA_antisense, 
rRNA, piRNA, rfam, scaRNA, tRNA and tRNA_like. Ref-
Seq_antisense represented the largest fraction of frequen-
ces derived from MS patients serum or urine exosomes (22 
to 28% of sequences).
Conclusion: Our data highlight a potential difference in 
serum and urine exosomes RNA in MS patients related to 
the clinical status of the patients that could lead to a disco-
very of new biomarkers of MS.
Disclosure: Supported by NCN PRELUDIUM grant to IS, 
NCN MAESTRO 2012/04/A/NZ6/004234 grant to KS and 
PSPB-007-2010 grant to MPM
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Understanding the characteristics of  
secondary progressive multiple sclerosis 
to facilitate early identification
D. Simsek1, E. Verdun1, R. Lahoz1, J. Pike2, E. Jones2
1Novartis Pharma AG, Basel, Switzerland, 2Adelphi Real 
World, Macclesfield, United Kingdom
Background and aims: The transition from Relapsing-re-
mitting Multiple Sclerosis (RRMS) to Secondary Progres-
sive Multiple Sclerosis (SPMS) may be lengthy and there 
is no single standard definition of SPMS broadly applied in 
clinical practice. We assessed the differences between late-
RRMS and early-SPMS patients on sociodemographics, 
daily activities and clinical characteristics including sym-
ptoms and MRI parameters.
Methods: Data were drawn from the Adelphi Multiple 
Sclerosis Disease Specific Program, a cross-sectional stu-
dy of 250 neurologists and 3294 patients in the US. 343 
patients diagnosed with MS at least 4 years and EDSS≥3 
were analyzed; 261 were defined as late-RRMS (Physician 
designation of RRMS and EDSS<6) and 82 as early-SPMS 
(Physician designation of SPMS ≤3 years). Fisher’s Exact 
test and Mann-Whitney test for categorical and continuous 
outcomes respectively, were used to determine unadjusted 
differences in the two groups. Further multivariate analyses 
are being performed.
Results: In unadjusted analyses, early-SPMS patients were 
found to be older, less likely to be employed, required more 
help with activities of daily living, suffered from more fre-
quent motor and urinary symptoms, and had more T2 lesi-
ons (Table). A near-significant difference was observed in 
the frequency of sensory symptoms.
Table: Sociodemographics and clinical characteristics of Late-RRMS 
and Early-SPMS patients (Unadjusted analysis)
Conclusion: These analyses highlight significant differen-
ces between RRMS and SPMS populations. These variab-
les could be useful parameters for physicians to consider 
when assessing the transition from RRMS to SPMS. Accu-
rate early identification of SPMS patients and use of the 
most appropriate treatments may result in better long-term 
outcomes for this population.
Disclosure: Study supported by: Novartis Pharma AG. 
James Pike and Eddie Jones are paid employees of Adelphi 
Real World, Macclesfield, United Kingdom  Deniz Simsek, 
Elisabetta Verdun, and Raquel Lahoz are paid employees of 
Novartis Pharma AG, Basel, Switzerland. 
P4153
Sympathetic autonomic system is  
differentially altered in progressive and 
relapsing multiple sclerosis
V. Studer, C. Rocchi, C. Motta, B. Lauretti, G.A. Marfia,  
D. Centonze, S. Rossi
Tor Vergata University, Rome, Italy
Background and aims: Sympathovagal imbalance has 
been associated to poor prognosis in several chronic disea-
ses, but conflicting evidence have been reported about auto-
nomic nervous system (ANS) dysfunction in multiple scle-
rosis (MS). We aimed to assess ANS dysfunction in MS and 
its correlation with progressive and worsening disability.
Methods: Heart rate variability (HRV) was analyzed in 120 
MS patients and 60 healthy controls (HC) during supine 
rest and head up tilt test (HUTT); the normalized unit of 
LF and HF power (LFnu; HFnu) were considered to assess 
sympathetic and vagal components, respectively. Correla-
tion analyses with clinical and radiological markers of di-
sease activity and progression were performed. 
Results: Sympathetic dysfunction was closely related to the 
progression of disability in MS: progressive MS patients 
showed altered HRV respect to HC and relapsing remitting 
patients (RRMS), with higher LFnu at rest and a lack of 
the expected LFnu increase during HUTT.  Among RRMS 
subjects disease activity, even subclinical, was associated 
to lower LFnu at rest, and to an enhanced sympathetic re-
activity during HUTT, whereas stable RRMS did not differ 
from HC. Higher LFnu increase during HUTT was obser-
ved in active patients without clinical expression of brain 
inflammation, while less sympathetic reactivity and high-
er LFnu at rest were associated with incomplete recovery 
from relapse. Sympathovagal balance was not influenced 
by the presence of infratentorial demyelinating lesions. 
Conclusion: The sympathetic system is overactive and 
exhausted in progressive disease, ineffective in worsening 
MS. ANS dysfunctions appear intimately linked with both 
the proinflammatory environment and the compensatory 
plastic processes in MS.
Disclosure: Nothing to disclose
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Multiple acyl-CoA dehydrogenase  
deficiency in an adult: a case report
C. Duque1, A. Gouveia1, J. Tomás1, E. Rodrigues2,  
M.D.C.R.R.M. Macário1
1Coimbra, Portugal, 2Centro Hospitalar do Funchal, Neurolo-
gy Department, Funchal, Portugal
Background and aims: Multiple acyl-CoA dehydrogenase 
deficiency (MADD) is caused by defects in the pathway for 
transferring electrons from the first step in oxidation to the 
electron transport system. MADD is a clinically heterogene-
ous disorder of fatty acid and amino acid oxidation caused 
by mutations in the ETFA, ETFB and ETFDH genes.
Methods: A 32-year-old man was referred to the neurology 
department for muscular pains with weakness exacerbated 
after exertion since the age of 6. Laboratory assessment re-
vealed an increased level of creatine kinase (529 mg/dL), 
ECG showed frequent ventricular extrasystoles, echocar-
diogram was normal and cardiac stress test was interrup-
ted at 10 minutes due to maximal fatigue with diminished 
functional capacity. Acylcarnitine profile analysis showed 
low C2 and free carnitine and increased carnitine C5-C14, 
which was diagnostic for MADD. Genetic analysis identi-
fied a pathogenic mutation in the ETFH gene (p.P534L). 
Exon sequencing was performed and identified other patho-
genic alterations, not previously described in the literature, 
in ETFA and ETFB genes (p.T171I and p.T245M, respec-
tively). After family genetic studies, the mother of the pa-
tient was identified as a carrier of the pathogenic mutation 
and, by exon sequencing, had also the new ETFB variant.    
Results: We report a patient with MADD diagnosed in 
adulthood, with a new genetic variant identified by exon 
sequencing, as combined polygenic heterozygosity.    
Conclusion: Clinical presentation of MADD may range 
from a severe neonatal presentation to a mild childhood/
adult disease with episodic metabolic decompensation, 
muscle weakness and respiratory failure, posing diagnostic 
challenge.
Disclosure: Nothing to disclose
P4157
Novel POLG1 mutations and variable  
clinical phenotypes in 13 italian patients
P. Da Pozzo1, E. Cardaioli1, A. Rubegni2, G.N. Gallus1,  
A. Malandrini1, A. Rufa1, C. Battisti1, M.A. Carluccio1,  
R. Rocchi1, F. Giannini1, A. Bianchi3, M. Mancuso4,  
G. Siciliano4, M.T. Dotti1, A. Federico1
1University of Siena, Department of Medical, Surgical and 
Neurological Sciences, Sienna, Italy, 2IRCCS Stella Maris, 
Pisa, Italy, 3Hospital, Department of Neuroscience, Arezzo, 
Italy, 4University of Pisa , Department of Neuroscience, Neu-
rological Clinic, Pisa, Italy
Background: The POLG gene encodes the catalytic subu-
nit of DNA polymerase gamma, essential for mitochondrial 
DNA (mtDNA) replication and repair. Mutations in POLG 
have been linked to a spectrum of clinical phenotypes, re-
sulting in autosomal recessive or dominant mitochondrial 
diseases. These mutations have been associated with he-
terogeneous phenotypes, presenting with varying severity 
and at different ages of onset, ranging from the neonatal 
period to late adult life.
Objective: To determine the spectrum of POLG mutations 
in a cohort of patients with clinical presentations sugges-
tive of POLG deficiency, to evaluate the pathogenicity of 
novel mutations and to establish genotype-phenotype cor-
relations.
Methods: We screened 13 patients for POLG mutations. 
All patients underwent a complete neurological examinati-
on, in most of cases muscle biopsy was performed.
Results: We detected 14 different mutations in 13 unrelated 
Italian patients. Three mutations were novel, 2 mapped in 
the pol domain (p.Thr989dup, p.Ala847Thr) and 1 in the 
linker region (p.His613Tyr) of the enzyme. We also report 
new cases carrying controversial mutations previously de-
scribed as incompletely penetrant or a variant of unknown 
significance. 
Discussion and Conclusions: Our results confirm the cli-
nical heterogeneity of POLG-related diseases, underlining 
some peculiar clinical features, such as early onset myo-
pathy with severe cerebellar atrophy, PEO associated with 
corneal edema, and epilepsy, severe neuropathy with acha-
lasia. The addition of three new substitutions, including the 
second report of an in-frame duplication, to the growing list 
of defects increases the value of POLG genetic diagnosis in 
a range of neurological presentations. 
Disclosure: Nothing to disclose
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Clinical and genetic heterogeneity in six 
patients with limb-girdle muscular  
dystrophy type 2A
G.N. Gallus1, A. Rubegni2, A. Malandrini1, S. Aguti1,  
F. Sicurelli1, C. Battisti1, A. Rufa3, G. Berti1, E. Cardaioli1,  
P. Da Pozzo1, A. Federico1
1University of Siena, Department of Medical, Surgical and 
Neurological Sciences, Sienna, Italy, 22IRCCS Fondazione 
Stella Maris, Pisa, Italy, 3University of Siena, Neurology and 
Neurometabolic Diseases Unit, Department of Medicine, 
Surgery and Neuroscience, Sienna, Italy
Background and aims: Limb-girdle muscular dystrophies 
type 2A (LGMD2A) is the most frequent form of recessive 
LGMD and it is caused by mutation in the CAPN3 gene. 
LGMD2A is characterized by progressive weakness of pro-
ximal muscles with onset ranging from two to 40 years.
To describe clinical, histological and molecular findings of 
six patients, belonging to four families, carrying CAPN3 
mutations.
Methods: Each patient underwent a complete neurological 
examination and a muscle biopsy. In all cases histological, 
immunohistochemical and genetic studies were performed. 
Results: All patients presented limb-girdle muscle weak-
ness but were still ambulant at the last observation. Muscle 
biopsy showed severe dystrophic features in two and mo-
derate myopathic changes in four cases. In the first patient 
we found the c.1401_1403delGGA and c.2257G>A (in cis) 
and the c.967G>T variant in CAPN3. In another family, 
two siblings harbored c.755T>G and c.1746-20C>G mu-
tations whereas a third sib, carried only the heterozygous 
c.755T>G. We detected only the heterozygous c.526G>A 
in the proband of the third family but we observed a stron-
gly decreased CAPN3 mRNA. Finally the sixth patient car-
ried the heterozygous missense mutation c.2458T>C. The 
latter mutations were novel. 
Conclusion: These findings further expands the spectrum 
of CAPN3 mutations.  We suggest that molecular analysis 
based on CAPN3 gene sequencing could not be conside-
red conclusive. In particular, in cases of heterozygosity the 
research of the second mutation, should continue with the 
analysis of the transcript and possible gene rearrangements. 
Finally, this study confirms the genetic and phenotypic va-
riability in patients with LGMD2A.  
Disclosure: Nothing to disclose
P4159
An adult patient with rare recessive  
lipodystrophy: autoinflammation,  
lipodystrophy, and dermatosis syndrome
A. Gouveia1, J. Cardoso2, C. Duque1, J. Tomás1, M. Gama3,  
I. Alonso3, J. Silva3, L. Ribeiro4, M.C. Macário1
1Coimbra University and Hospital Centre, Coimbra, Portu-
gal, Neurology, Coimbra, Portugal, 2Coimbra University and 
Hospital Centre, Coimbra, Portugal, Dermatology, Coimbra, 
Portugal, 3Institute for Molecular and Cell Biology, Porto, 
Portugal, Porto, Portugal, 4Coimbra University and Hospital 
Centre, Coimbra, Portugal, Hematology, Coimbra, Portugal
Background and aims: Autoinflammation, Lipodystro-
phy, and Dermatosis Syndrome (ALDS) is a rare genetic 
lipodystrophy, recently described, caused by homozygous 
mutation in the PSMB8 gene on chromosome 6p21. The 
few patients reported to date present panniculitis-induced 
childhood onset lipodystrophy, muscle atrophy, joint con-
tractures, microcytic anemia, hepatosplenomegaly and ba-
sal ganglia calcification.    
Case Report: We report the detailed phenotype of a 29-ye-
ar-old Portuguese male.    
Results: Our patient was born to consanguineous parents in 
third degree. In the first month of life, he presented recur-
rent erythematous skin lesions, hepatosplenomegaly and 
cortico-responsive microcytic anemia. During childhood, 
he developed progressive and severe lypodistrophy, muscle 
atrophy and joint contractures. In the adulthood, he mani-
fests corneal lesions, responsive to ophthalmic cyclospo-
rine. There is no evidence of cognitive dysfunction, how-
ever, the patient is highly dependent due to severe motor 
impairments. The patient underwent a thorough investigati-
on including muscle biopsy showing necrosis, atrophy and 
Sudan+ cells, and pallidal calcifications in the brain MRI. 
Genetic testing confirmed the presence of homozygous mu-
tation in the PSMB8 gene (c.224C> T).
Conclusion: We present a rare autosomal recessive lipo-
dystrophy with neurologic involvement. To our knowledge, 
compared to the patients reported in literature, our patient 
has the earliest onset and is the only one with corneal le-
sions. The remaining phenotype is similar. The cortico-
responsive anemia and the corneal lesions responsive to 
cyclosporine support the hypothesis of an immune dysre-
gulation physiopathology.    
Disclosure: Nothing to disclose
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Vanishing white matter disease – a single 
centre cohort
A. Gouveia1, J. Tomás1, C. Duque1, O. Galego2, M. Arenga1, 
F. Sobral1, I. Alonso3, J. Silva3, M. Gama3, F. Magalhães1,  
M.C. Macário1
1Coimbra University and Hospital Centre, Neurology, Coim-
bra, Portugal, 2Coimbra University and Hospital Centre, 
Neurorradiology, Coimbra, Portugal, 3Institute for Molecular 
and Cell Biology, Porto, Portugal, Porto, Portugal
Background and aims: Vanishing white matter disease 
(VWMD) is a genetic leucoencephalopathy, with great 
phenotypic variation. MRI is frequently diagnostic and in-
dicative of vanishing of the cerebral white matter (WM). 
Methods: Retrospective review of all patients followed in 
our neurometabolic outpatient clinic since 2003 with the 
diagnosis of VHMD.
Results: We identified 7 patients. 5 were female and two 
were sisters. The age of neurological symptoms onset 
was between 17 and 46 years. 4 patients had a progressi-
ve course with spastic tetraparesis or paraparesis, urinary 
incontinence, dysphasia and/or neuropsychiatric symptoms 
(aggressiveness, disinhibition, attention deficit or memory 
difficulties). 3 patients exhibit acute or hyperacute presen-
tation with seizures or subacute neurological neurological 
deficits followed by rapidly progressive deterioration, be-
coming wheel-chair bound and totally dependent in few 
days. Infertility was present in 2 women and hypogonadism 
in 1 man. All the patients fulfilled MRI VWMD criteria, na-
mely supratentorial WM involvement with signal intensity 
close to that of CSF on FLAIR imagens, cystic degenera-
tion, preservation of U fibers, corpus calosum atrophy and 
cerebellar WM involvement. All had homozygous mutation 
in EIF2B5 gene, except for one patient, who had compound 
heterozygous mutation in the same gene.
Conclusion: In our institution, VWMD is the most frequent 
leukodystrophy found in adulthood. Therefore, we think 
that in age group, VWMD should be excluded amongst the 
other currently known leukodystrophies, including that re-
lated to inborn errors of metabolism.
Disclosure: Nothing to disclose
P4161
De novo mutations in SPG3A: a challenge 
in differential diagnosis and genetic  
counselling
S. Haggiag1, L. Leonardi2, C. Marcotulli3, L. Lispi1,  
F. Pierelli2, A. Tessa4, M. Sessa5, S. Orcesi6, C. Cereda6,  
F.M. Santorelli4, C. Casali2
1San Camillo-Forlanini Hospital, Neurology, Rome, Italy, 
2“Sapienza“ University Polo Pontino, Latina, Italy, 3“La 
Sapienza“ University of Rome, SBMC, Rome, Italy, 4IRCCS 
Stella Maris, Developmental Neuroscience, Pisa, Italy, 
5IRCCS - Fondazione Centro S.Raffaele del Monte Tabor, 
Milan, Italy, 6IRCCS C. Mondino , Pavia, Italy
Background and aims: Early-onset HSP SPG3A (OMIM 
182600) is caused by mutations in the gene encoding the 
large oligomeric GTPase atlastin-1 protein. Mutations in 
SPG3A (also known as atlastin GTPase 1 [ATL1]) cause 
both pure and uncomplicated phenotypes with early onset 
and slow progression. SPG3A/ATL1 mutations represent 
the most frequent cause of early onset HSP. De novo occur-
rence of SPG3A/ATL1 mutations in isolated cases poses 
diagnostic challenge and patients are easily misdiagnosed 
with a non inheritable, non trasmissable form of spastic pa-
raplegia.  
Methods: Herein, we describe three patients with infantile 
onset HSP harbouring de novo mutations, including a new 
variant, in SPG3A/ATL1.
Results: Patient-1 is 50 y with clinically pure HSP, misdi-
agnosed in childhood as cerebral palsy. Genetic counseling 
in his early adulthood excluded hereditary diseases. Subse-
quently he fathered a similarly affected daughter. Both sub-
jects had a heterozygous c.859C>T (p.R239C) mutation in 
SPG3A gene. Patient-2 is 3 y, with a pure form of HSP, as-
sociated with (c.1308 T>A/p.N436K) mutation in SPG3A, 
which was absent in either his healthy parents. Patient-3 is 
15 y with a moderate form of HSP associated with axonal 
neuropathy since his childhood. A c.1040T>C (p.M347T) 
heterozygous mutation in SPG3A was identified in the pati-
ent but not in his healthy parents.
Conclusion: Infantile onset HSP represents a challenging 
differential diagnosis, particularly when there is no family 
history. Patients are often diagnosed as „infantile cerebral 
palsy“, no genetic counseling is offered and the diagnosis 
can be significantly delayed.    
Disclosure: Nothing to disclose
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Novel GBE1 gene mutation in Japanese  
family with adult polyglucosan body 
disease
Y. Harigaya1, T. Matsukawa2, Y. Fujita3, A. Sekine1,  
M. Imamura4, K. Mizushima1, Y. Ikeda3, S. Tsuji2
1Maebashi Red Cross Hospital, Neurology Service, Maeba-
shi, Japan, 2Tokyo University Graduate School of Medicine, 
Department of Neurology, Tokyo, Japan, 3Gunma University 
Graduate School of Medicine, Department of Neurology, Ma-
ebashi, Japan, 4Haramachi Red Cross Hospital, Department 
of Internal Medicine, Haramachi, Japan
Background and aims: Adult polyglucosan body disease 
(APBD) is an autosomal recessive leukoencephalopathy 
characterized by progressive neurogenic bladder, gait dis-
turbance and peripheral neuropathy due to polyglucosan 
bodies deposition in the central and peripheral nervous 
systems. Eleven disease-causing mutations in GBE1 gene 
have been described.
We performed exome sequencing and identified a GBE1 
homozygous novel mutation in Japanese brothers with 
APBD.
Methods: Two brothers (case 1, 2; 72, 66 years old, respec-
tively) with consanguineous parents were admitted for gait 
disturbance. Both showed leg muscle weakness with atro-
phy, generalized hyporeflexia, and urinary incontinentia. 
Extensor plantar reflexes and leg myoclonus were observed 
in case 1, and opthalmoplegia, bulbar palsy and distal lower 
extremity sensory disturbance in case 2.
Fluid attenuated inversion recovery magnetic resonance 
imaging demonstrated hyperintense white matter abnorma-
lities predominantly in the periventricular regions, posteri-
or limb of the internal capsule, and pyramidal tracts of the 
pons and medulla, and medulla and spine atrophy.
Electromyography and nerve conduction studies revealed 
axonal sensory-motor neuropathy predominantly in the lo-
wer limbs. Muscle biopsies showed small group atrophy 
indicating denervation.
Results: Exome sequencing demonstrated a G to A transiti-
on at position 929 in a homozygous state, with replacement 
of tyrosine with cysteine at codon 310 (Tyr310 Cys) of 
GBE1 gene, which was also found in a heterozygous state 
in their asymptomatic younger sister.
APBD was confirmed by deposition of polyglucosan bo-
dies in sural nerve biopsy from case 1.
Conclusion: We report a GBE1 homozygous novel muta-
tion causing APBD. For the differential diagnosis of leuko-
encephalopathy, APBD should be considered.
Disclosure: Nothing to disclose
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A distinct type of 3-methylglutaconic  
aciduria due to a novel mutation in the 
Translocase of Inner Mitochondrial  
Membrane 50 (TIMM50) gene
F. Serajee, A. Huq
Wayne State University, Pediatrics and Neurology, Detroit, 
USA
Background and aims: 3-methylglutaconic aciduria is 
a heterogeneous group of disorders and includes leucine 
metabolism abnormality and  several mitochondrial prote-
in import disorders. We report a homozygous mutation in 
mitochondrial TIMM50 gene in a family with 3 affected 
siblings with a distinctive type of 3-methylglutaconic aci-
duria. Currently TIMM50 gene mutation is not known to 
cause any Mendelian disorder in human.
Methods: We investigated a patient of South Asian ance-
stry with intractable epilepsy, microcephaly, developmental 
delay and spastic quadriplegia.  Parents were consanguine-
ous and two earlier-born sisters of the patient with  a simi-
lar phenotype had died unexpectedly after an infection.  All 
three siblings excreted large amount of 3-methyl glutaconic 
acid in urine. We performed full exome sequencing using 
genomic DNA isolated from one surviving patient, two 
healthy siblings and both parents.
Results: Exome sequencing identified a homozygous 
c.1114G>A (p.G372S) mutation in the gene TIMM50 
which encodes Tim50, an important component of mito-
chondrial import machinery. The G372 amino acid position 
is completely conserved evolutionally.  The p.G372S alte-
ration is predicted to be damaging and deleterious by Poly-
Phen and SIFT and is located in the conserved C-terminal 
domain of the Tim50 protein that interacts with  Tim23 
protein in the intermembrane space and regulates  import 
of presequence-containing polypeptides into mitochond-
ria.  Both parents were heterozygous.  The patient’s healthy 
sister was homozygous normal and her healthy  brother was 
heterozygous.  No other candidate alteration in exome exp-
lains the patient’s phenotype. 
Conclusion: TIMM50 gene mutation results in a novel mi-
tochondrial membrane associated disorder with a distinct 
phenotype and 3-methyl glutaconic aciduria
Disclosure: Nothing to disclose
© 2015 European Journal of Neurology, 22 (Suppl. 1), 120–483
Poster presentation with discussion      455
Neuroimaging 3
P4164
Multimodal characterization of default 
mode network structure and metabolism 
in patients with disorders of conscious-
ness using diffusion weighted-MRI and 
18F-FDG-PET.
J. Annen1, L. Heine1, E. Ziegler2, J. Stender3, M.A. Bahri2,  
S. Wannes1, M.-A. Bruno1, A. Thibaut1, C. Bernard4,  
G. Antonopoulos2, C. Di Perri2, C. Martial1, E. Amico2,  
A. Demertzi2, E. Salmon2, P. Maquet1, J.-F.L. Tshibanda4,  
R. Hustinx4, S. Laureys1
1University of Liège, Cyclotron Research Centre, Universi-
ty Hospital of Liège, Liege, Belgium, 2University of Liège, 
Cyclotron Research Centre, Liege, Belgium, 3University of 
Copenhagen, Department of neuroscience and pharmacology, 
Copenhagen, Denmark, 4University Hospital of Liège, Liege, 
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Background and aims: The precise relationship between 
white matter structural connectivity and metabolic function 
is not yet completely understood. Patients with disorders 
of consciousness offer a unique population to study this. 
Here we examined whether the relationship between struc-
tural connectivity and metabolic function is altered in these 
patients.
Methods: We studied 27 patients and 14 healthy subjects 
using two neuroimaging modalities: diffusion-weighted 
MRI and 18F-FDG-PET imaging (Figure 1). We analyzed 
the default mode network (thalamus, frontal cortex, precu-
neus, inferior parietal cortex) white matter integrity by con-
structing white matter brain networks using fiber tractogra-
phy, and calculating the fractional anisotropy within each 
connection between the four regions. Additionally, standar-
dized uptake values (SUV) were calculated for each region. 
Structural and functional markers from the best functioning 
hemisphere of each subject (defined by total SUV from all 
four regions) were examined for correlations.
Figure 1
Results: Healthy controls showed a positive linear correla-
tion between structural connectivity (fractional anisotropy) 
in the mesio-frontal to precuneus cingulate connection and 
brain metabolism (SUV) in the frontal cortex and precu-
neus, while the correlation was absent in brain injured pa-
tients (controls r=0.61 & 0.53 respectively, patients r=0.00 
& -0.04 respectively, Fisher’s z-score = -1.95 & -1.77, 
p<0.05, Figure 2).
Figure 2
Conclusion: These results imply that the coupling between 
structure (diffusion weighted-MRI) and brain metabolism 
(FDG-PET) existing in healthy volunteers is seemingly ab-
sent in severely brain injured patients.
Disclosure: Nothing to disclose
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Diagnostic accuracy of cerebral metabolic 
imaging in disorders of consciousness
G. Antonopoulos1, S. Wannez2, A. Thibaut1, A. Luxen1,  
M.A. Bahri1, R. Hustinx3, C. Bernard3, M.-A. Bruno4,  
C. Chatelle5, C. Phillips1, P. Maquet6, S. Laureys4
1University of Liège, Cyclotron Research Centre, Liege, 
Belgium, 2ULg, Cyclotron Research Centre, Liege, Belgium, 
3University Hospital of Liège, Liege, Belgium, 4Liege, Belgi-
um, 5Harvard Medical School, Rehabilitation Hospital, Liege, 
Belgium, 6University of Liège, Cyclotron Research Centre, 
University Hospital of Liège, Liege, Belgium
Background and aims: The high rate of misdiagnosis (1) 
reflects the difficulty of correctly diagnosing different sta-
tes of consciousness like minimally conscious state (MCS) 
and vegetative state/unresponsive wakefulness syndrome 
(VS/UWS). Currently, there is no method that can give an 
objective measure of consciousness and therefore multiple 
clinical examinations are required for the evaluation of a 
patient’s consciousness state. We here aim to develop an 
evaluation method by teaching a machine to detect the sta-
te of consciousness using fluorodeoxyglucose PET (18F-
FDG-PET) scans.
Methods: PET scans of 136 patients (table 1), were acqui-
red in the University Hospital of Liege. Each patients’ state 
of consciousness was evaluated with repeated assessments 
of Coma Recovery Scale. Data were preprocessed and ana-
lyzed by means of statistical parametric mapping (SPM12) 
(figure 1). For the intensity normalization purposes, skin 
metabolic activity was used. For classification and statisti-
cal inference we used the Pronto toolbox.
Figure 1: Top row represents PET-scans before (left) and after (right) 
normalization. Bottom row depicts the study specific template used for 
the normalization.
Results: The total classification accuracy was 78% by using 
a cross validation scheme. 83 out of 94 MCS patients were 
correctly classified. Since the classifier we used assigns one 
value to each voxel, this can be displayed as weight map 
(figure 2). This weight map depicts the lilkelihood for each 
voxel to belong to the MCS or the VS/UWS class.
Figure 2: Voxels‘ weights extracted from the training process of the 
classifier
Conclusion: Medial and lateral frontoparietal cortices and 
brain stem appear to play a key role in consciousness state, 
as shown by the weights assigned by the classifier to the 
voxels. Besides the absolute cortical metabolic activity (2), 
glucose consumption in different brain regions can affect 
the state of consciousness.
Disclosure: Nothing to disclose
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Usefulness of FDG-PET in the differential 
diagnosis of parkinsonian syndromes on 
an individual basis.
R. Ceravolo1, D. Frosini1, A. Accorroni1, A. Giorgetti2,  
G. Puccini3, E. Filidei2, D. Volterrani3, U. Bonuccelli1
1University of Pisa, Department of Clinical and Experimental 
Medicine, Pisa, Italy, 2Fondazione Monasterio, Nuclear Me-
dicine, Pisa, Italy, 3University of Pisa, Department of Trans-
lational Research and New Technologies in Medicine and 
Surgery, Pisa, Italy
Background and aims: Positron emission tomography 
(PET) with 18F-fluorodeoxyglucose (FDG) can identify 
characteristic patterns of regional glucose metabolism in 
Parkinson’s disease (PD) and atypical parkinsonisms, how-
ever most previous studies were conducted in late disease 
stages and based on a group-comparison approach. Aim of 
this study is to evaluate the diagnostic accuracy of FDG-
PET in parkinsonisms on an individual basis.
Methods: 101 patients with parkinsonisms underwent 
FDG-PET at baseline and were then followed-up for 5 ye-
ars, in order to maximize the diagnostic confidence. The 
FDG-PET were then retrospectively evaluated by two blin-
ded examiners after images post-processing by the soft-
ware Pneuro, which allows to obtain for each patient a map 
showing the regions with metabolic changes (p<0.01) res-
pect to a database of healthy controls    
Results: The diagnosis at follow-up were: 17 PD (mean 
age 65), 23 Multiple System Atrophy (MSA) (age 72), 30 
Progressive Supranuclear Palsy (PSP) (age 74), 16 Cortico-
Basal Degeneration (CBD) (age 72), 15 Lewy Body De-
mentia (LBD) (age 75). The sensitivity, specificity, positive 
and negative predictive value for atypical parkinsonisms 
with respect to PD for the two readers and both the diag-
nostic accuracy and concordance with clinical diagnosis for 
each disease on individual basis are reported in table 1. The 
inter-rater agreement was between 0.60 and 0.86 according 
to Cohen’s kappa coefficient.
FDG-PET diagnostic accuracy on individual basis in parkinsonisms
Conclusion: Our data demonstrate the usefulness of a com-
puter-supported FDG-PET analysis to help the clinicians in 
early distinction between PD, PSP, MSA, CBD and LBD 
from each other on a single case basis.
Disclosure: Nothing to disclose
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Pattern of regional cortical thickness in 
patients with Parkinson’s disease and  
impulse control disorders
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M. Amboni4, D. Corbo3, A. Giordano1, P. Barone5,  
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1Second University of Naples, Department of Neurology, 
Naples, Italy, 2Second University of Naples, Department of 
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5University of Salerno, Department of Medicine and Surgery, 
Salerno, Italy
Background and aims: To investigate the pattern of gray 
matter (GM) atrophy and cortical thickness (CTh) in pati-
ents with Parkinson’s disease (PD) with and without impul-
se control disorders (ICD).
Methods: 15 patients with PD with ICD (ICD+), 15 pa-
tients with PD without ICD (ICD-) and 24 age and sex-
matched healthy controls (HCs) were enrolled in the study. 
Patients were screened for ICDs by the Minnesota Impul-
sive Disorders Interview (MIDI). Whole brain structural 
imaging was performed on a 3T GE MR scanner. Surface-
based investigation of CTh was carried out by using Free-
surfer Software. We also used voxel-based morphometry 
to investigate the pattern of GM atrophy. We considered 
cortical areas with the p value less than 0.05 corrected for 
multiple comparisons as statistically significant.
Results: The voxel-wise analysis of the regional differen-
ces in CTh revealed a specific abnormal pattern involving 
the limbic system in the comparisons between: a) ICD- and 
ICD+ patients and b) ICD+ patients and HCs. In particular, 
ICD+ patients showed a statistically significant (p<0.05) 
cortical thickening when compared to both ICD-patients 
and HCs in the anterior cingulate (ACC) and orbitofrontal 
(OFC) cortices. Moreover, cortical thickening in these are-
as is correlated (p<0.05) to MIDI score. VBM data did not 
reveal any statistically significant differences in GM.
Conclusion: Our results demonstrated that ICD+ patients 
have a stronger pattern of CTh in limbic regions compared 
with ICD-. Thus, aberrant anatomical and cytoarchitectural 
features in OFC and ACC, involved in reward-related de-
cision making, may play a role in the lack of inhibition of 
compulsive behaviors.
Disclosure: Nothing to disclose
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The neural correlates of the emergence 
from disorders of consciousness: a multi-
modal neuroimaging study
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Background and aims: Between severe disorders of con-
sciousness (DOC, i.e. vegetative state/unresponsive wake-
fulness syndrome - VS/UWS - and minimally conscious 
state - MCS -) and normal consciousness (healthy controls) 
there is a widely under-investigated transition zone repre-
sented by those patients who regained capacity for functio-
nal communication and/or object use, also called emerging 
from minimally conscious state (EMCS).
We hereby aim to study the role of brain metabolism, grey 
matter volume, positive and negative resting state functio-
nal connectivity (i.e., neuronal correlation and anticorrela-
tion) in the emergence from DOC. 
Methods: We acquired FDG-PET, structural MRI and 
resting-state functional MRI in 58 severely brain injured 
patients (23 VS/UWS, 21 MCS, 14 EMCS) and 37 age-
matched healthy controls. Voxel-based neuroimaging ana-
lyses were performed using SPM8. We used a seed-based 
approach to investigate positive connectivity within the 
default mode network (DMN) and negative connectivity 
between default mode network (DMN) and task positive 
network (TPN).
Results: Brain metabolism in DMN and TPN was correla-
ted with the levels of consciousness.
Grey matter volume did not show a linear correlation with 
the levels of consciousness.
Positive connectivity within DMN could not discrimi-
nate EMCS from DOC (Fig.1A).   Negative connectivity 
between DMN and TPN disentangled EMCS from DOC 
(Fig.1B-C).  Brain metabolism was correlated with both 
positive and negative connectivity (Fig. 2).
Fig 1. VS/UWS vegetative state/unresponsive wakefulness; MCS mi-
nimally conscious state; EXT: emergence from minimally conscious 
state: CTR healthy controls; DMN default mode network; TPN task 
positive network. Results are p<0.05 FDR corrected
Fig 2. VS/UWS vegetative state unresponsive wakefulness syndrome: 
MCS minimally conscious state; EMCS emergence from minimally 
conscious state; HC healthy controls.
Conclusion: Negative functional connectivity between 
DMN and TPN is correlated to brain metabolism and seems 
critical for the emergence from DOC. 
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Cerebellar function in motor timing
P. Filip1, R. Mareček1, M. Bares2
1St. Anne University Hospital, Brno, Czech Republic, 2Brno, 
Czech Republic
Background and aims: The cerebellum has been associa-
ted exclusively with motor functions for a long time. How-
ever, its activation has been increasingly shown in a wide 
spectrum of different processes extending far beyond the 
typical cerebellar domain, including attention, motivation 
control, associative learning, and time assessment. The 
precise role of individual cerebellar lobuli in these func-
tions has lately been of great interest. In our study, we have 
focused on time assessment in specific motor timing task, 
previously shown to be closely associated with cerebellum.
Methods: Functional magnetic resonance imaging has been 
performed in 30 healthy individuals during an interception 
of a moving target. The subjects were asked to press a but-
ton in a precise time frame to hit the moving target. This 
action required complex time estimation and anticipation, 
as the subject had to react in advance according to the speed 
of the target to intercept it successfully. In a simplified con-
trol task, there was no need for reacting in advance, as the 
subjects were asked to press the button when the moving 
target reached a specific area marked with a cross.
Results: When subtracting the BOLD effect of the control 
task from the effect of the main task, we have found sever-
al cerebellar areas, specifically left cerebellar lobule 6, left 
cerebellar lobule 8 and vermis 8.
Conclusion: Our results suggest that the left cerebellar he-
misphere, mainly lobule 6 and 8, plays an essential role in 
motor timing, in accordance with the notions in the gro-
wing body of different research projects.
Disclosure: Nothing to disclose
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Representation of self-relevant motor 
information in ventromedial prefrontal 
cortex (vmPFC) in patients with functional 
conversion disorders (preliminary results)
S. Galli1, S. Aybek2, R. Blakemore2, I. Sinanaj2, T. Moulin1,  
P. Vuilleumier2
1Department of neurology, Besançon, France, 2Laboratory 
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Switzerland
Background and aims: Abnormal activation in the vmPFC 
has repeatedly been observed in functional neurological 
disorders (FNDs). Our aim is to test with fMRI for differen-
tial activation patterns in the vmPFC in motor FNDs during 
the visual presentation of stimuli (words) that call for motor 
or bodily representations relevant to the self.
Methods: Patients saw different word categories that in-
clude neurological symptoms relevant or not (e.g. paralysis 
or tremor), respiratory symptoms, motor bodily parts, res-
piratory parts, and a neutral word category. A second-level 
flexible factorial model was used with the following con-
trasts: motor bodily symptoms and/or motor bodily parts 
relative to the respiratory ones, and self-relevant versus 
non-relevant motor symptoms. A region of interest (ROI) 
analysis was performed for the vmPFC as determined by 
a separate localiser task using „self“ processing. Peaks at 
p<0.001 uncorrected with a number of voxels ≥10 were 
considered significant.
Results: 12 patients with motor FNDs were tested inclu-
ding 8 with deficit, 3 with abnormal movement, and 1 with 
both. The rectal orbitofrontal gyrus and posterior vmPFC 
were selectively reduced in response to words related to the 
motor system (body part & symptom), as compared to the 
respiratory system. These changes partly overlapped with a 
self-related ROI in vmPFC.
Contrast between motor and respiratory system
VmPFC activation by each condition
Conclusion: VmPFC activity decrease during the evoca-
tion of motor symptoms and body parts in FNDs, which 
may reflect a reduction in self attribution processes opera-
ting on motor and body related signals which may contri-
bute to the symptom. Comparison with a control group with 
organic motor symptoms will be important.
Disclosure: Nothing to disclose
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Widespread abnormalities of brain  
connectivity in patients with glaucoma
A. Giorgio, P. Frezzotti, F. Toto, A. De Leucio,  
S.A. Bagaglia, N. De Stefano
University of Siena, Sienna, Italy
Background and aims: Glaucoma is an important cause of 
irreversible blindness worldwide. Recent quantitative MRI 
studies showed that these patients can have damage in brain 
areas of the visual system. However, it is not clear whether 
brain changes also occurs beyond the visual system
Methods: We performed multimodal MRI in 105 subjects 
(patients with different glaucoma stages [n=76] and age-
matched normal controls [NC, n=29]). We used imaging 
tools from FMRIB Software Library (Oxford, UK) such as: 
i) tract-based spatial statistics for assessing diffusion tensor 
imaging-based anatomical connectivity across white matter 
(WM) tracts, and ii) independent component analysis fol-
lowed by individual timecourse regression for evaluating 
functional connectivity within the different resting state 
networks. A nonparametric permutation testing, p<0.005 
uncorrected, k>30 voxels was used for voxelwise statistics 
across the brain.
Results: Compared to NC, patients with glaucoma showed 
altered anatomical connectivity (i.e., reduced fractional an-
isotropy and increased axial diffusivity) not only along the 
visual pathway (optic radiations [inferior frontooccipital 
and longitudinal fascicles] and optic tracts) but also in non-
visual WM tracts (superior longitudinal fascicle, forceps 
major and minor, WM of the frontal gyrus, planum tem-
porale and postcentral gyrus) (p<0.001 for all). Moreover, 
functional connectivity was lower in patients with glauco-
ma than in NC in the visual network, working memory net-
work and default mode network (p<0.001 for all). 
Conclusion: These findings suggest that a classically visi-
on disorder such as glaucoma has a widespread neurologi-
cal involvement characterized by diffuse abnormalities in 
both anatomical and functional connectivity of the brain.
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Bilateral persistent otolith dysfunction in 
benign paroxysmal positional vertigo
S.-Y. Oh1, E.-J. Kim2, J.S. Kim3, B.-S. Shin4
1Jeonju city, Korea, Republic of, 2Chonbuk National univesity 
hospital, Jeonju, Korea, Republic of, 3Seoul National Univer-
sity Bundang Hospital, Seoul, Korea, Republic of, 4Chonbuk 
National , Jeonju, Korea, Republic of
Background and aims: The objective of this study was to 
evaluate utricular and saccular function depending on the 
subtypes and therapeutic results of benign paroxysmal po-
sitional vertigo (BPPV) using ocular and cervical vestibular 
evoked myogenic potentials (VEMPs) during the acute and 
resolved state after repositioning maneuvers.
Methods: Patients diagnosed with BPPV involving the 
vertical and horizontal semicircular canals (n=112) and 
normal controls (n=35) were included. Ocular and cervi-
cal VEMPs (oVEMP and cVEMP) to air-conducted sound 
(ACS; 1000 Hz tone burst, 125 dB Sound pressure level 
[SPL]) were measured for assessment of otolith function at 
the time of initial diagnosis and 2 months after successful 
repositioning maneuvers.
Results: The prevalence of abnormalities in cVEMP or 
oVEMP induced by ACS in patients with BPPV was sig-
nificantly higher compared to the control group (p<0.001). 
In affected ears, abnormal results were found in 47 patients 
(47/112, 42.0%), which included absent (31/47, 65.9%), 
reduced (6/47, 12.8%), and delayed responses (25/47, 
53.2%). Results from non-affected ears of BPPV patients 
also showed frequent abnormal VEMP responses. Compa-
red to the cVEMP findings, oVEMP abnormalities in the 
BPPV group were more frequent in both affected and non-
affected ears (33.6% in oVEMP vs. 17% in cVEMP, at the 
affected ear, p=0.003). The abnormal VEMPs did not reco-
ver after successful repositioning therapies.
Conclusion: This result suggests that degenerative patho-
logical changes of the saccular macular and more likely ut-
ricular macular in patients with idiopathic BPPV may cause 
bilateral and persistent VEMP abnormalities after repositi-
oning maneuvers.
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neuromyelitis optica spectrum disorder - 
evidence of brain parenchymal alterations 
associated with retinal damage
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1Charité, NeuroCure Clinical Research Center, Berlin, Ger-
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Background and aims: Neuromyelitis optica spectrum 
disorder (NMOSD) is an autoimmune disease of the CNS 
characterized by potentially devastating optic neuritis (ON) 
and myelitis. Data suggesting cerebral involvement in 
NMOSD is scarce. Here, we investigate brain parenchymal 
integrity alterations in NMOSD and their association with 
retinal nerve fiber layer (RNFL) and ganglion cell layer 
(GCL) thinning.
Methods: 21 patients with NMOSD and 21 sex and age 
matched healthy control (HC) subjects were enrolled. All 
participants underwent extensive 3T MRI and spectral do-
main OCT examinations with RNFL and GCL analysis. 
DTI was analyzed by Tract Based Spatial Statistics (TBSS).
Results: The cohort comprised 21 NMOSD patients inclu-
ding two testing sero-negative for AQP-4 antibodies (90.5 
% seropositive). Unilateral optic neuritis (ON) occurred in 
27 cases (64%), and 9 patients reported ON of both eyes 
(42 %). OCT analysis showed a marked reduction of both 
RNFL and GCL in NMOSD compared to HC.
DTI analysis revealed significantly reduced fractional an-
isotropy (FA) of the optic radiation (OR) in NMOSD com-
pared to HC. Reduced FA correlated with RNFL thickness.
Conclusion: ON is reflected by structural abnormalities of 
the OR in NMOSD patients, presumably caused by trans-
synaptic degeneration within the visual pathway subse-
quent to ON.
Disclosure: FlP, KR, JW and FrP are supported by the Ger-
man Ministry of Education and Research (BMBF/ KKN-
MS, Competence Network Multiple Sclerosis). Dr. J. Wu-
erfel serves on advisory boards for Novartis and Biogen 
Idec. He received a research grant from Novartis, and spea-
ker honoraria from Bayer, Novartis, Teva and Biogen Idec. 
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Activation of prefrontal cortex in complex 
postures: a near-infrared imaging study
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Background and aims: Posture control has predominantly 
been linked to subcortical structures based on animal stu-
dies. Hence, balance problems in humans are usually be-
lieved to depend on subcortical deficits. However, recent 
studies suggest that cortical areas are involved in postural 
responses to external perturbations. The aim of this work is 
to demonstrate the activation of the frontal lobe during the 
tandem-Romberg test (tR), an internally-perturbed, com-
plex posture commonly used in clinical examinations.
Methods: In 19 healthy volunteers, changes of oxyhemo-
globinewere measured over time in the superficial frontal 
lobe during 3 different sequences of tasks (figure C): stance 
with open and closed eyes (OE/CE), stance with OE and tR 
with CE, and stance with CE and tR with CE. A 22-channel 
3x5 array  (8emitters/7receptors) and 30 mm inter-optode 
distance (Hitachi ETG4000) was placed (reference Fpz, fi-
gures A&B).  After a wavelet-based and hemodynamic re-
sponse function filtering, a general linear model was used 
to contrast differences in oxyhemoglobine between tasks.
Results: A significant activation was found in channels that 
measured in bilateral dorsolateral and frontopolar cortices 
(Brodmann’s areas 10 and 46) of the middle and frontal 
gyri, in the second and third sequences of tasks (figure C) 
during tR with higher signal when the task wasfully done 
with CE.
Figure A, B and C
Conclusion: Dorsolateral and frontopolar cortices are rec-
ruited in the maintenance of internally-perturbed, complex 
postures. Clinical tests that were previously thought to be 
assessing only subcortical structures might therefore test a 
cortical-subcortical network devoted to balance control, in 
which the frontal lobe plays a prominent role.
Disclosure: This study was supported by the BMBF 
(DSGZ, grant 01EO1401) and by the DFG (Graduate 
School for Systemic Neuroscience).
P4175
Real-time computer based visual feedback 
improves visual acuity in downbeat  
nystagmus – a pilot study
J. Teufel1, S. Bardins1, O. Kremmyda1, M.L. Strupp1,  
R. Kalla2
1University of Munich (Großhadern), Munich, Germany, 
2Inselspital Bern, Neurologie, Berne, Switzerland
Background and aims: Patients with downbeat nystagmus 
syndrome suffer from oscillopsia, which leads to an unsta-
ble visual perception and therefore impaired visual acuity. 
The aim of this study was to use real-time computer based 
visual feedback to compensate for the destabilising slow 
phase eye movements.
Methods: The patients were sitting in front of a com-
puter screen with the head fixed on a chin rest. The eye 
movements were recorded by an eye tracking system 
(EyeSeeCam®). We tested the visual acuity with a fixed 
Landolt C (static) and during real-time feedback driven 
condition (dynamic) in gaze straight ahead and (20°) side-
ward gaze. In the dynamic condition, the Landolt C moved 
according to the slow phase eye velocity of the downbeat 
nystagmus.
Results: 10 patients with downbeat nystagmus were inclu-
ded in the study. Median age was 76 years and the median 
duration of symptoms was 6.3 years. The mean slow phase 
velocity was moderate during gaze straight ahead (1.44°/s, 
SD±1.18°/s) and increased significantly in sideward gaze 
(mean left 3.36°/s; right 3.58°/s).  In gaze straight ahead, 
we found no difference between the static and feedback dri-
ven condition. In sideward gaze, VA improved in five out of 
ten subjects during the feedback-driven condition (VA 0.1; 
Mann-Whitney-U-Test p=0,032).
Conclusion: We found an improvement of visual acuity in 
sideward gaze during the feedback driven condition. There-
fore, real-time visual feedback may be a promising aid for 
patients suffering from oscillopsia and impaired text rea-
ding on screen, but further research is needed.
Disclosure: Nothing to disclose
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Noisy galvanic vestibular stimulation  
improves dynamic walking stability in 
healthy subjects
M. Wuehr, E. Nusser, S. Krafczyk, T. Brandt, K. Jahn,  
R. Schniepp
University of Munich, German Center for Vertigo and Balan-
ce Disorders, Munich, Germany
Background and aims: We examined the effect of galva-
nic vestibular stimulation (GVS) delivered as zero-mean 
white noise current (noisy GVS) on the walking perfor-
mance in healthy subjects.    
Methods: The walking performance of 15 healthy subjects 
(mean age 23.0±1.3 years) at slow, preferred and fast wal-
king speed was examined during two different conditions: 
(1) walking with eyes closed and zero amplitude sham noi-
sy GVS, and (2) walking with eyes closed and non-zero 
amplitude noisy GVS set to 80% of the individual sensory 
threshold for GVS. We examined 10 gait parameters: stride 
time, stride length, base of support, swing time percentage, 
double support time percentage as well as the CV of stride 
time, stride length and base of support, gait asymmetry and 
bilateral phase synchronization. 
Results: Noisy GVS significantly improved stride time CV 
by 34% (p<0.019), stride length CV by 26% (p<0.048), 
base of support CV by 18% (p<0.004), gait asymmetry 
by 39% (p<0.037), and bilateral phase synchronization by 
19% (p<0.042). This ameliorating effect of noisy GVS on 
locomotion function was only observable during slow wal-
king speeds. 
Conclusion: Noisy GVS is effective in improving locomo-
tion function in healthy subjects. It predominantly targets 
the variability and bilateral coordination characteristics of 
the walking pattern, which are critically linked to dynamic 
walking stability. The predominant impact of noisy GVS 
during slow walking supports the principle of a speed-de-
pended role of sensory feedback in locomotion control. 
Disclosure: Nothing to disclose
P4177
Correlation between the bedside and  
video head impulse test
C.W. Yip1, M. Strupp2
1National Neuroscience Institute (SGH Campus), Neurology, 
Singapore, Singapore, 2University Munich, Department of 
Neurology, Munich, Germany
Background and aims: The bedside head impulse test 
(bHIT) rapidly assesses the function of the high-frequency 
vestibular-ocular reflex (VOR). This study compares the 
findings of the bHIT with the video HIT (vHIT) as the gold 
standard.
Methods: The double-blinded study prospectively enrolled 
all patients who presented with vertigo or dizziness as a 
chief complaint from a tertiary vertigo centre. Three expe-
rienced clinical raters performed the bHIT and documented 
their findings separately. The vHIT was done with the oto-
metrics video HIT system, at the end of the patient visit.
Results: 404 patients were examined in a standardized way. 
2056 bHITs and 808 vHITs were performed. With a cut-off 
value for a normal VOR gain of 0.7 the bHIT’s mean sen-
sitivity was 63%, mean specificity 84.4%, mean positive 
predictive value (PPV) 43.9%, and mean negative predicti-
ve value (NPV) 92.8%. With a vHIT VOR gain of 0.65 the 
bHIT’s sensitivity was 68.6% and with a vHIT VOR gain 
of 0.6 it was 75.7%. Inter-rater variability was moderate.
Conclusion: (i) The bHIT was only moderately sensitive 
with a poor PPV even with experienced physicians to dia-
gnose VOR deficits; (ii) however, with a vHIT gain cut-off 
value of 0.60 the majority of clinically relevant cases can 
be diagnosed; (iii) a normal bHIT has good specificity in 
experienced hands and detects >90% of the negative cases; 
(iv) the vHIT is a very useful clinical tool to quantify ves-
tibular function.
Disclosure: Nothing to disclose
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Correlation between dizziness handicap 
inventory (DHI) and vestibular function in 
patients with persistent peripheral  
vestibular disorders.
C.W. Yip1, M. Strupp2
1National Neuroscience Institute (SGH-Campus), Neurology, 
Singapore, Singapore, 2University Munich, Department of 
Neurology, Munich, Germany
Background and aims: Patients suffering from peripheral 
vestibular disorders may complain of persistent impairment 
in daily activities. They have abnormal vestibular function 
tests, and clinicians often use these results exclusively to 
explain the patients’ disability. The applicability of this 
cause-and-effect approach has not been studied. We aim 
to test this assumption by correlating the patient-reported 
disability using the Dizziness Handicap Inventory (DHI) 
with various vestibular test parameters.
Methods or Materials or Case Report: Patients with per-
sistent vestibular complaints due to a previously diagnosed 
peripheral vestibular disorder without evidence for central 
or functional dizziness were prospectively recruited from a 
tertiary vertigo centre. The diagnoses included: Menière’s 
disease, post vestibular neuritis, BPPV, vestibular paroxys-
mia, and bilateral vestibulopathy. They underwent at least 3 
of the following laboratory tests: bithermal binaural caloric 
testing, video head impulse testing (vHIT), cervical and 
ocular vestibular evoked myogenic potentials, and static 
posturography. In addition, they filled out the DHI.
Results: In 60 patients, the DHI was correlated with each 
individual test parameter (VOR gain, unilateral weakness 
on calorics, cVEMP/oVEMP for saccular/utricular func-
tion, sway paths on fixed and foam surface). None of these 
parameters were significantly correlated with the DHI.
Conclusion: This study suggests that abnormalities found 
in vestibular function tests, regardless of their severity, do 
not correlate with the DHI scores. Therefore, the clinician 
must be cautious and put vestibular testing into perspective 
when treating patients with persistent dizziness. So far ún-
quantifiable patient factors may be more important in deter-
mining the level of disability than the results of vestibular 
tests.
Disclosure: Nothing to disclose
P4179
Retinal damage in MOG-antibody-positive 
neuromyelitis optica spectrum disorder 
phenotype patients
H.G. Zimmermann1, J. Mikolajczak1, A. Lacheta1,  
F. Magerstädt1, K. Ruprecht2, F. Paul1, A. Brandt1, F. Pache1
1Charité University Medicine, NeuroCure Clinical Research 
Center, Berlin, Germany, 2Charité University Medicine, Clini-
cal and Experimental Multiple Sclerosis Research Centerand 
Department of Neurology, Berlin, Germany
Introduction: Neuromyelitis optica spectrum disorders 
(NMOSD) are a group of neuro-inflammatory disorders 
characterized by longitudinally extensive transverse my-
elitis and/or optic neuritis. About 70% of patients with a 
NMOSD phenotype have antibodies to the astrocytic water 
channel aquaporin (AQP)-4. Recently, antibodies to myelin 
oligodendrocyte glycoprotein (MOG) were discovered in a 
subset of patients with a clinical phenotype of NMOSD but 
without AQP4-antibodies. Here, we describe retinal dama-
ge in a series of MOG-antibody-positive patients display-
ing an NMOSD phenotype.
Methods: Retrospective analysis of four MOG-antibody-
positive patients (all female, age 19 - 77 years). None of the 
patients had AQP4-antibodies. Study data included optic 
neuritis (ON) relapse history, optical coherence tomogra-
phy of the peri-papillary retinal nerve fibre layer (RNFL) 
and the macula, visual acuity and visual evoked potentials.
Results: 3 patients had a history of ON in both eyes, 1 pa-
tient had no history of ON. In 5 of 6 ON eyes, ON was 
recurrent and presented with prolonged or absent P100 la-
tencies. 3 eyes of 2 patients were blind. RNFL thickness 
was severely reduced in ON eyes (53±18µm) with 5 of 6 
eyes in the lowest 1% percentile of the reference database. 
Macular microcysts were found in 2 eyes of 2 patients. 1 
patient presented with dynamic macular microcyst changes 
over a three-year follow-up.
Overview of demographic data, retinal morphology, visual acuity and 
VEP results of the included subjects. Abbreviations: ON: optic neuri-
tis; RNFL: retinal nerve fibre layer; VEP: Visual evoked potential
Conclusion: Albeit MOG-antibody-positive patients were 
shown to experience fewer attacks and better recovery than 
AQP4-antibody-positive NMOSD patients in earlier stu-
dies, this case series shows that retinal damage and thus 
visual dysfunction can be devastating.
Disclosure: KR, FrP, and FlP are supported by the German 
ministry of education and research (BMBF/KKNMS, Com-
petence Network Multiple Sclerosis) 
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Sleep disorders after traumatic brain  
injuries
B. Carlan1, S. Diaconu2, R. Mircea3, A. Voina3, S. Paripas3, 
M. Moarcas2, O. Deleanu4, D.C. Jianu5, C. Falup Pecurariu6
1Faculty of Medicine, Transilvania University Brasov, Brasov, 
Romania, 2Emergency Clinical County Hospital Brasov, Neu-
rology, Brasov, Romania, 3Emergency County Hospital Bra-
sov, Neurosurgery, Brasov, Romania, 4University of Medicine 
and Pharmacy „Carol Davila”, Bucharest, Romania; Nati-
onal Institute of Pneumology „Marius Nasta”, Pneumology, 
Bucharest, Romania, 5County Emergency Hospital, Victor 
Babes University of Medicine and Pharmacy, Neurology, 
Timisoara, Romania, 6Brasov, Romania
Background and aims: Traumatic brain injuries (TBI) 
have several immediate and long-term consequences on 
quality of life. The aim of this study is to assess the preva-
lence and effects of traumatic brain injury on sleep.
Methods: Prospective study of 41 patients with traumatic 
brain injury. Evaluation was done using Glasgow Coma 
Scale (GCS), Athens Insomnia Scale, Insomnia Severity 
Index (ISI), Berlin Questionnaire for Sleep Apnea, Pitts-
burgh Sleep Quality Index (PSQI) and Epworth Sleepiness 
Scale (ESS).
Results: There were 28 men (68.29%), with the mean age 
of 43.5±17.26 years. The most frequently encountered sleep 
disorder following TBI was insomnia (n=15; 37%). Exces-
sive daytime sleepiness (n=14; 34%) was considered when 
Epworth Sleepiness Scale score was higher than 10. Nine 
patients reported suggestive symptoms of sleep apnea. Less 
frequently reported were circadian rhythm disturbances. 27 
patients (68.85%) experienced mild daytime dysfunction 
due to poor quality of sleep (PSQ>5) and 69.69% of pa-
tients reported fatigability. There was correlation between 
severity of insomnia and daytime functioning impairment 
(p=0.03). Excessive daytime sleepiness was also correlated 
with loss of consciousness (p=0.008).
Conclusion: Sleep disorders represent important conse-
quences of traumatic brain injuries and need careful as-
sessment due to the significant negative impact of patient’s 
quality of life.
Disclosure: Nothing to disclose
P4181
A pilot study on the localization of  
symptoms in Restless Legs Syndrome 
(RLS)
F. Rinaldi1, M. Zucconi2, A. Oldani2, S. Marelli2,  
A. Galbiati2, M. Cusmai2, A. Gasperi2, L. Ferini Strambi2
1Università degli Studi di Brescia, Spedali Civili di Brescia, 
Neurology, Brescia, Italy, 2San Raffaele Scientific Institute, 
Dept of Clinical Neurosciences, Sleep Disorders Center, Mi-
lan, Italy
Background and aims: The accepted diagnostic criteria 
for RLS describe the symptoms as confined mainly to the 
legs. Nevertheless, in daily practice an amount of patients 
report symptoms also in the upper limbs. Our aim was to 
describe the topography and symmetry of RLS symptoms, 
identifying the relationship between localization and clini-
cal variables.
Methods: 146 RLS patients were studied. Information 
including localization of symptoms, age-at-onset, ferritin 
values and symptoms severity were collected. The RLS 
topography patterns were classified according to localiza-
tion in upper limbs (UL), lower limbs (LL) or both, and 
lateralization.
Results: Bilateral and symmetric lower limbs (LL) loca-
tion was the most common (74.7 %), while 4.1% exhibi-
ted asymmetric lower limbs localization. 1 patient (0.7%) 
showed symptoms confined to the upper limbs (UL), sym-
metrically. 4 limbs symmetrical involvement was found in 
17.8% of patients; symptoms were located asymmetrically 
at the 4 limbs in 2.7%. The severity of RLS was similar 
across the patients, independently of the localization of 
symptoms. Conversely, lower ferritin values were found in 
patients with symptoms located at the lower limbs. Patients 
with asymmetric symptoms had a younger age-at-onset; ne-
vertheless, the numerosity of the two samples was skewed, 
therefore an extended sample is needed to assess the stati-
stical significance.
Conclusion: RLS symptoms were typically in the lower 
extremities and symmetrical. LL patients had higher ferritin 
values, while patients with a younger age-at-onset showed 
more asymmetric distribution compared with older ones. A 
larger sample of patients is needed in order to ascertain the 
significance of this findings.
Disclosure: Nothing to disclose
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A clinical and polysomnographic study 
defining the phenotype of restless legs 
syndrome (RLS)
F. Rinaldi1, M. Zucconi2, A. Oldani2, S. Marelli2,  
A. Galbiati2, M. Cusmai2, A. Gasperi2, L. Ferini Strambi2
1Università degli Studi di Brescia, Spedali Civili di Brescia, 
Neurology, Brescia, Italy, 2San Raffaele Scientific Institute, 
Dept of Clinical Neurosciences, Sleep Disorders Center, Mi-
lan, Italy
Background and aims: Idiopathic and secondary RLS can 
have a familial component. Younger age-at-onset in fami-
lial and idiopathic cases has been previously found, with 
conflicting results. We aimed to determine the clinical and 
polysomnographic characteristics of a cohort of RLS pati-
ents. 
Methods: 400 RLS patients were studied,  including in-
formation on age-at-onset, comorbidities, familial history, 
time of symptoms onset and the presence of impulse con-
trol behaviours (ICBs). 
Results: Mean age-at-onset differed as a function of 
presence/absence of a familial history of RLS (40.44 
years±16.43 vs. 49.03 years±15.33, p=0,00). Clinical and 
polysomnographic characteristics were similar in both 
groups, but WASO was significantly longer in familial RLS 
(123.18 min±80.14 vs 91.65 min±96.36, p=0.019). No 
difference was found for the age-at-onset between idiopa-
thic and secondary RLS (44.89 years±16.35 vs. 45.02 ye-
ars±16.64, p=0.94). PLM index was higher in idiopathic 
RLS (145±44.65 vs. 83±31,91, p= 0.026). Time of onset of 
symptoms was in the evening or at bedtime in 28.04% and 
37.80% of patients respectively, but in 21.34% of patients 
onset was >1 h after sleep onset. ICBs were found in 23/173 
RLS patients on dopamine agonist (DA) therapy.
Conclusion: Our analyses support the hypothesis that RLS 
is divided into early and late onset disease,  but with smaller 
difference than previously reported.  A high percentage of 
patients showed a time of symptoms onset after sleep onset. 
RLS patients treated with DA showed  higher risk of ICBs 
than previously reported.
Disclosure: Nothing to disclose
P4183
Patients with insomnia and with  
obstructive sleep apnoea performing a 
visual search task
E. Giora, A. Galbiati, S. Marelli, L. Ferini Strambi
San Raffaele Scientific Institute, Dept of Clinical Neuroscien-
ces, Sleep Disorders Center, Milan, Italy
Background and aims: Although there is a huge evidence 
of how acute sleep deprivation affects cognitive functions, 
little is known about the effects of chronic sleep diseases 
on visual perception. The aim of this research is to test the 
efficiency of visual processing in insomnia and Obstructive 
Sleep Apnoea (OSA) patients. Visual efficiency was tested 
by means of a visual search paradigm.
Methods: Participants had to detect the presence/absence 
of a target (letter T) embedded into a set of characters (let-
ters Os, Xs, Ls, respectively). The test-stimuli were presen-
ted without time constraints and subjects had to perform the 
two-alternative-forced-choice task as soon as possible. The 
saliency of the target with respect to the contextual letters 
(T vs. Os, Xs, or Ls, respectively) and the distractors’ num-
ber (15, 30, 60) were manipulated. As dependent variables, 
accuracy and reaction times were recorded. The results of 
24 insomnia (mean age: 47±14 years) and 22 OSA (mean 
age: 51±11 years) patients were compared with the perfor-
mance obtained by 22 control subjects (mean age: 45±14 
years).
Results: While no difference was observed in accuracy, an 
overall increase of response latency was found in both cli-
nical groups compared to control subjects. However, while 
the difference in reaction times between OSA patients and 
controls was constant for all stimuli, insomniacs showed 
a selective higher impairment for the more difficult con-
ditions.
Conclusion: Those results indicate an overall reduced 
visual efficiency in populations suffering from sleep dis-
orders and an additional impairment for insomniacs when 
performing effortful visual search tasks.
Disclosure: Nothing to disclose
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Partnership and sexual dysfunction in  
narcolepsy
H. Hidalgo Pareja1, J. Mathis2, D. Hidalgo1, C. Bassetti2,  
U. Kallweit2
1Katzenelnbogen, Germany, 2Berne, Switzerland
Background and aims: Narcolepsy with cataplexy (NC) 
is a chronic neurological disorder affecting approximate-
ly 0.02% of the population worldwide. Little is known on 
the consequences of partnership and sexuality of concerned 
patients. We present an interim analysis of our study on se-
xual dysfunction in NC aiming at assessing its frequency, 
severity and impact on patient’s life. 
Methods: Consecutive NC patients treated at the sleep-
wake center Rhine-Lahn, Katzenelnbogen, Germany were 
included. Assessment was performed by using a detailed 
self-issued questionnaire about partnership and sexual 
functioning.     
Results: Up to now, 92 NC patients, aged between 18 and 
77 years, 47 of them women (61%) were included. 77 (83%) 
completed the questionnaire on partnership and sexuality.
Out of 77 NC patients, 30 (38%) had no partner. Narcolepsy 
led to failure of a partnership in 16%, problems in partner-
ship due to narcolepsy were described as “serious” in 25%, 
“sometimes” in 45%. Most impairing symptom was exces-
sive daytime sleepiness in 78%. Discontent with sexuality 
was described in 53%; most stressing symptoms were slee-
piness (48%), and cataplexy (22%). Lack of sexual interest 
was described in 49%; libido was reduced or vanished in 
57%. 40% rated this complaint as side effect of medication. 
Orgasmolepsy occurred in 42% (9% “always“). 
Conclusion: Sexual dysfunction in NC is frequent. Most 
annoying symptoms for partnership and sexuality were 
EDS, and to some extend cataplexy and orgasmolepsy. Re-
strictions in partnership and sexual life caused by diseases 
symptoms and medication should be observed in the treat-
ment of narcoleptic patients.    
Disclosure: Nothing to disclose
P4185
Delayed sleep phase may predispose to 
multiple nocturnal seizure occurrences in 
epilepsy
S. Khachatryan1, T. Stepanyan2, L. Ghahramanyan1,  
A. Karamyan1
1Somnus Sleep and Movement Disorders Clinic, Yerevan, 
Armenia, 2Erebouni MC, Republic Epilepsy Center, Yerevan, 
Armenia
Background and aims: Sleep complaints and disorders are 
frequently encountered in patients with epilepsy (PWE). 
Circadian rhythm sleep disturbances (CRSD), especially 
delayed sleep phase (DSP) type, are frequent in general 
population, but poorly studied in epilepsy. The aim of our 
study was to assess association between CRSD and noctur-
nal seizures.
Methods: Adult patients with epilepsy diagnosis proven 
at a tertiary epilepsy center were enrolled in the study, 
and classified into partial epilepsy (PE) and generalized 
epilepsy (GE) types according to simple conventional ap-
proach. Two types of CSR patterns were defined for this 
study: normal sleep rhythm (NSR) - fall asleep before 2AM, 
DSP - fall asleep after 2AM. Nocturnal seizure occurrence 
and multiple seizures per night cases were recorded and 
analyzed. Chi square test was used for statistical analysis.
Results: We included 150 PWE, aged 18-71, mean age - 
34.3; 64 females (42.7%). Of them 128 (85.3%) had NSR, 
and 22 (14.7%) had DSP. Of the sample, PE comprised 
76.9%, GE – 23.1%. There was no difference in nocturnal 
seizure occurrences between NSR and DSP. However, we 
found significantly more patients at risk of having frequent 
nights with 2 and more seizures in GE patients with DSP 
type (15.4%) compared to PE (3%), p<0.05.
Conclusion: Our data suggest that although nocturnal sei-
zures are not dependent on CRSD in our general sample, 
GE patients with CRSD of DSP type are more prone to 
have multiple seizures per single night than PE patients.
Disclosure: Nothing to disclose
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Study of the sleep pattern in patients with 
ischemic cerebrovascular stroke
J. Mekky1, D. Elsalamawy2, O. Elkholy3, N. Hafez3
1Alexandria, Egypt, 2Faculty of Medicine, Neuropsychiatry , 
3Alexandria university, Neuropsychiatry, Alexandria, Egypt
Background and aims: Cerebrovascular stroke is a com-
mon neurological disorder with many sequale, one of these 
underrecognised complications are sleep disorders.The aim 
of this study is to evaluate the sleep pattern in these patients 
following teir first ischemic  stroke,taking into considerati-
on the site and size of the lesion.
Methods: 93 patients with the first ischemic stroke ,admit-
ted to the ICU subjected to initial assessment with the Pitts-
burgh sleep index and then one month later. After one 
month an overnight polysomnography was performed to 
all the patients, and a matched control groupof 50 persons.
Results: There was a significant difference between pa-
teints and control, as regards the total sleep time and latency 
which were longer in patients. Meanwhile the  sleep effici-
ency was less and REM sleep duration were significantly 
shorter in the patient group. The sleep indices especially 
the arousal index, the Limb Movement Index were higher 
in the pateint group.In addition to that all the respiratory 
sleep indiced were significantly higher in the stroke pati-
ents, including the snoring index, apnea hypopnea index 
and desaturation index. The stroke site affected only the 
REM sleep, while the stroke size was positively correlated 
to the desaturation index and the lowest oxygen saturation 
during the polysomnography.
Conclusion: Different sleep disorders may appear fol-
lowing a stroke, this will directly affect the patients morbi-
dity. Neurologists should pay attention to the patient sleep 
complain and screen unrecognised sleep related breathing 
disorders as an example.The prompt treatment of these 
disorders will improve the outcome and qulity of life of 
patients.
Disclosure: Nothing to disclose
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Clinical impact of turnover during sleep 
quantitatively evaluated by accelerometer 
in patients with Parkinson’s disease
M. Akamatsu, M. Shiraishi, K. Uchino, F. Maki, A. Tsuruoka, 
S. Tanaka, D. Hara, Y. Hasegawa
St.Marianna University School of Medicine, Department of 
Internal Medicine Division of Neurology, Kawasaki, Japan
Background:To elucidate impact of motor complications 
during sleep in patients with Parkinson’s disease, we quan-
titatively evaluated turnover during sleep by accelerometer 
and related with UPDRS and sleep quality scales.
Methods: In 25 PD patients and 7 control subjects, turno-
ver movements were continuously monitored during sleep 
by using three-axis accelerometer. Turnover was identified 
by specific signal changes on the three axis (>0.25G). Sleep 
quality was evaluated by using the Epworth Sleepiness Sca-
le (ESS) and the Parkinson’s Sleep Scale-II (PDSS-Ⅱ). We 
also investigated changes in the number of turnover move-
ments and serum levodopa concentrations after administra-
tion of levodopa-carbidopa (50mg) at 6:00pm and 9:00pm.
Results: The number of turnover during sleep in PD patients 
and control subjects were 4.9±6.0 and 21.4±17.0, respec-
tively (p=0.005). The number of turnover was significant-
ly correlated with age (r=0.103, p=0.028), ESS (r=-0.322, 
p=0.040), and PDSS-Ⅱ (r=-0.350, p=0.048). The number 
of turnover in PD patients with 3rd tertile of UPDRS (>57) 
was significantly smaller than that in controls. Additional 
levodopa administration increased the number of turnover 
from 4.9±4.3 to 6.9±4.8, however, these changes were not 
correlated with serum levodopa concentrations.
Conclusion: Turnover movements in PD patients with high 
UPDRS score were significantly restricted and decreased 
turnover movements were associated with their daytime 
sleepiness. Monitoring of motor complications during sleep 
in PD patients by accelerometer is feasible and may be use-
ful to improve their QOL.
Disclosure: Nothing to disclose
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Usefulness of transcranial ultrasound in 
atypical parkinsonism: a cross-sectional 
study
A. Alonso-Canovas1, J.L. Lopez-Sendon1,  
A. DeFelipe-Mimbrera1, M.C. Matute-Lozano1,  
S. Sainz de la Maza-Cantero1, R. Alvarez-Velasco1,  
J. Buisan1, G. Garcia-Ribas1, I. Aviles-Olmos1,  
J. Masjuan Vallejo2, J.C. Martinez-Castrillo1
1Hospital Universitario Ramon y Cajal, Neurology, Madrid, 
Spain, 2Hospital Ramón y Cajal, Neurology, Madrid, Spain
Background and aims: Atypical Parkinsonian Syndromes 
(APS) diagnosis is challenging. Transcranial Ultrasound 
(TUS) has proven useful in Parkinson’s Disease (PD) and a 
building evidence indicates a potential role in APS.
Methods: Analysis of clinical and sonographic features of 
patients with progressive supranuclear palsy-PSP, multiple 
system atrophy-MSA, and corticobasal degeneration-CBD. 
Clinical diagnosis was established following consensus cri-
teria. TUS criteria for APS (substantia nigra-SN and lenticu-
lar nucleus-LN echogenicity, III ventricle-IIIV amplitude) 
were applied by an experienced sonographer and findings 
compared with 105 PD patients and 138 controls (C).
Results: 22 patients with APS (63.6% male, 73±10 years) 
underwent TUS. Clinical diagnosis was PSP in 9, MSA in 
8, CBD in 1, overlapping syndromes in 4. Two patients 
(9.1%) had billaterally absent transtemporal bone window. 
In the remaining 20, TUS showed atypical findings in 18 
(90%) and typical PD findings in 2 (10%). Clinical and ul-
trasound diagnoses were concordant in 15 cases (5 MSA, 
9 PSP, 1 CBD), and discordant in 1 (clinical CBD, TUS 
PSP); 2 patients had parkinsonism without TUS abnorma-
lities. There was SN hyperechogenicity in 40% of APS pa-
tients (83,3% of PD, p<0.0001; 10% of C, p:0.0022), LN 
hyperechogenicity in 63% (20.5% PD, p:0.0005; 6.8% C, 
p:0.0001), and enlargement of the IIIV in 40% (24.7% PD, 
NS; 11.5% C, p:0.0001).
Conclusion: TUS showed significantly distinct features 
in our APS patients when compared with PD and control 
subjects. TUS seems a reliable tecnique in APS diagnosis 
when applied by skilled sonographers following consensus 
criteria.
Disclosure: Nothing to disclose
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Drug induced parkinsonism: can  
transcranial ultrasound predict response 
to withdrawal of the offending drug?
A. Alonso-Canovas1, J.L. Lopez-Sendon1, 
A. DeFelipe-Mimbrera1, M.C. Matute-Lozano1,  
S. Sainz de la Maza-Cantero1, J. Buisan1,  
N. Garcia-Barragan1, I. Corral1, J. Masjuan Vallejo2,  
J.C. Martinez-Castrillo1
1Hospital Universitario Ramon y Cajal, Neurology, Madrid, 
Spain, 2Hospital Ramón y Cajal, Neurology, Madrid, Spain
Background and aims: Drug induced parkinsonism 
(DIP) occurs during treatment with certain offending drugs 
(OD), and remits after withdrawal. Clinical response to 
withdrawal and SPECT-DaT scan discriminate definite-DIP 
and underlying Parkinson’s disease (true-PD). Transcranial 
ultrasound (TUS) is useful in PD diagnosis, and has a po-
tential role in DIP.
Methods: Prospective observational study of clinical and 
sonographic variables in subjects with possible-DIP. Defi-
nite-DIP was diagnosed upon improvement after withdra-
wal of the OD or normal SPECT. Standard TUS protocol 
was followed.
Results: 73 subjects, 63% female, 72.6 years (38-88) were 
included. Tremor (65%), symmetric signs (51,4%), and 
non-motor symptoms (82%) were common. Substantia 
Nigra (SN) was assessable in 65 subjects (89%) and hy-
perechogenic in 21 (32.4%). SPECT was performed in 
29%. 66 subjects were followed after 10.1±7.2 months of 
withdrawal of the OD: 49 (74%) significantly improved 
(diagnosis definite-DIP) while 17 (26%) did not improve 
or worsened (true-PD). In multivariant analysis, normal 
SN echogenicity was significantly associated with clinical 
improvement (p<0.0021), and true-PD diagnosis with SN 
hyperechogenicity (p:0.0062), asymmetric parkinsonism 
(p:0.028), and hyposmia (p:0.016). TUS showed an 82% 
sensitivity, 85% specificity, and 97% negative predictive 
value for true-PD diagnosis. Analysis of 17 patients with 
available TUS and SPECT showed an 88.2% concordance 
[kappa 0.60±0.26].
Conclusion: TUS predicted accurately the outcome after 
withdrawal of the OD and was significatly associated with 
final diagnosis in our cohort of possible-DIP. A high negati-
ve predictive value for true-PD diagnosis supports a role of 
this non invasive tecnique as a screening tool in this setting.
Disclosure: Nothing to disclose
P4204
Clinically relevant benefits of safinamide 
in late-stage PD patients on levodopa and 
other PD medications
R. Anand1, R.D. Hartman2, V. Lucici3, E. Forrest3,  
R. Giuliani3, M. McBride4
1St Moritz, Switzerland, 2Neurwrite LLC, Morristown, USA, 
3Newron Pharmaceuticals SPA, Bresso, Italy, 4Instat Consul-
ting INC, Chatham, USA
Background and aims: Analyses were performed to deter-
mine if significant improvements for the primary endpoint 
(mean change in ON Time without troublesome dyskine-
sia), OFF Time and UPDRSIII in the 016 and SETTLE 
studies with safinamide (Xadago™, Zambon SpA, Italy) as 
add-on to levodopa in late-stage PD (LSPD) patients were 
clinically meaningful.
Methods: Pooled 016 and SETTLE studies were analysed 
using a modified Intent-to-Treat Population (mITT) based 
on randomized targeted doses (placebo; safinamide 50mg/
day; safinamide 100mg/day) for the percentage of patients 
with clinically relevant improvement of ≥60min in ON 
and OFF Time, ≥30% on UPDRSIII, and those meeting all 
3 criteria, and patients with improvement in CGIChange 
(CGI-C) were analysed. The differences in responder rates 
between treatment groups were compared using a logistic 
regression model (chi˗square test).
Results: The mITT Population for the Pooled Studies 016 
and SETTLE included 1188 patients (safinamide 50mg/
day, 217; safinamide 100mg/day, 486; placebo, 485). Stati-
stically significant (p<0.05) greater proportions of patients 
in the safinamide 50 and 100 mg/day groups, compared to 
placebo (Pbo), met each of the responder criteria defined 
above. A significantly greater percentage of safinamide-tre-
ated patients met the most stringent criteria, i.e. improve-
ment in ON Time, OFF Time and UPDRS III [50mg: 24.0% 
(p=0.007), 100mg: 21.6% (p<0.001), Pbo: 11.5%], or were 
rated improved on CGIC [50mg: 69.1% (p=0.001), 100mg: 
61.7% (p≤0.001), Pbo: 49.1%].
Conclusion: A statistically significant higher proportion of 
LSPD patients treated with safinamide as add-on to levodo-
pa improved by a clinically relevant magnitude, compared 
with a placebo.
Disclosure: Nothing to disclose
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Recognition of head-trunk and object mo-
tion signals at threshold levels is impaired 
in cervical dystonia
V. Skarlatou, D. Anastasopoulos
University of Athens, Physiology, Athens, Greece
Background and aims: Context dependent modification of 
postural reactions to head-trunk rotations has been shown 
to be deficient in cervical dystonia. As several sensory ab-
normalities, including impaired temporal discrimination of 
visual stimuli, have been described in patients, we hypo-
thesized that derangements in head stabilization may result 
from failure to adequately detect incoming head posture 
disturbances. Intact self-motion and object-motion detec-
tion may be particularly relevant in this respect as this kind 
of information is almost exclusively shaped by velocity si-
gnals and depends on correct time computations.
Methods: 16 patients and 18 age-matched healthy con-
trols were asked to recognize bidirectional head-trunk, 
whole-body and object motion sinusoidal signals at 0.1 
Hz. Stimulus intensity was gradually increased from a sub-
threshold up to a clearly perceived level. Subjects used a 
joy-stick to indicate the occurrence and direction of per-
ceived motion. Stimulus recognition was noted when the 
subject indicated for the first time both directions of moti-
on. Subsequently, stimulus velocity was gradually reduced 
and subjects ceased to indicate motion when intensity fell 
below threshold.  
Results: Patients were significantly less aware of head-
trunk and object motion stimuli than normal subjects. They 
recognized trunk-in-space motion (head stationary, isolated 
neck-proprioceptive stimulus) once stimulus peak velocity 
attained 2º/s (controls: 1º/s, p<0.04 ).  They indicated both 
directions of the horizontally rotating light spot (visuo-ocu-
lomotor stimulus) once peak velocity reached 0.5º/s (con-
trols 0.25º/s, p<0.05).  In contrast, whole-body rotations 
(vestibular stimulus) were correctly sensed by patients.   
Conclusion: The selective impairments of head-to-trunk 
and object motion perception may contribute to malfunc-
tioning head stabilization in patients. 
Disclosure: Nothing to disclose
P4206
Modulation of dystonia during sleep
E. Antelmi1, F. Raffaele2, C.L. Scaglione1, P. Martinelli1,  
F. Provini1, R. Liguori1
1Department of Biomedical and Neuromotor Sciences, Alma 
Mater Studiorum, University of Bologna, Bologna, Italy, 
2Sleep Research Centre, Department of Neurology, I.C., Oasi 
Institute (IRCCS), Troina, Italy
Background and aims: There is the general belief that 
dystonia disappears during sleep but polysomnographic 
(PSG) studies documenting this assumption lack. With the 
current study we aim to document the activity on dystonic 
muscles during the different sleep stages.
Methods: We prospectively recruited 20 patients suffe-
ring from idiopathic adult-onset cervical dystonia and 10 
age-matched healthy voluntaries. Both patients and sub-
jects were investigated by means of clinical interview and 
validated questionnaires for subjective sleep complains, 
excessive daytime sleepiness, sleep-related movements’ 
disorders and mood complains. Both patients and subjects 
underwent PSG with standard montage plus additional su-
perficial EMG leads placed bilaterally on the muscles of the 
cervical district.
Results: Patients (10 females) had a mean age of 50 years 
±10, a mean disease duration of 8 years±5 and a moderate 
disease severity. Questionnaire-based interview failed to 
disclose any significant subjective sleep problems or mood 
disorders. When evaluating PSG recordings we found a 
disrupted sleep pattern with reduced sleep efficiency in the 
patient group. The analysis of the EMG traces from neck 
muscles showed that EMG activity in dystonic patients per-
sisted throught all the night, althought showing a progressi-
ve decrease while approacching the deeper stages of sleep. 
Still, nearly 70% of the patients presented an improvement 
of the dystonic posture the morning after night-sleep.
Conclusion: Patients with dystonia had important sleep 
disruption but they did not report excessive daytime slee-
piness. Dystonic spasms persisted during all the sleep sta-
ges, but their amplitude decreased during slow-wave sleep. 
Dystonia improved after night-sleep.
Disclosure: Nothing to disclose
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Subclinical dysphagia in multiple sclerosis
Y. Beckmann1, N. Gürgör2, S. Arici3, T. Kurt İncesu1,  
Y. Secil3, C. Ertekin1
1Izmir, Turkey, 2Katip Çelebi University Atatürk Training and 
Research Hospital, , Neurology, Izmir, Turkey, 3Katip Celebi 
University, Atatürk Training and Research Hospital,, Izmir, 
Turkey
Background and aims: Swallowing mechanism and 
neurogenic dysphagia in MS have been rarely studied by 
electromyographical methods. This study aims to evaluate 
the presence of subclinical dysphagia in patients with mild 
multiple sclerosis(MS) using electrophysiological methods.
Methods or Materials or Case Report: A prospective stu-
dy of 51 patients with relapsing remitting MS (RRMS) and 
18 age-matched healthy adults were investigated. We used 
electromyography to measure the activity of the submental 
muscles during swallowing, as well as respiration, electro-
cardiographic and electrodermal activity during the proce-
dures of dysphagia limits and sequential water swallowing. 
Electrophysiological recordings of patients were obtained 
during relapse, after relapse and at any time in remission 
period.
Results: Clinical dysphagia was found in 12 % of MS pa-
tients while electrophysiological swallowing abnormalities 
were encountered in 33% of patients. Subclinical dyspha-
gia was determined in 35% of patients during an MS relap-
se, in 20 % of patients after a relapse, and in 25% of all 51 
patients in the remission period based on EMG findings. 
Duration of swallowing signal of submental muscles in all 
MS patients was found to be longer than in normal subjects 
(p=0.001). During swallowing of 50 ml of sequential water, 
the compensatory respiratory cycles occurred more often 
in MS patients than normal subjects, especially during a 
relapse (p=0.005).
Conclusion: This is the first electrophysiological study 
investigating swallowing abnormalities and subclinical 
dysphagia in MS patients with mild disability. The electro-
physiological tests described in this study are useful to un-
cover subclinical dysphagia since they have the advantage 
of being rapid, easy to apply, non-invasive and without risk 
for the patients.
Disclosure: Nothing to disclose
P4211
A dual role of CCR5d32 polymorphism in 
multiple sclerosis
A. Bettencourt1, A. Martins Silva2, B. Leal1, E. Santos2,  
P.P Costa3, B. Silva1, S. Cavaco4
1Abel Salazar Institute of Biomedical Sciences, University 
of Porto – ICBAS/UP, Unit for Multidisciplinary Research in 
Biomedicine (UMIB), 2Centro Hospitalar do Porto - Hospital 
Santo António, Neurology, 3Instituto Nacional de Saúde Dr. 
Ricardo Jorge, 4Centro Hospitalar do Porto, Neuropsychology 
Unit, Porto, Portugal
Background and aims: C-C chemokine receptor type-5 
(CCR5), regulates both trafficking and effector functions 
of Th1 cells, macrophages, NK cells, and immature dend-
ritic cells. A common 32-basepair deletion (CCR5delta32), 
in the coding region of CCR5 gene, originates a truncated 
non-functional receptor with reduced expression on the cell 
surface. The aim of this study was to investigate whether 
this deletion is associated with susceptibility and/or severi-
ty in Portuguese MS patients.
Methods or Materials or Case Report: A total of 500 
MS patients and 230 controls were studied. A subset of 
142 patients with disease duration of at least 10 years was 
divided into 2 groups according to severity: 100 patients 
were considered to have benign MS (EDSS≤3) and 42 ag-
gressive MS (EDSS≥6). Kaplan-Meier survival analysis of 
the distribution of time to reach mild (EDSS=3) and severe 
disability (EDSS=6) was performed.
Results: No significant difference was observed in the al-
lelic frequency of CCR5d32 between patients and controls 
(OR=0.659; p=0.054). Concerning disease severity, d32 
frequency was significantly higher in the aggressive group 
(OR=4.000 p=0.002). For EDSS=3 as the end point, the me-
dian progression time was 6 years for d32carriers  and 11 
years for d32non-carriers (p=0.011). To reach an EDSS=6 
the median progression time was 18 years for d32carriers 
and 23 years for the other group (p=0.039).
Conclusion: The 32 deletion may protect against the deve-
lopment of MS, although we could not confirm it in this stu-
dy. However, once the disease is diagnosed, carriers seem 
to progress more rapidly to an advanced EDSS, suggesting 
a possible dual effect of this deletion.
Disclosure: Nothing to disclose
474      Poster presentation with discussion
© 2015 European Journal of Neurology, 22 (Suppl. 1), 120–483
P4212
Neuromyelitis optica spectrum disorders 
with MOG-antibodies
D. Biotti1, L. Mahieu2, R. Bernard-Valnet3,  
D. Peaureaux-Averseng4, N. Fabre5, M. Clanet1,  
H. Dumas6, F. Bonneville7, R. Marignier8, D. Brassat1
1Hopital PPR - CHU Purpan, Neurology, Toulouse, France, 
2Hopital PPR - CHU Purpan, Ophthalmology, Toulouse, 
France, 3CHU Toulouse, Pôle Neuroscience, Neurology De-
partment, Toulouse, France, 4Hopital PPR - CHU Purpan, 
Neurology, toulouse, France, 5Department of neurology, 
Toulouse University Hospital, France, Toulouse, France, 6De-
partment of neuroradiology, Toulouse University Hospital, 
France, Toulouse, France, 7CHU Purpan, Neuroradiologie, 
toulouse, France, 8Lyons, France
Background and aims: The presence (transient or persis-
tent) of myelin-oligodendrocyte glycoprotein antibodies 
(MOG-Abs) has been reported in children during demye-
linating neurological manifestations, particularly with acu-
te disseminated encephalomyelitis (ADEM) and multiple 
sclerosis (MS). In adults, MOG-Abs have been found in 
up to 30% of patients diagnosed with seronegative AQP4-
Abs neuromyelitis optica spectrum disorders. When found, 
positive MOG-Abs allow earlier NMOSD diagnosis and 
treatment, increasing the odds for a better prognosis. Ne-
vertheless, many questions remain about these MOG-Abs 
positive patients. The first short case-series published have 
highlighted several differences between AQP4+ and MOG-
Abs + patients. In the latter group, caudal myelitis has been 
more frequently described and ophthalmological involve-
ment (bilateral simultaneous optic neuritis) appears com-
mon. Attacks seem less frequent and severe than in seropo-
sitive AQP4-Abs patients. The therapeutic strategy in these 
patients remains to be defined.
Methods: Here, we present a series of 6 new seropositive 
MOG patients and compare them with 22 AQP4 +.
Results: 5 of the 6 were female, 2 experienced isolated bi-
lateral optic neuritis, and 2 had a past history of myelitis 
and optic neuritis, 1 with relapsing optic neuritis and one 
with relapsing myelitis. Relapses were treated with high 
doses of steroids and/or PLEX. To prevent new relapse, all 
patients were treated with rituximab except for one who 
received Imurel because she was pregnant.
Conclusion: MOG antibodies appear as a new useful cli-
nical biomarker. The identification of neuromyelitis optica 
spectrum disorders with MOG-antibodies should make dis-
cuss the rapid introduction of immuno active drugs.
Disclosure: Nothing to disclose
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Avascular osteonecrosis in a cohort of  
MS patients treated with high dose  
methylprednisolone
M. Blinkenberg1, T. Petersen2, J.L. Frederiksen3,  
P. Soelberg Sørensen1, E.K. Narvestad4, M. Ravnborg5
1Copenhagen University Hospital, Rigshospitalet, Danish MS 
Center, Department of Neurology, Copenhagen, Denmark, 
2Aarhus University, Deptartment of Neurology, Aarhus, Den-
mark, 3Glostrup Hospital, University of Copenhagen, Clinic 
of Multiple Sclerosis and Optic Neuritis, Department of 
Neurology, Copenhagen, Denmark, 4Copenhagen University 
Hospital, Rigshospitalet, Deptartment of Radiology, Copen-
hagen, Denmark, 5Odense University Hospital, Department of 
Neurology, Odense, Denmark
Background and aims: Avascular osteonecrosis (AO) is 
considered to be a rare side effect to high cumulated doses 
of methylprednisolone (MP), although an unconfirmed stu-
dy has reported increased prevalence (15.2%) in patients 
with multiple sclerosis (MS). Our aim was to determine the 
prevalence of AO in a well characterized cohort of MS pati-
ents, treated with monthly courses of high dose MP.
Methods: We studied 40 Danish patients from the inter-
national multicenter randomized controlled trial MECOM-
BIN. All patients started on interferon beta-1a and were af-
terwards randomized to tablets of MP 500mg daily for three 
days, once monthly, or placebo, for three to four years. We 
registered the total dose of MP, as well as fractures and hip 
joint pain and performed bilateral femoral magnetic reso-
nance imaging (MRI) of the hips. 
Results: 22 patients received MP and 18 placebo. Cumu-
lated mean MP dose was 76.9±11.8g in the MP group and 
5.5±10.2g the placebo group. Fractures were reported in 
two patients in the MP group and two in the placebo group. 
Hip pain was present in 10 patients in the MP group and 
in 7 patients in the placebo group (p=0.68). MRI revealed 
AO in one patient in the MP group and none in the placebo 
group.  
Conclusion: The risk of AO is low in MS patients treated 
with high doses of MP, which does not corroborate previ-
ous findings. We found no increased risk of fractures or hip 
pain in patients receiving high cumulative doses of MP. 
Disclosure: The study was supported by a grant form Bio-
gen Idec
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Sodium intake has no impact on MS  
disease activity: a study in 390 patients
B. Pignolet1, B. Nassar1, F. Bucciarelli2, A. Naudin1,  
F. Umuhoza1, L. Scandella3, N. Breuil4, O. Outteryck5,  
C. Lebrun-Frenay6, H. Zephir7, G.L. Defer8, B. Brochet9,  
M. Debouverie10, P. Labauge11, D. Laplaud12, P. Clavelou13, 
E. Thouvenot14, C. Lubetzki15, B. Fontaine15, M. Clanet16,  
P. Vermersch17, J. de Seze18, D. Brassat16
1CHU Toulouse, Toulouse, France, 2Purpan, Toulouse, France, 
3chu toulouse, Toulouse, France, 4chu toulouse, toulouse, 
France, 5Chru Lille, Neurology, Lille Cedex, France, 6Nice, 
France, 7LILLE Cedex, France, 8CHU Côte de Nacre, Neu-
rology, Caen, France, 9CHU Bordeaux, Bordeaux, France, 
10CHU Nancy, Nancy, France, 11CHU Montpellier, Mont-
pellier, France, 12Nantes, France, 13CHU Clermont-Ferrand, 
Clermont-Ferrand, France, 14Nîmes, France, 15Paris, France, 
16Toulouse, France, 17Lille Cedex, France, 18University Hospi-
tal Strasbourg, Neurology, Strasbourg, France
Background and aims: Salt consumption is suspected to 
play a role in MS disease activity. In vivo in mice, ex vivo 
in humans, and recently in a cohort of 50 MS patients, salt 
level seems to be associated with higher numbers of Th17 
cells and a more severe disease course. In this study, we 
investigate the relationship between salt intake and MS di-
sease severity with different severity criteria in 390 patients
Methods: Patients were included in the BIONAT cohort, 
a prospective phase IV observational multicentric study 
of 1200 Tysabri treated patients. In 390 we collected urine 
samples so as to calculate salt intake with the Tanaka for-
mula. Disease severity was evaluated at baseline according 
to several definitions with the MSSS, various clinical and 
radiological criteria and response to Tysabri.
Results: A multivariate analysis did not show any associa-
tion between salt consumption and disease severity
Conclusion: We were not able to confirm that high salt in-
take is associated with MS disease activity in the largest 
cohort of patients studied so far.
Disclosure: Travel grants, honoraria for teaching and parti-
cipation in advisory board from Bayer, BiogenIdec, Merck, 
Novartis, Sanofi-Genzyme and TevaPharma
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Cyclophosphamide pulses therapy after 
natalizumab discontinuation in Multiple 
Sclerosis patients
M. Capobianco1, M. Lo  Re2, F. Sangalli3, L. Moiola3,  
G. Comi4, P. Perini5, P. Gallo6, M. Danni7, L. Provinciali7,  
A. Repice8, L. Massacesi8, F. Patti9, S. Messina9,  
A. Laroni10, G.L. Mancardi10, M. Calabrese11, S. Monaco11, 
E. Pucci12, G. Giuliani12, A. Bertolotto1
1AOU San Luigi Gonzaga, Orbassano, 2Palermo, Italy,  
3Milan, 4University Vita-Salute, Scientific Institute San Raffa-
ele, Milan, 5University of Padova, Padua, 6Padua, 7University 
of Ancona, Ancona, 8Florence, 9Catania, 10University of 
Genova, Genoa, 11University of Verona, Verona, Italy, 12MA-
Cerata, Italy
Background and aims: To collect data from patients with 
Multiple Sclerosis switching from natalizumab to cyclo-
phosphamide. Natalizumab discontinuation induces the re-
currence of MS disease activity: currently no therapeutic ap-
proach has been found able to abolish disease reactivation. 
Cyclophosphamide is an an alkylating agent that has been 
demonstrated to be effective in very aggressive forms of 
Multiple Sclerosis.
Methods: Data were collected from different Italian MS 
Centres and retrospectively evaluated from clinical records.
Results: In the early treatment group (washout period 
between natalizumab and cyclophosphamide less than 3 
months), only 3/23 patients (13%) experienced a clinical 
relapse and only 2 out of 13 (15%) patients showed brain 
MRI activity at 3 months while none developed MRI acti-
vity at 6 months after cyclophosphamide introduction. In 
the Late Treatment Group (washout period between natali-
zumab and cyclophosphamide more than 3 months) 12/22 
patients (54%) had relapses during the washout period and 
4/22 (18%) after the introduction of cyclophosphamide; 
MRI disease activity was shown in 5/9 (55%) at 3 months 
and in 5/14 (35%) at 6 months after cyclophosphamide in-
troduction.
Conclusion: These data show that cyclophosphamide 
could be able to reduce disease reactivation after natali-
zumab discontinuation, in particular with a short washout 
period after natalizumab discontinuation. It can be sugge-
sted that a short period (3-6 months) of cyclophosphamide 
monthly pulses could be used as “re-induction” treatment 
in this particular group of patients.
Disclosure: Nothing to disclose
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Daclizumab high-yield process reduced 
disabling relapses and the rate of  
serious/severe relapses: post hoc  
analyses of the SELECT and DECIDE  
studies
L. Kappos1, K. Selmaj2, D.L. Arnold3, E. Havrdova4,  
A. Boyko5, M. Kaufman6, H. Wiendl7, J. Rose8, X. You9,  
S. Shang9, W. Castro-Borrero9
1University Hospital Basel, Basel, Switzerland, 2Medical 
University of Lodz, Lodz, Poland, 3NeuroRx Research and 
McGill University, Montreal, Canada, 4First School of Medi-
cine, Charles University in Prague, Prague, Czech Republic, 
5Russian Science & Research Medical University named after 
N. I. Pirogov and Moscow Multiple Sclerosis Center, Moscow, 
Russian Federation, 6University of Tennessee - Knoxville, 
Cole Neurological Institute, Knoxville, TN, USA, 7University 
of Münster, Münster, Germany, 8University of Utah, Depart-
ment of Neurology and the Neurovirology Research Labo-
ratory, VASLCHCS, Salt Lake City, UT, USA, 9Biogen Idec, 
Cambridge, MA, USA
Background and aims: To evaluate the frequency of 
disabling relapses and the rate of serious/severe relap-
ses in patients with relapsing-remitting multiple sclerosis 
(RRMS) treated with daclizumab high-yield process (DAC 
HYP) versus placebo or interferon beta-1a (IFN beta-1a).
Methods: Data from SELECT and DECIDE studies of 
subcutaneous DAC HYP 150 mg once every 4 weeks and 
placebo (SELECT: DAC HYP, n=201; placebo, n=196) or 
intramuscular IFN beta-1a 30 mcg once weekly (DECIDE: 
DAC HYP, n=919; IFN beta-1a, n=922) were evaluated. 
Relapses leading to disability progression (disabling re-
lapses) were defined as the onset of disability progression 
(≥1.0- or ≥1.5-point increase in EDSS score from a baseline 
EDSS score of ≥1.0 or 0.0, respectively, confirmed after 24 
weeks) within 180 days following a relapse. The annualised 
rate of serious or severe relapses was evaluated based on 
relapses reported as severe/serious by the investigator.
Results: In SELECT at week 52, 1.0% of patients trea-
ted with DAC HYP experienced disabling relapses versus 
6.6% of patients treated with placebo (P=0.0032; Table). 
In DECIDE at end of treatment period visit, 2.9% of DAC 
HYP-treated patients experienced disabling relapses ver-
sus 5.8% of patients treated with IFN beta-1a (P=0.0031). 
DAC HYP treatment reduced the annualised rate of serious 
and severe relapses by 67% versus placebo (P<0.0001) and 
by 38% versus IFN beta-1a (P=0.0021; Table).
Effect of DAC HYP on Disabling Relapses and the Rate of Serious and 
Severe Relapses
Conclusion: DAC HYP reduced the proportion of patients 
with disabling relapses and the rate of serious or severe re-
lapses compared with placebo and IFN beta-1a. 
Disclosure: These studies were funded by Biogen Idec and 
AbbVie Biotherapeutics Inc. Writing and editorial support 
for the preparation of this abstract was provided by Excel 
Scientific Solutions; funding was provided by Biogen Idec 
and AbbVie Biotherapeutics Inc.
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Effect of fingolimod on the revised, more 
comprehensive measure of no evidence of 
disease activity and worsening (NEDA-4) 
at 12 and 24 months
L. Kappos1, E.-W. Radue2, T. Sprenger1, E. Havrdova3,  
M. Freedman4, B. Cree5, M.P. Sormani6, N. Sfikas7,  
N. Bergvall7, D. Piani Meier7, D. Tomic7, N. De Stefano8
1University Hospital Basel, Basel, Switzerland, 2Medical 
Image Analysis Center (MIAC), University Hospital, Basel, 
Basel, Switzerland, 3Department of Neurology, First Faculty 
of Medicine, Charles University in Prague, Prague, Czech 
Republic, 4Ottawa Hospital, Multiple Sclerosis Research 
Clinic, Ottawa, USA, 5University of California San Francisco, 
Department of Neurology, San Francisco, USA, 6University 
of Genoa, Biostatistics Unit, Department of Health Sciences, 
Genoa, Italy, 7Novartis Pharma AG, Basel, Switzerland, 8Uni-
versity of Siena, Sienna, Italy
Background and aims: Current definitions of ‘No Evi-
dence of Disease Activity and worsening’ (NEDA) in pa-
tients with relapsing MS (RMS) are based on assessment 
of EDSS progression, relapses, and active MRI lesions, but 
the MRI metric depicts mainly focal activity and less so 
outcomes related to diffuse damage such as brain volume 
loss (BVL). This study evaluates the impact of including 
BVL in a four-measure definition of NEDA, e.g. NEDA-4.
Methods: Pooled data of patients receiving fingolimod 
0.5 mg or placebo from two phase 3 trials (FREEDOMS/
FREEDOMS II) were compared. NEDA-4 was defined 
as: no confirmed relapses, no 6-month confirmed disabi-
lity progression, no new/enlarging T2-lesions and annual 
BVL (using SIENA method) less than 0.4%. This BVL cut-
off corresponds to approximately twice the average rate in 
non-MS individuals (0.1%–0.3%) but remains below the 
range of mean rates typically seen in MS patients (0.5%–
1.35%). NEDA-4 was compared for fingolimod vs. placebo 
at months (M) 12 and 24. 
Results: Significant (p<0.0001) difference (OR, 95% CI) 
in NEDA-4 status vs. placebo was observed, M12: 26.5% 
vs. 8.7%, 3.77 (2.77−5.12); M24: 19.7% vs. 5.3%, 4.41 
(3.03−6.42). In patients with high disease activity despite 
treatment with disease modifying therapies in the past year, 
effects were comparable (Table). Similar results observed 
with other BVL cut-offs (0.2%–1.2%).
Table: NEDA-4 status, by treatment in subgroup of patients who had 
high disease activity despite treatment with disease modifying thera-
pies* 
Conclusion: Significantly more fingolimod-treated pati-
ents achieved NEDA-4 versus placebo at both time-points. 
By integrating measures of both focal and diffuse damage, 
NEDA-4 may provide a more comprehensive assessment 
of disease activity and worsening in RMS. 
Disclosure: Ludwig Kappos’ institution, University Hos-
pital Basel, has (last 3 years) received the following fees 
which were used exclusively for research support: steering 
committee, advisory board and consultancy fees (Acte-
lion, Addex, Bayer Health Care, Biogen, Biotica, Genzy-
me, Lilly, Merck, Mitsubishi, Novartis, Ono Pharma, Pfi-
zer, Receptos, Sanofi-Aventis, Santhera, Siemens, Teva, 
UCB, Xenoport); speaker fees (Bayer Health Care, Biogen, 
Merck, Novartis, Sanofi-Aventis, Teva ); educational acti-
vities (Bayer Health Care, Biogen, CSL Behring, Genzy-
me, Merck, Novartis, Sanofi, Teva); royalties (Neurostatus 
Systems GmbH); grants (Bayer Health Care, Biogen, Eu-
ropean Union, Merck, Novartis, Roche, Roche Research 
Foundations, Swiss MS Society, Swiss National Research 
Foundation). 
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INSPIRE: standardized acquisition and 
centralized quantitative MRI evaluation 
of RRMS patients in German daily clinical 
practice
A. Gass1, J. Würfel2, J. Gregori3, S. Hoffmann3, A. Fuchs4,  
C. Cornelissen4
1University Hospital Mannheim, Neurology, Mannheim, Ger-
many, 2University Medicine Goettingen, Institute of Neuro-
radiology, Göttingen, Germany, 3mediri GmbH, Heidelberg, 
Germany, 4Novartis Pharma GmbH, Nuremberg, Germany
Background and aims: INSPIRE is a non-interventional 
nationwide German study, to validate the feasibility and 
potential benefit of standardized MR-acquisition and cen-
tral-quantitative MR-reading in RRMS-patients. MRI has 
become an integral part of MS patient-management. How-
ever, quantitative analyses e.g. of the lesion-load is not 
trivial and has been realized nearly exclusively in clinical 
trials. We here investigate whether additional quantitative 
information and visualization of the lesion-load gives ad-
ded value to the daily management of RRMS-patients.
Methods: This NIS will include 250 patients derived from 
30 centers. Sites underwent expert training and imple-
mentation of standardized MRI-sequences. In addition to 
routine local diagnostic reading, a centralized quantitative 
MRI-data analysis is performed (volume of T2w-lesions, 
T1w-hypointense and contrast-enhancing lesions, percen-
tage of brain volume change via boundary shift integral). 
The results are visualized and provided to the physicians.
Results: First patient visit was in June 2014. We present 
the study design and the procedures for quality assurance, 
MRI-protocols and the centralized quantitative MR-analy-
sis. Baseline characteristics and MRI-results of the first 100 
patients will be provided. Data are analyzed in regard to: 
1. feasibility of the proposed MRI-algorithm (site set-up, 
sequence implementation, embedding in a routine radiolo-
gical work-flow, data management, communication of cen-
tralized analysis results). 2. MRI-data quality and stability 
(consistency, artifacts, signal-to-noise-ratio, contrast-to-
noise-ratio). 3. usefulness for clinical patient management.
Conclusion: A more sophisticated, additional quantitative 
MRI-analysis is provided in a real world situation. Presen-
tation of quantiative data on T2w-lesion count and volumes 
as well as the visualization of MRI-abnormalities provide 
additional information to the treating neurologist and sup-
port patient management.
Disclosure: This study is supported by the Novartis Phar-
ma GmbH, Nuremberg, Germany
P4219
Natalizumab (NA) in pediatric multiple  
sclerosis (MS): results of the Italian  
registry
A. Ghezzi1, L. Moiola2, C. Pozzilli3, V. Brescia Morra4,  
P. Gallo5, L.M.E. Grimaldi6, P. Annovazzi1, M. Filippi7,  
G. Comi2
1Gallarate, Italy, 2Milan, Italy, 3Rome, Italy, 4Federico II 
University, Neurosciences, Reproductive and Odontostoma-
tological Sciences , Naples, Italy, 5Padua, Italy, 6Fondazione 
Istituto San Raffaele “G. Giglio” di Cefalù, Unità Operativa 
Neurologia, Cefalù, Italy, 7Institute of Experimental Neurolo-
gy, Division of Neuroscience, San Raffaele Scientific Institute, 
Vita-Salute San Raffaele University, Milan, Neuroimaging 
Research Unit, Milan, Italy
Background and aims: NA is a promising option for ped-
MS patients with active MS and a poor response to IFNB 
and GA but data are not available in large cohorts and after 
a long-term follow up. Our study has been carried out to 
provide further information on this topic.
Methods: A registry was established in 2007 in Italy to 
collect cases treated with NA before 18 years of age. 23 
MS Italian centres participated to this study
Results: 101 patients were included (69 females), mean 
age of MS onset 12.9±2.7 years, mean age at NA initiati-
on 14.7±2.4 years. Mean treatment duration was 34.2±18.3 
months.
A total of 15 relapses were recorded in 9 patients, annua-
lized relapse rate was 2.3±1.0 in the year prior to NA and 
decreased to 0.1±0.3 (p<0.001) at last NA infusion.
Mean EDSS decreased from 2.6±1.3 at initiation of NA to 
1.8±1.2 at the time of last visit (p<0.001). New lesions on 
T2 or Gd+ were observed in 10/91 patients after 6 months, 
in 6/87 after 12 months, in 2/61 after 18 months, in 2/68af-
ter 24 months, in 3/62 after 30 months, in 5/43 after a lon-
ger follow up. At the time of last observation 64% of pati-
ents were free from clinical (relapses/increased EDSS) and/
or MRI activity (figure)
No relevant adverse events were recorded.
Conclusion: A relevant reduction of relapse rate and EDSS 
was observed after NA treatment, compared to pre-treat-
ment period. NEDA (No evidence of disease activity) oc-
curred in about 65% of cases.
Disclosure: Nothing to disclose
© 2015 European Journal of Neurology, 22 (Suppl. 1), 120–483
Poster presentation with discussion      479
P4220
Long-term follow-up of the effect of  
delayed-release dimethyl fumarate on No 
Evidence of Disease Activity in patients 
with multiple sclerosis
G. Giovannoni1, E. Havrdova2, R. Gold3, R.J. Fox4,  
L. Kappos5, J.T. Phillips6, A. Zhang7, N.C. Kurukulasuriya7
1Blizard Institute, Queen Mary University of London, London, 
United Kingdom, 2Department of Neurology, First Faculty of 
Medicine, Charles University in Prague, Prague, Czech Repu-
blic, 3St. Josef Hospital, Ruhr University, Bochum, Germany, 
4Mellen Center for Multiple Sclerosis Treatment and Re-
search, Cleveland Clinic, Cleveland, USA, 5University Hospi-
tal, Basel Neurology, Basel, Switzerland, 6Multiple Sclerosis 
Program, Baylor Institute for Immunology Research, Dallas, 
USA, 7Biogen Idec, Inc., Cambridge, USA
Background and aims: ENDORSE is an 8-year extensi-
on of DEFINE/CONFIRM studying long-term effects of 
delayed-release dimethyl fumarate (DMF; also known as 
gastro-resistant DMF) in relapsing-remitting multiple scl-
erosis. In this post hoc analysis, we report annual no evi-
dence of disease activity (NEDA) outcomes.
Methods: Patients randomised to DMF 240 mg twice 
(BID) or three times daily (TID) in DEFINE/CONFIRM 
continued same dosage in ENDORSE; patients randomised 
to placebo (PBO) or glatiramer acetate (GA) were re-ran-
domised 1:1 to DMF BID or TID. Patients who fulfilled 
the following criteria (measured annually) were considered 
to have NEDA: no relapses, no 24-week Expanded Disa-
bility Status Scale–confirmed progression, no gadolinium-
enhanced lesions, and no new/enlarging T2 lesions. Data 
for DMF BID (as of 14 May 2014) are reported.
Results: Of 1,736 ENDORSE patients, 746 had efficacy 
assessments; 363 received DMF BID (211 BID/BID, 104 
PBO/BID, 48 GA/BID). For BID/BID patients, propor-
tions with NEDA during Years 1 and 2 (DEFINE/CON-
FIRM) and Years 3, 4, and 5 (ENDORSE) were 37.9%, 
50.2%, 47.9%, 52.0%, and 42.5%, respectively. For PBO/
BID, corresponding proportions with NEDA were 21.2%, 
25.0%, 23.1%, 42.5%, and 43.2%, respectively. For GA/
BID, corresponding proportions with NEDA were 16.7%, 
27.1%, 33.3%, 45.5%, and 31.6%, respectively. Absence 
of measured clinical activity and of measured magnetic 
resonance imaging (MRI) activity outcomes are presented 
below (Table).
Conclusion: Favourable NEDA outcomes were maintained 
throughout 5 years with continuous DMF treatment; ave-
rage NEDA rates over time were higher with early versus 
delayed DMF treatment. PBO/BID and GA/BID patients 
demonstrated improved NEDA after switching to DMF.
Disclosure: Study supported by: Biogen Idec
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Multiple sclerosis and social networks
A.-K. Göcke1, A. Tallner2, M. Mäurer1
1Caritias Krankenhaus Bad Mergentheim, Neurology, Würz-
burg, Germany, 2Institut für Sport und Sportwissenschaften, 
Erlangen, Germany
Background and aims: Modern electronic technologies 
and social networks have created a huge community of in-
ternet users. In Germany >75% of the general population 
has internet access and the „World Wide Web“ has become 
the most important source for health issues. Therefore we 
evaluated the role of social networks for health issues of 
MS patients.
Methods: We sent out questionaires to 1554 MS Patients 
registered in our database. 486 individuals returned the 
questionnaires (32%). Questionnaires comprise questions 
about disease course and symptoms, internet usage (hard-
ware, frequency, preferences) as well as depression and 
quality of life.
Results: 89% of our cohort indicates to use the PC to ac-
cess the world wide web, 56% use smartphones, but only 
26% tablet computers. 52% of our patients use social net-
works, and more than 60% report a daily use. Among the 
social networks Facebook is by far the most popular plat-
form, other providers like Xing, Instagram or Twitter are of 
minor importance. In addition only a minority of patients 
read private MSBlogs.
Although a high proportion of MS patients use social net-
works only a minority join MS support groups on social 
platforms (12%) and take part in MS assistant services de-
livered via the Internet (4%).
Conclusion: A high proportion of MS patients use social 
networks, in particular facebook. Actually health issues are 
not a primary reason to join a social network. Due to the in-
tensive usage of social networks we believe that these net-
works should become an important tool for MS care centers 
in order to deliver health education.
Disclosure: Nothing to disclose
P4222
Predictors of suicidal ideation in patients 
feeling severely affected by multiple  
sclerosis
H. Golla1, J. Strupp1, C. Ehmann1, M. Galushko1, R. Bücken1, 
S. Hamacher2, H. Pfaff3, R. Voltz1
1University Hospital Cologne, Department of Palliative Me-
dicine, Cologne, Germany, 2University Hospital Cologne, 
Institute of Medical Statistics, Informatics and Epidemiology, 
Cologne, Germany, 3University Hospital Cologne,  Institute 
of Medical Sociology, Health Services Research, Cologne, 
Germany
Background and aims: Being severely affected by Multi-
ple Sclerosis (MS) brings substantial physical and psycho-
logical challenges. Contrary to the commonly held notion 
that MS is not a lethal disease, it can lead to death and is 
reflected in alarming rates of assisted suicide and euthana-
sia among patients.
Analysis of independent variables promoting suicidal 
ideation in severely affected MS patients stating suicidal 
thoughts.
Methods: A self-report questionnaire with 25 needs cate-
gories including one item “prone to suicidal ideation” was 
applied. Connections between risk factors were tested with 
Spearman’s rank correlation. Relevant covariates showing 
a p-value <0.05 in the univariate analysis and remaining in 
the multivariable logistic regression model after stepwise, 
backward selection procedure were included in the final 
model.
Results: 573 patients completed the questionnaire. Median 
age was 51 years (range 20-83), 66.8% were female. 42.6% 
suffered from secondary progressive, 24.7% from relap-
sing-remitting and 21.9% from primary progressive MS. 
22.1% had suicidal ideation. A set of six statistically signi-
ficant criteria for suicidal ideation were found. Three items 
were predictors for suicidal ideation: the extent to which 
MS affects leisure time (p<0.001), depression (p<0.000), 
and feeling socially excluded (p<0.002). Three items redu-
ced the odds of suicidal ideation: having a purpose in life 
(p<0.000), being productive (p<0.000), and having comfort 
in faith and spiritual beliefs (p<0.024).
Conclusion: We identified several potentially modifiable 
factors that may help preventing suicide in people with 
MS. Integrating Palliative Care with its multidisciplinary 
approach might be important to reduce patients’ burden.
Disclosure: The study was funded by the “Gemeinnützige 
Hertie-Stiftung” (grant # 1.01.1/06/009).
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The configuration of gait temporal joint 
patterns is changed in patients with  
primary progressive multiple sclerosis: 
network and random forest analysis
D. Gómez Andrés1, I. Pulido-Valdeolivas1,  
I. González-Suárez2, J.A. Martín-Gonzalo3,  
I. Rodríguez-Andonaegui3, C. Oreja-Guevara2, E. Rausell1
1Universidad Autónoma de Madrid, Anatomy, Histology and 
Neuroscience, Madrid, Spain, 2Hospital Universitario Clí-
nico San Carlos, Neurology, Madrid, Spain, 3Physiotherapy 
School. ONCE-UAM, Madrid, Spain
Background and aims: Efficient gait relies on the abili-
ty of the central nervous system to command a system of 
sequential muscle synergy chains to manage weight sup-
port and translation, by setting gait cycle time-specific joint 
angle configurations. These switch in patients with primary 
progressive multiple sclerosis (PPMS) as an adaptive res-
ponse to maintain propositive gait. Our aims are to define 
which gait parameters switch from normal configuration 
to a more adaptive one and to assess the system’s global 
plasticity using random forest and network analysis respec-
tively.
Methods: 72 kinematic/spatiotemporal parameters 
(36left/36right) of 5 joints were acquired by instrumented 
gait analysis from 4-5 gait cycles (10 PPMS patients/12 
healthy volunteers). Random forests were trained to define 
classifier parameters for PPMS or healthy condition (good-
ness-of-fit assessment =1-OOB error rate). The influence 
of each predictor was estimated by mean percentage of de-
crease in model accuracy when variable is out-of-the-bag.
Two networks were generated (nodes=gait parameters, 
edge weight = bivariate Spearman’s correlation coefficients 
between nodes) and their properties and parameter organi-
zation (building-blocks) were assessed according to Rubi-
nov and Sporns, 2010.
Results: PPMS patients’ walking strategies differ from 
normal by more flexed knee at initial contact (leading fre-
cuently to recurvatum in stance), longer stance time, lower 
cadence and abnormal minimum hip flexion (goodness-of-
fit=95.7%), which reflects a poor distal joint support. PPMS 
gait system is rearranged to maintain maximum control of 
pelvic-femoral joints by setting more distributed relation-
ships with ankle/knee parameters.
Networks and cumulative distribution of node strength
Conclusion: New gait joint configurations are provided by 
plastic adaptation to the constraints imposed by brain da-
mage in PPMS.
Disclosure: Nothing to disclose
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Cervical cord atrophy in clinically isolated 
syndrome and early multiple sclerosis:  
a novel paraclinical risk marker for  
conversion to manifest multiple sclerosis?
I. Hagström1, B. Bellenberg1, R. Schneider2, A. Salmen2,  
F. Weiler3, R. Gold2, C. Lukas1
1Ruhr-University Bochum, Radiology, Bochum, Germany, 
2Ruhr-University Bochum, Neurology, Bochum, Germany, 
3Fraunhofer Mevis, Bremen, Bremen, Germany
Background and aims: Cervical cord atrophy predictive 
for disability progression in manifest Multiple Sclerosis 
(MS). We aimed to quantify and evaluate the clinical impact 
of atrophy of the upper cervical cord area (UCCA) in early 
MS and to assess differences between patients assigned cli-
nically isolated syndrome (CIS) or relapsing-remitting MS 
(RRMS). We compared UCCA in CIS patients converting 
to RRMS within 2 years with patients with stable CIS.
Methods: 45 CIS patients, 48 RRMS and 34 matched 
healthy controls underwent 3D-T1-weighted brain MR-
imaging at 3 Tesla covering the cervical cord. UCCA was 
quantified by a semi-automated volumetric method bet-
ween the C1 and C3 level. Clinical examination included 
the expanded disability status scale (EDSS), 9-hole peg test 
(9HPT) and disease duration.
Results: Although all patients had low EDSS and short 
disease durations at baseline (table 1), significant UCCA 
atrophy was detected in the entire group, driven by RRMS 
and CIS patients, who converted to RRMS during follow-
up (figure 1). In the entire group and in RRMS, UCCA cor-
related significantly with the pyramidal functional system 
score, the 9HPT score and by trend with EDSS (table 2). In 
converting CIS patients, a trend for correlation of UCCA to 
9HPT was observed.
Table 1: Demography and clinical parameters in the study groups
Table 2: Spearman correlation analyses of UCCA related to disability 
scores
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Figure 1: UCCA in different groups (boxes: median / interquartile ran-
ge, error bars: minimum / maximum); significance of group differen-
ces by t-tests; n.s.: not significant
Conclusion: UCCA atrophy was related to 9HPT perfor-
mance and pyramidal symptoms in early MS. We found 
evidence, that CIS patients converting to MS during 2 ye-
ars follow-up can be differentiated from stable CIS pati-
ents by UCCA atrophy at baseline. The predictive value of 
cord atrophy for conversion to MS should be addressed in 
further longitudinal studies.
Disclosure: This work was supported by the German Fede-
ral Ministry for Education and Research, BMBF, German 
Competence Network Multiple Sclerosis (KKNMS), grant 
no. 01GI0914. 
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Superior efficacy of alemtuzumab  
on disability outcomes versus  
subcutaneous interferon beta-1a in  
treatment-naïve multiple sclerosis  
patients using the SAD-plus composite 
endpoint
X. Montalban1, J.A. Cohen2, H.-P. Hartung3, E. Havrdova4, 
D.H. Margolin5, L. Kasten6, E.J. Fox7
1Vall d’Hebron University Hospital, Barcelona, Spain, 2Cle-
veland Clinic, Cleveland, Cleveland, USA, 3Heinrich-Heine-
University, Düsseldorf, Germany, 4First Medical Faculty, 
Charles University in Prague, Prague, Czech Republic, 5Gen-
zyme, a Sanofi company, Cambridge, USA, 6PROMETRIKA 
LLC, Cambridge, USA, 7Central Texas Neurology Consul-
tants, Round Rock, USA
Background and aims: Expanded Disability Status Scale 
(EDSS) score may not be sensitive enough to detect me-
aningful changes in neurological function in some relap-
sing-remitting multiple sclerosis (MS) patients. Here, we 
present a novel composite endpoint to examine disability 
outcomes in the CARE-MS I study (NCT00530348).
Methods: Treatment-naïve patients received 2 courses of 
alemtuzumab 12mg, or subcutaneous interferon beta-1a 
(SC IFNB-1a) 44µg 3 times/week for 2 years. Sustained 
accumulation of disability (SAD) was defined as ≥1.0-point 
increase in EDSS sustained over 6 months (≥1.5 point if 
baseline EDSS=0). Post hoc disability outcomes included 
6-month sustained worsening on the following measures: 
Timed 25-Foot Walk (T25FW; 20% increase from base-
line), 9-Hole Peg Test (9-HPT; 20% increase), or Sloan 
visual acuity at 2.5% contrast (7-letter worsening). Sustai-
ned worsening on any disability measure (T25FW, 9-HPT, 
Sloan, or SAD) was assessed (SAD-plus).
Results: Alemtuzumab (N=376) significantly reduced 
the risk of 6-month confirmed accumulation of disability, 
measured by SAD-plus, as compared with SC IFNB-1a 
(n=187). The proportion of patients achieving the compo-
site SAD-plus endpoint was 33% lower with alemtuzumab 
than SC IFNB-1a (30.4% vs 41.8%; P=0.0210). Treatment 
effects on each component measure were directionally si-
milar but not statistically significant: SAD (8.0% vs 11.1%; 
P=0.22), worsening on T25FW (8.3% vs 9.0%; P=0.76), 
9-HPT (4.0% vs 6.3%; P=0.27), or Sloan (11.2% vs 17.3%; 
P=0.11).
Conclusion: SAD-plus is more sensitive to clinically me-
aningful impairments than EDSS-based SAD alone. Post 
hoc analysis of this endpoint in CARE-MS I demonstrates 
alemtuzumab’s superior effect on disability relative to SC 
IFNB-1a in treatment-naïve patients with relapsing MS.
Disclosure: Study supported by Genzyme, a Sanofi compa-
ny, and Bayer Healthcare Pharmaceuticals.
